UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported) : May 11, 2017

 

Icagen, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   000-54748   20-0982060
(State or other jurisdiction
of incorporation)
  (Commission File Number)  

(I.R.S. Employer

Identification No.)

 

4222 Emperor Blvd., Suite
350 Research Triangle Park,

Durham, NC 27703

(Address of principal executive offices)

(zip code)

 

(919) 941-5206

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name or former address, if

changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company   þ  

 

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  þ

 

 

 

 
 

 

Item 1.01. Entry into a Material Definitive Agreement.

 

Securities Purchase Agreement and Notes

 

On May 15, 2017, Icagen, Inc., a Delaware corporation (the “ Parent ”), and its wholly owned subsidiary, Icagen-T, Inc. (“ Icagen-T ”), a Delaware corporation ( “ Icagen-T ”), entered into a Securities Purchase Agreement (the “ Securities Purchase Agreement ”) with GPB Debt Holdings II, LLC (the “ Purchaser ”), pursuant to which (i) the Parent issued to the Purchaser for an aggregate purchase price payable in cash to the Parent of $1,920,000, before reimbursement of expenses: (a) a Senior Secured Convertible Note in the aggregate principal amount of $2,000,000 (the “ Parent Note ”), which Parent Note is convertible into the Parent’s shares of common stock, $0.001 par value per share (“ Common Stock ”) at a conversion price of $3.50 per share, and (b) a warrant to purchase initially up to 857,143 shares of Common Stock (the “ Warrant ”) (the shares of Common Stock issuable pursuant to the terms of the Warrant, including, without limitation, upon exercise or otherwise, collectively, the “ Warrant Shares ”) in accordance with the terms of the Warrant; and (ii) Icagen-T issued to the Purchaser for an aggregate purchase price payable in cash to Icagen-T of $7,680,000, before reimbursement of expenses, a Senior Secured Convertible Note of Icagen-T (the “ Icagen-T Note ” and together with the Parent Note, the “ Notes ”), in the aggregate principal amount of $8,000,000, which Icagen-T Note is convertible into shares of Common Stock of the Parent at a conversion price of $3.50 per share (the shares of Common Stock issuable pursuant to the terms of the Icagen-T Note and the Parent Note, including without limitation, upon conversion or otherwise, collectively, the “ Parent Conversion Shares ”) in accordance with Icagen-T Note and the Parent Note.

 

Each Note was issued with a four (4%) percent original issue discount. The Notes have a maturity date of May 15, 2020 (the “ Maturity Date ”) and bear interest at a rate equal to 13% per annum (which interest rate is increased to 18% per annum upon the occurrence of an Event of Default (as defined in the Notes) (the “ Interest ”). The Purchaser may elect to have the Parent and/or Icagen-T redeem the respective Note upon the occurrence of certain events, including upon certain Events of Default (as defined in the Notes). The Notes contain customary Events of Default.

 

In addition, any time after issuance, so long as no Event of Default has occurred and/or is continuing, the Parent and Icagen-T, respectively, has the right to redeem all or part of the Conversion Amount (as defined below) of each Note then outstanding (the “ Company Optional Redemption Amount ”), with a minimum prepayment amount of $500,000, at any time upon five (5) business days’ notice to the Purchaser by paying an amount in cash equal to a range between 101% and 103% of the Conversion Amount being redeemed if paid in full and if an Event of Default has occurred and is continuing the Purchaser has the right to require the Company to redeem the Conversion Amount for an amount of cash equal to a range between 116% and 118% of the Conversion Amount being redeemed. The “ Conversion Amount ” means the sum of (a) the portion of the principal to be converted, redeemed or otherwise with respect to which this determination is being made, (b) all accrued and unpaid Interest with respect to such portion of such principal, (c) all accrued and unpaid late charges with respect to such portion of such principal and such Interest, if any, and (d) all other amounts due hereunder.

 

2

 

 

The Notes contain certain covenants, such as restrictions on the incurrence of indebtedness, the existence of liens, the payment of restricted payments, redemptions, the payment of cash dividends and the transfer of assets. If the Parent fails to timely deliver the shares underlying the Notes, it will be subject to certain buy-in provisions.

 

In addition, pursuant to the Securities Purchase Agreement, the Parent and Icagen-T have agreed to provide certain registration rights with respect to the Conversion Shares underlying the Icagen-T Note and, if Rule 144 under the Securities Act of 1933, as amended (the “ Securities Act ”), is unavailable, for the Warrant Shares and Parent Conversion Shares underlying the Parent Note.

 

In addition, pursuant to the Notes, neither the Parent nor Icagen-T shall enter into or be party to a Fundamental Transaction (as defined in the Notes) unless (i) the Successor Entity (as defined in the Notes) assumes in writing all of the obligations of the Parent, Icagen-T and each Subsidiary (the “ Subsidiaries ”) under the Notes and the other Transaction Documents (as defined in the Notes) pursuant to written agreements in form and substance reasonably satisfactory to the Purchaser and approved by the Purchaser prior to such Fundamental Transaction, including agreements to deliver to the Purchaser in exchange for this Note and securities of the Successor Entity evidenced by a written instrument substantially similar in form and substance to the Notes (which, for the avoidance of doubt, shall not include any terms or conditions less favorable to the Purchaser in any material respect than the terms and conditions set forth in the Notes), including, without limitation, having principal amounts, interest rates and late charges equal to the payment rights and amounts, principal amounts then outstanding, the interest rates and late charges in the Notes as well as having the conversion rights, redemption rights, rankings, Events of Default the same as in the Notes and satisfactory to the Purchaser, and (ii) the Successor Entity is a trading issuer whose common stock is registered under Section 12 of the Securities Exchange Act of 1934, as amended, and is quoted and/or listed for trading on a Qualifying Market (as defined in the Notes).

 

The Notes also contain certain anti-dilution provisions that apply in connection with any stock split, stock dividend, stock combination, recapitalization and sales of securities below the conversion price of the Notes.

 

In addition, subject to limited exceptions, a holder of the Parent Note and Icagen-T Note will not have the right to convert any portion of such note if such holder, together with its affiliates, would beneficially own in excess of 4.99% of the number of shares of the Common Stock outstanding immediately after giving effect to its conversion (the “ Beneficial Ownership Limitation ”).  A holder of the Parent Note and Icagen-T Note may adjust the Beneficial Ownership Limitation upon not less than 61 days’ prior notice to the Parent, provided that such Beneficial Ownership Limitation in no event shall exceed 9.99%.

 

The Parent intends to use the proceeds from this financing to repay $1,500,000 aggregate principal amount of 8% notes sold by the Parent in an April 2017 bridge financing and all accrued but unpaid interest thereon, and the balance for general corporate and working capital purposes, including payments in the amount of $500,000 owed by the Parent pursuant to the terms of a settlement agreement (the “ Settlement Agreement ”), and Icagen-T intends to use the net proceeds from the purchase price paid to Icagen-T for general corporate and working capital purposes of Icagen-T; provided , however , neither the Parent nor Icagen-T will use any of their respective net proceeds for (a) the repayment of any Indebtedness other than Permitted Indebtedness (as defined in the Notes), (b) the redemption or repurchase of any securities of the Parent, Icagen-T and the Subsidiaries, or (c) except for the payments pursuant to the Settlement Agreement, the settlement of any outstanding litigation; provided , further , Icagen-T will not use any of such proceeds in violation of its arrangements with Sanofi US Services, Inc.

 

The Purchaser was reimbursed for legal and due diligence fees and expenses from this private placement.

 

Warrant

 

The Parent issued the Warrant to the Purchaser at an initial exercise price of $3.50 per share (subject to applicable adjustments) (the “ Exercise Price ”). The Warrant expires on May 15, 2022.

 

In addition, subject to limited exceptions, a holder of the Warrant will not have the right to exercise any portion of the Warrant if such holder, together with its affiliates, would beneficially own in excess of the Beneficial Ownership Limitation.  A holder of the Warrant may adjust the Beneficial Ownership Limitation upon not less than 61 days’ prior notice to the Parent, provided that such Beneficial Ownership Limitation in no event shall exceed 9.99%.

 

The Warrant also contain certain anti-dilution provisions that apply in connection with any stock split, stock dividend, stock combination, recapitalization and issuances of securities at prices below the conversion price or similar transactions.

 

If, at the time a holder exercises its Warrant, there is no effective registration statement registering available for an issuance of the shares underlying the Warrant to the holder, then in lieu of making the cash payment otherwise contemplated to be made to the Parent upon such exercise in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of shares of Common Stock determined according to a formula set forth in the Warrant. If the Parent fails to timely deliver the shares underlying the Warrant, it will be subject to certain buy-in provisions.

 

The Warrant also provides that the Parent will not enter into or be party to a Fundamental Transaction unless (i) the Successor Entity (as defined in the Warrant) assumes in writing all of the obligations of the Parent under the Warrant and the other Transaction Documents (as defined in the Securities Purchase Agreement) pursuant to written agreements in form and substance satisfactory to the Purchaser, including agreements to deliver to the Purchaser in exchange for the Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to the Warrant; (ii) the Parent or the Successor Entity (as the case may be) agrees at the election of the Parent or the Successor Entity (as the case may be) to purchase the Warrant from the Purchaser by paying to the Purchaser cash in an amount equal to the Black Scholes Value (as defined in the Warrant); or (iii) the Purchaser, at its election, requires the Parent or the Successor Entity (as the case may be) to purchase the Warrant from the Purchaser by paying to the Purchaser cash in an amount equal to the Black Scholes Value.

 

3

 

 

Security and Pledge Agreements, Guaranties and Deed of Trust

 

The Parent Note is secured by a security interest in all of the existing and future assets of the Parent and the Domestic Subsidiaries (as defined in the Parent Security Agreements) (other than Icagen-T), including a pledge of all of the capital stock of each of the Domestic Subsidiaries (other than Icagen-T), subject to existing security interests (the “ Parent Collateral ”), for the benefit of the Purchaser, to secure the Parent’s obligations under the Parent Note, as evidenced by (i) a security and pledge agreement (the “ Parent Security Agreement ”), and (ii) a guaranty executed by each Domestic Subsidiary (other than Icagen-T) (the “ Parent Guaranty ”) pursuant to which the Domestic Subsidiaries (other than Icagen-T) guarantees all obligations of the Parent under the Transaction Documents.

 

The Icagen-T Note is secured by a security interest in all of the existing and future assets of the Parent, Icagen-T and the other Domestic Subsidiaries (as defined in the Icagen-T Security Agreement), including a pledge of all of the capital stock of each of the Domestic Subsidiaries (other than Icagen-T), subject to existing security interests (“ Icagen-T Collateral ” and together with the Parent Collateral, the “ Collateral ”), for the benefit of the Purchaser, to secure Icagen-T’s obligations under the Icagen-T Note, as evidenced by (i) a security and pledge agreement (the “ Icagen-T Security Agreement ”), and (ii) a guaranty executed by the Parent and each Domestic Subsidiary (other than Icagen-T) (the “ Icagen-T Guaranty ”) pursuant to which the Parent and the Domestic Subsidiaries (other than Icagen-T) guarantees all of the obligations of Icagen-T under the Transaction Documents.

 

In addition, the Parent and Icagen-T entered into a Subordinated Deed of Trust, Assignment of Rents, Fixture Filing and Security Agreement (the “ Deed of Trust ”) with the trustee named therein and the Purchaser as beneficiary, securing all of Icagen-T’s obligations to the Purchaser by a senior priority security interest in the Property/Facilities (as defined in the Deed of Trust), which is subordinated only to a Deed of Trust entered into with Sanofi US Services, Inc. The Parent and Icagen-T also executed an Affidavit of Confession of Judgment to secure their obligations under the Parent Note and Icagen-T Note.

 

Upon an Event of Default (as defined in the Notes), the Purchaser may, among other things, collect or take possession of the Parent Collateral or Icagen-T Collateral, as the case may be, proceed with the foreclosure of the security interest in the Collateral or sell, lease or dispose of the Collateral. Each of the Subsidiaries has also guaranteed all of the Parent’s obligations under the Note pursuant to the terms of the Parent Guaranty and the Icagen-T Guaranty.

 

The foregoing description of the terms of the Parent Note, the Icagen-T Note, the Securities Purchase Agreement, the Parent Security Agreement, the Icagen-T Security Agreement, the Parent Guaranty, Icagen-T Guaranty, the Warrant, the Deed of Trust and Affidavit of Confession of Judgment do not purport to be complete and are qualified in their entirety by reference to the provisions of such agreements, the forms of which are filed as exhibits 4.1, 4.2, 10.1, 10.2, 10.3, 10.4, 10.5, 10.6, 10.7 and 10.8, respectively, to this Current Report on Form 8-K.

 

The transactions contemplated by the Securities Purchase Agreement closed and funded on May 15, 2017.

 

Settlement and Release Agreement

 

On May 11, 2017, the Parent entered into a Settlement and Release Agreement (the “Agreement”) with Dentons US LLP (“Dentons”) relating to disputes arising between them under a Settlement and Release Agreement, dated July 5, 2013 (the “2013 Settlement Agreement”), a judgment thereafter obtained by Dentons on May 7, 2014 in the Circuit Court of Cook County, Illinois, Lawsuit based upon the 2013 Settlement in the amount of Three Million and Fifty Thousand Dollars ($3,050,000) (the “Judgment”), and a lawsuit filed by the Parent in San Francisco Superior Court (the “California Lawsuit”) in or about April 2014 against Dentons. In connection with the Agreement, the Parent has agreed to pay Dentons the sum of One Million Four Hundred Thousand Dollars ($1,400,000) over a fourteen month period of which: (i) $250,000 is due no later than May 15, 2017; and (ii) $250,000 is due no later than June 1, 2017 or the date of the closing of a debt financing by the Parent, whichever is sooner. In addition, to secure its obligations under the Agreement, the Parent executed and delivered to Dentons a Confession of Judgment Affidavit in Support of Confession of Judgment (the “Confession of Judgment”) in the amount of $3,891,549.32, representing the amount of the Judgment that had been obtained plus the costs of suit and interest accrued through May 15, 2017. The Confession of Judgment is not to be filed unless the Parent defaults on its obligations under the Agreement and it will be returned to the Parent upon payment in full under the Agreement. The Agreement included mutual releases of claims each party had against the other and the parties also agreed to dismiss the litigation between them with prejudice; provided, that Dentons’ obligations commence after it has received $500,000 of the payments from the Parent described above. The foregoing description of the Agreement and Confession of Judgment are qualified in its entirety to the full text of the Agreement and Confession of Judgment, copies of which are filed as Exhibit 10.9, respectively, to this Current Report on Form 8-K.

 

4

 

 

Item 2.03. Creation of a Direct Financial Obligation or an Obligation Under an Off-Balance Sheet Arrangement of a Registrant.

 

The information required by this Item 2.03 is set forth under Item 1.01 above and is hereby incorporated by reference in response to this Item 2.03.

 

Item 3.02.   Unregistered Sales of Equity Securities.

 

The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference into this Item 3.02 in its entirety. The Notes and the Warrant were, and any shares of Common Stock underlying the Notes and Warrant will be, issued in a transaction exempt from registration under the Securities Act in reliance on Section 4(a)(2) thereof and Rule 506 of Regulation D thereunder. The Purchaser represented that it was an “accredited investor,” as defined in Regulation D, and was acquiring the securities described herein for investment only and not with a view towards, or for resale in connection with, the public sale or distribution thereof. Accordingly, the Notes and Warrant and any shares of Common Stock underlying the Notes and Warrant have not been registered under the Securities Act and may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act and any applicable state securities laws. Neither this Current Report on Form 8-K nor the exhibits attached hereto is an offer to sell or the solicitation of an offer to buy Notes, Warrants or shares of Common Stock or any other securities of the Parent.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

The following exhibits are filed with this Current Report on Form 8-K:

 

Exhibit 4.1 Senior Secured Convertible Note, dated May 15, 2017, issued by Icagen, Inc.
   
Exhibit 4.2 Senior Secured Convertible Note, dated May 15, 2017, issued by Icagen-T, Inc.
   
Exhibit 10.1* Securities Purchase Agreement, dated May 15, 2017, by and among Icagen, Inc., Icagen-T, Inc., and GPB Debt Holdings II, LLC
   
Exhibit 10.2 Parent Security and Pledge Agreement, dated May 15, 2017, by and among Icagen, Inc., each of the Parent’s Subsidiaries named therein and GPB Debt Holdings II, LLC (in its capacity as collateral agent)
   
Exhibit 10.3 Icagen-T Security and Pledge Agreement, dated May 15, 2017, by and among Icagen, Inc., Icagen-T, Inc., each of their Subsidiaries named therein and GPB Debt Holdings II, LLC (in its capacity as collateral agent)
   
Exhibit 10.4 Guaranty of Obligations of Parent, dated May 15, 2017, by and among each of Icagen, Inc.’s Subsidiaries named therein and GPB Debt Holdings II, LLC (in its capacity as collateral agent)
   
Exhibit 10.5 Guaranty of Obligations of Icagen-T, dated May 15, 2017, by and among Icagen, Inc., each of Icagen-T, Inc.’s Subsidiaries named therein and GPB Debt Holdings II, LLC (in its capacity as collateral agent)
   
Exhibit 10.6 Warrant, dated May 15, 2017, issued by Icagen, Inc.
   
Exhibit 10.7 Subordinated Deed of Trust, Assignment of Rents, Fixture Filing and Security Agreement, dated May 15, 2017, by and among Icagen-T, Inc., GPB Debt Holdings II, LLC and the Trustee named therein
   
Exhibit 10.8 Confession of Judgment Affidavit in Support of Confession of Judgment
   
Exhibit 10.9*

Settlement and Release Agreement, dated May 11, 2017, by and between the Company and Dentons US LLP

 

 * Certain information in this exhibit has been omitted and filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Request submitted to the Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.

 

5

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: May 17, 2017 ICAGEN, INC.
     
  By:  /s/ Mark Korb
  Name: Mark Korb
  Title: Chief Financial Officer

 

 

6

 

 

Exhibit 4.1

 

Execution Version

 

NEITHER THE ISSUANCE AND SALE OF THIS NOTE NOR THE SECURITIES INTO WHICH THIS NOTE IS CONVERTIBLE INTO HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL TO THE PARENT OR THE HOLDER, IN A GENERALLY ACCEPTABLE FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES. ANY TRANSFEREE OF THIS NOTE SHOULD CAREFULLY REVIEW THE TERMS OF THIS NOTE, INCLUDING SECTIONS 3(c)(iii) AND 18(a) HEREOF. THE PRINCIPAL AMOUNT REPRESENTED BY THIS NOTE AND, ACCORDINGLY, THE SECURITIES ISSUABLE UPON CONVERSION HEREOF MAY BE LESS THAN THE AMOUNTS SET FORTH ON THE FACE HEREOF PURSUANT TO SECTION 3(c)(iii) OF THIS NOTE.

 

ICAGEN, INC.

SENIOR SECURED CONVERTIBLE NOTE

 

Note No: ICAGEN – GPB - 1

Issuance Date: May 15, 2017

  Original Principal Amount: U.S. $2,000,000

 

FOR VALUE RECEIVED ,   Icagen, Inc., a Delaware corporation (the “ Parent ”), hereby promises to pay to the order of GPB Debt Holdings II, LLC or its registered assigns (“ Holder ”) the amount set forth above as the Original Principal Amount (as reduced pursuant to the terms hereof pursuant to redemption, conversion or otherwise, the “ Principal ”) when due, whether upon the Maturity Date (as defined in Section 1 ), acceleration, conversion, redemption or otherwise (in each case in accordance with the terms hereof), and to pay interest (“ Interest ) on any outstanding Principal at the rate of thirteen (13%) percent per annum, as may be adjusted from time to time in accordance with Section 2 (the “ Interest Rate ”) from the date set out above as the Issuance Date (the “ Issuance Date ”) until the same becomes due and payable, whether upon an Interest Date (as defined below), the Maturity Date, acceleration, conversion, redemption or otherwise (in each case in accordance with the terms hereof). This Senior Secured Convertible Note (including all Senior Secured Convertible Notes issued in exchange, transfer or replacement hereof, this “ Note ”) was issued pursuant to the Securities Purchase Agreement, dated as of May 15, 2017 (the “ Subscription Date ”), by and among the Parent, Icagen-T, Inc. a Delaware corporation all of whose issued and outstanding capital stock is owned by the Parent (“ ICA-T ”) and the Holder (as amended from time to time, the “ Securities Purchase Agreement ”). Certain capitalized terms used herein are defined in Section 32 . Capitalized terms used but not defined herein shall have the meanings set forth in the Securities Purchase Agreement unless otherwise indicated herein as being defined by another Transaction Document.

 

 
 

 

This Note was issued with a four (4%) percent original issue discount (“ OID ”).

 

1.            PAYMENTS OF PRINCIPAL; PREPAYMENT . On the Maturity Date, the Parent shall pay to the Holder an amount in cash representing all then outstanding Principal, accrued and unpaid Interest, accrued and unpaid Late Charges (as defined in Section 25(c) ), on such Principal and Interest and all other amounts due hereunder. “ Maturity Date ” shall be May 15, 2020; provided , however , the Maturity Date may be extended at the sole option of the Holder in an express writing to the Parent (i) in the event that, and for so long as, an Event of Default (as defined below), shall have occurred and be continuing or any event shall have occurred and be continuing that with the passage of time or the giving of notice (or both) and the failure to cure would result in an Event of Default or (ii) through the date that is twenty (20) Business Days after the consummation of a Fundamental Transaction in the event that a Fundamental Transaction is publicly announced or a Fundamental Transaction Notice is delivered prior to the Maturity Date. Other than as expressly permitted by this Note, the Parent, may not prepay any portion of the outstanding Principal, accrued and unpaid Interest or accrued and unpaid Late Charges on Principal and Interest, if any. Notwithstanding anything herein to the contrary, with respect to any conversion or redemption hereunder, as applicable, the Parent shall convert or redeem, as applicable, First , all accrued and unpaid Interest on any Principal and Interest hereunder, Second , all accrued but unpaid Late Charges on any Principal and Interest hereunder, Third , all Principal outstanding hereunder, and Fourth , all other amounts outstanding hereunder.

 

2. INTEREST; DEFAULT INTEREST RATE .

 

(a)         Interest on this Note shall commence accruing on the Issuance Date at the Interest Rate computed on the basis of a 360-day year and twelve 30-day months, shall be payable in arrears on each Interest Date and shall be payable in accordance with the terms of this Note. Interest shall be payable on each Interest Date, to the record holder of this Note on the applicable Interest Date in cash.

 

(b)         Prior to the payment of Interest on an Interest Date, Interest on this Note shall accrue at the Interest Rate and be payable by way of inclusion of the Interest in the Conversion Amount (as defined below), on each Conversion Date (as defined below) in accordance with Section 3(b)(i) or upon any redemption in accordance with Section 12 or any required payment upon any Bankruptcy Event of Default (as defined below).

 

(c)         From and after the occurrence and during the continuation of any Event of Default, the Interest Rate shall automatically be increased to eighteen (18%) per annum. In the event that such Event of Default is subsequently cured, and no other Event of Default then exists, the adjustment referred to in the preceding sentence shall cease to be effective as of the calendar day immediately following the date of such cure; provided that the Interest as calculated and unpaid at such increased rate during the continuance of such Event of Default shall continue to apply to the extent relating to the days after the occurrence of such Event of Default through and including the date of such cure of such Event of Default.

 

  2  
 

 

3.            CONVERSION OF NOTE . At any time after the Issuance Date, this Note shall be convertible into validly issued, fully paid and non-assessable shares of Common Stock (as defined in Section 32 of this Note), on the terms and conditions set forth in this Section 3 .

 

(a)          Conversion Right . Subject to the provisions of Section 3(d) , at any time or times on or after the Issuance Date, the Holder shall be entitled to convert all or any portion of the outstanding and unpaid Conversion Amount into validly issued, fully paid and non-assessable shares of Common Stock in accordance with Section 3(c) , at the Conversion Rate. Parent shall not issue any fraction of a share of Common Stock upon any conversion. If the issuance would result in the issuance of a fraction of a share of Common Stock, Parent shall round such fraction of a share of Common Stock up to the nearest whole share. The Holder shall pay any and all transfer, stamp, issuance and similar taxes, costs and expenses (including, without limitation, fees and expenses of any transfer agent of the Parent (the “ Transfer Agent ”) and the Depository Trust Company (“ DTC ”)), that may be payable with respect to the issuance and delivery of Common Stock upon conversion of any Conversion Amount.

 

(b)          Conversion Rate . The number of shares of Common Stock issuable upon conversion of any Conversion Amount (as defined below) pursuant to Section 3(a) shall be determined by dividing (x) such Conversion Amount by (y) the Conversion Price (as defined below) (the “ Conversion Rate” ).

 

(i)          “ Conversion Amount ” means the sum of (A) the portion of the Principal to be converted, redeemed or otherwise with respect to which this determination is being made, (B) all accrued and unpaid Interest with respect to such portion of such Principal, (C) all accrued and unpaid Late Charges with respect to such portion of such Principal and such Interest, if any, and (D) all other amounts due hereunder.

 

(ii)         “ Conversion Price ” means $3.50, subject to adjustment as provided elsewhere in this Note.

 

(c) Mechanics of Conversion .

 

(i)           Optional Conversion . To convert any Conversion Amount into shares of Common Stock on any date (a “ Conversion Date ”), the Holder shall deliver (whether via facsimile, electronic mail or otherwise), for receipt on or prior to 11:59 p.m., New York time, on such date, a copy of an executed notice of conversion in the form attached hereto as Exhibit I (the “ Conversion Notice ”) to the Parent. If required by Section 3(c)(iii) , within three (3) Trading Days, following a conversion of this Note as aforesaid, the Holder shall surrender this Note to a nationally recognized overnight delivery service for delivery to the Parent (or an indemnification undertaking with respect to this Note in the case of its loss, theft or destruction as contemplated by Section 19(b)) . On or before the first (1st) Trading Day following the date of receipt of a Conversion Notice, the Parent shall transmit by facsimile or electronic mail an acknowledgment of confirmation and representation as to whether such shares of Common Stock may then be resold pursuant to Rule 144 or an effective and available registration statement, in the form attached hereto as Exhibit II , (which representation shall not include a factual analysis of whether any share caps have been exceeded) of receipt of such Conversion Notice to the Holder and the Transfer Agent which confirmation shall constitute an instruction to the Transfer Agent to process such Conversion Notice in accordance with the terms herein. On or before the third (3 rd ) Trading Day, following the date on which the Parent has received a Conversion Notice (or such earlier date as required pursuant to the 1934 Act or other applicable law, rule or regulation for the settlement of a trade initiated on the applicable Conversion Date of such shares of Common Stock issuable pursuant to such Conversion Notice) (the “ Share Delivery Deadline ”), the Parent shall (1) provided the Transfer Agent is participating in the DTC Fast Automated Securities Transfer Program, credit such aggregate number of shares of Common Stock to which the Holder shall be entitled pursuant to such conversion to the Holder’s or its designee’s balance account with DTC through its Deposit/Withdrawal at Custodian system, or (2) if the Transfer Agent is not participating in the DTC Fast Automated Securities Transfer Program, upon the request of the Holder, issue and deliver (via reputable overnight courier) to the address as specified in the Conversion Notice, a certificate, registered in the name of the Holder or its designee, for the number of shares of Common Stock to which the Holder shall be entitled pursuant to such conversion. If this Note is physically surrendered for conversion pursuant to Section 3(c)(iii) , and the outstanding Principal of this Note is greater than the Principal portion of the Conversion Amount being converted, then the Parent shall as soon as practicable and in no event later than three (3) Business Days after receipt of this Note and at its own expense, issue and deliver to the Holder (or its designee) a new Note (in accordance with Section 19(d) ) representing the outstanding Principal not converted. The Person or Persons entitled to receive the shares of Common Stock issuable upon a conversion of this Note shall be treated for all purposes as the record holder or holders of such shares of Common Stock on the Conversion Date. Notwithstanding anything to the contrary contained in this Note, the Securities Purchase Agreement and/or any other Transaction Document, after the effective date of any Registration Statement (as defined in the Securities Purchase Agreement), the Parent shall cause the Transfer Agent to deliver unlegended shares of Common Stock to the Holder (or its designee) in connection with any sale of Registrable Securities (as defined in the Securities Purchase Agreement) with respect to which the Holder has entered into a contract for sale, and delivered a copy of the prospectus included as part of the particular Registration Statement to the extent applicable, and for which the Holder has not yet settled.

 

  3  
 

 

(ii)           Parent’s Failure to Timely Convert . If the Parent fails on or prior to a Share Delivery Deadline to issue and deliver a certificate or credit the Holder’s or its designee’s account with DTC (as the case may be pursuant to this Section 3(c)(ii) and/or pursuant to the Parent’s obligation pursuant to clause (II) below for the number of shares of Common Stock to which the Holder is entitled, and if on or after such Share Delivery Deadline the Holder purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by the Holder of all or any portion of the number of shares of Common Stock issuable upon such conversion that the Holder anticipated receiving from the Parent (a “ Buy-In ”), then, in addition to all other remedies available to the Holder, the Parent shall, within three (3) Trading Days after receipt of the Holder’s request and in the Holder’s sole discretion, either, at the Holder’s option (I) pay cash to the Holder in an amount equal to the Holder’s total purchase price (including brokerage commissions and other out-of-pocket expenses, if any) for the shares of Common Stock so purchased (including, without limitation, by any other Person in respect, or on behalf, of the Holder) (the “ Buy-In Price ”), at which point the Parent’s obligation to so issue and deliver such certificate or credit the balance account of the Holder or the Holder’s designee, as applicable, with DTC for the number of shares of Common Stock to which the Holder is entitled upon the Holder’s conversion of the applicable Conversion Amount shall terminate, or (II) promptly (but in no event later than two (2) Trading Days following the request by the Holder) honor its obligation to so issue and deliver to the Holder a certificate or certificates representing such shares of Common Stock or credit the balance account of such Holder or such Holder’s designee, as applicable, with DTC for the number of shares of Common Stock to which the Holder anticipated receiving from the Parent and pay cash to the Holder in an amount equal to the excess (if any) of the Buy-In Price over the product of (x) such number of shares of Common Stock multiplied by (y) the lowest Closing Sale Price or Closing Bid Price (as the case may be) of the Common Stock on any Trading Day during the period commencing on the date of the applicable Conversion Notice and ending on the date of such issuance and payout under this clause II (or if the Parent is then not a Trading Issuer, the Conversion Price) (the “ Buy-In Payment Amount ”). Nothing herein or elsewhere shall limit the Holder’s right to pursue any other remedies available to it hereunder, at law or in equity, including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Parent’s failure to timely deliver certificates representing shares of Common Stock (or to timely electronically deliver such shares of Common Stock) upon the conversion of this Note as required pursuant to the terms hereof.

 

(iii)           Registration; Book-Entry . The Parent shall maintain a register (the “ Register ”) for the recordation of the name and address of the Holder and the principal amount of the Notes (and stated interest thereon) held by the Holder (the “ Registered Notes ”). The Parent and the Holder of the Note shall treat each Person whose name is recorded in the Register as the owner of a Note for all purposes (including, without limitation, the right to receive payments of Principal, Interest and Late Charges). A Registered Note may be assigned, transferred or sold in whole or in part by registration of such assignment or sale on the Register but only to a Buyer Affiliate (as defined in the Securities Purchase Agreement) and/or any other Person in accordance with Section 18 . Upon its receipt of a written request to assign, transfer or sell all or part of any Registered Note by the Holder, the Parent shall record the information contained therein in the Register and issue one or more new Registered Notes in the same aggregate Principal amount as the Principal amount of the surrendered Registered Note to the designated assignee or transferee pursuant to Section 19 , provided that if the Parent does not so record an assignment, transfer or sale (as the case may be) of all or part of any Registered Note within three (3) Business Days of such a request, then the Register shall be automatically deemed updated to reflect such assignment, transfer or sale (as the case may be). Notwithstanding anything to the contrary set forth in this Note or elsewhere, following conversion of any portion of this Note in accordance with the terms hereof, the Holder shall not be required to physically surrender this Note to the Parent unless (A) the full Conversion Amount represented by this Note is being converted (in which event this Note shall be delivered to the Parent following conversion thereof as contemplated by Section 3(c)(i) ) or (B) the Holder has provided the Parent with prior written notice (which notice may be included in a Conversion Notice) requesting reissuance of this Note upon physical surrender of this Note. The Holder and the Parent shall maintain records showing the Principal, Interest and Late Charges converted and/or paid (as the case may be) and the dates of such conversions and/or payments (as the case may be) or shall use such other method, reasonably satisfactory to the Holder and the Parent, so as not to require physical surrender of this Note upon conversion. If the Parent does not update the Register to record such Principal, Interest and Late Charges converted and/or paid (as the case may be) and the dates of such conversions and/or payments (as the case may be) within three (3) Business Days of such occurrence, then the Register shall be automatically deemed updated to reflect such occurrence.

 

  4  
 

 

(iv)          Disputes . In the event of a dispute as to the number of shares of Common Stock issuable to the Holder in connection with a conversion of this Note, the Parent shall issue to the Holder the number of shares of Common Stock not in dispute and resolve such dispute in accordance with Section 24 .

 

(d)          Limitations on Conversions . The Parent shall not effect the conversion of any portion of this Note, and the Holder shall not have the right to convert any portion of this Note pursuant to the terms and conditions of this Note and any such conversion shall be null and void and treated as if never made, to the extent that after giving effect to such conversion, the Holder together with the other Attribution Parties collectively would beneficially own in excess of 4.99% (the “ Maximum Percentage ”) of the shares of Common Stock outstanding immediately after giving effect to such conversion such determination to be based solely upon the Reported Outstanding Share Number (as defined below) and the number of shares disclosed to the Parent by Holder as being beneficially owned by the Holder and the other Attribution Parties. For purposes of the foregoing sentence, the aggregate number of shares of Common Stock beneficially owned by the Holder and the other Attribution Parties shall include the number of shares of Common Stock held by the Holder and all other Attribution Parties plus the number of shares of Common Stock issuable upon conversion of this Note with respect to which the determination of such sentence is being made, but shall exclude shares of Common Stock which would be issuable upon (A) conversion of the remaining, non-converted portion of this Note beneficially owned by the Holder or any of the other Attribution Parties and (B) exercise or conversion of the unexercised or non-converted portion of any other securities of the Parent (including, without limitation, any convertible notes or convertible preferred stock or warrants, including, without limitation, the ICA-T Note and the Parent Warrant) beneficially owned by the Holder or any other Attribution Party subject to a limitation on conversion or exercise analogous to the limitation contained in this Section 3(d) . For purposes of this Section 3(d) , beneficial ownership shall be calculated in accordance with Section 13(d) of the 1934 Act. For purposes of determining the number of outstanding shares of Common Stock the Holder may acquire upon the conversion of this Note without exceeding the Maximum Percentage, the Holder may rely on the number of outstanding shares of Common Stock as reflected in (x) the Parent’s most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q, Current Report on Form 8-K or other public filing with the SEC, as the case may be, (y) a more recent public announcement by the Parent or (z) any other written notice by the Parent or the Transfer Agent, if any, setting forth the number of shares of Common Stock outstanding (the “ Reported Outstanding Share Number ”). If the Parent receives a Conversion Notice from the Holder at a time when the actual number of outstanding shares of Common Stock is less than the Reported Outstanding Share Number, the Parent shall notify the Holder in writing of the number of shares of Common Stock then outstanding and, to the extent that such Conversion Notice would otherwise cause the Holder’s beneficial ownership, as determined pursuant to this Section 3(d) , to exceed the Maximum Percentage, the Holder must (i) notify the Parent of a reduced number of shares of Common Stock to be purchased pursuant to such Conversion Notice (the number of shares by which such purchase is reduced, the “ Reduction Shares ”) and (ii) as soon as reasonably practicable, the Parent shall return to the Holder any conversion price paid by the Holder for the Reduction Shares. For any reason at any time, upon the written or oral request of the Holder, the Parent shall within one (1) Business Day confirm orally and in writing or by electronic mail to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Parent, including this Note, by the Holder and any other Attribution Party since the date as of which the Reported Outstanding Share Number was reported. In the event that the issuance of shares of Common Stock to the Holder upon conversion of this Note results in the Holder and the other Attribution Parties being deemed to beneficially own, in the aggregate, more than the Maximum Percentage of the number of outstanding shares of Common Stock (as determined under Section 13(d) of the 1934 Act), the number of shares so issued by which the Holder’s and the other Attribution Parties’ aggregate beneficial ownership exceeds the Maximum Percentage (the “ Excess Shares ”) shall be deemed null and void and shall be cancelled ab initio , and the Holder shall not have the power to vote or to transfer the Excess Shares. Upon delivery of a written notice to the Parent, the Holder may from time to time increase (with such increase not effective until the sixty-first (61 st  ) day after delivery of such notice) or decrease the Maximum Percentage to any other percentage not in excess of 9.99% as specified in such notice; provided that any such increase in the Maximum Percentage will not be effective until the sixty-first (61 st  ) day after such notice is delivered to the Parent. For purposes of clarity, the shares of Common Stock issuable pursuant to the terms of this Note in excess of the Maximum Percentage shall not be deemed to be beneficially owned by the Holder for any purpose including for purposes of Section 13(d) or Rule 16a-1(a)(1) of the 1934 Act. No prior inability to convert this Note pursuant to this paragraph shall have any effect on the applicability of the provisions of this paragraph with respect to any subsequent determination of convertibility. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 3(d) to the extent necessary to correct this paragraph (or any portion of this paragraph) which may be defective or inconsistent with the intended beneficial ownership limitation contained in this Section 3(d) or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitation contained in this paragraph may not be waived and shall apply to a successor holder of this Note.

 

  5  
 

 

4. EVENTS OF DEFAULT; RIGHTS UPON EVENT OF DEFAULT .

 

(a)           Event of Default . Each of the following events shall constitute an “ Event of Default ” and each of the events in clauses (iv), (v) and (vi) shall constitute a “ Bankruptcy Event of Default ”:

 

(i)          the Parent’s, ICA-T’s and/or any Subsidiary’s failure to pay to the Holder any amount of Principal, Interest, Late Charges or other amounts when and as due under this Note (including, without limitation, the Parent’s, ICA-T’s and/or any Subsidiary’s failure to pay any redemption payments or amounts hereunder), any other Transaction Document to which the Parent, ICA-T and/or any Subsidiary is a party and/or any other agreement, document, certificate or other instrument delivered in connection with the transactions contemplated hereby and thereby, except, in the case of a failure to pay Interest and Late Charges when and as due, in which case only if such failure remains uncured for a period of at least five (5) calendar days;

 

(ii)          the Parent fails at any time to (A) remove any restrictive legend on any certificate or any shares of Common Stock issued and/or issuable to the Holder upon conversion or exercise and/or otherwise (as the case may be) of this Note and/or any shares of Common Stock issuable hereunder as and when required by such securities, this Note and/or the Securities Purchase Agreement, unless otherwise then prohibited by (I) applicable federal securities laws, and/or (II) any lock-up or similar written agreement to which the Holder and any underwriter of a Qualifying PO is a party to, and any such failure remains uncured for at least three (3) consecutive days, and (B) issue and deliver to the Holder such unlegended certificates including, but not limited to, for any shares of Common Stock issuable upon conversion and/or otherwise of this Note;

 

  6  
 

 

(iii)         the occurrence of any default under, redemption of or acceleration prior to maturity of at least $250,000 of Indebtedness of the Parent, ICA-T and/or any Subsidiary (whether together and/or individually);

 

(iv)        bankruptcy, insolvency, reorganization or liquidation proceedings or other proceedings for the relief of debtors shall be instituted by or against the Parent, ICA-T and/or any Subsidiary and, if instituted against the Parent, ICA-T and/or any Subsidiary by a third party, shall not be dismissed within forty-five (45) days of their initiation;

 

(v)         the commencement by the Parent, ICA-T and/or any Subsidiary of a voluntary case or proceeding under any applicable federal, state or foreign bankruptcy, insolvency, reorganization or other similar law or of any other case or proceeding to be adjudicated a bankrupt or insolvent, or the consent by it to the entry of a decree, order, judgment or other similar document in respect of the Parent, ICA-T and/or any Subsidiary in an involuntary case or proceeding under any applicable federal, state or foreign bankruptcy, insolvency, reorganization or other similar law or to the commencement of any bankruptcy or insolvency case or proceeding against it, or the filing by it of a petition or answer or consent seeking reorganization or relief under any applicable federal, state or foreign law, or the consent by it to the filing of such petition or to the appointment of or taking possession by a custodian, receiver, liquidator, assignee, trustee, sequestrator or other similar official of the Parent, ICA-T and/or any Subsidiary or of any substantial part of its property, or the making by it of an assignment for the benefit of creditors, or the execution of a composition of debts, or the occurrence of any other similar federal, state or foreign proceeding, or the admission by it in writing of its inability to pay its debts generally as they become due, the taking of corporate action by the Parent, ICA-T and/or any Subsidiary in furtherance of any such action or the taking of any action by any Person to commence a Uniform Commercial Code foreclosure sale or any other similar action under federal, state or foreign law;

 

(vi)         the entry by a court of (i) a decree, order, judgment or other similar document in respect of the Parent, ICA-T and/or any Subsidiary of a voluntary or involuntary case or proceeding under any applicable federal, state or foreign bankruptcy, insolvency, reorganization or other similar law or (ii) a decree, order, judgment or other similar document adjudging the Parent, ICA-T and/or any Subsidiary as bankrupt or insolvent, or approving as properly filed a petition seeking liquidation, reorganization, arrangement, adjustment or composition of or in respect of the Parent, ICA-T and/or any Subsidiary under any applicable federal, state or foreign law or (iii) a decree, order, judgment or other similar document appointing a custodian, receiver, liquidator, assignee, trustee, sequestrator or other similar official of the Parent, ICA-T and/or any Subsidiary or of any substantial part of its property, or ordering the winding up or liquidation of its affairs, and the continuance of any such decree, order, judgment or other similar document or any such other decree, order, judgment or other similar document unstayed and in effect for a period of sixty (60) consecutive days;

 

  7  
 

 

(vii)        a final judgment or judgments for the payment of money aggregating in excess of $300,000 are rendered against the Parent, ICA-T and/or any Subsidiary and which judgments are not, within forty-five (45) days after the entry thereof, bonded, discharged, settled or stayed pending appeal, or are not discharged within forty-five (45) days after the expiration of such stay; provided , however , any judgment which is covered by insurance or an indemnity from a credit worthy party shall not be included in calculating the $300,000 amount set forth above so long as the Parent, ICA-T and/or any Subsidiary provides the Holder a written statement from such insurer or indemnity provider (which written statement shall be reasonably satisfactory to the Holder) to the effect that such judgment is covered by insurance or an indemnity and the Parent, ICA-T and/or any Subsidiary will receive the proceeds of such insurance or indemnity within forty-five (45) days of the issuance of such judgment;

 

(viii)       the Parent, ICA-T and/or any Subsidiary either (i) fails to pay, when due, or within any applicable grace period, any payment with respect to any Indebtedness in excess of $250,000 due to any third party(ies) (other than, with respect to unsecured Indebtedness only, payments contested by the Parent, ICA-T and/or any Subsidiary in good faith by proper proceedings and with respect to which adequate reserves have been set aside for the payment thereof in accordance with GAAP) or is otherwise in breach or violation of any agreement for monies owed or owing in an amount in excess of $250,000, which breach or violation permits the other party thereto to declare a default or otherwise accelerate amounts due thereunder, or (ii) suffers to exist any other circumstance or event that would, with or without the passage of time or the giving of notice, result in a default or event of default under any agreement binding the Parent, ICA-T and/or any Subsidiary which default or event of default would or is likely to have a material adverse effect on the business, assets, operations (including results thereof), liabilities, properties, condition (including financial condition) of the Parent, ICA-T and/or any Subsidiary;

 

(ix)         other than as specifically set forth in another clause of this Section 4(a) , the Parent, ICA-T and/or any Subsidiary breaches any material representation, warranty, covenant or other term or condition of any Transaction Document (as defined in the Securities Purchase Agreement), except, in the case of a breach of a covenant or other term or condition that is curable, only if such breach remains uncured for a period of thirty (30) days;

 

(x)         any breach or failure in any material respect by the Parent, ICA-T and/or any Subsidiary of any provision of Section 14 of this Note;

 

(xi)        any Material Adverse Effect;

 

  8  
 

 

(xii)        any material provision of any Transaction Document to which the Parent, ICA-T and/or any Subsidiary is a party (including, without limitation, the Security Documents and the Guaranties) shall at any time for any reason (other than pursuant to the express terms thereof) cease to be valid and binding on or enforceable against the parties thereto, or the validity or enforceability thereof shall be contested by any party thereto, or a proceeding shall be commenced by the Parent, ICA-T and/or any Subsidiary or any governmental authority having jurisdiction over any of them, seeking to establish the invalidity or unenforceability thereof, or the Parent, ICA-T and/or any Subsidiary shall deny in writing that it has any Indebtedness, liability or obligation purported to be created under any Transaction Document (including, without limitation, the Security Documents and the Guaranties);

 

(xiii)       any Security Document to which the Parent, ICA-T and/or any Subsidiary is a party and/or any other security document to which the Parent, ICA-T and/or any Subsidiary is a party, shall at any time for any reason fail or cease to create a separate valid and perfected and, except to the extent permitted by the terms thereof, first priority Lien (as defined in the Securities Purchase Agreement) on any Collateral (as defined in the Security Agreement) in favor of the Collateral Agent (as defined in the Securities Purchase Agreement) or any material provision of any Security Document to which the Parent, ICA-T and/or any Subsidiary is a party, shall at any time for any reason cease to be valid and binding on or enforceable against, the Parent, ICA-T and/or any of the Subsidiaries or the validity or enforceability thereof shall be contested by any party thereto, or a proceeding shall be commenced by the Parent, ICA-T and/or any of the Subsidiaries or any governmental authority having jurisdiction over the Parent, ICA-T and/or any of the Subsidiaries, seeking to establish the invalidity or unenforceability thereof;

 

(xiv)       any material damage to, or loss, theft or destruction of, any Collateral, whether or not insured, or any strike, lockout, labor dispute, embargo, condemnation, act of God or public enemy, or other casualty which causes, for more than fifteen (15) consecutive calendar days, the cessation or substantial curtailment of revenue producing activities at any facility of the Parent, ICA-T and/or any Subsidiary if any such event or circumstance would have a Material Adverse Effect;

 

(xv)        if at any time following the first date the Parent becomes a Trading Issuer the suspension from trading, or the failure of the Common Stock to be trading or listed (as applicable) on an Eligible Market for a period of five (5) consecutive Trading Days or for more than an aggregate of ten (10) Trading Days in any 365-day period;

 

(xvi)       the Parent’s (A) failure to cure a Conversion Failure in this Note and/or the ICA-T Note or Exercise Failure in the Parent Warrant by delivery of the required number of shares of Common Stock upon conversion of this Note, the ICA-T Note and/or exercise of the Parent Warrant within three (3) Trading Days after the applicable Conversion Date or Exercise Date or (B) notice, written or oral, to any holder of this Note, the ICA-T Note and/or the Parent Warrant, including, without limitation, by way of public announcement or through any of its agents, at any time, of its intention not to comply, as required, with a request for conversion of this Note, the ICA-T Note and/or exercise of the Parent Warrant into shares of Common Stock that is requested in accordance with the provisions of this Note, other than pursuant to Section 3(d) ,;

 

  9  
 

 

(xvii)       except to the extent the Parent is in compliance with Section 11(b) at any time following the tenth (10 th ) consecutive day that the Required Reserve Amount (as defined in Section 11(a) below) is less than the number of shares of Parent Common Stock that the Holder would be entitled to receive upon a conversion by the Holder of the full Conversion Amount of this Note (without regard to any limitations on conversion set forth in this Note or otherwise);

 

(xviii)      any event of default and/or any event that with the giving of notice or the passage of time (or both) would constitute an event of default and/or any “default” (as used in the S/I Deed of Trust) occurs and/or with the giving of notice or the passage of time (or both) could occur under any of the Sanofi Documents (as defined in the Securities Purchase Agreement) including, but not limited to, the S/I MSA, the S/I APA, the S/I Warranty and Reverter Deed and/or the S/I Deed of Trust (each as defined in the Securities Purchase Agreement) and/or any other event (including, but not limited to, any sale, reversion and/or foreclosure and/or giving notice of the same of and/or relating to the Property, Property Income (as both terms are defined in the S/I Deed of Trust) and/or any other items set forth in the first paragraph of the S/I Deed of Trust used as collateral under the S/I Deed of Trust, and/or any other Lien on any personal property (including Intellectual Property) by or for the benefit of Sanofi that has and/or could reasonably be expected to have a Material Adverse Effect (as defined in the Securities Purchase Agreement), or a “default” occurs (as such term is used in any provision of the S/I Deed of Trust) and/or any of the same occurs with respect to any other assets of ICA-T including personal property and Intellectual Property of ICA-T;

 

(xix)       A false, misleading and/or inaccurate certification (including a false or inaccurate deemed certification) by the ICA-T, the Parent and/or any Subsidiary as to, among other items, whether any Event of Default has occurred in this Note and/or in the ICA-T Note;

 

(xx)        the Parent's failure for any reason immediately following the date a Registration Statement covering securities of the Parent sold in the Qualifying PO is declared effective by the SEC or at any other time following the first date the Parent becomes a Trading Issuer to satisfy the current public information requirement under Rule 144(c) of the 1933 Act;

 

  10  
 

 

(xxi)       the failure of any Registration Statement (as defined in the Securities Purchase Agreement) with respect to Registrable Securities (as defined in the Securities Purchase Agreement) to be declared effective by the SEC on or prior to the applicable Effectiveness Deadline (as defined in the Securities Purchase Agreement) unless at such time counsel to the Parent provides a legal opinion to the Holder and the Transfer Agent that (i) all Registrable Securities can be sold under Rule 144 without restriction, and (ii) at each time the Holder seeks to sell any such Registrable Securities such counsel provides a legal opinion to the Holder and the Transfer Agent removing all restrictive and other legends on such Registrable Securities no later than the Share Delivery Date;

 

(xxii)       while any applicable Registration Statement is required to be maintained effective pursuant to the terms of the Securities Purchase Agreement, the effectiveness of the applicable Registration Statement lapses for any reason (including, without limitation, the issuance of a stop order) or such Registration Statement (or the prospectus contained therein) is unavailable to any holder of Registrable Securities (as defined in the Securities Purchase Agreement) for sale of all of such holder’s Registrable Securities registered under such Registration Statement in accordance with the terms of the Securities Purchase Agreement, and such lapse or unavailability continues for a period of ten (10) consecutive business days or for more than an aggregate of ten (10) days in any 365-day period;

 

(xxiii)      any Controlled Account Agreement (as defined in the Security Agreement) shall for any reason fail or cease to create a separate valid and perfected and, except to the extent permitted by the terms hereof or thereof, first priority Lien on the Collateral (as defined below) in favor of the Holder and/or the Collateral Agent or any material provision of any Controlled Account Agreement shall at any time for any reason cease to be valid and binding on or enforceable against the Parent, ICA-T and/or any Subsidiary or the validity or enforceability thereof shall be contested by any party thereto, or a proceeding shall be commenced by the Parent, ICA-T and/or any Subsidiary or any Governmental Entity (as defined in the Securities Purchase Agreement) having jurisdiction over the Parent, ICA-T and/or any Subsidiary, seeking to establish the invalidity or unenforceability thereof;

 

(xxiv)      any Event of Default (as defined in the ICA-T Note) occurs under the ICA-T Note and/or any other Transaction Document.

 

  11  
 

 

(b)          Notice of an Event of Default; Redemption Right . Upon the occurrence of an Event of Default, the Parent shall within one (1) Business Day of such Event of Default deliver a mutual written notice thereof via facsimile or electronic mail and overnight courier (with next day delivery specified) (an “ Event of Default Notice ”) to the Holder. At any time after the earlier of the Holder’s receipt of an Event of Default Notice and the Holder becoming aware of an Event of Default (such earlier date, the “ Event of Default Right Commencement Date ”) and ending (such ending date, the “ Event of Default Right Expiration Date ”, and each such period, an “ Event of Default Redemption Right Period ”) on the tenth (10 th ) Trading Day after the later of (x) the date such Event of Default is cured and (y) the Holder’s receipt of an Event of Default Notice that includes (I) a reasonable description of the applicable Event of Default, (II) a certification as to whether, in the opinion of the Parent, such Event of Default is capable of being cured and, if applicable, a reasonable description of any existing plans of the Parent to cure such Event of Default and (III) a certification as to the date the Event of Default occurred and, if cured on or prior to the date of such Event of Default Notice, the applicable Event of Default Right Expiration Date, the Holder may require the Parent to redeem all or any portion of this Note by delivering written notice thereof (the “ Event of Default Redemption Notice ”) to the Parent, which Event of Default Redemption Notice shall indicate the portion of this Note the Holder is electing to redeem. Each portion of this Note subject to redemption by the Parent pursuant to this Section 4(b) shall be redeemed by the Parent at a price in cash equal to the product of (A) the Conversion Amount being redeemed multiplied by (B) (i) 116% if the applicable Event of Default Redemption Price is paid in full to the Holder on a date prior to May 15, 2018, (ii) 117% if the Event of Default Redemption Price is paid in full to the Holder after May 15, 2018 but prior to May 15, 2019 and (iii) 118% if the Event of Default Redemption Price is paid in full to the Holder after May 15, 2019 but on or prior to the Maturity Date (the “ Event of Default Redemption Price ”). Redemptions required by this Section 4(b) shall be made in accordance with the provisions of Section 12 . To the extent redemptions required by this Section 4(b) are deemed or determined by a court of competent jurisdiction to be prepayments of this Note by the Parent, such redemptions shall be deemed to be voluntary prepayments. Notwithstanding anything to the contrary in this Section 4 , but subject to Section 3(d) , until the Event of Default Redemption Price (together with any Late Charges thereon) is paid in full to the Holder as provided in this Note, the Conversion Amount submitted for redemption under this Section 4(b) (together with Late Charges thereon) may be converted in whole or in part by the Holder into shares of Common Stock pursuant to Section 3 of this Note. In the event of the Parent’s redemption of any portion of this Note under this Section 4(b) , the Holder’s damages would be uncertain and difficult to estimate because of the parties’ inability to predict future interest rates and the uncertainty of the availability of a suitable substitute investment opportunity for the Holder. Accordingly, any redemption premium due under this Section 4(b) is intended by the parties to be, and shall be deemed, a reasonable estimate of the Holder’s actual loss of its investment opportunity and not as a penalty. Any redemption upon an Event of Default shall not constitute an election of remedies by the Holder, and all other rights and remedies of the Holder shall be preserved.

 

(c)          Mandatory Redemption upon Bankruptcy Event of Default . Notwithstanding anything to the contrary herein, and notwithstanding any conversion that is then required or in process, upon any Bankruptcy Event of Default, whether occurring prior to or following the Maturity Date, the Parent shall immediately pay to the Holder an amount in cash representing the Event of Default Redemption Price (together with Late Charges thereon) in addition to any and all other amounts due hereunder, without the requirement for any notice or demand or other action by the Holder or any other person or entity, provided that the Holder may, in its sole discretion, waive such right to receive payment upon a Bankruptcy Event of Default, in whole or in part, and any such waiver shall not affect any other rights of the Holder hereunder, including any other rights in respect of such Bankruptcy Event of Default, any right to conversion and any right to payment of the Event of Default Redemption Price or any other Redemption Price, as applicable.

 

  12  
 

 

  5. RIGHTS UPON FUNDAMENTAL TRANSACTION .

 

(a)          Assumption . Neither the Parent, ICA-T and/or any Subsidiary shall enter into or be party to a Fundamental Transaction unless (i) the Successor Entity assumes in writing all of the obligations of the Parent, ICA-T and/or any Subsidiary under this Note, the ICA-T Note and the Parent Warrant (excluding the Parent Warrant if the Parent Warrant is redeemed pursuant and in accordance with the terms and conditions of the Parent Warrant) and the other Transaction Documents in accordance with the provisions of this Section 5(a) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder prior to such Fundamental Transaction, including agreements to deliver to the Holder in exchange for this Note, the ICA-T Note and the Parent Warrant (excluding the Parent Warrant if the Parent Warrant is purchased pursuant to the terms of the Parent Warrant) securities of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Note, the ICA-T Note and the Parent Warrant (excluding the Parent Warrant if the Parent Warrant is purchased pursuant to the terms of the Parent Warrant) (which, for the avoidance of doubt, shall not include any terms or conditions less favorable to the Holder of this Note, the ICA-T Note and the Parent Warrant in any material respect than the terms and conditions set forth in this Note, the ICA-T Note and the Parent Warrant, respectively as of such date of determination), including, without limitation, having principal amounts, interest rates and late charges equal to the payment rights and amounts, principal amounts then outstanding, the interest rates and Late Charges of this Note, the ICA-T Note and the Parent Warrant (excluding the Parent Warrant if the Parent Warrant is purchased pursuant to the terms of the Parent Warrant) as well as having the conversion rights, exercise rights, redemption rights, rankings, Events of Default (as applicable) the same as in this Note, the ICA-T Note and the Parent Warrant (excluding the Parent Warrant if the Parent Warrant is purchased pursuant to the terms of the Parent Warrant) and satisfactory to the Holder and, (ii) the Successor Entity (including its Parent Entity), is a Trading Issuer whose common stock is registered under Section 12 of the 1934 Act and is quoted and/or listed for trading on a Qualifying Market. Upon the occurrence of any Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Note, the ICA-T Note and the Parent Warrant (excluding the Parent Warrant if the Parent Warrant is purchased pursuant to the terms of the Parent Warrant) and the other Transaction Documents referring to the “ICA-T” and the “Parent” shall refer instead to the Successor Entity), and may exercise every right and power of the Parent and ICA-T, as applicable and shall assume all of the obligations of the Parent and ICA-T under this Note, the ICA-T Note and the Parent Warrant and the other Transaction Documents, with the same effect as if the Successor Entity (including its Parent Entity), had been named ICA-T and the Parent in this Note and in the Parent Warrant (excluding the Parent Warrant if the Parent Warrant is purchased pursuant to the terms of the Parent Warrant) and ICA-T in the ICA-T Note; and ICA-T and the Parent (and the Subsidiaries if any Subsidiary is named a party thereto) in the other Transaction Documents. Upon consummation of a Fundamental Transaction, the Successor Entity shall deliver to the Holder confirmation that there shall be issued upon conversion of this Note and the ICA-T Note and exercise of the Parent Warrant (excluding the Parent Warrant if the Parent Warrant is purchased pursuant to the terms of the Parent Warrant) at any time after the consummation of such Fundamental Transaction, in lieu of shares of Common Stock (or other securities, cash, assets or other property (except such items still issuable under Section 6 and Section 16 , (and the equivalent provisions in the Parent Warrant and the ICA-T Note), which shall continue to be receivable thereafter) issuable upon the conversion of this Note and the ICA-T Note and exercise of the Parent Warrant (excluding the Parent Warrant if the Parent Warrant is purchased pursuant to the terms of the Parent Warrant) prior to such Fundamental Transaction, such shares of publicly traded common stock (or their equivalent) of the Successor Entity (including its Parent Entity) which the Holder would have been entitled to receive upon the happening of such Fundamental Transaction had this Note and the Parent Note been converted and the Parent Warrant exercised (excluding the Parent Warrant if the Parent Warrant is purchased pursuant to the terms of the Parent Warrant) immediately prior to such Fundamental Transaction (without regard to any limitations on the conversion of this Note and the ICA-T Note and exercise of the Parent Warrant (excluding the Parent Warrant if the Parent Warrant is purchased pursuant to the terms of the Parent Warrant)), as adjusted in accordance with the provisions of this Note and the ICA-T Note and exercise of the Parent Warrant (excluding the Parent Warrant if the Parent Warrant is purchased pursuant to the terms of the Parent Warrant). The provisions of this Section 5(a) shall apply similarly and equally to successive Fundamental Transactions and shall be applied without regard to any limitations on the conversion of this Note, the Parent Note and/or exercise of the Parent Warrant.

 

  13  
 

 

(b)          Notice of a Fundamental Transaction; Redemption Right . No sooner than twenty (20) Trading Days nor later than ten (10) Trading Days prior to the consummation of a Fundamental Transaction, but not prior to the public announcement of such Fundamental Transaction, the Parent shall deliver a mutually executed written notice thereof via facsimile or electronic mail and overnight courier to the Holder (a “ Fundamental Transaction Notice ”). At any time during the period beginning after the Holder’s receipt of a Fundamental Transaction Notice or the Holder becoming aware of a Fundamental Transaction if a Fundamental Transaction Notice is not delivered to the Holder in accordance with the immediately preceding sentence (as applicable) and ending on the later of twenty (20) Trading Days after (i) consummation of such Fundamental Transaction and (ii) the date of receipt of such Fundamental Transaction Notice, the Holder may require the Parent to redeem all or any portion of this Note by delivering written notice thereof (“ Fundamental Transaction Redemption Notice ”) to the Parent, which Fundamental Transaction Redemption Notice shall indicate the Conversion Amount the Holder is electing to redeem. The portion of this Note subject to redemption pursuant to this Section 5(b) shall be redeemed by the Parent in cash at a price equal to the product of (A) the Conversion Amount being redeemed, and (B) (1) 101% if the Fundamental Transaction Redemption Price (as defined below) is paid in full to the Holder on a date prior to May 15, 2018, (2) 102% if the Fundamental Transaction Redemption Price is paid in full to the Holder on or after May 15, 2018 but prior to May 15, 2019, and (3) 103% if the Fundamental Transaction Price is paid in full to the Holder on a date following May 15, 2019 on or prior to the Maturity Date (the “ Fundamental Transaction Redemption Price ”). Redemptions required by this Section 5(b) shall be made in accordance with the provisions of Section 12 and shall have priority to payments to stockholders in connection with such Fundamental Transaction. To the extent redemptions required by this Section 5(b) are deemed or determined by a court of competent jurisdiction to be prepayments of this Note by the Parent, such redemptions shall be deemed to be voluntary prepayments. Notwithstanding anything to the contrary in this Section 5(b) , but subject to Section 3(d) , until the Fundamental Transaction Redemption Price (together with any Late Charges thereon) is paid in full, the Fundamental Transaction Redemption Price (together with any Late Charges thereon) may be converted, in whole or in part, by the Holder into Common Stock pursuant to Section 3 . In the event of the Parent’s redemption of any portion of this Note under this Section 5(b) , the Holder’s damages would be uncertain and difficult to estimate because of the parties’ inability to predict future interest rates and the uncertainty of the availability of a suitable substitute investment opportunity for the Holder. Accordingly, any redemption premium due under this Section 5(b) is intended by the parties to be, and shall be deemed, a reasonable estimate of the Holder’s actual loss of its investment opportunity and not as a penalty.

 

  6. RIGHTS UPON ISSUANCE OF PURCHASE RIGHTS AND OTHER CORPORATE EVENTS.

 

(a)          Purchase Rights. In addition to any adjustments pursuant to Section 7 below, elsewhere in this Agreement and/or in any other Transaction Document, if at any time the Parent, ICA-T and/or any Subsidiary grants, issues or sells any Common Stock Equivalents, Options, Convertible Securities or rights to purchase stock, warrants, securities or other property pro rata to all or substantially all of the record holders of any class of Common Stock (the “ Purchase Rights ”), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete conversion of this Note (without taking into account any limitations or restrictions on the convertibility of this Note and assuming for such purpose that the Note was converted at the Conversion Price as of the applicable record date) immediately prior to the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights; provided  however , that to the extent that the Holder’s right to participate in any such Purchase Right would result in the Holder and the other Attribution Parties exceeding the Maximum Percentage, then the Holder shall not be entitled to participate in such Purchase Right to the extent of the Maximum Percentage (and shall not be entitled to beneficial ownership of such shares of Common Stock as a result of such Purchase Right (and beneficial ownership) to the extent of any such excess) and such Purchase Right to such extent shall be held in abeyance (and, if such Purchase Right has an expiration date, maturity date or other similar provision, such term shall be extended by such number of days held in abeyance, if applicable) for the benefit of the Holder until such time or times, if ever, as its right thereto would not result in the Holder and the other Attribution Parties exceeding the Maximum Percentage, at which time or times the Holder shall be granted such right (and any Purchase Right granted, issued or sold on such initial Purchase Right or on any subsequent Purchase Right held similarly in abeyance (and, if such Purchase Right has an expiration date, maturity date or other similar provision, such term shall be extended by such number of days held in abeyance, if applicable)) to the same extent as if there had been no such limitation).

 

  14  
 

 

(b)          Other Corporate Events . In addition to and not in substitution for any other rights in this Note and/or in any other Transaction Document, prior to the consummation of any Fundamental Transaction pursuant to which holders of shares of Common Stock are entitled to receive securities or other assets with respect to or in exchange for shares of Common Stock (a “ Corporate Event ”), the Parent shall make appropriate provision to ensure that the Holder will thereafter have the right to receive upon a conversion of this Note, at the Holder’s option (i) in addition to the shares of Common Stock receivable upon such conversion, such securities or other assets to which the Holder would have been entitled with respect to such shares of Common Stock had such shares of Common Stock been held by the Holder upon the consummation of such Corporate Event (without taking into account any limitations or restrictions on the convertibility of this Note) or (ii) in lieu of the shares of Common Stock otherwise receivable upon such conversion, such securities or other assets received by the holders of shares of Common Stock in connection with the consummation of such Corporate Event in such amounts as the Holder would have been entitled to receive had this Note initially been issued with conversion rights for the form of such consideration (as opposed to shares of Common Stock) at a conversion rate for such consideration commensurate with the Conversion Rate. Provision made pursuant to the preceding sentence shall be in a form and substance satisfactory to the Holder. The provisions of this Section 6 shall apply similarly and equally to successive Corporate Events and shall be applied without regard to any limitations on the conversion or redemption of this Note.

 

  7. RIGHTS UPON ISSUANCE OF OTHER SECURITIES PRIOR TO AND FOLLOWING A QUALIFIED IPO .

 

(a)          Adjustment of Conversion Price upon Subdivision or Combination of Common Stock . In addition to any other rights of the Holder under this Note and/or any other Transaction Document and without limiting any provisions of Sections 5, 6, 7 and 16 hereof, if the Parent at any time on or after the Subscription Date subdivides (by any stock split, stock dividend, stock combination, recapitalization or other similar transaction) one or more classes of its outstanding shares of Common Stock into a greater number of shares, the Conversion Price in effect immediately prior to such subdivision will be proportionately reduced. Without limiting any provisions of Sections 5, 6 and 16.1(f) , the Parent at any time on or after the Subscription Date combines (by any stock split, stock dividend, stock combination, recapitalization or other similar transaction) one or more classes of its outstanding shares of Common Stock into a smaller number of shares, the Conversion Price in effect immediately prior to such combination will be proportionately increased. Any adjustment pursuant to this Section 7(a) shall become effective immediately after the effective date of such subdivision or combination. If any event requiring an adjustment under this Section 7(a) occurs during the period that a Conversion Price is calculated hereunder, then the calculation of such Conversion Price shall be adjusted appropriately to reflect such event.

 

  15  
 

 

(b)         Issuance of Securities Below the Conversion Price Prior to the Closing Date of a Qualifying PO . In addition to and not in limitation of any other rights of the Holder under this Note including, but not limited to, Section 7 and/or any other Transaction Document, if, at any time while this Note is outstanding and whenever on or after the Subscription Date but prior to the closing date of a Qualifying PO (as defined below), the Parent, ICA-T and/or any Subsidiary in any manner sells or grants any option to purchase, issues or sells or grants any right to reprice, and/or otherwise sells, disposes of and/or issues any shares of Common Stock or Common Stock Equivalents (as defined below) (including upon conversion, exercise or otherwise) entitling any Person to acquire shares of Common Stock at a price per share of Common Stock that is lower than the then Conversion Price (such lower price, the “ New Issuance Price ” and each such issuance, a “ Dilutive Issuance ” and collectively, “ Dilutive Issuances ”), (if the holder of shares of Common Stock or Common Stock Equivalents so issued and/or any holder of Common Stock and/or Common Stock Equivalents as of the Subscription Date or issued subsequent thereto, shall at any time, whether by amendment, supplement, operation of purchase price adjustments, reset provisions, floating conversion, exercise or exchange prices or otherwise be entitled under the terms of any such instruments to receive shares of Common Stock at a price per share that is lower than the Conversion Price, such issuance shall be deemed to have occurred for less than the Conversion Price on such date of the Dilutive Issuance), then the then Conversion Price shall be reduced to equal the New Issuance Price. For purposes of clarification, if the Parent, ICA-T and/or any Subsidiary issues, sells and/or otherwise disposes of any shares of Common Stock at a price less than the then Conversion Price, the then Conversion Price shall immediately be reduced to the New Issuance Price on the date of such Dilutive Issuance. All adjustments provided for in this Section 7(b) shall be made whenever any such Common Stock or Common Stock Equivalents are issued. Notwithstanding anything to the contrary in the foregoing, if a Dilutive Issuance consists of the issuance and/or sale of both Common Stock and Common Stock Equivalents or two or more Common Stock Equivalents as units (each, a “ Share and/or a CSE Issuance ”), in determining the value of the component parts of the unit issued and/or sold in a Share and/or a CSE Issuance no value will be attributed to Common Stock Equivalents and the New Issuance Price as a result thereof will be the lowest of (i) the lowest purchase price per unit, (ii) the lowest conversion, exercise and/or exchange price to acquire one (1) share of Common Stock of any Common Stock Equivalent included in a unit if a unit also includes shares of Common Stock, and (iii) if no shares of Common Stock are included in a unit, the lowest exercise, conversion and/or exchange price to acquire one (1) share of Common Stock of the Common Stock Equivalents comprising a unit, such lowest price of (i)-(iii) shall be the “ Lowest Price ;” provided , however, a Dilutive Issuance and a resulting New Issuance Price relating to a Share and/or a CSE Issuance shall only occur if the Lowest Price relating to a Share and/or a CSE Issuance is lower than the then Conversion Price. Notwithstanding the foregoing, no adjustment will be made under this Section 7(b) in respect of an Exempt Issuance. The Parent shall notify the Holder in writing, no later than the first Trading Day following the issuance of any Common Stock or Common Stock Equivalents subject to this Section 7(b) , indicating therein the applicable Lowest Price, issuance price, reset price, exchange price, conversion price and other pricing terms (such notice, the “ Dilutive Issuance Notice ”). For purposes of clarification, whether or not the Parent provides a Dilutive Issuance Notice upon the occurrence of any Dilutive Issuance, the Holder is entitled to receive a number of shares of Common Stock based upon the New Issuance Price on or after the date of such Dilutive Issuance, regardless of whether the Holder accurately refers to the New Issuance Price in any Notice of Conversion. For purposes hereof, the term “ Common Stock Equivalents ” means any securities (as defined under the 1933 Act) including, but not limited to, any Options and/or Convertible Securities of the Parent, ICA-T and/or any Subsidiaries which would entitle the Holder thereof to acquire at any time shares of Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the Holder thereof to receive, shares of Common Stock. If the Parent, ICA-T and/or any Subsidiary enters into a Variable Rate Transaction (as defined in the Securities Purchase Agreement) despite the prohibition set forth in the Securities Purchase Agreement, the Parent shall be deemed to have issued shares of Common Stock or Common Stock Equivalents at the lowest possible price at which such securities may be converted, exchanged and/or exercised under the terms of such Variable Rate Transaction.

 

  16  
 

 

(c)          Issuance of Securities Below the Conversion Price Following the First Trading Day Following the Closing of a Qualifying PO . In addition to and not in limitation of any other rights of the Holder under this Note including, but not limited to, Section 7 and/or any other Transaction Document, if, at any time while this Note is outstanding and whenever on or after the first Trading Day following the closing date of a Qualifying PO, the Parent, ICA-T and/or any Subsidiary in any manner sells or grants any option to purchase, issues or sells or grants any right to reprice, and/or otherwise sells, disposes of and/or issues any shares of Common Stock or Common Stock Equivalents entitling any Person to acquire shares of Common Stock at a price per share of Common Stock that is lower than the then Conversion Price (such lower price, the “ Post-QPO New Issuance Price ” and each such issuance, a “ Post-QPO Dilutive Issuance ” and collectively, “ Post-QPO Dilutive Issuances ”), then immediately after such Post-QPO Dilutive Issuance, the then Conversion Price shall be automatically reduced to an amount determined by multiplying the then Conversion Price by a fraction of which (i) the numerator shall be the sum of (A) the number of shares of Common Stock issued and outstanding immediately prior to such Post-QPO Dilutive Issuance (assuming all then issued and outstanding Common Stock Equivalents are exercised, exchanged and/or converted (as the case may be) in accordance with the terms, without giving effect to any limitations on conversions, exchanges and/or exercise in any such Common Stock Equivalents), plus (B) the number of shares of Common Stock which the aggregate consideration received by the Parent for such additional shares of Common Stock would purchase at the then Conversion Price (without giving effect to any limitations on conversions, exchanges and/or exercises in any outstanding Common Stock Equivalents), and (ii) the denominator of which shall be the number of shares of Common Stock issued and outstanding immediately after and including such Post-QPO Dilutive Issuance (assuming all then issued and outstanding Common Stock Equivalents were exercised, executed and/or converted (as the case may be) in accordance with the terms, without giving effect to any limitations on conversions, exchanges and/or exercise in any such Common Stock Equivalents, including this Note, the Parent Note and the Parent Warrant). For purposes of clarification, if the Parent, ICA-T and/or any Subsidiary issues, sells and/or otherwise disposes of any shares of Common Stock at a price less than the then Conversion Price, the then Conversion Price shall immediately be reduced to the Post-QPO New Issuance Price on the date of such Post-QPO Dilutive Issuance as determined above. All adjustments provided for in this Section 7(c) shall be made whenever any such Common Stock or Common Stock Equivalents are issued. Notwithstanding the foregoing, if a Dilutive Issuance results from a Share and/or a CSE Issuance no value will be attributed to Common Stock Equivalents and the New Issuance Price as a result thereof will be the Lowest Price; provided , however , a Dilutive Issuance and a resulting New Issuance Price relating to a Share and/or a CSE Issuance shall only occur if the Lowest Price relating to a Share and/or a CSE Issuance is lower than the then Conversion Price. Notwithstanding the foregoing, no adjustment will be made under this Section 7(b) in respect of an Exempt Issuance. The Parent shall provide to the Holder a Dilutive Issuance Notice no later than the first Trading Day following the issuance of any Common Stock or Common Stock Equivalents subject to this Section 7(c) . For purposes of clarification, whether or not the Parent provides a Dilutive Issuance Notice upon the occurrence of any Post-QPO Dilutive Issuance, the Holder is entitled to receive a number of shares of Common Stock based upon the Post-QPO New Issuance Price on or after the date of such Post-QPO Dilutive Issuance, regardless of whether the Holder accurately refers to the Post-QPO New Issuance Price in any Notice of Conversion. If the Parent, ICA-T and/or any Subsidiary enters into a Variable Rate Transaction despite the prohibition set forth in the Securities Purchase Agreement, the Parent shall be deemed to have issued shares of Common Stock or Common Stock Equivalents at the lowest possible price at which such securities may be converted, exchanged and/or exercised under the terms of such Variable Rate Transaction.

 

  17  
 

 

(d)          Record Date . If the Parent takes a record of the holders of shares of Common Stock for the purpose of entitling them (A) to receive a dividend or other distribution payable in shares of Common Stock and/or Common Stock Equivalents, or (B) to subscribe for or purchase shares of Common Stock and/or Common Stock Equivalents, then such record date will be deemed to be the date of the issuance or sale of the shares of Common Stock deemed to have been issued or sold upon the declaration of such dividend or the making of such other distribution or the date of the granting of such right of subscription or purchase (as the case may be).

 

(e)          Calculations . All calculations under this Section 7 shall be made by rounding to the nearest cent or the nearest 1/100 th  of a share, as applicable. The number of shares of Common Stock outstanding at any given time shall not include shares owned or held by or for the account of the Parent, and the disposition of any such shares shall be considered an issue or sale of Common Stock.

 

(f)          Voluntary Adjustability by the Parent . The Parent may at any time which this Note is outstanding, reduce the then Conversion Price to any amount and for any period of time decided appropriate by the Board of Directors.

 

8.          CERTAIN RESET RIGHTS UPON A QUALIFYING PO . If on or after the Subscription Date, the Parent consummates a Qualifying PO, and on the closing date of such Qualifying PO, the then Conversion Price is greater than the Qualifying PO Per Share Sale Price (as defined below), then the Conversion Price shall automatically and without any action by the Parent or otherwise, be reset to the Qualifying PO Per Share Sale Price. A “ Qualifying PO Per Share Sale Price ” shall be as applicable (i) the gross price a share of Common Stock is sold to the public in the Qualifying PO if only shares of Common Stock are sold to the public in such Qualifying PO, (ii) the gross price a unit consisting of shares of Common Stock and Common Stock Equivalents is sold to the public in the Qualifying PO, or (iii) the sum of the gross price that (a) one (1) share of Common Stock, and (b) a Common Stock Equivalent is sold to each purchaser in a Qualifying PO.

 

  18  
 

 

9.           REDEMPTIONS AT THE COMPANY’S ELECTION . Subject to compliance with all provisions of this Section 9 , any time after the Issuance Date, the Parent shall have the right to redeem all or a portion of the Conversion Amount then outstanding (the “ Parent Optional Redemption Amount ”) on the Parent Optional Redemption Date (as defined below) (a “ Parent Optional Redemption ”). So long as no Event of Default has occurred and is continuing, the portion of this Note subject to redemption pursuant to this Section 9 shall be redeemed by the Parent in cash at a price (the “ Parent Optional Redemption Price ”) equal to (i) if the Parent’s Optional Redemption Price is paid in full to the Holder on a date prior to May 15, 2018, 101% of the Conversion Amount being redeemed, (ii) if the Parent’s Optional Redemption Price is paid in full to the Holder on a date following May 15, 2018 but prior to May 15, 2019, 102% of the Conversion Amount being redeemed, and (iii) the Parent’s Optional Redemption Price is paid in full to the Holder after May 15, 2019 but prior to the Maturity Date, 103% of the Conversion Amount being redeemed; provided , however , that provided the Parent has complied with its obligations under Section 4(b) including the timely delivery of an Event of Default Notice, and if an Event of Default has occurred and is continuing, then on the Parent Optional Redemption Date, the Parent shall have the right to redeem all or a portion of the Conversion Amount outstanding by paying to the Holder the Event of Default Redemption Price in cash for all Conversion Amounts being redeemed on the Parent Optional Redemption Date, provided the Parent follows all of the provisions set forth in this Section 9 . This provision in no way shall limit the rights and remedies provided to the Holder pursuant to any provision of this Note and/or elsewhere including, but not limited to, Section 4 or this Section 9 of this Note. For clarity purposes, in no event shall the Parent (and any other Person) be entitled to redeem all or any portion of the Conversion Amount if an Event of Default has occurred and is continuing unless the Parent (i) complies with all provisions of this Section 9, and (ii) pays on the Parent Optional Redemption Date in cash to the Holder the Event of Default Redemption Price for all Conversion Amounts it is redeeming. The Parent may exercise its right to require redemption under this Section 9 by delivering a written notice thereof by facsimile or electronic mail and overnight courier to the Holder, which notice shall include the signature from the Parent acknowledging such redemption and the Holder’s conversion and related rights hereunder for the purpose of acknowledging and being aware of Holder’s conversion rights hereunder (the “ Parent Optional Redemption Notice ” and the date the Holder receives such notice is referred to as the “ Parent Optional Redemption Notice Date ”). The Parent may not deliver a Parent Optional Redemption Notice hereunder unless the aggregate Conversion Amount being redeemed pursuant to this Section 9 is at least Five Hundred Thousand Dollars ($500,000), and such Parent Optional Redemption Notice shall be irrevocable. The Parent Optional Redemption Notice shall (x) state the date on which the Parent Optional Redemption shall occur (the “ Parent Optional Redemption Date ”) which date shall not be less than twenty (20) Trading Days nor more than thirty (30) Trading Days following the Parent Optional Redemption Notice Date, (y) certify that no Event of Default has occurred or is continuing and/or with the giving of notice or the passage of time could occur (or with respect to a Parent Optional Redemption being made while an Event of Default is continuing as provided above), the date the Event of Default commenced and an explanation of the reasons why such Event of Default occurred and is continuing, and (z) state the aggregate Conversion Amount of this Note being redeemed in such Parent Optional Redemption from the Holder on the Parent Optional Redemption Date. Redemptions made pursuant to this Section  9 shall be made in accordance with Section 12 . To the extent redemptions required by this Section 9(a) are deemed or determined by a court of competent jurisdiction to be prepayments of this Note by the Parent, such redemptions shall be deemed to be voluntary prepayments. Notwithstanding anything herein to the contrary, but subject to Section 3(d) , at any time prior to the date the applicable Parent Optional Redemption Price is paid in full (together with Late Charges, if any are owed, thereon), such applicable Parent Optional Redemption Amount (together with Late Charges, if any are owed, thereon), may be converted, in whole or in part by the Holder into shares of Common Stock pursuant to Section 3 . The parties agree that in the event of the Parent’s redemption of any portion of this Note under this Section 9, the Holder’s damages would be uncertain and difficult to estimate because of the parties’ inability to predict future interest rates and the uncertainty of the availability of a suitable substitute investment opportunity for the Holder. Accordingly, any redemption premium due under this Section 9 is intended by the parties to be, and shall be deemed, a reasonable estimate of the Holder’s actual loss of its investment opportunity and not as a penalty. For the avoidance of doubt and notwithstanding anything to the contrary provided herein or elsewhere, without the express written consent of the Holder, the Parent shall have no right to effect a Parent Optional Redemption if at any time commencing on the Parent’s Optional Redemption Notice Date and terminating on the Parent’s Optional Redemption Date, any Event of Default has occurred and continuing (and/or with the giving of notice or the passage of time could occur as a result of the applicable Parent Optional Redemption, but any Event of Default shall have no effect upon the Holder’s right to convert this Note in its discretion.

 

  19  
 

 

10.          NONCIRCUMVENTION . The Parent hereby covenants and agrees that neither by amendment of its respective Certificate of Incorporation (as defined in the Securities Purchase Agreement), Bylaws (as defined in the Securities Purchase Agreement) or through any reorganization, transfer of assets, consolidation, merger, scheme of arrangement, dissolution, issue or sale of securities, or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Note, and will at all times in good faith carry out all of the provisions of this Note and take all action as may be required to protect the rights of the Holder of this Note. Without limiting the generality of the foregoing or any other provision of this Note or the other Transaction Documents, the Parent (a) shall not increase the par value of any shares of Common Stock receivable upon conversion of this Note above the Conversion Price then in effect, and (b) shall take all such actions as may be necessary or appropriate in order that the Parent may validly and legally issue fully paid and nonassessable shares of Common Stock upon each conversion of this Note.

 

  11. RESERVATION OF AUTHORIZED SHARES .

 

(a)          Reservation . Commencing as of the Subscription Date and for as long as this Note remains outstanding (the “ Share Reserve Period ”), the Parent shall at all times have and keep reserved (and shall not reduce such reserve) at least 200% of the maximum number of shares of Common Stock as shall from time to time be necessary to effect the full conversion of this Note (without regard to any limitations or conversions and assuming for purposes of this Section 11(a) that this Note remains outstanding and is paid in full in cash on May 15, 2020, and the redemption price on such date is the Event of Default Redemption Price (the “ Required Reserve Amount ”).

 

(b)          Insufficient Authorized Shares . If, notwithstanding Section 11(a) , and not in limitation thereof, at any time while this Note remains outstanding, the Parent does not have a sufficient number of authorized and unreserved shares of Common Stock to satisfy its obligation to reserve for issuance upon conversion of this Note at least a number of shares of Common Stock equal to the Required Reserve Amount (an “ Authorized Share Failure ”), then the Parent shall immediately take all action necessary to increase the Parent authorized shares of Common Stock to an amount sufficient to allow the Parent to reserve the Required Reserve Amount for this Note. Without limiting the generality of the foregoing sentence, as soon as practicable after the date of the occurrence of an Authorized Share Failure, but in no event later than ninety (90) days, after the occurrence of such Authorized Share Failure, the Parent shall either (i) hold a meeting of its stockholders for the approval of an increase in the number of authorized shares of Common Stock, or (ii) have cured the Authorized Share Failure by, among other required items, obtaining a written consent of the required percentage of holders of shares of Common Stock for the required increase in authorized shares and had taken any and all other such action necessary to rectify the Authorized Share Failure including, but not limited to, providing the non-consenting stockholders with an information statement and a Form 14(C) and filed with the SEC such Form 14(C). In connection with such meeting as set forth in (i) above, the Parent shall provide each stockholder with a proxy statement and shall use its best efforts to solicit its stockholders’ approval of such increase in authorized shares of Common Stock and to cause its board of directors to recommend to the stockholders that they approve such proposal. In the event that the Parent is prohibited from issuing shares of Common Stock upon one or more conversions of this Note by the Buyer pursuant to the terms of this Note due to the failure by the Parent to have sufficient shares of Common Stock available out of the authorized but unissued shares of Common Stock (such unavailable number of shares of Common Stock, the “ Authorized Failure Shares ”), in lieu of delivering such Authorized Failure Shares to the Holder, the Parent shall pay cash in exchange for the redemption of such portion of the Conversion Amount convertible into such Authorized Failure Shares at a price equal to the sum of (i) the product of (x) such number of Authorized Failure Shares multiplied by (y) the greatest Closing Sale Price or Closing Bid Price (as the case may be) of the Common Stock on any Trading Day during the period commencing on the date the Holder delivers the applicable Conversion Notice with respect to such Authorization Failure Shares to the Parent and ending on the date of such issuance and payment under this Section 11(b) (or the Conversion Price if the Parent is not then a Trading Issuer); and (ii) to the extent the Holder purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by the Holder of Authorized Failure Shares, any brokerage commissions and other out-of-pocket expenses, if any, of the Holder incurred in connection therewith. Nothing contained in Section 11(a) or this Section 11(b) shall limit any obligations of the Parent under any provision of this Note, the Securities Purchase Agreement and/or any other Transaction Document.

 

  20  
 

 

  12. REDEMPTIONS .

 

(a)          Mechanics . The Parent shall deliver the applicable Event of Default Redemption Price to the Holder in cash within five (5) Business Days after the Parent’s receipt of the Holder’s Event of Default Redemption Notice. If the Holder has submitted a Fundamental Transaction Redemption Notice in accordance with Section 5(b) , the Parent shall deliver the applicable Fundamental Transaction Redemption Price to the Holder in cash concurrently with the consummation of such Fundamental Transaction if such notice is received prior to the consummation of such Fundamental Transaction and within five (5) Business Days after the Parent’s receipt of such notice otherwise. The Parent shall deliver the applicable Parent Optional Redemption Price to the Holder in cash on the applicable Parent Optional Redemption Date. Notwithstanding anything herein to the contrary, in connection with any redemption hereunder at a time the Holder is entitled to receive a cash payment under any of the other Transaction Documents, at the option of the Holder delivered in writing to the Parent, the applicable Redemption Price hereunder shall be increased by the amount of such cash payment owed to the Holder under such other Transaction Documents and, upon payment in full or conversion in accordance herewith, shall satisfy the Parent’s then payment obligation under such other Transaction Documents. In the event of a redemption of less than all of the Conversion Amount of this Note (to the extent permitted hereunder), the Parent shall promptly cause to be issued and delivered to the Holder a new Note (in accordance with Section 19(d) ) representing the outstanding Principal which has not been redeemed. In the event that the Parent does not pay the applicable Redemption Price (together with Late Charges thereon), to the Holder within the time period required, at any time thereafter and until the Parent pays such unpaid Redemption Price (together with Late Charges thereon), in full, the Holder shall have the option, in lieu of redemption, to require the Parent to promptly return to the Holder all or any portion of this Note representing the Conversion Amount that was submitted for redemption and for which the applicable Redemption Price (together with any Late Charges thereon) has not been paid. Upon the Parent’s receipt of such notice, (x) the applicable Redemption Notice shall be null and void with respect to such Conversion Amount, and (y) the Parent shall immediately return this Note, or issue a new Note (in accordance with Section 19(d) ), to the Holder, and in each case the Principal amount of this Note or such new Note (as the case may be) shall be increased by an amount equal to the difference between (1) the applicable Redemption Price (as the case may be, and as adjusted pursuant to this Section 12 , if applicable) minus (2) the Principal portion of the Conversion Amount submitted for redemption. The Holder’s delivery of a notice voiding a Redemption Notice and exercise of its rights following such notice shall not affect the Parent’s obligations to make any payments of Late Charges which have accrued prior to the date of such notice with respect to the Conversion Amount subject to such notice.

 

13.         VOTING RIGHTS . The Holder shall have no voting rights as the holder of this Note, except as required by law (including, without limitation, the Delaware General Corporation Law) and as expressly provided in this Note.

 

14.          COVENANTS . Until this Note has been converted, redeemed or otherwise satisfied in accordance with their terms:

 

(a)          Rank . This Note shall rank (i) pari passu with all other Notes, if any, and (ii) senior in all respects to all other Indebtedness of the Parent, except Permitted Indebtedness secured by Permitted Liens if and to the extent the terms of such Indebtedness requires such Indebtedness to be senior to this Note.

 

  21  
 

 

(b)          Incurrence of Indebtedness . Neither the Parent nor ICA-T shall, and the Parent and ICA-T shall cause all of the Subsidiaries to not, directly or indirectly, incur or guarantee, assume or suffer to exist any Indebtedness (other than (i) the Indebtedness evidenced by this Note and the Parent Note, and (ii) other Permitted Indebtedness, until the ninety-first (91 st ) calendar day after the date this Note and the Parent Note is no longer outstanding.

 

(c)          Existence of Liens . Neither the Parent nor ICA-T shall, and the Parent and ICA-T shall cause each Subsidiary to not, directly or indirectly, allow or suffer to exist any mortgage, lien, pledge, charge, security interest or other encumbrance upon or in any property or assets owned by the Parent, ICA-T and/or any of the Subsidiaries (collectively, “ Liens ”) other than Permitted Liens.

 

(d)          Restricted Payments . Neither the Parent nor ICA-T shall, and the Parent and ICA-T shall cause all of the Subsidiaries to not, directly or indirectly, redeem, defease, repurchase, repay or make any payments in respect of, by the payment of cash or cash equivalents (in whole or in part, whether by way of open market purchases, tender offers, private transactions or otherwise), all or any portion of any Indebtedness of the Parent, ICA-T and/or any Subsidiary other than this Note and the Parent Note and Permitted Indebtedness that is secured by a Permitted Lien (which by the terms of such particular Permitted Indebtedness the payment thereof is senior by the terms thereof in right of payment to the Parent Note and/or this Note), whether by way of payment in respect of principal of (or premium, if any), interest on, such Indebtedness if at the time such payment is due or is otherwise made or, after giving effect to such payment, (i) an event constituting an Event of Default has occurred and is continuing or (ii) an event that with the passage of time and/or the giving of notice and without being cured would constitute an Event of Default has occurred and is continuing.

 

(e)          Restriction on Redemption and Cash Dividends . Until the ninety-first (91 st ) calendar day after the date no Securities are outstanding and except as specifically provided below, neither the Parent nor ICA-T shall, and the Parent and ICA-T shall cause each of the Subsidiaries to not, directly or indirectly, redeem, repurchase or declare or pay any cash dividend or distribution on any of its Equity Interests other than intercompany dividends to the Parent, ICA-T or any Domestic Subsidiary (as defined in the Securities Purchase Agreement), (“ Intercompany Dividends ”), provided no Domestic Subsidiary shall be permitted at any time to declare, pay and/or accrue any Intercompany Dividend, unless such Domestic Subsidiary’s operations are located in the United States and it does not have any bank and/or similar accounts located outside of the United States; provided , however , that notwithstanding anything to the contrary provided herein or elsewhere, all Intercompany Dividends otherwise permitted in this Section 14(e) , shall be prohibited during the period commencing on the date an Event of Default occurs and is continuing through and including the tenth (10 th ) Business Day following the date the Collateral Agent receives written notice from the Parent and ICA-T signed by the CEO (or the President) and the CFO of the Parent and ICA-T that such Event of Default has been cured and no longer exists. For purposes hereof, “ Equity Interests ” means (a) all shares of capital stock (whether denominated as common capital stock or preferred capital stock), equity interests, beneficial, partnership or membership interests, joint venture interests, participations or other ownership or profit interests in or equivalents (regardless of how designated) of or in a Person (other than an individual), whether voting or non-voting and (b) all securities convertible into or exchangeable for any of the foregoing and all warrants, options or other rights to purchase, subscribe for or otherwise acquire any of the foregoing, whether or not presently convertible, exchangeable or exercisable.

 

  22  
 

 

(f)          Restriction on Transfer of Assets . Neither the Parent nor ICA-T shall, and the Parent and ICA-T shall cause all of the Subsidiaries to not, directly or indirectly, sell, lease, license, assign, transfer, spin-off, split-off, close, convey or otherwise dispose of any assets or rights of the ICA-T, the Parent and/or any of the Subsidiaries whether in a single transaction or a series of related transactions, other than (i) sales, leases, licenses, assignments, transfers, conveyances and other dispositions of such assets or rights by the ICA-T the Parent and/or the Subsidiaries in the ordinary course of business consistent with its past practices and (ii) sales of inventory and product in the ordinary course of business.

 

(g)          Maturity of Indebtedness . Neither the Parent nor ICA-T shall, and the Parent and ICA-T shall cause all of the Subsidiaries to not, directly or indirectly, permit any Indebtedness of the Parent, ICA-T and/or any of the Subsidiaries to mature or accelerate prior to the ninety-first (91 st ) calendar day after the date that this Note and the Parent Note is no longer outstanding other than Permitted Indebtedness that is secured by Permitted Indebtedness outstanding on the date hereof.

 

(h)          Change in Nature of Business . Neither ICA-T nor the Parent shall, and the ICA-T and the Parent shall cause each of the Subsidiaries to not, directly or indirectly, make any change in the nature of its business including, but not limited to, engage in any material line of business substantially different from those lines of business conducted by the Parent, ICA-T and each of the Subsidiaries on the Subscription Date described in the Parent’s Annual Report on Form 10-K for the year ended 2016. Neither the Parent nor ICA-T shall, and the Parent and ICA-T shall cause each of the Subsidiaries to not, directly or indirectly, modify its or their corporate structure or purpose.

 

(i)           Preservation of Existence, Etc.  The Parent and ICA-T shall maintain and preserve, and cause each of the Subsidiaries to maintain and preserve, its existence, rights and privileges, and become or remain, and cause each of the Subsidiaries to become or remain, duly qualified and in good standing in each jurisdiction in which the character of the properties owned or leased by it or in which the transaction of its business makes such qualification necessary.

 

(j)          Maintenance of Properties, Etc.  The Parent and ICA-T shall maintain and preserve, and cause each of the Subsidiaries to maintain and preserve, all of their respective properties which are necessary or useful in the proper conduct of its business in good working order and condition, ordinary wear and tear excepted, and comply, and shall and shall cause each of the Subsidiaries to comply, at all times with the provisions of all leases to which it is a party as lessee or under which it occupies property, so as to prevent any loss or forfeiture thereof or thereunder.

 

  23  
 

 

(k)          Maintenance of Intellectual Property . The Parent and ICA-T will, and will cause each of the Subsidiaries to, take all action necessary or advisable to maintain all of the Intellectual Property Rights (as defined in the Securities Purchase Agreement) of the ICA-T, the Parent and each of the Subsidiaries that are necessary or material to the conduct of its business in full force and effect.

 

(l)          Maintenance of Insurance . The Parent and ICA-T shall maintain, and cause each of the Subsidiaries to maintain, insurance with responsible and reputable insurance companies or associations (including, without limitation, comprehensive general liability, hazard, rent and business interruption insurance) with respect to its properties (including all real properties leased or owned by it) and business, in such amounts and covering such risks as is required by any governmental authority having jurisdiction with respect thereto or as is carried generally in accordance with sound business practice by companies in similar businesses similarly situated.

 

(m)          Transactions with Affiliates . Except as set forth under Section 14(e) , neither the Parent nor ICA-T shall, nor shall the Parent or ICA-T permit any of the Subsidiaries to, enter into, renew, extend or be a party to, any transaction or series of related transactions (including, without limitation, the purchase, sale, lease, transfer or exchange of property or assets of any kind or the rendering of services of any kind) with any Affiliate, except transactions (i) approved by a majority of the Parent’s and ICA-T’s (as the case may be) independent directors, and (ii) in the ordinary course of business in a manner and to an extent consistent with past practice and necessary or desirable for the prudent operation of its business, for fair consideration and on terms no less favorable to the Parent, ICA-T and/or any of the Subsidiaries than would be obtainable in a comparable arm’s length transaction with a Person that is not an Affiliate thereof.

 

(n)          Restricted Issuances . Neither ICA-T nor any Subsidiary shall directly and/or indirectly issue and/or sell any securities other than ICA-T issuing the ICA-Note to the Holder and/or to the Holder as required by this Note. The Parent shall not, directly or indirectly (i) issue any Notes and/or other Notes (other than as contemplated by the Securities Purchase Agreement), (ii) issue any shares of preferred stock whose terms and rights (1) provide the requirement or option to declare, accrue and pay a cash dividend while this Note and/or the ICA-T Note are outstanding and/or (2) permit the redemption of such shares of preferred stock of the Parent while this Note and/or the ICA-T Note are outstanding, and/or (iii) issue any other securities that would cause a breach or default under any of the Securities.

 

(o)          New Subsidiaries; No Foreign Subsidiaries . Simultaneously with the acquisition or formation of each New Subsidiary, the Parent and ICA-T shall take and the Parent and the ICA-T shall cause all Subsidiaries including any New Subsidiary, to take any and all actions under the Security Documents. None of the Parent, ICA-T or any Subsidiary shall directly and/or indirectly make any payments to, or transfer any assets, including, but not limited to, by way of any dividend and/or distribution to any Subsidiary including any Domestic Subsidiary if such Domestic Subsidiary is not located in the United States and/or has a bank or similar account outside of the United States.

 

  24  
 

 

(p)          Change in Collateral; Collateral Records . The Parent and ICA-T shall and shall cause each Subsidiary to (i) give the Collateral Agent not less than thirty (30) days’ prior written notice of any change in the location of any Collateral (as defined in the Security Documents), other than to locations set forth in the Perfection Certificates (as defined in the Security Documents) hereto and with respect to which the Collateral Agent has filed financing statements and otherwise fully perfected its Liens thereon (other than transfers of inventory to customers in the ordinary course of business in a manner and to an extent consistent with past practice), (ii) advise the Collateral Agent promptly, in sufficient detail, of any material adverse change relating to the type, quantity or quality of the Collateral or the Lien granted thereon and (iii) execute and deliver, and cause each of the Subsidiaries to execute and deliver, to the Collateral Agent for the benefit of the Holder from time to time, solely for the Collateral Agent’s convenience in maintaining a record of Collateral, such written statements and schedules as the Collateral Agent or any Holder may reasonably require, designating, identifying or describing the Collateral. In addition, the Parent and ICA-T shall and shall cause each Subsidiary to provide to the Collateral Agent upon filing, copies of all UCC-1 Financing Statements, amendments to all UCC-1 Financing Statements, all UCC-3 filings and all other similar filings made with any Governmental Entity (as defined in the Securities Purchase Agreement) including, but not limited to, the USPTO.

 

(q) [INTENTIONALLY LEFT BLANK]

 

(r)            Independent Investigation . At the request of the Holder either (x) at any time when an Event of Default has occurred and is continuing, (y) upon the occurrence of an event that with the passage of time or giving of notice would constitute an Event of Default or (z) at any time the Holder reasonably believes an Event of Default may have occurred or be continuing, the Parent and ICA-T shall hire an independent, reputable investment bank selected by the Parent and ICA-T and approved by the Holder to investigate as to whether any breach of this Note and/or the ICA-T Note has occurred (the “ Independent Investigator ”). If the Independent Investigator determines that such breach of this Note and/or the ICA-T Note has occurred, the Independent Investigator shall notify the Parent and ICA-T of such breach and the Parent and ICA-T shall deliver written notice to each holder of this Note and/or the ICA-T Note of such breach. In connection with such investigation, the Independent Investigator may, during normal business hours, inspect all contracts, books, records, personnel, offices and other facilities and properties of the Parent and ICA-T and each of the Subsidiaries and, to the extent available to the Parent and ICA-T after the Parent and ICA-T uses reasonable efforts to obtain them, the records of its legal advisors and accountants (including the accountants’ work papers) and any books of account, records, reports and other papers not contractually required of the Parent, ICA-T and the Subsidiaries to be confidential or secret, or subject to attorney-client or other evidentiary privilege, and the Independent Investigator may make such copies and inspections thereof as the Independent Investigator may reasonably request. The Parent and ICA-T shall furnish the Independent Investigator with such financial and operating data and other information with respect to the business and properties of the Parent, ICA-T and each Subsidiary as the Independent Investigator may reasonably request. The Parent and ICA-T shall permit the Independent Investigator to discuss the affairs, finances and accounts of the Parent, ICA-T and each Subsidiary with, and to make proposals and furnish advice with respect thereto to, the Parent’s, ICA-T’s and the Subsidiary’s officers, directors, key employees and independent public accountants or any of them (and by this provision the Parent and ICA-T each authorize said accountants to discuss with such Independent Investigator the finances and affairs of the Parent, ICA-T and the Subsidiaries), all at such reasonable times, upon reasonable notice, and as often as may be reasonably requested.

 

  25  
 

 

15.         SECURITY . This Note is secured to the extent and in the manner set forth in the Transaction Documents (including, without limitation, the Security Agreements, the other Security Documents and the Guaranties).

 

16.          DISTRIBUTION OF ASSETS . In addition to all other rights and adjustments provided in this Note and/or any other Transaction Document or elsewhere, if the Parent shall declare or make any dividend or other distributions of its assets (or rights to acquire its assets) to any or all holders of shares of Common Stock, by way of return of capital or otherwise (including without limitation, any distribution of cash, stock or other securities (including, but not limited to, shares of Common Stock and/or Common Stock Equivalents), property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (the “ Distributions ”), then the Holder will be entitled to such Distributions as if the Holder had held the number of shares of Common Stock acquirable upon complete conversion of this Note (without taking into account any limitations or restrictions on the convertibility of this Note and assuming for such purpose that this Note was converted at the Conversion Price as of the applicable record date) immediately prior to the date on which a record is taken for such Distribution or, if no such record is taken, the date as of which the record holders of Common Stock are to be determined for such Distributions (provided, however, that to the extent that the Holder’s right to participate in any such Distribution would result in the Holder and the other Attribution Parties exceeding the Maximum Percentage, then the Holder shall not be entitled to participate in such Distribution to the extent of the Maximum Percentage (and shall not be entitled to beneficial ownership of such shares of Common Stock as a result of such Distribution (and beneficial ownership) to the extent of any such excess) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time or times, if ever, as its right thereto would not result in the Holder and the other Attribution Parties exceeding the Maximum Percentage, at which time or times the Holder shall be granted such Distribution (and any Distributions declared or made on such initial Distribution or on any subsequent Distribution held similarly in abeyance) to the same extent as if there had been no such limitation).

 

17.          AMENDING THE TERMS OF THIS NOTE . The prior written consent of the Holder of this Note shall be required for any change, waiver or amendment to this Note.

 

18.         TRANSFER . This Note and any shares of Common Stock issued and/or issuable upon conversion of this Note may be offered, sold, assigned or transferred by the Holder without the consent of the Parent, in whole or in part, at any time and from time to time, subject only to the provisions of Section 2(g) of the Securities Purchase Agreement.

 

  26  
 

 

  19. REISSUANCE OF THIS NOTE .

 

(a)          Transfer . If this Note is to be transferred, the Holder shall surrender this Note to the Parent , whereupon the Parent will forthwith issue and deliver upon the order of the Holder a new Note (in accordance with Section 19(d) ), registered as the Holder may request, representing the outstanding Principal being transferred by the Holder and, if less than the entire outstanding Principal is being transferred, a new Note (in accordance with Section 19(d) ) to the Holder representing the outstanding Principal not being transferred. The Holder and any assignee, by acceptance of this Note, acknowledge and agree that, by reason of the provisions of Section 3(c)(iii) following conversion or redemption of any portion of this Note, the outstanding Principal represented by this Note may be less than the Principal stated on the face of this Note.

 

(b)          Lost, Stolen or Mutilated Note . Upon receipt by the Parent of evidence reasonably satisfactory to the Parent of the loss, theft, destruction or mutilation of this Note (as to which a written certification and the indemnification contemplated below shall suffice as such evidence), and, in the case of loss, theft or destruction, of any indemnification undertaking by the Holder to the Parent in customary and reasonable form and, in the case of mutilation, upon surrender and cancellation of this Note, the Parent shall execute and deliver to the Holder a new Note (in accordance with Section 19(d) ) representing the outstanding Principal.

 

(c)          Note Exchangeable for Different Denominations . This Note is exchangeable, upon the surrender hereof by the Holder at the principal office of the Parent , for a new Note or Notes (in accordance with Section 19(d) and in principal amounts of at least $1,000) representing in the aggregate the outstanding Principal of this Note, and each such new Note will represent such portion of such outstanding Principal as is designated by the Holder at the time of such surrender.

 

(d)          Issuance of New Notes; Signatures . Whenever the Parent is required to issue a new Note pursuant to the terms of this Note, such new Note (i) shall be of like tenor with this Note, (ii) shall represent, as indicated on the face of such new Note, the Principal remaining outstanding (or in the case of a new Note being issued pursuant to Section 19(a) or Section 19(c) , the Principal designated by the Holder which, when added to the principal represented by the other new Notes issued in connection with such issuance, does not exceed the Principal remaining outstanding under this Note immediately prior to such issuance of new Notes), (iii) shall have an issuance date, as indicated on the face of such new Note, which is the same as the Issuance Date of this Note, (iv) shall have the same rights, remedies and conditions as this Note, (v) shall represent accrued and unpaid Interest and Late Charges on the Principal and Interest of this Note, from the Issuance Date, and (vi) shall be executed by the Parent .

 

  27  
 

 

20.          REMEDIES, CHARACTERIZATIONS, OTHER OBLIGATIONS, BREACHES AND INJUNCTIVE RELIEF . The remedies provided in this Note shall be cumulative and in addition to all other remedies available under this Note and any of the other Transaction Documents at law or in equity (including a decree of specific performance and/or other injunctive relief), and nothing herein shall limit the Holder’s right to pursue actual and consequential damages for any failure by the Parent and/or ICA-T to comply with the terms of this Note. The Parent and ICA-T jointly and severally covenant to the Holder that there shall be no characterization concerning this instrument other than as expressly provided herein. Amounts set forth or provided for herein with respect to payments, conversion, redemptions and the like (and the computation thereof) shall be the amounts to be received by the Holder and shall not, except as expressly provided herein, be subject to any other obligation of the Parent, ICA-T and/or any Subsidiary (or the performance thereof). The Parent and ICA-T jointly and severally acknowledge that a breach by either of them of the obligations hereunder will cause irreparable harm to the Holder and that the remedy at law for any such breach may be inadequate. The Parent and ICA-T each therefore agree that, in the event of any such breach or threatened breach, the Holder shall be entitled, in addition to all other available remedies, to specific performance and/or temporary, preliminary and permanent injunctive or other equitable relief restraining and/or preventing any such breach or threatened breach without the necessity of showing economic harm and without posting a bond or other security being required. The Parent and ICA-T shall provide all information and documentation to the Holder that is requested by the Holder to enable the Holder to confirm the Parent’s and ICA-T’s compliance with the terms and conditions of this Note (including, without limitation, compliance with Sections 4, 5 and 7 ).

 

21.         PAYMENT OF COLLECTION, ENFORCEMENT AND OTHER COSTS . If (a) this Note is placed in the hands of an attorney for collection or enforcement or is collected or enforced through any legal proceeding or the Holder otherwise takes action to collect amounts due under this Note or to enforce the provisions of this Note or (b) there occurs any bankruptcy, reorganization, receivership of the Parent, ICA-T and/or any Subsidiary or other proceedings affecting the Parent’s, ICA-T’s and/or any Subsidiary’s creditors’ rights and involving a claim under this Note, then the Parent, ICA-T and each Subsidiary shall jointly and severally be obligated and pay the costs incurred by the Holder for such collection, enforcement or action or in connection with such bankruptcy, reorganization, receivership or other proceeding, including, without limitation, attorneys’ fees and disbursements. The Parent and ICA-T expressly each acknowledge and agree that no amounts due under this Note shall be affected, or limited, by the fact that the purchase price paid for this Note was less than the original Principal amount hereof.

 

22.          CONSTRUCTION; HEADINGS . This Note shall be deemed to be jointly drafted by the Parent and the initial Holder and shall not be construed against any such Person as the drafter hereof. The headings of this Note are for convenience of reference and shall not form part of, or affect the interpretation of, this Note. Unless the context clearly indicates otherwise, each pronoun herein shall be deemed to include the masculine, feminine, neuter, singular and plural forms thereof. The terms “including, “includes,” “include” and words of like import shall be construed broadly as if followed by the words “without limitation.” The terms “herein,” “hereunder,” “hereof” and words of like import refer to this entire Note instead of just the provision in which they are found. Unless expressly indicated otherwise, all section references are to sections of this Note. Terms used in this Note and not otherwise defined herein, but defined in the other Transaction Documents, shall have the meanings ascribed to such terms on the Closing Date in such other Transaction Documents unless otherwise consented to in writing by the Holder.

 

23.          FAILURE OR INDULGENCE NOT WAIVER . No failure or delay on the part of the Holder in the exercise of any power, right or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such power, right or privilege preclude other or further exercise thereof or of any other right, power or privilege. No waiver shall be effective unless it is in writing and signed by an authorized representative of the waiving party.

 

  28  
 

 

  24. DISPUTE RESOLUTION .

 

(a) Submission to Dispute Resolution .

 

(i)          In the case of a dispute relating to a Conversion Price, a Closing Sale Price, a Closing Bid Price, a Lowest Price, or a fair market value or the arithmetic calculation of a Conversion Rate, any Redemption Price or any other calculation under this Note (as the case may be) (including, without limitation, a dispute relating to the determination of any of the foregoing), the Parent or the Holder (as the case may be) shall submit the dispute to the other party via facsimile or electronic mail (A) if by the Parent, within five (5) Business Days after the occurrence of the circumstances giving rise to such dispute or (B) if by the Holder, within five (5) Business Days after the Holder learned of the circumstances giving rise to such dispute. If the Holder and the Parent are unable to promptly resolve such dispute relating to such Conversion Price, such Lowest Price, such Closing Sale Price, such Closing Bid Price, or such fair market value or such arithmetic calculation of such Conversion Rate, any such Redemption Price or any other calculation under this Note (as the case may be), (including, without limitation, a dispute relating to the determination of any of the foregoing) at any time after the second (2 nd  ) Business Day following such initial notice by the Parent or the Holder (as the case may be) of such dispute to the Parent or the Holder (as the case may be), then the Holder and the Parent shall together select an independent, reputable investment bank to resolve such dispute and if they do not agree upon an independent, reputable investment bank to resolve such dispute within a fifteen (15) day period, then the Holder shall be entitled to make such selection.

 

(ii)          The Holder and the Parent (as applicable) shall each deliver to such investment bank (A) a copy of the initial dispute submission so delivered in accordance with the first sentence of this Section 24 and (B) written documentation supporting its position with respect to such dispute, in each case, no later than 5:00 p.m. (New York time) by the fifth (5 ) Business Day immediately following the date on which the Holder selected such investment bank (the “ Dispute Submission Deadline ”) (the documents referred to in the immediately preceding clauses (A) and (B) are collectively referred to herein as the “ Required Dispute Documentation ”) (it being understood and agreed that if either the Holder and/or the Parent fails to so deliver all of the Required Dispute Documentation by the Dispute Submission Deadline, then the party who fails to so submit all of the Required Dispute Documentation shall no longer be entitled to (and hereby waives its right to) deliver or submit any written documentation or other support to such investment bank with respect to such dispute and such investment bank shall resolve such dispute based solely on the Required Dispute Documentation that was delivered to such investment bank prior to the Dispute Submission Deadline). Unless otherwise agreed to in writing by both the Parent and the Holder or otherwise requested by such investment bank, neither the Parent nor the Holder shall be entitled to deliver or submit any written documentation or other support to such investment bank in connection with such dispute (other than the Required Dispute Documentation).

 

  29  
 

 

(iii)         The Parent and the Holder (as the case may be) shall cause such investment bank to determine the resolution of such dispute and notify the Parent and the Holder of such resolution no later than ten (10) Business Days immediately following the Dispute Submission Deadline. The fees and expenses of such investment bank shall be borne solely by the Parent in such dispute, and such investment bank’s resolution of such dispute shall be final and binding upon all parties absent manifest error.

 

(b)          Miscellaneous . The Parent and the Holder each expressly acknowledge and agree that (i) this Section 24 constitutes an agreement to arbitrate between the Parent and the Holder (and constitutes an arbitration agreement) under § 7501, et seq. of the New York Civil Practice Law and Rules (“ CPLR ”) and that the Holder is authorized to apply for an order to compel arbitration pursuant to CPLR § 7503(a) in order to compel compliance with this Section 24 , (ii) a dispute relating to a Conversion Price, (iii) the terms of this Note and each other applicable Transaction Document shall serve as the basis for the selected investment bank’s resolution of the applicable dispute, such investment bank shall be entitled (and is hereby expressly authorized) to make all findings, determinations and the like that such investment bank determines are required to be made by such investment bank in connection with its resolution of such dispute and in resolving such dispute such investment bank shall apply such findings, determinations and the like to the terms of this Note and any other applicable Transaction Documents, (iv) the Holder (and only the Holder), in its sole discretion, shall have the right to submit any dispute described in this Section 24 to any state or federal court sitting in The City of New York, Borough of Manhattan in lieu of utilizing the procedures set forth in this Section 24 and (v) nothing in this Section 24 shall limit the Holder from obtaining any injunctive relief or other equitable remedies (including, without limitation, with respect to any matters described in this Section 24 ).

 

  25. NOTICES; CURRENCY; PAYMENTS .

 

(a)          Notices . Whenever notice is required to be given under this Note, unless otherwise provided herein, such notice shall be given in accordance with Section 9(f) of the Securities Purchase Agreement. The Parent shall provide the Holder with prompt written notice of all actions taken pursuant to this Note, including in reasonable detail a description of such action and the reason therefore. Without limiting the generality of the foregoing, the Parent will give written notice to the Holder (i) immediately upon any adjustment of the Conversion Price, setting forth in reasonable detail, and certifying, the calculation of such adjustment and (ii) at least fifteen (15) days prior to the date on which the Parent, ICA-T and/or any Subsidiary closes its books or takes a record (A) with respect to any dividend or distribution upon the Common Stock (and/or any Intercompany Dividend and/or Intercompany Payment), and/or (B) for determining rights to vote with respect to any Fundamental Transaction, dissolution or liquidation, provided in each case that such information shall be made known to the public prior to or in conjunction with such notice being provided to the Holder.

 

  30  
 

 

(b)          Currency . All dollar amounts referred to in this Note are in United States Dollars (“ U.S. Dollars ”), and all amounts owing under this Note shall be paid in U.S. Dollars. All amounts denominated in other currencies (if any) shall be converted into the U.S. Dollar equivalent amount in accordance with the Exchange Rate on the date of calculation. “ Exchange Rate ” means, in relation to any amount of currency to be converted into U.S. Dollars pursuant to this Note, the U.S. Dollar exchange rate as published in the Wall Street Journal on the relevant date of calculation (it being understood and agreed that where an amount is calculated with reference to, or over, a period of time, the date of calculation shall be the final date of such period of time).

 

(c)          Payments . Whenever any payment of cash is to be made by the Parent to any Person pursuant to this Note, such payment shall be made in lawful money of the United States of America by a certified check drawn on the account of the Parent and sent via overnight courier service to such Person at such address as previously provided to the Parent in writing (which address, in the case of the Holder, shall initially be as set forth in the Securities Purchase Agreement), provided that the Holder may elect to receive a payment of cash via wire transfer of immediately available funds by providing the Parent with prior written notice setting out such request and the Holder’s wire transfer instructions. Whenever any amount expressed to be due by the terms of this Note is due on any day which is not a Business Day, the same shall instead be due on the next succeeding day which is a Business Day. Any amount of Principal, Interest, Late Charges and/or other amounts due under this Note and the other Transaction Documents which is not paid when due (following any cure period, if any) shall result in a late charge being incurred and payable by the Parent in an amount equal to interest on such amount at the rate of eighteen percent (18%) per annum from the date such amount was due until the same is paid in full (“ Late Charge ”).

 

26.          CANCELLATION . After all Principal, accrued Interest, Late Charges and other amounts at any time owed on this Note have been paid in full, this Note shall automatically be deemed canceled, shall be surrendered to the Parent for cancellation and shall not be reissued.

 

27.         WAIVER OF NOTICE . To the maximum extent permitted by law, the Parent hereby irrevocably waives demand, notice, presentment, protest and all other demands and notices in connection with the delivery, acceptance, performance, default or enforcement of this Note and/or any of the other Transaction Documents.

 

  31  
 

 

28.          GOVERNING LAW . All questions concerning the construction, validity, enforcement and interpretation of this Note shall be governed by the internal laws of the State of New York, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of New York or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of New York. Except as expressly set forth in Section 24 , the Parent hereby irrevocably submit to the exclusive jurisdiction of the state and federal courts sitting in The City of New York, Borough of Manhattan, for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper. The Parent and the Holder each hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof to such party at the address for such notices to it under this Note and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein or elsewhere, shall be deemed to limit in any way any right to serve process in any manner permitted by law. Nothing contained herein or elsewhere, (i) shall be deemed or operate to preclude the Holder from directly and/or indirectly bringing suit or taking other legal action against the Parent, ICA-T and/or any of the Subsidiaries and/or any of their respective Affiliates and/or other Persons in any other jurisdiction to protect and/or enforce the Holder rights under this Note and/or any of the other Transaction Documents and/or collect on the Parent’s, ICA-T’s and/or the Subsidiary’s obligations to the Holder or to enforce a judgment or other court ruling in favor of the Holder or (ii) shall limit, or shall be deemed or construed to limit any provision of Section 24 . THE PARENT AND THE HOLDER EACH HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR UNDER ANY OTHER TRANSACTION DOCUMENT OR IN CONNECTION WITH OR ARISING OUT OF THIS NOTE, OR ANY TRANSACTION CONTEMPLATED HEREBY OR THEREBY.

 

  29. JUDGMENT CURRENCY .

 

(a)          If for the purpose of obtaining or enforcing judgment against the Parent in any court in any jurisdiction it becomes necessary to convert into any other currency (such other currency being hereinafter in this Section 29 referred to as the “ Judgment Currency ”) an amount due in U.S. Dollars under this Note, the conversion shall be made at the Exchange Rate prevailing on the Trading Day immediately preceding:

 

(i)          the date actual payment of the amount due, in the case of any proceeding in the courts of New York or in the courts of any other jurisdiction that will give effect to such conversion being made on such date: or

 

(ii)         the date on which the foreign court determines, in the case of any proceeding in the courts of any other jurisdiction (the date as of which such conversion is made pursuant to this Section 29(a)(ii) being hereinafter referred to as the “ Judgment Conversion Date ”).

 

(b)         If in the case of any proceeding in the court of any jurisdiction referred to in Section 29(a)(ii) above, there is a change in the Exchange Rate prevailing between the Judgment Conversion Date and the date of actual payment of the amount due, the applicable party shall pay such adjusted amount as may be necessary to ensure that the amount paid in the Judgment Currency, when converted at the Exchange Rate prevailing on the date of payment, will produce the amount of U.S. Dollars which could have been purchased with the amount of Judgment Currency stipulated in the judgment or judicial order at the Exchange Rate prevailing on the Judgment Conversion Date.

 

  32  
 

 

(c)         Any amount due from the Parent, ICA-T and/or the Subsidiaries under this provision shall be due as a separate debt and shall not be affected by judgment being obtained for any other amounts due under or in respect of this Note.

 

30.          SEVERABILITY . If any provision of this Note is prohibited by law or otherwise determined to be invalid or unenforceable by a court of competent jurisdiction, the provision that would otherwise be prohibited, invalid or unenforceable shall be deemed amended to apply to the broadest extent that it would be valid and enforceable, and the invalidity or unenforceability of such provision shall not affect the validity of the remaining provisions of this Note so long as this Note as so modified continues to express, without material change, the original intentions of the parties as to the subject matter hereof and the prohibited nature, invalidity or unenforceability of the provision(s) in question does not substantially impair the respective expectations or reciprocal obligations of the parties or the practical realization of the benefits that would otherwise be conferred upon the parties. The parties will endeavor in good faith negotiations to replace the prohibited, invalid or unenforceable provision(s) with a valid provision(s), the effect of which comes as close as possible to that of the prohibited, invalid or unenforceable provision(s).

 

31.          MAXIMUM PAYMENTS . Without limiting Section 9(d) of the Securities Purchase Agreement, nothing contained herein shall be deemed to establish or require the payment of a rate of interest or other charges in excess of the maximum permitted by applicable law. In the event that the rate of interest required to be paid or other charges hereunder exceed the maximum permitted by such law, any payments in excess of such maximum shall be credited against amounts owed by the Parent to the Holder and thus refunded to the Parent.

 

  32. CERTAIN DEFINITIONS . For purposes of this Note, the following terms shall have the following meanings:

 

(a)         “ 1933 Act ” means the Securities Act of 1933, as amended, and the rules and regulations thereunder.

 

(b)         “ 1934 Act ” means the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder.

 

(c)         “ Affiliate ” or “ affiliate ” means, with respect to any Person, any other Person that directly or indirectly controls, is controlled by, or is under common control with, such Person, it being understood for purposes of this definition that “control” of a Person means the power directly or indirectly either to vote 10% or more of the stock having ordinary voting power for the election of directors of such Person or direct or cause the direction of the management and policies of such Person whether by contract or otherwise.

 

(d)         “ Attribution Parties ” means, collectively, the following Persons and entities: (i) any investment vehicle, including, any funds, feeder funds or managed accounts, currently, or from time to time after the Issuance Date, directly or indirectly managed or advised by the Holder’s investment manager or any of its Affiliates or principals, (ii) any direct or indirect Affiliates of the Holder or any of the foregoing, (iii) any Person acting or who could be deemed to be acting as a Group together with the Holder or any of the foregoing and (iv) any other Persons whose beneficial ownership of the Common Stock would or could be aggregated with the Holder’s and the other Attribution Parties for purposes of Section 13(d) of the 1934 Act. For clarity, the purpose of the foregoing is to subject collectively the Holder and all other Attribution Parties to the Maximum Percentage.

 

  33  
 

 

(e)         “ Bloomberg ” means Bloomberg, L.P.

 

(f)         “ Business Day ” means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized or required by law to remain closed.

 

(g)         “ Closing Date ” shall have the meaning set forth in the Securities Purchase Agreement, which date is the date the Parent initially issued this Note and the Parent Warrant and ICA-T issued the ICA-T Note to the Holder pursuant to the terms of the Securities Purchase Agreement.

 

(h)         “ Closing Bid Price ” and “ Closing Sale Price ” means, for any security as of any date, the last closing bid price and last closing trade price, respectively, for such security on the Principal Market, as reported by Bloomberg, or, if the Principal Market begins to operate on an extended hours basis and does not designate the closing bid price or the closing trade price (as the case may be) then the last bid price or last trade price, respectively, of such security prior to 4:00:00 p.m., New York time, as reported by Bloomberg, or, if the Principal Market is not the principal securities exchange or trading market for such security, the last closing bid price or last trade price, respectively, of such security on the principal securities exchange or trading market where such security is listed or traded as reported by Bloomberg, or if the foregoing do not apply, the last closing bid price or last trade price, respectively, of such security in the over-the-counter market on the electronic bulletin board for such security as reported by Bloomberg, or, if no closing bid price or last trade price, respectively, is reported for such security by Bloomberg, the average of the bid prices, or the ask prices, respectively, of any market makers for such security as reported in the “pink sheets” by OTC Markets Group Inc. (formerly Pink Sheets LLC). If the Closing Bid Price or the Closing Sale Price cannot be calculated for a security on a particular date on any of the foregoing bases, the Closing Bid Price or the Closing Sale Price (as the case may be) of such security on such date shall be the fair market value as mutually determined by the Parent and the Holder. If the Parent and the Holder are unable to agree upon the fair market value of such security, then such dispute shall be resolved in accordance with the procedures in Section 24 . All such determinations shall be appropriately adjusted for any stock splits, stock dividends, stock combinations, recapitalizations or other similar transactions during such period.

 

(i)          “ Collateral Agent ” shall have the meaning set forth in the Securities Purchase Agreement.

 

  34  
 

 

(j)          “ Common Stock ” means (i) the shares of common stock, $0.001 par value per share of the Parent, and (ii) any capital stock into which such common stock shall have been changed or any share capital resulting from a reclassification of such common stock.

 

(k)         “ Convertible Securities ” means any stock or other security (other than Options) that is at any time and under any circumstances, directly or indirectly, convertible into, exercisable or exchangeable for, or which otherwise entitles the holder thereof to acquire, any shares of Common Stock.

 

(l)          “ Current Subsidiary ” means any Person in which the Parent or ICA-T on the Subscription Date, directly or indirectly, (i) owns a majority of the outstanding capital stock, voting stock or holds a majority of the equity or similar interest of such Person or (ii) controls or operates a substantial portion of the business, operations, management or administration of such Person, and all of the foregoing, collectively, “ Current Subsidiaries ”.

 

(m)        “ Eligible Market ” means any of the following markets or exchanges on which the Common Stock (or any other common stock of any other Person that references an Eligible Market for its common stock) is listed or quoted for trading on the date in question: the OTC Bulletin Board, the NASDAQ Global Market, the NASDAQ Global Select Market, the NASDAQ Capital Market, the New York Stock Exchange, NYSE Arca, the NYSE MKT, or the OTCQX Marketplace, the OTCQB Marketplace, the OTCPink Marketplace or any other tier operated by OTC Markets Group Inc. (or any successor to any of the foregoing).

 

(n)         “ Fundamental Transaction ” means that (i) the Parent, ICA-T and/or any of the Subsidiaries shall, directly or indirectly, in one or more or a series of related transactions, (1) consolidate or merge with or into (whether or not the Parent, ICA-T and/or any of the Subsidiaries is the surviving corporation) any other Person and/or each other, or (2) sell, lease, license, assign, transfer, convey or otherwise dispose of all or substantially all of its respective properties or assets to any other Person, or (3) allow any other Person to make a purchase, tender or exchange offer that is accepted by the holders of more than 50% of the outstanding shares of Voting Stock of the Parent and/or ICA-T (not including any shares of Voting Stock of the Parent and/or ICA-T held by the Person or Persons making or party to, or associated or affiliated with the Persons making or party to, such purchase, tender or exchange offer), or (4) consummate a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with any other Person whereby such other Person acquires more than 50% of the outstanding shares of Voting Stock of the Parent and/or ICA-T (not including any shares of Voting Stock of the Parent, ICA-T and/or any Subsidiary held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business combination), or (ii) any “person” or “group” (as these terms are used for purposes of Sections 13(d) and 14(d) of the 1934 Act and the rules and regulations promulgated thereunder) is or shall become the “beneficial owner” (as defined in Rule 13d-3 under the 1934 Act), directly or indirectly, of 50% of the aggregate ordinary voting power represented by issued and outstanding Voting Stock of the Parent and/or ICA-T. Notwithstanding anything to the contrary provided herein or elsewhere, nothing in this definition of Fundamental Transaction shall provide any right to the Parent, ICA-T and/or any Subsidiary to do or take any actions otherwise prohibited herein and/or in the other Transaction Documents. Notwithstanding the above, a Fundamental Transaction shall not be deemed to occur as a result of a reincorporation merger of the Parent, ICA-T and/or any Subsidiary provided other than the place of incorporation of the Parent, ICA-T and/or any Subsidiary no other material changes occur to the Parent, ICA-T and/or any Subsidiary and/or any rights of the Holder under this Note and/or any other Transaction Document, as a result of such reincorporation merger.

 

  35  
 

 

(o)         “ GAAP ” means United States generally accepted accounting principles, consistently applied.

 

(p)        “ ICA-T Note ” has the meaning set forth in the Securities Purchase Agreement.

 

(q)         “ Indebtedness ” shall have the meaning ascribed to such term in the Securities Purchase Agreement.

 

(r)          “ Interest Date ” means the first (1 st ) calendar day of each calendar month beginning with the first calendar day of the first month following the Closing Date.

 

(s)         “ Material Adverse Effect ” means any material adverse effect on (i) the business, properties, assets, liabilities, operations (including results thereof), condition (financial or otherwise) or prospects of the Parent, ICA-T and/or any of the Subsidiaries, individually or taken as a whole, (ii) the transactions contemplated hereby or in any of the other Transaction Documents or any other agreements or instruments to be entered into in connection herewith or therewith or (iii) the authority or ability of the ICA-T, the Parent and/or any of the Subsidiaries to perform any of the obligations under any of the Transaction Documents.

 

(t)          [INTENTIONALLY LEFT BLANK]

 

(u)         “ New Subsidiary ” means, as of any date of determination, any Person in which the Parent, ICA-T and/or any Subsidiary after the Subscription Date, directly or indirectly, (i) owns or acquires a majority of the outstanding capital stock, voting stock, or holds a majority of the equity or similar interest of such Person or (ii) controls or operates a substantial portion of the business, its management, operations or administration of such Person, and all of the foregoing, collectively, “ New Subsidiaries ”.

 

(v)         “ Options ” means any rights, warrants or options to subscribe for or purchase shares of Common Stock or Convertible Securities.

 

(w)         “ Parent Entity ” of a Person means an entity that, directly or indirectly, controls the applicable Person or, if there is more than one such Person or Parent Entity, the Person or Parent Entity with the largest public market capitalization (or if both are not Trading Issuers, the largest private company valuation, as determined by the Holder) as of the date of consummation of the Fundamental Transaction.

 

  36  
 

 

(x)         “ Parent Warrants ” has the meaning ascribed to such term in the Securities Purchase Agreement, and shall include all warrants issued in exchange therefor or replacement thereof.

 

(y)         “ Permitted Indebtedness ” means (i) Indebtedness of the Parent under this Note and/or any other Transaction Document, (ii) Indebtedness of the Parent set forth on Schedule 3(q) to the Securities Purchase Agreement, as in effect as of the Subscription Date, (iii) Indebtedness of the Parent incurred pursuant to accounts receivable and/or inventory financing, provided such is secured it is secured solely by the accounts receivable and/or inventory of the Company (iv) Indebtedness incurred for the acquisition of services, supplies or inventory of the Parent on normal trade credit in the ordinary course of business; (v) Indebtedness of the Parent secured by Permitted Liens or unsecured as described in clauses (iv) and (v) of the definition of Permitted Liens, (vi) $1,400,000 of Indebtedness owed to Dentons USA LLP (“ Dentons ”) under terms of a settlement and release agreement dated May 11, 2017 by and between Dentons and the Parent (the “ Dentons Settlement Agreement ”), and (vii) Intercompany Indebtedness of the Parent (to the extent not prohibited by the Sanofi Documents) between the Parent, ICA-T and any wholly-owned Domestic Subsidiary of the Parent, to the extent so permitted under this Note.

 

(z)         “ Permitted Liens ” means (i) any Lien for taxes not yet due or delinquent of the Parent or being contested in good faith by appropriate proceedings for which adequate reserves have been established in accordance with GAAP, (ii) any statutory Lien arising in the ordinary course of business by operation of law with respect to a liability of the Parent that is not yet due or delinquent, (iii) any Lien created by operation of law, such as materialmen’s liens, mechanics’ liens and other similar liens, arising in the ordinary course of business of the Parent with respect to a liability of the Parent that is not yet due or delinquent or that are being contested in good faith by appropriate proceedings, (iv) Liens (A) upon or in any equipment acquired or held by the Parent solely to secure the purchase price of such Parent equipment or Parent Indebtedness incurred solely by the Parent for the purpose of financing the acquisition or lease of such equipment of the Parent, or (B) existing on such equipment at the time of its acquisition, provided that the Lien is confined solely to the property of the Parent so acquired by the Parent and improvements thereon, and the proceeds of such equipment, in either case, with respect to Indebtedness of the Parent in an aggregate amount not to exceed together with the same type of ICA-T $250,000, (v) Liens incurred in connection with the extension, renewal or refinancing of the Indebtedness of the Parent secured by Liens of the type described in clause (iv) above, provided that any extension, renewal or replacement Lien shall be limited to the property encumbered by the existing Lien and the principal amount of the Indebtedness being extended, renewed or refinanced does not increase, (vi) Liens in favor of customs and revenue authorities arising as a matter of law to secure payments of custom duties in connection with the importation of goods for the Parent, (viii) Liens with respect to accounts receivable and inventory financing of the Parent provided such Liens are solely on the accounts receivable of the Parent that are being used to obtain such accounts receivable and/or inventory financing for the Parent as expressly identified and in such amounts as provided in writing in such accounts receivable and/or inventory financing documentation, and (ix) Liens in favor of the Collateral Agent and/or the Holder perfecting the Collateral Agent’s and/or the Holder’s security interests in the assets of the Parent to the extent provided for in the Security Documents securing all obligations of the Parent to the Holder and/or the Collateral Agent under this Note and/or any of the other Transaction Documents.

 

  37  
 

 

(aa)        “ Person ” means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization, any other entity or a government or any department or agency thereof.

 

(bb)        “ Principal Market ” means as of a particular date, the Eligible Market on such date that the Common Stock is principally traded or quoted on.

 

(cc)        “ Qualifying PO ” means the first firm commitment underwritten public offering by the Parent on or following the Subscription Date in which shares of Common Stock are sold for the account of the Parent solely for cash to the public resulting in proceeds to the Parent of no less than $8,000,000 (after deduction only of underwriter discounts and commissions) and where the shares of Common Stock registered under the 1933 Act and sold in such public offering, are simultaneously listed and commence trading on the Nasdaq Global Market, the Nasdaq Global Select Market, the Nasdaq Capital Market, the New York Stock Exchange or the NYSE Market (a “ Qualify Market ”).

 

(dd)       “ Redemption Notices ” means, collectively, the Event of Default Redemption Notices, the Fundamental Transaction Redemption Notices and the Parent Optional Redemption Notices and each of the foregoing, individually, a “ Redemption Notice.

 

(ee)        “ Redemption Prices ” means, collectively, the Parent Optional Redemption Prices, Event of Default Redemption Prices, Fundamental Transaction Redemption Prices and each of the foregoing, individually, a “ Redemption Price.

 

(ff)         “ SEC ” means the United States Securities and Exchange Commission or any successor thereto.

 

(gg)       “ Securities Purchase Agreement ” shall have the meaning set forth on the first page of this Note.

 

(hh)       “ Security Agreements ” shall have the meaning as set forth in the Securities Purchase Agreement.

 

(ii)         “ Security Documents ” shall have the meaning as set forth in the Securities Purchase Agreement.

 

(jj)          “ Subsidiaries ” means, as of any date of determination, collectively, all Current Subsidiaries including, but not limited to, all New Subsidiaries, and each of the foregoing, individually, a “ Subsidiary .”

 

(kk)        “ Successor Entity ” means the Person (or, if so elected by the Holder, the Parent Entity) formed by, resulting from or surviving any Fundamental Transaction or the Person (or, if so elected by the Holder, the Parent Entity) with which such Fundamental Transaction shall have been entered into.

 

  38  
 

 

(ll)        “ Trading Day ” means, (I) as applicable, (x) with respect to all price or trading volume determinations relating to the Common Stock, any day on which the Common Stock is traded on the Principal Market, or, if the Principal Market is not the principal trading market for the Common Stock, then on an Eligible Market the principal securities exchange or securities market on which the Common Stock is then traded or eligible for quotation, provided that “Trading Day” shall not include any day on which the Common Stock is scheduled to trade on such exchange or market for less than 4.5 hours or any day that the Common Stock is suspended from trading or quotation during the final hour of trading on such exchange or market (or if such exchange or market does not designate in advance the closing time of trading on such exchange or market, then during the hour ending at 4:00:00 p.m., New York time) unless such day is otherwise designated as a Trading Day in writing by the Holder or (y) with respect to all determinations other than price determinations relating to the Common Stock, any day on which The New York Stock Exchange (or any successor thereto) is open for trading of securities, or (II) if the Parent is not a Trading Issuer, the term “ Trading Day ” shall mean Business Day.

 

(mm)      “ Trading Issuer ” means any Person whose shares of common stock are listed for trading or eligible for quotation on an Eligible Market.

 

(nn)       “ Transaction Documents ” shall have the meaning as set forth in the Securities Purchase Agreement.

 

(oo)       “ Voting Stock ” of a Person means capital stock of such Person of the class or classes pursuant to which the holders thereof have the general voting power to elect, or the general power to appoint, at least a majority of the board of directors, managers, trustees or other similar governing body of such Person (irrespective of whether or not at the time capital stock of any other class or classes shall have or might have voting power by reason of the happening of any contingency).

 

33.          DISCLOSURE . Upon receipt or delivery by the Parent or ICA-T of any notice in accordance with the terms of this Note and subject to the other terms of this Section 33 , unless the Parent or ICA-T has in good faith determined that the matters relating to such notice do not constitute material, non-public information relating to the Parent, ICA-T and/or any of the Subsidiaries or the Holder has provided prior written consent to receive such material non-public information, the Parent shall and the Parent shall within two (2) Trading Days after any such receipt or delivery publicly disclose such material, non-public information on a Current Report on Form 8-K or otherwise. In the event that the Parent or ICA-T believes that a notice contains material, non-public information relating to the Parent, ICA-T and/or any of the Subsidiaries, the Parent and/or ICA-T so shall indicate to the Holder contemporaneously with delivery of such notice, and in the absence of any such indication, the Holder shall be allowed to presume that all matters relating to such notice do not constitute material, non-public information relating to the Parent, ICA-T and/or any of the Subsidiaries. If the Parent, ICA-T and/or any of the Subsidiaries provides material non-public information to the Holder that is not simultaneously filed in a Current Report on Form 8-K and the Holder has not agreed in writing to receive such material non-public information, the Parent and ICA-T hereby covenant and agree that the Holder shall not have any duty of confidentiality to them and/or the Subsidiaries or any of the officers, directors, employees, affiliates or agents with respect to, any such information or a duty to any of the foregoing not to trade on the basis of such material non-public information. Nothing contained in this Section 33 shall limit any obligations of the Parent and/or ICA-T, or any rights or remedies of the Holder, under the Securities Purchase Agreement. Notwithstanding anything to the contrary contained herein, neither the Parent, ICA-T nor any Subsidiary shall be required to publicly disclose any material, non-public information relating to the Parent, ICA-T or any Subsidiary if the Holder has provided its prior written consent to the receipt of such information.

 

  39  
 

 

[SENIOR SECURED CONVERTIBLE NOTE – SIGNATURE PAGE]

 

IN WITNESS WHEREOF , Icagen, Inc. has caused this Note to be duly executed as of the Issuance Date set out above.

 

  ICAGEN, INC.
     
  By: /s/ Richard Cunningham
    Name: Richard Cunningham
    Title: President and CEO

 

  40  
 

 

EXHIBIT I

 

Icagen, Inc. Conversion Notice

 

Reference is made to the Senior Secured Convertible Note (the “ Note ”) issued to the undersigned by Icagen-T, Inc., a Delaware corporation (the “ Parent ”). In accordance with and pursuant to the Note, the undersigned hereby elects to convert the Conversion Amount (as defined in the Note) of the Note indicated below into shares of common stock, $0.001 par value per share (the “ Common Stock ”), of Icagen, Inc., as of the date specified below. Capitalized terms not defined herein shall have the meaning as set forth in the Note.

 

  Date of Conversion:  
     
  Aggregate Principal to be converted:  
     
  Aggregate accrued and unpaid Interest to be converted:  
     
  Aggregate accrued and unpaid Late Charges with respect to such portion of the Aggregate Principal and Aggregate Interest to be converted:  
     
  AGGREGATE CONVERSION  
  AMOUNT TO BE CONVERTED:  

 

Please confirm the following information:

 

  Conversion Price:  
     
  Number of shares of Common Stock to be issued:  

 

Please issue the shares of Common Stock into the Note is being converted to Holder, or for its benefit, as follows:

 

☐   Check here if requesting delivery as a certificate to the following name and to the following address:

 

  Issue to:  
     
     

 

i
 

 

☐  Check here if requesting delivery by Deposit/Withdrawal at Custodian as follows:

 

  DTC Participant:  
     
  DTC Number:  
     
Account Number:  

 

Notwithstanding anything to the contrary contained herein, this Conversion Notice shall constitute a representation by the Holder of the Note submitting this Conversion Notice that after giving effect to the conversion provided for in this Conversion Notice, such Holder (together with its affiliates) will not have beneficial ownership (together with the beneficial ownership of such Person’s affiliates) of a number of shares of Common Stock which exceeds the Maximum Percentage (as defined in the Note) of the total outstanding shares of Common Stock of the Company as determined pursuant to the provisions of Section 3(d) of the Note.

 

Date: _____________ __,  
   
 
Name of Registered Holder  

 

By:      
  Name:    
  Title:    
       
  Tax ID: ____________________________    
       
  Facsimile: __________________________    
       
  E-mail Address: ______________________    

 

ii
 

 

Exhibit II

 

ACKNOWLEDGMENT

 

Icagen, Inc. hereby (a) acknowledges this Conversion Notice, (b) certifies that the above indicated number of shares of Common Stock [are][are not] eligible to be resold by the Holder either (i) pursuant to Rule 144 (subject to the Holder’s execution and delivery to the Parent of a customary 144 representation letter) or (ii) an effective and available registration statement and (c) hereby directs _________________ to issue the above indicated number of shares of Common Stock in accordance with the Transfer Agent Instructions dated May 15, 2017 from Icagen, Inc. and acknowledged and agreed to by American Stock Transfer & Trust Company.

 

  ICAGEN, INC. 
     
  By:  
    Name:
    Title:

 

 

i

 

Exhibit 4.2

 

Execution Version

 

NEITHER THE ISSUANCE AND SALE OF THIS NOTE NOR THE SECURITIES INTO WHICH THIS NOTE IS CONVERTIBLE INTO HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL TO THE PARENT OR THE HOLDER, IN A GENERALLY ACCEPTABLE FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES. ANY TRANSFEREE OF THIS NOTE SHOULD CAREFULLY REVIEW THE TERMS OF THIS NOTE, INCLUDING SECTIONS 3(c)(iii) AND 18(a) HEREOF. THE PRINCIPAL AMOUNT REPRESENTED BY THIS NOTE AND, ACCORDINGLY, THE SECURITIES ISSUABLE UPON CONVERSION HEREOF MAY BE LESS THAN THE AMOUNTS SET FORTH ON THE FACE HEREOF PURSUANT TO SECTION 3(c)(iii) OF THIS NOTE.

 

ICAGEN-T, INC.

 

SENIOR SECURED CONVERTIBLE NOTE

 

 

Note No: ICA-T – GPB - 1

Issuance Date: May 15, 2017

  Original Principal Amount: U.S. $8,000,000

 

FOR VALUE RECEIVED ,   Icagen-T, Inc., a Delaware corporation (“ ICA-T ” or the “ Company ”), hereby promises to pay to the order of GPB Debt Holdings II, LLC or its registered assigns (“ Holder ”) the amount set forth above as the Original Principal Amount (as reduced pursuant to the terms hereof pursuant to redemption, conversion or otherwise, the “ Principal ”) when due, whether upon the Maturity Date (as defined in Section 1 ), acceleration, conversion, redemption or otherwise (in each case in accordance with the terms hereof), and to pay interest (“ Interest ) on any outstanding Principal at the rate of thirteen (13%) percent per annum, as may be adjusted from time to time in accordance with Section 2 (the “ Interest Rate ”) from the date set out above as the Issuance Date (the “ Issuance Date ”) until the same becomes due and payable, whether upon an Interest Date (as defined below), the Maturity Date, acceleration, conversion, redemption or otherwise (in each case in accordance with the terms hereof). This Senior Secured Convertible Note (including all Senior Secured Convertible Notes issued in exchange, transfer or replacement hereof, this “ Note ”) was issued pursuant to the Securities Purchase Agreement, dated as of May 15, 2017 (the “ Subscription Date ”), by and among the Company, Icagen, Inc. a Delaware corporation and the owner of all of the issued and outstanding capital stock of the Company (the “ Parent ”) and the Holder (as amended from time to time, the “ Securities Purchase Agreement ”). Certain capitalized terms used herein are defined in Section 32 . Capitalized terms used but not defined herein shall have the meanings set forth in the Securities Purchase Agreement unless otherwise indicated herein as being defined by another Transaction Document.

 

 
 

 

This Note was issued with a four (4%) percent original issue discount (“ OID ”).

 

1.              PAYMENTS OF PRINCIPAL; PREPAYMENT . On the Maturity Date, the Company shall pay to the Holder an amount in cash representing all then outstanding Principal, accrued and unpaid Interest, accrued and unpaid Late Charges (as defined in Section 25(c) ), on such Principal and Interest and all other amounts due hereunder. “ Maturity Date ” shall be May 15, 2020; provided , however , the Maturity Date may be extended at the sole option of the Holder in an express writing to the Company (i) in the event that, and for so long as, an Event of Default (as defined below), shall have occurred and be continuing or any event shall have occurred and be continuing that with the passage of time or the giving of notice (or both) and the failure to cure would result in an Event of Default or (ii) through the date that is twenty (20) Business Days after the consummation of a Fundamental Transaction in the event that a Fundamental Transaction is publicly announced or a Fundamental Transaction Notice is delivered prior to the Maturity Date. Other than as expressly permitted by this Note, the Company, may not prepay any portion of the outstanding Principal, accrued and unpaid Interest or accrued and unpaid Late Charges on Principal and Interest, if any. Notwithstanding anything herein to the contrary, with respect to any conversion or redemption hereunder, as applicable, the Company shall convert or redeem, as applicable, First , all accrued and unpaid Interest on any Principal and Interest hereunder, Second , all accrued but unpaid Late Charges on any Principal and Interest hereunder, Third , all Principal outstanding hereunder, and Fourth , all other amounts outstanding hereunder.

 

2. INTEREST; DEFAULT INTEREST RATE .

 

(a)          Interest on this Note shall commence accruing on the Issuance Date at the Interest Rate computed on the basis of a 360-day year and twelve 30-day months, shall be payable in arrears on each Interest Date and shall be payable in accordance with the terms of this Note. Interest shall be payable on each Interest Date, to the record holder of this Note on the applicable Interest Date in cash.

 

(b)         Prior to the payment of Interest on an Interest Date, Interest on this Note shall accrue at the Interest Rate and be payable by way of inclusion of the Interest in the Conversion Amount (as defined below), on each Conversion Date (as defined below) in accordance with Section 3(b)(i) or upon any redemption in accordance with Section 12 or any required payment upon any Bankruptcy Event of Default (as defined below).

 

(c)          From and after the occurrence and during the continuation of any Event of Default, the Interest Rate shall automatically be increased to eighteen (18%) per annum. In the event that such Event of Default is subsequently cured, and no other Event of Default then exists, the adjustment referred to in the preceding sentence shall cease to be effective as of the calendar day immediately following the date of such cure; provided that the Interest as calculated and unpaid at such increased rate during the continuance of such Event of Default shall continue to apply to the extent relating to the days after the occurrence of such Event of Default through and including the date of such cure of such Event of Default.

 

  2  
 

 

3.              CONVERSION OF NOTE . At any time after the Issuance Date, this Note shall be convertible into validly issued, fully paid and non-assessable shares of Parent Common Stock (as defined in Section 32 of this Note), on the terms and conditions set forth in this Section 3 .

 

(a)           Conversion Right . Subject to the provisions of Section 3(d) , at any time or times on or after the Issuance Date, the Holder shall be entitled to convert all or any portion of the outstanding and unpaid Conversion Amount into validly issued, fully paid and non-assessable shares of Parent Common Stock in accordance with Section 3(c) , at the Conversion Rate. Parent shall not issue any fraction of a share of Parent Common Stock upon any conversion. If the issuance would result in the issuance of a fraction of a share of Parent Common Stock, Parent shall round such fraction of a share of Parent Common Stock up to the nearest whole share. The Holder shall pay any and all transfer, stamp, issuance and similar taxes, costs and expenses (including, without limitation, fees and expenses of any transfer agent of Parent (the “ Transfer Agent ”) and the Depository Trust Company (“ DTC ”)), that may be payable with respect to the issuance and delivery of Parent Common Stock upon conversion of any Conversion Amount.

 

(b)           Conversion Rate . The number of shares of Parent Common Stock issuable upon conversion of any Conversion Amount (as defined below) pursuant to Section 3(a) shall be determined by dividing (x) such Conversion Amount by (y) the Conversion Price (as defined below) (the “ Conversion Rate” ).

 

(i)           “ Conversion Amount ” means the sum of (A) the portion of the Principal to be converted, redeemed or otherwise with respect to which this determination is being made, (B) all accrued and unpaid Interest with respect to such portion of such Principal, (C) all accrued and unpaid Late Charges with respect to such portion of such Principal and such Interest, if any, and (D) all other amounts due hereunder.

 

(ii)          “ Conversion Price ” means $3.50, subject to adjustment as provided elsewhere in this Note.

 

  3  
 

 

(c) Mechanics of Conversion .

  

(i)            Optional Conversion . To convert any Conversion Amount into shares of Parent Common Stock on any date (a “ Conversion Date ”), the Holder shall deliver (whether via facsimile, electronic mail or otherwise), for receipt on or prior to 11:59 p.m., New York time, on such date, a copy of an executed notice of conversion in the form attached hereto as Exhibit I (the “ Conversion Notice ”) to the Parent. If required by Section 3(c)(iii) , within three (3) Trading Days, following a conversion of this Note as aforesaid, the Holder shall surrender this Note to a nationally recognized overnight delivery service for delivery to the Company (or an indemnification undertaking with respect to this Note in the case of its loss, theft or destruction as contemplated by Section 19(b)) . On or before the first (1st) Trading Day following the date of receipt of a Conversion Notice, the Parent shall transmit by facsimile or electronic mail an acknowledgment of confirmation and representation as to whether such shares of Parent Common Stock may then be resold pursuant to Rule 144 or an effective and available registration statement, in the form attached hereto as Exhibit II , (which representation shall not include a factual analysis of whether any share caps have been exceeded) of receipt of such Conversion Notice to the Holder and the Transfer Agent which confirmation shall constitute an instruction to the Transfer Agent to process such Conversion Notice in accordance with the terms herein. On or before the third (3 rd ) Trading Day, following the date on which the Parent has received a Conversion Notice (or such earlier date as required pursuant to the 1934 Act or other applicable law, rule or regulation for the settlement of a trade initiated on the applicable Conversion Date of such shares of Parent Common Stock issuable pursuant to such Conversion Notice) (the “ Share Delivery Deadline ”), the Parent shall (1) provided the Transfer Agent is participating in the DTC Fast Automated Securities Transfer Program, credit such aggregate number of shares of Parent Common Stock to which the Holder shall be entitled pursuant to such conversion to the Holder’s or its designee’s balance account with DTC through its Deposit/Withdrawal at Custodian system, or (2) if the Transfer Agent is not participating in the DTC Fast Automated Securities Transfer Program, upon the request of the Holder, issue and deliver (via reputable overnight courier) to the address as specified in the Conversion Notice, a certificate, registered in the name of the Holder or its designee, for the number of shares of Parent Common Stock to which the Holder shall be entitled pursuant to such conversion. If this Note is physically surrendered for conversion pursuant to Section 3(c)(iii) , and the outstanding Principal of this Note is greater than the Principal portion of the Conversion Amount being converted, then the Company shall as soon as practicable and in no event later than three (3) Business Days after receipt of this Note and at its own expense, issue and deliver to the Holder (or its designee) a new Note (in accordance with Section 19(d) ) representing the outstanding Principal not converted. The Person or Persons entitled to receive the shares of Parent Common Stock issuable upon a conversion of this Note shall be treated for all purposes as the record holder or holders of such shares of Parent Common Stock on the Conversion Date. Notwithstanding anything to the contrary contained in this Note, the Securities Purchase Agreement and/or any other Transaction Document, after the effective date of any Registration Statement (as defined in the Securities Purchase Agreement), the Parent shall cause the Transfer Agent to deliver unlegended shares of Common Stock to the Holder (or its designee) in connection with any sale of Registrable Securities (as defined in the Securities Purchase Agreement) with respect to which the Holder has entered into a contract for sale, and delivered a copy of the prospectus included as part of the particular Registration Statement to the extent applicable, and for which the Holder has not yet settled.

 

  4  
 

 

(ii)            Parent’s Failure to Timely Convert . If the Parent fails on or prior to a Share Delivery Deadline to issue and deliver a certificate or credit the Holder’s or its designee’s account with DTC (as the case may be pursuant to this Section 3(c)(ii) and/or pursuant to the Parent’s obligation pursuant to clause (II) below for the number of shares of Parent Common Stock to which the Holder is entitled, and if on or after such Share Delivery Deadline the Holder purchases (in an open market transaction or otherwise) shares of Parent Common Stock to deliver in satisfaction of a sale by the Holder of all or any portion of the number of shares of Parent Common Stock issuable upon such conversion that the Holder anticipated receiving from the Parent (a “ Buy-In ”), then, in addition to all other remedies available to the Holder, the Parent shall, within three (3) Trading Days after receipt of the Holder’s request and in the Holder’s sole discretion, either, at the Holder’s option (I) pay cash to the Holder in an amount equal to the Holder’s total purchase price (including brokerage commissions and other out-of-pocket expenses, if any) for the shares of Parent Common Stock so purchased (including, without limitation, by any other Person in respect, or on behalf, of the Holder) (the “ Buy-In Price ”), at which point the Parent’s obligation to so issue and deliver such certificate or credit the balance account of the Holder or the Holder’s designee, as applicable, with DTC for the number of shares of Parent Common Stock to which the Holder is entitled upon the Holder’s conversion of the applicable Conversion Amount shall terminate, or (II) promptly (but in no event later than two (2) Trading Days following the request by the Holder) honor its obligation to so issue and deliver to the Holder a certificate or certificates representing such shares of Parent Common Stock or credit the balance account of such Holder or such Holder’s designee, as applicable, with DTC for the number of shares of Parent Common Stock to which the Holder anticipated receiving from the Parent and pay cash to the Holder in an amount equal to the excess (if any) of the Buy-In Price over the product of (x) such number of shares of Parent Common Stock multiplied by (y) the lowest Closing Sale Price or Closing Bid Price (as the case may be) of the Parent Common Stock on any Trading Day during the period commencing on the date of the applicable Conversion Notice and ending on the date of such issuance and payout under this clause II (or if the Parent is then not a Trading Issuer, the Conversion Price) (the “ Buy-In Payment Amount ”). Nothing herein or elsewhere shall limit the Holder’s right to pursue any other remedies available to it hereunder, at law or in equity, including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Parent’s failure to timely deliver certificates representing shares of Parent Common Stock (or to timely electronically deliver such shares of Parent Common Stock) upon the conversion of this Note as required pursuant to the terms hereof.

 

  5  
 

 

(iii)           Registration; Book-Entry . The Parent and the Company shall maintain a register (the “ Register ”) for the recordation of the name and address of the Holder and the principal amount of the Notes (and stated interest thereon) held by the Holder (the “ Registered Notes ”). The Parent and the Holder of the Note shall treat each Person whose name is recorded in the Register as the owner of a Note for all purposes (including, without limitation, the right to receive payments of Principal, Interest and Late Charges). A Registered Note may be assigned, transferred or sold in whole or in part by registration of such assignment or sale on the Register but only to a Buyer Affiliate (as defined in the Securities Purchase Agreement) and/or any other Person in accordance with Section 18 . Upon its receipt of a written request to assign, transfer or sell all or part of any Registered Note by the Holder, the Parent shall record the information contained therein in the Register and issue one or more new Registered Notes in the same aggregate Principal amount as the Principal amount of the surrendered Registered Note to the designated assignee or transferee pursuant to Section 19 , provided that if the Parent does not so record an assignment, transfer or sale (as the case may be) of all or part of any Registered Note within three (3) Business Days of such a request, then the Register shall be automatically deemed updated to reflect such assignment, transfer or sale (as the case may be). Notwithstanding anything to the contrary set forth in this Note or elsewhere, following conversion of any portion of this Note in accordance with the terms hereof, the Holder shall not be required to physically surrender this Note to the Company unless (A) the full Conversion Amount represented by this Note is being converted (in which event this Note shall be delivered to the Company following conversion thereof as contemplated by Section 3(c)(i) ) or (B) the Holder has provided the Parent with prior written notice (which notice may be included in a Conversion Notice) requesting reissuance of this Note upon physical surrender of this Note. The Holder and the Parent shall maintain records showing the Principal, Interest and Late Charges converted and/or paid (as the case may be) and the dates of such conversions and/or payments (as the case may be) or shall use such other method, reasonably satisfactory to the Holder and the Parent, so as not to require physical surrender of this Note upon conversion. If the Parent does not update the Register to record such Principal, Interest and Late Charges converted and/or paid (as the case may be) and the dates of such conversions and/or payments (as the case may be) within three (3) Business Days of such occurrence, then the Register shall be automatically deemed updated to reflect such occurrence.

 

(iv)          Disputes . In the event of a dispute as to the number of shares of Parent Common Stock issuable to the Holder in connection with a conversion of this Note, the Parent shall issue to the Holder the number of shares of Parent Common Stock not in dispute and resolve such dispute in accordance with Section 24 .

 

  6  
 

 

(d)           Limitations on Conversions . Neither the Company nor the Parent shall effect the conversion of any portion of this Note, and the Holder shall not have the right to convert any portion of this Note pursuant to the terms and conditions of this Note and any such conversion shall be null and void and treated as if never made, to the extent that after giving effect to such conversion, the Holder together with the other Attribution Parties collectively would beneficially own in excess of 4.99% (the “ Maximum Percentage ”) of the shares of Parent Common Stock outstanding immediately after giving effect to such conversion such determination to be based solely upon the Reported Outstanding Share Number (as defined below) and the number of shares disclosed to the Parent by Holder as being beneficially owned by the Holder and the other Attribution Parties. For purposes of the foregoing sentence, the aggregate number of shares of Parent Common Stock beneficially owned by the Holder and the other Attribution Parties shall include the number of shares of Parent Common Stock held by the Holder and all other Attribution Parties plus the number of shares of Parent Common Stock issuable upon conversion of this Note with respect to which the determination of such sentence is being made, but shall exclude shares of Parent Common Stock which would be issuable upon (A) conversion of the remaining, non-converted portion of this Note beneficially owned by the Holder or any of the other Attribution Parties and (B) exercise or conversion of the unexercised or non-converted portion of any other securities of the Parent (including, without limitation, any convertible notes or convertible preferred stock or warrants, including, without limitation, the Parent Note and the Parent Warrant) beneficially owned by the Holder or any other Attribution Party subject to a limitation on conversion or exercise analogous to the limitation contained in this Section 3(d) . For purposes of this Section 3(d) , beneficial ownership shall be calculated in accordance with Section 13(d) of the 1934 Act. For purposes of determining the number of outstanding shares of Parent Common Stock the Holder may acquire upon the conversion of this Note without exceeding the Maximum Percentage, the Holder may rely on the number of outstanding shares of Parent Common Stock as reflected in (x) the Parent’s most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q, Current Report on Form 8-K or other public filing with the SEC, as the case may be, (y) a more recent public announcement by the Parent or (z) any other written notice by the Parent or the Transfer Agent, if any, setting forth the number of shares of Parent Common Stock outstanding (the “ Reported Outstanding Share Number ”). If the Parent receives a Conversion Notice from the Holder at a time when the actual number of outstanding shares of Parent Common Stock is less than the Reported Outstanding Share Number, the Parent shall notify the Holder in writing of the number of shares of Parent Common Stock then outstanding and, to the extent that such Conversion Notice would otherwise cause the Holder’s beneficial ownership, as determined pursuant to this Section 3(d) , to exceed the Maximum Percentage, the Holder must (i) notify the Parent of a reduced number of shares of Parent Common Stock to be purchased pursuant to such Conversion Notice (the number of shares by which such purchase is reduced, the “ Reduction Shares ”) and (ii) as soon as reasonably practicable, the Parent shall return to the Holder any conversion price paid by the Holder for the Reduction Shares. For any reason at any time, upon the written or oral request of the Holder, the Parent shall within one (1) Business Day confirm orally and in writing or by electronic mail to the Holder the number of shares of Parent Common Stock then outstanding. In any case, the number of outstanding shares of Parent Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Parent, including this Note, by the Holder and any other Attribution Party since the date as of which the Reported Outstanding Share Number was reported. In the event that the issuance of shares of Parent Common Stock to the Holder upon conversion of this Note results in the Holder and the other Attribution Parties being deemed to beneficially own, in the aggregate, more than the Maximum Percentage of the number of outstanding shares of Parent Common Stock (as determined under Section 13(d) of the 1934 Act), the number of shares so issued by which the Holder’s and the other Attribution Parties’ aggregate beneficial ownership exceeds the Maximum Percentage (the “ Excess Shares ”) shall be deemed null and void and shall be cancelled ab initio , and the Holder shall not have the power to vote or to transfer the Excess Shares. Upon delivery of a written notice to the Parent, the Holder may from time to time increase (with such increase not effective until the sixty-first (61 st  ) day after delivery of such notice) or decrease the Maximum Percentage to any other percentage not in excess of 9.99% as specified in such notice; provided that any such increase in the Maximum Percentage will not be effective until the sixty-first (61 st  ) day after such notice is delivered to the Parent. For purposes of clarity, the shares of Parent Common Stock issuable pursuant to the terms of this Note in excess of the Maximum Percentage shall not be deemed to be beneficially owned by the Holder for any purpose including for purposes of Section 13(d) or Rule 16a-1(a)(1) of the 1934 Act. No prior inability to convert this Note pursuant to this paragraph shall have any effect on the applicability of the provisions of this paragraph with respect to any subsequent determination of convertibility. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 3(d) to the extent necessary to correct this paragraph (or any portion of this paragraph) which may be defective or inconsistent with the intended beneficial ownership limitation contained in this Section 3(d) or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitation contained in this paragraph may not be waived and shall apply to a successor holder of this Note.

 

  7  
 

 

4. EVENTS OF DEFAULT; RIGHTS UPON EVENT OF DEFAULT .

 

(a)            Event of Default . Each of the following events shall constitute an “ Event of Default ” and each of the events in clauses (iv), (v) and (vi) shall constitute a “ Bankruptcy Event of Default ”:

 

(i)           the Company’s, the Parent’s and/or any of the Subsidiary’s failure to pay to the Holder any amount of Principal, Interest, Late Charges or other amounts when and as due under this Note (including, without limitation, the Company’s, the Parent’s and/or any Subsidiary’s failure to pay any redemption payments or amounts hereunder), any other Transaction Document to which the Company is a party and/or any other agreement, document, certificate or other instrument delivered in connection with the transactions contemplated hereby and thereby, except, in the case of a failure to pay Interest and Late Charges when and as due, in which case only if such failure remains uncured for a period of at least five (5) calendar days;

 

(ii)          the Parent fails at any time to (A) remove any restrictive legend on any certificate or any shares of Parent Common Stock issued and/or issuable to the Holder upon conversion or exercise and/or otherwise (as the case may be) of this Note and/or any shares of Parent Common Stock issuable hereunder as and when required by such securities, this Note and/or the Securities Purchase Agreement, unless otherwise then prohibited by (I) applicable federal securities laws, and/or (II) any lock-up or similar written agreement to which the Holder and any underwriter of a Qualifying PO is a party to, and any such failure remains uncured for at least three (3) consecutive days, and (B) issue and deliver to the Holder such unlegended certificates including, but not limited to, for any shares of Parent Common Stock issuable upon conversion and/or otherwise of this Note;

 

(iii)         the occurrence of any default under, redemption of or acceleration prior to maturity of at least $250,000 of Indebtedness of the Company;

 

(iv)         bankruptcy, insolvency, reorganization or liquidation proceedings or other proceedings for the relief of debtors shall be instituted by or against the Company and, if instituted against the Company by a third party, shall not be dismissed within forty-five (45) days of their initiation;

 

(v)          the commencement by the Company of a voluntary case or proceeding under any applicable federal, state or foreign bankruptcy, insolvency, reorganization or other similar law or of any other case or proceeding to be adjudicated a bankrupt or insolvent, or the consent by it to the entry of a decree, order, judgment or other similar document in respect of the Company in an involuntary case or proceeding under any applicable federal, state or foreign bankruptcy, insolvency, reorganization or other similar law or to the commencement of any bankruptcy or insolvency case or proceeding against it, or the filing by it of a petition or answer or consent seeking reorganization or relief under any applicable federal, state or foreign law, or the consent by it to the filing of such petition or to the appointment of or taking possession by a custodian, receiver, liquidator, assignee, trustee, sequestrator or other similar official of the Company or of any substantial part of its property, or the making by it of an assignment for the benefit of creditors, or the execution of a composition of debts, or the occurrence of any other similar federal, state or foreign proceeding, or the admission by it in writing of its inability to pay its debts generally as they become due, the taking of corporate action by the Company in furtherance of any such action or the taking of any action by any Person to commence a Uniform Commercial Code foreclosure sale or any other similar action under federal, state or foreign law;

 

  8  
 

 

(vi)         the entry by a court of (i) a decree, order, judgment or other similar document in respect of the Company of a voluntary or involuntary case or proceeding under any applicable federal, state or foreign bankruptcy, insolvency, reorganization or other similar law or (ii) a decree, order, judgment or other similar document adjudging the Company as bankrupt or insolvent, or approving as properly filed a petition seeking liquidation, reorganization, arrangement, adjustment or composition of or in respect of the Company under any applicable federal, state or foreign law or (iii) a decree, order, judgment or other similar document appointing a custodian, receiver, liquidator, assignee, trustee, sequestrator or other similar official of the Company or of any substantial part of its property, or ordering the winding up or liquidation of its affairs, and the continuance of any such decree, order, judgment or other similar document or any such other decree, order, judgment or other similar document unstayed and in effect for a period of sixty (60) consecutive days;

 

(vii)        a final judgment or judgments for the payment of money aggregating in excess of $300,000 are rendered against the Company and which judgments are not, within forty-five (45) days after the entry thereof, bonded, discharged, settled or stayed pending appeal, or are not discharged within forty-five (45) days after the expiration of such stay; provided , however , any judgment which is covered by insurance or an indemnity from a credit worthy party shall not be included in calculating the $300,000 amount set forth above so long as the Company provides the Holder a written statement from such insurer or indemnity provider (which written statement shall be reasonably satisfactory to the Holder) to the effect that such judgment is covered by insurance or an indemnity and the Company will receive the proceeds of such insurance or indemnity within forty-five (45) days of the issuance of such judgment;

 

(viii)       the Company either (i) fails to pay, when due, or within any applicable grace period, any payment with respect to any Indebtedness in excess of $250,000 due to any third party(ies) (other than, with respect to unsecured Indebtedness only, payments contested by the Company in good faith by proper proceedings and with respect to which adequate reserves have been set aside for the payment thereof in accordance with GAAP) or is otherwise in breach or violation of any agreement for monies owed or owing in an amount in excess of $250,000, which breach or violation permits the other party thereto to declare a default or otherwise accelerate amounts due thereunder, or (ii) suffers to exist any other circumstance or event that would, with or without the passage of time or the giving of notice, result in a default or event of default under any agreement binding the Company which default or event of default would or is likely to have a material adverse effect on the business, assets, operations (including results thereof), liabilities, properties, condition (including financial condition) of the Company;

 

(ix)          other than as specifically set forth in another clause of this Section 4(a) , the Company breaches any material representation, warranty, covenant or other term or condition of any Transaction Document to which it is a party (as defined in the Securities Purchase Agreement), except, in the case of a breach of a covenant or other term or condition that is curable, only if such breach remains uncured for a period of thirty (30) days;

 

(x)          any breach or failure in any material respect by the Company of any provision of Section 14 of this Note;

 

  9  
 

 

(xi)          any material adverse effect on (i) the business, properties, assets, liabilities, operations (including results thereof), condition (financial or otherwise) or prospects of the Company (ii) the transactions contemplated hereby or in any of the other Transaction Documents to which the Company is a party or (iii) the authority or ability of the Company to perform any of the obligations under any of the Transaction Documents to which the Company is a party;

 

(xii)         any material provision of any Transaction Document to which the Company is a party (including, without limitation, the Security Documents and the Guaranties) shall at any time for any reason (other than pursuant to the express terms thereof) cease to be valid and binding on or enforceable against the parties thereto, or the validity or enforceability thereof shall be contested by any party thereto, or a proceeding shall be commenced by the Company or any governmental authority having jurisdiction over any of them, seeking to establish the invalidity or unenforceability thereof, or the Company shall deny in writing that it has any Indebtedness, liability or obligation purported to be created under any Transaction Document (including, without limitation, the Security Documents and the Guaranties);

 

(xiii)        any Security Document to which the Company is a party and/or any other security document to which the Company is a party, shall at any time for any reason fail or cease to create a separate valid and perfected and, except to the extent permitted by the terms thereof, first priority Lien (as defined in the Securities Purchase Agreement) on any Collateral (as defined in the Security Agreement) of the Company (“ Company Collateral ”) in favor of the Collateral Agent (as defined in the Securities Purchase Agreement) or any material provision of any Security Document to which the Company is a party, shall at any time for any reason cease to be valid and binding on or enforceable against the Company, the Parent and/or any of the Subsidiaries or the validity or enforceability thereof shall be contested by any party thereto, or a proceeding shall be commenced by the Company, the Parent, and/or any of the Subsidiaries or any governmental authority having jurisdiction over the Company, the Parent and/or any of the Subsidiaries, seeking to establish the invalidity or unenforceability thereof;

 

(xiv)        any material damage to, or loss, theft or destruction of, any Company Collateral, whether or not insured, or any strike, lockout, labor dispute, embargo, condemnation, act of God or public enemy, or other casualty which causes, for more than fifteen (15) consecutive calendar days, the cessation or substantial curtailment of revenue producing activities at any facility of the Company if any such event or circumstance would have a Material Adverse Effect;

 

(xv)         if at any time following the first date the Parent becomes a Trading Issuer the suspension from trading, or the failure of the Parent Common Stock to be trading or listed (as applicable) on an Eligible Market for a period of five (5) consecutive Trading Days or for more than an aggregate of ten (10) Trading Days in any 365-day period;

 

  10  
 

 

(xvi)        the Parent’s (A) failure to cure a Conversion Failure by delivery of the required number of shares of Parent Common Stock upon conversion of this Note within three (3)  Trading Days after the applicable Conversion Date or (B) notice, written or oral, to any holder of this Note, including, without limitation, by way of public announcement or through any of its agents, at any time, of its intention not to comply, as required, with a request for conversion of this Note into shares of Parent Common Stock that is requested in accordance with the provisions of this Note, other than pursuant to Section 3(d) ,;

 

(xvii)       except to the extent the Parent is in compliance with Section 11(b) at any time following the tenth (10 th ) consecutive day that the Required Reserve Amount (as defined in Section 11(a) below) is less than the number of shares of Parent  Common Stock that the Holder would be entitled to receive upon a conversion by the Holder of the full Conversion Amount of this Note (without regard to any limitations on conversion set forth in this Note or otherwise);

 

(xviii)      any event of default and/or any event that with the giving of notice or the passage of time (or both) would constitute an event of default, under any of the Sanofi Documents (as defined in the Securities Purchase Agreement) including, but not limited to, the S/I MSA, the S/I APA, the S/I Warranty and Reverter Deed and/or the S/I Deed of Trust (each as defined in the Securities Purchase Agreement) and/or any other event (including, but not limited to, any sale and/or foreclosure and/or giving notice of the same of the Property, Property Income (as both terms are defined in the S/I Deed of Trust) and/or any other items set forth in the first paragraph of the S/I Deed of Trust used as collateral under the S/I Deed of Trust, by or for the benefit of Sanofi that has and/or could reasonably be expected to have a Material Adverse Effect (as defined in the Securities Purchase Agreement), or a “default” occurs (as such term is used in any provision of the S/I Deed of Trust);

 

(xix)       A false, misleading and/or inaccurate certification (including a false or inaccurate deemed certification) by the Company, the Parent and/or any Subsidiary as to, among other items, whether any Event of Default has occurred;

 

(xx)         the Parent's failure for any reason immediately following the date a Registration Statement covering securities of the Parent sold in the Qualifying PO is declared effective by the SEC or at any other time following the first date the Parent becomes a Trading Issuer to satisfy the current public information requirement under Rule 144(c) of the 1933 Act;

 

(xxi)       the failure of any Registration Statement (as defined in the Securities Purchase Agreement) with respect to Registrable Securities to be declared effective by the SEC on or prior to the applicable Effectiveness Deadline (as defined in the Securities Purchase Agreement) unless at such time counsel to the Company provides a legal opinion to the Holder and the Transfer Agent that (i) all Registrable Securities can be sold under Rule 144 without restriction, and (ii) at each time the Holder seeks to sell any such Registrable Securities such counsel provides a legal opinion to the Buyer and the Transfer Agent removing all restrictive and other legends on such Registrable Securities no later than the Share Delivery Date;

 

  11  
 

 

(xxii)       while any applicable Registration Statement is required to be maintained effective pursuant to the terms of the Securities Purchase Agreement, the effectiveness of the applicable Registration Statement lapses for any reason (including, without limitation, the issuance of a stop order) or such Registration Statement (or the prospectus contained therein) is unavailable to any holder of Registrable Securities (as defined in the Securities Purchase Agreement) for sale of all of such holder’s Registrable Securities registered under such Registration Statement in accordance with the terms of the Securities Purchase Agreement, and such lapse or unavailability continues for a period of ten (10) consecutive business days or for more than an aggregate of ten (10) days in any 365-day period;

 

(xxiii)      any Controlled Account Agreement (as defined in the Security Agreement) of the Company shall for any reason fail or cease to create a separate valid and perfected and, except to the extent permitted by the terms hereof or thereof, first priority Lien on the Collateral (as defined below) in favor of the Holder and/or the Collateral Agent or any material provision of any Controlled Account Agreement of the Company shall at any time for any reason cease to be valid and binding on or enforceable against ICA-T or the validity or enforceability thereof shall be contested by any party thereto, or a proceeding shall be commenced by ICA-T or any Governmental Entity (as defined in the Securities Purchase Agreement) having jurisdiction over ICA-T, seeking to establish the invalidity or unenforceability thereof.

 

(b)           Notice of an Event of Default; Redemption Right . Upon the occurrence of an Event of Default, the Company and the Parent shall within one (1) Business Day of such Event of Default deliver a mutual written notice thereof via facsimile or electronic mail and overnight courier (with next day delivery specified) (an “ Event of Default Notice ”) to the Holder. At any time after the earlier of the Holder’s receipt of an Event of Default Notice and the Holder becoming aware of an Event of Default (such earlier date, the “ Event of Default Right Commencement Date ”) and ending (such ending date, the “ Event of Default Right Expiration Date ”, and each such period, an “ Event of Default Redemption Right Period ”) on the tenth (10 th ) Trading Day after the later of (x) the date such Event of Default is cured and (y) the Holder’s receipt of an Event of Default Notice that includes (I) a reasonable description of the applicable Event of Default, (II) a certification as to whether, in the opinion of the Company and the Parent, such Event of Default is capable of being cured and, if applicable, a reasonable description of any existing plans of the Company and/or the Parent to cure such Event of Default and (III) a certification as to the date the Event of Default occurred and, if cured on or prior to the date of such Event of Default Notice, the applicable Event of Default Right Expiration Date, the Holder may require the Company and/or the Parent to redeem all or any portion of this Note by delivering written notice thereof (the “ Event of Default Redemption Notice ”) to the Company and/or the Parent, which Event of Default Redemption Notice shall indicate the portion of this Note the Holder is electing to redeem. Each portion of this Note subject to redemption by the Company and/or the Parent pursuant to this Section 4(b) shall be redeemed by the Company and/or the Parent at a price in cash equal to the product of (A) the Conversion Amount being redeemed multiplied by (B) (i) 116% if the applicable Event of Default Redemption Price is paid in full to the Holder on a date prior to May 15, 2018, (ii) 117% if the Event of Default Redemption Price is paid in full to the Holder after May 15, 2018 but prior to May 15, 2019 and (iii) 118% if the Event of Default Redemption Price is paid in full to the Holder after May 15, 2019 but on or prior to the Maturity Date (the “ Event of Default Redemption Price ”). Redemptions required by this Section 4(b) shall be made in accordance with the provisions of Section 12 . To the extent redemptions required by this Section 4(b) are deemed or determined by a court of competent jurisdiction to be prepayments of this Note by the Company and/or the Parent, such redemptions shall be deemed to be voluntary prepayments. Notwithstanding anything to the contrary in this Section 4 , but subject to Section 3(d) , until the Event of Default Redemption Price (together with any Late Charges thereon) is paid in full to the Holder as provided in this Note, the Conversion Amount submitted for redemption under this Section 4(b) (together with Late Charges thereon) may be converted in whole or in part by the Holder into shares of Parent Common Stock pursuant to Section 3 of this Note. In the event of the Company’s and/or the Parent’s redemption of any portion of this Note under this Section 4(b) , the Holder’s damages would be uncertain and difficult to estimate because of the parties’ inability to predict future interest rates and the uncertainty of the availability of a suitable substitute investment opportunity for the Holder. Accordingly, any redemption premium due under this Section 4(b) is intended by the parties to be, and shall be deemed, a reasonable estimate of the Holder’s actual loss of its investment opportunity and not as a penalty. Any redemption upon an Event of Default shall not constitute an election of remedies by the Holder, and all other rights and remedies of the Holder shall be preserved.

 

  12  
 

 

(c)           Mandatory Redemption upon Bankruptcy Event of Default . Notwithstanding anything to the contrary herein, and notwithstanding any conversion that is then required or in process, upon any Bankruptcy Event of Default, whether occurring prior to or following the Maturity Date, the Company shall immediately pay to the Holder an amount in cash representing the Event of Default Redemption Price (together with Late Charges thereon) in addition to any and all other amounts due hereunder, without the requirement for any notice or demand or other action by the Holder or any other person or entity, provided that the Holder may, in its sole discretion, waive such right to receive payment upon a Bankruptcy Event of Default, in whole or in part, and any such waiver shall not affect any other rights of the Holder hereunder, including any other rights in respect of such Bankruptcy Event of Default, any right to conversion and any right to payment of the Event of Default Redemption Price or any other Redemption Price, as applicable.

  

5.              RIGHTS UPON FUNDAMENTAL TRANSACTION .

 

(a)           Assumption . Neither the Company nor the Parent shall not enter into or be party to a Fundamental Transaction unless (i) the Successor Entity assumes in writing all of the obligations of the Company, the Parent and each Subsidiary under this Note and the other Transaction Documents in accordance with the provisions of this Section 5(a) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder prior to such Fundamental Transaction, including agreements to deliver to the Holder in exchange for this Note and securities of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Note (which, for the avoidance of doubt, shall not include any terms or conditions less favorable to the Holder of this Note in any material respect than the terms and conditions set forth in this Note as of such date of determination), including, without limitation, having principal amounts, interest rates and late charges equal to the payment rights and amounts, principal amounts then outstanding, the interest rates and Late Charges of this Note as well as having the conversion rights, redemption rights, rankings, Events of Default the same as in this Note and satisfactory to the Holder and, (ii) the Successor Entity (including its Parent Entity), is a Trading Issuer whose common stock is registered under Section 12 of the 1934 Act and is quoted and/or listed for trading on a Qualifying Market. Upon the occurrence of any Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Note and the other Transaction Documents referring to the “Company” and the “Parent” shall refer instead to the Successor Entity), and may exercise every right and power of the Company and the Parent and shall assume all of the obligations of the Company and the Parent under this Note and the other Transaction Documents, with the same effect as if the Successor Entity (including its Parent Entity), had been named the Company and the Parent herein and in the other Transaction Documents. Upon consummation of a Fundamental Transaction, the Successor Entity shall deliver to the Holder confirmation that there shall be issued upon conversion of this Note at any time after the consummation of such Fundamental Transaction, in lieu of the shares of Parent Common Stock (or other securities, cash, assets or other property (except such items still issuable under Section 6 and Section 16 , which shall continue to be receivable thereafter) issuable upon the conversion of this Note prior to such Fundamental Transaction, such shares of publicly traded common stock (or their equivalent) of the Successor Entity (including its Parent Entity) which the Holder would have been entitled to receive upon the happening of such Fundamental Transaction had this Note been converted immediately prior to such Fundamental Transaction (without regard to any limitations on the conversion of this Note), as adjusted in accordance with the provisions of this Note. The provisions of this Section 5(a) shall apply similarly and equally to successive Fundamental Transactions and shall be applied without regard to any limitations on the conversion of this Note.

 

  13  
 

 

(b)            Notice of a Fundamental Transaction; Redemption Right . No sooner than twenty (20) Trading Days nor later than ten (10) Trading Days prior to the consummation of a Fundamental Transaction, but not prior to the public announcement of such Fundamental Transaction, the Company and the Parent shall deliver a mutually executed written notice thereof via facsimile or electronic mail and overnight courier to the Holder (a “ Fundamental Transaction Notice ”). At any time during the period beginning after the Holder’s receipt of a Fundamental Transaction Notice or the Holder becoming aware of a Fundamental Transaction if a Fundamental Transaction Notice is not delivered to the Holder in accordance with the immediately preceding sentence (as applicable) and ending on the later of twenty (20) Trading Days after (i) consummation of such Fundamental Transaction and (ii) the date of receipt of such Fundamental Transaction Notice, the Holder may require the Company to redeem all or any portion of this Note by delivering written notice thereof (“ Fundamental Transaction Redemption Notice ”) to the Company and the Parent, which Fundamental Transaction Redemption Notice shall indicate the Conversion Amount the Holder is electing to redeem. The portion of this Note subject to redemption pursuant to this Section 5(b) shall be redeemed by the Company in cash at a price equal to the product of (A) the Conversion Amount being redeemed, and (B) (1) 101% if the Fundamental Transaction Redemption Price (as defined below) is paid in full to the Holder on a date prior to May 15, 2018, (2) 102% if the Fundamental Transaction Redemption Price is paid in full to the Holder on or after May 15, 2018 but prior to May 15, 2019, and (3) 103% if the Fundamental Transaction Price is paid in full to the Holder on a date following May 15, 2019 on or prior to the Maturity Date (the “ Fundamental Transaction Redemption Price ”). Redemptions required by this Section 5(b) shall be made in accordance with the provisions of Section 12 and shall have priority to payments to stockholders in connection with such Fundamental Transaction. To the extent redemptions required by this Section 5(b) are deemed or determined by a court of competent jurisdiction to be prepayments of this Note by the Company, such redemptions shall be deemed to be voluntary prepayments. Notwithstanding anything to the contrary in this Section 5(b) , but subject to Section 3(d) , until the Fundamental Transaction Redemption Price (together with any Late Charges thereon) is paid in full, the Fundamental Transaction Redemption Price (together with any Late Charges thereon) may be converted, in whole or in part, by the Holder into Parent Common Stock pursuant to Section 3 . In the event of the Company’s redemption of any portion of this Note under this Section 5(b) , the Holder’s damages would be uncertain and difficult to estimate because of the parties’ inability to predict future interest rates and the uncertainty of the availability of a suitable substitute investment opportunity for the Holder. Accordingly, any redemption premium due under this Section 5(b) is intended by the parties to be, and shall be deemed, a reasonable estimate of the Holder’s actual loss of its investment opportunity and not as a penalty.

 

6.              RIGHTS UPON ISSUANCE OF PURCHASE RIGHTS AND OTHER CORPORATE EVENTS.

 

(a)            Purchase Rights. In addition to any adjustments pursuant to Section 7 below, elsewhere in this Agreement and/or in any other Transaction Document, if at any time the Parent grants, issues or sells any Common Stock Equivalents, Options, Convertible Securities or rights to purchase stock, warrants, securities or other property pro rata to all or substantially all of the record holders of any class of Parent Common Stock (the “ Purchase Rights ”), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Parent Common Stock acquirable upon complete conversion of this Note (without taking into account any limitations or restrictions on the convertibility of this Note and assuming for such purpose that the Note was converted at the Conversion Price as of the applicable record date) immediately prior to the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Parent Common Stock are to be determined for the grant, issue or sale of such Purchase Rights; provided  however , that to the extent that the Holder’s right to participate in any such Purchase Right would result in the Holder and the other Attribution Parties exceeding the Maximum Percentage, then the Holder shall not be entitled to participate in such Purchase Right to the extent of the Maximum Percentage (and shall not be entitled to beneficial ownership of such shares of Parent Common Stock as a result of such Purchase Right (and beneficial ownership) to the extent of any such excess) and such Purchase Right to such extent shall be held in abeyance (and, if such Purchase Right has an expiration date, maturity date or other similar provision, such term shall be extended by such number of days held in abeyance, if applicable) for the benefit of the Holder until such time or times, if ever, as its right thereto would not result in the Holder and the other Attribution Parties exceeding the Maximum Percentage, at which time or times the Holder shall be granted such right (and any Purchase Right granted, issued or sold on such initial Purchase Right or on any subsequent Purchase Right held similarly in abeyance (and, if such Purchase Right has an expiration date, maturity date or other similar provision, such term shall be extended by such number of days held in abeyance, if applicable)) to the same extent as if there had been no such limitation).

 

  14  
 

 

(b)            Other Corporate Events . In addition to and not in substitution for any other rights in this Note and/or in any other Transaction Document, prior to the consummation of any Fundamental Transaction pursuant to which holders of shares of Parent Common Stock are entitled to receive securities or other assets with respect to or in exchange for shares of Parent Common Stock (a “ Corporate Event ”), the Company and the Parent shall make appropriate provision to ensure that the Holder will thereafter have the right to receive upon a conversion of this Note, at the Holder’s option (i) in addition to the shares of Parent Common Stock receivable upon such conversion, such securities or other assets to which the Holder would have been entitled with respect to such shares of Parent Common Stock had such shares of Parent Common Stock been held by the Holder upon the consummation of such Corporate Event (without taking into account any limitations or restrictions on the convertibility of this Note) or (ii) in lieu of the shares of Parent Common Stock otherwise receivable upon such conversion, such securities or other assets received by the holders of shares of Parent Common Stock in connection with the consummation of such Corporate Event in such amounts as the Holder would have been entitled to receive had this Note initially been issued with conversion rights for the form of such consideration (as opposed to shares of Parent Common Stock) at a conversion rate for such consideration commensurate with the Conversion Rate. Provision made pursuant to the preceding sentence shall be in a form and substance satisfactory to the Holder. The provisions of this Section 6 shall apply similarly and equally to successive Corporate Events and shall be applied without regard to any limitations on the conversion or redemption of this Note.

 

  7.   RIGHTS UPON ISSUANCE OF OTHER SECURITIES PRIOR TO AND FOLLOWING A QUALIFIED IPO .

 

(a)           Adjustment of Conversion Price upon Subdivision or Combination of Parent Common Stock . In addition to any other rights of the Holder under this Note and/or any other Transaction Document and without limiting any provisions of Sections 5, 6, 7 and 16 hereof, if the Parent at any time on or after the Subscription Date subdivides (by any stock split, stock dividend, stock combination, recapitalization or other similar transaction) one or more classes of its outstanding shares of Parent Common Stock into a greater number of shares, the Conversion Price in effect immediately prior to such subdivision will be proportionately reduced. Without limiting any provisions of Sections 5, 6 and 16.1(f) , the Parent at any time on or after the Subscription Date combines (by any stock split, stock dividend, stock combination, recapitalization or other similar transaction) one or more classes of its outstanding shares of Parent Common Stock into a smaller number of shares, the Conversion Price in effect immediately prior to such combination will be proportionately increased. Any adjustment pursuant to this Section 7(a) shall become effective immediately after the effective date of such subdivision or combination. If any event requiring an adjustment under this Section 7(a) occurs during the period that a Conversion Price is calculated hereunder, then the calculation of such Conversion Price shall be adjusted appropriately to reflect such event.

 

  15  
 

 

(b)           Issuance of Securities Below the Conversion Price Prior to the Closing Date of a Qualifying PO .  In addition to and not in limitation of any other rights of the Holder under this Note including, but not limited to, Section 7 and/or any other Transaction Document, if, at any time while this Note is outstanding and whenever on or after the Subscription Date but prior to the closing date of a Qualifying PO (as defined below), the Company, the Parent and/or any Subsidiary in any manner sells or grants any option to purchase, issues or sells or grants any right to reprice, and/or otherwise sells, disposes of and/or issues any shares of Parent Common Stock or Common Stock Equivalents (as defined below) (including upon conversion, exercise or otherwise) entitling any Person to acquire shares of Parent Common Stock at a price per share of Parent Common Stock that is lower than the then Conversion Price (such lower price, the “ New Issuance Price ” and each such issuance, a “ Dilutive Issuance ” and collectively, “ Dilutive Issuances ”), (if the holder of shares of Parent Common Stock or Common Stock Equivalents so issued and/or any holder of Parent Common Stock and/or Common Stock Equivalents as of the Subscription Date or issued subsequent thereto, shall at any time, whether by amendment, supplement, operation of purchase price adjustments, reset provisions, floating conversion, exercise or exchange prices or otherwise be entitled under the terms of any such instruments to receive shares of Parent Common Stock at a price per share that is lower than the Conversion Price, such issuance shall be deemed to have occurred for less than the Conversion Price on such date of the Dilutive Issuance), then the then Conversion Price shall be reduced to equal the New Issuance Price.  For purposes of clarification, if the Company, the Parent and/or any Subsidiary issues, sells and/or otherwise disposes of any shares of Parent Common Stock at a price less than the then Conversion Price, the then Conversion Price shall immediately be reduced to the New Issuance Price on the date of such Dilutive Issuance. All adjustments provided for in this Section 7(b) shall be made whenever any such Parent Common Stock or Common Stock Equivalents are issued. Notwithstanding anything to the contrary in the foregoing, if a Dilutive Issuance consists of the issuance and/or sale of both Parent Common Stock and Common Stock Equivalents or two or more Common Stock Equivalents as units (each, a “ Share and/or a CSE Issuance ”), in determining the value of the component parts of the unit issued and/or sold in a Share and/or a CSE Issuance no value will be attributed to Common Stock Equivalents and the New Issuance Price as a result thereof will be the lowest of (i) the lowest purchase price per unit, (ii) the lowest conversion, exercise and/or exchange price to acquire one (1) share of Parent Common Stock of any Common Stock Equivalent included in a unit if a unit also includes shares of Parent Common Stock, and (iii) if no shares of Parent Common Stock are included in a unit, the lowest exercise, conversion and/or exchange price to acquire one (1) share of Parent Common Stock of the Common Stock Equivalents comprising a unit, such lowest price of (i)-(iii) shall be the “ Lowest Price ;” provided , however, a Dilutive Issuance and a resulting New Issuance Price relating to a Share and/or a CSE Issuance shall only occur if the Lowest Price relating to a Share and/or a CSE Issuance is lower than the then Conversion Price. Notwithstanding the foregoing, no adjustment will be made under this Section 7(b) in respect of an Exempt Issuance.   The Company and the Parent shall notify the Holder in writing, no later than the first Trading Day following the issuance of any Parent Common Stock or Common Stock Equivalents subject to this Section 7(b) , indicating therein the applicable Lowest Price, issuance price, reset price, exchange price, conversion price and other pricing terms (such notice, the “ Dilutive Issuance Notice ”). For purposes of clarification, whether or not the Parent provides a Dilutive Issuance Notice upon the occurrence of any Dilutive Issuance, the Holder is entitled to receive a number of shares of Parent Common Stock based upon the New Issuance Price on or after the date of such Dilutive Issuance, regardless of whether the Holder accurately refers to the New Issuance Price in any Notice of Conversion. For purposes hereof, the term “ Common Stock Equivalents ” means any securities (as defined under the 1933 Act) including, but not limited to, any Options and/or Convertible Securities of the Company, the Parent and/or any Subsidiaries which would entitle the Holder thereof to acquire at any time shares of Parent Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the Holder thereof to receive, shares of Parent Common Stock. If the Parent, the Company and/or any Subsidiary enters into a Variable Rate Transaction (as defined in the Securities Purchase Agreement) despite the prohibition set forth in the Securities Purchase Agreement, the Parent shall be deemed to have issued shares of Parent Common Stock or Common Stock Equivalents at the lowest possible price at which such securities may be converted, exchanged and/or exercised under the terms of such Variable Rate Transaction.

 

  16  
 

 

(c)           Issuance of Securities Below the Conversion Price Following the First Trading Day Following the Closing of a Qualifying PO .  In addition to and not in limitation of any other rights of the Holder under this Note including, but not limited to, Section 7 and/or any other Transaction Document, if, at any time while this Note is outstanding and whenever on or after the first Trading Day following the closing date of a Qualifying PO, the Company, the Parent and/or any Subsidiary in any manner sells or grants any option to purchase, issues or sells or grants any right to reprice, and/or otherwise sells, disposes of and/or issues any shares of Parent Common Stock or Common Stock Equivalents entitling any Person to acquire shares of Parent Common Stock at a price per share of Parent Common Stock that is lower than the then Conversion Price (such lower price, the “ Post-QPO New Issuance Price ” and each such issuance, a “ Post-QPO Dilutive Issuance ” and collectively, “ Post-QPO Dilutive Issuances ”), then immediately after such Post-QPO Dilutive Issuance, the then Conversion Price shall be automatically reduced to an amount determined by multiplying the then Conversion Price by a fraction of which (i) the numerator shall be the sum of (A) the number of shares of Parent Common Stock issued and outstanding immediately prior to such Post-QPO Dilutive Issuance (assuming all then issued and outstanding Common Stock Equivalents are exercised, exchanged and/or converted (as the case may be) in accordance with the terms, without giving effect to any limitations on conversions, exchanges and/or exercise in any such Common Stock Equivalents), plus (B) the number of shares of Parent Common Stock which the aggregate consideration received by the Parent for such additional shares of Parent Common Stock would purchase at the then Conversion Price (without giving effect to any limitations on conversions, exchanges and/or exercises in any outstanding Common Stock Equivalents), and (ii) the denominator of which shall be the number of shares of Parent Common Stock issued and outstanding immediately after and including such Post-QPO Dilutive Issuance (assuming all then issued and outstanding Common Stock Equivalents were exercised, executed and/or converted (as the case may be) in accordance with the terms, without giving effect to any limitations on conversions, exchanges and/or exercise in any such Common Stock Equivalents, including this Note, the Parent Note and the Parent Warrant). For purposes of clarification, if the Company, the Parent and/or any Subsidiary issues, sells and/or otherwise disposes of any shares of Parent Common Stock at a price less than the then Conversion Price, the then Conversion Price shall immediately be reduced to the Post-QPO New Issuance Price on the date of such Post-QPO Dilutive Issuance as determined above. All adjustments provided for in this Section 7(c) shall be made whenever any such Parent Common Stock or Common Stock Equivalents are issued. Notwithstanding the foregoing, if a Dilutive Issuance results from a Share and/or a CSE Issuance no value will be attributed to Common Stock Equivalents and the New Issuance Price as a result thereof will be the Lowest Price; provided , however , a Dilutive Issuance and a resulting New Issuance Price relating to a Share and/or a CSE Issuance shall only occur if the Lowest Price relating to a Share and/or a CSE Issuance is lower than the then Conversion Price. Notwithstanding the foregoing, no adjustment will be made under this Section 7(b) in respect of an Exempt Issuance.  The Company and the Parent shall provide to the Holder a Dilutive Issuance Notice no later than the first Trading Day following the issuance of any Parent Common Stock or Common Stock Equivalents subject to this Section 7(c) . For purposes of clarification, whether or not the Parent provides a Dilutive Issuance Notice upon the occurrence of any Post-QPO Dilutive Issuance, the Holder is entitled to receive a number of shares of Parent Common Stock based upon the Post-QPO New Issuance Price on or after the date of such Post-QPO Dilutive Issuance, regardless of whether the Holder accurately refers to the Post-QPO New Issuance Price in any Notice of Conversion. If the Parent, the Company and/or any Subsidiary enters into a Variable Rate Transaction despite the prohibition set forth in the Securities Purchase Agreement, the Parent shall be deemed to have issued shares of Parent Common Stock or Common Stock Equivalents at the lowest possible price at which such securities may be converted, exchanged and/or exercised under the terms of such Variable Rate Transaction.

 

(d)           Record Date . If the Parent takes a record of the holders of shares of Parent Common Stock for the purpose of entitling them (A) to receive a dividend or other distribution payable in shares of Parent Common Stock and/or Common Stock Equivalents, or (B) to subscribe for or purchase shares of Parent Common Stock and/or Common Stock Equivalents, then such record date will be deemed to be the date of the issuance or sale of the shares of Parent Common Stock deemed to have been issued or sold upon the declaration of such dividend or the making of such other distribution or the date of the granting of such right of subscription or purchase (as the case may be).

 

  17  
 

 

(e)            Calculations . All calculations under this Section 7 shall be made by rounding to the nearest cent or the nearest 1/100 th  of a share, as applicable. The number of shares of Parent Common Stock outstanding at any given time shall not include shares owned or held by or for the account of the Company, and the disposition of any such shares shall be considered an issue or sale of Parent Common Stock.

 

(f)            Voluntary Adjustability by the Parent . The Parent may at any time which this Note is outstanding, reduce the then Conversion Price to any amount and for any period of time decided appropriate by the Board of Directors.

 

8.            CERTAIN RESET RIGHTS UPON A QUALIFYING PO .  If on or after the Subscription Date, the Company consummates a Qualifying PO, and on the closing date of such Qualifying PO, the then Conversion Price is greater than the Qualifying PO Per Share Sale Price (as defined below), then the Conversion Price shall automatically and without any action by the Company or otherwise, be reset to the Qualifying PO Per Share Sale Price.  A “ Qualifying PO Per Share Sale Price ” shall be as applicable (i) the gross price a share of Parent Common Stock is sold to the public in the Qualifying PO if only shares of Parent Common Stock are sold to the public in such Qualifying PO, (ii) the gross price a unit consisting of shares of Parent Common Stock and Common Stock Equivalents is sold to the public in the Qualifying PO, or (iii) the sum of the gross price that (a) one (1) share of Parent Common Stock, and (b) a Common Stock Equivalent is sold to each purchaser in a Qualifying PO.

 

9.              REDEMPTIONS AT THE COMPANY’S ELECTION . Subject to compliance with all of the provisions of this Section 9 , at any time after the Issuance Date, the Company shall have the right to redeem all or a portion of the Conversion Amount then outstanding (the “ Company Optional Redemption Amount ”) on the Company Optional Redemption Date (as defined below) (a “ Company Optional Redemption ”).  So long as no Event of Default has occurred and is continuing, the portion of this Note subject to redemption pursuant to this Section 9 shall be redeemed by the Company in cash at a price (the “ Company Optional Redemption Price ”) equal to (i) if the Company’s Optional Redemption Price is paid in full to the Holder on a date prior to May 15, 2018, 101% of the Conversion Amount being redeemed, (ii) if the Company’s Optional Redemption Price is paid in full to the Holder on a date following May 15, 2018 but prior to May 15, 2019, 102% of the Conversion Amount being redeemed, and (iii) the Company’s Optional Redemption Price is paid in full to the Holder after May 15, 2019 but prior to the Maturity Date, 103% of the Conversion Amount being redeemed; provided , however , that provided the Company has complied with its obligations under Section 4(b) including the timely delivery of an Event of Default Notice, and if an Event of Default has occurred and is continuing, then on the Company Optional Redemption Date, the Company shall have the right to redeem all or a portion of the Conversion Amount outstanding by the Event of Default Redemption Price in cash on the Company Optional Redemption Date, provided the Company follows all of the provisions set forth in this Section 9 . This provision in no way shall limit the right and remedies provided to the Holder pursuant to any provision of this Note and/or elsewhere including, but not limited to, Section 4 or this Section 9 of this Note.  The Company may exercise its right to require redemption under this Section 9 by delivering a written notice thereof by facsimile or electronic mail and overnight courier to the Holder, which notice shall include the signature from the Parent acknowledging such redemption and the Holder’s conversion and related rights hereunder for the purpose of acknowledging and being aware of Holder’s conversion rights hereunder (the “ Company Optional Redemption Notice ” and the date the Holder receives such notice is referred to as the “ Company Optional Redemption Notice Date ”).  The Company may not deliver a Company Optional Redemption Notice hereunder unless the aggregate Conversion Amount being redeemed pursuant to this Section 9 is at least Five Hundred Thousand Dollars ($500,000), and such Company Optional Redemption Notice shall be irrevocable.  The Company Optional Redemption Notice shall (x) state the date on which the Company Optional Redemption shall occur (the “ Company Optional Redemption Date ”) which date shall not be less than twenty (20) Trading Days nor more than thirty (30) Trading Days following the Company Optional Redemption Notice Date, (y) certify that no Event of Default has occurred or is continuing and/or with the giving of notice or the passage of time could occur (or with respect to a Permitted Company EOD Redemption Exception, the date the Event of Default commenced that such Event of Default has been continuing through the date of the Company Optional Redemption Notice Date, and (z) state the aggregate Conversion Amount of this Note being redeemed in such Company Optional Redemption from the Holder on the Company Optional Redemption Date.  Redemptions made pursuant to this Section  9 shall be made in accordance with Section 12 . To the extent redemptions required by this Section 9(a) are deemed or determined by a court of competent jurisdiction to be prepayments of this Note by the Company, such redemptions shall be deemed to be voluntary prepayments. Notwithstanding anything herein to the contrary, but subject to Section 3(d) , at any time prior to the date the applicable Company Optional Redemption Price is paid in full (together with Late Charges, if any are owed, thereon), such applicable Company Optional Redemption Amount (together with Late Charges, if any are owed, thereon), may be converted, in whole or in part by the Holder into shares of Parent Common Stock pursuant to Section 3 . The parties agree that in the event of the Company’s redemption of any portion of this Note under this Section 9, the Holder’s damages would be uncertain and difficult to estimate because of the parties’ inability to predict future interest rates and the uncertainty of the availability of a suitable substitute investment opportunity for the Holder. Accordingly, any redemption premium due under this Section 9 is intended by the parties to be, and shall be deemed, a reasonable estimate of the Holder’s actual loss of its investment opportunity and not as a penalty. For the avoidance of doubt and notwithstanding anything to the contrary provided herein or elsewhere, without the express written consent of the Holder, the Company shall have no right to effect a Company Optional Redemption if at any time commencing on the Company’s Optional Redemption Notice Date and terminating on the Company’s Optional Redemption Date, any Event of Default has occurred and continuing (and/or with the giving of notice or the passage of time could occur as a result of the applicable Company Optional Redemption, but any Event of Default shall have no effect upon the Holder’s right to convert this Note in its discretion.

 

  18  
 

 

10.            NONCIRCUMVENTION . The Company and the Parent hereby each covenant and agree that neither by amendment of its respective Certificate of Incorporation (as defined in the Securities Purchase Agreement), Bylaws (as defined in the Securities Purchase Agreement) or through any reorganization, transfer of assets, consolidation, merger, scheme of arrangement, dissolution, issue or sale of securities, or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Note, and will at all times in good faith carry out all of the provisions of this Note and take all action as may be required to protect the rights of the Holder of this Note. Without limiting the generality of the foregoing or any other provision of this Note or the other Transaction Documents, the Parent (a) shall not increase the par value of any shares of Parent Common Stock receivable upon conversion of this Note above the Conversion Price then in effect, and (b) shall take all such actions as may be necessary or appropriate in order that the Parent may validly and legally issue fully paid and nonassessable shares of Parent Common Stock upon each conversion of this Note.

 

11.            RESERVATION OF AUTHORIZED SHARES .

 

(a)        Reservation . Commencing as of the Subscription Date and for as long as this Note remains outstanding (the “ Share Reserve Period ”), the Parent shall at all times have and keep reserved (and shall not reduce such reserve) at least 200% of the maximum number of shares of Parent Common Stock as shall from time to time be necessary to effect the full conversion of this Note (without regard to any limitations or conversions and assuming for purposes of this Section 11(a) that this Note remains outstanding and is paid in full in cash on May 15, 2020, and the redemption price on such date is the Event of Default Redemption Price (the “ Required Reserve Amount ”).

 

(b)        Insufficient Authorized Shares . If, notwithstanding Section 11(a) , and not in limitation thereof, at any time while this Note remains outstanding, the Parent does not have a sufficient number of authorized and unreserved shares of Parent Common Stock to satisfy its obligation to reserve for issuance upon conversion of this Note at least a number of shares of Parent Common Stock equal to the Required Reserve Amount (an “ Authorized Share Failure ”), then the Parent shall immediately take all action necessary to increase the Parent authorized shares of Parent Common Stock to an amount sufficient to allow the Parent to reserve the Required Reserve Amount for this Note. Without limiting the generality of the foregoing sentence, as soon as practicable after the date of the occurrence of an Authorized Share Failure, but in no event later than ninety (90) days, after the occurrence of such Authorized Share Failure, the Parent shall either (i) hold a meeting of its stockholders for the approval of an increase in the number of authorized shares of Parent Common Stock, or (ii) have cured the Authorized Share Failure by, among other required items, obtaining a written consent of the required percentage of holders of shares of Parent Common Stock for the required increase in authorized shares and had taken any and all other such action necessary to rectify the Authorized Share Failure including, but not limited to, providing the non-consenting stockholders with an information statement and a Form 14(C) and filed with the SEC such Form 14(C). In connection with such meeting as set forth in (i) above, the Parent shall provide each stockholder with a proxy statement and shall use its best efforts to solicit its stockholders’ approval of such increase in authorized shares of Parent Common Stock and to cause its board of directors to recommend to the stockholders that they approve such proposal. In the event that the Parent is prohibited from issuing shares of Parent Common Stock upon one or more conversions of this Note by the Buyer pursuant to the terms of this Note due to the failure by the Parent to have sufficient shares of Parent Common Stock available out of the authorized but unissued shares of Parent Common Stock (such unavailable number of shares of Parent Common Stock, the “ Authorized Failure Shares ”), in lieu of delivering such Authorized Failure Shares to the Holder, the Company shall pay cash in exchange for the redemption of such portion of the Conversion Amount convertible into such Authorized Failure Shares at a price equal to the sum of (i) the product of (x) such number of Authorized Failure Shares multiplied by (y)  the greatest Closing Sale Price or Closing Bid Price (as the case may be) of the Parent Common Stock on any Trading Day during the period commencing on the date the Holder delivers the applicable Conversion Notice with respect to such Authorization Failure Shares to the Parent and ending on the date of such issuance and payment under this Section 11(b) (or the Conversion Price if the Parent and/or the Company is not then a Trading Issuer); and (ii) to the extent the Holder purchases (in an open market transaction or otherwise) shares of Parent Common Stock to deliver in satisfaction of a sale by the Holder of Authorized Failure Shares, any brokerage commissions and other out-of-pocket expenses, if any, of the Holder incurred in connection therewith. Nothing contained in Section 11(a) or this Section 11(b) shall limit any obligations of the Parent and/or the Company under any provision of this Note, the Securities Purchase Agreement and/or any other Transaction Document.

 

  19  
 

 

12.            REDEMPTIONS .

 

(a)        Mechanics . The Company shall deliver the applicable Event of Default Redemption Price to the Holder in cash within five (5) Business Days after the Company’s receipt of the Holder’s Event of Default Redemption Notice. If the Holder has submitted a Fundamental Transaction Redemption Notice in accordance with Section 5(b) , the Company shall deliver the applicable Fundamental Transaction Redemption Price to the Holder in cash concurrently with the consummation of such Fundamental Transaction if such notice is received prior to the consummation of such Fundamental Transaction and within five (5) Business Days after the Company’s receipt of such notice otherwise. The Company shall deliver the applicable Company Optional Redemption Price to the Holder in cash on the applicable Company Optional Redemption Date. Notwithstanding anything herein to the contrary, in connection with any redemption hereunder at a time the Holder is entitled to receive a cash payment under any of the other Transaction Documents, at the option of the Holder delivered in writing to the Company, the applicable Redemption Price hereunder shall be increased by the amount of such cash payment owed to the Holder under such other Transaction Documents and, upon payment in full or conversion in accordance herewith, shall satisfy the Company’s then payment obligation under such other Transaction Documents. In the event of a redemption of less than all of the Conversion Amount of this Note (to the extent permitted hereunder), the Company shall promptly cause to be issued and delivered to the Holder a new Note (in accordance with Section 19(d) ) representing the outstanding Principal which has not been redeemed. In the event that the Company does not pay the applicable Redemption Price (together with Late Charges thereon), to the Holder within the time period required, at any time thereafter and until the Company pays such unpaid Redemption Price (together with Late Charges thereon), in full, the Holder shall have the option, in lieu of redemption, to require the Company to promptly return to the Holder all or any portion of this Note representing the Conversion Amount that was submitted for redemption and for which the applicable Redemption Price (together with any Late Charges thereon) has not been paid. Upon the Company’s receipt of such notice, (x) the applicable Redemption Notice shall be null and void with respect to such Conversion Amount, and (y) the Company shall immediately return this Note, or issue a new Note (in accordance with Section 19(d) ), to the Holder, and in each case the Principal amount of this Note or such new Note (as the case may be) shall be increased by an amount equal to the difference between (1) the applicable Redemption Price (as the case may be, and as adjusted pursuant to this Section 12 , if applicable) minus (2) the Principal portion of the Conversion Amount submitted for redemption. The Holder’s delivery of a notice voiding a Redemption Notice and exercise of its rights following such notice shall not affect the Company’s obligations to make any payments of Late Charges which have accrued prior to the date of such notice with respect to the Conversion Amount subject to such notice.

 

  20  
 

 

13.           VOTING RIGHTS . The Holder shall have no voting rights as the holder of this Note, except as required by law (including, without limitation, the Delaware General Corporation Law) and as expressly provided in this Note.

 

14.           COVENANTS . Until this Note has been converted, redeemed or otherwise satisfied in accordance with their terms:

 

(a)           Rank . This Note shall rank (i) pari passu with all other Notes, if any, and (ii) be senior in all respects to all other Indebtedness of the Company, other than Permitted Indebtedness secured by Permitted Liens if and to the extent the terms of such Indebtedness requires such Indebtedness to be senior to all other Indebtedness of the Company.

 

(b)           Incurrence of Indebtedness . Neither the Company nor the Parent shall, and the Company and the Parent shall cause all of the Subsidiaries to not, directly or indirectly, incur or guarantee, assume or suffer to exist any Indebtedness (other than (i) the Indebtedness evidenced by this Note and the Parent Note, and (ii) other Permitted Indebtedness, until the ninety-first (91 st ) calendar day after the date this Note and the Parent Note is no longer outstanding.

 

(c)           Existence of Liens . Neither the Company nor the Parent shall, and the Company and the Parent shall cause each Subsidiary to not, directly or indirectly, allow or suffer to exist any mortgage, lien, pledge, charge, security interest or other encumbrance upon or in any property or assets owned by the Company, the Parent and/or any of the Subsidiaries (collectively, “ Liens ”) other than Permitted Liens.

 

(d)           Restricted Payments . Neither the Company nor the Parent shall, and the Company and the Parent shall cause all of the Subsidiaries to not, directly or indirectly, redeem, defease, repurchase, repay or make any payments in respect of, by the payment of cash or cash equivalents (in whole or in part, whether by way of open market purchases, tender offers, private transactions or otherwise), all or any portion of any Indebtedness of the Company, the Parent and/or any Subsidiary other than this Note and the Parent Note and Permitted Indebtedness that is secured by a Permitted Lien (which by the terms of such particular Permitted Indebtedness the payment thereof is senior in right of payment to the Parent Note and/or this Note), whether by way of payment in respect of principal of (or premium, if any), interest on, such Indebtedness if at the time such payment is due or is otherwise made or, after giving effect to such payment, (i) an event constituting an Event of Default has occurred and is continuing or (ii) an event that with the passage of time and/or the giving of notice and without being cured would constitute an Event of Default has occurred and is continuing.

 

  21  
 

 

(e)           Restriction on Redemption and Cash Dividends . Until the ninety-first (91 st ) calendar day after the date no Securities are outstanding and except as specifically provided below, neither the Company nor the Parent shall, and the Company and the Parent shall cause each of the Subsidiaries to not, directly or indirectly, redeem, repurchase or declare or pay any cash dividend or distribution on any of its Equity Interests other than intercompany dividends to the Parent, the Company or any Domestic Subsidiary (as defined in the Securities Purchase Agreement), (“ Intercompany Dividend ”), provided no such Domestic Subsidiary shall be permitted at any time to declare, pay and/or accrue any Intercompany Dividend, unless such Domestic Subsidiary’s operations are located in the United States and it does not have any bank and/or similar accounts located outside of the United States; provided , however , that notwithstanding anything to the contrary provided herein or elsewhere, all Intercompany Dividends otherwise permitted in this Section 14(e) , shall be prohibited during the period commencing on the date an Event of Default occurs and is continuing through and including the tenth (10 th ) Business Day following the date the Collateral Agent receives written notice from the Company and the Parent signed by the CEO (or the President) and the CFO of the Company and the Parent that such Event of Default has been cured and no longer exists. For purposes hereof, “ Equity Interests ” means (a) all shares of capital stock (whether denominated as common capital stock or preferred capital stock), equity interests, beneficial, partnership or membership interests, joint venture interests, participations or other ownership or profit interests in or equivalents (regardless of how designated) of or in a Person (other than an individual), whether voting or non-voting and (b) all securities convertible into or exchangeable for any of the foregoing and all warrants, options or other rights to purchase, subscribe for or otherwise acquire any of the foregoing, whether or not presently convertible, exchangeable or exercisable.

 

(f)            Restriction on Transfer of Assets . Neither the Company nor the Parent shall, and the Company and the Parent shall cause all of the Subsidiaries to not, directly or indirectly, sell, lease, license, assign, transfer, spin-off, split-off, close, convey or otherwise dispose of any assets or rights of the Company, the Parent and/or any of the Subsidiaries whether in a single transaction or a series of related transactions, other than (i) sales, leases, licenses, assignments, transfers, conveyances and other dispositions of such assets or rights by the Company the Parent and the Subsidiaries in the ordinary course of business consistent with its past practices and (ii) sales of inventory and product in the ordinary course of business.

 

(g)           Maturity of Indebtedness . Neither the Company nor the Parent shall, and the Company and the Parent shall cause all of the Subsidiaries to not, directly or indirectly, permit any Indebtedness of the Company, the Parent and/or any of the Subsidiaries to mature or accelerate prior to the ninety-first (91 st ) calendar day after the date that this Note and the Parent Note is no longer outstanding other than Permitted Indebtedness outstanding on the date hereof.

 

(h)           Change in Nature of Business . Neither the Company nor the Parent shall, and the Company and the Parent shall cause each of the Subsidiaries to not, directly or indirectly, make any change in the nature of its business including, but not limited to, engage in any material line of business substantially different from those lines of business conducted by the Company, the Parent and each of the Subsidiaries on the Subscription Date described in the Parent’s Annual Report on Form 10-K for the year ended 2016. Neither the Company nor the Parent shall, and the Company and the Parent shall cause each of the Subsidiaries to not, directly or indirectly, modify its or their corporate structure or purpose.

 

  22  
 

 

(i)            Preservation of Existence, Etc.  The Company and the Parent shall maintain and preserve, and cause each of the Subsidiaries to maintain and preserve, its existence, rights and privileges, and become or remain, and cause each of the Subsidiaries to become or remain, duly qualified and in good standing in each jurisdiction in which the character of the properties owned or leased by it or in which the transaction of its business makes such qualification necessary.

 

(j)            Maintenance of Properties, Etc.  The Company and the Parent shall maintain and preserve, and cause each of the Subsidiaries to maintain and preserve, all of its properties which are necessary or useful in the proper conduct of its business in good working order and condition, ordinary wear and tear excepted, and comply, and cause each of the Subsidiaries to comply, at all times with the provisions of all leases to which it is a party as lessee or under which it occupies property, so as to prevent any loss or forfeiture thereof or thereunder.

 

(k)           Maintenance of Intellectual Property . The Company and the Parent will, and will cause each of the Subsidiaries to, take all action necessary or advisable to maintain all of the Intellectual Property Rights (as defined in the Securities Purchase Agreement) of the Company, the Parent and each of the Subsidiaries that are necessary or material to the conduct of its business in full force and effect.

 

(l)            Maintenance of Insurance . The Company and the Parent shall maintain, and cause each of the Subsidiaries to maintain, insurance with responsible and reputable insurance companies or associations (including, without limitation, comprehensive general liability, hazard, rent and business interruption insurance) with respect to its properties (including all real properties leased or owned by it) and business, in such amounts and covering such risks as is required by any governmental authority having jurisdiction with respect thereto or as is carried generally in accordance with sound business practice by companies in similar businesses similarly situated.

 

(m)          Transactions with Affiliates . Except as set forth under Section 14(e) , neither the Company nor the Parent shall, nor shall the Company or the Parent permit any of the Subsidiaries to, enter into, renew, extend or be a party to, any transaction or series of related transactions (including, without limitation, the purchase, sale, lease, transfer or exchange of property or assets of any kind or the rendering of services of any kind) with any Affiliate, except transactions (i) approved by a majority of the Company’s and the Parent’s (as the case may be) independent directors, and (ii) in the ordinary course of business in a manner and to an extent consistent with past practice and necessary or desirable for the prudent operation of its business, for fair consideration and on terms no less favorable to the Company, the Parent and/or any of the Subsidiaries than would be obtainable in a comparable arm’s length transaction with a Person that is not an Affiliate thereof.

 

(n)          Restricted Issuances . The Company shall not directly and/or indirectly issue and/or sell any securities other than this Note and/or to the Holder as required by this Note. The Parent shall not, directly or indirectly (i) issue any Parent Notes (other than as contemplated by the Securities Purchase Agreement), (ii) issue any shares of preferred stock whose terms and rights (1) provide the requirement or option to declare, accrue and pay a cash dividend while this Note and/or any Parent Note are outstanding and/or (2) permit the redemption of such shares of preferred stock of the Parent while this Note and/or any Parent Note are outstanding, and/or (iii) issue any other securities that would cause a breach or default under any of the Securities.

 

  23  
 

 

(o)           New Subsidiaries; No Foreign Subsidiaries . Simultaneously with the acquisition or formation of each New Subsidiary, the Company and the Parent shall take and the Parent and the Company shall cause all Subsidiaries including any New Subsidiary, to take any and all actions under the Security Documents. None of the Company, the Parent or any Subsidiary shall directly and/or indirectly make any payments to, or transfer any assets, including, but not limited to, by way of any dividend and/or distribution to any Subsidiary including any Domestic Subsidiary if such Domestic Subsidiary is not located in the United States and/or has a bank or similar account outside of the United States, without the prior written consent of the Holder.

 

(p)           Change in Collateral; Collateral Records . The Company and the Parent shall each (i) give the Collateral Agent not less than thirty (30) days’ prior written notice of any change in the location of any Collateral (as defined in the Security Documents), other than to locations set forth in the Perfection Certificates (as defined in the Security Documents) hereto and with respect to which the Collateral Agent has filed financing statements and otherwise fully perfected its Liens thereon (other than transfers of inventory to customers in the ordinary course of business in a manner and to an extent consistent with past practice), (ii) advise the Collateral Agent promptly, in sufficient detail, of any material adverse change relating to the type, quantity or quality of the Collateral or the Lien granted thereon and (iii) execute and deliver, and cause each of the Subsidiaries to execute and deliver, to the Collateral Agent for the benefit of the Holder from time to time, solely for the Collateral Agent’s convenience in maintaining a record of Collateral, such written statements and schedules as the Collateral Agent or any Holder may reasonably require, designating, identifying or describing the Collateral. In addition, the Company and the Parent shall provide to the Collateral Agent upon filing, copies of all UCC-1 Financing Statements, amendments to all UCC-1 Financing Statements, all UCC-3 filings and all other similar filings made with any Governmental Entity (as defined in the Securities Purchase Agreement) including, but not limited to, the USPTO.

 

(q) [INTENTIONALLY LEFT BLANK]

 

(r)            Independent Investigation . At the request of the Holder either (x) at any time when an Event of Default has occurred and is continuing, (y) upon the occurrence of an event that with the passage of time or giving of notice would constitute an Event of Default or (z) at any time the Holder reasonably believes an Event of Default may have occurred or be continuing, the Company and the Parent shall hire an independent, reputable investment bank selected by the Company and the Parent and approved by the Holder to investigate as to whether any breach of this Note has occurred (the “ Independent Investigator ”). If the Independent Investigator determines that such breach of this Note has occurred, the Independent Investigator shall notify the Company and the Parent of such breach and the Company and the Parent shall deliver written notice to each holder of a Note of such breach. In connection with such investigation, the Independent Investigator may, during normal business hours, inspect all contracts, books, records, personnel, offices and other facilities and properties of the Company, the Parent and each of the Subsidiaries and, to the extent available to the Company and the Parent after the Company and the Parent uses reasonable efforts to obtain them, the records of its legal advisors and accountants (including the accountants’ work papers) and any books of account, records, reports and other papers not contractually required of the Company and the Parent to be confidential or secret, or subject to attorney-client or other evidentiary privilege, and the Independent Investigator may make such copies and inspections thereof as the Independent Investigator may reasonably request. The Company and the Parent shall furnish the Independent Investigator with such financial and operating data and other information with respect to the business and properties of the Company and the Parent as the Independent Investigator may reasonably request. The Company and the Parent shall permit the Independent Investigator to discuss the affairs, finances and accounts of the Company and the Parent with, and to make proposals and furnish advice with respect thereto to, the Company’s and the Parent’s officers, directors, key employees and independent public accountants or any of them (and by this provision the Company and the Parent each authorize said accountants to discuss with such Independent Investigator the finances and affairs of the Company, the Parent and the Subsidiaries), all at such reasonable times, upon reasonable notice, and as often as may be reasonably requested.

 

  24  
 

 

15.            SECURITY . This Note is secured to the extent and in the manner set forth in the Transaction Documents (including, without limitation, the Security Agreements, the other Security Documents and the Guaranties).

 

16.            DISTRIBUTION OF ASSETS . In addition to all other rights and adjustments provided in this Note and/or any other Transaction Document or elsewhere, if the Parent shall declare or make any dividend or other distributions of its assets (or rights to acquire its assets) to any or all holders of shares of Parent Common Stock, by way of return of capital or otherwise (including without limitation, any distribution of cash, stock or other securities (including, but not limited to, shares of Parent Common Stock and/or Common Stock Equivalents), property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (the “ Distributions ”), then the Holder will be entitled to such Distributions as if the Holder had held the number of shares of Parent Common Stock acquirable upon complete conversion of this Note (without taking into account any limitations or restrictions on the convertibility of this Note and assuming for such purpose that this Note was converted at the Conversion Price as of the applicable record date) immediately prior to the date on which a record is taken for such Distribution or, if no such record is taken, the date as of which the record holders of Parent Common Stock are to be determined for such Distributions (provided, however, that to the extent that the Holder’s right to participate in any such Distribution would result in the Holder and the other Attribution Parties exceeding the Maximum Percentage, then the Holder shall not be entitled to participate in such Distribution to the extent of the Maximum Percentage (and shall not be entitled to beneficial ownership of such shares of Parent Common Stock as a result of such Distribution (and beneficial ownership) to the extent of any such excess) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time or times, if ever, as its right thereto would not result in the Holder and the other Attribution Parties exceeding the Maximum Percentage, at which time or times the Holder shall be granted such Distribution (and any Distributions declared or made on such initial Distribution or on any subsequent Distribution held similarly in abeyance) to the same extent as if there had been no such limitation).

 

  25  
 

 

17.            AMENDING THE TERMS OF THIS NOTE . The prior written consent of the Holder of this Note shall be required for any change, waiver or amendment to this Note.

 

18.           TRANSFER . This Note and any shares of Parent Common Stock issued and/or issuable upon conversion of this Note may be offered, sold, assigned or transferred by the Holder without the consent of the Company, in whole or in part, at any time and from time to time, subject only to the provisions of Section 2(g) of the Securities Purchase Agreement.

 

19.            REISSUANCE OF THIS NOTE .

 

(a)           Transfer . If this Note is to be transferred, the Holder shall surrender this Note to the Company, whereupon the Company will forthwith issue and deliver upon the order of the Holder a new Note (in accordance with Section 19(d) ), registered as the Holder may request, representing the outstanding Principal being transferred by the Holder and, if less than the entire outstanding Principal is being transferred, a new Note (in accordance with Section 19(d) ) to the Holder representing the outstanding Principal not being transferred. The Holder and any assignee, by acceptance of this Note, acknowledge and agree that, by reason of the provisions of Section 3(c)(iii) following conversion or redemption of any portion of this Note, the outstanding Principal represented by this Note may be less than the Principal stated on the face of this Note.

 

(b)           Lost, Stolen or Mutilated Note . Upon receipt by the Company of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Note (as to which a written certification and the indemnification contemplated below shall suffice as such evidence), and, in the case of loss, theft or destruction, of any indemnification undertaking by the Holder to the Company in customary and reasonable form and, in the case of mutilation, upon surrender and cancellation of this Note, the Company shall execute and deliver to the Holder a new Note (in accordance with Section 19(d) ) representing the outstanding Principal.

 

(c)           Note Exchangeable for Different Denominations . This Note is exchangeable, upon the surrender hereof by the Holder at the principal office of the Company, for a new Note or Notes (in accordance with Section 19(d) and in principal amounts of at least $1,000) representing in the aggregate the outstanding Principal of this Note, and each such new Note will represent such portion of such outstanding Principal as is designated by the Holder at the time of such surrender.

 

(d)           Issuance of New Notes; Signatures . Whenever the Company is required to issue a new Note pursuant to the terms of this Note, such new Note (i) shall be of like tenor with this Note, (ii) shall represent, as indicated on the face of such new Note, the Principal remaining outstanding (or in the case of a new Note being issued pursuant to Section 19(a) or Section 19(c) , the Principal designated by the Holder which, when added to the principal represented by the other new Notes issued in connection with such issuance, does not exceed the Principal remaining outstanding under this Note immediately prior to such issuance of new Notes), (iii) shall have an issuance date, as indicated on the face of such new Note, which is the same as the Issuance Date of this Note, (iv) shall have the same rights, remedies and conditions as this Note, (v) shall represent accrued and unpaid Interest and Late Charges on the Principal and Interest of this Note, from the Issuance Date, and (vi) shall be executed by the Company.

 

  26  
 

 

20.           REMEDIES, CHARACTERIZATIONS, OTHER OBLIGATIONS, BREACHES AND INJUNCTIVE RELIEF . The remedies provided in this Note shall be cumulative and in addition to all other remedies available under this Note and any of the other Transaction Documents at law or in equity (including a decree of specific performance and/or other injunctive relief), and nothing herein shall limit the Holder’s right to pursue actual and consequential damages for any failure by the Company and/or the Parent to comply with the terms of this Note. The Company and the Parent jointly and severally covenant to the Holder that there shall be no characterization concerning this instrument other than as expressly provided herein. Amounts set forth or provided for herein with respect to payments, conversion, redemptions and the like (and the computation thereof) shall be the amounts to be received by the Holder and shall not, except as expressly provided herein, be subject to any other obligation of the Company and/or the Parent (or the performance thereof). The Company and the Parent jointly and severally acknowledge that a breach by either of them of the obligations hereunder will cause irreparable harm to the Holder and that the remedy at law for any such breach may be inadequate. The Company and the Parent each therefore agree that, in the event of any such breach or threatened breach, the Holder shall be entitled, in addition to all other available remedies, to specific performance and/or temporary, preliminary and permanent injunctive or other equitable relief restraining and/or preventing any such breach or threatened breach without the necessity of showing economic harm and without posting a bond or other security being required. The Company and the Parent shall provide all information and documentation to the Holder that is requested by the Holder to enable the Holder to confirm the Company’s and the Parent’s compliance with the terms and conditions of this Note (including, without limitation, compliance with Sections 4, 5 and 7 ).

 

21.           PAYMENT OF COLLECTION, ENFORCEMENT AND OTHER COSTS . If (a) this Note is placed in the hands of an attorney for collection or enforcement or is collected or enforced through any legal proceeding or the Holder otherwise takes action to collect amounts due under this Note or to enforce the provisions of this Note or (b) there occurs any bankruptcy, reorganization, receivership of the Company or other proceedings affecting Company’s creditors’ rights and involving a claim under this Note, then the Company and the Parent shall jointly and severally be obligated and pay the costs incurred by the Holder for such collection, enforcement or action or in connection with such bankruptcy, reorganization, receivership or other proceeding, including, without limitation, attorneys’ fees and disbursements. The Company and the Parent expressly each acknowledge and agree that no amounts due under this Note shall be affected, or limited, by the fact that the purchase price paid for this Note was less than the original Principal amount hereof.

 

22.           CONSTRUCTION; HEADINGS . This Note shall be deemed to be jointly drafted by the Company, the Parent and the initial Holder and shall not be construed against any such Person as the drafter hereof. The headings of this Note are for convenience of reference and shall not form part of, or affect the interpretation of, this Note. Unless the context clearly indicates otherwise, each pronoun herein shall be deemed to include the masculine, feminine, neuter, singular and plural forms thereof. The terms “including, “includes,” “include” and words of like import shall be construed broadly as if followed by the words “without limitation.” The terms “herein,” “hereunder,” “hereof” and words of like import refer to this entire Note instead of just the provision in which they are found. Unless expressly indicated otherwise, all section references are to sections of this Note. Terms used in this Note and not otherwise defined herein, but defined in the other Transaction Documents, shall have the meanings ascribed to such terms on the Closing Date in such other Transaction Documents unless otherwise consented to in writing by the Holder.

 

  27  
 

 

23.            FAILURE OR INDULGENCE NOT WAIVER . No failure or delay on the part of the Holder in the exercise of any power, right or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such power, right or privilege preclude other or further exercise thereof or of any other right, power or privilege. No waiver shall be effective unless it is in writing and signed by an authorized representative of the waiving party.

 

24.            DISPUTE RESOLUTION .

 

(a) Submission to Dispute Resolution .

 

(i)           In the case of a dispute relating to a Conversion Price, a Closing Sale Price, a Closing Bid Price, a Lowest Price, or a fair market value or the arithmetic calculation of a Conversion Rate, any Redemption Price or any other calculation under this Note (as the case may be) (including, without limitation, a dispute relating to the determination of any of the foregoing), the Company, the Parent or the Holder (as the case may be) shall submit the dispute to the other party via facsimile or electronic mail (A) if by the Company or the Parent, within five (5) Business Days after the occurrence of the circumstances giving rise to such dispute or (B) if by the Holder, within five (5) Business Days after the Holder learned of the circumstances giving rise to such dispute. If the Holder and the Company and/or the Parent are unable to promptly resolve such dispute relating to such Conversion Price, such Lowest Price, such Closing Sale Price, such Closing Bid Price, or such fair market value or such arithmetic calculation of such Conversion Rate, any such Redemption Price or any other calculation under this Note (as the case may be), (including, without limitation, a dispute relating to the determination of any of the foregoing) at any time after the second (2 nd  ) Business Day following such initial notice by the Company, the Parent or the Holder (as the case may be) of such dispute to the Company, the Parent or the Holder (as the case may be), then the Holder and the Company shall together select an independent, reputable investment bank to resolve such dispute and if they do not agree upon an independent, reputable investment bank to resolve such dispute within a fifteen (15) day period, then the Holder shall be entitled to make such selection.

 

  28  
 

 

(ii)          The Holder and the Company and/or the Parent (as applicable) shall each deliver to such investment bank (A) a copy of the initial dispute submission so delivered in accordance with the first sentence of this Section 24 and (B) written documentation supporting its position with respect to such dispute, in each case, no later than 5:00 p.m. (New York time) by the fifth (5 ) Business Day immediately following the date on which the Holder selected such investment bank (the “ Dispute Submission Deadline ”) (the documents referred to in the immediately preceding clauses (A) and (B) are collectively referred to herein as the “ Required Dispute Documentation ”) (it being understood and agreed that if either the Holder, the Parent or the Company fails to so deliver all of the Required Dispute Documentation by the Dispute Submission Deadline, then the party who fails to so submit all of the Required Dispute Documentation shall no longer be entitled to (and hereby waives its right to) deliver or submit any written documentation or other support to such investment bank with respect to such dispute and such investment bank shall resolve such dispute based solely on the Required Dispute Documentation that was delivered to such investment bank prior to the Dispute Submission Deadline). Unless otherwise agreed to in writing by both the Company and the Holder or otherwise requested by such investment bank, neither the Company nor the Holder shall be entitled to deliver or submit any written documentation or other support to such investment bank in connection with such dispute (other than the Required Dispute Documentation).

 

(iii)         The Company, the Parent and the Holder (as the case may be) shall cause such investment bank to determine the resolution of such dispute and notify the Company, the Parent and the Holder of such resolution no later than ten (10) Business Days immediately following the Dispute Submission Deadline. The fees and expenses of such investment bank shall be borne solely by the Company in such dispute, and such investment bank’s resolution of such dispute shall be final and binding upon all parties absent manifest error.

  

(b)           Miscellaneous . The Company, the Parent and the Holder each expressly acknowledges and agrees that (i) this Section 24 constitutes an agreement to arbitrate between the Company, the Parent and the Holder (and constitutes an arbitration agreement) under § 7501, et seq. of the New York Civil Practice Law and Rules (“ CPLR ”) and that the Holder is authorized to apply for an order to compel arbitration pursuant to CPLR § 7503(a) in order to compel compliance with this Section 24 , (ii) a dispute relating to a Conversion Price, (iii) the terms of this Note and each other applicable Transaction Document shall serve as the basis for the selected investment bank’s resolution of the applicable dispute, such investment bank shall be entitled (and is hereby expressly authorized) to make all findings, determinations and the like that such investment bank determines are required to be made by such investment bank in connection with its resolution of such dispute and in resolving such dispute such investment bank shall apply such findings, determinations and the like to the terms of this Note and any other applicable Transaction Documents, (iv) the Holder (and only the Holder), in its sole discretion, shall have the right to submit any dispute described in this Section 24 to any state or federal court sitting in The City of New York, Borough of Manhattan in lieu of utilizing the procedures set forth in this Section 24 and (v) nothing in this Section 24 shall limit the Holder from obtaining any injunctive relief or other equitable remedies (including, without limitation, with respect to any matters described in this Section 24 ).

 

  29  
 

 

25.           NOTICES; CURRENCY; PAYMENTS .

 

(a)           Notices . Whenever notice is required to be given under this Note, unless otherwise provided herein, such notice shall be given in accordance with Section 9(f) of the Securities Purchase Agreement. The Company and the Parent shall provide the Holder with prompt written notice of all actions taken pursuant to this Note, including in reasonable detail a description of such action and the reason therefore. Without limiting the generality of the foregoing, the Company and the Parent will give written notice to the Holder (i) immediately upon any adjustment of the Conversion Price, setting forth in reasonable detail, and certifying, the calculation of such adjustment and (ii) at least fifteen (15) days prior to the date on which the Company or the Parent closes its books or takes a record (A) with respect to any dividend or distribution upon the Parent Common Stock, and/or (B) for determining rights to vote with respect to any Fundamental Transaction, dissolution or liquidation, provided in each case that such information shall be made known to the public prior to or in conjunction with such notice being provided to the Holder.

 

(b)            Currency . All dollar amounts referred to in this Note are in United States Dollars (“ U.S. Dollars ”), and all amounts owing under this Note shall be paid in U.S. Dollars. All amounts denominated in other currencies (if any) shall be converted into the U.S. Dollar equivalent amount in accordance with the Exchange Rate on the date of calculation. “ Exchange Rate ” means, in relation to any amount of currency to be converted into U.S. Dollars pursuant to this Note, the U.S. Dollar exchange rate as published in the Wall Street Journal on the relevant date of calculation (it being understood and agreed that where an amount is calculated with reference to, or over, a period of time, the date of calculation shall be the final date of such period of time).

 

(c)            Payments . Whenever any payment of cash is to be made by the Company and/or the Parent to any Person pursuant to this Note, such payment shall be made in lawful money of the United States of America by a certified check drawn on the account of the Company and/or the Parent (as the case may be) and sent via overnight courier service to such Person at such address as previously provided to the Company and/or the Parent in writing (which address, in the case of the Holder, shall initially be as set forth in the Securities Purchase Agreement), provided that the Holder may elect to receive a payment of cash via wire transfer of immediately available funds by providing the Company with prior written notice setting out such request and the Holder’s wire transfer instructions. Whenever any amount expressed to be due by the terms of this Note is due on any day which is not a Business Day, the same shall instead be due on the next succeeding day which is a Business Day. Any amount of Principal, Interest, Late Charges and/or other amounts due under this Note and the other Transaction Documents which is not paid when due (following any cure period, if any) shall result in a late charge being incurred and payable by the Company in an amount equal to interest on such amount at the rate of eighteen percent (18%) per annum from the date such amount was due until the same is paid in full (“ Late Charge ”).

 

26.           CANCELLATION . After all Principal, accrued Interest, Late Charges and other amounts at any time owed on this Note have been paid in full, this Note shall automatically be deemed canceled, shall be surrendered to the Company for cancellation and shall not be reissued.

 

  30  
 

 

27.           WAIVER OF NOTICE . To the maximum extent permitted by law, the Company and the Parent each hereby irrevocably waives demand, notice, presentment, protest and all other demands and notices in connection with the delivery, acceptance, performance, default or enforcement of this Note, the Parent Note, the Parent Warrant, the Securities Purchase Agreement and the other Transaction Documents.

 

28.           GOVERNING LAW . All questions concerning the construction, validity, enforcement and interpretation of this Note shall be governed by the internal laws of the State of New York, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of New York or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of New York. Except as expressly set forth in Section 24 , the Company and the Parent hereby irrevocably submit to the exclusive jurisdiction of the state and federal courts sitting in The City of New York, Borough of Manhattan, for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper. The Company, the Parent and the Holder each hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof to such party at the address for such notices to it under this Note and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein or elsewhere, shall be deemed to limit in any way any right to serve process in any manner permitted by law. Nothing contained herein or elsewhere, (i) shall be deemed or operate to preclude the Holder from directly and/or indirectly bringing suit or taking other legal action against the Company, the Parent and/or any of the Subsidiaries and/or Affiliates or other Persons in any other jurisdiction to protect and/or enforce the Holders rights under this Note and/or the other Transaction Documents including the Securities Purchase Agreement, the Warrant, the Security Documents and the Guarantees and/or collect on the Company’s and/or the Parent’s obligations to the Holder or to enforce a judgment or other court ruling in favor of the Holder or (ii) shall limit, or shall be deemed or construed to limit any provision of Section 24 . THE COMPANY AND THE HOLDER EACH HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR UNDER ANY OTHER TRANSACTION DOCUMENT OR IN CONNECTION WITH OR ARISING OUT OF THIS NOTE, OR ANY TRANSACTION CONTEMPLATED HEREBY OR THEREBY.

 

29.            JUDGMENT CURRENCY .

 

(a)           If for the purpose of obtaining or enforcing judgment against the Company in any court in any jurisdiction it becomes necessary to convert into any other currency (such other currency being hereinafter in this Section 29 referred to as the “ Judgment Currency ”) an amount due in U.S. Dollars under this Note, the conversion shall be made at the Exchange Rate prevailing on the Trading Day immediately preceding:

 

(i)           the date actual payment of the amount due, in the case of any proceeding in the courts of New York or in the courts of any other jurisdiction that will give effect to such conversion being made on such date: or

 

(ii)          the date on which the foreign court determines, in the case of any proceeding in the courts of any other jurisdiction (the date as of which such conversion is made pursuant to this Section 29(a)(ii) being hereinafter referred to as the “ Judgment Conversion Date ”).

 

  31  
 

 

(b)          If in the case of any proceeding in the court of any jurisdiction referred to in Section 29(a)(ii) above, there is a change in the Exchange Rate prevailing between the Judgment Conversion Date and the date of actual payment of the amount due, the applicable party shall pay such adjusted amount as may be necessary to ensure that the amount paid in the Judgment Currency, when converted at the Exchange Rate prevailing on the date of payment, will produce the amount of U.S. Dollars which could have been purchased with the amount of Judgment Currency stipulated in the judgment or judicial order at the Exchange Rate prevailing on the Judgment Conversion Date.

 

(c)          Any amount due from the Company and/or the Parent under this provision shall be due as a separate debt and shall not be affected by judgment being obtained for any other amounts due under or in respect of this Note.

 

30.           SEVERABILITY . If any provision of this Note is prohibited by law or otherwise determined to be invalid or unenforceable by a court of competent jurisdiction, the provision that would otherwise be prohibited, invalid or unenforceable shall be deemed amended to apply to the broadest extent that it would be valid and enforceable, and the invalidity or unenforceability of such provision shall not affect the validity of the remaining provisions of this Note so long as this Note as so modified continues to express, without material change, the original intentions of the parties as to the subject matter hereof and the prohibited nature, invalidity or unenforceability of the provision(s) in question does not substantially impair the respective expectations or reciprocal obligations of the parties or the practical realization of the benefits that would otherwise be conferred upon the parties. The parties will endeavor in good faith negotiations to replace the prohibited, invalid or unenforceable provision(s) with a valid provision(s), the effect of which comes as close as possible to that of the prohibited, invalid or unenforceable provision(s).

 

31.           MAXIMUM PAYMENTS . Without limiting Section 9(d) of the Securities Purchase Agreement, nothing contained herein shall be deemed to establish or require the payment of a rate of interest or other charges in excess of the maximum permitted by applicable law. In the event that the rate of interest required to be paid or other charges hereunder exceed the maximum permitted by such law, any payments in excess of such maximum shall be credited against amounts owed by the Company and/or the Parent to the Holder and thus refunded to the Company and/or the Parent.

 

  32  
 

 

32.           CERTAIN DEFINITIONS . For purposes of this Note, the following terms shall have the following meanings:

 

(a)          “ 1933 Act ” means the Securities Act of 1933, as amended, and the rules and regulations thereunder.

 

(b)          “ 1934 Act ” means the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder.

 

(c)          “ Affiliate ” or “ affiliate ” means, with respect to any Person, any other Person that directly or indirectly controls, is controlled by, or is under common control with, such Person, it being understood for purposes of this definition that “control” of a Person means the power directly or indirectly either to vote 10% or more of the stock having ordinary voting power for the election of directors of such Person or direct or cause the direction of the management and policies of such Person whether by contract or otherwise.

 

(d)          “ Attribution Parties ” means, collectively, the following Persons and entities: (i) any investment vehicle, including, any funds, feeder funds or managed accounts, currently, or from time to time after the Issuance Date, directly or indirectly managed or advised by the Holder’s investment manager or any of its Affiliates or principals, (ii) any direct or indirect Affiliates of the Holder or any of the foregoing, (iii) any Person acting or who could be deemed to be acting as a Group together with the Holder or any of the foregoing and (iv) any other Persons whose beneficial ownership of the Parent Common Stock would or could be aggregated with the Holder’s and the other Attribution Parties for purposes of Section 13(d) of the 1934 Act. For clarity, the purpose of the foregoing is to subject collectively the Holder and all other Attribution Parties to the Maximum Percentage.

 

(e)          “ Bloomberg ” means Bloomberg, L.P.

 

(f)           “ Business Day ” means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized or required by law to remain closed.

 

(g)          “ Closing Date ” shall have the meaning set forth in the Securities Purchase Agreement, which date is the date the Company initially issued this Note pursuant to the terms of the Securities Purchase Agreement.

 

(h)          “ Closing Bid Price ” and “ Closing Sale Price ” means, for any security as of any date, the last closing bid price and last closing trade price, respectively, for such security on the Principal Market, as reported by Bloomberg, or, if the Principal Market begins to operate on an extended hours basis and does not designate the closing bid price or the closing trade price (as the case may be) then the last bid price or last trade price, respectively, of such security prior to 4:00:00 p.m., New York time, as reported by Bloomberg, or, if the Principal Market is not the principal securities exchange or trading market for such security, the last closing bid price or last trade price, respectively, of such security on the principal securities exchange or trading market where such security is listed or traded as reported by Bloomberg, or if the foregoing do not apply, the last closing bid price or last trade price, respectively, of such security in the over-the-counter market on the electronic bulletin board for such security as reported by Bloomberg, or, if no closing bid price or last trade price, respectively, is reported for such security by Bloomberg, the average of the bid prices, or the ask prices, respectively, of any market makers for such security as reported in the “pink sheets” by OTC Markets Group Inc. (formerly Pink Sheets LLC). If the Closing Bid Price or the Closing Sale Price cannot be calculated for a security on a particular date on any of the foregoing bases, the Closing Bid Price or the Closing Sale Price (as the case may be) of such security on such date shall be the fair market value as mutually determined by the Company and the Holder. If the Company and the Holder are unable to agree upon the fair market value of such security, then such dispute shall be resolved in accordance with the procedures in Section 24 . All such determinations shall be appropriately adjusted for any stock splits, stock dividends, stock combinations, recapitalizations or other similar transactions during such period.

 

  33  
 

 

(i)           “ Collateral Agent ” shall have the meaning set forth in the Securities Purchase Agreement.

 

(j)           “ Convertible Securities ” means any stock or other security (other than Options) that is at any time and under any circumstances, directly or indirectly, convertible into, exercisable or exchangeable for, or which otherwise entitles the holder thereof to acquire, any shares of Parent Common Stock.

 

(k)          “ Current Subsidiary ” means any Person in which the Company or the Parent on the Subscription Date, directly or indirectly, (i) owns a majority of the outstanding capital stock, voting stock or holds a majority of the equity or similar interest of such Person or (ii) controls or operates a substantial portion of the business, operations, management or administration of such Person, and all of the foregoing, collectively, “ Current Subsidiaries ”.

 

(l)           “ Eligible Market ” means any of the following markets or exchanges on which the Parent Common Stock (or any other common stock of any other Person that references an Eligible Market for its common stock) is listed or quoted for trading on the date in question: the OTC Bulletin Board, the NASDAQ Global Market, the NASDAQ Global Select Market, the NASDAQ Capital Market, the New York Stock Exchange, NYSE Arca, the NYSE MKT, or the OTCQX Marketplace, the OTCQB Marketplace, the OTCPink Marketplace or any other tier operated by OTC Markets Group Inc. (or any successor to any of the foregoing).

 

(m)         “ Fundamental Transaction ” means that (i) the Company, the Parent and/or any of the Subsidiaries shall, directly or indirectly, in one or more or a series of related transactions, (1) consolidate or merge with or into (whether or not the Company and/or the Parent and/or any of the Subsidiaries is the surviving corporation) any other Person and/or each other, or (2) sell, lease, license, assign, transfer, convey or otherwise dispose of all or substantially all of its respective properties or assets to any other Person, or (3) allow any other Person to make a purchase, tender or exchange offer that is accepted by the holders of more than 50% of the outstanding shares of Voting Stock of the Company and/or the Parent (not including any shares of Voting Stock of the Company and/or the Parent held by the Person or Persons making or party to, or associated or affiliated with the Persons making or party to, such purchase, tender or exchange offer), or (4) consummate a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with any other Person whereby such other Person acquires more than 50% of the outstanding shares of Voting Stock of the Company and/or the Parent (not including any shares of Voting Stock of the Company, the Parent and/or any Subsidiary and/or the Company held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business combination), or (ii) any “person” or “group” (as these terms are used for purposes of Sections 13(d) and 14(d) of the 1934 Act and the rules and regulations promulgated thereunder) is or shall become the “beneficial owner” (as defined in Rule 13d-3 under the 1934 Act), directly or indirectly, of 50% of the aggregate ordinary voting power represented by issued and outstanding Voting Stock of the Company and/or the Parent. Notwithstanding anything to the contrary provided herein or elsewhere, nothing in this definition of Fundamental Transaction shall provide any right to the Company or the Parent to do or take any actions otherwise prohibited herein and/or in the other Transaction Documents. Notwithstanding the above, a Fundamental Transaction shall not be deemed to occur as a result of a reincorporation merger of the Parent provided other than the place of incorporation of the Parent no other material changes occur to the Parent and/or any rights of the Holder under this Note and/or any other Transaction Document, as a result of such reincorporation merger.

 

  34  
 

 

(n)          “ GAAP ” means United States generally accepted accounting principles, consistently applied.

 

(o)          “ Indebtedness ” shall have the meaning ascribed to such term in the Securities Purchase Agreement.

 

(p)          “ Interest Date ” means the first (1 st ) calendar day of each calendar month beginning with the first calendar day of the first month following the Closing Date.

 

(q)          “ Material Adverse Effect ” means any material adverse effect on (i) the business, properties, assets, liabilities, operations (including results thereof), condition (financial or otherwise) or prospects of the Company, the Parent and/or any of the Subsidiaries, individually or taken as a whole, (ii) the transactions contemplated hereby or in any of the other Transaction Documents or any other agreements or instruments to be entered into in connection herewith or therewith or (iii) the authority or ability of the Company, the Parent and/or any of the Subsidiaries to perform any of the obligations under any of the Transaction Documents.

 

(r)           [INTENTIONALLY LEFT BLANK]

 

(s)          “ New Subsidiary ” means, as of any date of determination, any Person in which the Company and/or the Parent after the Subscription Date, directly or indirectly, (i) owns or acquires a majority of the outstanding capital stock, voting stock, or holds a majority of the equity or similar interest of such Person or (ii) controls or operates a substantial portion of the business, its management, operations or administration of such Person, and all of the foregoing, collectively, “ New Subsidiaries ”.

 

(t)           “ Options ” means any rights, warrants or options to subscribe for or purchase shares of Parent Common Stock or Convertible Securities.

 

(u)          “ Parent Common Stock ” means (i) the shares of common stock, $0.001 par value per share of the Parent, and (ii) any capital stock into which such common stock shall have been changed or any share capital resulting from a reclassification of such common stock.

 

(v)         “ Parent Entity ” of a Person means an entity that, directly or indirectly, controls the applicable Person or, if there is more than one such Person or Parent Entity, the Person or Parent Entity with the largest public market capitalization (or if both are not Trading Issuers, the largest private company valuation, as determined by the Holder) as of the date of consummation of the Fundamental Transaction.

 

(w)        “ Parent Note ” has the meaning set forth in the Securities Purchase Agreement.

 

(x)          “ Parent Warrants ” has the meaning ascribed to such term in the Securities Purchase Agreement, and shall include all warrants issued in exchange therefor or replacement thereof.

 

(y)         “ Permitted Indebtedness ” means (i) Indebtedness of the Company under this Note and/or any other Transaction Document, (ii) Indebtedness of the Company expressly identified as such on Schedule 3(q) to the Securities Purchase Agreement, as in effect as of the Subscription Date including, but not limited to, Sanofi Indebtedness to the extent such Sanofi Indebtedness is secured by a Permitted Lien, (iii) Indebtedness of the Company incurred pursuant to accounts receivable financing, provided if such is secured it is secured solely by the accounts receivable of the Company, (iv) Indebtedness incurred for the acquisition of services, supplies or inventory on normal trade credit in the ordinary course of business; (v) Indebtedness secured by Permitted Liens or unsecured as described in clauses (iv) and (v) of the definition of Permitted Liens and (vi) intercompany Indebtedness (to the extent not prohibited by the Sanofi Documents) between the Company, the Parent and any wholly-owned Domestic Subsidiary of the Parent, to the extent so permitted under this Note and the other Transaction Documents.

 

  35  
 

 

(z)          “ Permitted Liens ” means (i) any Lien for taxes not yet due or delinquent or being contested in good faith by appropriate proceedings for which adequate reserves have been established in accordance with GAAP, (ii) any statutory Lien arising in the ordinary course of business of the Company by operation of law with respect to a liability of the Company that is not yet due or delinquent, (iii) any Lien created by operation of law, such as materialmen’s liens, mechanics’ liens and other similar liens, arising in the ordinary course of business of the Company with respect to a liability of the Company that is not yet due or delinquent or that are being contested in good faith by appropriate proceedings, (iv) Liens (A) upon or in any equipment acquired or held by the Company solely to secure the purchase price of such equipment or Indebtedness incurred solely for the purpose of financing the acquisition or lease of such equipment of the Company, or (B) existing on such equipment at the time of its acquisition, provided that the Lien is confined solely to the property of the Company so acquired and improvements thereon, and the proceeds of such equipment, in either case, with respect to Indebtedness in an aggregate amount not to exceed $250,000, (v) Liens incurred in connection with the extension, renewal or refinancing of the Indebtedness secured by Liens of the type described in clause (iv) above, provided that any extension, renewal or replacement Lien shall be limited to the property encumbered by the existing Lien and the principal amount of the Indebtedness being extended, renewed or refinanced does not increase, (vi) Liens in favor of customs and revenue authorities arising as a matter of law to secure payments of custom duties in connection with the importation of goods for the Company, (viii) Liens with respect to accounts receivable and inventory financing of the Company provided such Liens are solely on the accounts receivable of the Company that are being used to obtain such accounts receivable financing for the Company as expressly identified and in such amounts as provided in writing in such accounts receivable financing documentation, (ix) Liens in favor of Sanofi to the extent permitted in the Deed of Trust as of the Subscription Date, and (x) Liens in favor of the Collateral Agent and/or the Holder perfecting the Collateral Agent’s and/or the Holder’s security interests in the assets of the Company to the extent provided for in the Security Documents.

 

(aa)       “ Person ” means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization, any other entity or a government or any department or agency thereof.

 

(bb)       “ Principal Market ” means as of a particular date, the Eligible Market on such date that the Parent Common Stock is principally traded or quoted on.

 

(cc)        “ Qualifying PO ” means the first firm commitment underwritten public offering by the Parent on or following the Subscription Date in which shares of Parent Common Stock are sold for the account of the Parent solely for cash to the public resulting in proceeds to the Parent and/or the Company of no less than $8,000,000 (after deduction only of underwriter discounts and commissions) and where the shares of Parent Common Stock registered under the 1933 Act and sold in such public offering, are simultaneously listed and commence trading on the Nasdaq Global Market, the Nasdaq Global Select Market, the Nasdaq Capital Market, the New York Stock Exchange or the NYSE Market (a “ Qualify Market ”).

 

(dd)        “ Redemption Notices ” means, collectively, the Event of Default Redemption Notices, the Fundamental Transaction Redemption Notices and the Company Optional Redemption Notices and each of the foregoing, individually, a “ Redemption Notice.

 

(ee)        “ Redemption Prices ” means, collectively, the Company Optional Redemption Prices, Event of Default Redemption Prices, Fundamental Transaction Redemption Prices and each of the foregoing, individually, a “ Redemption Price.

 

  36  
 

 

(ff)          “ SEC ” means the United States Securities and Exchange Commission or any successor thereto.

 

(gg)        “ Securities Purchase Agreement ” shall have the meaning set forth on the first page of this Note.

 

(hh)        “ Security Agreements ” shall have the meaning as set forth in the Securities Purchase Agreement.

 

(ii)           “ Security Documents ” shall have the meaning as set forth in the Securities Purchase Agreement.

 

(jj)           “ Subsidiaries ” means, as of any date of determination, collectively, all Current Subsidiaries including, but not limited to, all New Subsidiaries, and each of the foregoing, individually, a “ Subsidiary .”

 

(kk)        “ Successor Entity ” means the Person (or, if so elected by the Holder, the Parent Entity) formed by, resulting from or surviving any Fundamental Transaction or the Person (or, if so elected by the Holder, the Parent Entity) with which such Fundamental Transaction shall have been entered into.

 

(ll)          “ Trading Day ” means, (I) as applicable, (x) with respect to all price or trading volume determinations relating to the Parent Common Stock, any day on which the Parent Common Stock is traded on the Principal Market, or, if the Principal Market is not the principal trading market for the Parent Common Stock, then on an Eligible Market the principal securities exchange or securities market on which the Parent Common Stock is then traded or eligible for quotation, provided that “Trading Day” shall not include any day on which the Parent Common Stock is scheduled to trade on such exchange or market for less than 4.5 hours or any day that the Parent Common Stock is suspended from trading or quotation during the final hour of trading on such exchange or market (or if such exchange or market does not designate in advance the closing time of trading on such exchange or market, then during the hour ending at 4:00:00 p.m., New York time) unless such day is otherwise designated as a Trading Day in writing by the Holder or (y) with respect to all determinations other than price determinations relating to the Parent Common Stock, any day on which The New York Stock Exchange (or any successor thereto) is open for trading of securities, or (II) if the Parent is not a Trading Issuer, the term “ Trading Day ” shall mean Business Day.

 

(mm)       “ Trading Issuer ” means any Person whose shares of common stock are listed for trading or eligible for quotation on an Eligible Market.

 

(nn)        “ Transaction Documents ” shall have the meaning as set forth in the Securities Purchase Agreement.

 

(oo)        “ Voting Stock ” of a Person means capital stock of such Person of the class or classes pursuant to which the holders thereof have the general voting power to elect, or the general power to appoint, at least a majority of the board of directors, managers, trustees or other similar governing body of such Person (irrespective of whether or not at the time capital stock of any other class or classes shall have or might have voting power by reason of the happening of any contingency).

 

  37  
 

 

33.            DISCLOSURE . Upon receipt or delivery by the Company or the Parent of any notice in accordance with the terms of this Note and subject to the other terms of this Section 33 , unless the Company or the Parent has in good faith determined that the matters relating to such notice do not constitute material, non-public information relating to the Company, the Parent and/or any of the Subsidiaries or the Holder has provided prior written consent to receive such material non-public information, the Company shall and the Parent shall within two (2) Trading Days after any such receipt or delivery publicly disclose such material, non-public information on a Current Report on Form 8-K or otherwise. In the event that the Company or the Parent believes that a notice contains material, non-public information relating to the Company, the Parent and/or any of the Subsidiaries, the Company and/or the Parent so shall indicate to the Holder contemporaneously with delivery of such notice, and in the absence of any such indication, the Holder shall be allowed to presume that all matters relating to such notice do not constitute material, non-public information relating to the Company, the Parent and/or any of the Subsidiaries. If the Company, the Parent and/or any of the Subsidiaries provides material non-public information to the Holder that is not simultaneously filed in a Current Report on Form 8-K and the Holder has not agreed in writing to receive such material non-public information, the Company and the Parent hereby covenant and agree that the Holder shall not have any duty of confidentiality to them and/or the Subsidiaries or any of the officers, directors, employees, affiliates or agents with respect to, any such information or a duty to any of the foregoing not to trade on the basis of such material non-public information. Nothing contained in this Section 33 shall limit any obligations of the Company and/or the Parent, or any rights or remedies of the Holder, under the Securities Purchase Agreement. Notwithstanding anything to the contrary contained herein, neither the Parent, the ICA-T nor any Subsidiary shall be required to publicly disclose any material, non-public information relating to the Parent, ICA-T or any Subsidiary if the Holder has provided its prior written consent to the receipt of such information.

  

  38  
 

 

[SENIOR SECURED CONVERTIBLE NOTE – SIGNATURE PAGE]

  

IN WITNESS WHEREOF , the Company and Parent has caused this Note to be duly executed as of the Issuance Date set out above.

  

  ICAGEN-T INC.
     
  By: /s/ Richard Cunningham
    Name: Richard Cunningham
    Title: Chief Executive Officer

 

  ICAGEN, INC.
     
  By: /s/ Richard Cunningham
    Name: Richard Cunningham
    Title: Chief Executive Officer

 

  39  
 

 

EXHIBIT I

 

Icagen, Inc. Conversion Notice

 

Reference is made to the Senior Secured Convertible Note (the “ Note ”) issued to the undersigned by Icagen-T, Inc., a Delaware corporation (the “ Company ”). In accordance with and pursuant to the Note, the undersigned hereby elects to convert the Conversion Amount (as defined in the Note) of the Note indicated below into shares of common stock, $0.001 par value per share (the “ Parent Common Stock ”), of Icagen, Inc., as of the date specified below. Capitalized terms not defined herein shall have the meaning as set forth in the Note.

 

  Date of Conversion:  
     
  Aggregate Principal to be converted:  
     
  Aggregate accrued and unpaid Interest to be converted:  
     
  Aggregate accrued and unpaid Late Charges with respect to such portion of the Aggregate Principal and Aggregate Interest to be converted:  
     
  AGGREGATE CONVERSION  
  AMOUNT TO BE CONVERTED:  

 

Please confirm the following information:

 

  Conversion Price:  
     
  Number of shares of Common Stock to be issued:  

 

Please issue the shares of Parent Common Stock into the Note is being converted to Holder, or for its benefit, as follows:

 

☐   Check here if requesting delivery as a certificate to the following name and to the following address:

 

  Issue to:  
     
     

 

i
 

 

☐  Check here if requesting delivery by Deposit/Withdrawal at Custodian as follows if the Company is a Trading Issuer:

 

  DTC Participant:  
     
  DTC Number:  
     
Account Number:  

 

Notwithstanding anything to the contrary contained herein, this Conversion Notice shall constitute a representation by the Holder of the Note submitting this Conversion Notice that after giving effect to the conversion provided for in this Conversion Notice, such Holder (together with its affiliates) will not have beneficial ownership (together with the beneficial ownership of such Person’s affiliates) of a number of shares of Parent Common Stock which exceeds the Maximum Percentage (as defined in the Note) of the total outstanding shares of Parent Common Stock as determined pursuant to the provisions of Section 3(d) of the Note.

 

Date: _____________ __,  
   
 
Name of Registered Holder  

 

By:      
  Name:    
  Title:    
       
  Tax ID: ____________________________    
       
  Facsimile: __________________________    
       
  E-mail Address: ______________________    

 

ii
 

 

Exhibit II

 

ACKNOWLEDGMENT

 

Icagen, Inc. and Icagen-T, Inc. hereby (a) acknowledge this Conversion Notice, (b) certify that the above indicated number of shares of Parent Common Stock [are][are not] eligible to be resold by the Holder either (i) pursuant to Rule 144 (subject to the Holder’s execution and delivery to the Company of a customary 144 representation letter) or (ii) an effective and available registration statement and (c) hereby directs _________________ to issue the above indicated number of shares of Parent Common Stock in accordance with the Transfer Agent Instructions dated May 15, 2017 from Icagen, Inc. and acknowledged and agreed to by American Stock Transfer & Trust Company.

 

 

  ICAGEN, INC. 
     
  By:  
    Name:
    Title:

 

  ICAGEN-T, INC. 
     
  By:  
    Name:
    Title:

 

 

i

Exhibit 10.1

 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

SECURITIES PURCHASE AGREEMENT

 

This SECURITIES PURCHASE AGREEMENT (the “ Agreement ”), dated as of May 15, 2017, is by and among Icagen, Inc., a Delaware corporation with its executive offices located at 4222 Emperor Blvd., Suite 350, Research Triangle Park, Durham, NC, 27703 (the “ Parent ”), Icagen-T, Inc., a Delaware corporation and a wholly-owned Subsidiary (as defined below) of the Parent with offices located at 2090 E. Innovation Park Drive, Oro Valley, Arizona 85755 (“ ICA-T ” or the “ Company ”) and GPB Debt Holdings II, LLC (the “ Buyer ”).

 

RECITALS

 

A.       ICA-T, the Parent and the Buyer are each executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by Section 4(a)(2) of the Securities Act of 1933, as amended (the “ 1933 Act ”), and/or Rule 506(b) of Regulation D (“ Regulation D ”) as promulgated by the United States Securities and Exchange Commission (the “ SEC ”) under the 1933 Act.

 

B.       Upon the terms and subject to the conditions set forth in this Agreement, the Buyer desires to purchase and (i) ICA-T desires to issue and sell to the Buyer, a senior secured convertible note of ICA-T, in the aggregate original principal amount of $8,000,000, substantially in the form attached hereto as Exhibit A (the “ ICA-T Note ”), which ICA-T Note shall be convertible into shares of Parent Common Stock (as defined below), (the shares of Parent Common Stock issuable pursuant to the terms of the ICA-T Note and the Parent Note (as defined below), including without limitation, upon conversion or otherwise, collectively, the “ Parent Conversion Shares ”) in accordance with ICA-T Note and the Parent Note (as the case may be), and (ii) the Parent desires to issue and sell to the Buyer a (a) senior secured convertible note of the Parent in the aggregate principal amount of $2,000,000, substantially in the form attached hereto as Exhibit B (the “ Parent Note ,” and together with ICA-T Note, collectively the “ Notes ”), which Parent Note shall be convertible into Parent Conversion Shares in accordance with the terms of the Parent Note, and (b) warrant to purchase initially up to 857,143 shares of Parent Common Stock substantially in the form attached hereto as Exhibit C (the “ Parent Warrant ”) (the shares of Parent Common Stock issuable pursuant to the terms of the Parent Warrant, including, without limitation, upon exercise or otherwise, collectively, the “ Parent Warrant Shares ,” and together with the Parent Conversion Shares, collectively, the “ Parent Underlying Shares ”) in accordance with the terms of the Parent Warrant.

 

C.       ICA-T Note, the Parent Note, the Parent Conversion Shares, the Parent Warrant and the Parent Warrant Shares collectively are referred to herein as the “ Securities ”.

 

 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

D.       The Parent Note shall rank with respect to all present and future Parent Indebtedness as provided in the Parent Note; and the ICA-T Note shall rank with respect to all present and future Indebtedness of ICA-T as provided in the ICA-T Note, however, as provided in the ICA-T Note, the ICA-T Note shall rank senior to all Indebtedness of ICA-T (other than Indebtedness of ICA-T owed by ICA-T to Sanofi (as defined below) set forth in the Sanofi Documents to the extent that the Sanofi Documents expressly require such Indebtedness of ICA-T to Sanofi to be senior in right of payment to other Indebtedness of ICA-T and the payment and/or repayment of which is secured by a senior security interest on the assets of ICA-T expressly identified in and pursuant to the S/I Deed of Trust (as defined below) (the “ Sanofi Indebtedness ”), which under the ICA-T Note shall constitute Permitted Indebtedness (as defined in the ICA-T Note) secured by Permitted Liens (as defined in the ICA-T Note), and which (A) the ICA-T Note will be secured by a security interest in all of the existing and future assets of the Parent, ICA-T and the other Subsidiaries (as defined in the ICA-T Security Documents), including a pledge of all of the capital stock of each of the Subsidiaries (other than ICA-T), as evidenced by (i) a security and pledge agreement in the form attached hereto as Exhibit D (the “ ICA-T Security Agreement ”) and (ii) a guaranty executed by the Parent and each Subsidiary (other than ICA-T), in the form attached hereto as Exhibit E (the “ ICA-T Guaranty ”, and together with the ICA-T Security Agreement, the Perfection Certificate (as defined below) and the other security documents and agreements (including, but not limited to, a Deed of Trust and Assignment of Rents between ICA-T, as trustor, the trustee named therein and the Buyer as beneficiary, securing all of ICA-T’s obligations to the Buyer by a senior priority security interest in the Property/Facilities (as defined below), subordinated only to the S/I Deed of Trust, the S/I Warranty and Reverter Deed the form of which is annexed hereto as Exhibit F (the “ Buyer Deed of Trust Documents ,” as each may be amended or modified from time to time and together with all schedules and exhibits to each and all other instruments, filings, documents, agreements and related items securing, establishing, perfecting, protecting and/or maintaining a security interest in and a perfected Lien on the assets of ICA-T in favor of the Collateral Agent and/or the Buyer, collectively, the “ ICA-T Security Documents ”) pursuant to which the Parent and the Subsidiaries (other than ICA-T) shall guarantee all of the Indebtedness and other obligations of ICA-T under the Transaction Documents (as defined below), and (B) the Parent Note will be secured by a security interest in all of the existing and future assets of the Parent and the Subsidiaries (other than ICA-T), including a pledge of all of the capital stock of each of the Subsidiaries (other than ICA-T), as evidenced by (i) a security and pledge agreement in the form attached hereto as Exhibit G (the “ Parent Security Agreement ” and together with the ICA-T Security Agreement, collectively, the “ Security Agreements ”) and (ii) a guaranty executed by each Subsidiary (other than ICA-T), in the form attached hereto as Exhibit H (the “ Parent Guaranty ”, and together with the ICA-T Guaranty, collectively, the “ Guaranty Agreements ” and together with the Parent Security Agreement, the Perfection Certificate and the other Parent security documents and agreements entered into in connection with this Agreement and each of such other documents and agreements, as each may be amended or modified from time to time, and together will all schedules and exhibits to each of such items and together with will all schedules and exhibits to each and all other instruments, filings, documents, agreements and related items securing, establishing, perfecting, protecting and/or maintaining a security interest in and a perfected Lien on the assets of the Parent and the Subsidiaries in favor of the Collateral Agent and/or the Buyer, collectively, the “ Parent Security Documents ” and together with the ICA-T Security Documents, collectively, the “ Security Documents ”) pursuant to which the Subsidiaries (other than ICA-T) shall guarantee the Indebtedness and all obligations of the Parent under the Transaction Documents.

 

  2  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

AGREEMENT

 

NOW, THEREFORE, in consideration of the premises and the mutual covenants contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, ICA-T, the Parent and the Buyer hereby agrees as follows:

 

1. PURCHASE AND SALE OF NOTES AND WARRANTS.

 

(a)        Purchase of Notes and Parent Warrants . Subject to the satisfaction (or waiver) of the conditions set forth in Section 6 and Section 7 , at the Closing (as defined below), on the Closing Date (as defined below), (i) ICA-T shall issue and sell to the Buyer, and the Buyer agrees to purchase from ICA-T, the ICA-T Note in the original aggregate principal amount of $8,000,000, and (ii) the Parent shall issue and sell to the Buyer, and the Buyer agrees to purchase from the Parent (A) the Parent Note in the original aggregate principal amount of $2,000,000, and (B) the Parent Warrant to initially acquire up to 857,143 Parent Warrant Shares. The purchase and sales set forth in this Section 1(a)(i) and (ii) shall be contingent upon and deemed to occur simultaneously with each other.

 

(b)        Closing . The closing (the “ Closing ”) of the purchase of the Notes and the Parent Warrant by the Buyer shall occur at the offices of Gusrae Kaplan Nusbaum PLLC, 120 Wall Street, New York, NY 10005. The date and time of the Closing (the “ Closing Date ”) shall be 10:00 a.m., New York time, on the first (1st) Business Day on which the conditions to the Closing set forth in Section 6 and Section 7 below are satisfied or waived (or such other date as is mutually agreed to by the Parent, ICA-T and the Buyer). As used herein “ Business Day ” means any day other than a Saturday, Sunday or other day on which commercial banks in New York, New York are authorized or required by law to remain closed.

 

(c)        Purchase Price . The aggregate purchase price to be paid by the Buyer for (i) the ICA-T Note shall be $7,680,000 (the “ ICA-T Purchase Price ”), and (ii) the Parent Note and the Parent Warrant shall be $1,920,000 (the “ Parent Purchase Price ” and together with the ICA-T Purchase Price, collectively, the “ Purchase Price ”). The Buyer and the Parent agree that the Parent Note and the Parent Warrant constitute an “investment unit” for purposes of Section 1273(c)(2) of the Internal Revenue Code of 1986, as amended (the “ Code ”). The Buyer, the Parent and ICA-T shall prior to Closing mutually agree in writing to the allocation of the issue price of such investment unit between the Parent Note and the Parent Warrant in accordance with Section 1273(c)(2) of the Code and Treasury Regulation Section 1.1273-2(h) and neither the Buyer, the Parent nor ICA-T shall take any position inconsistent with such allocation in any tax return or in any judicial or administrative proceeding in respect of taxes. For avoidance of doubt, the Buyer shall pay approximately (i) $960.00 for each $1,000 aggregate principal amount of ICA-T Note, and (ii) $960.00 for each $1,000 of aggregate principal amount of the Parent and corresponding portion of the Parent Warrant.

 

  3  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

(d)        Form of Payment . On the Closing Date (i) the Buyer shall pay (A) to the Parent, the Parent Purchase Price for the Parent Note and Parent Warrant to be issued and sold to the Buyer by the Parent at Closing, and (B) to ICA-T, the ICA-T Purchase Price for ICA-T Note to be issued and sold to the Buyer by ICA-T at the Closing (less, in both cases, all amounts withheld and paid for by and on behalf of the Parent and/or ICA-T by the Buyer pursuant to Section 4(g) ), in cash by wire transfer of immediately available funds in accordance with the Flow of Funds Letter (as defined below), and (ii) (A) the Parent shall deliver to the Buyer, the Parent Note in the aggregate principal amount of $2,000,000 and the Parent Warrant to initially acquire 857,143 Warrant Shares, and (B) ICA-T shall deliver to the Buyer, the ICA-T Note in the aggregate principal amount of $8,000,000, in each case duly executed on behalf of the Parent and ICA-T, as applicable, and registered in the name of the Buyer or its designee.

 

(e)        Residency . The Buyer is a resident of that jurisdiction specified below its address in Section 9(f) .

 

2.     BUYER’S REPRESENTATIONS AND WARRANTIES.

 

The Buyer represents and warrants to ICA-T and the Parent, as of the date hereof and as of the Closing Date:

 

(a)        Organization; Authority . Buyer is an entity duly organized, validly existing and in good standing under the laws of the jurisdiction of its organization with the requisite power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents to which it is a party and otherwise to carry out its obligations hereunder and thereunder.

 

(b)        No Public Sale or Distribution . Buyer (i) is acquiring the Notes and the Parent Warrant, and (ii) upon conversion and exercise of the Notes and the Parent Warrant, respectively, will acquire the Parent Underlying Shares, respectively, in each case for its own account and not with a view towards, or for resale in connection with, the public sale or distribution thereof in violation of applicable securities laws, except pursuant to sales registered or exempted under the 1933 Act; provided , however , by making the representations herein, the Buyer does not agree, or make any representation or warranty, to hold any of the Securities for any minimum or other specific term and reserves the right to dispose of the Securities at any time in accordance with or pursuant to a registration statement or an exemption from registration under the 1933 Act. The Buyer does not presently have any agreement or understanding, directly or indirectly, with any Person to distribute any of the Securities in violation of applicable securities laws. For purposes of this Agreement, “ Person ” means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization, any other entity and any Governmental Entity or any department or agency thereof.

 

(c)        Accredited Investor Status . The Buyer is an “accredited investor” as that term is defined in Rule 501(a) of Regulation D.

 

(d)        Reliance on Exemptions . The Buyer understands that the Securities are being offered and sold to it in reliance on specific exemptions from the registration requirements of United States federal and state securities laws and that ICA-T and the Parent are relying in part upon the truth and accuracy of, and the Buyer’s compliance with, the representations, warranties, agreements, acknowledgments and understandings of the Buyer set forth herein in order to determine the availability of such exemptions and the eligibility of the Buyer to acquire the Securities. None of the managers or directors or executive officers of the Buyer is subject to any of the “Bad Actor” disqualifications described in Rule 506(d)(1)(i) to (viii) under the 1933 Act.

 

  4  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

(e)        Information . The Buyer and its advisors, if any, have been furnished with all materials relating to the business, finances and operations of ICA-T and the Parent and materials relating to the offer and sale of the Securities that have been requested by the Buyer. The Buyer and its advisors, if any, have been afforded the opportunity to ask questions of ICA-T and the Parent. Neither such inquiries nor any other due diligence investigations conducted by the Buyer or its advisors, if any, or its representatives shall modify, amend or affect the Buyer’s right to rely on ICA-T’s and the Parent’s representations and warranties contained herein. The Buyer understands that its investment in the Securities involves a high degree of risk. The Buyer has sought such accounting, legal and tax advice as it has considered necessary to make an informed investment decision with respect to its acquisition of the Securities.

 

(f)        No Governmental Review . The Buyer understands that no United States federal or state agency or any other government or governmental agency has passed on or made any recommendation or endorsement of the Securities or the fairness or suitability of the investment in the Securities nor have such authorities passed upon or endorsed the merits of the offering of the Securities.

 

(g)        Transfer or Resale . The Buyer understands that except for the registration rights provided in this Agreement (i) the Securities have not been and are not being registered under the 1933 Act or any state securities laws, and may not be offered for sale, sold, assigned or transferred unless (A) subsequently registered thereunder, (B) the Buyer shall have delivered to the Parent (if requested by the Parent), an opinion of counsel, in a form reasonably acceptable to the Parent, to the effect that such Securities to be sold, assigned or transferred may be sold, assigned or transferred pursuant to an exemption from such registration, (C) the Buyer provides the Parent with reasonable assurance that such Securities can be sold, assigned or transferred pursuant to Rule 144 or Rule 144A promulgated under the 1933 Act (or a successor rule thereto) (collectively, “ Rule 144 ”), or (D) the Parent’s counsel shall have provided the opinion required pursuant to Section 4(a)(xxi) of the ICA-T Note or otherwise, (ii) any sale of the Securities made in reliance on Rule 144 may be made only in accordance with the terms of Rule 144, and further, if Rule 144 is not applicable, any resale of the Securities under circumstances in which the Buyer (or the Person through whom the sale is made) may be deemed to be an underwriter (as that term is defined in the 1933 Act) may require compliance with some other exemption under the 1933 Act or the rules and regulations of the SEC promulgated thereunder; (iii) although the Parent Common Stock is registered under Section 12(g) of the Securities Exchange Act of 1934, as amended (the “ 1934 Act ”), none of the Securities including the Parent Common Stock currently are listed for trading on any Eligible Market (as defined in the Notes), and (iv) neither the Parent, ICA-T, nor any other Person is under any obligation to register the Securities under the 1933 Act or any state securities laws or to comply with the terms and conditions of any exemption thereunder. Notwithstanding the foregoing, the Securities may be pledged by the Buyer or its assignee in connection with a bona fide margin account or other loan or financing arrangement secured by the Securities and such pledge of Securities shall not be deemed to be a transfer, sale or assignment of the Securities hereunder, and the Buyer or such other Person shall not be required to provide the Parent with any notice thereof or otherwise make any delivery to the Parent pursuant to this Agreement or any other Transaction Document (including, without limitation, this Section 2(g) ).

 

  5  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

(h)        Validity; Enforcement . This Agreement has been duly and validly authorized, executed and delivered on behalf of the Buyer and shall constitute the legal, valid and binding obligations of the Buyer enforceable against the Buyer in accordance with their respective terms, except as such enforceability may be limited by general principles of equity or to applicable bankruptcy, insolvency, reorganization, moratorium, liquidation and other similar laws relating to, or affecting generally, the enforcement of applicable creditors’ rights and remedies.

 

(i)        No Conflicts . The execution, delivery and performance by the Buyer of this Agreement and the consummation by the Buyer of the transactions contemplated hereby and thereby will not (i) result in a violation of the organizational documents of the Buyer, or (ii) conflict with, or constitute a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which the Buyer is a party, or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including federal and state securities laws) applicable to the Buyer, except in the case of clauses (ii) and (iii) above, for such conflicts, defaults, rights or violations which could not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the ability of the Buyer to perform its obligations hereunder.

 

3. REPRESENTATIONS AND WARRANTIES OF ICA-T AND THE PARENT.

 

ICA-T and the Parent each severally represent and warrant to the Buyer that, as of the date hereof and as of the Closing Date:

 

(a)        Organization and Qualification . Each of the Parent, ICA-T and the Subsidiaries are entities duly organized and validly existing and in good standing under the laws of the jurisdiction in which they are formed, and have the requisite power and authority to own their properties and to carry on their business as now being conducted and as presently proposed to be conducted. Each of the Parent, ICA-T and the Subsidiaries are duly qualified as a foreign entity to do business and is in good standing in every jurisdiction in which its ownership of property or the nature of the business conducted by it makes such qualification necessary, except to the extent that the failure to be so qualified or be in good standing would not reasonably be expected to have a Material Adverse Effect. As used in this Agreement, “ Material Adverse Effect ” means any material adverse effect on (i) the business, properties, assets, liabilities, operations (including results thereof), condition (financial or otherwise) or prospects of the Parent, ICA-T and the Subsidiaries individually or taken as a whole, (ii) the transactions contemplated hereby or in any of the other Transaction Documents or any other agreements or instruments to be entered into in connection herewith or therewith or (iii) the authority or ability of the Parent, ICA-T and/or the Subsidiaries to perform any of their respective obligations under any of the Transaction Documents. Other than the Persons (as defined below) set forth on Schedule 3(a) , the Parent nor ICA-T has any Subsidiaries including, but not limited to, any Foreign Subsidiaries. “ Foreign Subsidiary ” means at any time of determination any Subsidiary of ICA-T or the Parent organized under the laws of a jurisdiction other than the United States, any of the states thereof, Puerto Rico or the District of Columbia. “ Subsidiaries ” means at any time of determination any Person in which ICA-T or the Parent, directly or indirectly (A) owns any of the outstanding capital stock or holds any equity or similar interest of such Person or (B) controls or operates all or any part of the business, operations or administration of such Person, and each of the foregoing, is individually referred to herein as a “ Subsidiary .”

 

  6  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

(b)        Authorization; Enforcement; Validity . The Parent, ICA-T and the Subsidiaries have the requisite power and authority to enter into and perform its obligations under this Agreement and the other Transaction Documents and to issue their respective Securities in accordance with the terms hereof and thereof. Each Subsidiary has the requisite power and authority to enter into and perform its obligations under the Transaction Documents to which it is a party. The execution and delivery of this Agreement and the other Transaction Documents by the Parent, ICA-T and the Subsidiaries, and the consummation by the Parent, ICA-T and the Subsidiaries of the transactions contemplated hereby and thereby (including, without limitation, the issuance and sale of the Parent Note, the Parent Warrant and the ICA-T Note the SPA Share Reservation, the reservation for issuance and the issuance of the Parent Underlying Shares upon conversion of the ICA-T and the Parent Note and exercise of the Parent Warrant and the Security Documents) have been duly authorized by the Parent’s and ICA-T’s board of directors and the Subsidiaries’ board of directors or other governing body, as applicable (and to the extent necessary, the stockholders of the Parent, ICA-T and the Subsidiaries), and other than (i) the filing with the SEC of one or more Registration Statements in accordance with the requirements set forth in this Agreement, (ii) the filing of a Form D with the SEC, (iii) all other filing(s) required by applicable state securities agencies, (iv) the Form 8-K filing (as defined below), and (v) the filings of such documents, instruments and/or items required to effectuate and perfect all Liens and security interests of the Buyer under the Transaction Documents including the Security Documents (the items set forth in (i)-(v), collectively, the “ Required Filings ”) no further filing, consent or authorization is required by the Parent, ICA-T or any of their respective Subsidiaries, their respective boards of directors or their stockholders or other governing body in connection with the execution and performance of this Agreement and the other Transaction Documents and the performance of their respective obligations hereunder and thereunder. This Agreement and the other Transaction Documents to which it is a party will be prior to the Closing, duly executed and delivered by the Parent, ICA-T and the Subsidiaries, and each constitutes the legal, valid and binding obligations of ICA-T, the Parent and the Subsidiaries, enforceable against ICA-T, the Parent and the Subsidiaries in accordance with their respective terms, except as such enforceability may be limited by general principles of equity or applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws relating to, or affecting generally, the enforcement of applicable creditors’ rights and remedies and except as rights to indemnification and to contribution may be limited by federal or state securities law. Prior to the Closing, the Transaction Documents to which each Subsidiary is a party will be duly executed and delivered by each such Subsidiary, and shall constitute the legal, valid and binding obligations of each such Subsidiary, enforceable against each such Subsidiary in accordance with their respective terms, except as such enforceability may be limited by general principles of equity or applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws relating to, or affecting generally, the enforcement of applicable creditors’ rights and remedies and except as rights to indemnification and to contribution may be limited by federal or state securities law. “ Transaction Documents ” means, collectively, this Agreement, the Parent Note, ICA-T Note, the Parent Warrant, the Parent Common Stock, the Parent Conversion Shares, the Parent Warrant Shares, the Parent Underlying Shares, the Flow of Funds Letter, the Buyer Deed of Trust, the Irrevocable Transfer Agent Instructions (as defined below), the Confession of Judgment (as defined below), the Guaranties, the IP Security Agreement (as defined in the Security Agreements), the Security Agreements, the other Security Documents, all Closing documents and each of the other agreements, certificates and instruments entered into or delivered by any of the parties hereto in connection with the transactions contemplated hereby and thereby, as may be amended and/or modified from time to time and includes for each all amendments, supplements and/or other modifications and all schedules, exhibits and/or annexes to each.

 

  7  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

(c)        Issuance of Securities . The issuance of the Securities are duly authorized and upon issuance in accordance with the terms shall be validly issued, fully paid and nonassessable, and free from all preemptive or similar rights, mortgages, defects, claims, liens, pledges, charges, taxes, rights of first refusal, encumbrances, security interests and other encumbrances (collectively “ Liens ”) with respect to the issuance thereof. As of the Closing, the Parent shall have reserved from its duly authorized capital stock the SPA Required Reserve Amount (as defined below). Upon issuance and conversion in accordance with the Parent Note and ICA-T Note and exercise of the Parent Warrant, respectively, the Parent Conversion Shares and Parent Warrant Shares, respectively, when issued, will be validly issued, fully paid and nonassessable and free from all preemptive or similar rights or Liens with respect to the issue thereof, with the holder being entitled to all rights accorded to a holder of Parent Common Stock. Subject to the accuracy of the representations and warranties of the Buyer in this Agreement, the offer, issuance and sale by the Parent and ICA-T of their respective Securities is exempt from registration under the 1933 Act.

 

(d)        No Conflicts . The execution, delivery and performance of the Transaction Documents by the Parent, ICA-T and the Subsidiaries and the consummation by the Parent, ICA-T and the Subsidiaries of the transactions contemplated hereby and thereby (including, without limitation, the issuance of the Securities, the reservation of the SPA Required Reserve Amount, the offer, issuance and sale of the Securities and the entering into of the Security Documents and the performance by the Parent, ICA-T and the Subsidiaries thereof including, but not limited to, the creation of and perfection of the Lien on the Property/ Facility pursuant to the Buyer Deed of Trust) will not (i) result in a violation of the Certificate of Incorporation (as defined below) (including, without limitation, any certificate of designation contained therein), By-Laws (as defined below), certificate of formation, memorandum of association, articles of association, certificate of incorporation, bylaws or other organizational documents of the Parent, ICA-T and the Subsidiaries, or any capital stock or other securities of the Parent, ICA-T and the Subsidiaries, (ii) conflict with, or constitute a default (or an event which with notice or lapse of time or both would become a default or an event of default) in any respect under or pursuant to, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which the Parent, ICA-T and the Subsidiaries are a party and/or any of their respective assets and/or property are bound by including, but not limited to, any of the Sanofi Documents, or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including, without limitation, foreign, federal and state securities laws and regulations) applicable to the Parent, ICA-T and the Subsidiaries or by which any property or asset of the Parent, ICA-T and/o any of their respective Subsidiaries is bound or affected. The “ Sanofi Documents ” mean, collectively, (A) the Asset Purchase Agreement dated June 27, 2016 by and between Sanofi US Services, Inc. (“ Sanofi ”) and ICA-T (as amended, supplemented and/or modified and together with all exhibits thereto, collectively, the “ S/I APA ”), (B) the Master Services Agreement dated July 15, 2016 by and between Sanofi and ICA-T (as amended, supplemented and/or modified and together with all exhibits thereto, collectively, the “ S/I MSA ”), (C) the Special Warranty Deed with Reverter dated July 13, 2016 with Sanofi as the Grantor and ICA-T as the Grantee, as filed with the Official Records of the Pima County, Arizona Recorder’s Office on July 15, 2016 (as amended, supplemented and/or modified and together with all exhibits thereto, collectively, the “ S/I Warranty and Reverter Deed ”), (D) the Deed of Trust and Assignment of Rents Agreement between ICA-T, as Trustor, Sanofi, as Beneficiary and Patricia E. Nolan as Trustee relating to, among other items set forth herein, the real estate located at 2090 E. Innovation Park Drive, Oro Valley, Arizona 85755, Arizona and the building thereon (the “ Property/ Facility ”) (as amended, supplemented and/or modified and including all exhibits thereto including, but not limited to, Exhibit A thereto, collectively, the “ S/I Deed of Trust ”), (E) the Transition Services Agreement dated July 15 2016 between ICA-T, Sanofi (as amended, supplemented and/or modified and including all exhibits thereto, collectively, the “ S/I TSA ”), and (F) all other agreements, instruments, certificates, documents and related items between, among and/or involving Sanofi and/or its affiliates and ICA-T including those set forth in Section 4.2 of the S/I APA.

 

  8  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

(e)        Consents . Neither ICA-T, the Parent nor any Subsidiary is required by law, contract or otherwise to obtain any consent from, authorization or order of, or make any filing or registration with (other than the Required Filings), any Governmental Entity (as defined below) or any regulatory or self-regulatory agency or any other Person including, but not limited to, Sanofi and/or any of its respective affiliates and/or related parties in order for the Parent, ICA-T and the Subsidiaries to enter into, execute and/or deliver the Transaction Documents and/or perform all of their respective obligations under or contemplated by the Transaction Documents, in each case, in accordance with the terms hereof or thereof. All consents, authorizations, orders, filings and registrations which the Parent, ICA-T and the Subsidiaries are required to obtain pursuant to the preceding sentence are set forth on Schedule 3(e) and have been or will be obtained or effected on or prior to the Closing Date, and neither the Parent, ICA-T nor the Subsidiaries are aware of any facts or circumstances which might prevent the Parent, ICA-T and the Subsidiaries from obtaining or effecting any of the same including any registrations, applications or filings contemplated by the Transaction Documents. “ Governmental Entity ” means any nation, state, county, city, town, village, district, or other political jurisdiction of any nature, federal, state, local, municipal, foreign, or other government, governmental or quasi-governmental authority of any nature (including any governmental agency, branch, department, official, or entity and any court or other tribunal), multi-national organization or body; or body exercising, or entitled to exercise, any administrative, executive, judicial, legislative, police, regulatory, or taxing authority or power of any nature or instrumentality of any of the foregoing, including any entity or enterprise owned or controlled by a government or a public international organization or any of the foregoing.

 

(f)        Acknowledgment Regarding Buyer’s Purchase of Securities . The Parent and ICA-T each acknowledges and agrees that the Buyer is acting solely in the capacity of an arm’s length purchaser with respect to the Transaction Documents and the transactions contemplated hereby and thereby and that the Buyer is not (i) an officer or director of the Parent, ICA-T and the Subsidiaries, (ii) an “affiliate” (as defined in Rule 144) of the Parent, ICA-T and the Subsidiaries or (iii) a “beneficial owner” of more than 9.99% of the shares of Parent Common Stock (as defined for purposes of Rule 13d-3 of the 1934 Act). The Parent and ICA-T each further acknowledges that the Buyer is not acting as a financial advisor or fiduciary of the Parent, ICA-T and the Subsidiaries (or in any similar capacity) with respect to the Transaction Documents and the transactions contemplated hereby and thereby, and any advice given by the Buyer or any of its representatives or agents in connection with the Transaction Documents and the transactions contemplated hereby and thereby is merely incidental to the Buyer’s purchase of the Securities. The Parent and ICA-T further represents to the Buyer that ICA-T’s, the Parent’s and the Subsidiary’s decision to enter into the Transaction Documents to which it is a party and perform all of its obligations under the Transaction Documents has been based solely on the independent evaluation by ICA-T, the Parent and the Subsidiary and their respective representatives.

 

(g)        No General Solicitation; Placement Agent Fees . Neither ICA-T, the Parent nor the Subsidiaries or affiliates, nor any Person acting on its or their behalf, has engaged in any form of general solicitation or general advertising (within the meaning of Regulation D) in connection with the offer or sale of the Securities. Neither ICA-T, the Parent nor the Subsidiaries has any direct and/or indirect obligations to pay any placement agent’s fees, financial advisory fees, brokers’ commissions and/or related fees (whether in cash, services or other type of payment) relating to or arising out of the transactions contemplated hereby. ICA-T, the Parent and the Subsidiaries shall jointly and severally pay, and hold the Buyer and its affiliates harmless against, any liability, loss or expense (including, without limitation, attorney’s fees and out-of-pocket expenses) arising in connection with any such claim. The Parent and ICA-T acknowledge, represent, warrant and agree that neither has engaged any placement agent, finder, other agent and/or any Person in connection with the offer or sale of the Securities.

 

(h)        No Integrated Offering . None of ICA-T, the Parent, nor the Subsidiaries, Affiliates, nor any Person acting on any of their behalf has, directly or indirectly, made any offers or sales of any securities (as defined in the 1933 Act) or solicited any offers to buy any securities, under circumstances that would require registration of any of the Securities under the 1933 Act, whether through integration with prior offerings or otherwise, or cause this offering of the Securities to require approval of stockholders of ICA-T or the Parent for purposes of the 1933 Act or under any applicable stockholder approval provisions. None of the Parent, ICA-T and/or any the Subsidiaries, Affiliates nor any Person acting on any of their behalf will take any action or steps that would require registration of any of the Securities under the 1933 Act or cause the issuance and sale of any of the Securities to be integrated with other offerings of securities of ICA-T or the Parent. Since its inception, ICA-T has not directly and/or indirectly effectuated any issuance or sale of any of its Securities other than to the Parent. Since December 31, 2015, the only offerings of its Securities made by the Parent is set forth on Schedule 3(h) .

 

  9  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

(i)        Application of Takeover Protections; Rights Agreement . Neither the Parent, ICA-T nor any of their respective board of directors have taken any necessary action to implement a poison pill (including, without limitation, any distribution under a rights agreement), stockholder rights plan or other similar anti-takeover provision under the Certificate of Incorporation, Bylaws or other organizational documents or the laws of the jurisdiction of its incorporation.

 

(j)        SEC Documents; Financial Statements . During the two (2) years prior to the date hereof, the Parent has filed all reports, schedules, forms, proxy statements, information statements and other documents required to be filed by it with the SEC pursuant to the reporting requirements of the 1934 Act (all of the foregoing filed prior to the date hereof including, without limitation, Current Reports on Form 8-K by the Parent with the SEC whether required to be filed or not (but excluding Item 7.01 thereunder) and all exhibits and appendices included therein other than Exhibits 99.1 to Form 8-K) and financial statements, notes and schedules thereto and documents incorporated by reference therein being hereinafter referred to as the “ SEC Documents ”). The Parent has delivered or has made available to the Buyer or their respective representatives true, correct and complete copies of each of the SEC Documents not available on the EDGAR system (if any). As of their respective dates, the SEC Documents complied in all material respects with the requirements of the 1934 Act and the rules and regulations of the SEC promulgated thereunder applicable to the SEC Documents, and none of the SEC Documents, at the time they were filed with the SEC, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. As of their respective dates, the financial statements (including, without limitation, any notes or any letter of the independent accountants of the Parent and ICA-T with respect thereto) of the Parent and/or ICA-T included in the SEC Documents (the “ Financial Statements ”) complied in all material respects with applicable accounting requirements and the published rules and regulations of the SEC with respect thereto as in effect as of the time of filing. Such Financial Statements have been prepared in accordance with generally accepted accounting principles (“ GAAP ”), consistently applied, during the periods involved (except (i) as may be otherwise indicated in such Financial Statements or the notes thereto, or (ii) in the case of unaudited interim statements, to the extent they may exclude footnotes or may be condensed or summary statements) and fairly present in all material respects the financial position of the Parent as of the dates thereof and the results of its operations and cash flows for the periods then ended (subject, in the case of unaudited statements, to normal year-end audit adjustments which will not be material, either individually or in the aggregate). The reserves, if any, established by ICA-T and the Parent or the lack of reserves, if applicable, are reasonable based upon facts and circumstances known by ICA-T and the Parent on the date hereof and there are no loss contingencies that are required to be accrued by the Statement of Financial Accounting Standard No. 5 of the Financial Accounting Standards Board which are not provided for by the Parent in its Financial Statements or otherwise. No other information provided by or on behalf of the Parent, ICA-T and the Subsidiaries to the Buyer which is not included in the SEC Documents (including, without limitation, information referred to in Section 2(e) of this Agreement or in the disclosure schedules to this Agreement and/or any other Transaction Document) contains any untrue statement of a material fact or omits to state any material fact necessary in order to make the statements therein not misleading, in the light of the circumstance under which they are or were made. Neither the Parent nor ICA-T is currently contemplating to amend or restate any of the Financial Statements nor is the Parent or ICA-T currently aware of facts or circumstances which would require the Parent or ICA-T to amend or restate any of the Financial Statements, in each case, in order for any of the Financials Statements to be in compliance with GAAP and the rules and regulations of the SEC. Neither the Parent nor ICA-T has been informed by its independent accountants that they recommend that the Parent or ICA-T amend or restate any of the Financial Statements or that there is any need for the Parent or ICA-T to amend or restate any of the Financial Statements. The Parent Common Stock is registered as a class registered under Section 12(g) of the 1934 Act.

 

  10  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

(k)        Absence of Certain Changes . Other than as set forth on Schedule 3(k) , since the date of the Parent’s most recent audited financial statements contained in a Form 10-K, there has been no material adverse change and no material adverse development in the business, assets, liabilities, properties, operations (including results thereof), condition (financial or otherwise) or prospects of the Parent, ICA-T and the Subsidiaries. Since the date of the Parent’s most recent audited financial statements contained in a Form 10-K, neither the Parent, ICA-T nor the Subsidiaries has (i) declared or paid any dividends, (ii) sold any assets, individually or in the aggregate, outside of the ordinary course of business or (iii) made any capital expenditures, individually or in the aggregate, outside of the ordinary course of business. Neither the Parent, ICA-T nor the Subsidiaries has taken any steps to seek protection pursuant to any law or statute relating to bankruptcy, insolvency, reorganization, receivership, liquidation or winding up, nor does the Parent, ICA-T or their respective Subsidiaries have any knowledge or reason to believe that any of their respective creditors intend to initiate involuntary bankruptcy proceedings or any actual knowledge of any fact which would reasonably lead a creditor to do so. Neither the Parent, ICA-T and/or the Subsidiaries, individually and/or on a consolidated basis, are not as of the date hereof, and after giving effect to the transactions contemplated hereby to occur at the Closing, will not be Insolvent (as defined below). For purposes of this Section 3(k) , “ Insolvent ” means (i) with respect to the Parent, ICA-T and the Subsidiaries, on a consolidated basis, (A) the present fair saleable value of the Parent’s, ICA-T’s and the Subsidiaries’ assets is less than the amount required to pay the Parent’s, ICA-T’s and the Subsidiaries’ total Indebtedness, (B) the Parent, ICA-T and the Subsidiaries are unable to pay their debts and liabilities, subordinated, contingent or otherwise, as such debts and liabilities become absolute and matured or (C) the Parent, ICA-T and the Subsidiaries intend to incur or believe that they will incur debts that would be beyond their ability to pay as such debts mature; and (ii) with respect to the Parent, ICA-T and the following Subsidiaries individually (but with respect to the following Subsidiaries, Caldera Discover, Inc., XrPro Sciences, Inc. and Icagen Corp, any such calculation shall exclude the obligations of each such particular Subsidiary pursuant to the Guaranty such Subsidiary will enter into at the Closing) (A) the present fair saleable value of the Parent’s, ICA-T’s or such Subsidiary’s (as the case may be) assets is less than the amount required to pay its respective total Indebtedness, (B) the Parent, ICA-T or such Subsidiary (as the case may be) is unable to pay its respective debts and liabilities, subordinated, contingent or otherwise, as such debts and liabilities become absolute and matured or (C) the Parent, ICA-T or such Subsidiary (as the case may be) intends to incur or believes that it will incur debts that would be beyond its respective ability to pay as such debts mature. Neither the Parent, ICA-T nor the Subsidiaries has engaged in any business or in any transaction, and is not about to engage in any business or in any transaction, for which the Parent’s, ICA-T’s or their respective Subsidiary’s remaining assets constitute unreasonably small capital with which to conduct the business in which it is engaged as such business is now conducted and is proposed to be conducted. ICA-T is in compliance in all material respects with the Sanofi Documents and no event of default exists and/or will exist with the passage of time or the giving of notice, or both, under the Sanofi Documents. ICA-T and the Parent have no reason to believe that Sanofi may seek to modify and/or terminate any of the Sanofi Documents and/or seek to take any action under the Deed of Trust including, but not limited to, foreclosing and/or selling the Property/Facilities and/or reduce the payments it has agreed to pay to ICA-T and/or the services it has contracted to receive from ICA-T under the Sanofi Documents and/or an event of default may occur in the immediate future under any of the Sanofi Documents. The Parent is in compliance in all material respects with its documents and agreements with Icagen, Inc., a subsidiary of Pfizer, Inc. (“ Pfizer ”) including, but not limited to, the Asset Purchase and Collaboration Agreement dated as of June 26, 2015, as amended (the “ Pfizer APA ” and collectively, the “ Pfizer Documents ”) and no event of default exists and/or will exist with the passage of time or the giving of notice, or both, under the Pfizer Documents. The Parent has no reason to believe that Pfizer may seek to modify and/or terminate any of the Pfizer Documents and/or seek to take any such action to reduce the amount of business/services it has contracted for from the Parent and/or not pay or modify the $1,000,000 guaranteed payment owed by Pfizer to the Parent due on or about June 30, 2017. The Parent has no reason to believe that any event has occurred that would or could result in a violation of any of the Pfizer Documents and/or could result in Pfizer seeking to terminate and/or otherwise modify any of the Pfizer Documents and/or the scope of its business relationship with the Parent.

 

  11  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

(l)        No Undisclosed Events, Liabilities, Developments or Circumstances . Other than as set forth on Schedule 3(l) and the transactions contemplated by this, no event, liability, development or circumstance has occurred or exists, or is reasonably expected to exist or occur with respect to the Parent, ICA-T, any of their respective Subsidiaries or any of their respective businesses, properties, liabilities, prospects, operations (including results thereof) or condition (financial or otherwise), that (i) would be required to be disclosed by the Parent, ICA-T and the Subsidiaries under applicable securities laws on a registration statement on Form S-1 filed with the SEC relating to an issuance and sale by the Parent of its Parent Common Stock to the public and which has not been publicly announced, (ii) could have a material adverse effect on any Buyer’s investment hereunder or (iii) could have a Material Adverse Effect.

 

(m)        Conduct of Business; Regulatory Permits . Neither the Parent, ICA-T nor any of the Subsidiaries are in violation of any term of or in default under its Certificate of Incorporation, any certificate of designation, preferences or rights of any other outstanding series of preferred stock of the Parent, ICA-T or any of the Subsidiaries or Bylaws or their organizational charter, certificate of formation, memorandum of association, articles of association, Certificate of Incorporation or certificate of incorporation or bylaws, respectively. Neither the Parent, ICA-T nor the Subsidiaries are in violation of any judgment, decree or order or any statute, ordinance, rule or regulation (each a “ Legal Requirement ”) applicable to the Parent, ICA-T and the Subsidiaries, and neither the Parent, ICA-T nor the Subsidiaries will conduct its business in violation of any of the foregoing, except in all cases for possible violations which could not, individually or in the aggregate, have a Material Adverse Effect. The Parent, ICA-T and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate regulatory authorities necessary to conduct their respective businesses, except where the failure to possess such certificates, authorizations or permits would not have, individually or in the aggregate, a Material Adverse Effect, and neither ICA-T, the Parent, nor the Subsidiaries has received any notice of proceedings relating to the revocation or modification of any such certificate, authorization or permit. There is no agreement, commitment, judgment, injunction, order or decree binding upon the Parent, ICA-T nor the Subsidiaries or to which the Parent, ICA-T or any of their respective Subsidiaries is a party which has or would reasonably be expected to have the effect of prohibiting or materially impairing any business practice of the Parent, ICA-T and the Subsidiaries, any acquisition of property by the Parent, ICA-T and the Subsidiaries or the conduct of business by the Parent, ICA-T and the Subsidiaries as currently conducted other than such effects, individually or in the aggregate, which have not had and would not reasonably be expected to have a Material Adverse Effect on the Parent, ICA-T and the Subsidiaries. Neither the Parent Common Stock nor any other securities of the Parent, ICA-T and the Subsidiaries are listed and/or quoted on any Eligible Market and/or any other trading medium and the Parent has not taken any actions nor to the best of its knowledge has any Person taken any action for the purpose of having any such securities become listed and/or eligible for quotation on any Eligible Market or other trading medium.

 

  12  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

(n)        Foreign Corrupt Practices . Neither the Parent, ICA-T nor any of the Subsidiaries nor to the knowledge of the Parent and ICA-T, any director, officer, agent, employee, affiliate or any other Person acting for or on behalf of the foregoing (individually and collectively, an “ Icagen Affiliate ”) have violated the U.S. Foreign Corrupt Practices Act (the “ FCPA ”) or any other applicable anti-bribery or anti-corruption laws, nor has any Icagen Affiliate offered, paid, promised to pay, or authorized the payment of any money, or offered, given, promised to give, or authorized the giving of anything of value, to any officer, employee or any other person acting in an official capacity for any Governmental Entity to any political party or official thereof or to any candidate for political office (individually and collectively, a “ Government Official ”) or to any person under circumstances where such Icagen Affiliate knew or was aware of a high probability that all or a portion of such money or thing of value would be offered, given or promised, directly or indirectly, to any Government Official, for the purpose of:

 

(i)       influencing any act or decision of such Government Official in his/her official capacity, (B) inducing such Government Official to do or omit to do any act in violation of his/her lawful duty, (C) securing any improper advantage, or (D) inducing such Government Official to influence or affect any act or decision of any Governmental Entity, or

 

(ii)       assisting the Parent, ICA-T and the Subsidiaries in obtaining or retaining business for or with, or directing business to, the Parent, ICA-T and the Subsidiaries.

 

(o)        Sarbanes-Oxley Act . The Parent, ICA-T and the Subsidiaries are in compliance with any and all applicable requirements of the Sarbanes-Oxley Act of 2002, as amended, and any and all applicable rules and regulations promulgated by the SEC thereunder.

 

(p)        Transactions With Affiliates . Since December 31, 2015 and except as set forth in Schedule 3(p) , no current employee, partner, director officer or stockholder of the Parent, ICA-T or any of their respective Subsidiaries or, to the knowledge of the Parent or ICA-T, the Parent, any affiliate of any thereof, or any relative with a relationship no more remote than first cousin of any of the foregoing, is presently, or has been, (i) a party to any transaction with the Parent, ICA-T or any of their respective Subsidiaries (including any contract, agreement or other arrangement providing for the furnishing of services by, or rental of real or personal property from, or otherwise requiring payments to, any such director, officer or stockholder or such associate or affiliate or relative Subsidiaries (other than for ordinary course services as employees, officers or directors of the Parent, ICA-T and the Subsidiaries)) or (ii) the direct or indirect owner of an interest in any corporation, firm, association or business organization which is a competitor, supplier or customer of the Parent, ICA-T or any of their respective Subsidiaries (except for a passive investment (direct or indirect) in less than 2% of the common stock of a company whose securities are traded on or quoted through an Eligible Market (as defined in the Note)), nor does any such Person receive income from any source other than the Parent, ICA-T or any of their respective Subsidiaries which relates to the business of the Parent, ICA-T or any of their respective Subsidiaries or should properly accrue to the Parent, ICA-T or any of their respective Subsidiaries. Except as set forth in Schedule 3(p) , no employee, officer, stockholder or director of the Parent, ICA-T and the Subsidiaries or member of his or her immediate family is indebted to the Parent, ICA-T or any of their respective Subsidiaries, as the case may be, nor is the Parent, ICA-T and the Subsidiaries indebted (or committed to make loans or extend or guarantee credit) to any of them, other than (i) for payment of salary for services rendered, (ii) reimbursement for reasonable expenses incurred on behalf of the Parent or ICA-T, and (iii) for other standard employee benefits made generally available to all employees or executives (including stock option agreements or restricted stock agreements outstanding under any stock option plan or other stock incentive plan approved by the Board of Directors of ICA-T, the Parent and the Subsidiaries).

 

  13  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

(q)       Equity Capitalization .

 

(i)        Definitions :

 

A.       “ Parent Common Stock ” or “ Common Stock ” means (x) the Parent’s shares of common stock, $0.001 par value per share, and (y) any capital stock into which such common stock shall have been changed or any share capital resulting from a reclassification of such common stock.

 

B.        “ Preferred Stock ” means (x) the Parent’s blank check preferred stock, $0.001 par value per share, the terms of which may be designated by the board of directors of the Parent in a certificate of designations and (y) any capital stock into which such preferred stock shall have been changed or any share capital resulting from a reclassification of such preferred stock (other than a conversion of such preferred stock into Parent Common Stock in accordance with the terms of such certificate of designations).

 

(ii)        Authorized and Outstanding Capital Stock . The authorized capital stock of the Parent consists of (A) 50,000,000 shares of Parent Common Stock, of which, 6,720, 017shares are issued and 6,393,107 outstanding and 3,850,932 shares are reserved for issuance pursuant to Options (as defined in the Note) and/or Convertible Securities (as defined in the Note) (other than the Notes and the Parent Warrant) exercisable or exchangeable for, or convertible into, shares of Parent Common Stock and (B) 10,000,000 shares of Preferred Stock of which (1) 400,000 shares are designated Series A Cumulative Convertible Preferred Stock (the “ A Shares ”), (2) 3,000,000 are designated Series B Cumulative Convertible Preferred Stock (the “ B Shares ”), and (3) 6,600,000 are undesignated. No Preferred Stock including A Shares or B Shares are issued and outstanding. As of the date hereof, the authorized capital of ICA-T consists of 100 Shares, all of which are owned by the Parent.

 

(iii)        Valid Issuance; Available Shares; Affiliates . All of such outstanding shares are duly authorized and have been, or upon issuance will be, validly issued and are fully paid and nonassessable. Schedule 3(q)(iii) sets forth the number of shares of Parent Common Stock that are as of the date hereof (A) reserved for issuance pursuant to Options and/or Convertible Securities (other than the Notes and the Parent Warrant) and (B) are owned by Persons who are “affiliates” (as defined in Rule 405 of the 1933 Act and calculated based on the assumption that only officers, directors and holders of at least 10% of the Parent’s issued and outstanding Parent Common Stock are “affiliates” without conceding that any such Persons are “affiliates” for purposes of federal securities laws) of the Parent, ICA-T and the Subsidiaries. To the Parent’s and ICA-T’s knowledge, other than as set forth on Schedule 3(q)(iii) , no Person owns (beneficially or otherwise) 10% or more of the issued and outstanding shares of Parent Common Stock (calculated based on the assumption that all Convertible Securities, whether or not presently exercisable or convertible, have been fully exercised or converted (as the case may be) taking account of any limitations on exercise or conversion (including “blockers”) contained therein without conceding that such identified Person is a 10% stockholder for purposes of federal securities laws).

 

  14  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

(iv)        Existing Securities; Obligations; Transfer Agent . Except as disclosed on Schedule 3(q)(iv) : (A) none of the Parent’s, ICA-T’s or the Subsidiary’s capital stock including, but not limited to, the Parent Common Stock, Preferred Stock or interests, capital stock or other securities (as defined in the 1933 Act) is subject to preemptive rights or any other similar rights or Liens suffered or permitted by the Parent, ICA-T and the Subsidiaries; (B) there are no outstanding options, warrants, scrip, rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities or rights convertible into, or exercisable or exchangeable for, any shares, interests or capital stock of the Parent, ICA-T and the Subsidiaries, or contracts, commitments, understandings or arrangements by which the Parent, ICA-T and the Subsidiaries are or may become bound to issue additional shares, interests or capital stock of the Parent, ICA-T and the Subsidiaries or options, warrants, scrip, rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities or rights convertible into, or exercisable or exchangeable for, any shares, interests or capital stock of the Parent, ICA-T and the Subsidiaries; (C) there are no agreements or arrangements under which the Parent, ICA-T and the Subsidiaries are obligated to register the sale of any of their securities under the 1933 Act; (D) there are no outstanding securities, agreements, arrangements or instruments of the Parent, ICA-T and the Subsidiaries which contain any redemption or similar provisions, and there are no contracts, commitments, understandings or arrangements by which the Parent, ICA-T and the Subsidiaries are or may become bound to redeem a security of the Parent, ICA-T and the Subsidiaries; (E) there are no securities or instruments containing anti-dilution or similar provisions that will be triggered by the issuance of the Securities; (F) there are no outstanding securities, arrangements, agreements and/or instruments providing any Person with any pre-emptive rights, rights of first refusal and/or similar rights relating to any securities of the Parent, ICA-T and the Subsidiaries including any that would be triggered by the transactions contemplated herein, and (G) neither the Parent, ICA-T nor the Subsidiaries has any stock appreciation rights or “phantom stock” plans or agreements or any similar plan or agreement. All prior issuances and/or any sale of securities by the Parent, ICA-T and the Subsidiaries complied in all respects with all state “blue sky” laws and no Person has any rescission rights (whether mature or unmatured, contingent and/or matured) with respect to any securities purchased from the Parent, ICA-T and the Subsidiaries.

 

(v)        Organizational Documents . Attached hereto as Exhibit I are true, correct and complete copies of (I) (x) each of (A) ICA-T’s and (B) the Parent’s Certificate of Incorporation (or similar document), as amended and as in effect on the date hereof and on the Closing Date ( the Certificate of Incorporation ”), and (II) (x) each of (A) ICA-T’s and (B) the Parent’s bylaws, as amended and as in effect on the date hereof and on the Closing Date (the “ Bylaws ”), and the terms of all Convertible Securities and the material rights of the holders thereof in respect thereto.

 

(vi)        Transfer Agent . American Stock Transfer and Trust Company (the “ Transfer Agent ”) is the Parent’s stock transfer company and the Transfer Agent participates in the DTC Fast Automated Securities Transfer Program.

 

(r)        Indebtedness and Other Contracts . Except as disclosed on Schedule 3(r) hereto, neither the Parent, ICA-T nor the Subsidiaries, (i) has any outstanding debt securities, notes, credit agreements, credit facilities or other agreements, documents or instruments evidencing Indebtedness of the Parent, ICA-T and the Subsidiaries or by which the Parent, ICA-T and the Subsidiaries and/or any of their respective properties is and/or may become bound, (ii) is a party to any contract, agreement or instrument, the violation of which, or default under which, by the other party(ies) to such contract, agreement or instrument could reasonably be expected to result in a Material Adverse Effect, (iii) has any financing statements and/or other filings or recordings or its and/or any of their real property and/or other assets are subject to securing obligations in any amounts filed and/or recorded in connection with the Parent, ICA-T and the Subsidiaries; (iv) is in violation of any representation, warranty, covenant, agreement, provision and/or term of, or in default under, any contract, agreement or instrument relating to any Indebtedness including, but not limited to, any Indebtedness and/or other obligations owed to Sanofi and/or any of its affiliates and/or related pursuant to the Sanofi Documents or otherwise, or (v) is a party to any contract, agreement or instrument relating to any Indebtedness, the performance of which, in the judgment of the Parent and/or ICA-T, has or is expected to have a Material Adverse Effect. Neither the Parent, ICA-T nor the Subsidiaries have any liabilities, obligations and/or Indebtedness required to be disclosed in the Financial Statements which are not so disclosed. For purposes of this Agreement: (x) “ Indebtedness ” of any Person means, without duplication, (A) all indebtedness for borrowed money, (B) all obligations issued, undertaken or assumed as the deferred purchase price of property or services (including, without limitation, “capital leases” in accordance with GAAP) (other than trade payables entered into in the ordinary course of business consistent with past practice), (C) all reimbursement or payment obligations with respect to letters of credit, surety bonds and other similar instruments, (D) all obligations evidenced by notes, bonds, debentures or similar instruments, including obligations so evidenced incurred in connection with the acquisition of property, assets or businesses, (E) all indebtedness created or arising under any conditional sale or other title retention agreement, or incurred as financing, in either case with respect to any property or assets acquired with the proceeds of such indebtedness (even though the rights and remedies of the seller or bank under such agreement in the event of default are limited to repossession or sale of such property), (F) all monetary obligations under any leasing or similar arrangement which, in connection with GAAP, consistently applied for the periods covered thereby, is classified as a capital lease, (G) all indebtedness referred to in clauses (A) through (F) above secured by (or for which the holder of such Indebtedness has an existing right, contingent or otherwise, to be secured by) any Lien upon or in any property or assets (including accounts and contract rights) owned by any Person, even though the Person which owns such assets or property has not assumed or become liable for the payment of such indebtedness, and (H) all Contingent Obligations (as defined below) in respect of indebtedness or obligations of others of the kinds referred to in clauses (A) through (G) above; and (y) “ Contingent Obligation ” means, as to any Person, any direct or indirect liability, contingent or otherwise, of that Person with respect to any Indebtedness, lease, dividend or other obligation of another Person if the primary purpose or intent of the Person incurring such liability, or the primary effect thereof, is to provide assurance to the obligee of such liability that such liability will be paid or discharged, or that any agreements relating thereto will be complied with, or that the holders of such liability will be protected (in whole or in part) against loss with respect thereto.

 

  15  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

(s)        Litigation . Except as set forth in Schedule 3(s) , there is no material action, suit, arbitration, proceeding, inquiry or investigation before or by any court, public board, other Governmental Entity, self-regulatory organization or body pending or, to the knowledge of the Parent or ICA-T, threatened against or affecting the Parent, ICA-T and the Subsidiaries, the Parent Common Stock or any of the Parent’s, ICA-T’s or the Subsidiaries’ officers or directors , whether of a civil or criminal nature or otherwise, in their capacities as such. No director, officer or employee of the Parent, ICA-T or any of their respective Subsidiaries has willfully violated 18 U.S.C. §1519 or engaged in spoliation in reasonable anticipation of litigation. Without limitation of the foregoing, there has not been, and to the knowledge of the Parent or ICA-T, there is not pending or contemplated, any investigation by the SEC involving the Parent or ICA-T, any of their respective Subsidiaries or any current or former director or officer of the Parent, ICA-T or each of their respective Subsidiaries. The SEC has not issued any stop order or other order suspending the effectiveness of any registration statement filed by the Parent or ICA-T under the 1933 Act or the 1934 Act with respect to Registrable Securities. After reasonable inquiry of its employees, neither the Parent nor ICA-T is aware of any fact which might result in or form the basis for any such action, suit, arbitration, investigation, inquiry or other proceeding. Neither the Parent, ICA-T nor the Subsidiaries are subject to any order, writ, judgment, injunction, decree, determination or award of any Governmental Entity. The Parent, ICA-T and each Subsidiary is current in all payment obligations with respect to all settlement and/or similar agreements including, but not limited to, with Dentons US LLP (“ Dentons ”) and American Millings, LP.

 

(t)        Insurance . The Parent, ICA-T and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in such amounts as management of the Parent, ICA-T and the Subsidiaries believes to be prudent and customary in the businesses in which the Parent, ICA-T and the Subsidiaries are engaged (and/or as required by an agreement, documents and/or instrument) including, but not limited to, all insurance required to be obtained, maintained and in the amounts as provided and/or pursuant to the Sanofi Documents including, but not limited to, the S/I APA, the S/I MSA and the S/I Deed of Trust including, but not limited to, a $5,000,000, 10-year pollution legal liability insurance policy pursuant to the S/I APA in the name of ICA-T with Sanofi being named an additional insured party under such policy (the “$5,000,000 Pollution Policy ”). The Parent, ICA-T and the Subsidiaries have timely paid and are current with respect to all premiums and other payment amounts due under such all insurance policies including the $5,000,000 Pollution Policy. All insurance and related policies of the Parent, ICA-T and the Subsidiaries including, but not limited to, the $5,000,000 Pollution Policy are set forth on Schedule 3(t) . Neither the Parent, ICA-T nor the Subsidiaries has been refused any insurance coverage sought or applied for, and neither the Parent, ICA-T nor the Subsidiaries has any reason to believe that it will be unable to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business at a cost that would not have a Material Adverse Effect.

 

(u)        Employee Matters; Benefit Plans .

 

(i)       Except as set forth on Schedule 3(u)(i) , the employment of each officer and employee of the Parent, ICA-T and the Subsidiaries are terminable at the will of the Parent, ICA-T and the Subsidiaries, respectively. The Parent, ICA-T and the Subsidiaries have complied in all material respects with all applicable laws relating to wages, hours, equal opportunity, collective bargaining, workers’ compensation insurance and the payment of social security and other taxes. Neither the Parent, ICA-T nor each of their respective Subsidiaries is aware that any officer, key employee or group of employees intends to terminate his, her or their employment with the Parent, ICA-T or any of their respective Subsidiaries, as the case may be, nor does the Parent, ICA-T or each of their respective Subsidiaries have a present intention, or know of a present intention, to terminate the employment of any officer, key employee or group of employees of either the Parent, ICA-T or any of their respective Subsidiaries. There are no pending or, to the knowledge of the Parent, ICA-T and the Subsidiaries, threatened employment discrimination charges or complaints against or involving the Parent, ICA-T or any of their respective Subsidiaries before any federal, state, or local board, department, commission or agency, or unfair labor practice charges or complaints, disputes or grievances affecting the Parent, ICA-T or any of their respective Subsidiaries.

 

  16  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

(ii)       Since the Parent’s, ICA-T’s and the Subsidiaries’ inception, neither the Parent, ICA-T nor the Subsidiaries has experienced any labor disputes, union organization attempts or work stoppage due to labor disagreements. There are no unfair labor practice charges or complaints against the Parent, ICA-T or any of their respective Subsidiaries pending, or to the knowledge of the Parent, ICA-T or any of their respective Subsidiaries, threatened before the National Labor Relations Board or any comparable state agency or authority. There are no written or oral contracts, commitments, agreements, understandings or other arrangements with any labor organization, nor work rules or practices agreed to with any labor organization or employee association, applicable to employees of the Parent, ICA-T and the Subsidiaries, nor is the Parent, ICA-T or any of their respective Subsidiaries a party to, or bound by, any collective bargaining or similar agreement; there is not, and since the Parent’s, ICA-T’s and the Subsidiaries’ inception there has not been, any representation of the employees of the Parent, ICA-T or any of their respective Subsidiaries by any labor organization and, to the knowledge of the Parent, ICA-T and the Subsidiaries, there are no union organizing activities among the employees of the Parent, ICA-T or any of their respective Subsidiaries, and to the knowledge of the Parent, ICA-T and the Subsidiaries, no question concerning representation has been raised or is threatened respecting the employees of the Parent, ICA-T or any of their respective Subsidiaries.

 

(iii)        Schedule 3(u)(iii) contains a true, correct and complete list of each pension, retirement, savings, deferred compensation and profit-sharing plan and each stock option, stock appreciation, stock purchase, performance share, bonus or other incentive plan, severance plan, health, group insurance or other welfare plan, or other similar plan (whether written or otherwise) and any “employee benefit plan” within the meaning of Section 3(3) of the Employee Retirement Income Security Act of 1974, as amended (“ ERISA ”), under which the Parent and ICA-T has any current or future obligation or liability (including any potential, contingent or secondary liability under Title IV of ERISA) or under which any employee or former employee (or beneficiary of any employee or former employee) of the Parent and ICA-T has or may have any current or future right to benefits (the term “plan” shall include any contract, agreement (including an employment or independent contractor agreement), policy or understanding, each such plan being hereinafter referred to in this Agreement individually as a “ Benefit Plan ”). The Parent and ICA-T have delivered to the Buyer true, correct and complete copies of (i) each material Benefit Plan, including any amendments thereto, (ii) the summary plan description, if any, for each Benefit Plan, including any summaries of material modifications made since the most recent summary plan description, (iii) the latest annual report which has been filed with the Internal Revenue Service (the “ IRS ”) for each Benefit Plan required to file an annual report, and (iv) the most recent IRS determination letter for each Benefit Plan that is a pension plan (as defined in ERISA) intended to be qualified under Section 401(a) of the Code. Each Benefit Plan intended to be tax qualified under Sections 401(a) and 501(a) of the Code is and has been determined by the IRS to be tax qualified under Sections 401(a) and 501(a) of the Code and, since such determination, no amendment to or failure to amend any such Benefit Plan and no other event or circumstance has occurred that could reasonably be expected to adversely affect its tax qualified status.

 

  17  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

(iv)       There are no actions, claims, audits, lawsuits or arbitrations pending, or, to the knowledge of the Parent, ICA-T and the Subsidiaries, threatened, with respect to any Benefit Plan or the assets of any Benefit Plan. Except as set forth in Schedule 3(u)(iv) , each Benefit Plan has been administered in all material respects in accordance with its terms and with all applicable Legal Requirements (including, without limitation, the Code and ERISA).

 

(v)       The consummation of the transactions contemplated by this Agreement will not (1) entitle any employee or independent contractor of the Parent, ICA-T or any of their respective Subsidiaries to severance pay or termination benefits, (2) accelerate the time of payment or vesting, or increase the amount of compensation due to any current or former employee or independent contractor of the Parent, ICA-T or any of their respective Subsidiaries, (3) obligate Parent, ICA-T or any of their respective Subsidiaries, or any of their respective affiliates to pay or otherwise be liable for any compensation, vacation days, pension contribution or other benefits to any current or former employee, consultant, agent or independent contractor of the Parent, ICA-T or any of their respective Subsidiaries for periods before the applicable Closing Date, (4) require assets to be set aside or other forms of security to be provided with respect to any liability under a Benefit Plan, or (5) result in any “parachute payment” (within the meaning of Section 280G of the Code) under any Benefit Plan.

 

(vi)       No Benefit Plan is subject to the provisions of Section 412 of the Code or Part 3 of Subtitle B of Title I of ERISA. No Benefit Plan is subject to Title IV of ERISA and no Benefit Plan is a “multiemployer plan” (within the meaning of Section 3(37) of ERISA). Since inception, neither the Parent, ICA-T, their respective Subsidiaries, nor any business or entity treated as a single employer with the Parent, ICA-T or any of their respective Subsidiaries for purposes of Title IV of ERISA contributed to or was obliged to contribute to a pension plan that was at any time subject to Title IV of ERISA.

 

(vii)       No Benefit Plan has provided, been required to provide, provides or is required to provide, at any time in the past, present, or future, health, medical, dental, accident, disability, death or survivor benefits to or in respect of any Person beyond one year following termination of employment, except to the extent required under any state insurance law or under Part 6 of Subtitle B of Title I of ERISA and under Section 4980B of the Code. No Benefit Plan covers any individual that is not an employee or advisor of the Parent, ICA-T or any of their respective Subsidiaries, other than spouses and dependents of employees under health and child care policies listed in Schedule 3(u)(vii) , true and complete copies of which have been made available to the Buyer. Except as set forth on Schedule 3(u)(vii) or except as otherwise permitted pursuant to employment agreements with the Parent or ICA-T disclosed to the Buyer, each officer of the Parent and ICA-T is currently devoting all of such officer’s business time to the conduct of the business of the Parent or ICA-T. Except as otherwise permitted pursuant to employment agreements with the Parent or ICA-T disclosed to the Buyer, the Parent and ICA-T are not aware of any officer or key employee of the Parent, ICA-T and the Subsidiaries planning to work less than full time at the Parent, ICA-T or any of their respective Subsidiaries in the future.

 

  18  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

(viii)       The Parent and ICA-T are in compliance with all federal, state, local and foreign laws and regulations respecting labor, employment and employment practices and benefits, terms and conditions of employment and wages and hours, except where failure to be in compliance would not, either individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect.

 

(v) Title.

 

(i)        Real Property . Each of the Parent, ICA-T and the Subsidiaries holds good title to all real property, leases in real property, facilities or other interests in real property owned or held by the Parent, ICA-T and the Subsidiaries, all of which are set forth on Schedule 3(v)(i) (collectively, the “ Real Property ”). Schedule 3(v)(i) sets forth all Real Property of the Parent, ICA-T and the Subsidiaries and other than as set forth on Schedule 3(v)(i) , the Real Property is free and clear of all Liens and is not subject to any rights of way, building use restrictions, exceptions, variances, reservations, or limitations of any nature. Any Real Property held under lease by the Parent, ICA-T and the Subsidiaries are held by them under valid, subsisting and enforceable leases with such exceptions as are not material and do not interfere with the use made and proposed to be made of such property and buildings by the Parent, ICA-T and the Subsidiaries.

 

(ii)        Fixtures and Equipment . Except as set forth on Schedule 3(v)(ii), each of the Parent, ICA-T and the Subsidiaries (as applicable) has good title to, or a valid leasehold interest in, the tangible personal property, equipment, improvements, fixtures, and other personal property and appurtenances that are used by the Parent, ICA-T and the Subsidiaries in connection with the conduct of its business (the “ Fixtures and Equipment ”). The Fixtures and Equipment are structurally sound, are in good operating condition and repair, are adequate for the uses to which they are being put, are not in need of maintenance or repairs except for ordinary, routine maintenance and repairs and are sufficient for the conduct of the Parent’s, ICA-T’s and the Subsidiaries’ businesses (as applicable) in the manner as conducted prior to the Closing. Except as set forth on Schedule 3(v)(ii) , each of the Parent, ICA-T and the Subsidiaries own all of their respective Fixtures and Equipment free and clear of all Liens.

 

  19  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

(w) Intellectual Property .

 

(i)       Except as set forth on Schedule 3(w)(i) , the Parent, ICA-T and the Subsidiaries own all right, title and interest in and to, or have a valid and enforceable license to use all the Intellectual Property used by them in connection with the their respective businesses. Except as set forth on Schedule 3(w)(i) , none of the Parent’s, ICA-T’s and the Subsidiaries’ Intellectual Property have expired or terminated or have been abandoned or expected to expire or terminate or are expected to be abandoned within five (5) years from this Agreement. The Parent, ICA-T and the Subsidiaries are in compliance with all contractual obligations relating to the protection of such of the Intellectual Property as they use pursuant to licenses or other agreements. The conduct of the business of the Parent, ICA-T and the Subsidiaries, to the knowledge of the Parent, ICA-T and the Subsidiaries, as currently conducted, or as reasonably be expected to be conducted, does not, and is not reasonably expected to, knowingly, conflict with or infringe any proprietary right or Intellectual Property of any third party, including, without limitation, the transmission, reproduction, use, display or modification of any content or material (including framing, and linking web site content) on a web site, bulletin board or other like medium hosted by or on behalf of the Parent, ICA-T and the Subsidiaries, except for such infringements and conflicts which would not reasonably be expected to have a Material Adverse Effect. Neither the Parent, ICA-T not their respective Subsidiaries has any knowledge of any infringement by the Parent, ICA-T or any of their respective Subsidiaries of Intellectual Property of others. There is no claim action or proceeding being made or brought, or to the knowledge of the Parent, ICA-T and the Subsidiaries, being threatened, against the Parent, ICA-T and the Subsidiaries regarding its Intellectual Property. Neither the Parent, ICA-T nor the Subsidiaries are aware of any facts or circumstances that could reasonably be expected to give rise to any of the foregoing infringements or claims, actions or proceedings. The Parent, ICA-T and the Subsidiaries have taken reasonable security measures to protect the secrecy, confidentiality and value of their Intellectual Property.

 

(ii)        Schedule 3(w)(ii) sets forth a complete and current list of registered trademarks or copyrights, issued patents, applications therefor, or other forms of Intellectual Property registration anywhere in the world that is owned by the Parent, ICA-T or their respective Subsidiaries (“ Listed Intellectual Property ”) and the owner of record, date of application or issuance and relevant jurisdiction as to each. Except as set forth on Schedule 3(w)(ii) , all Listed Intellectual Property is owned by the Parent, ICA-T or their respective Subsidiaries, free and clear of security interests, liens, encumbrances or claims of any nature. All Listed Intellectual Property is subsisting, unexpired, in proper form and all renewal fees and other maintenance fees that have fallen due on or prior to the effective date of this Agreement have been paid. No Listed Intellectual Property is the subject of any proceeding before any governmental, registration or other authority in any jurisdiction, except as set forth on Schedule 3(v)(ii) . The consummation of the transactions contemplated hereby will not alter or impair any Intellectual Property that is owned or licensed by the Parent, ICA-T or their respective Subsidiaries.

 

(iii)        Schedule 3(w)(iii) sets forth a complete list of all agreements relating to Intellectual Property to which the Parent, ICA-T or their respective Subsidiaries is a party, subject or bound (the “ Intellectual Property Contracts ”) (other than agreements involving (A) the license of the Parent, ICA-T or their respective Subsidiaries of standard, generally commercially available “off-the-shelf” third party products that are not and will not to any extent be part of any product, service or intellectual property offering of the Parent, ICA-T or their respective Subsidiaries or (B) non-disclosure or non-use of information). Each Intellectual Property Contract: (i) is valid and binding on the Parent, ICA-T or their respective Subsidiaries, as the case may be, and, the counterparties thereto, and is in full force and effect and (ii) upon consummation of the transactions contemplated hereby shall continue in full force and effect without penalty or other adverse consequence.

 

  20  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

(iv)       Except as set forth on Schedule 3(w)(iv) , the Parent, ICA-T and the Subsidiaries are not under any obligation to pay royalties or other payments in connection with any agreement, nor restricted from assigning their rights respecting Intellectual Property nor will the Parent, ICA-T or their respective Subsidiaries otherwise be, as a result of the execution and delivery of this Agreement or the performance of the Parent’s or ICA-T’s obligations under this Agreement, in breach of any agreement relating to the Intellectual Property.

  

(v)       Except as set forth on Schedule 3(w)(v) , no present or former employee, officer or director of the Parent, ICA-T or their respective Subsidiaries, or agent or outside contractor of the Parent, ICA-T or any of their respective Subsidiaries, holds any right, title or interest, directly or indirectly, in whole or in part, in or to any Intellectual Property that is owned or licensed by the Parent, ICA-T or their respective Subsidiaries.

 

(vi)       To the Parent’s and ICA-T’s knowledge: (i) none of the Listed Intellectual Property has been used, disclosed or appropriated to the detriment of the Parent, ICA-T or their respective Subsidiaries for the benefit of any Person other than the Parent, ICA-T or their respective Subsidiaries; and (ii) no employee, independent contractor or agent of the Parent, ICA-T or their respective Subsidiaries has misappropriated any trade secrets or other confidential information of any other Person in the course of the performance of his or her duties as an employee, independent contractor or agent of the Parent, ICA-T or their respective Subsidiaries.

 

(vii)       Except as set forth on Schedule 3(w)(vii) , any programs, modifications, enhancements or other inventions, improvements, discoveries, methods or works of authorship (“ Works ”) that were created by employees of the Parent, ICA-T or their respective Subsidiaries were made in the regular course of such employees’ employment or service relationships with the Parent, ICA-T or their respective Subsidiaries using the Parent’s, ICA-T’s or their respective Subsidiaries’ facilities and resources and, as such, constitute either works made for hire or all rights and title to and in such Works have been fully assigned to the Parent, ICA-T or their respective Subsidiaries. Each such employee who has created Works or any employee who in the regular course of his employment may create Works and all consultants have signed an assignment or similar agreement with the Parent, ICA-T or their respective Subsidiaries confirming the Parent’s, ICA-T’s or their respective Subsidiaries’ ownership or, in the alternate, transferring and assigning to the Parent, ICA-T or their respective Subsidiaries all right, title and interest in and to such programs, modifications, enhancements or other inventions including copyright and other intellectual property rights therein.

 

  21  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

(viii)       For the purpose of this Agreement, “ Intellectual Property ” shall mean all of the following: (A) trademarks, service marks, service mark registrations, service names, trade dress, product configurations, trade names and other indications of origin, applications or registrations in any jurisdiction pertaining to the foregoing and all goodwill associated therewith; (B) inventions, discoveries, improvements, ideas, know-how, formula methodology, processes, technology, software (including password unprotected interpretive code or source code, object code, development documentation, programming tools, drawings, specifications and data) and applications and patents in any jurisdiction pertaining to the foregoing, including re-issues, continuations, divisions, continuations-in-part, renewals or extensions; (C) trade secrets, including confidential information and the right in any jurisdiction to limit the use or disclosure thereof; (D) copyrights in writings, designs software, mask works or other works, applications or registrations in any jurisdiction for the foregoing and all moral rights related thereto; (E) database rights; (F) Internet Web sites, domain names and applications and registrations pertaining thereto and all intellectual property used in connection with or contained in all versions of the Parent’s, ICA-T’s or their respective Subsidiaries’ Web sites; (G) rights under all agreements (including a license agreement) relating to the foregoing; (H) books and records pertaining to the foregoing; (I) governmental authorizations, and (J) claims or causes of action arising out of or related to past, present or future infringement or misappropriation of the foregoing.

 

(x)        Environmental Laws .

 

(i)       The Parent, ICA-T and the Subsidiaries (A) are in compliance with any and all Environmental Laws (as defined below), (B) have received all permits, licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses and (C) are in compliance with all terms and conditions of any such permit, license or approval where, in each of the foregoing clauses (A), (B) and (C), the failure to so comply could be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect. The term “ Environmental Laws ” means all federal, state, local or foreign laws relating to pollution or protection of human health or the environment (including, without limitation, ambient air, surface water, groundwater, land surface or subsurface strata), including, without limitation, laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants, or toxic or hazardous substances or wastes (collectively, “ Hazardous Materials ”) into the environment, or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials, as well as all authorizations, codes, decrees, demands or demand letters, injunctions, judgments, licenses, notices or notice letters, orders, permits, plans or regulations issued, entered, promulgated or approved thereunder.

 

  22  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

 

(ii) No Hazardous Materials :

 

a. have been disposed of or otherwise released from any Interest of the Parent, ICA-T and the Subsidiaries in violation of any Environmental Laws; or

 

b. are present on, over, beneath, in or upon an Interest or any portion thereof in quantities that would constitute a violation of any Environmental Laws. No prior use by the Parent, ICA-T and the Subsidiaries of any Interest has occurred that violates any Environmental Laws, which violation would have a material adverse effect on the business of the Parent, ICA-T and the Subsidiaries.

 

(iii)        Neither the Parent, ICA-T nor the Subsidiaries knows of any other person who or entity which has stored, treated, recycled, disposed of or otherwise located on any Interest any Hazardous Materials, including, without limitation, such substances as asbestos and polychlorinated biphenyls.

 

(iv)       None of the Real Property is on any federal or state “Superfund” list or Liability Information System (“ CERCLIS ”) list or any state environmental agency list of sites under consideration for CERCLIS, nor subject to any environmental related Liens.

 

(y)        Subsidiary Rights . Except with respect to ICA-T but if and only to the extent ICA-T is so restricted at a time in question pursuant to the S/I MSA, the Parent has the unrestricted right to vote in all respects, and (subject to limitations imposed by applicable law) to receive dividends and distributions on, all capital securities of ICA-T and each of the Subsidiaries. Except with respect to the stock of ICA-T, all outstanding securities of each Subsidiary of the Parent and ICA-T is owned free and clear of all Liens by the Parent.

 

(z)        Tax Status .

 

(i)       Each of the Parent, ICA-T and the Subsidiaries has filed or caused to be filed in a timely manner (within any applicable extension periods) and in the appropriate jurisdictions all material returns, reports, information statements and other documentation (including any additional or supporting materials) filed or maintained, or required to be filed or maintained, in connection with the calculation, determination, assessment or collection of any and all federal, state, local, foreign and other taxes, levies, fees, imposts, duties, governmental fees and charges of whatever kind (including any interest, penalties or additions to the tax imposed in connection therewith or with respect thereto), including, without limitation, taxes imposed on, or measured by, income, franchise, profits, gross income or gross receipts, and also ad valorem , value added, sales, use, service, real or personal property, capital stock, stock transfer, license, payroll, withholding, employment, social security, workers’ compensation, unemployment compensation, utility, severance, production, excise, stamp, occupation, premium, windfall profits, environmental, transfer and gains taxes and customs duties (each a “ Tax ”) and shall include amended returns required as a result of examination adjustments made by the IRS or other Governmental Entity responsible for the imposition of any Tax (collectively, the “ Returns ”) and such Returns are true, correct and complete in all material respects.

 

  23  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

(ii)       Each of the Parent, ICA-T and the Subsidiaries has paid all material Taxes and other assessments due from and payable by the Parent, ICA-T and the Subsidiaries on or prior to the date hereof on a timely basis except as to those set forth in Schedule 3(z)(ii) . The charges, accruals, and reserves for Taxes with respect to the Parent, ICA-T and the Subsidiaries are adequate to cover Tax liabilities of the Parent, ICA-T and the Subsidiaries accruing throughout the date thereof. Except as set forth in Schedule 3(z)(ii) , each of the Parent, ICA-T and the Subsidiaries has complied in all material respects with all applicable Legal Requirements relating to the payment and withholding of Taxes (including withholding and reporting requirements under Sections 1441 through 1464, 3401 through 3406, and 6041 and 6049 of the Code and similar provisions under any other applicable Legal Requirements) and, within the time and in the manner prescribed by law, has withheld from wages, fees and other payments and paid over to the proper governmental or regulatory authorities all amounts required. Except as set forth in Schedule 3(z)(ii) , neither the Parent, ICA-T nor the Subsidiaries has received notice of assessment or proposed assessment of any Taxes claimed to be owed by it or any other Person on its behalf. Except as set forth in Schedule 3(z)(ii) , no Returns filed by or on behalf of the Parent, ICA-T and the Subsidiaries with respect to Taxes are currently being audited or examined. Except as set forth in Schedule 3(z)(ii) , neither the Parent, ICA-T nor the Subsidiaries has received notice of any such audit or examination. Except as set forth in Schedule 3(z)(ii) , no issue has been raised by any taxing authority with respect to the Parent, ICA-T and the Subsidiaries in any audit or examination which, by application of similar principles, could reasonably be expected to result in a proposed material adjustment to the liability for Taxes for any period not so examined.

 

(iii)       Except as set forth in Schedule 3(z)(iii) , no known Liens have been filed and no claims are being asserted by or against the Parent, ICA-T and the Subsidiaries with respect to any Taxes (other than Liens for Taxes not yet due and payable). Neither the Parent, ICA-T nor the Subsidiaries has currently elected pursuant to the Code to be treated as an S corporation or any comparable provision of local, state or foreign law, or has made any other elections pursuant to the Code (other than elections that relate solely to entity classification, methods of accounting, depreciation, or amortization) that would have a material effect on the business, properties, prospects, or financial condition of the Parent, ICA-T and the Subsidiaries, individually or in the aggregate.

 

  24  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

(iv)       No claim has ever been made, or, to the knowledge of the Parent or ICA-T, is threatened or pending, by any authority in a jurisdiction where the Parent, ICA-T and the Subsidiaries, respectively, does not file Returns that the Parent, ICA-T and the Subsidiaries are or may be subject to taxation by that jurisdiction, and neither the Parent, ICA-T nor the Subsidiaries has received any notice or request for information from any such authority. Neither the Parent, ICA-T nor the Subsidiaries has been a member of an affiliated group (as defined in Section 1504(a) of the Code) or filed or been included in a combined, consolidated or unitary income tax return other than the affiliated group of which ICA-T is currently the common parent. Neither the Parent, ICA-T nor the Subsidiaries are required to include in income any adjustment pursuant to Section 481(a) of the Code by reason of a voluntary change in accounting methods initiated by the Parent, ICA-T and the Subsidiaries, and no Governmental Entity has proposed an adjustment or change in accounting method. All transactions or methods of accounting that could give rise to a substantial understatement of federal income tax as described in Section 6662(d)(2)(B)(i) of the Code have been adequately disclosed on the Parent’s, ICA-T’s and the Subsidiaries’ federal income tax returns in accordance with Section 6662(d)(2)(B) of the Code. Neither the Parent, ICA-T nor the Subsidiaries are a party to any Tax sharing or Tax indemnity agreement or any other agreement of a similar nature that remains in effect. Neither the Parent, ICA-T nor the Subsidiaries has consented to any waiver of the statute of limitations for the assessment of any Taxes or has requested any extension of time for the payment of any Taxes. Neither the Parent, ICA-T nor the Subsidiaries has ever held a material beneficial interest in any other Person, other than those listed in Schedule 3(z)(iv) . Neither the Parent, ICA-T nor the Subsidiaries are obligated to make, nor as a result of any event connected with the transactions contemplated by this Agreement will become obligated to make, any payment that would not be deductible under Section 280G of the Code. Neither the Parent, ICA-T nor the Subsidiaries are a “passive foreign investment company” within the meaning of Section 1296 of the Code (a “ PFIC ”), and neither the Parent nor ICA-T anticipates that the Parent or ICA-T or any additional foreign Subsidiaries will become a PFIC in the foreseeable future.

  

(v)       The net operating loss carryforwards (“ NOLs ”) for United States federal income tax purposes of the consolidated group of which the Parent or ICA-T is the common parent, if any, shall not be adversely effected by the transactions contemplated hereby. The transactions contemplated hereby do not constitute an “ownership change” within the meaning of Section 382 of the Code, thereby preserving the Parent’s or ICA-T’s ability to utilize such NOLs.

 

(aa)      Internal Accounting and Disclosure Controls . Except as disclosed in Schedule 3(aa) , the Parent, ICA-T and the Subsidiaries maintains internal control over financial reporting (as such term is defined in Rule 13a-15(f) under the 1934 Act) that is effective to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles, including that (i) transactions are executed in accordance with management’s general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset and liability accountability, (iii) access to assets or incurrence of liabilities is permitted only in accordance with management’s general or specific authorization and (iv) the recorded accountability for assets and liabilities is compared with the existing assets and liabilities at reasonable intervals and appropriate action is taken with respect to any difference. Except as disclosed in Schedule 3(aa) , the Parent maintains disclosure controls and procedures (as such term is defined in Rule 13a-15(e) under the 1934 Act) that are effective in ensuring that information required to be disclosed by the Parent in the reports that it files or submits under the 1934 Act is recorded, processed, summarized and reported, within the time periods specified in the rules and forms of the SEC, including, without limitation, controls and procedures designed to ensure that information required to be disclosed by the Parent in the reports that it files or submits under the 1934 Act is accumulated and communicated to the Parent’s management, including its principal executive officer or officers and its principal financial officer or officers, as appropriate, to allow timely decisions regarding required disclosure. Neither the Parent, ICA-T nor the Subsidiaries has received any notice or correspondence from any accountant, Governmental Entity or other Person relating to any potential material weakness or significant deficiency in any part of the internal controls over financial reporting of the Parent, ICA-T and the Subsidiaries.

 

  25  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

(bb)     Off Balance Sheet Arrangements . There is no transaction, arrangement, or other relationship between the Parent, ICA-T and the Subsidiaries and an unconsolidated or other off balance sheet entity that is required to be disclosed by the Parent in its 1934 Act filings and is not so disclosed or that otherwise could be reasonably likely to have a Material Adverse Effect.

 

(cc)       Investment Company Status . Neither the Parent, ICA-T nor the Subsidiaries are and upon consummation of the sale of the Securities will not be, an “investment company,” an affiliate of an “investment company,” a company controlled by an “investment company” or an “affiliated person” of, or “promoter” or “principal underwriter” for, an “investment company” as such terms are defined in the Investment Company Act of 1940, as amended.

 

(dd)     U.S. Real Property Holding Corporation . Neither the Parent, ICA-T nor the Subsidiaries are, or has ever been, and so long as any of the Securities are held by the Buyer, shall become a U.S. real property holding corporation within the meaning of Section 897 of the Code, and the Parent, ICA-T and each Subsidiary shall so certify upon the Buyer’s request.

 

(ee)     Transfer Taxes . On the Closing Date, all stock transfer or other taxes (other than income or similar taxes) which are required to be paid in connection with the issuance, sale and transfer of the Securities to be sold to the Buyer hereunder will be, or will have been, fully paid or provided for by the Parent and/or ICA-T, and all laws imposing such taxes will be or will have been complied with.

 

(ff)       Bank Holding Company Act . Neither the Parent, ICA-T nor the Subsidiaries are subject to the Bank Holding Company Act of 1956, as amended (the “ BHCA ”) and to regulation by the Board of Governors of the Federal Reserve System (the “ Federal Reserve ”). Neither the Parent, ICA-T nor the Subsidiaries or affiliates owns or controls, directly or indirectly, five percent (5%) or more of the outstanding shares of any class of voting securities or twenty-five percent (25%) or more of the total equity of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither the Parent, ICA-T nor the Subsidiaries or affiliates exercises a controlling influence over the management or policies of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve.

 

  26  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

(gg)     Illegal or Unauthorized Payments; Political Contributions . Neither the Parent, ICA-T nor the Subsidiaries nor, to the best of ICA-T’s knowledge (after reasonable inquiry of its officers and directors), any of the officers, directors, employees, agents or other representatives of the Parent, ICA-T and the Subsidiaries or any other business entity or enterprise with which the Parent, ICA-T or their respective Subsidiaries is or has been affiliated or associated, has, directly or indirectly, made or authorized any payment, contribution or gift of money, property, or services, whether or not in contravention of applicable law, (i) as a kickback or bribe to any Person or (ii) to any political organization, or the holder of or any aspirant to any elective or appointive public office except for personal political contributions not involving the direct or indirect use of funds of the Parent, ICA-T and the Subsidiaries.

 

(hh)     Money Laundering . The Parent, ICA-T and the Subsidiaries are in compliance with, and have not previously violated, the USA Patriot Act of 2001 and all other applicable U.S. and non-U.S. anti-money laundering laws and regulations, including, without limitation, the laws, regulations and Executive Orders and sanctions programs administered by the U.S. Office of Foreign Assets Control, including, but not limited, to (i) Executive Order 13224 of September 23, 2001 entitled, “Blocking Property and Prohibiting Transactions With Persons Who Commit, Threaten to Commit, or Support Terrorism” (66 Fed. Reg. 49079 (2001)); and (ii) any regulations contained in 31 CFR, Subtitle B, Chapter V.

 

(ii)        Books and Records . The books of account, ledgers, order books, records and documents of the Parent, ICA-T and the Subsidiaries accurately and completely reflect all information relating to the respective businesses of the Parent, ICA-T and the Subsidiaries, the nature, acquisition, maintenance, location and collection of each of their respective assets, and the nature of all transactions giving rise to material obligations or accounts receivable of the Parent, ICA-T or any of their respective Subsidiaries, as the case may be, except where the failure to so reflect such information would not have a Material Adverse Effect. The minute books of the Parent, ICA-T and the Subsidiaries contain accurate records of all material meetings and accurately reflect all other material actions taken by the stockholders, boards of directors and all committees of the boards of directors, and other governing Persons of the Parent, ICA-T and the Subsidiaries, respectively.

 

(jj)       Management . Except as set forth in Schedule 3(jj) hereto, during the past five year period, no current or former officer or director or, to the knowledge of the Parent and ICA-T, no current ten percent (10%) or greater stockholder of the Parent, ICA-T and the Subsidiaries has been the subject of:

 

(i)       a petition under bankruptcy laws or any other insolvency or moratorium law or the appointment by a court of a receiver, fiscal agent or similar officer for such Person, or any partnership in which such person was a general partner at or within two years before the filing of such petition or such appointment, or any corporation or business association of which such person was an executive officer at or within two years before the time of the filing of such petition or such appointment;

 

(ii)       a conviction in a criminal proceeding or a named subject of a pending criminal proceeding (excluding traffic violations that do not relate to driving while intoxicated or driving under the influence);

 

  27  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

(iii)       any order, judgment or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining any such person from, or otherwise limiting, the following activities:

 

1. Acting as a futures commission merchant, introducing broker, commodity trading advisor, commodity pool operator, floor broker, leverage transaction merchant, any other person regulated by the United States Commodity Futures Trading Commission or an associated person of any of the foregoing, or as an investment adviser, underwriter, broker or dealer in securities, or as an affiliated person, director or employee of any investment company, bank, savings and loan association or insurance company, or engaging in or continuing any conduct or practice in connection with such activity;

 

2. Engaging in any particular type of business practice; or

 

3. Engaging in any activity in connection with the purchase or sale of any security or commodity or in connection with any violation of securities laws or commodities laws;

 

(iv)        any order, judgment or decree, not subsequently reversed, suspended or vacated, of any authority barring, suspending or otherwise limiting for more than sixty (60) days the right of any such person to engage in any activity described in the preceding sub paragraph, or to be associated with persons engaged in any such activity;

 

(v)       a finding by a court of competent jurisdiction in a civil action or by the SEC or other authority to have violated any securities law, regulation or decree and the judgment in such civil action or finding by the SEC or any other authority has not been subsequently reversed, suspended or vacated; or

 

(vi)       a finding by a court of competent jurisdiction in a civil action or by the Commodity Futures Trading Commission to have violated any federal commodities law, and the judgment in such civil action or finding has not been subsequently reversed, suspended or vacated.

 

(kk)      Stock Option Plans . Neither the Parent, ICA-T nor the Subsidiaries has any stock option, equity incentive and/or other related or similar plans except as set forth in the SEC Documents (collectively, the “ SOP’s ”). Schedule 3(kk) sets forth for each SOP the type of and aggregate amount of securities eligible to be issued under each SOP, the categories of eligible participants thereunder and the aggregate number of equity incentive or other securities issued thereunder. Each stock option, other securities or equity incentives under the SOPs granted by the Parent, ICA-T and the Subsidiaries (as the case may be), was granted and/or issued (i) in accordance with the terms of the applicable SOP and (ii) with an exercise price at least equal to the fair market value of the Parent Common Stock or common stock or other securities on the date such would be considered granted and/or issued under GAAP and applicable law. No stock option, other securities or equity incentives granted under the SOP’s has been backdated.

 

  28  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

(ll)      No Disagreements with Accountants and Lawyers . Except as disclosed in the SEC Documents, there are no material disagreements of any kind presently existing, or reasonably anticipated by the Parent, ICA-T and the Subsidiaries to arise, between the Parent, ICA-T and the Subsidiaries and the accountants and lawyers formerly or presently employed by the Parent, ICA-T and the Subsidiaries and the Parent, ICA-T and the Subsidiaries are current with respect to any fees owed to its accountants and lawyers which could affect ICA-T’s and the Subsidiary’s ability to perform any of its obligations under any of the Transaction Documents. In addition, on or prior to the date hereof, the Parent, ICA-T and the Subsidiaries had discussions with its accountants about its Financial Statements previously filed with the SEC. Based on those discussions and/or otherwise, neither the Parent nor ICA-T has no reason to believe that it will need to restate any Financial Statements or any part thereof.

 

(mm)   No Disqualification Events . With respect to Securities to be offered and sold hereunder in reliance on Rule 506(b) under the 1933 Act (“ Regulation D Securities ”), none of the Parent, ICA-T, any of their respective predecessors, any affiliated issuer, any director, executive officer, other officer of the Parent or ICA-T participating in the purchase and sale of any of the Securities (or other transactions) contemplated hereby and in the Transaction Documents, any beneficial owner of 20% or more of the Parent’s outstanding voting equity securities, calculated on the basis of voting power, nor any promoter (as that term is defined in Rule 405 under the 1933 Act) connected with the Parent or ICA-T in any capacity at the time of sale (each, an “ Issuer Covered Person ” and, together, “ Issuer Covered Persons ”) is subject to any of the “Bad Actor” disqualifications described in Rule 506(d)(1)(i) to (viii) under the 1933 Act (a “ Disqualification Event ”), except for a Disqualification Event covered by Rule 506(d)(2) or (d)(3). The Parent and ICA-T have exercised reasonable care to determine whether any Issuer Covered Person is subject to a Disqualification Event. The Parent and ICA-T have complied, to the extent applicable, with its disclosure obligations under Rule 506(e), and has furnished to the Buyer a copy of any disclosures provided thereunder.

 

(nn)   Other Covered Persons and Related Matters . Except as disclosed in Schedule 3(nn) , the Parent and ICA-T are not aware of any Person that has been or will be paid (directly or indirectly) remuneration for solicitation of the Buyer or potential purchasers in connection with the sale of any Regulation D Securities. To the best knowledge of the Parent and/or ICA-T, no holder of any securities of the Parent, ICA-T nor any employee, officer, director and/or consultant or advisor to or of the Parent, ICA-T and the Subsidiaries are a Bad Actor subject to a Disqualification Event.

 

(oo)    No Additional Agreements . Neither the Parent nor ICA-T have any agreement or understanding with the Buyer with respect to the transactions contemplated by the Transaction Documents other than as specified in the Transaction Documents.

 

  29  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

(pp)    Public Utility Holding Act . None of the Parent, ICA-T nor the Subsidiaries are a “holding company,” or an “affiliate” of a “holding company,” as such terms are defined in the Public Utility Holding Act of 2005.

 

(qq)   Federal Power Act . None of the Parent, ICA-T nor the Subsidiaries are subject to regulation as a “public utility” under the Federal Power Act, as amended.

 

(rr)      Ranking of Notes . Other than as set forth on Schedule 3(rr) , no Indebtedness of the Parent, ICA-T and/or any Subsidiaries, at the Closing will be in any manner and/or for any reason (i) senior to the Notes and/or any other liabilities and/or obligations of the Parent, ICA-T and/or any Subsidiaries to the Buyer in right of payment or otherwise, and/or (ii) pari passu with the Notes and/or any other liabilities and/or obligations of the Parent, ICA-T and/or any Subsidiaries to the Buyer in right of payment and/or in otherwise, whether with respect to payment, redemptions, principal, interest, Late Charges (as defined in the Note), damages, upon liquidation, dissolution or otherwise.

 

(ss)     Customers; Suppliers .

 

(i)        Schedule 3(ss)(i) attached hereto sets forth a true and correct list of (a) all customers of the Parent, ICA-T and the Subsidiaries with annual gross sales (as calculated pursuant to GAAP, consistently applied in accordance with past practices) in excess of $250,000 in terms of gross sales during the fiscal year ended December 31, 2016 and for the twelve month period ended as of the date hereof (collectively, the “ Major Customers ”).

 

(ii)        Schedule 3(ss)(ii) attached hereto lists, and the Parent and ICA-T have previously provided to the Buyer a copy of, all written contracts, commitments, agreements and other arrangements with Major Customers, including all amendments, modifications and supplements thereto. Except as set forth on Schedule 3(ss)(ii) , there are no material oral contracts, commitments, agreements and other arrangements between the Parent, ICA-T or each of their respective Subsidiaries, on the one hand, and any Major Customer, on the other hand.

 

(iii)       Except as disclosed Schedule 3(ss)(iii) , neither the Parent, ICA-T nor the Subsidiaries has received any written or oral notice, and neither the Parent, ICA-T nor the Subsidiaries has any reason to believe, that any Major Customer (i) has ceased, or in the reasonably foreseeable future may cease, to use the services of the Parent, ICA-T and the Subsidiaries, (ii) has substantially reduced, or in the reasonably foreseeable future may substantially reduce, the use of the services of the Parent, ICA-T and the Subsidiaries or (iii) has terminated or materially altered, or in the reasonably foreseeable future would reasonably be expected to terminate or materially alter its business relations with the Parent, ICA-T and the Subsidiaries, in each case as a result of the consummation of the transactions contemplated hereby or otherwise.

 

  30  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

(iv)       Neither the Parent, ICA-T nor the Subsidiaries has received any written or oral notice, and neither the Parent, ICA-T nor the Subsidiaries has any reason to believe, that any material partner, supplier or vendor to the Parent, ICA-T and the Subsidiaries has terminated or materially altered, or in the reasonably foreseeable future would reasonably be likely to terminate or materially alter, its business relations with the Parent, ICA-T and the Subsidiaries, in each case as a result of the transactions contemplated hereby or otherwise.

 

(tt)     Dilutive Effect. The Parent and ICA-T each understands and acknowledges that the number of Parent Underlying Shares will increase in certain circumstances. The Parent and ICA-T each further acknowledges that the Parent’s obligation to issue the Parent Conversion Shares pursuant to the terms of the Notes and Parent Warrant Shares pursuant to the terms of the Parent Warrant in accordance with this Agreement, the Notes and the Parent Warrant is, in each case, absolute and unconditional regardless of the dilutive effect that such issuance may have on the ownership interests of other stockholders of the Parent.

 

(uu)    Disclosure . No statement made by the Parent or ICA-T in this Agreement, any other Transaction Document or the exhibits and schedules attached hereto or in any certificate or schedule furnished or to be furnished by or on behalf of the Parent and/or ICA-T to the Buyer or any of their representatives in connection with the transactions contemplated hereby and/or thereby and/or in any other Transaction Document contains any untrue statement of a material fact or omits to state a material fact necessary in order to make the statements contained herein or therein not misleading. The Parent and ICA-T each confirms that neither it nor any other Person acting on its behalf has provided the Buyer or its agents or counsel with any information that constitutes or could reasonably be expected to constitute material, non-public information concerning the Parent, ICA-T and the Subsidiaries, other than the existence of the transactions contemplated by this Agreement and the other Transaction Documents. The Parent and ICA-T each understands and confirms that the Buyer will rely on the foregoing representations in effecting transactions in securities of the Parent and ICA-T each. Each press release issued by the Parent, ICA-T and the Subsidiaries during the twelve (12) months preceding the date of this Agreement did not at the time of release contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they are made, not misleading. To each of the Parent’s and ICA-T’s knowledge, no event or circumstance has occurred or information exists with respect to the Parent, ICA-T and the Subsidiaries or its or their business, properties, liabilities, prospects, operations (including results thereof) or conditions (financial or otherwise), which, under applicable law, rule or regulation, requires public disclosure at or before the date hereof or announcement by the Parent or ICA-T but which has not been so publicly disclosed. The due diligence materials previously provided by or on behalf of the Parent and ICA-T to the Buyer (the “ Due Diligence Materials ”), have been prepared in a good faith effort by the Parent and ICA-T to describe the Parent and ICA-T’s present and proposed products, and projected growth of the Parent and ICA-T and do not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein not misleading, except that with respect to assumptions, projections and expressions of opinion or predictions contained in the Due Diligence Materials. The Parent and ICA-T each acknowledge and agree that the Buyer does not make nor has made any representations or warranties with respect to the transactions contemplated hereby and/or in the other Transaction Documents other than those specifically set forth in Section 2 .

 

  31  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

(vv) Acknowledgement Regarding Buyer’s Trading Activity . It is understood and acknowledged by the Parent and ICA-T that (i) following the public disclosure of the transactions contemplated by the Transaction Documents, in accordance with the terms thereof, the Buyer has not been asked by the Parent, ICA-T and the Subsidiaries to agree, nor has any Buyer agreed with the Parent, ICA-T and the Subsidiaries, to desist from effecting any transactions in or with respect to (including, without limitation, purchasing or selling, long and/or short) any securities of the Parent and/or ICA-T, or “derivative” securities based on securities issued by the Parent and/or ICA-T or to hold any of the Securities for any specified term; (ii) the Buyer, and counterparties in “derivative” transactions to which the Buyer is a party, directly or indirectly, presently may have a “short” position in the Parent Common Stock which was established prior to the Buyer’s knowledge of the transactions contemplated by the Transaction Documents; and (iii) the Buyer shall not be deemed to have any affiliation with or control over any arm’s length counterparty in any “derivative” transaction. The Parent and ICA-T each further understands and acknowledges that following the public disclosure of the transactions contemplated by the Transaction Documents pursuant to the Press Release (as defined below) the Buyer may engage in hedging and/or trading activities at various times during the period that the Securities are outstanding, including, without limitation, during the periods that the value and/or number of the Parent Warrant Shares or Parent Conversion Shares, as applicable, deliverable with respect to the Securities are being determined and such hedging and/or trading activities, if any, can reduce the value of the existing stockholders’ equity interest in the Parent and ICA-T both at and after the time the hedging and/or trading activities are being conducted. The Parent and ICA-T each acknowledges that such aforementioned hedging and/or trading activities do not constitute a breach of this Agreement, the Notes, the Parent Warrant or any other Transaction Document or any of the documents executed in connection herewith or therewith.

 

(ww)   Liens . Other than as set forth on Schedule 3(ww) , there are no Liens on any of the assets of the Parent, ICA-T and/or the Subsidiaries.

 

(xx)      Shell Company Status . The Parent is not, and has never been, an issuer identified in, or subject to, Rule 144(i).

 

(yy)   Material Contracts . All Material Contracts of the Parent and the Subsidiaries are set forth on Schedule 3(yy) and each has been filed with the SEC (as defined below). An accurate, current and complete copy of each of the Material Contracts has been furnished to Buyers and each of the Material Contracts constitutes the entire agreement of the respective parties thereto relating to the subject matter thereof. Each of the Material Contracts is in full force and effect and is a valid and binding obligation of the parties thereto in accordance with the terms and conditions thereof. To the knowledge of the Parent and ICA-T and each of their respective officers, all obligations required to be performed under the terms of each of the Material Contracts by any party thereto have been fully performed by all parties thereto, and no party to any Material Contracts is in default with respect to any term or condition thereof, nor has any event occurred which, through the passage of time or the giving of notice, or both, would constitute a default thereunder or would cause the acceleration or modification of any obligation of any party thereto or the creation of any encumbrance upon any of the assets of the Parent and ICA-T. Further, the neither the Parent nor ICA-T has received notice, nor does ICA-T or the Parent have any knowledge, of any pending or contemplated termination of any of the Material Contracts and, no such termination is proposed or has been threatened, whether in writing or orally. “ Material Contract ” means any contract to which the Parent, ICA-T and the Subsidiaries are a party or by which it is bound which has been filed or is required to have been filed as an exhibit to the SEC Filings pursuant to Item 601(b)(4) or Item 601(b)(10) of Regulation S-K promulgated by the SEC. Notwithstanding anything to the contrary provided herein or elsewhere, for purposes of the Transaction Documents, the term Material Contracts includes the Sanofi Documents.

 

(zz)     Registration Eligibility . The Parent is eligible to register the Registrable Securities (as defined below) for sale or resale on a Registration Statement on Form S-1.

 

  32  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

4. COVENANTS.

 

(a)        Best Efforts . The Buyer shall use its best efforts to timely satisfy each of the covenants under this Section 4 and conditions to be satisfied by it as provided in Section 6 of this Agreement. The Parent and ICA-T shall each use its best efforts to timely satisfy each of the covenants hereunder and conditions to be satisfied by it as provided in Section 7 of this Agreement.

 

(b)        Form D and Blue Sky . The Parent and ICA-T shall each file a Form D with respect to the Securities issued and/or sold by each as required under Regulation D and to provide a copy thereof to the Buyer promptly after such filing. The Parent and ICA-T shall, on or before the Closing Date, take such action as the Parent and ICA-T shall reasonably determine is necessary in order to obtain an exemption for, or to, qualify the Securities for sale to the Buyer at the Closing pursuant to this Agreement under applicable securities or “Blue Sky” laws of the states of the United States (or to obtain an exemption from such qualification), and shall provide evidence of any such action so taken to the Buyer on or prior to the Closing Date. Without limiting any other obligation of the Parent and ICA-T under this Agreement, the Parent and ICA-T shall timely make all filings and reports relating to the offer and sale of the Securities required under all applicable securities laws (including, without limitation, all applicable federal securities laws and all applicable “Blue Sky” laws), and the Parent and ICA-T shall comply with all applicable foreign, federal, state and local laws, statutes, rules, regulations and the like relating to the offering and sale of the Securities to the Buyer.

 

(c)        Reporting Status . Until the Business Day immediately following to the day on which the Buyer or any transferee or assignee thereof to which the Buyer assigns its rights as a holder of Securities (each an “ Investor ”, and collectively, the “ Investors ”) shall have sold all of the Parent Underlying Shares (the “ Reporting Period ”), the Parent (or its Successor Entity (as defined in the Notes)), shall timely file all reports required to be filed with the SEC pursuant to the 1934 Act, and the Parent (or its Successor Entity (as defined in the Notes)) shall not terminate the registration of the Parent Common Stock under Section 12 of the 1934 Act and/or the Parent’s status as an issuer required to file reports under the 1934 Act even if the 1934 Act or the rules and regulations thereunder would no longer require or otherwise permit such termination. The Parent shall maintain its eligibility to register the Registrable Securities on Form S-1.

 

  33  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

(d)        Use of Proceeds . (i) the Parent shall use the net proceeds from the Parent Purchase Price to (A) repay the $1,500,000 aggregate principal amount of the 8% notes sold by the Parent in April 2017 (the “ Parent Bridge Notes ”) and all accrued but unpaid interest thereon, and (B) the balance for general corporate and working capital purposes including payments made against the $1,400,000 amount owed by the Parent to Dentons pursuant to the Settlement and Release Agreement dated May 11, 2017 by and between Dentons and the Parent (the “ Denton Settlement Agreement ”), and (ii) ICA-T shall use the net proceeds from the ICA-T Purchase Price for general corporate and working capital purposes of ICA-T; provided , however , notwithstanding anything to the contrary provided herein or elsewhere, except as expressly provided in this “d,” neither the Parent nor ICA-T shall use any of the net proceeds of the Parent Purchase Price or ICA-T Purchase Price, respectively, for (A) as to ICA-T, the repayment of any Indebtedness of ICA-T other than Permitted Indebtedness (as defined in the ICA-T Note), as to the Parent, other than Permitted Indebtedness (as defined in the Parent Note), (B) the redemption or repurchase of any securities of the Parent, ICA-T and the Subsidiaries, or (C) except for the payments pursuant to the Denton Settlement Agreement, the settlement of any outstanding litigation; provided , further , ICA-T will not use any of such proceeds in violation of the Sanofi Documents.

 

(e)        Financial and Other Information . The Parent agrees to send the following to each Investor during the Reporting Period (i) unless the following are filed with the SEC through EDGAR and are available to the public through the EDGAR system, within one (1) Business Day after the filing thereof with the SEC, a copy of its Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, any interim reports or any consolidated balance sheets, income, statements, stockholder’s equity statements and/or cash flow statements for any period other than annually, any Current Reports on Form 8-K, any registration statements (other than on Form S-8) or amendments filed pursuant to the 1933 Act, (ii) unless the following are either filed with the SEC through EDGAR or are otherwise widely disseminated via a recognized news release service (such as PR Newswire), on the same day as the release thereof, facsimile copies of all press releases issued by the Parent, ICA-T and the Subsidiaries and (iii) unless the following are filed with the SEC through EDGAR or made permanently available on the Parent or ICA-T’s website, copies of any notices and other information made available or given to the stockholders of the Parent generally, contemporaneously with the making available or giving thereof to the stockholders.

 

(f)        Inspection . In addition to the inspection and related rights of the Buyer as set forth in the Notes, the Parent and ICA-T shall permit any representative that the Buyer or the Collateral Agent authorizes, including attorneys and accountants, to inspect the Collateral and examine and make copies and abstracts of the books of account and records of the Parent, ICA-T and the Subsidiaries at reasonable times and upon reasonable notice during normal business hours but no more than once per quarter; provided that they execute the Parent’s and/or ICA-T’s standard confidentiality agreement. In addition, any such representative shall have the right to meet with management and officers of the Parent, ICA-T and the Subsidiaries and/or their representatives to discuss such books of account and records including, but not limited to, the accountants and legal counsels of the Parent, ICA-T and the Subsidiaries. In addition, the Collateral Agent and the Buyer shall be entitled at reasonable times and intervals to consult with and advise the management and officers of the Parent, ICA-T and the Subsidiaries concerning significant business issues affecting the Parent, ICA-T and the Subsidiaries.

 

  34  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

(g)        Listing . In the event the Parent becomes a Trading Issuer (as defined in the Note) or the Parent Common Stock otherwise becomes listed or designated for quotation (as the case may be) on an Eligible Market or otherwise, the Parent shall take any and all action to ensure all Parent Underlying Shares are listed or designated for quotation (as the case may be) on such Eligible Market and shall maintain the listing or designation for quotation (as the case may be) of all Parent Underlying Shares from time to time issuable under the terms of the Transaction Documents on the Eligible Market upon which the Parent Common Stock is then listed or designated for quotation (as the case may be) or any other Eligible Market. The Parent shall pay all fees and expenses in connection with satisfying its obligations under this Section 4(g) . No event has occurred and to the best knowledge of the Parent, there is no reason why the Parent Common Stock cannot be listed and trade on any Eligible Market, subject to meet the specific shareholder and financial requirements thereof.

 

(h)        Fees, Etc . At and as a condition to the Closing, the Parent and ICA-T shall reimburse the Buyer for all costs and expenses incurred by it or its affiliates in connection with its due diligence up to $20,000 of which $6,000 was previously paid, structuring, documentation, negotiation and closing of the transactions contemplated by the Transaction Documents. Notwithstanding and in addition to the above, the Parent and ICA-T shall also pay (i) the legal fees incurred by the Buyer to Gusrae Kaplan Nusbaum PLLC, legal counsel to the Buyer, and local real estate counsel to the Buyer in the State where any Real Property of the Parent, ICA-T and the Subsidiaries are located, up to $75,000 in the aggregate less $10,000 previously paid, and (ii) all documented costs and expenses incurred by such legal counsels including, but not limited to Lien, judgment, tax, and UCC and related searches, and all filing fees including, but not limited to, all UCC-1 Financing Statements, UCC-3 Termination Statements, if any, USPTO filings and all recordation fees and related costs and expenses (collectively, the “ Transaction Expenses ”). Such Transaction Expenses shall be withheld by the Buyer from the Purchase Price paid to the Parent and ICA-T at the Closing, less $10,000 previously paid by the Parent to the Buyer; provided , that ICA-T shall promptly reimburse Buyer and Gusrae Kaplan Nusbaum PLLC on demand for all Transaction Expenses not so invoiced and/or reimbursed through such withholding at the Closing or otherwise upon the provision of reasonable satisfactory evidence of such expense including, but not limited to, all Lien (UCC, USPTO, Etc.), judgment, bankruptcy searches, which will be paid upon delivery of each invoice from the service provider or other Person. The Parent and ICA-T shall be responsible for the payment of any placement agent’s fees, financial advisory fees, Controlled Account Bank fees, DTC fees, transfer agent fees, listing fees, if any, fees or broker’s commissions, filing and/or recordation fees, blue sky fees relating to or arising out of the transactions contemplated hereby and in the other Transaction Documents. The Parent and ICA-T shall pay, and hold the Buyer harmless against, any liability, loss or expense (including, without limitation, reasonable attorneys’ fees and out-of-pocket expenses as and when incurred) arising in connection with any claim relating to any such payment. Except as otherwise set forth in the Transaction Documents, each party to this Agreement and/or any other Transaction Document shall bear its own expenses in connection with the sale of the Securities to the Buyer. The Parent and ICA-T, however, shall be jointly and severally responsible and pay any and all reasonable attorneys’ and other professionals’ fees and expenses incurred by the Collateral Agent and/or the Buyer (as and when incurred) after the Closing in connection with or related to: (a) the Transaction Documents and/or any of the transactions contemplated and/or arising therefrom; (b) the administration, collection, or enforcement of the Transaction Documents; (c) the amendment or modification of the Transaction Documents; (d) any waiver, consent, release, or termination under the Transaction Documents; (e) the perfection of Liens on, the protection, preservation, sale, lease, liquidation, or disposition of Collateral or the exercise of remedies with respect to the Collateral; (f) any legal, litigation, regulatory, administrative, arbitration, or out of court proceeding in connection with or related to the Parent, ICA-T, each of their respective Subsidiaries, Collateral, any of the Transaction Documents and/or any transaction contemplated hereby and/or thereby or otherwise, related to and/or arising therefrom and from any appeal or review thereof; and (g) any bankruptcy, restructuring, reorganization, assignment for the benefit of creditors, workout, foreclosure, or other action related to the Parent, ICA-T, each of their respective Subsidiaries, the Collateral, the Transaction Documents, including representing the Collateral Agent and the Buyer in any adversary proceeding or contested matter commenced or continued by or on behalf of the Parent, ICA-T and the Subsidiaries’ estate, property and/or any appeal or review thereof.

 

  35  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

(i)        Pledge of Securities . Notwithstanding anything to the contrary contained in this Agreement, the Parent and ICA-T each acknowledge and agree that the Securities may be pledged by an Investor in connection with a bona fide margin agreement or other loan or financing arrangement that is secured by the Securities. The pledge of Securities shall not be deemed to be a transfer, sale or assignment of the Securities hereunder, and no Investor effecting a pledge of Securities shall be required to provide the Parent or ICA-T, as the case may be, with any notice thereof or otherwise make any delivery to the Parent or ICA-T, as the case may be pursuant to this Agreement or any other Transaction Document, including, without limitation, Section 2(g) hereof; provided that an Investor and its pledgee shall be required to comply with the provisions of Section 2(g) hereof in order to effect a sale, transfer or assignment of Securities to such pledgee. The Parent and ICA-T each hereby agrees to execute and deliver such documentation as a pledgee of the Securities as the Buyer may reasonably request in connection with a pledge of the Securities to such pledgee by the Buyer.

 

(j)        Disclosure of Transaction, Etc .

 

(i)        Disclosure of Transaction . The Parent shall, on or before 9:30 a.m., New York time, no later than the fourth (4 th ) Business Day after the date of this Agreement, issue a press release (the “ Press Release ”) reasonably acceptable to the Buyer disclosing all the material terms of the transactions contemplated by the Transaction Documents. On or before 9:30 a.m., New York time, no later than the fourth (4 th ) Business Day after the date of this Agreement, the Parent shall file a Current Report on Form 8-K describing all the material terms of the transactions contemplated by the Transaction Documents in the form required by the 1934 Act and attaching all the material Transaction Documents (including, without limitation, this Agreement (and all schedules to this Agreement), the form of Note, the form of the Parent Warrant, the form of Guaranties and the form of Security Documents) (including all attachments, the “ 8-K Filing ”).

 

(ii)        Limitations on Disclosure . The Parent and ICA-T shall not, and the Parent and ICA-T shall cause each of the Subsidiaries and each of its and their respective officers, directors, employees and agents not to, provide any Buyer with any material, non-public information regarding the Parent, ICA-T and/or any of the Subsidiaries from and after the date hereof without the express prior written consent of the Buyer (which may be granted or withheld in the Buyer’s sole discretion). In the event of a breach of any of the foregoing covenants, including, without limitation, Section 4(m) of this Agreement, or any of the covenants or agreements contained in any other Transaction Document, by the Parent, ICA-T and/or any of the Subsidiaries, or any of its or their respective officers, directors, employees and agents (as determined in the reasonable good faith judgment of the Buyer), in addition to any other remedy provided herein or in the Transaction Documents, the Buyer shall have the right to make a public disclosure, in the form of a press release, public advertisement or otherwise, of such breach or such material, non-public information, as applicable, without the prior approval by the Parent, ICA-T, any of their respective Subsidiaries, or any of its or their respective officers, directors, employees or agents. The Buyer shall not have any liability to the Parent, ICA-T, any of the Subsidiaries, or any of its or their respective officers, directors, employees, affiliates, stockholders or agents, for any such disclosure. To the extent that the Parent, ICA-T or any of the Subsidiaries delivers any material, non-public information to the Buyer without the Buyer’s prior written consent, the Parent and ICA-T hereby covenant and agree that the Buyer shall not have any duty of confidentiality with respect to, or a duty not to trade on the basis of, such material, non-public information. Subject to the foregoing, neither the Parent, ICA-T nor the Subsidiaries nor any Buyer shall issue any press releases or any other public statements (other than the filing of a Current Report on Form 8-K) with respect to the transactions contemplated hereby; provided, however, the Parent shall be entitled, without the prior approval of any Buyer, to make the Press Release and any press release or other public disclosure with respect to such transactions (i) in substantial conformity with the 8-K Filing and (ii) as is required by applicable law and regulations (provided that in the case of clause (i) the Buyer shall be notified by the Parent of any such press release or other public disclosure prior to its release). Notwithstanding anything contained in this Agreement to the contrary and without implication that the contrary would otherwise be true, the Parent expressly acknowledges and agrees that the Buyer shall not have any duty of confidentiality with respect to, or a duty not to trade on the basis of, any material, non-public information regarding the Parent, the Parent and/or any of their respective Subsidiaries.

 

  36  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

(iii)        Other Confidential Information . In addition to other remedies set forth in this Section 4(j) , and without limiting anything set forth in any other Transaction Document, at any time after the Closing Date if the Parent, ICA-T, any of their respective Subsidiaries, or any of their respective officers, directors, employees or agents, provides the Buyer with material non-public information relating to the Parent, ICA-T and/or any of the Subsidiaries (each, the “ Confidential Information ”), and such disclosure is without the consent of the Buyer, the Parent shall on the Required Disclosure Date (as defined below), publicly disclose such Confidential Information on a Current Report on Form 8-K or otherwise (each, a “ Disclosure ”). From and after such Disclosure, the Parent shall have disclosed all Confidential Information provided to the Buyer and/or any of its affiliates by the Parent, ICA-T and the Subsidiaries or any of their respective officers, directors, employees or agents in connection with the transactions contemplated by the Transaction Documents other than material non-public information relating to the Parent, ICA-T and/or any of the Subsidiaries provided to the Buyer prior written consent of the Buyer. In addition, effective upon such Disclosure, the Parent and ICA-T acknowledge and agree that any and all confidentiality or similar obligations under any agreement, whether written or oral, between the Parent, ICA-T, any of the Subsidiaries or any of their respective officers, directors, affiliates, employees or agents, on the one hand, and the Buyer or any of their affiliates, on the other hand, shall terminate with respect to material non-public information relating to the Parent, ICA-T and/or any of the Subsidiaries provided to the Buyer without the Buyer’s prior written consent . For purposes of this Agreement, the term “ Required Disclosure Date ” means (x) if the Buyer authorized the delivery of such Confidential Information, either (I) if the Parent and the Buyer have mutually agreed upon a date (as evidenced by an e-mail or other writing) of Disclosure of such Confidential Information, such agreed upon date or (II) otherwise, the fifth (5 th ) calendar day after the date the Buyer first received any Confidential Information or (y) if the Buyer did not authorize the delivery of such Confidential Information, the first (1 st ) Business Day after the Buyer’s receipt of such Confidential Information. Notwithstanding anything to the contrary contained in this Agreement, the Parent and ICA-T shall not be required to publicly disclose any material, non-public information relating to ICA-T, the Parent and/or any of the Subsidiaries that is provided to the Buyer if the Buyer consents in writing to the receipt of such information.

 

(k)        Conduct of Business . The business of the Parent, ICA-T and the Subsidiaries shall not be conducted in violation of any law, ordinance or regulation of any Governmental Entity.

 

(l)        Other Notes; Variable Securities . So long as the Buyer and/or any of its transferees, affiliates and/or related persons own (beneficially or otherwise) any Securities, neither the Parent, ICA-T or any of the Subsidiaries shall issue, sell and/or enter into an agreement to effect any sale of Notes and/or any Variable Rate Transaction. “ Variable Rate Transaction ” means a transaction in which the Parent, ICA-T or any of the Subsidiaries (i) issues or sells any Common Stock Equivalents (as defined in the Notes), Convertible Securities (as defined in the Notes) either (A) at a conversion, exercise or exchange rate or other price that is based upon and/or varies with the trading prices of or quotations for the shares of Parent Common Stock at any time after the initial issuance of such Convertible Securities, or (B) with a conversion, exercise or exchange price that is subject to being reset at some future date after the initial issuance of such Convertible Securities or upon the occurrence of specified or contingent events directly or indirectly related to the business of the Parent, ICA-T and/or any Subsidiary or the market for the Parent Common Stock, or (ii) enters into any agreement (including, without limitation, an equity line of credit) whereby the Parent, ICA-T and the Subsidiaries may sell securities at a future determined price (other than standard and customary “preemptive” or “participation” rights). The Buyer shall be entitled to obtain injunctive relief against the Parent, ICA-T and/or any of the Subsidiaries to preclude any such issuance, which remedy shall be in addition to any right to collect damages. Notwithstanding anything to the contrary provided herein or elsewhere, neither ICA-T nor any other Subsidiary shall directly and/or indirectly issue any capital stock (other than the 100 shares of ICA-T capital stock and the capital stock of each Subsidiary) issued and outstanding as of the date hereof, all of which and all of whose voting stock is owned solely and exclusively by the Parent. Notwithstanding anything to the contrary contained herein, a Variable Rate Transaction shall not include an “at the market” offering.

 

  37  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

(m)        Participation Right . Until the two (2) year anniversary of the Closing Date, the Buyer shall have the right (the “ Participation Right ”), but not the obligation to participate in all Subsequent Placements, up to the aggregate initial original principal amount of the Notes at Closing, other than Exempt Issuances, on the terms and conditions so negotiated between the Parent and/or ICA-T on the one hand and the Buyer on the other. For the purpose of this Agreement, the following definitions shall apply:

 

a.        “Exempt Issuance ” means the issuance of (a) shares of Parent Common Stock or options to purchase shares of Parent Common Stock issued pursuant to any stock or option plan duly adopted for such purpose, by the Parent’s board of directors and a majority of the non-employee members of the board of directors or a majority of the members of a committee of non-employee directors established for such purpose, (b) shares of Parent Common Stock issuable upon the exercise or exchange of or conversion of any of the Notes, the Parent Warrant issued hereunder and/or any Common Stock Equivalents issued and outstanding on the date of this Agreement, provided that such securities have not been amended since their original issue, (c) securities issued in lieu of cash pursuant to merger, consolidation, acquisition or strategic transactions approved by a majority of the disinterested directors of the Parent, provided that any such issuance shall only be to a Person which is, itself or through its subsidiaries, an operating company in a business synergistic with the business of the Parent and in which the Parent receives benefits in addition to any investment of funds, but shall not include a transaction in which the Parent is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities and/or being issued to affiliates, employees and/or related persons of the Parent and/or any of its affiliates, (d) securities issued pursuant to any equipment loan or leasing arrangement, real property leasing arrangement or debt financing having such terms and on such terms and conditions and from a bank or similar financial institution, all as approved by a majority of the disinterested directors of the Parent, (e) securities to an entity as a component of any business relationship with such entity primarily for the purpose of a joint venture or licensing activity or another arrangement involving a corporate partner primarily for purposes other than raising capital, and (f) issuance of securities pursuant to a stock dividend or stock split except as otherwise prohibited and/or limited in this Note and/or any other Transaction Document.

 

b.        “ Subsequent Placement ” means any issuance, offer, sale, grant for capital raising purposes of any option or right to purchase, or other disposal by the Parent or any of its affiliates and/or Subsidiaries, directly or indirectly, of any debt securities including, but not limited to, convertible debt, debt issued with equity components or debt not considered a “security” under the 1933 Act and any short term instruments (as defined in the 1933 Act) of the Parent, ICA-T and the Subsidiaries.

 

  38  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

(n)        Passive Foreign Investment Company . ICA-T and the Parent shall conduct its business, and shall each cause each of its Subsidiaries to conduct their respective businesses, in such a manner as will ensure that ICA-T and the Parent will not be deemed to constitute a passive foreign investment company within the meaning of Section 1297 of the Code.

 

(o)        Restriction on Redemption and Cash Dividends . So long as any Securities are outstanding and except as expressly provided herein, neither the Parent nor ICA-T shall, and the Parent and ICA-T shall cause each Subsidiary not to, directly or indirectly, redeem, or declare or pay any cash dividend or distribution on, any securities (other than Securities) of the Parent, ICA-T or any Subsidiary without the prior express written consent of the Buyer, other than intercompany dividends (“ Intercompany Dividends ”) from any Subsidiary to the Parent provided all of such Subsidiary’s operations are in the United States and it does not have any foreign bank or similar account; provided , however , that notwithstanding anything to the contrary provided herein or elsewhere, all Intercompany Dividends shall be prohibited commencing on the date an Event of Default occurs and continuing through and including the tenth (10 th ) Business Day following the date the Collateral Agent receives written notice from ICA-T and the Parent signed by the CFO of ICA-T and the Parent that such Event of Default has been cured and no longer exists.

 

(p)        Corporate Existence . So long as the Buyer beneficially owns the Notes and the Parent Warrant, the Parent shall not and shall cause each Subsidiary not to be a party to any Fundamental Transaction (as defined in the Note) unless the Parent is in compliance with the applicable provisions governing Fundamental Transactions set forth in the Notes, this Agreement and the Parent Warrant.

 

(q)        Stock Splits . Until the Notes are no longer outstanding, the Parent shall not effect any stock combination, reverse stock split or other similar transaction submitted for stockholder approval at a meeting of the shareholders of the Parent or via written consent of stockholders (or make any public announcement or disclosure with respect to any of the foregoing) without the prior written consent of the Buyer, which consent shall not be unreasonably withheld.

 

(r)        Collateral Agent . The Buyer is the collateral agent hereunder, under the other Security Documents and the other Transaction Documents (in such capacity, the “ Collateral Agent ”), and (ii) as the Collateral Agent (as well as its officers, directors, employees and agents) is and shall be entitled to take such action on the Buyer’s and any of its assignees’ and/or transferees’ behalf in accordance with the terms hereof and thereof. The Collateral Agent shall not have, by reason hereof, the other Transaction Documents including the Security Documents, a fiduciary relationship in respect of any assignee and/or transferee of the Buyer. Neither the Collateral Agent nor any of its officers, directors, employees or agents shall have any liability to any assignee and/or transferee of the Buyer for any action taken or omitted to be taken in connection hereof or any other Security Document except to the extent caused by its own gross negligence or willful misconduct, any assignee and/or transferee of the Buyer agrees to defend, protect, indemnify and hold harmless the Collateral Agent and all of its officers, directors, employees, affiliates and agents (collectively, the “ Collateral Agent Indemnitees ”) from and against any losses, damages, liabilities, obligations, penalties, actions, judgments, suits, fees, costs and expenses (including, without limitation, reasonable attorneys’ fees, costs and expenses) incurred by such Collateral Agent Indemnitee, whether direct, indirect or consequential, arising from or in connection with the performance by such Collateral Agent Indemnitee of the duties and obligations of Collateral Agent pursuant hereto or any of the Security Documents. The Collateral Agent shall be entitled to rely upon any written notices, statements, certificates, orders or other documents or any telephone message believed by it in good faith to be genuine and correct and to have been signed, sent or made by the proper Person, and with respect to all matters pertaining to this Agreement or any of the other Transaction Documents and its duties hereunder or thereunder, upon advice of counsel selected by it.

 

  39  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

(s)        Successor Collateral Agent.

 

(i)       The Collateral Agent may resign from the performance of all its functions and duties hereunder and under the other Transaction Documents at any time by giving at least ten (10) Business Days’ prior written notice to the Parent and ICA-T and each holder of the Notes. Such resignation shall take effect upon the acceptance by a successor Collateral Agent of appointment pursuant to clauses (ii) and (iii) below or as otherwise provided below.

 

(ii)       Upon any such notice of resignation or removal, the Buyer shall appoint a successor collateral agent. Upon the acceptance of any appointment as Collateral Agent hereunder by a successor agent, such successor collateral agent shall thereupon succeed to and become vested with all the rights, powers, privileges and duties of the collateral agent, and the Collateral Agent shall be discharged from its duties and obligations under this Agreement and the other Transaction Documents. After the Collateral Agent’s resignation or removal hereunder as the collateral agent, the provisions of this Section 4(s) shall inure to its benefit as to any actions taken or omitted to be taken by it while it was the Collateral Agent under this Agreement and the other Transaction Documents.

 

(iii)       If a successor collateral agent shall not have been so appointed within ten (10) Business Days of receipt of a written notice of resignation or removal, the Collateral Agent shall then appoint a successor collateral agent who shall serve as the Collateral Agent until such time, if any, as the Buyer appoints a successor collateral agent as provided above.

 

(iv)       In the event that a successor Collateral Agent is appointed pursuant to the provisions of this Section 4(s) that is not the Buyer or an affiliate of the Buyer (or the Buyer or the Collateral Agent (or its successor), as applicable, notify the Parent and ICA-T that they or it wants to appoint such a successor Collateral Agent pursuant to the terms of this Section 4(s) ), the Parent, ICA-T and each Subsidiary thereof covenants and agrees to promptly take all actions reasonably requested by the Buyer or the Collateral Agent (or its successor), as applicable, from time to time, to secure a successor Collateral Agent satisfactory to the requesting part(y)(ies), in their sole discretion, including, without limitation, by paying all reasonable and customary fees and expenses of such successor Collateral Agent, by having the Parent, ICA-T and each Subsidiary thereof agree to indemnify any successor Collateral Agent pursuant to reasonable and customary terms and by each of the Parent, ICA-T and each Subsidiary thereof executing a collateral agency agreement or similar agreement and/or any amendment to the Security Documents reasonably requested or required by the successor Collateral Agent.

 

  40  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

(t)        New Subsidiaries . Neither the Parent, ICA-T nor the Subsidiaries shall form or acquire any Foreign Subsidiaries without the express prior written consent of the Collateral Agent and the Buyer, which written consent shall, among other conditions, be conditioned upon, among other items, compliance by the Parent, ICA-T and each Subsidiary of Section 4(x) .

 

(u)        General Solicitation . None of the Parent, ICA-T, any of their respective affiliates or any Person acting on behalf of the Parent, ICA-T or any such affiliate will solicit any offer to buy or offer or sell the Securities by means of any form of general solicitation or general advertising within the meaning of Regulation D, including: any advertisement, article, notice or other communication published in any newspaper, magazine or similar medium or broadcast over television or radio; and any seminar or meeting whose attendees have been invited by any general solicitation or general advertising.

 

(v)        Integration . None of the Parent, ICA-T, any of their respective affiliates or any Person acting on behalf of the Parent, ICA-T or any such affiliates will sell, offer for sale, or solicit offers to buy or otherwise negotiate in respect of any security which will be integrated with the sale of the Securities in a manner which would require the registration of any of the Securities under the 1933 Act or result in rescission rights.

 

(w)        Notice of Disqualification Events . The Parent and ICA-T will notify the Buyer in writing, prior to the Closing Date of (i) any Disqualification Event relating to any Issuer Covered Person and (ii) any event that would, with the passage of time, become a Disqualification Event relating to any Issuer Covered Person.

 

(x)        Subsidiary Guarantees, Etc . For so long as any of the Notes remain outstanding, upon any entity becoming a Subsidiary, the Parent and ICA-T shall cause each such Subsidiary to become party to all of the Security Documents, to the extent required in the Security Documents and take all actions required by the Security Documents in form and substance satisfactory to the Collateral Agent and the Buyer.

 

(y)        Public Information . At any time during the period commencing on Closing Date and ending at such time that all of the Parent Conversion Shares and Parent Warrant Shares may be sold without restriction or limitation pursuant to Rule 144 and without the requirement to be in compliance with Rule 144(c)(1), if the Parent shall (i) fail for any reason to satisfy the requirements of Rule 144(c)(1), including, without limitation, the failure to satisfy the current public information requirement under Rule 144(c) or (ii) if the Parent becomes an issuer described in Rule 144(i)(1)(i), and the Parent shall fail to satisfy any condition set forth in Rule 144(i)(2) (a “ Public Information Failure ”), then, as partial relief for the damages to any holder of the Notes, the Parent Warrant and/or the Parent Conversion Shares by reason of any such delay in or reduction of its ability to sell these securities (which remedy shall not be exclusive of any other remedies available at law or in equity), the Parent shall pay to each such holder an amount in cash equal to two percent (2.0%) of the aggregate Purchase Price of such holder’s Notes and Parent Conversion Shares and Parent Warrant Shares on the day of a Public Information Failure and on every thirtieth day (pro-rated for periods totaling less than thirty days) thereafter until the earlier of (i) the date such Public Information Failure is cured and (ii) such time that such Public Information Failure no longer prevents a holder of Notes, the Parent Warrant, the Parent Warrant Shares and/or Parent Conversion Shares from selling such securities pursuant to Rule 144 without any restrictions or limitations. The payments to which a holder shall be entitled pursuant to this Section 4(y) are referred to herein as “ Public Information Failure Payments .” Public Information Failure Payments shall be paid in cash, by wire transfer to the Buyer on the earlier of (I) the last day of the calendar month during which such Public Information Failure Payments are incurred and (II) the third Business Day after the event or failure giving rise to the Public Information Failure Payments is cured. In the event the Parent fails to make Public Information Failure Payments in a timely manner, such Public Information Failure Payments shall bear interest at the rate of 1.5% per month (prorated for partial months) until paid in full.

 

  41  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

(z)        Books and Records . The Parent and ICA-T will keep proper books of record and account, in which full and correct entries shall be made of all financial transactions and the asset and business of the Parent, ICA-T and the Subsidiaries in accordance with GAAP.

 

(aa)    Closing Documents . On or prior to ten (10) calendar days after the Closing Date, the Parent and ICA-T each agree to deliver, or cause to be delivered, to the Buyer and Gusrae Kaplan Nusbaum PLLC a complete closing set of the executed Transaction Documents, Securities, Parent Underlying Shares and any other document required to be delivered to any party pursuant to Section 7 hereof or otherwise.

 

(bb)   Information Related to Sanofi . Notwithstanding anything to the contrary provided herein or elsewhere including, but not limited to, any of the other Transaction Documents, and in addition to all other requirements of the Parent, ICA-T and each Subsidiary to provide to the Buyer and the Buyer’s rights to obtain from the Parent, ICA-T and each Subsidiary, whether provided in this Agreement and/or any other Transaction Document, the Parent and ICA-T shall immediately but no later than two (2) business days or three (3) calendar days following (i) ICA-T and/or the Parent becoming aware of and/or receipt by any such party from Sanofi, the Trustee (as defined in the S/I Deed of Trust) and/or any of their respective affiliates, officers, directors, agents and/or representatives of notice (whether oral, in writing or otherwise) of any event of default (or any event that with the passage of time or the giving of notice (or both) would constitute an event of default), a default and/or a breach by the ICA-T and/or the Parent under any of the Sanofi Documents (including, but not limited to, any sale and/or notice of any intended sale of the Property/Facilities and/or any foreclosure or notice of foreclosure relating to the Property/Facilities including under the S/I Deed of Trust, any intended or actual termination of any Sanofi Documents and/or any claim made against ICA-T and/or the Parent including a claim for indemnification under any S/I Document (even if contemplated in any such of the following documents) to the S/I MSA, the S/I Deed of Trust and/or the S/I APA.

 

(cc)   Conversion/Exercise Procedures . The form of Conversion Notice (as defined in the Note) and Notice of Exercise (as defined in the Parent Warrant) set forth the totality of the procedures required of the Buyer in order to convert the Notes and/or exercise the Parent Warrant. Except as provided in Section 5(c) , no additional legal opinion, other information or instructions shall be required of the Buyer to convert their Notes or exercise their Parent Warrant. The Parent shall honor conversions of the Notes and exercises of the Parent Warrant and shall deliver the Parent Underlying Shares in accordance with the terms, conditions and time periods set forth in the Notes and the Parent Warrant.

 

  42  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

(dd)    [INTENTIONALLY LEFT BLANK]

 

(ee)    No Foreign Subsidiaries . None of the Parent, ICA-T and/or any Subsidiary shall directly and/or indirectly make any direct and/or indirect payment in any form and/or manner (including, but not limited to, dividends and/or distributions and/or otherwise to or for the benefit of any Foreign Subsidiary without the express prior written consent of the Buyer so long as any Securities remain outstanding.

 

(ff)     Information Rights . For so long any of the Notes remain outstanding, but prior to the closing date of the earliest to occur of a (i) Qualified PO, (ii) the sale of all of substantially all of the assets of the Parent, ICA-T and the Subsidiaries, and (iii) the sale of all of the issued and outstanding securities of the Parent, ICA-T and the Subsidiaries, and regardless of whether or not the Parent is required to file any forms, reports or documents with the SEC, the Parent and ICA-T shall deliver to the Buyer, the following financial statements and/or information of the Parent, ICA-T and the Subsidiaries and the Buyer hereby consents to the delivery of the information set forth below in accordance with the terms hereof despite the fact that such information may constitute Confidential Information, provided that the Parent, the Company and/or each Subsidiary who is providing any such information to the Buyer, shall inform the Buyer in writing at least three (3) Business Days prior to the date any such information is actually delivered to the Buyer (“ Information Delivery Date ”), and the Buyer shall have the right until 11:59pm on the date 2 Business Days from the date the Buyer received written notice that such information was being delivered to it, to inform the Parent that the Buyer does not want to receive such information and as a result thereof, such information shall not be delivered to the Buyer:

 

(I)       Within twenty one (21) calendar days after the end of each calendar month (with May 2017 being the first month) (A) unaudited interim and year-to-date financial statements as of the end of such month (prepared on a consolidated and consolidating basis, if applicable), including balance sheet and related statements of income and cash flows, (B) monthly accounts receivable and accounts payable statements as of the last day of each month, and which items set forth in (A)–(B) shall be accompanied by a report detailing any material contingencies (including the commencement of any material litigation by or against the Parent, ICA-T and the Subsidiaries) or any other occurrence that would reasonably be expected to have a Material Adverse Effect on the Parent, ICA-T and the Subsidiaries, all certified in writing by the Parent’s and ICA-T’s Chief Executive Officer and Chief Financial Officer stating that they have been prepared in accordance with GAAP, except (i) for the absence of footnotes, and (ii) that they are subject to normal year-end adjustments;

 

(II)       Within forty five (45) calendar days (or 50 calendar days if the Parent files a Notification of Late filing on Form 12b-25 with the SEC (a “ 12b-25 ”) for such period) after the end of each calendar quarter (A) unaudited interim and year-to-date financial statements as of the end of such calendar quarter (prepared on a consolidated and consolidating basis, if applicable), including balance sheet and related statements of income and cash flows, and (B) monthly accounts receivable and accounts payable statements as of the last day of each month accompanied by a report detailing any material contingencies (including the commencement of any material litigation by or against the Parent, ICA-T and the Subsidiaries) or any other occurrence that would reasonably be expected to have a Material Adverse Effect on the Parent, ICA-T and the Subsidiaries, certified by the Parent’s and ICA-T’s Chief Executive Officer and Chief Financial Officer to the effect that they have been prepared in accordance with GAAP, except (i) for the absence of footnotes, and (ii) that they are subject to normal year-end adjustments. The Parent and ICA-T shall provide both such information, the most recent capitalization table for the Parent, ICA-T and the Subsidiary, including the exercise price of all employee stock options and other securities issued during such period, as certified by the CEO and CFO of the Parent and ICA-T;

 

  43  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

(III)       within ninety (90) calendar days (or one hundred twenty (120) calendar days if the Parent files a 12b-25 for such period)) after the end of each fiscal year audited financial statements as of the end of such year (prepared on a consolidated and consolidating basis, if applicable), including balance sheet and related statements of income and cash flows, and setting forth in comparative form the corresponding figures for the preceding fiscal year, certified by a firm of independent certified public accountants selected by the Parent and reasonably acceptable to the Collateral Agent, accompanied by any management report from such accountants, and (B) monthly accounts receivable and accounts payable statements as of the last day of each month of the Parent, ICA-T and the Subsidiaries. The Parent also shall provide to the Buyer with such information the most recent capitalization table for the Parent, ICA-T and each of their respective Subsidiaries, including the exercise price of all employee stock options and other securities issued during such period, as certified by the CEO and CFO of the Parent and ICA-T;

 

(IV)       Additionally, no later than the twenty first (21 st ) Business Day from the last calendar day of each calendar month, the Parent and ICA-T shall deliver to the Buyer (simultaneously with the information required in Section 4(ff)(I) ) monthly account payable and account receivable statements.

 

(V)       All monthly, quarterly and annual information required to be provided by the Parent and ICA-T to the Buyer shall be in writing and in form and substance reasonably satisfactory to the Buyer. All such information shall be certified in a writing signed by the Parent’s and ICA-T’s Chief Executive Officer and Chief Financial Officer as being true and correct.

 

(VI)       In addition to the above, upon request from the Buyer, the Parent and ICA-T shall provide the Buyer, no later than the third (3 rd ) Business Day of any request, a status update on matters relating to the business and operations of the Parent, ICA-T and the Subsidiaries, including, but not limited to, manufacturing and capital expenditures, shipment of products, sales pipeline, decisions of the board of directors of the Parent, ICA-T and the Subsidiaries and regulatory and licensing issues, and such information and such other information including, but not limited to, status updates, clarifications of previously provided information including supporting documentation and written explanations.

 

(VII)       The Parent and ICA-T may satisfy its obligations under clauses “II” and “III” of this Section 4(ff)(II) and (III) (as applicable) by delivery (i) for each calendar quarter, a quarterly report on Form 10-Q for such quarter, if timely filed with the SEC in accordance with SEC rules and regulations, and (ii) for each calendar year, an Annual Report on Form 10-K for such year, if timely filed with the SEC in accordance with SEC rules and regulations.

 

(gg)    Reservation of Shares . So long as any of the Notes and/or the Parent Warrant remain outstanding, the Parent and ICA-T shall take all action necessary to at all times have authorized, and reserved for the purpose of issuance, no less than the sum of (x) the sum of (A) ICA-T’s Required Reserve Amount (as defined in and related to ICA-T Note), and (B) the Parent’s Required Reserve Amount (as defined in and related to the Parent Note), plus (y) the Required Reserved Amount (as defined in and relating to the Parent Warrant) (collectively, the “ SPA Required Reserve Amount ”); provided that at no time shall the number of shares of Parent Common Stock reserved pursuant to this Section 4(gg) be reduced. If at any time the number of shares of Parent Common Stock authorized and reserved for issuance is not sufficient to meet the SPA Required Reserve Amount (an “ Authorized Share Failure ”), the Parent shall immediately take all action necessary to increase the Parent authorized shares of Parent Common Stock to an amount sufficient to allow the Parent to reserve the SPA Required Reserve Amount. Without limiting the generality of the foregoing sentence, as soon as practicable after the date of the occurrence of an Authorized Share Failure, but in no event later than ninety (90) days after the occurrence of such Authorized Share Failure, the Parent shall either (i) hold a meeting of its stockholders for the approval of an increase in the number of authorized shares of Parent Common Stock or (ii) have rectified such Authorized Share Failure by increasing the required SPA Reserve Amount by obtaining approval by written request of the required percentage of issued and outstanding shares of Parent Common Stock and having taken all other such actions to effectuate the same. In connection with a meeting described in “(i)” above, the Parent shall provide each stockholder with a proxy statement and shall use its best efforts to solicit its stockholders’ approval of such increase in authorized shares of Parent Common Stock and to cause its board of directors to recommend to the stockholders that they approve such proposal. Nothing contained in this Section 4(gg) shall limit any obligations of the Parent and/or ICA-T under any provision of the Transaction Documents.

 

  44  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

5. REGISTER; LEGEND.

 

(a)        Register . (i) The Parent (and ICA-T as to the ICA-T Note) shall maintain at its principal executive offices (or such other office or agency of the Parent (or ICA-T with regard to holders of any ICA-T Notes) as it may designate by notice to each holder of Securities), a register for the Notes, the Parent Warrant and the Parent Underlying Shares in which the Parent shall record the name and address of the Person in whose name the Notes, the Parent Warrant and the Parent Underlying Shares have been issued; provided that such information is provided to the Parent by the Buyer (including the name and address of each transferee) and the principal amount of the Notes held by such Person and number of shares issuable upon exercise of the Parent Warrant. The Parent shall keep the register open and available at all times during business hours for inspection of the Buyer or its legal representatives.

 

(b)        Legends . The Buyer understands that the Securities have been and will be issued pursuant to an exemption from registration or qualification under the 1933 Act and applicable state securities laws, and except as set forth below, the Securities shall bear any legend as required by the “blue sky” laws of any state and a restrictive legend in substantially the following form (and a stop-transfer order may be placed against transfer of such stock certificates):

 

[NEITHER THIS NOTE NOR THE SECURITIES ISSUABLE UPON CONVERSION OF THIS NOTE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS.][THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN] REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL TO THE HOLDER OR THE PARENT IN A FORM REASONABLY ACCEPTABLE TO THE PARENT, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.

 

[NEITHER THIS WARRANT NOR THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE ACCEPTABLE TO THE PARENT. THESE SECURITIES AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT SECURED BY SUCH SECURITIES.]

 

  45  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

(c)        Transfer Agent Instructions. The Parent and ICA-T shall issue irrevocable instructions to the Transfer Agent and any subsequent transfer agent (as applicable, the “ Transfer Agent ”) in the form annexed hereto as Exhibit J (the “ Irrevocable Transfer Agent Instructions ”) to issue certificates or credit shares to the applicable balance accounts at The Depository Trust Company (“ DTC ”), registered in the name of the Buyer or its respective nominee(s), for the shares of Parent Common Stock issuable upon conversions of the Notes and exercise of the Parent Warrant in such amounts as specified from time to time by the Buyer to the Parent and ICA-T upon conversions of the Notes and/or exercises of the Parent Warrant. The Parent and ICA-T each represent and warrant that no instruction other than the Irrevocable Transfer Agent Instructions referred to in this Section 5(c) , and stop transfer instructions to give effect to Section 2(g) hereof, will be given by the Parent and ICA-T to the Transfer Agent with respect to the Securities, and that the Securities (as the case may be) and ending on the date of receipt by the Buyer of such shares without restrictive legend and the required payment. Such shares shall be freely transferable on the books and records of the Parent and ICA-T, as applicable, to the extent provided in this Agreement and the other Transaction Documents. If the Buyer effects a sale, assignment or transfer of the Securities in accordance with Section 2(g) , the Parent and ICA-T shall permit the transfer and shall promptly instruct the Transfer Agent to issue one or more certificates or credit shares to the applicable balance accounts at DTC in such name and in such denominations as specified by the Buyer to effect such sale, transfer or assignment. In the event that such sale, assignment or transfer involves shares of Parent Common Stock issuable upon conversions of the Notes or exercise of the Parent Warrant sold, assigned or transferred pursuant to an effective registration statement or in compliance with Rule 144, the Transfer Agent shall issue such shares of Parent Common Stock to the Buyer, assignee or transferee (as the case may be) without any restrictive legend in accordance with Section 5(d) below. The Parent and ICA-T each acknowledge that a breach by it of its obligations hereunder will cause irreparable harm to the Buyer and/or any of its assignees and/or transferees. Accordingly, the Parent and ICA-T acknowledge that the remedy at law for a breach of its obligations under this Section 5(c) will be inadequate and agrees, in the event of a breach or threatened breach by the Parent and ICA-T of the provisions of this Section 5(c) , the Buyer and/or any of its assignees and/or transferees shall be entitled, in addition to all other available remedies, to an order and/or injunction restraining any breach and requiring immediate issuance and transfer, without the necessity of showing economic loss and without any bond or other security being required. The Parent shall cause its legal counsel to issue the legal opinion referred to in the Irrevocable Transfer Agent Instructions to the Parent’s Transfer Agent on each Effective Date. Any fees (with respect to the Transfer Agent, DTC, counsel to the Parent or otherwise) associated with the issuance of such opinion or the removal of any legends on any of the Securities shall be borne by the Parent.

 

(d)        Removal of Legends . Certificates evidencing the Securities shall not be required to contain the legend set forth in Section 5(b) above or any other legend (i) while a registration statement (including a Registration Statement) covering the resale of such Securities is effective under the 1933 Act, (ii) following any sale of such Securities (as the case may be), pursuant to Rule 144 (assuming the transferor is not an affiliate of the Parent or ICA-T), (iii) if such Securities (as the case may be), are eligible to be sold, assigned or transferred under Rule 144 (provided that the Buyer provides the Parent with reasonable assurances that such Securities are eligible for sale, assignment or transfer under Rule 144 which shall not include an opinion of Buyer’s counsel), (iv) in connection with a sale, assignment or other transfer (other than under Rule 144), provided that the Buyer provides the Parent with an opinion of counsel to the Buyer, in a form reasonably acceptable to the Parent, to the effect that such sale, assignment or transfer of the Securities may be made without registration under the applicable requirements of the 1933 Act, (v) if legal counsel to the Parent and/or ICA-T provides the legal opinion required pursuant to Section 4(a)(xxi) of the ICA-T Note or otherwise, or (vi) if such legend is not required under applicable requirements of the 1933 Act (including, without limitation, controlling judicial interpretations and pronouncements issued by the SEC). If a legend is not required pursuant to the foregoing, the Parent shall no later than two (2) Trading Days (as defined in the Notes) (or such earlier date as required pursuant to the 1934 Act or other applicable law, rule or regulation for the settlement of a trade initiated on the date the Buyer delivers such legended certificate representing such Securities to the Parent) following the delivery by the Buyer to the Parent or its Transfer Agent (with notice to the Parent) of a legended certificate representing such Securities (endorsed or with stock powers attached, signatures guaranteed, and otherwise in form necessary to affect the reissuance and/or transfer, if applicable), together with any other deliveries from the Buyer as may be required above in this Section 5(d) , as directed by the Buyer, either: (A) provided that the Transfer Agent is participating in the DTC Fast Automated Securities Transfer Program and such Securities are shares of Parent Common Stock credit the aggregate number of shares of Parent Common Stock to which the Buyer shall be entitled to the Buyer’s or its designee’s balance account with DTC through its Deposit/Withdrawal at Custodian system or (B) if the Transfer Agent is not participating in the DTC Fast Automated Securities Transfer Program, issue and deliver (via reputable overnight courier) to the Buyer, a certificate representing such Securities that is free from all restrictive and other legends, registered in the name of the Buyer or its designee (the date by which such credit is so required to be made to the balance account of such Buyer’s or such Buyer’s designee with DTC or such certificate is required to be delivered to such Buyer pursuant to the foregoing is referred to herein as the “ Required Delivery Date ”, and the date such shares of Parent Common Stock are actually delivered without restrictive legend to such Buyer or such Buyer’s designee with DTC, as applicable, the “ Share Delivery Date ”). The Parent shall be responsible for any transfer agent fees or DTC fees with respect to any issuance of Securities or the removal of any legends with respect to any Securities in accordance herewith.

 

  46  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

(e)        Failure to timely Deliver; Buy-In . If the Parent fails for any reason or no reason, to issue and deliver (or cause to be delivered) to the Buyer (or its designee) by the Required Delivery Date, either (i) if the Transfer Agent is not participating in the DTC Fast Automated Securities Transfer Program, a certificate for the number of shares of Parent Common Stock to which the Buyer is entitled without any restrictive and/or other legend and register such shares of Parent Common Stock on the Parent 's share register, or (ii) if the Transfer Agent is participating in the DTC Fast Automated Securities Transfer Program, credit the balance account of the Buyer or the Buyer’s designee with DTC for the number of shares of Parent Common Stock to which the Buyer submitted for legend removal by the Buyer pursuant to Section 5(d) above and if on or after such Trading Day the Buyer purchases (in an open market transaction or otherwise) shares of Parent Common Stock corresponding to all or any portion of Parent Conversion Shares or Parent Warrant Shares (as the case may be) submitted for legend removal by the Buyer pursuant to Section 5(d) above that the Buyer is entitled to receive from the Parent (a “ Buy-In ”), then the Parent shall, within two (2) Trading Days after the Buyer’s request and in the Buyer’s discretion, either (i) pay cash to the Buyer in an amount equal to the Buyer’s total purchase price (including brokerage commissions and other out-of-pocket expenses, if any, for the shares of Parent Common Stock so purchased) (the “ Buy-In Price ”), at which point the Parent’s obligation to so deliver such certificate or credit the Buyer’s (or its designee’s account) balance account with the DTC through its Deposit Withdrawal at Custodian System, shall terminate and such shares shall be cancelled, or (ii) promptly honor its obligation to so deliver to the Buyer a certificate or certificates or credit the balance account of the Buyer or the Buyer’s designee with the DTC through its Deposit Withdrawal at Custodian System representing such number of Parent Conversion Shares or Parent Warrant Shares (as the case may be) that would have been so delivered if the Parent timely complied with its obligations hereunder and pay cash to the Buyer in an amount equal to the excess (if any) of the Buy-In Price over the product of (A) such number of shares of Parent Conversion Shares or Parent Warrant Shares (as the case may be) that the Parent was required to deliver to the Buyer by the Required Delivery Date multiplied by (B) the lowest Closing Sale Price or Closing Bid Price (as the case may be and as defined in the Note) of the Parent Common Stock on any Trading Day during the period commencing on the date of the applicable Conversion Notice or Exercise Notice (as the case may be) and ending on the date of such delivery and payment under this clause (ii). Nothing shall limit the Buyer’s right to pursue any other remedies available to it hereunder, at law or in equity, including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Parent’s failure to timely deliver certificates representing shares of Parent Common Stock (or to electronically deliver such shares of Parent Common Stock) as required pursuant to the terms hereof.

 

(f)        Transfer Agent and FAST Compliance . While any Notes or Parent Warrants are outstanding, the Parent shall maintain a Transfer Agent that participates in the DTC Fast Automated Securities Transfer Program.

 

6. CONDITIONS TO THE PARENT’S AND ICA-T’S OBLIGATION TO SELL.

 

(a)       The obligation of (i) the Parent to issue and sell the Parent Note and the Parent Warrant, and (ii) ICA-T to issue and sell the ICA-T Note to the Buyer at the Closing is subject to the satisfaction, at or before the Closing Date, of each of the following conditions, provided that these conditions are for the Parent’s and ICA-T’s sole benefit and may be waived by the Parent or ICA-T at any time in its sole discretion by providing the Buyer with prior written notice thereof:

 

(A)       The Buyer shall have executed each of the Transaction Documents to which it is a party and delivered the same to the Parent or ICA-T (as the case may be).

 

(B)       The Buyer shall have executed and delivered to the Parent Lock Up Agreement in form and substance reasonably satisfactory to the Buyer (the “ Lock-Up Agreement ”)

 

(C)       The Buyer shall have delivered to (I) the Parent, the Parent Purchase Price and (II) ICA-T, the ICA-T Purchase Price (less the amounts withheld pursuant to Section 4(h) hereof) for the Parent Note and the Parent Warrant; and the ICA-T Note, respectively, being purchased by the Buyer at the Closing by wire transfer of immediately available funds in accordance with the Flow of Funds Letter.

 

  47  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

(D)       The representations and warranties of the Buyer shall be true and correct in all material respects as of the date when made and as of the Closing Date as though originally made at that time (except for representations and warranties that speak as of a specific date, which shall be true and correct as of such specific date), and the Buyer shall have performed, satisfied and complied in all material respects with the covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Buyer at or prior to the Closing Date.

 

7. CONDITIONS TO THE BUYER’S OBLIGATION TO PURCHASE.

 

(a)       The obligation of the Buyer hereunder to purchase the Notes and the Parent Warrant at the Closing is subject to the satisfaction, at or before the Closing Date, of each of the following conditions, provided that these conditions are for the Buyer’s sole benefit and may be waived by the Buyer at any time in its sole discretion by providing the Parent and ICA-T with prior written notice thereof:

 

(i)       (A) The Parent, ICA-T and each Subsidiary shall have duly executed and delivered to the Buyer each of the Transaction Documents to which it is a party, and (B (I) the Parent, with regard to the Parent Note and the Parent Warrant initially to purchase 857,143 shares of Parent Common Stock, and (II) ICA-T, with regard to the ICA-T Note, shall have duly executed and delivered to the Buyer such instruments, respectively.

 

(ii)       The Buyer shall have received the legal opinion of Gracin & Marlow, LLP, the Parent’s and ICA-T’s corporate securities counsel, dated the Closing Date, in the form acceptable to the Buyer.

 

(iii)       The Buyer shall have received the legal opinion of Morgan, Lewis and Bockius LLP, the Parent’s, ICA-T’s and the Subsidiaries’ intellectual property counsel, dated the Closing Date in form and substance acceptable to the Buyer.

 

(iv)       The Parent and ICA-T shall have delivered to the Buyer a certificate evidencing the formation and good standing of the Parent, ICA-T and each Subsidiary in each such entity’s jurisdiction of formation issued by the Secretary of State (or comparable office) of such jurisdiction of formation as of a date within five (5) days of the Closing Date.

 

(v)       The Parent and ICA-T shall have delivered to the Buyer a certificate evidencing the Parent, ICA-T’s and each Subsidiary’s qualification as a foreign corporation and good standing issued by the Secretary of State (or comparable office) of each jurisdiction in which the Parent, ICA-T and each Subsidiary conducts business and is required to so qualify, as of a date within five (5) days of the Closing Date.

 

  48  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

(vi)       The Parent and ICA-T shall have delivered to the Buyer a certified copy of their respective certificate of incorporation as certified by the Delaware Secretary of State within five (5) days of the Closing Date.

 

(vii)       The Parent and ICA-T shall have delivered to the Buyer a certified copy of the certificate of incorporation (or such equivalent organizational document) of each Subsidiary as certified by the Secretary of State (or comparable office) of each such Subsidiary’s jurisdiction of incorporation within five (5) days of the Closing Date.

 

(viii)       The Parent, ICA-T and each Subsidiary shall have delivered to the Buyer a certificate, in the form acceptable to the Buyer, executed by the secretary of the Parent, ICA-T and each Subsidiary dated as of the Closing Date, as to (i) the resolutions consistent with Section 3(b) as adopted by the Parent’s, ICA-T’s and each Subsidiary’s board of directors in a form acceptable to the Buyer, (ii) Certificate of Incorporation of each of the Parent, ICA-T and each Subsidiary, and (iii) the Bylaws of the Parent, ICA-T and each Subsidiary, each as in effect at the Closing.

 

(ix)       Each and every representation and warranty of the Parent and ICA-T made herein and of the Parent, ICA-T and each Subsidiary in each other Transaction Document shall be true and correct as of the date when made and as of the Closing Date as though originally made at that time (except for representations and warranties that speak as of a specific date, which shall be true and correct as of such specific date) and the Parent, ICA-T and each Subsidiary shall have performed, satisfied and complied in all material respects with the covenants, agreements and conditions required to be performed, satisfied or complied with by the Parent, ICA-T and each Subsidiary at or prior to the Closing Date. The Buyer shall have received a certificate, duly executed by the Chief Executive Officer of the Parent, ICA-T and each Subsidiary, dated as of the Closing Date, to the foregoing effect and as to such other matters as may be reasonably requested by the Buyer in the form acceptable to the Buyer.

 

(x)       The Parent and ICA-T shall have obtained all governmental, regulatory and third party consents and approvals, if any, necessary for the sale of the Securities.

 

(xi)       No statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed by any court or Governmental Entity of competent jurisdiction that prohibits the consummation of any of the transactions contemplated by the Transaction Documents.

 

(xii)       No event or series of events shall have occurred that reasonably could or result in a Material Adverse Effect.

 

  49  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

(xiii)       In accordance with the terms of the Security Documents, the Parent and ICA-T shall have delivered to the Collateral Agent (A) original certificates (I) representing 100% of outstanding capital stock of each Subsidiary (other than ICA-T) to the extent such Subsidiary is a corporation or otherwise has certificated equity and (II) representing all other equity interests to be pledged thereunder, in each case, accompanied by undated stock powers executed in blank and other proper instruments of transfer and (B) appropriate financing statements on Form UCC-1 and such other financing or similar statement to be filed with the United States Patent and Trademark Office and/or any other governmental body or agency to be duly filed in such office or offices as may be necessary or, in the opinion of the Collateral Agent, desirable to perfect the security interests purported to be created by each Security Document (the “ Perfection Certificate ”).

 

(xiv)       Within two (2) Business Days prior to the Closing, the Parent and ICA-T shall have delivered or caused to be delivered to the Buyer and the Collateral Agent a perfection certificate, duly completed and executed by the Parent, ICA-T and each Subsidiary, in form and substance satisfactory to the Buyer.

 

(xv)       The Collateral Agent shall have received the Security Agreements and the other Security Documents, duly executed by the Parent, ICA-T and each Subsidiary (as applicable).

 

(xvi)       With respect to the Intellectual Property of the Parent, ICA-T and each Subsidiary, the Parent, ICA-T and each Subsidiary shall have duly executed and delivered to the Collateral Agent and the Buyer the Intellectual Property Security Agreements and Assignment for Security for the Intellectual Property of the Parent, ICA-T and each Subsidiary, in the form attached as Exhibit A to the Security Agreements.

 

(xvii)       Each Control Account Bank (as defined in the Security Agreement), the Collateral Agent and each of the Parent, ICA-T and the Subsidiaries (as applicable) shall have duly executed and delivered to the Buyer a Controlled Account Agreement (as defined in the Security Agreement) with respect to each account of the Parent, ICA-T and each of the Subsidiaries held at each Control Account Bank; provided , however , that notwithstanding anything to the contrary provided herein or elsewhere, the Closing conditions set forth in this “(xvii)” shall if not satisfied at Closing, become a “post-Closing condition” and shall be satisfied if all duly executed Collateral Account Agreements are delivered to the Collateral Agent with fourteen (14) calendar days from the Closing Date.

 

(xviii)       The Buyer shall have received a letter on the letterhead of the Parent and ICA-T, duly executed by the Chief Executive Officer of the Parent and ICA-T, setting forth the wire amounts of the Buyer and the wire transfer instructions of the Parent and ICA-T (the “ Flow of Funds Letter ”).

 

(xix)       The Parent shall have delivered to the Buyer fully executed Pay-Off Letters from each holder of the Parent Bridge Notes demonstrating that the $1,500,000 aggregate principal amount of and all accrued but unpaid interest thereon has been paid in full and such other executed documents reasonably requested by the Buyer demonstrating that all Liens and security interests in any assets of the Parent, ICA-T and/or any Subsidiary securing such Parent Bridge Notes have been terminated including, but not limited to, the filing of any Lien termination and/or release documents with any Governmental Entity including a UCC-3 Termination Statement (whether such is required to be signed or not).

 

  50  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

(xx)       The Parent and ICA-T shall have delivered to the Buyer a copy of the Irrevocable Transfer Agent Instructions, in the form and substance reasonably acceptable to the Buyer, fully executed by the Parent, ICA-T and the Buyer which instructions shall have been delivered to and acknowledged by execution thereof by the Transfer Agent.

 

(xxi)        The Parent and ICA-T shall have duly executed and delivered to the Buyer the Leak-Out Agreement.

 

(xxii)       The Buyer shall have received the fully executed Buyer Deed of Trust with proof of filing with the appropriate Governmental Entity and such other documents necessary and/or reasonably requested by the Buyer to satisfy itself it has a senior secured interest in and a perfected Lien on the Property/Facilities securing all Indebtedness and other obligations of ICA-T to the Buyer.

 

(xxiii)       The Parent shall have delivered to the Buyer a stockholder list dated within 2 days of the Closing Date from and certified by the Transfer Agent showing (I) the number of shares of Parent Common Stock issued and outstanding, (II) the number of shares of Parent Common Stock that (x) contain 1933 Act restrictive legends, (y) that are unlegended, and (II) the number of shares that are held by “Cede & Co.”

 

(xxiv)       [INTENTIONALLY LEFT BLANK.]

 

(xxv)       The Buyer shall have received legal opinion of Ballard Spahr LLP, real property legal counsel to the Parent and ICA-T as to matters relating to, among other related matters, the Property/Facilities, the Deed of Trust, the Buyer Deed of Trust, the security interests created in the Collateral and the Liens evidencing a security interest in such Collateral and the perfection thereof including, but not limited to, the Property/Facilities, dated the Closing Date in form and substance acceptable to the Buyer.

 

(xxvi)       The Parent, ICA-T and the Subsidiaries shall have delivered to the Buyer such other documents, instruments, opinions or certificates relating to the transactions contemplated by this Agreement as the Buyer or its counsel may reasonably request.

 

(xxvii)       The Parent and ICA-T shall have delivered to the Buyer a fully executed Pay-off Letter in the form attached hereto as Exhibit K .

 

  51  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

(xxviii)        The Parent and ICA-T shall execute and deliver to the Collateral Agent separate Confession of Judgments in the form attached hereto as Exhibit M (the “ Confession of Judgments ”), with such other documents, affidavits and related items as are deemed necessary and/or advisable by counsel to the Buyer.

 

(xxix)       The Parent and each Subsidiary (other than ICA-T) shall have delivered to the Collateral Agent the fully executed Guaranty Agreements.

 

8. MISCELLANEOUS.

 

(a)        Governing Law; Jurisdiction; Jury Trial . All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by the internal laws of the State of New York, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of New York or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of New York. The Parent and ICA-T hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in The City of New York, Borough of Manhattan, for the adjudication of any dispute hereunder or in connection herewith or under any of the other Transaction Documents or with any transaction contemplated hereby or thereby, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof to such party at the address for such notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. Nothing contained herein shall be deemed or operate to preclude the Buyer from bringing suit or taking other legal action against the Parent and ICA-T in any other jurisdiction to collect on the Parent’s and ICA-T’s obligations to the Buyer or to enforce a judgment or other court ruling in favor of the Buyer. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR UNDER ANY OTHER TRANSACTION DOCUMENT OR IN CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT, ANY OTHER TRANSACTION DOCUMENT OR ANY TRANSACTION CONTEMPLATED HEREBY OR THEREBY.

 

(b)        Counterparts . This Agreement may be executed in two or more identical counterparts, all of which shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party. In the event that any signature is delivered by facsimile transmission or by an e-mail which contains a portable document format (.pdf) file of an executed signature page, such signature page shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such signature page were an original thereof.

 

  52  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

(c)        Headings; Gender . The headings of this Agreement are for convenience of reference and shall not form part of, or affect the interpretation of, this Agreement. Unless the context clearly indicates otherwise, each pronoun herein shall be deemed to include the masculine, feminine, neuter, singular and plural forms thereof. The terms “including,” “includes,” “include” and words of like import shall be construed broadly as if followed by the words “without limitation.” The terms “herein,” “hereunder,” “hereof” and words of like import refer to this entire Agreement instead of just the provision in which they are found.

 

(d)        Severability; Maximum Payment Amounts . If any provision of this Agreement is prohibited by law or otherwise determined to be invalid or unenforceable by a court of competent jurisdiction, the provision that would otherwise be prohibited, invalid or unenforceable shall be deemed amended to apply to the broadest extent that it would be valid and enforceable, and the invalidity or unenforceability of such provision shall not affect the validity of the remaining provisions of this Agreement so long as this Agreement as so modified continues to express, without material change, the original intentions of the parties as to the subject matter hereof and the prohibited nature, invalidity or unenforceability of the provision(s) in question does not substantially impair the respective expectations or reciprocal obligations of the parties or the practical realization of the benefits that would otherwise be conferred upon the parties. The parties will endeavor in good faith negotiations to replace the prohibited, invalid or unenforceable provision(s) with a valid provision(s), the effect of which comes as close as possible to that of the prohibited, invalid or unenforceable provision(s). Notwithstanding anything to the contrary contained in this Agreement or any other Transaction Document (and without implication that the following is required or applicable), it is the intention of the parties that in no event shall amounts and value paid by the Parent, ICA-T and/or any of the Subsidiaries (as the case may be), or payable to or received by the Buyer, under the Transaction Documents (including without limitation, any amounts that would be characterized as “interest” under applicable law) exceed amounts permitted under any applicable law. Accordingly, if any obligation to pay, payment made to the Buyer, or collection by the Buyer pursuant the Transaction Documents is finally judicially determined to be contrary to any such applicable law, such obligation to pay, payment or collection shall be deemed to have been made by mutual mistake of the Buyer, the Parent, ICA-T and/or any of the Subsidiaries and such amount shall be deemed to have been adjusted with retroactive effect to the maximum amount or rate of interest, as the case may be, as would not be so prohibited by the applicable law. Such adjustment shall be effected, to the extent necessary, by reducing or refunding, at the option of the Buyer, the amount of interest or any other amounts which would constitute unlawful amounts required to be paid or actually paid to the Buyer under the Transaction Documents. For greater certainty, to the extent that any interest, charges, fees, expenses or other amounts required to be paid to or received by the Buyer under any of the Transaction Documents or related thereto are held to be within the meaning of “interest” or another applicable term to otherwise be violative of applicable law, such amounts shall be pro-rated over the period of time to which they relate.

 

  53  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

(e)        Entire Agreement; Amendments . This Agreement, the other Transaction Documents and the schedules and exhibits attached hereto and thereto and the instruments referenced herein and therein supersede all other prior oral or written agreements between the Buyer, the Parent, ICA-T and/or any of the Subsidiaries, their respective affiliates and Persons acting on their behalf, including, without limitation, any transactions by the Buyer with respect to Parent Common Stock or the Securities, and the other matters contained herein and therein. For clarification purposes, the Recitals are part of this Agreement. No provision of this Agreement may be amended other than by an instrument in writing signed by the Parent and ICA-T and the Buyer, and any amendment to any provision of this Agreement made in conformity with the provisions of this Section 9(e) shall be binding on the Buyer and holders of Securities, as applicable. No waiver shall be effective unless it is in writing and signed by an authorized representative of the waiving party. As a material inducement for the Buyer to enter into this Agreement, the Parent and ICA-T expressly acknowledges and agrees that (x) no due diligence or other investigation or inquiry conducted by the Buyer, any of its advisors or any of its representatives shall affect the Buyer’s right to rely on, or shall modify or qualify in any manner or be an exception to any of, the Parent and ICA-T’s representations and warranties contained in this Agreement or any other Transaction Document and (y) unless a provision of this Agreement or any other Transaction Document is expressly preceded by the phrase “except as disclosed in the SEC Documents,” (or a substantially similar term) nothing contained in any of the SEC Documents shall affect the Buyer’s right to rely on, or shall modify or qualify in any manner or be an exception to any of, the Parent and ICA-T’s representations and warranties contained in this Agreement or any other Transaction Document.

 

(f)        Notices . Any notices, consents, waivers or other communications required or permitted to be given under the terms of this Agreement must be in writing and will be deemed to have been delivered: (i) upon receipt, when delivered personally; (ii) upon receipt, when sent by facsimile (provided confirmation of transmission is mechanically or electronically generated and kept on file by the sending party) or electronic mail; or (iii) one (1) Business Day after deposit with an overnight courier service with next day delivery specified, in each case, properly addressed to the party to receive the same. The addresses, facsimile numbers and e-mail addresses for such communications shall be:

 

If to the Parent:

 

Icagen, Inc.

4222 Emperor Blvd., Suite 350

Research Triangle Park

Durham, NC 27703

Telephone: (919) 941-5206

Facsimile: (919) 941-0813

Attention: Richard Cunningham, Chief Executive Officer

Email: rcunningham@icagen.com

 

with a copy (for informational purpose only) to:

 

Gracin & Marlow, LLP

The Chrysler Building

405 Lexington Avenue, 26 th Floor

New York, NY 10174

Telephone: (212) 907-6457

Facsimile: (212) 208-4657

Attention: Leslie Marlow, Esq.

Email: lmarlow@gracinmarlow.com

 

If to ICA-T:

 

Icagen-T, Inc.

2090 E. Innovation Park Drive

Oro Valley, Arizona 85755

Telephone: (520) 544-6800

Facsimile: (520) 544-6805

Attention: Richie Cunningham

Email: rcunningham@icagen.com

 

  54  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

with a copy (for informational purpose only) to:

 

Gracin & Marlow, LLP

The Chrysler Building

405 Lexington Avenue, 26 th Floor

New York, NY 10174

Telephone: (212) 907-6457

Facsimile: (212) 208-4657

Attention: Leslie Marlow, Esq.

Email: lmarlow@gracinmarlow.com

 

If to the Buyer:

 

GPB Debt Holdings II, LLC

535 West 24 th Street, 4 th Floor

New York, NY 10011

Telephone: (212) 558-9199

Facsimile: (212) 235-2651

Attention: Tim Creutz

Email: tcreutz@gpb-cap.com

 

with a copy (for informational purpose only) to:

 

Gusrae Kaplan Nusbaum PLLC

120 Wall Street

New York, NY 10005

Telephone (212) 269-1400

Facsimile: (212) 809-4147

Attention: Lawrence G. Nusbaum, Esq.

Email: lnusbaum@gusraekaplan.com

 

or to such other address, e-mail address and/or facsimile number and/or to the attention of such other Person as the recipient party has specified by written notice given to each other party five (5) days prior to the effectiveness of such change. Written confirmation of receipt (A) given by the recipient of such notice, consent, waiver or other communication, (B) mechanically or electronically generated by the sender’s facsimile machine or e-mail containing the time, date, recipient facsimile number and, with respect to each facsimile transmission, an image of the first page of such transmission or (C) provided by an overnight courier service shall be rebuttable evidence of personal service, receipt by facsimile or receipt from an overnight courier service in accordance with clause (i), (ii) or (iii) above, respectively.

 

(g)        Successors and Assigns . This Agreement shall be binding upon and inure to the benefit of the parties and their respective successors and assigns, including any purchasers of any of the Notes, Parent Warrant and Parent Underlying Shares. Neither the Parent nor ICA-T shall assign this Agreement or any rights or obligations hereunder without the prior written consent of the Buyer, including, without limitation, by way of a Fundamental Transaction (as defined in the Notes and Parent Warrant) (unless the Parent and ICA-T are in compliance with the applicable provisions governing Fundamental Transactions set forth in the Notes and Parent Warrants). The Buyer may assign some or all of its rights hereunder in connection with any transfer of any of its Securities to an Affiliate of the Buyer without the consent of the Parent and ICA-T, in which event such assignee shall be deemed to be a “Buyer” hereunder with respect to such assigned rights.

 

  55  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

(h)        No Third Party Beneficiaries . This Agreement is intended for the benefit of the parties hereto and their respective permitted successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, other than the Indemnitees referred to in Section 8(k) .

 

(i)        Survival . The representations, warranties, agreements and covenants shall survive the Closing.

 

(j)        Further Assurances . Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as any other party may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.

 

(k)        Indemnification .

 

(i)       In consideration of the Buyer’s execution and delivery of the Transaction Documents and acquiring the Securities thereunder and in addition to all of the Parent and ICA-T’s other obligations under the Transaction Documents, to the full extent required by law, the Parent and ICA-T each will and hereby does, jointly and severally, defend, protect, indemnify and hold harmless the Buyer and each other holder of any Securities and all of their predecessors, successors, advisors, stockholders, partners, members, managers, officers, directors, employees and direct or indirect investors and any of the foregoing Persons’ agents or other representatives including in-house and outside legal counsels (including, without limitation, those retained in connection with the transactions contemplated by this Agreement) (collectively, the “ Indemnitees ”) from and against any and all actions, causes of action, suits, claims, losses, costs, penalties, fees, liabilities and damages, and expenses in connection therewith (irrespective of whether any such Indemnitee is a party to the action for which indemnification hereunder is sought), and including reasonable attorneys’ fees and disbursements (the “ Indemnified Liabilities ”), incurred by any Indemnitee as a result of, or arising out of, or relating to (i) any misrepresentation or breach of any representation or warranty made by the Parent, ICA-T and/or any of the Subsidiaries in any of the Transaction Documents, (ii) any breach of any material covenant, agreement or obligation of the Parent, ICA-T and/or any of the Subsidiaries contained in any of the Transaction Documents or (iii) any cause of action, suit, arbitration, proceeding or claim brought or made against such Indemnitee by a third party (including for these purposes a derivative action brought on behalf of the Parent, ICA-T and/or any of the Subsidiaries) or which otherwise involves such Indemnitee that arises out of or results from (A) the execution, delivery, performance or enforcement of any of the Transaction Documents, (B) any of the transactions contemplated by any of the Transaction Documents including, but not limited to, any transaction financed or to be financed in whole or in part, directly or indirectly, with the proceeds of the issuance of the Securities, (C) any disclosure properly made by the Buyer pursuant to Section 4(i) , or (D) the status of the Buyer or any other holder of the Securities either as an investor in the Parent and ICA-T pursuant to the transactions contemplated by the Transaction Documents or as a party to this Agreement and/or any other Transaction Document (including, without limitation, as a party in interest or otherwise in any action or proceeding for injunctive or other equitable relief). To the extent that the foregoing undertaking by the Parent and ICA-T may be unenforceable for any reason, the Parent and ICA-T shall and shall cause each Subsidiary to make the maximum contribution to the payment and satisfaction of each of the Indemnified Liabilities which is permissible under applicable law. The rights and remedies of an Indemnitee and the obligations and responsibilities of the Parent and ICA-T as set forth in this Section 8(k) are in addition and not in limitation to those set forth in Section 8(q) of this Agreement.

 

  56  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

(ii)       Promptly after receipt by an Indemnitee under this Section 8(k) of notice of the commencement of any action or proceeding (including any governmental or regulatory action or proceeding) involving an Indemnified Liability, such Indemnitee shall, if a claim in respect thereof is to be made against the Parent and ICA-T under this Section 8(k) , deliver to the Parent and ICA-T a written notice of the commencement thereof, and the Parent and ICA-T shall have the right to participate in, and, to the extent the Parent and ICA-T so desires, to assume control of the defense thereof with counsel mutually satisfactory to the Parent and ICA-T and the Indemnitee; provided , however , that an Indemnitee shall have the right to retain its own counsel with the fees and expenses of such counsel to be paid by the Parent and ICA-T if: (A) the Parent and ICA-T has agreed in writing to pay such fees and expenses; (B) the Parent and ICA-T shall have failed promptly to assume the defense of such Indemnified Liability and to employ counsel reasonably satisfactory to such Indemnitee in any such Indemnified Liability; or (C) the named parties to any such Indemnified Liability (including any impleaded parties) include both such Indemnitee and the Parent and ICA-T, and such Indemnitee shall have been advised by counsel that a conflict of interest is likely to exist if the same counsel were to represent such Indemnitee and the Parent and ICA-T (in which case, if such Indemnitee notifies the Parent and ICA-T in writing that it elects to employ separate counsel at the expense of the Parent and ICA-T, then the Parent and ICA-T shall not have the right to assume the defense thereof and such counsel shall be at the expense of the Parent and ICA-T); provided , further , that in the case of clause (C) above the Parent and ICA-T shall not be responsible for the reasonable fees and expenses of more than one (1) separate legal counsel for the Indemnitees. The Indemnitee shall reasonably cooperate with the Parent and ICA-T in connection with any negotiation or defense of any such action or Indemnified Liability by the Parent and ICA-T and shall furnish to the Parent and ICA-T all information reasonably available to the Indemnitee which relates to such action or Indemnified Liability. The Parent and ICA-T shall keep the Indemnitee reasonably apprised at all times as to the status of the defense or any settlement negotiations with respect thereto. The Parent and ICA-T shall not be liable for any settlement of any action, claim or proceeding effected without its prior written consent, provided, however, that the Parent and ICA-T shall not unreasonably withhold, delay or condition its consent. The Parent and ICA-T shall not, without the prior written consent of the Indemnitee, consent to entry of any judgment or enter into any settlement or other compromise which does not include as an unconditional term thereof the giving by the claimant or plaintiff to such Indemnitee of a release from all liability in respect to such Indemnified Liability or litigation, and such settlement shall not include any admission as to fault on the part of the Indemnitee. Following indemnification as provided for hereunder, the Parent and ICA-T shall be subrogated to all rights of the Indemnitee with respect to all third parties, firms or corporations relating to the matter for which indemnification has been made. The failure to deliver written notice to the Parent and ICA-T within a reasonable time of the commencement of any such action shall not relieve the Parent and ICA-T of any liability to the Indemnitee under this Section 8(k) , except to the extent that the Parent and ICA-T is materially and adversely prejudiced in its ability to defend such action.

 

  57  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

(iii)       All representations and warranties contained in the Transaction Documents shall survive until the Notes are repaid in full are no longer outstanding. The covenants and agreements which by their terms do not contemplate performance after the Closing Date shall survive until the Notes are paid in full are no longer outstanding. The covenants and agreements which by their terms contemplate performance after the Closing Date shall survive the Closing Date in accordance with their terms until 60 days following the expiration of any applicable statute of limitations (after giving effect to any waivers and extensions thereof). The indemnification required by this Section 8(k) shall be made by periodic wire payments of the amount thereof during the course of the investigation or defense, within ten (10) days after bills are received or Indemnified Liabilities are incurred.

 

(iv)       The indemnity agreement contained herein shall be in addition to (A) any cause of action or similar right of the Indemnitee against the Parent and ICA-T or others, B) any liabilities the Parent and ICA-T may be subject to pursuant to the law, and (C) those provided in Section 8(q)(xi) .

 

(l)        Construction . The language used in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent, and no rules of strict construction will be applied against any party. No specific representation or warranty shall limit the generality or applicability of a more general representation or warranty. Each and every reference to share prices, shares of Parent Common Stock and any other numbers in this Agreement that relate to the Parent Common Stock shall be automatically adjusted for any stock splits, stock dividends, stock combinations, recapitalizations or other similar transactions that occur with respect to the Parent Common Stock after the date of this Agreement. It is expressly understood and agreed that for all purposes of this Agreement, and without implication that the contrary would otherwise be true, neither transactions nor purchases nor sales shall include the location and/or reservation of borrowable shares of Parent Common Stock.

 

  58  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

(m)        Remedies . The Buyer and in the event of assignment by Buyer of its rights and obligations hereunder, each holder of Securities, shall have all rights and remedies set forth in the Transaction Documents and all rights and remedies which such holders have been granted at any time under any other agreement or contract and all of the rights which such holders have under any law. Any Person having any rights under any provision of this Agreement shall be entitled to enforce such rights specifically (without posting a bond or other security), to recover damages by reason of any breach of any provision of this Agreement and to exercise all other rights granted by law. Furthermore, the Parent and ICA-T recognize that in the event that it or any Subsidiary fails to perform, observe, or discharge any or all of its or such Subsidiary’s (as the case may be) obligations under the Transaction Documents, any remedy at law may prove to be inadequate relief to the Buyer. The Parent and ICA-T therefore agrees that the Buyer shall be entitled to seek specific performance and/or temporary, preliminary and permanent injunctive or other equitable relief from any court of competent jurisdiction in any such case without the necessity of proving actual damages and without posting a bond or other security. The remedies provided in this Agreement and the other Transaction Documents shall be cumulative and in addition to all other remedies available under this Agreement and the other Transaction Documents, at law or in equity (including a decree of specific performance and/or other injunctive relief).

 

(n)        Withdrawal Right . Notwithstanding anything to the contrary contained in (and without limiting any similar provisions of) the Transaction Documents, whenever the Buyer exercises a right, election, demand or option under a Transaction Document and the Parent, ICA-T or their respective Subsidiaries does not timely perform its related obligations within the periods therein provided, then the Buyer may rescind or withdraw, in its sole discretion from time to time upon written notice to the Parent and ICA-T or such Subsidiary (as the case may be), any relevant notice, demand or election in whole or in part without prejudice to its future actions and rights.

 

(o)        Payment Set Aside; Currency . To the extent that the Parent and ICA-T makes a payment or payments to the Buyer hereunder or pursuant to any of the other Transaction Documents or the Buyer enforce or exercise their rights hereunder or thereunder, and such payment or payments or the proceeds of such enforcement or exercise or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged by or are required to be refunded, repaid or otherwise restored to the Parent and ICA-T, a trustee, receiver or any other Person under any law (including, without limitation, any bankruptcy law, foreign, state or federal law, common law or equitable cause of action), then to the extent of any such restoration the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect as if such payment had not been made or such enforcement or setoff had not occurred. Unless otherwise expressly indicated, all dollar amounts referred to in this Agreement and the other Transaction Documents are in United States Dollars (“ U.S. Dollars ”), and all amounts owing under this Agreement and all other Transaction Documents shall be paid in U.S. Dollars. All amounts denominated in other currencies (if any) shall be converted into the U.S. Dollar equivalent amount in accordance with the Exchange Rate on the date of calculation. “ Exchange Rate ” means, in relation to any amount of currency to be converted into U.S. Dollars pursuant to this Agreement, the U.S. Dollar exchange rate as published in the Wall Street Journal on the relevant date of calculation.

 

  59  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

(p)        Judgment Currency .

 

(i)       If for the purpose of obtaining or enforcing judgment against the Parent and ICA-T in connection with this Agreement or any other Transaction Document in any court in any jurisdiction it becomes necessary to convert into any other currency (such other currency being hereinafter in this Section 9(p) referred to as the “ Judgment Currency ”) an amount due in US Dollars under this Agreement, the conversion shall be made at the Exchange Rate prevailing on the Business Day immediately preceding:

 

a. the date actual payment of the amount due, in the case of any proceeding in the courts of New York or in the courts of any other jurisdiction that will give effect to such conversion being made on such date; or

 

b. the date on which the foreign court determines, in the case of any proceeding in the courts of any other jurisdiction (the date as of which such conversion is made pursuant to this Section 9(p)(i)(2) being hereinafter referred to as the “ Judgment Conversion Date ”).

 

(ii)       If in the case of any proceeding in the court of any jurisdiction referred to in Section 9(p)(i)(2) above, there is a change in the Exchange Rate prevailing between the Judgment Conversion Date and the date of actual payment of the amount due, the applicable party shall pay such adjusted amount as may be necessary to ensure that the amount paid in the Judgment Currency, when converted at the Exchange Rate prevailing on the date of payment, will produce the amount of US Dollars which could have been purchased with the amount of Judgment Currency stipulated in the judgment or judicial order at the Exchange Rate prevailing on the Judgment Conversion Date.

 

(iii)       Any amount due from the Parent and ICA-T under this provision shall be due as a separate debt and shall not be affected by judgment being obtained for any other amounts due under or in respect of this Agreement or any other Transaction Document.

 

  60  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

(q)        Registration Rights, Etc .

 

(i)        Filing; Effectiveness, Etc . The Parent and ICA-T hereby agree that the Parent shall prepare and file with the SEC an initial Registration Statement (as defined below) on Form S-3 covering the resale of all of the Registrable Securities (as defined below)subject to the provisions of Section 8(q)(v) below; provided that such initial Registration Statement shall register for resale at least the number of shares of Parent Common Stock equal to the Required Registration Amount (as defined below) as of the date such Registration Statement is initially filed with the SEC; provided further that if Form S-3 is unavailable for such a registration, the Parent shall use such other form as is required by Section 8(q)(iii) . Such initial Registration Statement, and each other Registration Statement required to be filed pursuant to the terms of this Agreement, shall contain (except if otherwise directed by the Buyer in accordance with the rules and regulations of the 1933 Act) the “Selling Stockholders” and “Plan of Distribution” sections in substantially the form provided to the Parent by the Holder within ten (10) days from such request by the Parent. After the filing of the Registration Statement and each other Registration Statement required to be filed by the Parent hereunder with the SEC, the Parent shall use its commercially reasonable efforts to cause such Registration Statement to be declared effective by the SEC (the date the SEC declares the Registration Statement and/or any other Registration Statement covering Registrable Securities effective shall be the “ Effective Date ”), as soon as possible, but in no event later than the applicable Effectiveness Deadline (as defined below). Following the Effective Date, the Parent shall use its commercially reasonable efforts to ensure the Registration Statement remains effective at all times so that a holder of Registrable Securities can effectuate sales of such Registrable Securities pursuant to such Registration Statement and such other Registration Statement until the date three (3) months following the date the ICA-T Note is no longer outstanding. For purposes hereof, the terms “ Registrable Securities ” means (i) the shares of Parent Common Stock issuable upon (a) conversion of the ICA-T Note, and (b) conversion of the Parent Note and/or exercise of the Parent Warrant solely to the extent such shares of Parent Common Stock are required to be included in a Registration Statement because such shares of Parent Common Stock are not eligible for issuance and/or sale under Rule 144 without restrictive legend(the “ Other Registrable Securities ”), and (ii) any capital stock of the Parent issued or issuable with respect to the Other Registrable Securities and the shares of Parent Common Stock issuable upon conversion of the ICA-T Note and/or the Other Registrable Securities including, without limitation, (1) as a result of any stock split, stock dividend, recapitalization, exchange or similar event or otherwise and (2) shares of capital stock of the Parent into which the shares of Parent Common Stock and/or are converted, exercised or exchanged and shares of capital stock of a Successor Entity (as defined in the ICA-T Note, the Parent Note and/or the Parent Warrant, as applicable) into which the shares of Parent Common Stock are converted or exchanged into (but with regard to the Other Registrable Securities, to the extent such Other Registrable Securities are required to be included in a Registration Statement because they are not eligible for issuance and/or sale under Rule 144 without restrictive legend), in each case, without regard to any limitations on conversion of the ICA-T Note the Parent Note and/or the Parent Warrant, as applicable. “ Registration Statement ” means a registration statement or registration statements of the Parent filed under the 1933 Act covering Registrable Securities. “ Effectiveness Deadline ” means except as provided in Section 8(q)(v), (i) with respect to the initial Registration Statement required to be filed pursuant to Section 8(q)(i) , the date six (6) months following the closing of a Qualifying PO, , and (ii) with respect to any additional Registration Statements that may be required to be filed by the Parent pursuant to this Section 8(q) , the earlier of (A) ninety (90) calendar days following the date on which the Parent was required to file such additional Registration Statement (or in the event such Registration Statement receives a “full review” by the Staff (as defined below), the one hundred twentieth (120 th ) day following such filing date), and (B) 2 nd Business Day after the date the Parent is notified (orally or in writing, whichever is earlier) by the SEC that such Registration Statement will not be reviewed or will not be subject to further review. “ Required Registration Amount ” means, as of any given date, 125% of the sum of the maximum number of Parent Conversion Shares then issuable upon conversion of the ICA-T Note (assuming for purposes hereof that (x) the ICA-T Note is convertible at 75% the then Conversion Price (as defined in the Notes) in effect on such given date, and (y) any such calculation shall not take into account any limitations on the conversion of the ICA-T Note set forth in the ICA-T Note), all subject to adjustment as provided in Section 8(q)(ii) and/or Section 8(q)(v) .

 

(ii)        Sufficient Number of Registrable Securities Registered . In the event the number of Registrable Securities available under any Registration Statement is insufficient to cover all of the Registrable Securities required to be covered by such Registration Statement, the Parent shall amend such Registration Statement (if permissible), or file with the SEC a new Registration Statement (on the shortest form available therefor, if applicable), or both, so as to cover at least the Required Registration Amount as of the Trading Day immediately preceding the date of the filing of such amendment or new Registration Statement, in each case, as soon as practicable, but in any event not later than thirty (30) days after the necessity therefor arises (but taking account of any SEC Staff (the “ Staff ”) position with respect to the date on which the Staff will permit such amendment to the Registration Statement and/or such new Registration Statement (as the case may be) to be filed with the SEC). The Parent shall use its reasonable best efforts to cause such amendment to such Registration Statement and/or such new Registration Statement (as the case may be) to become effective as soon as practicable following the filing thereof with the SEC, but in no event later than the applicable Effectiveness Deadline for such Registration Statement. For purposes of the foregoing provision, the number of shares available under a Registration Statement shall be deemed “insufficient to cover all of the shares of Parent Common Stock Registrable Securities” if at any time the number of shares of Parent Common Stock available for resale under the applicable Registration Statement is less than the Required Registration Amount.

 

  61  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

(iii)        Ineligibility to Use Form S-3 . In the event that Form S-3 is not available for the registration of the resale of Registrable Securities hereunder, the Parent shall (i) register the resale of the Registrable Securities on Form S-1 or another appropriate form reasonably acceptable to the Buyer and (ii) undertake to register the resale of the Registrable Securities on Form S-3 as soon as such form is available, provided that the Parent shall maintain the effectiveness of all Registration Statements then in effect until such time as a Registration Statement on Form S-3 covering the resale of all the Registrable Securities has been declared effective by the SEC and the prospectus contained therein is available for use.

 

(iv)        Effect of Failure to File and Obtain and Maintain Effectiveness of any Registration Statement . If the (a) a Registration Statement covering the resale of all of the Registrable Securities required to be covered thereby (subject to any reduction pursuant to Section 8(q)(v) ) pursuant to this Agreement is not declared effective by the SEC on or before the Effectiveness Deadline for such Registration Statement (an “ Effectiveness Failure ”), (it being understood that if on the Business Day immediately following the Effective Date for such Registration Statement the Parent shall not have filed a “final” prospectus for such Registration Statement with the SEC under Rule 424(b) (whether or not such a prospectus is technically required by such rule), the Parent shall be deemed to not have satisfied this clause and such event shall be deemed to be an Effectiveness Failure), (b) on any day after the Effective Date of a Registration Statement sales of all Registrable Securities required to be included on such Registration Statement (disregarding any reduction pursuant to Section 8(v) of this Agreement) cannot be made pursuant to such Registration Statement (including, without limitation, because of a failure to keep such Registration Statement effective, a failure to disclose such information as is necessary for sales to be made pursuant to such Registration Statement, a suspension or delisting of (or a failure to timely list) the shares of Parent Common Stock on the Principal Market (as defined below) or any other limitations imposed by the Principal Market, or a failure to register a sufficient number of shares of Parent Common Stock or by reason of a stop order) or the prospectus contained therein is not available for use for any reason (a “ Maintenance Failure ”), or (c) if a Registration Statement is not effective for any reason or the prospectus contained therein is not available for use for any reason and either (x) the Parent fails for any reason to satisfy the requirements of Rule 144(c)(1), including, without limitation, the failure to satisfy the current public information requirement under Rule 144(c) or (y) the Parent has ever been an issuer described in Rule 144(i)(1)(i) or becomes such an issuer in the future, and the Parent shall fail to satisfy any condition set forth in Rule 144(i)(2) (a “ Current Public Information Failure ”) as a result of which the Buyer is unable to sell Registrable Securities without restriction under Rule 144 (including, without limitation, volume restrictions), then, as partial relief for the damages to the Buyer by reason of any such delay in, or reduction of, its ability to sell Registrable Securities (which remedy shall not be exclusive of any other remedies available at law or in equity, including, without limitation, specific performance), the Parent shall pay to the Buyer of Registrable Securities an amount in cash equal to two (2%) percent of the product of (x) the number of Registrable Securities of the Buyer required hereunder to be included in such Registration Statement and (y) the Closing Sale Price or Closing Bid Price (as the case may be and as defined in the ICA-T Note) as of the Trading Day immediately prior to the date a Registration Delay Payment (as defined below) is due hereunder (1) on the date of such Effectiveness Failure, Maintenance Failure or Current Public Information Failure, as applicable, and (2) on every thirty (30) day anniversary of (I) an Effectiveness Failure until such Effectiveness Failure is cured; (II) a Maintenance Failure until such Maintenance Failure is cured; and (III) a Current Public Information Failure until the earlier of (i) the date such Current Public Information Failure is cured and (ii) such time that such public information is no longer required pursuant to Rule 144 (in each case, pro-rated for periods totaling less than thirty (30) days). The payments to which a holder of Registrable Securities shall be entitled pursuant to this Section 8(iv) are referred to herein as “ Registration Delay Payments ”, it being understood that no Registration Delay Payments shall be payable to the Buyer with respect to each Effectiveness Failure, and/or Maintenance Failure or a Current Public Information Failure to the extent (x) such Registration Delay Payments relate to such Registrable Securities the Buyer elects not to include in such Registration Statement or (y) the Buyer fails to timely perform its obligations hereunder. Following the initial Registration Delay Payment for any particular event or failure (which shall be paid on the date of such event or failure, as set forth above), without limiting the foregoing, if an event or failure giving rise to the Registration Delay Payments is cured prior to any thirty (30) day anniversary of such event or failure, then such Registration Delay Payment shall be made on the third (3 rd ) Business Day after such cure. In the event the Parent fails to make Registration Delay Payments in a timely manner in accordance with the foregoing, such Registration Delay Payments shall bear interest at the rate of one and one half percent (1.5%) per month (prorated for partial months) until paid in full. “ Principal Market ” means the NYSE MKT, New York Stock Exchange, the NASDAQ Global Market, the NASDAQ Global Select Market, the NASDAQ Capital Market, the OTCQB Market, the OTCQX Market, or the OTC Pink Market, or any successor or subsequent market or exchange, which is at the time the principal trading exchange or market for the Parent Common Stock, based upon share volume.

 

  62  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

(v)        Offering . Notwithstanding anything to the contrary contained in this Agreement in the event the staff of the SEC (the “ Staff ”) or the SEC seeks to characterize any offering pursuant to a Registration Statement filed pursuant to this Agreement as constituting an offering of securities by, or on behalf of, the Parent, or in any other manner, such that the Staff or the SEC do not permit such Registration Statement to become effective and used for resales in a manner that does not constitute such an offering and that permits the continuous resale at the market by the Buyer then the Parent shall reduce the number of shares to be included in such Registration Statement by the Buyer until such time as the Staff and the SEC shall so permit such Registration Statement to become effective as aforesaid. In addition, in the event that the Staff or the SEC requires the Buyer to be specifically identified as an ”underwriter” in order to permit such Registration Statement to become effective, and the Buyer does not consent to being so named as an underwriter in such Registration Statement, then, in each such case, the Parent shall reduce the total number of Registrable Securities to be registered on behalf of the Buyer, until such time as the Staff or the SEC does not require such identification or until the Buyer accepts such identification and the manner thereof. With regard to any reduced Registrable Securities, upon a written request to the Parent signed by the Buyer, the Parent shall file a registration statement within twenty (20) days of such request (subject to any restrictions imposed by Rule 415 or required by the Staff or the SEC) for resale by the Buyer in a manner acceptable to the Buyer, and the Parent shall following such request cause to be and keep effective such Registration Statement in the same manner as otherwise contemplated in this Agreement for other registration statements hereunder, in each case until such time as: (i) all Registrable Securities held by the Buyer have been registered and sold pursuant to an effective Registration Statement in a manner acceptable to the Buyer or (ii) all Registrable Securities may be resold by the Buyer without restriction (including, without limitation, volume limitations) pursuant to Rule 144 (taking account of any Staff position with respect to “affiliate” status) and without the need for current public information required by Rule 144(c)(1) (or Rule 144(i)(2), if applicable) and legal counsel to the Parent provides and opinion to such effect to the Buyer in form reasonably acceptable to the Buyer or (iii) the Buyer agrees to be named as an underwriter in any such Registration Statement in a manner acceptable to the Buyer as to all Registrable Securities held by the Buyer and that have not theretofore been included in a Registration Statement under this Agreement (it being understood that the special demand right under this sentence may be exercised by the Buyer multiple times and with respect to limited amounts of Registrable Securities in order to permit the resale thereof by the Buyer as contemplated above).

 

(vi)        Piggyback Registrations . Without limiting any obligation of the Parent hereunder, under this Agreement and/or under the ICA-T Note, the Parent Note and/or the Parent Warrant, if at any time following a Qualifying PO, there is not an effective Registration Statement covering all of the Registrable Securities or the prospectus contained therein is not available for use and the Parent shall determine to prepare and file with the SEC a registration statement relating to an offering for its own account or the account of others under the 1933 Act of any of its equity securities (other than on Form S-4 or Form S-8 (each as promulgated under the 1933 Act) or their then equivalents relating to equity securities to be issued solely in connection with any acquisition of any entity or business or a business combination subject to Rule 145 under the 1933 Act or equity securities issuable in connection with the Parent’s stock option or other employee benefit plans), then the Parent shall deliver to the Buyer a written notice of such determination and, if within fifteen (15) days after the date of actual receipt of such notice, the Buyer shall so request in writing, the Parent shall include in such registration statement all or any part of such shares of Parent Common Stock the Buyer requests to be registered; provided , however , the Parent shall not be required to register any shares of Parent Common Stock pursuant to this Section 8(q)(vi) that are the subject of a then-effective Registration Statement.

 

  63  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

(vii)        No Inclusion of Other Securities . Except with respect to a registration statement filed under Section 8(q)(vi), the Parent shall in no event include any securities other than Registrable Securities on any Registration Statement filed in accordance herewith without the prior written consent of the Buyer. Until the date 90 days following the Effective Date of a Registration Statement, the Parent shall not enter into any agreement providing any registration rights to any of its security holders other than the Buyer, or filed a registration statement or have a previously filed registration statement declared effective by the SEC or file a prospectus supplement to permit sales of securities pursuant to an already declared effective registration statement for any holders of its securities, except the Buyer.

 

(viii)       If the Buyer may be required under applicable securities law to be described in any Registration Statement as an underwriter and the Buyer consents in writing to so being named an underwriter, upon the written request of the Buyer, the Parent shall make available for inspection by (i) the Buyer, (ii) legal counsel for the Buyer and (iii) one (1) firm of accountants or other agents retained by the Buyer (collectively, the “ Inspectors ”), all pertinent financial and other records, and pertinent corporate documents and properties of the Parent, ICA-T and each Subsidiary (collectively, the “ Records ”), as shall be reasonably deemed necessary by each Inspector, and cause the Parent’s, ICA-T’s and each Subsidiary’s officers, directors and employees to supply all information which any Inspector may reasonably request; provided, however, each Inspector shall agree in writing to hold in strict confidence and not to make any disclosure (except to the Buyer or its agents, representatives and Affiliates) or use of any Record or other information which the Parent’s board of directors determines in good faith to be confidential, and of which determination the Inspectors are so notified, unless (1) the disclosure of such Records is necessary to avoid or correct a misstatement or omission in any Registration Statement or is otherwise required under the 1933 Act, (2) the release of such Records is ordered pursuant to a final, non-appealable subpoena or order from a court or government body of competent jurisdiction, or (3) the information in such Records has been made generally available to the public other than by disclosure in violation of this Agreement or any other Transaction Document. The Buyer agrees that it shall, upon learning that disclosure of such Records is sought in or by a court or governmental body of competent jurisdiction or through other means, give prompt notice to the Parent and allow the Parent, at its expense, to undertake appropriate action to prevent disclosure of, or to obtain a protective order for, the Records deemed confidential. Nothing herein (or in any other confidentiality agreement between the Parent and the Buyer, if any) shall be deemed to limit the Buyer’s ability to sell Registrable Securities in a manner which is otherwise consistent with applicable laws and regulations. If the Buyer may be required under applicable securities law to be described in any Registration Statement as an underwriter and the Buyer consents to so being named an underwriter, at the request of the Buyer, the Parent shall furnish to the Buyer, on the date of the effectiveness of such Registration Statement and thereafter from time to time on such dates as the Buyer may reasonably request (i) a letter, dated such date, from the Parent’s independent certified public accountants in form and substance as is customarily given by independent certified public accountants to underwriters in an underwritten public offering, addressed to the Buyer, and (ii) an opinion, dated as of such date, of counsel representing the Parent for purposes of such Registration Statement, in form, scope and substance as is customarily given in an underwritten public offering, addressed to the Buyer.

 

  64  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

(ix)       In addition, without limiting any obligation of the Parent under this Agreement, the Parent shall use its reasonable best efforts either to (i) cause all of the Registrable Securities covered by each Registration Statement to be listed on each securities exchange on which securities of the same class or series issued by the Parent are then listed, if any, if the listing of such Registrable Securities is then permitted under the rules of such exchange, (ii) secure designation and quotation of all of the Registrable Securities covered by each Registration Statement on an Eligible Market (as defined in the ICA-T Note), or (iii) if, despite the Parent’s reasonable best efforts to satisfy the preceding clauses (i) or (ii) the Parent is unsuccessful in satisfying the preceding clauses (i) or (ii), without limiting the generality of the foregoing, to use its best efforts to arrange for at least two market makers to register with the Financial Industry Regulatory Authority (“ FINRA ”) as such with respect to such Registrable Securities. In addition, the Parent shall cooperate with the Buyer and any broker or dealer through which the Buyer proposes to sell its Registrable Securities in effecting a filing with FINRA pursuant to FINRA Rule 5110 as requested by the Buyer. The Parent shall pay all fees and expenses in connection with satisfying its obligations under this Section 8(q)(ix) .

 

(x)       The obligations of the Parent under this Section 8(q) , except those set forth in Section 8(q)(xi) and (xii) shall terminate three months after the ICA-T Note (and the Parent Note if the shares of Parent Common Stock issuable upon conversion of the Parent Note constitute Registrable Securities) is no longer outstanding or the Parent has credited to the Buyer’s account at DTC all Registrable Securities without registration of such shares on any Registration Statement; provided that notwithstanding anything to the contrary provided herein or elsewhere, the Buyer shall in no event be required to deliver any legal opinion removing any legend on any Registrable Securities, which obligation to deliver a legal opinion shall be the sole responsibility and expense of the Parent.

 

(xi)       In addition to and not in limitation of the rights and remedies of an Indemnitee and the obligations and responsibilities of the Parent and ICA-T set forth in Section 8(k) hereof or elsewhere, to the fullest extent permitted by law, the Parent and ICA-T will, and each hereby does, jointly and severally, indemnify, hold harmless and defend the Buyer and each other holder of Registrable Securities and each of its directors, officers, shareholders, members, partners, employees, agents, advisors, representatives (and any other Person with a functionally equivalent role of a Person holding such titles notwithstanding the lack of such title or any other title) and each Person, if any, who controls the Buyer within the meaning of the 1933 Act or the 1934 Act and each of the directors, officers, shareholders, members, partners, employees, agents, advisors, representatives (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding the lack of such title or any other title) of such controlling Persons (each, an “ Indemnified Person ”), against any losses, obligations, claims, damages, liabilities, contingencies, judgments, fines, penalties, charges, costs (including, without limitation, court costs, reasonable attorneys’ fees and costs of defense and investigation), amounts paid in settlement or expenses, joint or several, (collectively, “ Claims ”) incurred in investigating, preparing or defending any action, claim, suit, inquiry, proceeding, investigation or appeal taken from the foregoing by or before any court or governmental, administrative or other regulatory agency, body or the SEC, whether pending or threatened, whether or not an Indemnified Person is or may be a party thereto (“ Indemnified Damages ”), to which any of them may become subject insofar as such Claims (or actions or proceedings, whether commenced or threatened, in respect thereof) arise out of or are based upon: (i) any untrue statement or alleged untrue statement of a material fact in a Registration Statement or any post-effective amendment thereto or in any filing made in connection with the qualification of the offering under the securities or other “blue sky” laws of any jurisdiction in which Registrable Securities are offered (“ Blue Sky Filing ”), or the omission or alleged omission to state a material fact required to be stated therein or necessary to make the statements therein not misleading, (ii) any untrue statement or alleged untrue statement of a material fact contained in any preliminary prospectus if used prior to the effective date of such Registration Statement, or contained in the final prospectus (as amended or supplemented, if the Parent files any amendment thereof or supplement thereto with the SEC) or the omission or alleged omission to state therein any material fact necessary to make the statements made therein, in light of the circumstances under which the statements therein were made, not misleading or (iii) any violation or alleged violation by the Parent of the 1933 Act, the 1934 Act, any other law, including, without limitation, any state securities law, or any rule or regulation thereunder relating to the offer or sale of the Registrable Securities pursuant to a Registration Statement or (iv) any violation of this Agreement (the matters in the foregoing clauses (i) through (iv) being, collectively, “ Violations ”). The Parent and ICA-T shall reimburse the Indemnified Persons, promptly as such expenses are incurred and are due and payable, for any legal fees or other reasonable expenses incurred by them in connection with investigating or defending any such Claim. Notwithstanding anything to the contrary contained herein, the indemnification agreement contained in this Section 8(q)(xi) : (i) shall not apply to a Claim by an Indemnified Person arising out of or based upon a Violation which occurs in reliance upon and in conformity with information furnished in writing to the Parent by such Indemnified Person for such Indemnified Person expressly for use in connection with the preparation of such Registration Statement or any such amendment thereof or supplement thereto, if such prospectus was timely made available by the Parent pursuant to Section 3(d) ; and (ii) shall not apply to amounts paid in settlement of any Claim if such settlement is effected without the prior written consent of the Parent and/or ICA-T, which consent shall not be unreasonably withheld or delayed. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of the Indemnified Person and shall survive the transfer of any of the Registrable Securities by the Buyer pursuant to Section 8(q)(xiii) or elsewhere.

 

  65  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

(xii)       To the extent any indemnification by an Indemnifying party is prohibited or limited by law, the indemnifying party agrees to make the maximum contribution with respect to any amounts for which it would otherwise be liable under Section 8(q)(xi) to the fullest extent permitted by law. In addition, as otherwise set forth in this Section 8(q)(xi) , the mechanics and procedures with respect to the rights of the Buyer and the obligations of the Parent and ICA-T under this Section 8(q)(xi) shall be the same as those set forth in Section 8(k) of this Agreement and the provisions set forth in Section 8(k)(iii) shall apply to the provisions of this Section 8(q) , as applicable.

 

(xiii)       All or any portion of the rights of the Buyer under this Section 8(q) shall be automatically assignable by the Buyer to any transferee or assignee (as the case may be) of all or any portion of such Buyer’s Registrable Securities or Notes and/or Parent Warrant if: (i) the Buyer agrees in writing with such transferee or assignee (as the case may be) to assign all or any portion of such rights, and a copy of such agreement is furnished to the Parent within a reasonable time after such transfer or assignment (as the case may be); (ii) the Parent is, within a reasonable time after such transfer or assignment (as the case may be), furnished with written notice of (a) the name and address of such transferee or assignee (as the case may be), and (b) the securities with respect to which such registration rights are being transferred or assigned (as the case may be); (iii) immediately following such transfer or assignment (as the case may be) the further disposition of such securities by such transferee or assignee (as the case may be) is restricted under the 1933 Act or applicable state securities laws if so required; (iv) at or before the time the Parent receives the written notice contemplated by clause (ii) of this sentence such transferee or assignee (as the case may be) agrees in writing with the Parent to be bound by all of the provisions contained herein; (v) such transfer or assignment (as the case may be) shall have been made in accordance with the applicable requirements of the Securities Purchase Agreement and the Notes and the Parent Warrant; and (vi) such transfer or assignment (as the case may be) shall have been conducted in accordance with all applicable federal and state securities laws.

 

(xiv)       Without limiting any other obligation of the Parent under the Securities Purchase Agreement, the Parent shall use its reasonable best efforts (I) either to (i) cause all of the Registrable Securities covered by each Registration Statement to be listed on each securities exchange on which securities of the same class or series issued by the Parent are then listed, if any, (ii) secure designation and quotation of all of the Registrable Securities covered by each Registration Statement on an Eligible Market (as defined in the Securities Purchase Agreement), or (iii) if, despite the Parent’s reasonable best efforts to satisfy the preceding clauses (i) or (ii) the Parent is unsuccessful in satisfying the preceding clauses (i) or (ii), without limiting the generality of the foregoing, to use its best efforts to arrange for at least two market makers to register with the Financial Industry Regulatory Authority (“ FINRA ”) as such with respect to such Registrable Securities, and (II) register and qualify, unless an exemption from registration and qualification applies, the resale by the Buyer of the Registrable Securities covered by a Registration Statement under such other securities or “blue sky” laws of all applicable jurisdictions in the United States, provided this provision “II” shall not require the Parent to qualify to do business in any jurisdiction where it would not otherwise be required to qualify but for this provision “II.”

 

  66  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

(xv)       The Parent shall permit Gusrae Kaplan Nusbaum PLLC, legal counsel for the Holder (“ Legal Counsel ”) to review and comment upon (i) each Registration Statement at least five (5) Business Days prior to its filing with the SEC and (ii) all amendments and supplements to each Registration Statement (including, without limitation, the prospectus contained therein) (except for Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and any similar or successor reports, collectively, the “ Excluded Review Materials ”) within a reasonable number of days prior to their filing with the SEC. The Parent shall promptly furnish to Legal Counsel, without charge (i) copies of any correspondence from the SEC or the Staff to the Company or its representatives relating to each Registration Statement, provided that such correspondence shall not contain any material, non-public information regarding the Company or any of its Subsidiaries (as defined in the Securities Purchase Agreement), (ii) after the same is prepared and filed with the SEC, one (1) copy of each Registration Statement and any amendment(s) and supplement(s) thereto, including, without limitation, financial statements and schedules, all documents incorporated therein by reference, if requested by an Investor, and all exhibits, unless such materials are publicly available via EDGAR, and (iii) upon the effectiveness of each Registration Statement, one (1) copy of the prospectus included in such Registration Statement and all amendments and supplements thereto.

 

(r)       The parties agree that the Confession of Judgment relating to each respective Note shall not be filed unless a default has occurred under such Note, which default has not been cured pursuant to the terms of such Note. Upon the occurrence of any default under any of the Notes (which default has not been cured in accordance with the Notes), each of ICA-T and the Parent hereby consent to the filing and enforcement by the Buyer of the Confession of Judgment relating to such Note (or Notes) that are in default.

 

[ Signature pages follow ]

 

  67  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

[ICA-T AND THE PARENT SIGNATURE PAGE]

 

IN WITNESS WHEREOF, the Buyer, ICA-T and the Parent have caused their respective signature page to this Agreement to be duly executed as of the date first written above.

 

  PARENT:
     
  ICAGEN, INC.
     
  By: /s/ Richard Cunningham
    Name: Richard Cunningham
    Title: Chief Executive Officer
     
  ICA-T :
   
  ICAGEN-T, INC.
     
  By: /s/ Richard Cunningham
    Name: Richard Cunningham
    Title: Chief Executive Officer

 

[END OF ICA-T AND THE PARENT SIGNATURE PAGE; BUYER SIGNATURE PAGE ON NEXT PAGE]

 

  S-1  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

[BUYER SIGNATURE PAGE]

 

IN WITNESS WHEREOF, the Buyer and ICA-T have caused their respective signature page to this Agreement to be duly executed as of the date first written above.

 

  BUYER:
     
  GPB DEBT HOLDINGS II, LLC
     
  By: /s/ David Gentile
    Name: David Gentile
    Title: Manager

  

[END OF BUYER SIGNATURE PAGE]

 

  S- 1  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

LIST OF EXHIBITS AND SCHEDULES

 

EXHIBITS

     
A. Form of Note
B. Form of Parent Note
C. Form of Parent Warrant
D. Form of Parent Security Agreement
E. Form of ICA-T Security Agreement
F. Form of Parent Guaranty
G. Form of Subsidiary Guaranty
H. Buyer Deed of Trust
I. Organizational Documents of the Parent and ICA-T
(i) By-Laws (with amendments)
(ii) Certificate of Incorporation (amendments)
J. Form of Irrevocable Transfer Agent Instructions
K. Pay-Off Letter
L. [IP Termination Agreement ]
M. Confession of Judgment

 

SCHEDULES

 

Schedule 3(a) – Subsidiaries

Schedule 3(e) – Consents

Schedule 3(h) – Offerings

Schedule 3(k) – Absence of Material Changes

Schedule 3(l) – Undisclosed Events, Liabilities, Developments or Circumstances

Schedule 3(p) – Transaction with Affiliates

Schedule 3(q)(iii) – Certain Shares Information

Schedule 3(q)(iv) – Pre-emptive Rights, Securities, Etc.

Schedule 3(r) – Indebtedness, Etc.

Schedule 3(s) – Litigation, Etc.

Schedule 3(t) – Insurance

Schedule 3(u)(i) – Employee Matters, Etc.

Schedule 3(u)(iii) – Benefit Plans, Etc.

Schedule 3(u)(iv) – Exception to Benefit Plan, Etc.

Schedule 3(u)(vii) – Other exceptions to Benefit Plans

Schedule 3(v)(i) – Real Property, Etc.

Schedule 3(v)(ii) – Fixtures and Equipment

Schedule 3(w)(i) – Enforceability of Intellectual Property

Schedule 3(w)(ii) – List of IP, Etc.

Schedule 3(w)(iii) – Agreements relating to Intellectual Property

Schedule 3(w)(v) – IP Royalty Payments

Schedule 3(w)(v) – Ownership of IP

Schedule 3(w)(vii) – Works

Schedule 3(z)(ii) – Exception to payment of Taxes, Etc.

Schedule 3(z)(iii) – Tax Liens, Etc.

Schedule 3(z)(iv) – Certain Beneficial interests in other Persons

Schedule 3(aa) – Internal Accounting and Disclosure Controls

Schedule 3(jj) – Management Actions

Schedule 3(kk) – Stock option plans, Etc.

Schedule 3(nn) – Other Covered Persons and Related Matters, Remuneration

Schedule 3(rr) – Ranking of Notes

Schedule 3(ss)(i) – Customers

Schedule 3(ss)(ii) – Contracts, etc. with Major Customers

Schedule 3(ss)(iii) – Termination or possible termination of arrangements with Major Customer

Schedule 3(ww) – Liens

Schedule 3(yy) – Material Contracts

 

  E/S List - 1  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

Disclosure Schedules

 

to

 

Securities Purchase Agreement

 

Attached to and forming a part of the Securities Purchase Agreement, dated as of May 15, 2017 (the “ Purchase Agreement ”), by and among Icagen, Inc. (“ Icagen ”), Icagen-T, Inc., a Delaware corporation and a wholly-owned Subsidiary of Icagen (“ ICA-T ”) and GPB Debt Holdings II, LLC are the disclosure schedules of Icagen and ICA-T (collectively, the “ Disclosure Schedules ”). Capitalized terms used but not defined in the Disclosure Schedules have the meanings ascribed to such terms in the Purchase Agreement. The information disclosed in these Disclosure Schedules is intended to qualify the representations and warranties contained in the Purchase Agreement and shall not be deemed to expand in any way the scope or effect of any of such representations and warranties on the part of the party making such representation or warranty.

 

The inclusion of any item in these Disclosure Schedules (i) does not represent a determination that such item is material or establish a standard of materiality; (ii) does not represent a determination that such item did not arise in the ordinary course of business; (iii) does not represent a determination that the transactions contemplated by the Purchase Agreement require the consent of third parties, except as specifically noted; and (iv) shall not constitute, or be deemed to be, an admission to any third party concerning such item. No disclosure in these Disclosure Schedules relating to any possible breach or violation of any agreement or law shall be construed as an admission or indication that any such breach or violation actually occurred. The fact that a matter has been included in these Disclosure Schedules shall not necessarily mean that such matter must or should have been disclosed in order that the corresponding representation or warranty be accurate, or is otherwise required to be disclosed, pursuant to the terms and conditions of the Purchase Agreement.

 

Section headings and numbers used in these Disclosure Schedules refer to the corresponding sections of the Purchase Agreement, and these and other headings and numbers are for convenience only and are not to be used to interpret any provision of the Purchase Agreement or these Disclosure Schedules. Any matters disclosed in one section of these Disclosure Schedules shall be deemed disclosed for all purposes in all other sections of these Disclosure Schedules to the extent that such disclosure is made in such a way as to make its relevance with respect to any such other section of these Disclosure Schedules reasonably apparent on its face. These Disclosure Schedules (i) include matters set forth in documents referenced in these Disclosure Schedules and (ii) do not purport to disclose any agreements, contracts or instruments that may be entered into pursuant to the terms of the Purchase Agreement. Furthermore, these Disclosure Schedules were created for the purpose of disclosure solely to Icagen and not to any Person that is not party to the Purchase Agreement.

 

 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

Schedule 3(a)

 

Subsidiaries

 

Icagen-T, Inc. Delaware
   
Caldera Discovery, Inc. Delaware
   
XRpro Sciences, Inc. Delaware
   
Icagen Corp. Nevada

 

 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

Schedule 3(e)

 

Consents

 

None

 

 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

Schedule 3(g)

 

Placement Agents Fees

 

None

 

 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

Schedule 3(h)

 

Securities Issuance since December 31, 2015

 

Icagen, Inc

 

1. Options issued on May 19, 2016 to purchase an aggregate of 302,500 shares of common stock
2. Issuance in June 2016 and July 2016 of (i) notes in the principal amount of $1,145,000; (ii) investor warrants to purchase 171,750 shares of common stock; and (iii) placement agent warrants to purchase 28,625 shares of common stock
3. Options issued on July 15, 2016 to purchase 250,000 shares of common stock
4. Options issued on August 22, 2016 to purchase 50,000 shares of common stock
5. Options issued on March 15, 2017, 2016 to purchase 120,000 shares of common stock
6. Issuance in April 2017 of (i) notes in the principal amount of $1,500,000; (ii) investor warrants to purchase 225,000 shares of common stock; and (iii) placement agent warrants to purchase 25,000 shares of common stock

 

Icagen-T

 

Issuance of 100 shares of common stock to Icagen, Inc.

 

 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

Schedule 3(j)

 

SEC Documents: Financial Statements

 

Potential Contingency-confession of judgement filed by SRN Dentons

 

 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

Schedule 3(k)

 

Absence of Certain Changes

 

None

 

 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

Schedule 3(l)

 

Undisclosed Events, Liabilities, Developments or Circumstances

 

None

 

 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

Schedule 3(p)

 

Transactions With Affiliates

 

See Schedule 3(h)

 

Timothy Tyson

 

On May 19, 2016, Icagen Inc., issued ten-year options exercisable for 12,500 shares of common stock at $3.50 per share to Mr. Tyson.

 

On July 6, 2016, Icagen Inc., entered into a Securities Purchase Agreement and issued a secured 8% Bridge Note for $100,000 to Mr. Tyson in consideration of $100,000.

 

On July 6, 2016, Icagen, Inc. issued Mr. Tyson five year Warrants to acquire 15,000 shares of common stock exercisable at $3.50 per share.

 

On March 15, 2017, Icagen, Inc. issued Mr. Tyson ten-year options exercisable for 10,000 shares of common stock at $3.50 per share.

 

On April 13, 2017, Icagen Inc., entered into a Securities Purchase Agreement and issued a secured 8% Bridge Note for $500,000 to Mr. Tyson in consideration of $500,000.

 

On April 13, 2017, Icagen, Inc. issued Mr. Tyson five year Warrants to acquire 75,000 shares of common stock exercisable at $3.50 per share. These warrants are also exchangeable, at the option of the holder, for a like number of warrants issued to any lender in the next debt financing.

 

Michael Taglich

 

On May 19, 2016, Icagen Inc., issued ten-year options exercisable for 12,500 shares of common stock at $3.50 per share to Mr. Taglich.

 

On June 30, 2016, Icagen Inc., entered into a Securities Purchase Agreement and issued a secured 8% Bridge Note for $250,000 to Mr. Taglich in consideration of $250,000.

 

On June 30, 2016, Icagen, Inc. issued five year Warrants to acquire 37,500 shares of common stock exercisable at $3.50 per share.

 

Icagen Inc., retained Taglich Brothers, Inc. as the exclusive placement agent for the 2016 Bridge Note Offering. Icagen Inc., agreed to pay the placement agent a six percent (6%) commission from the gross proceeds of the Offering ($1,145,000) and agreed to reimburse approximately $15,000 in respect of out of pocket expenses incurred by the placement agent in connection with the Offering. Icagen Inc., also issued the placement agent the same warrant that the investors received exercisable for an aggregate amount of 28,625 shares of Common Stock at an exercise price of $3.50 per share (the “Placement Agent Warrants”).

 

As an employee and Principal of Taglich Brothers Inc., Mr. Taglich was issued 2016 Placement Agent Warrants to purchase 7,820 shares of Common stock at an exercise price of $3.50 per share.

 

 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

On March 15, 2017, Icagen, Inc. issued Mr. Taglich ten-year options exercisable for 10,000 shares of common stock at $3.50 per share.

 

On April 12, 2017, Icagen Inc., entered into a Securities Purchase Agreement and issued a secured 8% Bridge Note for $500,000 to Mr. Taglich in consideration of $500,000.

 

On April 12, 2017, Icagen Inc., issued five year Warrants to acquire 75,000 shares of common stock exercisable at $3.50 per share. These warrants are also exchangeable, at the option of the holder, for a like number of warrants issued to any lender in the next debt financing.

 

Icagen Inc., retained Taglich Brothers, Inc. as the exclusive placement agent for the 2017 Bridge Note Offering. Icagen Inc., agreed to pay the placement agent a six percent (6%) commission from the gross proceeds of the Offering (excluding $500,000 invested by the Chairman of the Board of Directors, Timothy Tyson) for a total commission of $60,000. Icagen Inc., also issued the Placement Agent the same warrant that the investors received exercisable for an aggregate amount of 25,000 shares of Common Stock at an exercise price of $3.50 per share (the “2017 Placement Agent Warrants”). The Placement Agent has the right to exchange the Placement Agent Warrants for a like number of warrants to be issued to the lender in the next debt financing.

 

As an employee and Principal of Taglich Brothers Inc., Mr. Taglich was issued 2017 Placement Agent Warrants to purchase 7,500 shares of Common stock.

 

Vincent Palmieri

 

On May 19, 2016, Icagen, Inc. issued ten-year options exercisable for 12,500 shares of common stock at $3.50 per share to Mr. Palmieri.

 

On June 30, 2016, Icagen, Inc. issued entered into a Securities Purchase Agreement and issued a secured 8% Bridge Note for $50,000 to Mr. Palmieri in consideration of $50,000.

 

On June 30, 2016, Icagen, Inc. issued Mr. Palmieri five year Warrants to acquire 7,500 shares of common stock exercisable at $3.50 per share.

 

As an employee of Taglich Brothers Inc., Mr. Palmieri was issued 2016 Placement Agent warrants to purchase 6,000 shares of Common stock at an exercise price of $3.50v per share.

 

On March 15, 2017, Icagen, Inc. issued Mr. Palmieri ten-year options exercisable for10,000 shares of common stock at $3.50 per share.

 

As an employee of Taglich Brothers Inc., Mr. Palmieri was issued 2017 Placement Agent Warrants to purchase 6,000 shares of Common stock at an exercise price of $3.50 per share.

 

Clive Kabatznik

 

On May 19, 2016, Icagen Inc., issued ten-year options exercisable for 12,500 shares of common stock at $3.50 per share to Mr. Kabatznik.

 

On June 30, 2016, Icagen Inc., entered into a Securities Purchase Agreement and issued a secured 8% Bridge Note for $50,000 to Mr. Kabatznik in consideration of $50,000 in cash.

 

On June 30, 2016, Icagen, Inc. issued Mr. Kabatznik five year Warrants to acquire 7,500 shares of common stock exercisable at $3.50 per share.

 

 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

On March 15, 2017, Icagen, Inc. issued Mr. Kabatznik ten-year options exercisable for 10,000 shares of common stock at $3.50 per share.

 

Edward Roffman

 

On May 19, 2016, Icagen Inc., issued ten-year options exercisable for 12,500 shares of common stock at $3.50 per share to Mr. Roffman.

 

On June 30, 2016, Icagen Inc., entered into a Securities Purchase Agreement and issued a secured 8% Bridge Note for $25,000 to Mr. Roffman in consideration of $25,000.

 

On June 30, 2016, Icagen, Inc. issued Mr. Roffman five year Warrants to acquire 3,750 shares of common stock exercisable at $3.50 per share.

 

On March 15, 2017, Icagen, Inc. issued Mr. Roffman ten-year options exercisable for 10,000 shares of common stock at $3.50 per share.

 

Douglas Krafte

 

On May 19, 2016, Icagen Inc., issued ten-year options exercisable for 100,000 shares of common stock at $3.50 per common shares to Mr. Krafte.

 

Richard Cunningham

 

On March 15, 2017, Icagen, Inc. issued Mr. Cunningham ten-year options exercisable for 20,000 shares of common stock at $3.50 per share.

 

 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

Schedule 3(q)(iii)

 

Valid Issuance; Available Shares; Affiliates

 

(A) Icagen, Inc. -Reserved for Issuance pursuant to options and convertible Securities:

 

1. Options exercisable for 1,453,291 shares of common stock, of which 730,791 were issued under the 2005 Stock Option Plan and 722,500 were issued under the 2015 Stock Option Plan.

 

2. Warrants exercisable for 2,397,641 shares of common stock.

 

3. No convertible securities in issue.

 

(B) Icagen, Inc. Equity Held by Affiliates:

 

1. Richard Cunningham

 

Options exercisable for 270,000 shares of common stock

 

2. Douglas Krafte

 

Options exercisable for 100,000 shares of common stock

 

3. Mark Korb

 

Options exercisable for 37,500 shares of common stock

 

Indirect holding of 25,000 shares of common stock, via First SA Management

 

4. Timothy Tyson

 

142,856 shares of common stock

 

Warrants exercisable for 125,714 shares of common stock

 

Options exercisable for 98,500 shares of common stock

 

5. Clive Kabatznik

 

Indirect holding of 25,000 shares of common stock via First SA Management

 

Warrants exercisable for 22,500 shares of common stock

 

Option exercisable for 60,000 shares of common stock

 

6. Vincent Palmieri

 

53,308 shares of common stock

 

Warrants exercisable for 162,133 shares of common stock

 

Options exercisable for 32,500 shares of common stock

 

 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

7. Edward Roffman

 

29,000 shares of common stock

 

Warrants exercisable for 3,750 shares of common stock

 

Options exercisable for 47,500 shares of common stock

 

8. Michael Taglich

 

431,885 shares of common stock, beneficially owned

 

Warrants exercisable for 417,587 shares of common stock, beneficially owned

 

Options exercisable for 32,500 shares of common stock.

 

9. Dr. Benjamin Warner

 

1,497,385 shares of common stock, beneficially owned

 

Options exercisable for 92,500 shares of common stock

 

10. Robert Taglich (10% holder)

 

352,410 shares of common stock, beneficially owned

 

Warrants exercisable for 355,030 shares of common stock, beneficially owned

 

 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

Schedule 3(q)(iv)

 

Icagen, Inc.-Existing Securities; Obligations; Transfer Agent

 

 

[*****]

 

The Series A Preferred and Series B Preferred provide for registration rights however no preferred stock is outstanding

 

The Series A Preferred has a redemption right, however no Series A Preferred stock is outstanding.

 

The warrants issued in the April 2017 bridge financing provide that they can be exchanged for warrants issued in the Company’s debt financing.

 

 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

Schedule 3(r)

 

Indebtedness and Other Contracts

 

Icagen, Inc. has outstanding notes in the principal amount of $1,500,000 outstanding that were issued in April 2017

 

Icagen, Inc. owes American Milling $333,333.34 pursuant to the terms of a settlement agreement

 

Icagen, Inc. owes SNR Dentons $1,400,000 pursuant to the terms of a settlement agreement

 

Icagen, Corp. has a Purchase Money lease obligation for Synchropatch Equipment supplied by Nanio0n Technologies

 

Icagen, Corp. owes deferred purchase consideration due to Pfizer of $10,000,000 in the form of an annual royalty payment payable quarterly commencing on May 31, 2017.

 

Agreements with Material Adverse Effect

 

Icagen-T-MSA and related agreements with Sanofi

 

Icagen, Inc.-MSA and other related agreements with Pfizer

 

Secured Obligations

 

Icagen -T -Deed of Trust and Assignment of Rents in favor of Sanofi US Services Inc., Deed of Sale and Reverter and UCC-1 for real estate and fixtures located at 2090 E. Innovation Park drive, Oro Valley, Arizona

 

Icagen-T-Sanofi US Services Inc UCC-1 on assets remaining at the Tucson site that are owned by Sanofi

 

Icagen, Inc.-MSA and other related agreements with Pfizer

 

Icagen, Inc. -U.S. Bank Equipment Finance UCC-1

 

 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

Schedule 3(s)

 

Litigation

 

Icagen Inc., SNR Dentons threatened litigation

 

 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

Schedule 3(t)

 

[*****]

 

 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

Schedule 3(u)(i)

 

[*****]

 

 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

Schedule 3(u)(iii)

 

[*****]

 

 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

Schedule 3(u)(iv)

 

Actions, Claims, Audits, Lawsuits or Arbitrations Pending against Benefit Plans

 

None

 

 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

Schedule 3(u)(vii)

 

Additional Benefits

 

Mark Korb and Ben Warner work less than full time

 

 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

Schedule 3(v)(i)

 

Real Property

 

Facility and Real Estate located at 2090 E. Innovation Park Drive, Oro Valley, Arizona owned by Icagen-T subject to lien

 

The Facility in Tucson is subject to a $5 million lien and certain of the equipment located on the property is subject to a lien by Sanofi

 

Sublease between Icagen, Inc. and Pfizer with respect to property located at 4222 Emperor Blvd., Durham, NC

 

 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

Schedule 3(v)(ii)

 

Fixtures and Equipment

 

Certain Equipment located at 2090 E. Innovation Park drive, Oro Valley, Arizona owned by Sanofi

 

[*****]

 

Icagen Corp Purchase Money lease obligation for Synchropatch Equipment as supplied by Nanion Technologies

 

 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

Schedule 3(w)(i)

 

Expired or Terminated Intellectual Property

 

Patents due to expire within 5 years:

 

US 7,858,385
EP 1525459
JP 4560403
SG 109345
US 9,157,875

 

 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

Schedule 3(w)(ii)

 

List of Patents and Trademarks

 

Reference   Title   Country   Application No.   Pub. No.   Patent No.   Status
ICA-001   METHOD FOR DETECTING BINDING EVENTS USING MICRO-X-RAY FLUORESCENCE SPECTROMETRY   United States   09/859,701   2003-0027129   7,858,385   Patented
ICA-002EP   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   Europe   3748920   1525458   1525458   Patented
ICA-002BE   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   Belgium   3748920   1525458   1525458   Patented
ICA-002CH   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   Switzerland   3748920   1525458   1525458   Patented
ICA-002DE   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   Germany   3748920   1525458   1525458   Patented
ICA-002DK   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   Denmark   3748920   1525458   1525458   Patented

 

 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

Reference   Title   Country   Application No.   Pub. No.   Patent No.   Status
ICA-002ES   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   Spain   3748920   1525458   1525458   Patented
ICA-002FI   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   Finland   3748920   1525458   1525458   Patented
ICA-002FR   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   France   3748920   1525458   1525458   Patented
ICA-002GB   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   United Kingdom   3748920   1525458   1525458   Patented
ICA-002IT   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   Italy   3748920   1525458   1525458   Patented
ICA-002SE   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   Sweden   3748920   1525458   1525458   Patented
ICA-002NL   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   Netherlands   3748920   1525458   1525458   Patented
ICA-002JP   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   Japan   2004-524531   2006-503268   4560403   Patented

 

 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

Reference   Title   Country   Application No.   Pub. No.   Patent No.   Status
ICA-002SG   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   Singapore   200500360-3   109345   109345   Patented
ICA-002C2   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   United States   11/444,660   2007-0003008   7,519,145   Patented
ICA-002C3   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   United States   12/396,592   2009-0175410   7,929,662   Patented
ICA-003EP   METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING   Europe   4755687.3   1644095   1644095   Patented
ICA-003CH   METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING   Switzerland/
Liechtenstein
  4755687.3   1644095   1644095   Patented
ICA-003DE   METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING   Germany   4755687.3   1644095   1644095   Patented
ICA-003FR   METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING   France   4755687.3   1644095   1644095   Patented

 

 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

Reference   Title   Country   Application No.   Pub. No.   Patent No.   Status
ICA-003GB   METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING   United Kingdom   4755687.3   1644095   1644095   Patented
ICA-003IE   METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING   Ireland   4755687.3   1644095   1644095   Patented
ICA-003NL   METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING   Netherlands   4755687.3   1644095   1644095   Patented
ICA-003JP   METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING   Japan   2006-520181   2007527524   4782676   Patented
ICA-003SG   METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING   Singapore   2005085584       118682   Patented
ICA-003   METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING   United States   10/621,825   2005-0011818   6,858,148   Patented
ICA-003C1   METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING   United States   10/986,519   2005-0095636   7,241,381   Patented
ICA-004   DRUG DEVELOPMENT AND MANUFACTURING   United States   10/880,388   2004-0235059   9,157,875   Patented
ICA-005EP   X-RAY FLUORESCENCE ANALYSIS METHOD   Europe   7874491.9   2084519   2084519   Patented
ICA-005CH   X-RAY FLUORESCENCE ANALYSIS METHOD   Switzerland/
Liechtenstein
  07 874 491.9   2084519   2084519   Patented
ICA-005DE   X-RAY FLUORESCENCE ANALYSIS METHOD   Germany   60 2007 024 468.4   2084519   608007024468.4   Patented

 

 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

Reference   Title   Country   Application No.   Pub. No.   Patent No.   Status
ICA-005DK   X-RAY FLUORESCENCE ANALYSIS METHOD   Denmark   07 874 491.9   2084519   2084519   Patented
ICA-005FR1   X-RAY FLUORESCENCE ANALYSIS METHOD   France   07 874 491.9   2084519   2084519   Patented
ICA-005GB   X-RAY FLUORESCENCE ANALYSIS METHOD   United Kingdom   7874491.9   2084519   2084519   Patented
ICA-005HK   ADVANCED DRUG DEVELOPMENT AND MANUFACTURING   Hong Kong (via EP -005EPDV)   13104259.3   1177280   1177280   Patented
ICA-005IE   X-RAY FLUORESCENCE ANALYSIS METHOD   Ireland   7874491.9   1177280   2084519   Patented
ICA-005IT   X-RAY FLUORESCENCE ANALYSIS METHOD   Italy   7874491.9   1177280   2084519   Patented
ICA-005NL   X-RAY FLUORESCENCE ANALYSIS METHOD   Netherlands   7874491.9   1177280   2084519   Patented
ICA-005SE   X-RAY FLUORESCENCE ANALYSIS METHOD   Sweden   7874491.9   1177280   2084519   Patented
ICA-005EPDV   X-RAY MICROSCOPE   Europe   12164870.3   2511844   2511844   Patented
ICA-005CHDV   X-RAY MICROSCOPE   Switzerland and Lichtenstein   12164870.3   2511844   2511844   Patented
ICA-005DEDV   X-RAY MICROSCOPE   Germany   12164870.3   2511844   602007042616.2   Patented
ICA-005FRDV   X-RAY MICROSCOPE   France   12164870.3   2511844   2511844   Patented

 

 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

Reference   Title   Country   Application No.   Pub. No.   Patent No.   Status
ICA-005GBDV   X-RAY MICROSCOPE   United Kingdom   12164870.3   2511844   2511844   Patented
ICA-005HK   ADVANCED DRUG DEVELOPMENT AND MANUFACTURING   Hong Kong (via EP -005EPDV)   2013104259.3   1177280   1177280   Patented
ICA-005IEDV   X-RAY MICROSCOPE   Ireland   12164870.3   2511844   2511844   Patented
ICA-005JP   ADVANCED DRUG DEVELOPMENT AND MANUFACTURING   Japan   2009-532446   2010509566   5143841   Patented
ICA-005JPDV2   ADVANCED DRUG DEVELOPMENT AND MANUFACTURING   Japan   2014-123249   2014-123249   5913441   Patented
ICA-005C1   ADVANCED DRUG DEVELOPMENT AND MANUFACTURING   United States   14/693,094   2015-0309021   N/A   Pending
ICA-006EP   WELL PLATE   Europe   8798006.6   2183644   2183644   Patented
ICA-006BE   WELL PLATE   Belgium   8798007.6   2183644   2183644   Patented
ICA-006CH   WELL PLATE   Switzerland   8798008.6   2183644   2183644   Patented
ICA-006DE   WELL PLATE   Germany   8798009.6   2183644   602008044640.9   Patented
ICA-006DK   WELL PLATE   Denmark   8798010.6   2183644   2183644   Patented
ICA-006ES   WELL PLATE   Spain   8798011.6   2183644   2183644   Patented
ICA-006FI   WELL PLATE   Finland   8798012.6   2183644   2183644   Patented
ICA-006FR   WELL PLATE   France   8798013.6   2183644   2183644   Patented
ICA-006GB   WELL PLATE   United Kingdom   8798014.6   2183644   2183644   Patented
ICA-006IE   WELL PLATE   Ireland   8798015.6   2183644   2183644   Patented
ICA-006IT   WELL PLATE   Italy   8798016.6   2183644   2183644   Patented
ICA-006 NL   WELL PLATE   Netherlands   8798017.6   2183644   2183644   Patented
ICA-006NO   WELL PLATE   Norway   8798018.6   2183644   2183644   Patented
ICA-006SE   WELL PLATE   Sweden   8798019.6   2183644   2183644   Patented
ICA-006JP   WELL PLATE   Japan   2010-521206   2010537171   5628035   Patented

 

 

 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

Reference   Title   Country   Application No.   Pub. No.   Patent No.   Status
ICA-006JPDV   WELL PLATE   Japan   2013-117600   2013224946   5755682   Patented
ICA-006JPDV2   WELL PLATE   Japan   2014-202871   2015004692   6076308   Patented
ICA-006   WELL PLATE   United States   12/192,762   2009-0046832   8,238,515   Patented
ICA-006C1   WELL PLATE   United States   13/567,613   2013-0034205   8,873,707   Patented
ICA-006C2   WELL PLATE   United States   14/508,322   2015-0023467   9,476,846   Patented
ICA-006C3   WELL PLATE   United States   15/273,767   2017-0010228   N/A   Pending
ICA-007JP   METHOD AND APPARATUS FOR MEASURING PROTEIN POST-TRANSLATIONAL MODIFICATION   Japan   2010-5272   2010539944   5743135   Patented
ICA-007JPDV1   METHOD AND APPARATUS FOR MEASURING PROTEIN POST-TRANSLATIONAL MODIFICATION   Japan   2014-221166   2015033386   N/A   Pending
ICA-007C1/XR7-US2   METHOD AND APPARATUS FOR MEASURING PROTEIN POST-TRANSLATIONAL MODIFICATION   United States   15/052,914   2016-0201111   N/A   Pending
ICA-008CN   METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS   China   200980125952.3   102083365   ZL 200980125952.3   Patented
ICA-008CNDV   METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS   China   201310298029.8   103411988   2077368   Patented

 

 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

Reference   Title   Country   Application No.   Pub. No.   Patent No.   Status
ICA-008CNDV2   METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS   China   201510083796.6   N/A   N/A   Pending
ICA-008EP   METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS   Europe   09774467.6   2306897   N/A   Allowed
ICA-008HK   METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS   Hong Kong   11112984.0   1158478   1158478   Patented
ICA-008   METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS USING X-RAY FLUORESCENCE   United States   12/496,532   2010-0003697   8,431,357   Patented
ICA-008C1   METHOD FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS USING X-RAY FLUORESCENCE USING X-RAY FLUORESCENCE   United States   13/871,697   2013-0236887   9,063,154   Patented
ICA-008C2   METHOD FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS USING X-RAY FLUORESCENCE   United States   14/669,923   2015-0198615   9,506,931   Patented
ICA-008C3   METHOD FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS USING X-RAY FLUORESCENCE   United States   15/334,854   2017-0045530   N/A   Pending
ICA-009   METHOD FOR ANALYSIS USING X-RAY FLUORESCENCE   United States   13/317,341   2012-0093286   9,063,066   Patented
ICA-009C1   METHOD FOR ANALYSIS USING X-RAY FLUORESCENCE   United States   14/715,206   2015-0276631   9,435,756   Patented

 

 

 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

Reference   Title   Country   Application No.   Pub. No.   Patent No.   Status
ICA-009C2   METHOD FOR ANALYSIS USING X-RAY FLUORESCENCE   United States   14/715,218   2015-0276632   9,442,085   Patented
ICA-009C3   METHOD FOR ANALYSIS USING X-RAY FLUORESCENCE   United States   14/715,233   2015-0260664   9,335,284   Patented
ICA-009C4   METHOD FOR ANALYSIS USING X-RAY FLUORESCENCE   United States   15/227,292   2016-0341678   N/A   Pending
ICA-010PC   METHODS AND APPARATUS FOR MEASURING METALS AND METALLOIDS   International   PCT/US17/28064   N/A   N/A   Pending

 

 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

 

 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

 

 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

 

 

 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

Schedule 3(w)(iii)

 

Agreements Relating to Intellectual Property

 

None

 

 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

Schedule 3(w)(iv)

 

Payments on Intellectual Property

 

None

 

 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

Schedule 3(w)(v)

 

Title to Intellectual Property Present or Former Employees

 

None

 

 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

Schedule 3(w)(vii)

 

Works Created by Employees or Affiliates of the Company

 

None

 

 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

Schedule 3(z)(ii)

 

Tax Status

 

None

 

 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

Schedule 3(z)(iii)

 

Tax Liens

 

None

 

 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

Schedule 3(z)(iv)

 

Material Beneficial Interest

 

None

 

 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

Schedule 3(aa)

 

Internal Control

 

As disclosed in Icagen, Inc’s Annual Report on Form 10-K for the year ended December 31, 2016, Icagen, Inc. has a weakness in internal control over financial reporting and disclosure controls

 

 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

Schedule 3(jj)

 

Judgments Against Management

 

None

 

 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

Schedule 3(kk)

 

Stock Option Plans

 

The following table sets forth information about the securities of Icagen, Inc. authorized for issuance under our equity compensation plans for the

 

    Number of securities to be issued upon exercise of outstanding options     Weighted average exercise price of outstanding options     Number of securities remaining for future issuance under equity compensation plans  
Equity Compensation plans approved by the stockholders                  
2005 Stock incentive plan     730,791     $ 3.67       -  
2015 stock incentive plan     722,500     $ 3.50       77,500  
                         
      1,453,291     $ 3.59       77,500  

 

 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

Schedule 3(nn)

 

Other Covered Persons and Related Matters

 

Taglich Brothers has been paid commission on prior private placements

 

 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

Schedule 3(rr)

 

Ranking of Notes

 

Icagen-T-Sanofi lien on the real estate is a senior lien

 

Icagen, Inc.-Purchase Money lease obligation for Synchropatch equipment is a prior lien

 

 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

Schedule 3(ss)(i)

 

Customers with Gross Sales over $250,000

 

Sanofi

 

Pfizer

 

[*****]

 

 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

Schedule 3(ss)(ii)

 

Contracts with Major Customers

 

Sanofi

 

Pfizer

 

[*****]

 

 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

Schedule 3(ss)(iii)

 

Termination of Agreements

 

The MSA with Sanofi and the MSA with Pfizer have reductions in services to be provided over time.

 

 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

Schedule 3(ww)

 

Liens

 

Icagen-T-Deed of Trust and assignment of Rents in favor of Sanofi US Services Inc., Deed of Sale with Reverter and UCC-1 for real estate located at 2090 E. Innovation Park drive, Oro Valley, Arizona

 

Icagen, Inc.-U.S. Bank Equipment Finance UCC-1

 

 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

Schedule 3(yy)

 

Material Contracts

 

4.1 Form of Warrant to Purchase Common Stock (Incorporated by reference to the Registration Statement on Form S-1 filed February 14, 2012, File No. 333-179508)
4.2 Promissory Note, dated September 21, 2006, in the principal amount of $2,200,000 payable to the Incorporated County of Los Alamos (Incorporated by reference to the Registration Statement on Form S-1 filed February 14, 2012, File No. 333-179508)
4.3 Stock Option Plan (Incorporated by reference to the Registration Statement on Form S-1 filed February 14, 2012, File No. 333- 179508)
4.4 List of Warrant Holders (Incorporated by reference to the Registration Statement on Form S-1 filed February 14, 2012, File No. 333-179508)
4.5 Form of Bridge Warrant (Incorporated by reference to the Annual report filed on Form 10-K filed April 1, 2013, File No. 000- 54748)
4.6 Form of Bridge Note (Incorporated by reference to the Annual report filed on Form 10-K filed April 1, 2013, File No. 000-54748)
4.7 Promissory Note dated May 23, 2012 in the principal amount of $750,000 payable to Los Alamos National Bank (Incorporated by reference to the Annual report filed on Form 10-K filed April 1, 2013, File No. 000-54748)
4.8 Promissory Note dated June 8, 2012 in the principal amount of $148,500 payable to Los Alamos National Bank (Incorporated by reference to the Annual report filed on Form 10-K filed April 1, 2013, File No. 000-54748)
4.9 Promissory Note dated May 23, 2011 in the principal amount of $750,000 payable to Los Alamos National Bank and Commercial Loan Agreement dated May 23, 2011 between Los Alamos National Bank and Caldera Pharmaceuticals, Inc. (Incorporated by reference to the Annual report filed on Form 10-K filed April 1, 2013, File No. 000-54748)
4.10 Commercial Loan Agreement dated June 8, 2012 between Los Alamos National Bank, Caldera Pharmaceuticals, Inc. and XPRO Corp (Incorporated by reference to the Annual report filed on Form 10-K filed April 1, 2013, File No. 000-54748)
4.11 Certificate of designations for Series B Preferred Stocks (Incorporated by reference to Current Report on Form 8-K filed April 29, 2013, File No. 000-54748)
4.12 Form of Advisor Warrant (Incorporated by reference to Current Report on Form 8-K filed April 29, 2013)
4.13 Form of Placement Agent Warrant (Incorporated by reference to Current Report on Form 8-K filed April 29, 2013, File No. 000- 54748)
4.14 Form of Securities Purchase Agreement (Incorporated by reference to Current Report on Form 8-K filed April 29, 2013, File No. 000-54748)
4.15 Form of Investor Warrant (Incorporated by reference to Current Report on Form 8-K filed April 29, 2013)
4.16 Form of Investor Warrant (Incorporated by reference to Current Report on Form 8-K filed January 7, 2015 File No. 000-54748)
4.17 Form of Placement Agent Warrant (Incorporated by reference to Current Report on Form 8-K filed January 7, 2015 File No. 000- 54748)
4.18 Form of Bridge Exchange Warrant (Incorporated by reference to the Current Report on Form 8-K filed on February 3, 2015, File No. 000-54748)
4.19 Form of Series B Exchange Warrant (Incorporated by reference to the Current Report on Form 8-K filed on February 3, 2015, File No. 000-54748)

 

 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

4.20 Form of Placement Agent Exchange Warrant (Incorporated by reference to the Current Report on Form 8-K filed on February 3, 2015, File No. 000-54748)
4.21 Form of Stock Option Agreement 2005 Incentive Stock Plan Warrant (Incorporated by reference to the Registration Statement on Form S-8 filed on August 17, 2017, File No. 333-213173)
4.22 Icagen, Inc. Stock Incentive Plan (Incorporated by reference to Exhibit B to the Preliminary Information Statement on Schedule 14C filed with the Securities and Exchange Commission on December 24, 2015 and to the Current Report on Form 8-K filed on December 29, 2015, File No. 000-54748)
4.23 Icagen, Inc. Stock Option Agreement under the 2015 Stock Incentive Plan, as amended (Incorporated by reference to the Current Report on Form 8-K filed on December 29, 2015, File No. 000-54748)
4.24 Form of Note issued to Investors (Incorporated by reference to the Current Report on Form 8-K filed on July 7, 2016, File No. 000-54748)
4.25 Form of Warrant issued to investors (Incorporated by reference to the Current Report on Form 8-K filed on July 7, 2016, File No. 000-54748)
4.26 Form of note issued to Investors (Incorporated by reference to the Current Report on Form 8-K filed on April 14, 2017, File No. 000-54748)
4.27 Form of Warrant issued to investors (Incorporated by reference to the Current Report on Form 8-k filed on April 14, 2017, file No. 000-54748)
10.1 Employment Agreement with Lori Peterson (nee Court) *(Incorporated by reference to the Registration Statement on Form S-1 filed February 14, 2012, File No. 333-179508)
10.2 Exclusive Patent License Agreement, dated September 8, 2005, by and between the Company and The Regents of the University of California *(Incorporated by reference to the Registration Statement on Form S-1/A filed June 14, 2012, File No. 333-179508)
10.3 Project Participation Agreement, dated as of September 21, 2006, by and between the Company and the Incorporated County of Los Alamos (Incorporated by reference to the Registration Statement on Form S-1 filed February 14, 2012, File No. 333-179508)
10.4 Amendment No. 1 to Participation Agreement, dated as of February 21, 2007, by and between the Company and the Incorporated County of Los Alamos (Incorporated by reference to the Registration Statement on Form S-1 filed February 14, 2012, File No. 333- 179508)
10.5 OEM Agreement, dated July 5, 2011, by and between the Company and our equipment supplier (Incorporated by reference to the Registration Statement on Form S-1/A filed June 8, 2012, File No. 333-179508)
10.6 Assignment of Exclusive License Agreement by The Regents of the University of California to Los Alamos National Security, LLC (Incorporated by reference to the Registration Statement on Form S-1/A filed April 20, 2012, File No. 333-179508)
10.7 Lease Agreement with Reeves & Associates, LLC in connection with Suite C (Incorporated by reference to the Registration Statement on Form S-1/A filed April 20, 2012, File No. 333-179508)
10.8 Lease Agreement with Reeves & Associates, LLC in connection with Suite D (Incorporated by reference to the Registration Statement on Form S-1/A filed April 20, 2012, File No. 333-179508)
10.9 Extension and Modification of Lease Agreements (Incorporated by reference to the Registration Statement on Form S-1/A filed April 20, 2012, File No. 333-179508)
10.10 Contract 2R44AI079935-03 with the National Institutes of Health; to develop strontium-selective therapies, contract amount: $3,000,000.00, operative from 08/24/2011 - 07/31/2014, $184,954.01. (Incorporated by reference to the Registration Statement on Form S-1/A filed April 20,2012, File No. 333-179508)
10.11 Contract 1R43GM090387-01 with the National Institutes of Health; to develop assays for carcinogens, contract amount: $200,000.00, operative from 08/06/2010 - 08/05/2012. (Incorporated by reference to the Registration Statement on Form S-1/A filed April 20, 2012, File No. 000-54748)
10.12 Employment Agreement with Benjamin Warner dated March 15, 2013* (Incorporated by reference to the Annual Report on Form 10-K filed April 1, 2013, File No. 000-54748)

 

 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

10.13 Security Agreement dated June 8, 2012 between Los Alamos National Bank and XPRO Corp (Incorporated by reference to the Annual Report on Form 10-K filed April 1, 2013, File No. 000-54748)
10.14 Guaranty dated June 8, 2012 by and among Los Alamos National Bank, Caldera Pharmaceuticals, Inc., XPRO Corp and Ellen K. McBee (Incorporated by reference to the Annual Report on Form 10-K filed April 1, 2013, File No. 000-54748)
10.15 Settlement Agreement and Release between the Company and Gary Altman dated as of July 30, 2014 (Incorporated by reference to the Quarterly Report on Form 10-Q for quarter ended June 30, 2014 filed on August 14, 2014, File No. 000-54748)
10.16 Employment Agreement with Richard Cunningham dated as of November 24, 2014* (Incorporated by reference to the Current Report on Form 8-K filed on November 17, 2014, File No. 000-54748)
10.17 Securities Purchase Agreement (Incorporated by reference to the Current Report on Form 8-K filed January 7, 2015, File No. 000- 54748)
10.18 Form of Series B Preferred Stock Exchange Agreement (Incorporated by reference to the Current Report on Form 8-K filed on February 3, 2015, File No. 000-54748)
10.19 Form of Bridge Warrant Exchange Agreement (Incorporated by reference to the Current Report on Form 8-K filed on February 3, 2015, File No. 000-54748)
10.20 Form of Series B Preferred Stock and Warrant Exchange Agreement (Incorporated by reference to the Current Report on Form 8-K filed on February 3, 2015, File No. 000-54748)
10.21 The Placement Agent Exchange Agreement (Incorporated by reference to the Current Report on Form 8-K filed on February 3, 2015, File No. 000-54748)
10.22 Asset Purchase Agreement and Collaboration Agreement dated as of June 26, 2015 between XRpro Sciences, Inc. and Icagen, Inc. (2) (Incorporated by reference to the Current Report on Form 8-K filed on July 2, 2015, File No. 000-54748)
10.23 Master Service Agreement dated as of June 26, 2015 between XRpro Sciences and Icagen, Inc. (2)(3) (Incorporated by reference to the Current Report on Form 8-K filed on July 2, 2015, File No. 000-54748)
10.24 Mutual Release and Settlement Agreement (Incorporated by reference to the Current Report on Form 8-K filed October 2, 2015, File No. 000-54748)
10.25 Master Services Agreement between Icagen-T, Inc. and Sanofi US Services Inc. (Incorporated by reference to the Current Report on Form 8-K filed July 19, 2016 File No. 000-54748)
10.26 Deed of Trust dated July 15, 2016 (Incorporated by reference to the Current Report on Form 8-K filed July 19, 2016 File No. 000-54748)
10.27 Deed of Sale dated July 15, 2016 (Incorporated by reference to the Current Report on Form 8-K filed July 19, 2016 File No. 000-54748)
10.28 Amendment to Asset Purchase and Collaboration Agreement between Icagen, Inc. Pfizer (Incorporated by reference to the Current Report on Form 8-K filed July 19, 2016 File No. 000-54748)
10.29 Form of Securities Purchase Agreement between Icagen, Inc. and investors (Incorporated by reference to the Current Report on Form 8-K filed July 7, 2016 File No. 000-54748)
10.30 Form of Security and Pledge Agreement between Icagen, Inc and investors (Incorporated by reference to the Current Report on Form 8-K filed July 7, 2016 File No. 000-54748)
10.31 Form of Securities Purchase Agreement between Icagen, Inc., and investors (Incorporated by reference to the Current Report on Form 8-K filed on April 14, 2017, File No. 000-54748)
10.32 Form of Security and Pledge Agreement between Icagen, Inc., and Investors (Incorporated by reference to the Current Report on Form 8-K filed on April 14, 2017, File No. 000-54748)

 

 

Exhibit 10.2

 

Execution Version

 

SECURITY AND PLEDGE AGREEMENT FOR OBLIGATIONS OF PARENT

 

SECURITY AND PLEDGE AGREEMENT FOR OBLIGATIONS OF PARENT , dated as of May 15, 2017 (this “ Agreement ”), made by Icagen, Inc., a Delaware corporation with offices located at 4222 Emperor Blvd., Suite 350, Research Triangle Park, Durham, NC, 27703 (the “ Parent ”) and each of the undersigned direct and indirect Subsidiaries (as defined below) from time to time other than Icagen-T, Inc. (together with the Parent, collectively, the “ Grantors ” and each a “ Grantor ”), in favor of GPB Debt Holdings II, LLC (in its capacity as collateral agent for itself as purchaser of the Notes (as defined below) and each other Person who may become a Noteholder (as defined below), the “ Collateral Agent ;” and in its capacity as the purchaser of the Notes, the “ Buyer ”), pursuant to the Securities Purchase Agreement, dated as of May 15, 2017 (as amended, modified, supplemented, extended, renewed, restated or replaced from time to time, the “ Securities Purchase Agreement ”).

 

W I T N E S S E T H :

 

WHEREAS, the Parent, Icagen-T, Inc., a Delaware corporation and a wholly-owned Subsidiary of the Parent (“ ICA-T ”) and the Buyer are parties to the Securities Purchase Agreement, pursuant to which, among other items (i) ICA-T issued and sold an $8,000,000 aggregate principal amount senior secured convertible note of ICA-T (as such may be amended, modified, supplemented, extended, renewed, restated or replaced from time to time (the “ ICA-T Note ”), and (ii) the Parent issued and sold, among other securities, a $2,000,000 aggregate principal amount senior secured convertible note of the Parent (as such may be amended, modified, supplemented, extended, renewed, restated or replaced from time to time (the “ Parent Note ” and together with the ICA-T Note, collectively, the “ Notes ), to the Buyer;”

 

WHEREAS, the Parent and certain other Grantors from time to time (each a “ Guarantor ” and collectively, the “ Guarantors ”) may execute and deliver one or more guaranties including, but not limited to, that Guaranty of Obligations of Parent (as defined below) in form and substance acceptable to and in favor of the Collateral Agent, for the benefit of itself as a Noteholder and any other Noteholder with respect to all of Parent’s obligations under the Notes, the Securities Purchase Agreement and the other Transaction Documents (as defined in the Securities Purchase Agreement);

 

WHEREAS, it is a condition precedent to the Buyer’s obligation to purchase the Notes issued pursuant to the Securities Purchase Agreement, that the Grantors shall have executed and delivered to the Collateral Agent this Agreement providing for the grant to the Collateral Agent, for the benefit of itself as a Noteholder and any other Noteholder, of a valid, enforceable, and perfected security interest in all personal property of each Grantor to secure all of (i) the Parent’s and ICA-T’s obligations under the Notes and other Transaction Documents, (ii) the Grantors’ obligations under the Guaranty of Obligations of Parent; and (iii) the Grantors’ obligations under the Guaranty of Obligations of ICA-T (as defined below); and

 

WHEREAS, each Grantor has determined that the execution, delivery and performance of this Agreement directly and/or indirectly benefits, and is in the best interest of, such Grantor;

 

 

 

 

NOW, THEREFORE, in consideration of the premises and the agreements herein and such other consideration which the parties hereto recognize and acknowledge the sufficiency of and in order to induce the Buyer to perform its obligations under the Securities Purchase Agreement, each Grantor agrees with the Collateral Agent, for the benefit of the Collateral Agent and the Noteholders, as follows:

 

SECTION 1. Definitions.

 

(a)       Reference is hereby made to the Securities Purchase Agreement and the Notes for a statement of the terms thereof. All terms used in this Agreement and the recitals hereto which are defined in the Securities Purchase Agreement, the Notes or in the Code (as defined below), and which are not otherwise defined herein shall have the same meanings herein as set forth therein; provided that terms used herein which are defined in the Code on the date hereof shall continue to have the same meaning notwithstanding any replacement or amendment of the Code except as the Collateral Agent may otherwise determine.

 

(b)       The following terms shall have the respective meanings provided for in the Code: “Accounts” “Account Debtor”, “Cash Proceeds”, “Certificate of Title”, “Chattel Paper”, “Commercial Tort Claim”, “Commodity Account”, “Commodity Contracts”, “Deposit Account”, “Documents”, “Electronic Chattel Paper”, “Equipment”, “Fixtures”, “General Intangibles”, “Goods”, “Instruments”, “Inventory”, “Investment Property”, “Letter-of-Credit Rights”, “Payment Intangibles”, “Proceeds”, “Promissory Notes”, “Security”, “Record”, “Security Account”, “Software”, and “Supporting Obligations”.

 

(c)       As used in this Agreement, the following terms shall have the respective meanings indicated below, such meanings to be applicable equally to both the singular and plural forms of such terms:

 

Affiliate ” of any Person means any other Person which, directly or indirectly, controls or is controlled by or is under common control with such Person and any officer or director of such Person. A Person shall be deemed to be “controlled by” any other Person if such Person possesses, directly or indirectly, power to vote 10% or more of the securities (on a fully diluted basis) having ordinary voting power for the election of directors or managers or power to direct or cause the direction of the management and policies of such Person, whether by contract or otherwise.

 

Bankruptcy Code ” means Chapter 11 of Title 11 of the United States Code, 11 U.S.C §§ 101 et seq. (or other applicable bankruptcy, insolvency or similar laws).

 

Business Day ” means any day other than Saturday, Sunday or other day on which commercial banks in New York City are authorized or required by law to remain closed.

 

Buyer ” shall have the meaning set forth in the recitals hereto.

 

Capital Stock ” means (i) with respect to any Person that is a corporation, any and all shares, interests, participations or other equivalents (however designated and whether or not voting) of corporate stock (including, without limitation, any warrants, options, rights or other securities exercisable or convertible into equity interests or securities of such Person), and (ii) with respect to any Person that is not a corporation, any and all partnership, membership or other equity interests of such Person.

 

  2  

 

 

Closing Date ” means the date of the sale by (i) ICA-T of the ICA-T Note, and (ii) the Parent of the Parent Note and the Parent Warrant to the Buyer pursuant to the terms of the Securities Purchase Agreement.

 

Code ” means Articles 8 or 9 of the Uniform Commercial Code as in effect from time to time in the State of New York; provided that, if perfection or the effect of perfection or non-perfection or the priority of any security interest in any Collateral is governed by the Uniform Commercial Code as in effect in a jurisdiction other than the State of New York, “Code” means the Uniform Commercial Code as in effect from time to time in such other jurisdiction for purposes of the provisions hereof relating to such perfection, effect of perfection or non-perfection or priority.

 

Collateral ” shall have the meaning set forth in Section 2(a) of this Agreement.

 

Collateral Agent ” shall have the meaning set forth in the preamble hereto.

 

Controlled Account Agreement ” means a deposit account control agreement or securities account control agreement with respect to a Pledged Account, in form and substance satisfactory to the Collateral Agent, as the same may be amended, modified, supplemented, extended, renewed, restated or replaced from time to time.

 

Controlled Accounts” means the Deposit Accounts, Commodity Accounts, Securities Accounts, and/or Foreign Currency Controlled Account of the Grantors listed on Schedule I attached hereto.

 

Copyright Licenses ” means all licenses, contracts or other agreements, whether written or oral, naming any Grantor as licensee or licensor and providing for the grant of any right to use or sell any works covered by any Copyright (including, without limitation, all Copyright Licenses set forth in Schedule II hereto).

 

Copyrights ” means all domestic and foreign copyrights, whether registered or not, including, without limitation, all copyright rights throughout the universe (whether now or hereafter arising) in any and all media (whether now or hereafter developed), in and to all original works of authorship fixed in any tangible medium of expression, acquired or used by any Grantor (including, without limitation, all copyrights described in Schedule II hereto), all applications, registrations and recordings thereof (including, without limitation, applications, registrations and recordings in the United States Copyright Office or in any similar office or agency of the United States or any other country or any political subdivision thereof), and all reissues, divisions, continuations, continuations in part and extensions or renewals thereof.

 

Domestic Subsidiary ” means any Subsidiary other than a Foreign Subsidiary.

 

Event of Default ” shall have the meaning set forth in Section 4(a) of each of the Notes.

 

  3  

 

 

Excluded Collateral ” means (A) the voting Capital Stock of any Foreign Subsidiary to the extent that (i) such Capital Stock represents more than 65% of the issued and outstanding voting Capital Stock of such Foreign Subsidiary and (ii) to the extent the pledge thereof is prohibited by the laws of such Foreign Subsidiary’s Organization or pledging more than 65% of the total outstanding voting Capital Stock of such Foreign Subsidiary would result in a material adverse tax consequence to a Grantor, (B) accounts receivable and/or Inventory of each Grantor, but only if and to the extent as of any time of determination any such Grantor’s accounts receivable and/or Inventory is being factored pursuant to an existing accounts receivable and/or Inventory financing arrangement between the provider of such financing and such Grantor, provided at all times commencing on the Closing Date (as defined in the Securities Purchase Agreement) that a Grantor’s accounts receivable and/or Inventory does not constitute Excluded Collateral pursuant to (B) of this definition of Excluded Collateral, such shall constitute Collateral and the Collateral Agent for the benefit of itself as a Noteholder and any other Noteholders shall have a senior secured security interest in and a valid, enforceable perfected senior priority Lien on such Grantor’s accounts receivable and/or Inventory and the Parent and each Grantor shall take at any time and from time to time any and all action necessary and/or as reasonably requested by the Collateral Agent to effectuate the same including, but not limited to, providing an opinion of legal counsel to the Parent relating to the above in form and substance satisfactory to the Collateral Agent, and (C) the Capital Stock of ICA-T; provided, the Capital Stock of ICA-T shall not be considered Excluded Collateral and shall constitute Collateral and “ Pledged Equity ” and ICA-T shall be a Pledged Entity commencing on the first calendar day following the date that the Master Services Agreement dated July 15, 2016 by and between Sanofi US Services, Inc. (“ Sanofi ”) and ICA-T (as amended, restated and/or otherwise modified, the “ MSA ”) shall not prohibit the Capital Stock of ICA-T from being pledged as Collateral (the “ Restriction End Date ”) and in connection therewith, ICA-T and the Parent shall take any and all such actions necessary and/or requested by the Collateral Agent to satisfy the Collateral Agent that such and the following has been effectuated and that the Collateral Agent for the benefit of itself as a Noteholder and any other Noteholders has a senior secured security interest in and a perfected senior priority Lien on the Capital Stock of ICA-T and that the Capital Stock of ICA-T is not directly and/or indirectly subject to any security interest and/or Lien of Sanofi and/or any other Person (except the Collateral Agent for the benefit of itself as a Noteholder and the holder of the Parent Note and any other Noteholder and/or other holder of a Parent Note) including, but not limited to, providing an opinion of legal counsel to the Parent relating to the above in form and substance satisfactory to the Collateral Agent (the “ ICA-T Capital Stock Actions ”).

 

Foreign Currency Controlled Accounts” means any Controlled Account of the Parent or its Subsidiaries holding non-United States dollar deposits.

 

Foreign Subsidiary ” means any Subsidiary of a Grantor organized under the laws of a jurisdiction other than the United States, any of the states thereof, Puerto Rico or the District of Columbia.

 

GAAP ” means U.S. generally accepted accounting principles consistently applied.

 

Governmental Authority ” means any nation or government, any Federal, state, city, town, municipality, county, local, foreign or other political subdivision thereof or thereto and any department, commission, board, bureau, instrumentality, agency or other entity exercising executive, legislative, judicial, taxing, regulatory or administrative powers or functions of or pertaining to government.

 

  4  

 

 

Guaranteed Obligations of Parent ” shall have the meaning set forth in Section 2 of the Guaranty of Obligations of Parent.

 

Guaranteed Obligations of ICA-T ” shall have the meaning set forth in Section 2 of the Guaranty of Obligations of ICA-T.

 

Guarantor ” or “ Guarantors ” shall have the meaning set forth in the recitals hereto.

 

Guaranty ” or “ Guaranties ” shall mean any additional guaranties required to be entered into pursuant to the Transaction Documents.

 

Guaranty of Obligations of ICA-T ” shall mean that Guaranty of Obligations of ICA-T dated the date hereof made by the Grantors and any future grantors.

 

Guaranty of Obligations of Parent ” shall mean that Guaranty of Obligations of Parent dated the date hereof made by the Grantors and any future grantors.

 

ICA-T Note ” shall have the meaning set forth in the recitals hereto.

 

Insolvency Proceeding ” means any proceeding commenced by or against any Person under any provision of the Bankruptcy Code or under any other bankruptcy or insolvency law, assignments for the benefit of creditors, formal or informal moratoria, compositions, or extensions generally with creditors, or proceedings seeking reorganization, arrangement, or other similar relief.

 

Intellectual Property ” means, collectively, the Copyrights, Trademarks and Patents.

 

Intellectual Property Security Agreement ” means the Intellectual Property Security Agreement required to be delivered pursuant to Section 5(h)(i) of this Agreement, in the form attached hereto as Exhibit A .

 

Licenses ” means, collectively, the Copyright Licenses, the Trademark Licenses and the Patent Licenses, provided any such License does not contain a provision expressly prohibiting the pledge of such License.

 

Lien ” means any mortgage, lien, pledge, charge, security interest, adverse claim or other encumbrance upon or in any property or assets.

 

“Noteholder” means, at any time, the holders of all or any portion of the Notes at such time.

 

Obligations ” shall have the meaning set forth in Section 3 of this Agreement.

 

Paid in Full” or “ Payment in Full” means the indefeasible payment in full (including by way of redemption) of all Obligations in cash (and/or through the issuance of shares of Parent Common Stock (as defined in the Parent Note), by ICA-T, Parent or a Subsidiary but only if and to the extent permitted by each of the Notes and the other Transaction Documents).

 

Parent ” shall have the meaning set forth in the preamble hereto.

 

  5  

 

 

Patent Licenses ” means all licenses, contracts or other agreements, whether written or oral, naming any Grantor as licensee or licensor and providing for the grant of any right to manufacture, use or sell any invention covered by any Patent (including, without limitation, all Patent Licenses set forth in Schedule III hereto).

 

Patents ” means all domestic and foreign letters patent, design patents, utility patents, industrial designs, inventions, trade secrets, ideas, concepts, methods, techniques, processes, proprietary information, technology, know-how, formulae, rights of publicity and other general intangibles of like nature, now existing or hereafter acquired (including, without limitation, all domestic and foreign letters patent, design patents, utility patents, industrial designs, inventions, trade secrets, ideas, concepts, methods, techniques, processes, proprietary information, technology, know-how and formulae described in Schedule III hereto), all applications, registrations and recordings thereof (including, without limitation, applications, registrations and recordings in the United States Patent and Trademark Office, or in any similar office or agency of the United States or any other country or any political subdivision thereof), and all reissues, reexaminations, divisions, continuations, continuations in part and extensions or renewals thereof.

 

Perfection Requirement” or “Perfection Requirements ” shall have the meaning set forth in Section 4(j) of this Agreement.

 

Person ” means an individual, corporation, limited liability Parent, partnership, association, joint-stock Parent, trust, unincorporated organization, joint venture or other enterprise or entity or Governmental Authority.

 

Pledged Accounts ” means all of each Grantor’s right, title and interest in all of its Deposit Accounts, Commodity Accounts and Securities Accounts (in all cases, including, without limitation, all Controlled Accounts and Foreign Currency Control Accounts).

 

Pledged Entity ” means, each Person listed from time to time on Schedule IV hereto as a “Pledged Entity,” together with each other Person, any right in or interest in or to all or a portion of whose Capital Stock is acquired or otherwise owned by a Grantor after the date hereof.

 

Pledged Equity ” means all of each Grantor’s right, title and interest in and to all of the Securities and Capital Stock now or hereafter owned by such Grantor, regardless of class or designation, including all substitutions therefor and replacements thereof, all proceeds thereof and all rights relating thereto, also including any certificates representing the Securities and/or Capital Stock, the right to receive any certificates representing any of the Securities and/or Capital Stock, all warrants, options, share appreciation rights and other rights, contractual or otherwise, in respect thereof, and the right to receive dividends, distributions of income, profits, surplus, or other compensation by way of income or liquidating distributions, in cash or in kind, and cash, instruments, and other property from time to time received, receivable, or otherwise distributed in respect of or in addition to, in substitution of, on account of, or in exchange for any or all of the foregoing; provided , however , that the term Pledged Equity shall include all ICA-T Capital Stock commencing on the Restriction End Date and the Parent, ICA-T and each other Grantor shall take all ICA-T Capital Stock Actions.

 

  6  

 

 

Pledged Operating Agreements ” means all of each Grantor’s rights, powers and remedies under the limited liability Parent operating agreements of each of the Pledged Entities that are limited liability companies, as may be amended, modified, supplemented, extended, renewed, restated or replaced from time to time.

 

Pledged Partnership Agreements ” means all of each Grantor’s rights, powers, and remedies under the partnership agreements of each of the Pledged Entities that are partnerships, as may be amended, modified, supplemented, extended, renewed, restated or replaced from time to time.

 

Securities Purchase Agreement ” shall have the meaning set forth in the recitals hereto.

 

“Subsidiary” means any Person in which a Grantor directly or indirectly (i) owns a majority of the outstanding Capital Stock, voting stock or holds a majority of any equity or similar interest of such Person or (ii) controls or operates a substantial portion of the business, operations or administration of such Person, and all of the foregoing, collectively, “ Subsidiaries ”.

 

Trademark Licenses ” means all licenses, contracts or other agreements, whether written or oral, naming any Grantor as licensor or licensee and providing for the grant of any right concerning any Trademark, together with any goodwill connected with and symbolized by any such licenses, contracts or agreements and the right to prepare for sale or lease and sell or lease any and all Inventory now or hereafter owned by any Grantor and now or hereafter covered by such licenses, contracts or agreements (including, without limitation, all Trademark Licenses described in Schedule V hereto).

 

Trademarks ” means all domestic and foreign trademarks, service marks, collective marks, certification marks, trade names, business names, d/b/a’s, assumed names, Internet domain names, trade styles, designs, logos and other source or business identifiers and all general intangibles of like nature, now or hereafter owned, adopted, acquired or used by any Grantor (including, without limitation, all domestic and foreign trademarks, service marks, collective marks, certification marks, trade names, business names, d/b/a’s, assumed names, Internet domain names, trade styles, designs, logos and other source or business identifiers described in Schedule V(a) hereto), all applications, registrations and recordings thereof (including, without limitation, applications, registrations and recordings in the United States Patent and Trademark Office or in any similar office or agency of the United States, any state thereof or any other country or any political subdivision thereof), and all reissues, extensions or renewals thereof, together with all goodwill of the business symbolized by such marks and all customer lists, formulae and other Records of any Grantor relating to the distribution of products and services in connection with which any of such marks are used.

 

SECTION 2. Grant of Security Interest.

 

(a)       As collateral security for the due and punctual payment and performance of all of the Obligations, as and when due, each Grantor hereby pledges, assigns and grants to the Collateral Agent, for the benefit of itself as a Noteholder itself and for the benefit of any other Noteholders, a continuing security interest in, all personal property and assets of such Grantor, wherever located and whether now or hereafter existing and whether now owned or hereafter acquired, of every kind, nature and description, whether tangible or intangible (collectively, the “ Collateral ”), including, without limitation, the following:

 

(i)        All Accounts (but with regard to accounts receivable, subject to the provisions of Section (B) of the definition of Excluded Collateral);

 

  7  

 

 

(ii)       all Chattel Paper (whether tangible or Electronic Chattel Paper) having a value in excess of $25,000;

 

(iii)      all Commercial Tort Claims having a value in excess of $25,000, including, without limitation, those specified on Schedule VI hereto;

 

(iv)      all Documents;

 

(v)       all Equipment;

 

(vi)      all Fixtures;

 

(vii)     all General Intangibles (including, without limitation, all Payment Intangibles);

 

(viii)     all Goods;

 

(ix)       all Inventory (subject to the provisions of Section (B) of the definition of Excluded Collateral);

 

(x)        all Instruments (including, without limitation, all Promissory Notes and each certificated Security);

 

(xi)       all Investment Property (and, regardless of whether classified as Investment Property under the Code, all Pledged Equity, Pledged Operating Agreements and Pledged Partnership Agreements);

 

(xii)      all Intellectual Property and Licenses;

 

(xiii)     all Letters of Credit and Letter-of-Credit Rights;

 

(xiv)     all Pledged Accounts, all cash and other property from time to time deposited therein, and all monies and property in the possession or under the control of the Collateral Agent or any Noteholder or any Affiliate, representative, agent or correspondent of the Collateral Agent or any such Noteholder;

 

(xv)      all Supporting Obligations;

 

  8  

 

 

(xvi)     all other tangible and intangible personal property of each Grantor (whether or not subject to the Code), including, without limitation, all those relating to all compound libraries owned by the Grantors pursuant to which a security interest can be granted upon, all  cell line and plasmid repositories owned by the Grantors and related items, all Deposit and other accounts and all cash and all investments therein, all proceeds, products, offspring, accessions, rents, profits, income, benefits, substitutions and replacements of and to any of the property of any Grantor described in the preceding clauses of this Section 2(a) (including, without limitation, any proceeds of insurance thereon and all causes of action, claims and warranties now or hereafter held by each Grantor in respect of any of the items listed above), and all books, correspondence, files and other Records, including, without limitation, all tapes, desks, cards, Software, data and computer programs in the possession or under the control of any Grantor or any other Person from time to time acting for any Grantor, in each case, to the extent of such Grantor’s rights therein, that at any time evidence or contain information relating to any of the property described in the preceding clauses of this Section 2(a) or are otherwise necessary or helpful in the collection or realization thereof; and

 

(xvii)    all Proceeds, including all Cash Proceeds and Noncash Proceeds, and products of any and all of the foregoing Collateral;

 

in each case howsoever any Grantor’s interest therein may arise or appear (whether by ownership, security interest, claim or otherwise).

 

(b)       Notwithstanding anything herein to the contrary, the term “ Collateral ” shall not include any Excluded Collateral.

 

(c)       Except for Permitted Liens, each Grantor agrees not to further encumber, or permit any other Lien to exist that encumbers, any of its Copyrights, Copyright applications, Copyright registrations and like protections in each work of authorship and derivative work, whether published or unpublished, any Licenses other than by the parties to the License, Patents, Patent applications and like protections, including improvements, divisions, continuations, renewals, reissues, extensions, and continuations-in-part of the same, Trademarks, service marks and, to the extent permitted under applicable law, any applications therefor, whether registered or not, and the goodwill of the business of such Grantor connected with and symbolized thereby, know-how, operating manuals, trade secret rights, rights to unpatented inventions, and any claims for damage by way of any past, present, or future infringement of any of the foregoing, in each case without the Collateral Agent’s prior written consent (which consent may be withheld or given in the Collateral Agent’s sole discretion).

 

(d)       The Grantors agree that the pledge of the shares of Capital Stock acquired by a Grantor of any and all Persons now or hereafter existing who is a Foreign Subsidiary may be supplemented by one or more separate pledge agreements, deeds of pledge, share charges or other similar agreements or instruments, executed and delivered by the relevant Grantors in favor of the Collateral Agent, which pledge agreements will provide for the pledge of such shares of Capital Stock in accordance with the laws of the applicable foreign jurisdiction but in no event shall Excluded Collateral be pledged. With respect to such shares of Capital Stock, the Collateral Agent may, at any time and from time to time, in its sole discretion, take such actions in such foreign jurisdictions that will result in the perfection of the Lien created in such shares of Capital Stock.

 

(e)       In addition, to secure the prompt and complete payment, performance and observance of the Obligations and in order to induce the Buyer as aforesaid, each Grantor hereby grants to the Collateral Agent, for itself and for the ratable benefit of the Noteholders, a right of set-off against the property of such Grantor held by the Collateral Agent, for itself and for the ratable benefit of the Noteholders, consisting of property described above in Section 2(a) now or hereafter in the possession or custody of or in transit to the Collateral Agent, for any purpose, including safekeeping, collection or pledge, for the account of such Grantor, or as to which such Grantor may have any right or power; provided that such right shall only to be exercised after an Event of Default has occurred and is continuing.

 

  9  

 

 

SECTION 3. Security for Obligations . The security interest created hereby in the Collateral constitutes continuing collateral security for all of the following obligations, whether direct or indirect, absolute or contingent, and whether now existing or hereafter incurred (collectively, the “ Obligations ”):

 

(a)       (i) all payments by the Parent as and when due and payable (by scheduled maturity, required prepayment, redemption, acceleration, demand or otherwise), of all amounts from time to time owing by it in respect of the Securities Purchase Agreement, this Agreement, the Parent Note, the ICA-T Note and the other Transaction Documents, and (ii) in the case of the Guarantors, the payment by such Guarantors, as and when due and payable of all (x) Guaranteed Obligations of Parent under the Guaranty of Obligations of Parent and (y) Guaranteed Obligations of ICA-T under the Guaranty of Obligations of ICA-T, including, without limitation, in all cases set forth in (i) – (ii) above, (A) all principal of, interest, redemption amounts, Late Charges (as defined in the Notes) and other amounts on the Notes and the other Transaction Documents (including, without limitation, all interest, redemption amounts, Late Charges and other amounts that accrue after the commencement of any Insolvency Proceeding of any Grantor, whether or not the payment of such interest is enforceable or is allowable in such Insolvency Proceeding), and (B) all fees (including legal fees), interest, Late Charges, premiums, penalties, contract causes of action, costs, commissions, expense reimbursements, indemnifications and all other amounts due or to become due under this Agreement or any of the Transaction Documents; and

 

(b)       the due performance and observance by each Grantor of all of its other obligations from time to time existing in respect of any of the Transaction Documents, including without limitation, with respect to any conversion or redemption rights of the Noteholders under the Notes.

 

SECTION 4. Representations and Warranties . Each Grantor represents and warrants as follows:

 

(a)        Schedule VII hereto sets forth (i) the exact legal name of each Grantor, and (ii) the state of incorporation, organization or formation and the organizational identification number of each Grantor in such state. The information set forth in Schedule VII hereto with respect to such Grantor is true and accurate in all respects. Such Grantor has not previously changed its name (or operated under any other name), jurisdiction of organization or organizational identification number from those set forth in Schedule VII hereto except as disclosed in Schedule VII hereto.

 

  10  

 

 

(b)       There is no pending or, to its knowledge, written notice threatening any action, suit, proceeding or claim affecting any Grantor before any Governmental Authority or any arbitrator, or any order, judgment or award issued by any Governmental Authority or arbitrator, in each case, that may adversely affect the grant by any Grantor, or the perfection, of the security interest purported to be created hereby in the Collateral, or the exercise by the Collateral Agent of any of its rights or remedies hereunder.

 

(c)       All Federal, state and local tax returns and other reports required by applicable law to be filed by any Grantor have been filed, or extensions have been obtained, and all taxes, assessments and other governmental charges imposed upon any Grantor or any property of any Grantor (including, without limitation, all federal income and social security taxes on employees’ wages) and which have become due and payable on or prior to the date hereof have been paid, except to the extent contested in good faith by proper proceedings which stay the imposition of any penalty, fine or Lien resulting from the non-payment thereof and with respect to which adequate reserves have been set aside for the payment thereof in accordance with GAAP.

 

(d)       All Equipment, Fixtures, Goods and Inventory of each Grantor now existing are, and all Equipment, Fixtures, Goods and Inventory of each Grantor hereafter existing will be, located and/or based at the addresses specified therefor in Schedule VIII hereto, except that each Grantor will give the Collateral Agent written notice of any change in the location of any such Collateral within 20 days of such change, other than to locations set forth on Schedule VIII hereto (and with respect to which the Collateral Agent has filed financing statements and otherwise fully perfected its Liens thereon). Each Grantor’s principal place of business and chief executive office, the place where each Grantor keeps its Records concerning the Collateral and all located at the addresses specified therefor in Schedule VIII hereto. None of the Accounts is or will be evidenced by Promissory Notes or other Instruments.

 

(e)       Set forth in Schedule IX hereto is a complete and accurate list, as of the date of this Agreement, of (i) each Promissory Note, Security and other Instrument owned by each Grantor, (ii) each Pledged Account of each Grantor, together with the name and address of each institution at which each such Pledged Account is maintained, the account number for each such Pledged Account and a description of the purpose of each such Pledged Account and (iii) the name of each Foreign Currency Controlled Account, together with the name and address of each institution at which each such Foreign Currency Controlled Account is maintained and the amount of cash or cash equivalents held in each such Foreign Currency Controlled Account. Set forth in Schedule IX hereto is a complete and correct list of each trade name used by each Grantor and the name of, and each trade name used by, each Person from which each Grantor has acquired any substantial part of the Collateral.

 

  11  

 

 

(f)       Each Grantor has delivered to the Collateral Agent complete and correct copies of each License described in Schedule X hereto, including all schedules and exhibits thereto, which represent all of the Licenses of the Grantors existing on the date of this Agreement. Each such License sets forth the entire agreement and understanding of the parties thereto relating to the subject matter thereof, and there are no other agreements, arrangements or understandings, written or oral, relating to the matters covered thereby or the rights of such Grantor or any of its Affiliates in respect thereof. Each material License now existing is, and any material License entered into in the future will be, the legal, valid and binding obligation of the parties thereto, enforceable against such parties in accordance with its terms except as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization, and similar laws of general application relating to or affecting the rights and remedies of creditors and by general principles of equity. No default under any material License by any such party has occurred, nor does any defense, offset, deduction or counterclaim exist thereunder in favor of any such party.

 

(g)       Each Grantor owns and controls, or otherwise possesses adequate rights to use, all of its Intellectual Property. Schedule XI hereto sets forth a true and complete list of all Intellectual Property and Licenses owned or used by each Grantor as of the date hereof, and applications for grant or registration of Intellectual Property. To the knowledge of each Grantor, all such Intellectual Property of such Grantor is subsisting and in full force and effect, has not been adjudged invalid or unenforceable, and has not been abandoned in whole or in part. Except as set forth in Schedule XI , no such Intellectual Property is the subject of any licensing or franchising agreement. Except as set forth in Schedule XI , no Grantor has any knowledge of any infringement upon or conflict with the Patent, Trademark, Copyright, trade secret rights of others and, each Grantor is not now knowingly infringing or knowingly in conflict with any Patent, Trademark, Copyright, trade secret or similar rights of others, and to the knowledge of each Grantor, no other Person is now infringing or in conflict in any material respect with any such properties, assets and rights owned or used by each Grantor. No Grantor has received any notice that it is violating or has violated the Trademarks, Patents, Copyrights, inventions, trade secrets, proprietary information and technology, know-how, formulae, rights of publicity or other intellectual property rights of any third party.

 

(h)       Each Grantor is and will be at all times the sole and exclusive owner of the Collateral pledged by such Grantor hereunder free and clear of any Liens, except for Permitted Liens thereon. No effective financing statement or other instrument similar in effect covering all or any part of the Collateral is on file in any recording or filing office except such as (i) may have been filed in favor of the Collateral Agent and/or the Noteholders relating to this Agreement or the other Transaction Documents, and (ii) are securing Permitted Liens as of the date hereof and disclosed on Schedule XII hereto.

 

(i)        The exercise by the Collateral Agent of any of its rights and remedies hereunder will not contravene any law or any contractual restriction binding on or otherwise affecting each Grantor or any of its properties and will not result in or require the creation of any Lien, upon or with respect to any of its properties.

 

  12  

 

 

(j)       No authorization or approval or other action by, and no notice to or filing with, any Governmental Authority, is required for (i) the grant by each Grantor, or the perfection, of the security interest purported to be created hereby in the Collateral, or (ii) the exercise by the Collateral Agent of any of its rights and remedies hereunder, except for (A) the filing under the Code as in effect in the applicable jurisdiction of the financing statements described in Schedule XII hereto, all of which financing statements have been duly filed and are in full force and effect, (B) with respect to all Pledged Accounts, and all cash and other property from time to time deposited therein, the execution of a Controlled Account Agreement with the depository or other institution with which the applicable Pledged Accounts are maintained, as provided in Section 5(h)(i) , (C) with respect to Commodity Contracts, the execution of a control agreement with the commodity intermediary with which such Commodity Contract is carried, as provided in Section 5(h)(i) , (D) with respect to the perfection of the security interest created hereby in the United States Intellectual Property and Licenses, the recording of the appropriate Intellectual Property Security Agreement in the United States Patent and Trademark Office or the United States Copyright Office, as applicable (E) with respect to the perfection of the security interest created hereby in any Letter-of-Credit Rights, the consent of the issuer of the applicable letter of credit to the assignment of proceeds as provided in the Code as in effect in the applicable jurisdiction, (G) with respect to Investment Property constituting uncertificated securities, the applicable Grantor causing the issuer thereof either (i) to register the Collateral Agent as the registered owner of such securities or (ii) to agree in an authenticated record with such Grantor and the Collateral Agent that such issuer will comply with instructions with respect to such securities originated by the Collateral Agent without further consent of such Grantor, such authenticated record to be in form and substance satisfactory to the Collateral Agent, (H) with respect to Investment Property constituting certificated securities or instruments, such items to be delivered to and held by or on behalf of the Collateral Agent pursuant hereto in suitable form for transfer by delivery or accompanied by duly executed instruments of transfer or assignment in blank, all in form and substance satisfactory to the Collateral Agent, (I) with respect to any action that may be necessary to obtain control of Collateral constituting Commodity Contracts, Electronic Chattel Paper or Letter of Credit Rights, the taking of such actions, and (J) the Collateral Agent having possession of all Documents, Chattel Paper, Instruments and cash constituting Collateral (subclauses (A) through (J) each a “ Perfection Requirement ” and collectively, the “ Perfection Requirements ”).

 

(k)       This Agreement creates in favor of the Collateral Agent a legal, valid and enforceable security interest in the Collateral, as security for the Obligations. The performance of the Perfection Requirements results in the perfection of such security interest in the Collateral. Such security interest is (or in the case of Collateral in which each Grantor obtains rights after the date hereof, will be), subject only to Permitted Liens and the Perfection Requirements, a first priority, valid, enforceable and perfected security interests in all personal property of each Grantor (other than Excluded Collateral). Such recordings and filings and all other action necessary to perfect and protect such security interest have been duly taken (and, in the case of Collateral in which any Grantor obtains rights after the date hereof, will be duly taken), except for the Collateral Agent’s having possession of all Documents, Chattel Paper, Instruments and cash constituting Collateral after the date hereof and the other actions, filings and recordations described above, including the Perfection Requirements.

 

(l)        As of the date hereof, no Grantor holds any Commercial Tort Claims or has knowledge of any pending Commercial Tort Claims, except for the Commercial Tort Claims described in Schedule VI .

 

  13  

 

 

(m)      All of the Pledged Equity is presently owned by the applicable Grantor as set forth in Schedule XV , and is presently represented by the certificates listed on Schedule XV hereto (if applicable). As of the date hereof, there are no existing options, warrants, calls or commitments of any character whatsoever relating to the Pledged Equity other than as contemplated and permitted by the Transaction Documents. Each Grantor is the sole holder of record and the sole beneficial owner of the Pledged Equity, as applicable. None of the Pledged Equity has been issued or transferred in violation of the securities registration, securities disclosure or similar laws of any jurisdiction to which such issuance or transfer may be subject. The Pledged Equity constitutes 100% or such other percentage as set forth on Schedule XV of the issued and outstanding shares of Capital Stock of the applicable Pledged Entity.

 

(n)       Such Grantor (i) is a corporation, limited liability company or limited partnership, as applicable, duly organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation, organization or formation, (ii) has all requisite corporate, limited liability company or limited partnership power and authority to conduct its business as now conducted and as presently contemplated and to execute and deliver this Agreement and each other Transaction Document to which such Grantor is a party, and to consummate the transactions contemplated hereby and thereby and (iii) is duly qualified to do business and is in good standing in each jurisdiction in which the character of the properties owned or leased by it or in which the transaction of its business makes such qualification necessary, except where the failure to be so qualified would not result in a Material Adverse Effect.

 

(o)       The execution, delivery and performance by each Grantor of this Agreement and each other Transaction Document to which such Grantor is a party (i) have been duly authorized by all necessary corporate, limited liability company or limited partnership action, (ii) do not and will not contravene its charter or by-laws, limited liability company or operating agreement, certificate of partnership or partnership agreement, as applicable, or any applicable law or any contractual restriction binding on such Grantor or its properties, (iii) do not and will not result in or require the creation of any Lien (other than pursuant to any Transaction Document) upon or with respect to any of its assets or properties, and (iv) do not and will not result in any default, noncompliance, suspension, revocation, impairment, forfeiture or nonrenewal of any material permit, license, authorization or approval applicable to it or its operations or any of its assets or properties.

 

(p)       This Agreement and each of the other Transaction Documents to which any Grantor is or will be a party, when delivered, will be, a legal, valid and binding obligation of such Grantor, enforceable against such Grantor in accordance with its terms, except as may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, suretyship or other similar laws and equitable principles (regardless of whether enforcement is sought in equity or at law).

 

(q)       There are no conditions precedent to the effectiveness of this Agreement that have not been satisfied or waived.

 

  14  

 

 

SECTION 5. Covenants as to the Collateral . So long as any of the Obligations shall remain outstanding, unless the Collateral Agent shall otherwise consent in writing:

 

(a)        Further Assurances . Each Grantor will, at its expense, at any time and from time to time, promptly execute and deliver all further instruments and documents and take all further action that the Collateral Agent may reasonably request in order to: (i) perfect and protect the security interest of the Collateral Agent created hereby; (ii) enable the Collateral Agent to exercise and enforce its rights and remedies hereunder in respect of the Collateral, including, without limitation, the Controlled Accounts; or (iii) otherwise effect the purposes of this Agreement, including, without limitation: (A) marking conspicuously all Chattel Paper and each License and, at the request of the Collateral Agent, each of its Records pertaining to the Collateral with a legend, in form and substance satisfactory to the Collateral Agent, indicating that such Chattel Paper, License or Collateral is subject to the security interest created hereby, (B) delivering and pledging to the Collateral Agent each Promissory Note, Security (subject to the limitations set forth in Section 2 ), Chattel Paper or other Instrument, now or hereafter owned by any Grantor, duly endorsed and accompanied by executed instruments of transfer or assignment, all in form and substance satisfactory to the Collateral Agent, (C) executing and filing (to the extent, if any, that any Grantor’s signature is required thereon) or authenticating the filing of, such financing or continuation statements, or amendments thereto, as may be necessary or that the Collateral Agent may reasonably request in order to perfect and preserve the security interest created hereby, (D) furnishing to the Collateral Agent from time to time statements and schedules further identifying and describing the Collateral and such other reports in connection with the Collateral in each case as the Collateral Agent may reasonably request, all in reasonable detail, (E) if any Collateral shall be in the possession of a third party, notifying such Person of the Collateral Agent’s security interest created hereby and obtaining a written acknowledgment from such Person, in form and substance reasonably satisfactory to the Collateral Agent, that such Person holds possession of the Collateral for the benefit of the Collateral Agent (for the benefit the Noteholders), (F) if at any time after the date hereof, any Grantor acquires or holds any Commercial Tort Claim, promptly notifying the Collateral Agent in a writing signed by such Grantor setting forth a brief description of such Commercial Tort Claim and granting to the Collateral Agent a security interest therein and in the proceeds thereof, which writing shall incorporate the provisions hereof and shall be in form and substance satisfactory to the Collateral Agent, (G) upon the acquisition after the date hereof by any Grantor of any motor vehicle or other Equipment subject to a certificate of title or ownership (other than a motor vehicle or Equipment that is subject to a purchase money security interest), causing the Collateral Agent to be listed as the lienholder on such certificate of title or ownership and delivering evidence of the same to the Collateral Agent in accordance with Section 5(j) hereof; and (H) taking all actions required by the Code or by other law, as applicable, in any relevant Code jurisdiction, or by other law as applicable in any foreign jurisdiction.

 

(b)        Location of Collateral . Each Grantor will keep the Collateral (i) at the locations specified therefor on Schedule XVI hereto, or (ii) at such other locations set forth on Schedule XVI and with respect to which the Collateral Agent has filed financing statements and otherwise fully perfected its Liens thereon, or (iii) at such other locations in the United States , provided that 30 days prior to any change in the location of any Collateral to such other location, or upon the acquisition of any Collateral to be kept at such other locations, the Grantors shall give the Collateral Agent written notice thereof and deliver to the Collateral Agent a new Schedule XVI indicating such new locations and such other written statements and schedules as the Collateral Agent may require.

 

(c)        Condition of Equipment . Each Grantor will maintain or cause to be maintained and preserved in good condition, repair and working order, ordinary wear and tear excepted, the Equipment (necessary or useful to its business) and will forthwith, or in the case of any loss or damage to any Equipment of any Grantor within a commercially reasonable time after the occurrence thereof, make or cause to be made all repairs, replacements and other improvements in connection therewith which are necessary or desirable, consistent with past practice, or which the Collateral Agent may request to such end. Any Grantor will promptly furnish to the Collateral Agent a statement describing in reasonable detail any such loss or damage in excess of $50,000 per occurrence to any Equipment.

 

  15  

 

 

(d)        Taxes, Etc . Each Grantor agrees to pay promptly when due all property and other taxes, assessments and governmental charges or levies imposed upon, and all claims (including claims for labor, materials and supplies) against, the Equipment and Inventory, except to the extent the validity thereof is being contested in good faith by proper proceedings which stay the imposition of any penalty, fine or Lien resulting from the non-payment thereof and with respect to which adequate reserves in accordance with GAAP have been set aside for the payment thereof.

 

(e)        Insurance .

 

(i)       Each Grantor will, at its own expense, maintain insurance (including, without limitation, comprehensive general liability, hazard, rent and business interruption insurance) with respect to its properties (including all real properties leased or owned by it) and business, in such amounts and covering such risks, in such form and with responsible and reputable insurance companies or associations as is required by any Governmental Authority having jurisdiction with respect thereto or as is carried generally in accordance with sound business practice by companies in similar businesses similarly situated and in any event, in amount, adequacy and scope reasonably satisfactory to the Collateral Agent.

 

(ii)      To the extent requested by the Collateral Agent at any time and from time to time, each such policy for liability insurance shall provide for all losses to be paid on behalf of the Collateral Agent and any Grantor as their respective interests may appear, and each policy for property damage insurance shall provide for all losses to be adjusted with, and paid directly to, the Collateral Agent. In addition to and without limiting the foregoing, to the extent requested by the Collateral Agent at any time and from time to time, each such policy shall in addition (A) name the Collateral Agent as an additional insured party and/or loss payee, as applicable, thereunder (without any representation or warranty by or obligation upon the Collateral Agent) as its interests may appear, (B) contain an agreement by the insurer that any loss thereunder shall be payable to the Collateral Agent on its own account notwithstanding any action, inaction or breach of representation or warranty by any Grantor, (C) provide that there shall be no recourse against the Collateral Agent for payment of premiums or other amounts with respect thereto, and (D) provide that at least 30 days’ prior written notice of cancellation, lapse, expiration or other adverse change shall be given to the Collateral Agent by the insurer. Any Grantor will, if so requested by the Collateral Agent, deliver to the Collateral Agent original or duplicate policies of such insurance (including certificates demonstrating compliance with this Section 5(e)) and, as often as the Collateral Agent may reasonably request, a report of a reputable insurance broker with respect to such insurance. Any Grantor will also, at the request of the Collateral Agent, execute and deliver instruments of assignment of such insurance policies and cause the respective insurers to acknowledge notice of such assignment.

 

  16  

 

 

(iii)      Reimbursement under any liability insurance maintained by any Grantor pursuant to this Section 5(e) may be paid directly to the Person who shall have incurred liability covered by such insurance. In the case of any loss involving damage to Equipment or Inventory, to the extent paragraph (iv) of this Section 5(e) is not applicable, any proceeds of insurance involving such damage shall be paid to the Collateral Agent, and any Grantor will make or cause to be made the necessary repairs to or replacements of such Equipment or Inventory, and any proceeds of insurance maintained by any Grantor pursuant to this Section 5(e) (except as otherwise provided in paragraph (iv) in this Section 5(e) ) shall be paid by the Collateral Agent to any Grantor as reimbursement for the reasonable costs of such repairs or replacements.

 

(iv)      Notwithstanding anything to the contrary in subsection 5(e)(iii) above, following and during the continuance of an Event of Default (as defined in the Securities Purchase Agreement and the Notes), all insurance payments in respect of each Grantor’s properties and business shall be paid to the Collateral Agent and applied as specified in Section 7(b) hereof.

 

(f)        Provisions Concerning the Accounts and the Licenses .

 

(i)        Each Grantor will (A) give the Collateral Agent at least 30 days’ prior written notice of any change in such Grantor’s name, identity or organizational structure, (B) maintain its jurisdiction of incorporation, organization or formation as set forth in Schedule VII hereto, (C) immediately notify the Collateral Agent upon obtaining an organizational identification number, if on the date hereof such Grantor did not have such identification number, and (D) keep adequate records concerning the Collateral and permit representatives of the Collateral Agent during normal business hours on reasonable notice to such Grantor, to inspect and make abstracts from such records.

 

  17  

 

 

(ii)       Each Grantor will (except as otherwise provided in this subsection (f)), continue to collect, at its own expense, all amounts due or to become due under the Accounts. In connection with such collections, any Grantor may (and, at the Collateral Agent’s direction, will) take such action as any Grantor or the Collateral Agent may deem necessary or advisable to enforce collection or performance of the Accounts that are not Excluded Collateral; provided , however , that the Collateral Agent shall have the right at any time following the occurrence and during the continuance of an Event of Default to notify the Account Debtors or obligors under any Accounts that are not Excluded Collateral of the assignment of such Accounts to the Collateral Agent and to direct such Account Debtors or obligors to make payment of all amounts due or to become due to any Grantor thereunder directly to the Collateral Agent or its designated agent and, upon such notification and at the expense of any Grantor and to the extent permitted by applicable law, to enforce collection of any such Accounts and to adjust, settle or compromise the amount or payment thereof, in the same manner and to the same extent as any Grantor might have done. After receipt by any Grantor of a notice from the Collateral Agent that the Collateral Agent has notified, intends to notify, or has enforced or intends to enforce any Grantor’s rights against the Account Debtors or obligors under any Accounts as referred to in the proviso to the immediately preceding sentence, (A) all amounts and proceeds (including Instruments) received by any Grantor in respect of the Accounts shall be received in trust for the benefit of the Collateral Agent hereunder (for the benefit the Noteholders), shall be segregated from other funds of any Grantor and shall be forthwith paid over to the Collateral Agent in the same form as so received (with any necessary endorsement) to be applied as specified in Section 7(b) hereof, and (B) no Grantor will adjust, settle or compromise the amount or payment of any Account or release wholly or partly any Account Debtor or obligor thereof or allow any credit or discount thereon. In addition, upon the occurrence and during the continuance of an Event of Default, the Collateral Agent may (in its sole and absolute discretion) direct any or all of the banks and financial institutions with which any Grantor either maintains a Deposit Account or a lockbox (including, without limitation, any Controlled Account) or deposits the proceeds of any Accounts to send immediately to the Collateral Agent by wire transfer (to such deposit account as the Collateral Agent shall specify, or in such other manner as the Collateral Agent shall direct) all or a portion of such securities, cash, investments and other items held by such institution. Any such securities, cash, investments and other items so received by the Collateral Agent shall be applied as specified in accordance with Section 7(b) hereof.

 

(iii)       Upon the occurrence and during the continuance of any breach or default under any material License referred to in Schedule XVII hereto by any party thereto other than any Grantor, each Grantor party thereto will, promptly after obtaining knowledge thereof, give the Collateral Agent written notice of the nature and duration thereof, specifying what action, if any, it has taken and proposes to take with respect thereto and thereafter will take reasonable steps to protect and preserve its rights and remedies in respect of such breach or default, or will obtain or acquire an appropriate substitute License.

 

(iv)       Each Grantor will, at its expense, promptly deliver to the Collateral Agent a copy of each notice or other communication received by it by which any other party to any material License referred to in Schedule XVIII hereto purports to exercise any of its rights or affect any of its obligations thereunder, together with a copy of any reply by such Grantor thereto.

 

(v)        Each Grantor will exercise promptly and diligently each and every right which it may have under each material License (other than any right of termination) and will duly perform and observe in all respects all of its obligations under each material License and will take all action reasonably necessary to maintain such Licenses in full force and effect. No Grantor will, without the prior written consent of the Collateral Agent, cancel, terminate, amend or otherwise modify in any respect, or waive any provision of, any material License referred to in Schedule XIX hereto.

 

  18  

 

 

(g)        Transfers and Other Liens .

 

(i)       Except as otherwise expressly permitted in the other Transaction Documents, no Grantor shall, directly or indirectly, sell, lease, license, assign, transfer, spin-off, split-off, close, convey or otherwise dispose of any Collateral whether in a single transaction or a series of related transactions, other than (A) sales, leases, licenses, assignments, transfers, conveyances and other dispositions of such assets or rights by such Grantor for value in the ordinary course of business consistent with past practices; and (B) sales of Inventory and product in the ordinary course of business.

 

(ii)      Except if expressly permitted under Section 14(e) of the Notes, no Grantor shall, directly or indirectly, redeem, repurchase or declare or pay any cash dividend or distribution on any of its Capital Stock.

 

(iii)     No Grantor shall, directly or indirectly, without the prior written consent of the Required Holders issue any securities that would cause a breach or default under the Notes, the Securities Purchase Agreement and/or any other Transaction Document.

 

(iv)     Except for payments to Taglich Brothers, Inc. or an Affiliate thereof for fundraising services they provide (but no payments shall be made to any such parties related to any financing provided to any Grantor by the Buyer), no Grantor shall enter into, renew, extend or be a party to, any transaction or series of related transactions (including, without limitation, the purchase, sale, lease, transfer or exchange of property or assets of any kind or the rendering of services of any kind) with any Affiliate, except in the ordinary course of business in a manner and to an extent consistent with past practice and necessary or desirable for the prudent operation of its business, for fair consideration and on terms no less favorable to it than would be obtainable in a comparable arm’s length transaction with a Person that is not an Affiliate thereof.

 

(v)       No Grantor will create, suffer to exist or grant any Lien upon or with respect to any Collateral other than a Permitted Lien.

 

  19  

 

 

(h)        Intellectual Property .

 

(i)       If applicable, each Grantor shall duly execute and deliver the applicable Intellectual Property Security Agreement. Each Grantor (either itself or through licensees) will, and will cause each licensee thereof to, take all action reasonably necessary and/or requested by the Collateral Agent to maintain all of the Intellectual Property in full force and effect, including, without limitation, using the proper statutory notices, numbers and markings (relating to patent, trademark and copyright rights) and using the Trademarks on each applicable trademark class of goods in order to so maintain the Trademarks in full force and free from any claim of abandonment for non-use, and each Grantor will not (nor permit any licensee thereof to) do any act or knowingly omit to do any act whereby any Intellectual Property may become abandoned, cancelled or invalidated; provided , however , that so long as no Event of Default has occurred and is continuing, no Grantor shall have an obligation to use or to maintain any Intellectual Property (A) that relates solely to any product or work, that is no longer necessary or material and has been, or is in the process of being, discontinued, abandoned or terminated in the ordinary course of business and consistent with the exercise of reasonable business judgment, (B) that is being replaced with Intellectual Property substantially similar to the Intellectual Property that may be abandoned or otherwise become invalid, so long as the failure to use or maintain such Intellectual Property does not materially adversely affect the validity of such replacement Intellectual Property and so long as such replacement Intellectual Property is subject to the Lien created by this Agreement and does not have a Material Adverse Effect on the business of any Grantor or (C) that is substantially the same as another Intellectual Property that is in full force, so long the failure to use or maintain such Intellectual Property does not materially adversely affect the validity of such replacement Intellectual Property and so long as such other Intellectual Property is subject to the Lien and security interest created by this Agreement and does not have a material adverse effect on the business of any Grantor. Each Grantor will cause to be taken all necessary steps in any proceeding before the United States Patent and Trademark Office and the United States Copyright Office or any similar office or agency in any other country or political subdivision thereof to maintain each registration of the Intellectual Property and application for registration of Intellectual Property (other than the Intellectual Property described in the proviso to the immediately preceding sentence), including, without limitation, filing of renewals, affidavits of use, affidavits of incontestability and opposition, interference and cancellation proceedings and payment of maintenance fees, filing fees, taxes or other governmental fees. If any Intellectual Property (other than Intellectual Property described in the proviso to the second sentence of subsection (i) of this clause (h)) is infringed, misappropriated, diluted or otherwise violated in any material respect by a third party, each Grantor shall (x) upon learning of such infringement, misappropriation, dilution or other violation, promptly (but in no event more than five (5) business days after learning of such) notify the Collateral Agent and (y) if reasonably requested by the Collateral Agent promptly sue for infringement, misappropriation, dilution or other violation, seek injunctive relief where appropriate and recover any and all damages for such infringement, misappropriation, dilution or other violation, or take such other actions as such Grantor shall deem appropriate under the circumstances to protect such Intellectual Property. Each Grantor shall furnish to the Collateral Agent from time to time upon its request statements and schedules further identifying and describing the Intellectual Property and Licenses and such other reports in connection with the Intellectual Property and Licenses as the Collateral Agent may reasonably request, all in reasonable detail and promptly upon request of the Collateral Agent, following receipt by the Collateral Agent of any such statements, schedules or reports, each Grantor shall modify this Agreement by amending Schedules II, III and IV and any other applicable Schedule hereto, as the case may be, to include any Intellectual Property and License, as the case may be, which is or hereafter becomes part of the Collateral under this Agreement and shall execute and authenticate such documents and do such acts as shall be necessary or, in the reasonable judgment of the Collateral Agent, desirable to subject such Intellectual Property and Licenses to the Lien and security interest created by this Agreement. Notwithstanding anything herein to the contrary, upon the occurrence and during the continuance of an Event of Default, no Grantor may abandon, surrender or otherwise permit any Intellectual Property to become abandoned, cancelled or invalid without the prior written consent of the Collateral Agent, and if any Intellectual Property is infringed, misappropriated, diluted or otherwise violated in any material respect by a third party, each Grantor will take such reasonable action as the Collateral Agent shall deem appropriate under the circumstances to protect such Intellectual Property.

 

  20  

 

 

(ii)       In the event that any Grantor, either itself or through any agent, employee, licensee or designee, files an application for the registration of any Patent, Trademark or Copyright or the United States Copyright Office or the United States Patent and Trademark Office, as applicable, or in any similar office or agency of the United States or any country or any political subdivision thereof, it shall give the Collateral Agent prompt written notice thereof (but in no event more than one (1) business day after the initial filing of application). Upon request of the Collateral Agent, any Grantor shall execute, authenticate and deliver any and all assignments, agreements, instruments, documents and papers as the Collateral Agent may reasonably request to evidence the Collateral Agent’s security interest hereunder in such Intellectual Property and the General Intangibles of any Grantor relating thereto or represented thereby, and each Grantor hereby appoints the Collateral Agent its attorney-in-fact to execute and/or authenticate and file all such writings for the foregoing purposes, all acts of such attorney being hereby ratified and confirmed, and such power (being coupled with an interest) shall be irrevocable until all Obligations are Paid in Full.

 

(i)        Pledged Accounts .

 

(A)       Each Grantor shall use its reasonable best efforts to, as soon as practical following the Closing Date, but in no event more than (60) sixty calendar days following the Closing Date (the “ CAB Period ”) cause each bank and other financial institution which maintains a Controlled Account (each a “ Controlled Account Bank ”) to execute and deliver to the Collateral Agent, in form and substance satisfactory to the Collateral Agent, a Controlled Account Agreement with respect to such Controlled Account, duly executed by each Grantor and such Controlled Account Bank, pursuant to which such Controlled Account Bank among other things shall irrevocably agree, with respect to such Controlled Account, that (i) at any time after any Grantor, the Collateral Agent or the Buyer shall have notified such Controlled Account Bank that an Event of Default has occurred or is continuing, such Controlled Account Bank will comply with any and all instructions originated by the Collateral Agent directing the disposition of the funds in such Controlled Account without further consent by such Grantor, (ii) such Controlled Account Bank shall waive, subordinate or agree not to exercise any rights of setoff or recoupment or any other claim against the applicable Controlled Account other than for payment of its service fees and other charges directly related to the administration of such Controlled Account and for returned checks or other items of payment, (iii) at any time after any Grantor, the Collateral Agent or the Buyer shall have notified such Controlled Account Bank that an Event of Default has occurred or is continuing, with respect to each such Controlled Account, such Controlled Account Bank shall not comply with any instructions, directions or orders of any form with respect to such Controlled Accounts other than instructions, directions or orders originated by the Collateral Agent, (iv) all funds deposited by any Grantor with such Controlled Account Bank shall be subject to a perfected, first priority security interest in favor of the Collateral Agent, and (v) upon receipt of written notice from the Collateral Agent during the continuance of an Event of Default, such Controlled Account Bank shall immediately send to the Collateral Agent by wire transfer (to such account as the Collateral Agent shall specify, or in such other manner as the Collateral Agent shall direct) all such funds and other items held by it.] No Grantor shall create or maintain any Pledged Account without the prior written consent of the Collateral Agent and complying with the terms of this Agreement.

 

  21  

 

 

(B)       If at any time after the expiration of the CAB Period, the average daily balance of any Account that is not subject to a Controlled Account Agreement exceeds $100,000 during any calendar month (including the calendar month in which the Closing Date occurs), the Parent shall, either (x) within two (2) Business Days following such date, transfer to a Controlled Account an amount sufficient to reduce the total aggregate amount of the cash in such Account to an amount not in excess of $100,000 or (y) within twenty-one (21) calendar days following the last day of such calendar month, deliver to the Collateral Agent a Controlled Account Agreement with respect to such Account, duly executed by such Grantor and the depositary bank in which such Account is maintained.

 

(C)       Notwithstanding anything to the contrary contained in Section 5(i)(B) above, and without limiting any of the foregoing, if at any time after the expiration of the CAB Period, the total aggregate amount of the cash of the Parent and any of its Subsidiaries, in the aggregate, that is not held in a Controlled Account exceeds $150,000 (the “ Maximum Free Cash Amount ”), the Parent shall within twenty one (21) Business Days following such date, either (x) transfer to a Controlled Account an amount sufficient to reduce the total aggregate amount of the cash that is not held in a Controlled Account to an amount not in excess of the Maximum Free Cash Amount or (y) deliver to the Collateral Agent a Controlled Account Agreement with respect to such Account (or Accounts), duly executed by such Grantor and the depositary bank in which such Account (or Accounts) is maintained, as necessary to reduce the total aggregate amount of the cash that is not held in a Controlled Account to an amount not in excess of the Maximum Free Cash Amount.

 

(j)        Control . Each Grantor hereby agrees to take any or all action that may be necessary or that the Collateral Agent may reasonably request in order for the Collateral Agent to obtain “control” in accordance with Sections 9-105 through 9-107 of the Code with respect to the following Collateral: (i) Electronic Chattel Paper, (ii) Investment Property, and (iii) Letter-of-Credit Rights.

 

  22  

 

 

(k)        Inspection and Reporting . Each Grantor shall permit the Collateral Agent, or any agent or representatives thereof or such professionals or other Persons as the Collateral Agent may designate at Grantors’ sole cost and expense no more than once per quarter (the “ Quarterly Limitations ”), unless an Event of Default exists and/or with the passage of time, the occurrence of an event or the giving of notice an Event of Default would exist, in which event there shall be no limitations including, but not limited to, the Quarterly Limitations (i) to examine and make copies of and abstracts from any Grantor’s records and books of account, (ii) to visit and inspect its properties, (iii) to verify materials, leases, Instruments, Accounts, Inventory and other assets of any Grantor from time to time, and (iv) to conduct audits, physical counts, appraisals and/or valuations, examinations at the locations of any Grantor. Each Grantor shall also permit the Collateral Agent, or any agent or representatives thereof or such attorneys, accountants or other professionals or other Persons as the Collateral Agent may designate to discuss such Grantor’s affairs, finances and accounts with any of its directors, officers, members, managers managerial employees, independent accountants or any of its other representatives. Without limiting the foregoing, the Collateral Agent may, at any time, in the Collateral Agent’s own name, in the name of a nominee of the Collateral Agent, or in the name of any Grantor communicate (by mail, telephone, facsimile or otherwise) with the Account Debtors of such Grantor, parties to contracts with such Grantor and/or obligors in respect of Instruments of such Grantor to verify with such Persons, to the Collateral Agent’s satisfaction, the existence, amount, terms of, and any other matter relating to, Accounts, Instruments, Chattel Paper, payment intangibles and/or other receivables.

 

(l)        Future Subsidiaries . If any Grantor hereafter creates or acquires any Subsidiary, simultaneously with the creation or acquisition of such Subsidiary, such Grantor shall (i) if such Subsidiary is a Domestic Subsidiary, cause such Subsidiary to become a party to this Agreement as an additional “Grantor” hereunder, (ii) deliver to the Collateral Agent updated Schedules to this Agreement, as appropriate (including, without limitation, an updated Schedule IV to reflect the grant by such Grantor of a Lien on all Pledged Equity now or hereafter owned by such Grantor), (iii) if such Subsidiary is a Domestic Subsidiary, cause such Subsidiary to duly execute and deliver a guaranty of the Obligations in favor of the Collateral Agent in form and substance acceptable to the Collateral Agent, (iv) if such Subsidiary is a (a) Domestic Subsidiary, deliver to the Collateral Agent the stock certificates representing all, and (b) so long as permitted by applicable law, Foreign Subsidiary, deliver to the Collateral Agent the stock certificates representing 65%, of the Capital Stock of such Subsidiary, along with undated stock powers for each such certificates, executed in blank (or, if any such shares of Capital Stock are uncertificated, confirmation and evidence reasonably satisfactory to the Collateral Agent that the security interest in such uncertificated securities has been transferred to and perfected by the Collateral Agent, in accordance with Sections 8-313, 8-321 and 9-115 of the Code or any other similar or local or foreign law that may be applicable), and (v) duly execute and/or cause to be delivered to the Collateral Agent, in form and substance acceptable to the Collateral Agent, such opinions of counsel and other documents as the Collateral Agent shall request with respect thereto; provided , however , that no Grantor shall be required to pledge any Excluded Collateral. Each Grantor hereby authorizes the Collateral Agent to attach such updated Schedules to this Agreement and agrees that all Pledged Equity listed on any updated Schedule delivered to the Collateral Agent shall for all purposes hereunder be considered Collateral. The Grantors agree that the pledge of the shares of Capital Stock acquired by a Grantor of Foreign Subsidiary may be supplemented by one or more separate pledge agreements, deeds of pledge, share charges, or other similar agreements or instruments, executed and delivered by the relevant Grantor in favor of the Collateral Agent, which pledge agreements will provide for the pledge of such shares of Capital Stock in accordance with the laws of the applicable foreign jurisdiction. With respect to such shares of Capital Stock, the Collateral Agent may, at any time and from time to time, in its sole discretion, take actions in such foreign jurisdictions that will result in the perfection of the Lien created in such shares of Capital Stock other than Excluded Collateral.

 

  23  

 

 

SECTION 6. Additional Provisions Concerning the Collateral.

 

(a)       To the maximum extent permitted by applicable law, and for the purpose of taking any action that the Collateral Agent may deem necessary or advisable to accomplish the purposes of this Agreement, each Grantor hereby (i) authorizes the Collateral Agent to execute any such agreements, instruments or other documents in such Grantor’s name and to file such agreements, instruments or other documents in such Grantor’s name and in any appropriate filing office, (ii) authorizes the Collateral Agent at any time and from time to time to file, one or more financing or continuation statements, and amendments thereto, relating to the Collateral (including, without limitation, any such financing statements that (A) describe the Collateral as “all assets” or “all personal property” (or words of similar effect) other than Excluded Collateral or that describe or identify the Collateral by type or in any other manner as the Collateral Agent may determine regardless of whether any particular asset of such Grantor falls within the scope of Article 9 of the Code or whether any particular asset of such Grantor constitutes part of the Collateral, and (B) contain any other information required by Part 5 of Article 9 of the Code for the sufficiency or filing office acceptance of any financing statement, continuation statement or amendment, including, without limitation, whether such Grantor is an organization, the type of organization and any organizational identification number issued to such Grantor) and (iii) ratifies such authorization to the extent that the Collateral Agent has filed any such financing or continuation statements, or amendments thereto, prior to the date hereof. A photocopy or other reproduction of this Agreement or any financing statement covering the Collateral or any part thereof shall be sufficient as a financing statement where permitted by law.

 

(b)       Each Grantor hereby irrevocably appoints (but Collateral Agent shall not use such power until an Event of Default occurs) the Collateral Agent as its attorney-in-fact and proxy, with full authority in the place and stead of such Grantor and in the name of such Grantor or otherwise, from time to time in the Collateral Agent’s discretion to take any action and to execute any instrument which the Collateral Agent may deem necessary or advisable to accomplish the purposes of this Agreement, including, without limitation, (i) to obtain and adjust insurance required to be paid to the Collateral Agent pursuant to Section 5(e) hereof, (ii) to ask, demand, collect, sue for, recover, compound, receive and give acquittance and receipts for moneys due and to become due under or in respect of any Collateral, (iii) to receive, endorse, and collect any drafts or other instruments, documents and chattel paper in connection with clause (i) or (ii) above, (iv) to file any claims or take any action or institute any proceedings which the Collateral Agent may deem necessary or desirable for the collection of any Collateral or otherwise to enforce the rights of the Collateral Agent and the Noteholders with respect to any Collateral, (v) to execute assignments, licenses and other documents to enforce the rights of the Collateral Agent and the Noteholders with respect to any Collateral, and (vi) to verify any and all information with respect to any and all Accounts. This power is coupled with an interest and is irrevocable until all of the Obligations are Paid in Full.

 

  24  

 

 

(c)       For the purpose of enabling the Collateral Agent to exercise rights and remedies hereunder, at such time as the Collateral Agent shall be lawfully entitled to exercise such rights and remedies, and for no other purpose, each Grantor hereby grants to the Collateral Agent, to the extent assignable, an irrevocable, non-exclusive license (exercisable without payment of royalty or other compensation to any Grantor) to use, assign, license or sublicense any Intellectual Property now owned or hereafter acquired by such Grantor, wherever the same may be located, including in such license reasonable access to all media in which any of the licensed items may be recorded or stored and to all computer programs used for the compilation or printout thereof. Notwithstanding anything contained herein to the contrary, but subject to the provisions of the Securities Purchase Agreement that limit the right of any Grantor to dispose of its property, and Section 5(g) and Section 5(h) hereof, so long as no Event of Default shall have occurred and be continuing, any Grantor may exploit, use, enjoy, protect, license, sublicense, assign, sell, dispose of or take other actions with respect to the Intellectual Property in the ordinary course of its business and as otherwise expressly permitted by any of the other Transaction Documents. In furtherance of the foregoing, unless an Event of Default shall have occurred and be continuing, the Collateral Agent shall from time to time, upon the request of any Grantor, execute and deliver any instruments, certificates or other documents, in the form so requested, which such Grantor shall have certified are appropriate (in such Grantor’s judgment) to allow it to take any action permitted above (including relinquishment of the license provided pursuant to this clause (c) as to any Intellectual Property). Further, upon the Payment in Full of all of the Obligations, the Collateral Agent (subject to Section 10(e) hereof) shall release and reassign to any Grantor all of the Collateral Agent’s right, title and interest in and to the Collateral, including the Intellectual Property, and the Licenses, all without recourse, representation or warranty whatsoever. The exercise of rights and remedies hereunder by the Collateral Agent shall not terminate the rights of the holders of any licenses or sublicenses theretofore granted by each Grantor in accordance with the second sentence of this clause (c). Each Grantor hereby releases the Collateral Agent from any claims, causes of action and demands at any time arising out of or with respect to any actions taken or omitted to be taken by the Collateral Agent under the powers of attorney granted herein other than actions taken or omitted to be taken through the Collateral Agent’s gross negligence or willful misconduct, as determined by a final determination of a court of competent jurisdiction.

 

(d)       If any Grantor fails to perform any agreement or obligation contained herein, upon an Event of Default, the Collateral Agent may itself perform, or cause performance of, such agreement or obligation, in the name of such Grantor or the Collateral Agent, and the expenses of the Collateral Agent incurred in connection therewith shall be payable by such Grantor pursuant to Section 8 hereof and shall be secured by the Collateral.

 

  25  

 

 

(e)       The powers conferred on the Collateral Agent hereunder are solely to protect its interest in the Collateral and shall not impose any duty upon it to exercise any such powers. Except for the safe custody of any Collateral in its possession and the accounting for moneys actually received by it hereunder, the Collateral Agent shall have no duty as to any Collateral or as to the taking of any necessary steps to preserve rights against prior parties or any other rights pertaining to any Collateral.

 

(f)       Anything herein to the contrary notwithstanding (i) each Grantor shall remain liable under the Licenses and otherwise with respect to any of the Collateral to the extent set forth therein to perform all of its obligations thereunder to the same extent as if this Agreement had not been executed, (ii) the exercise by the Collateral Agent of any of its rights hereunder shall not release any Grantor from any of its obligations under the Licenses or otherwise in respect of the Collateral, and (iii) the Collateral Agent shall not have any obligation or liability by reason of this Agreement under the Licenses or with respect to any of the other Collateral, nor shall the Collateral Agent be obligated to perform any of the obligations or duties of any Grantor thereunder or to take any action to collect or enforce any claim for payment assigned hereunder.

 

(g)       As long as no Event of Default (as defined under the Notes) shall have occurred and be continuing and until written notice shall be given to the applicable Grantor:

 

(i)       Each Grantor shall have the right, from time to time, to vote and give consents with respect to the Pledged Equity, or any part thereof for all purposes not inconsistent with the provisions of this Agreement, the Securities Purchase Agreement or any other Transaction Document; provided , however , that no vote shall be cast, and no consent shall be given or action taken, which would have the effect of impairing the position or interest of the Collateral Agent in respect of the Pledged Equity or which would authorize, effect or consent to (unless and to the extent expressly permitted by the Securities Purchase Agreement):

 

(A)       the dissolution or liquidation, in whole or in part, of a Pledged Entity;

 

(B)       the consolidation or merger of a Pledged Entity with any other Person;

 

(C)       the sale, disposition or encumbrance of all or substantially all of the assets of a Pledged Entity, except for Liens in favor of the Collateral Agent;

 

(D)       any change in the authorized number of shares, the stated capital or the authorized share capital of a Pledged Entity or the issuance of any additional shares of its Capital Stock; or

 

(E)       the alteration of the voting rights with respect to the Capital Stock of a Pledged Entity.

 

  26  

 

 

(ii)       Each Grantor shall be entitled, from time to time, to collect and receive for its own use all cash dividends and interest paid in respect of the Pledged Equity to the extent not in violation of the Securities Purchase Agreement other than any and all: (A) dividends and interest paid or payable other than in cash in respect of any Pledged Equity, and instruments and other property received, receivable or otherwise distributed in respect of, or in exchange for, any Pledged Equity; (B) dividends and other distributions paid or payable in cash in respect of any Pledged Equity in connection with a partial or total liquidation or dissolution or in connection with a reduction of capital, capital surplus or paid-in capital of a Pledged Entity; and (C) cash paid, payable or otherwise distributed, in respect of principal of, or in redemption of, or in exchange for, any Pledged Equity; provided , however , that until actually paid all rights to such distributions shall remain subject to the Lien created by this Agreement; and

 

(iii)       all dividends and interest (other than such cash dividends and interest as are permitted to be paid to any Grantor in accordance with clause (i) above) and all other distributions in respect of any of the Pledged Equity, whenever paid or made, shall be delivered to the Collateral Agent to hold as Pledged Equity and shall, if received by any Grantor, be received in trust for the benefit of the Collateral Agent (for the benefit of the Noteholders), be segregated from the other property or funds of such Grantor, and be forthwith delivered to the Collateral Agent as Pledged Equity in the same form as so received (with any necessary endorsement).

 

SECTION 7. Remedies Upon Event of Default; Application of Proceeds . If any Event of Default shall have occurred and be continuing:

 

(a)       The Collateral Agent may exercise in respect of the Collateral, in addition to any other rights and remedies provided for herein, in any other Transaction Document or otherwise available to it, all of the rights and remedies of a secured party upon default under the Code (whether or not the Code applies to the affected Collateral), and also may (i) take absolute control of the Collateral, including, without limitation, transfer into the Collateral Agent’s name or into the name of its nominee or nominees (to the extent the Collateral Agent has not theretofore done so) and thereafter receive, for the benefit of the Noteholders, all payments made thereon, give all consents, waivers and ratifications in respect thereof and otherwise act with respect thereto as though it were the outright owner thereof, (ii) require each Grantor to, and each Grantor hereby agrees that it will at its expense and upon request of the Collateral Agent forthwith, assemble all or part of its respective Collateral as directed by the Collateral Agent and make it available to the Collateral Agent at a place or places to be designated by the Collateral Agent that is reasonably convenient to both parties, and the Collateral Agent may enter into and occupy any premises owned or leased by any Grantor where the Collateral or any part thereof is located or assembled for a reasonable period in order to effectuate the Collateral Agent’s rights and remedies hereunder or under law, without obligation to any Grantor in respect of such occupation, and (iii) without notice except as specified below and without any obligation to prepare or process the Collateral for sale, (A) sell the Collateral or any part thereof in one or more parcels at public or private sale (including, without limitation, by credit bid), at any of the Collateral Agent’s offices or elsewhere, for cash, on credit or for future delivery, and at such price or prices and upon such other terms as the Collateral Agent may deem commercially reasonable and/or (B) lease, license or dispose of the Collateral or any part thereof upon such terms as the Collateral Agent may deem commercially reasonable. Each Grantor agrees that, to the extent notice of sale or any other disposition of its respective Collateral shall be required by law, at least ten (10) days’ notice to any Grantor of the time and place of any public sale or the time after which any private sale or other disposition of its respective Collateral is to be made shall constitute reasonable notification. The Collateral Agent shall not be obligated to make any sale or other disposition of any Collateral regardless of notice of sale having been given. The Collateral Agent may adjourn any public or private sale from time to time by announcement at the time and place fixed therefor, and such sale may, without further notice, be made at the time and place to which it was so adjourned. Each Grantor hereby waives any claims against the Collateral Agent and the Noteholders arising by reason of the fact that the price at which its respective Collateral may have been sold at a private sale was less than the price which might have been obtained at a public sale or was less than the aggregate amount of the Obligations, even if the Collateral Agent accepts the first offer received and does not offer such Collateral to more than one offeree, and waives all rights that any Grantor may have to require that all or any part of such Collateral be marshaled upon any sale (public or private) thereof. Each Grantor hereby acknowledges that (i) any such sale of its respective Collateral by the Collateral Agent shall be made without warranty, (ii) the Collateral Agent may specifically disclaim any warranties of title, possession, quiet enjoyment or the like, and (iii) such actions set forth in clauses (i) and (ii) above shall not adversely affect the commercial reasonableness of any such sale of Collateral. In addition to the foregoing, (1) upon written notice to any Grantor from the Collateral Agent after and during the continuance of an Event of Default, such Grantor shall cease any use of the Intellectual Property or any trademark, patent or copyright similar thereto for any purpose described in such notice; (2) the Collateral Agent may, at any time and from time to time after and during the continuance of an Event of Default, upon 5 days’ prior notice to such Grantor, license, whether general, special or otherwise, and whether on an exclusive or non-exclusive basis, any of the Intellectual Property, throughout the universe for such term or terms, on such conditions, and in such manner, as the Collateral Agent shall in its sole discretion determine; and (3) the Collateral Agent may, at any time, pursuant to the authority granted in Section 6 hereof or otherwise (such authority being effective upon the occurrence and during the continuance of an Event of Default), execute and deliver on behalf of such Grantor, one or more instruments of assignment of the Intellectual Property (or any application or registration thereof), in form suitable for filing, recording or registration in any country.

 

  27  

 

 

(b)       Any cash held by the Collateral Agent as Collateral and all Cash Proceeds received by the Collateral Agent in respect of any sale or disposition of or collection from, or other realization upon, all or any part of the Collateral shall be applied as follows (subject to the provisions of the Securities Purchase Agreement): first , to pay any fees, indemnities or expense reimbursements then due to the Collateral Agent (including those described in Section 8 hereof); second , to pay any fees, indemnities or expense reimbursements then due to the Noteholders, on a pro rata basis; third to pay interest due under the Notes owing to the Noteholders, on a pro rata basis; fourth , to pay or prepay principal in respect of the Note, whether or not then due, owing to the Noteholders, on a pro rata basis; fifth , to pay or prepay any other Obligations, whether or not then due, in such order and manner as the Collateral Agent shall elect, consistent with the provisions of the Securities Purchase Agreement and any other Transaction Document. Any surplus of such cash or Cash Proceeds held by the Collateral Agent and remaining after the Payment in Full of all of the Obligations shall be paid over to whomsoever shall be lawfully entitled to receive the same or as a court of competent jurisdiction shall direct.

 

(c)       In the event that the proceeds of any such sale, disposition, collection or realization are insufficient to pay all amounts to which the Collateral Agent and the Noteholders are legally entitled, each Grantor shall be, jointly and severally, liable for the deficiency, together with interest thereon at the highest rate specified in the Notes for interest on overdue principal thereof or such other rate as shall be fixed by applicable law, together with the costs of collection and the fees, costs, expenses and other charges of any attorneys employed by the Collateral Agent to collect such deficiency.

 

(d)       To the extent that applicable law imposes duties on the Collateral Agent to exercise remedies in a commercially reasonable manner, each Grantor acknowledges and agrees that it is commercially reasonable for the Collateral Agent (i) to fail to incur expenses deemed significant by the Collateral Agent to prepare Collateral for disposition or otherwise to transform raw material or work in process into finished goods or other finished products for disposition, (ii) to fail to obtain third party consents for access to Collateral to be disposed of, or to obtain or, if not required by other law, to fail to obtain governmental or third party consents for the collection or disposition of Collateral to be collected or disposed of, (iii) to fail to exercise collection remedies against Account Debtors or other Persons obligated on Collateral or to remove Liens on or any adverse claims against Collateral, (iv) to exercise collection remedies against Account Debtors and other Persons obligated on Collateral directly or through the use of collection agencies and other collection specialists, (v) to advertise dispositions of Collateral through publications or media of general circulation, whether or not the Collateral is of a specialized nature, (vi) to contact other Persons, whether or not in the same business as any Grantor, for expressions of interest in acquiring all or any portion of such Collateral, (vii) to hire one or more professional auctioneers to assist in the disposition of Collateral, whether or not the Collateral is of a specialized nature, (viii) to dispose of Collateral by utilizing internet sites that provide for the auction of assets of the types included in the Collateral or that have the reasonable capacity of doing so, or that match buyers and sellers of assets, (ix) to dispose of assets in wholesale rather than retail markets, (x) to disclaim disposition warranties, such as title, possession or quiet enjoyment, (xi) to purchase insurance or credit enhancements to insure the Collateral Agent against risks of loss, collection or disposition of Collateral or to provide to the Collateral Agent a guaranteed return from the collection or disposition of Collateral, or (xii) to the extent deemed appropriate by the Collateral Agent, to obtain the services of brokers, investment bankers, consultants, attorneys and other professionals to assist the Collateral Agent in the collection or disposition of any of the Collateral. Each Grantor acknowledges that the purpose of this section is to provide non-exhaustive indications of what actions or omissions by the Collateral Agent would be commercially reasonable in the Collateral Agent’s exercise of remedies against the Collateral and that other actions or omissions by the Collateral Agent shall not be deemed commercially unreasonable solely on account of not being indicated in this section. Without limitation upon the foregoing, nothing contained in this section shall be construed to grant any rights to any Grantor or to impose any duties on the Collateral Agent that would not have been granted or imposed by this Agreement or by applicable law in the absence of this section.

 

  28  

 

 

(e)       The Collateral Agent shall not be required to marshal any present or future collateral security (including, but not limited to, this Agreement and the Collateral) for, or other assurances of payment of, the Obligations or any of them or to resort to such collateral security or other assurances of payment in any particular order, and all of the Collateral Agent’s rights hereunder and in respect of such collateral security and other assurances of payment shall be cumulative and in addition to all other rights, however existing or arising. To the extent that any Grantor lawfully may, each Grantor hereby agrees that it will not invoke any law relating to the marshaling of collateral which might cause delay in or impede the enforcement of the Collateral Agent’s rights under this Agreement or under any other instrument creating or evidencing any of the Obligations or under which any of the Obligations is outstanding or by which any of the Obligations is secured or payment thereof is otherwise assured, and, to the extent that it lawfully may, each Grantor hereby irrevocably waives the benefits of all such laws.

 

SECTION 8. Indemnity and Expenses.

 

(a)       Each Grantor agrees, jointly and severally, to defend, protect, indemnify and hold the Collateral Agent and each of the Noteholders harmless from and against any and all claims, damages, losses, liabilities, obligations, penalties, fees, costs and expenses (including, without limitation, legal fees, costs, expenses, and disbursements of such Person’s counsel) to the extent that they arise out of or otherwise result from this Agreement (including, without limitation, enforcement of this Agreement), except to the extent resulting from such Person’s gross negligence or willful misconduct, as determined by a final judgment of a court of competent jurisdiction no longer subject to appeal.

 

(b)       Each Grantor agrees, jointly and severally, to pay to the Collateral Agent upon demand the amount of any and all costs and expenses, including the reasonable fees, costs, expenses and disbursements of counsel for the Collateral Agent and of any experts and agents (including, without limitation, any collateral trustee which may act as agent of the Collateral Agent), which the Collateral Agent may incur in connection with (i) the preparation, negotiation, execution, delivery, recordation, administration, amendment, waiver or other modification or termination of this Agreement, (ii) the custody, preservation, use or operation of, or the sale of, collection from, or other realization upon, any Collateral, (iii) the exercise or enforcement of any of the rights of the Collateral Agent hereunder, or (iv) the failure by any Grantor to perform or observe any of the provisions hereof.

 

SECTION 9. Notices, Etc . All notices and other communications provided for hereunder shall be in writing and shall be mailed (by certified mail, first-class postage prepaid and return receipt requested), telecopied, e-mailed or delivered, if to any Grantor, to the Parent’s address, if to Parent, to Parent’s address or if to the Collateral Agent or any Noteholder, to it at its respective address, each as set forth in Section 9(f) of the Securities Purchase Agreement; or as to any such Person, at such other address as shall be designated by such Person in a written notice to all other parties hereto complying as to delivery with the terms of this Section 9 . All such notices and other communications shall be effective (a) if sent by certified mail, return receipt requested, when received or three (3) Business Days after deposited in the mails, whichever occurs first, (b) if telecopied or e-mailed, when transmitted (during normal business hours) and confirmation is received, and otherwise, the day after the notice or communication was transmitted and confirmation is received, or (c) if delivered in person, upon delivery. For the avoidance of doubt, all Foreign Subsidiaries, as Grantors, hereby appoint the Parent as its agent for receipt of service of process and all notices and other communications in the United States at the address specified below.

 

  29  

 

 

SECTION 10. Miscellaneous.

 

(a)       No amendment of any provision of this Agreement shall be effective unless it is in writing and signed by each Grantor and the Collateral Agent (and approved by the Required Holders), and no waiver of any provision of this Agreement, and no consent to any departure by each Grantor therefrom, shall be effective unless it is in writing and signed by each Grantor and the Collateral Agent (and approved by the Required Holders), and then such waiver or consent shall be effective only in the specific instance and for the specific purpose for which given.

 

(b)       No failure on the part of the Collateral Agent to exercise, and no delay in exercising, any right reasonably hereunder or under any of the other Transaction Documents shall operate as a waiver thereof; nor shall any single or partial exercise of any such right reasonably preclude any other or further exercise thereof or the exercise of any other right. The rights and remedies of the Collateral Agent or any Noteholder provided herein and in the other Transaction Documents are cumulative and are in addition to, and not exclusive of, any rights or remedies provided by law. The rights of the Collateral Agent or any Noteholder under any of the other Transaction Documents against any party thereto are not conditional or contingent on any attempt by such Person to exercise any of its rights under any of the other Transaction Documents against such party or against any other Person, including but not limited to, any Grantor.

 

(c)       If any provision of this Agreement or any Transaction Document is prohibited by law or otherwise determined to be invalid or unenforceable by a court of competent jurisdiction, the provision that would otherwise be prohibited, invalid or unenforceable shall be deemed amended to apply to the broadest extent that it would be valid and enforceable, and the invalidity or unenforceability of such provision shall not affect the validity of the remaining provisions of this Agreement so long as this Agreement as so modified continues to express, without material change, the original intentions of the parties as to the subject matter hereof and the prohibited nature, invalidity or unenforceability of the provision(s) in question does not substantially impair the respective expectations or reciprocal obligations of the parties or the practical realization of the benefits that would otherwise be conferred upon the parties.  The parties will endeavor in good faith negotiations to replace the prohibited, invalid or unenforceable provision(s) with a valid provision(s), the effect of which comes as close as possible to that of the prohibited, invalid or unenforceable provision(s).

 

(d)       This Agreement shall create a continuing security interest in the Collateral and shall (i) remain in full force and effect until Payment in Full of the Obligations, and (ii) be binding on each Grantor and all other Persons who become bound as debtor to this Agreement in accordance with Section 9-203(d) of the Code and shall inure, together with all rights and remedies of the Collateral Agent and the Noteholders hereunder, to the benefit of the Collateral Agent and the Noteholders and their respective permitted successors, transferees and assigns. Without limiting the generality of clause (ii) of the immediately preceding sentence, without notice to any Grantor, the Collateral Agent and the Noteholders may assign or otherwise transfer their rights and obligations under this Agreement and any of the other Transaction Documents, to any other Person and such other Person shall thereupon become vested with all of the benefits in respect thereof granted to the Collateral Agent and the Noteholders herein or otherwise. Upon any such assignment or transfer, all references in this Agreement to the Collateral Agent or any such Noteholder shall mean the assignee of the Collateral Agent or such Noteholder. None of the rights or obligations of any Grantor hereunder may be assigned or otherwise transferred without the prior written consent of the Collateral Agent, and any such assignment or transfer without such consent of the Collateral Agent shall be null and void.

 

  30  

 

 

(e)       Upon the Payment in Full of the Obligations, (i) this Agreement and the security interests created hereby shall terminate and all rights to the Collateral shall revert to the respective Grantor that granted such security interests hereunder, and (ii) the Collateral Agent will, upon any Grantor’s request and at such Grantor’s expense, (A) return to such Grantor such of the Collateral as shall not have been sold or otherwise disposed of or applied pursuant to the terms hereof and (B) execute and deliver to such Grantor such documents as such Grantor shall reasonably request to evidence such termination, all without any representation, warranty or recourse whatsoever.

 

(f)        Governing Law; Jurisdiction; Jury Trial .

 

(i)       All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed exclusively by the internal laws of the State of New York, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of New York or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of New York.

 

(ii)      Each Grantor hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in The City of New York, Borough of Manhattan, for the adjudication of any dispute hereunder or in connection herewith or under any of the other Transaction Documents or with any transaction contemplated hereby or thereby, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim, defense or objection that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof to such party at the address for such notices to it under Section 9(f) of the Securities Purchase Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. Nothing contained herein shall be deemed or operate to preclude the Collateral Agent or the Noteholders from bringing suit or taking other legal action against any Grantor in any other jurisdiction to collect on a Grantor’s obligations or to enforce a judgment or other court ruling in favor of the Collateral Agent or a Noteholder.

 

  31  

 

 

(iii)        WAIVER OF JURY TRIAL, ETC . EACH GRANTOR IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR UNDER ANY OTHER TRANSACTION DOCUMENT OR IN CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT, ANY OTHER TRANSACTION DOCUMENT OR ANY TRANSACTION CONTEMPLATED HEREBY OR THEREBY.

 

(iv)       Each Grantor irrevocably and unconditionally waives any right it may have to claim or recover in any legal action, suit or proceeding referred to in this Section any special, exemplary, indirect, incidental, punitive or consequential damages.

 

(g)       Section headings herein are included for convenience of reference only and shall not constitute a part of this Agreement for any other purpose.

 

(h)       This Agreement may be executed in any number of counterparts and by different parties hereto in separate counterparts, each of which shall be deemed to be an original, but all of which taken together constitute one and the same Agreement. Delivery of any executed counterpart of a signature page of this Agreement by pdf, facsimile or other electronic transmission shall be effective as delivery of a manually executed counterpart of this Agreement.

 

(i)       This Agreement shall continue to be effective or be reinstated, as the case may be, if at any time any payment of any of the Obligations is rescinded or must otherwise be returned by the Collateral Agent, any Noteholder or any other Person (upon (i) the occurrence of any Insolvency Proceeding of any of the Parent or any Grantor or (ii) otherwise, in all cases as though such payment had not been made).

 

SECTION 11. Material Non-Public Information . Upon receipt or delivery by the Parent of any notice in accordance with the terms of this Agreement, unless the Parent has in good faith determined that the matters relating to such notice do not constitute material, non-public information relating to the Parent or any of its Subsidiaries, the Parent shall within two (2) Business Days after any such receipt or delivery publicly disclose such material, non-public information on a Current Report on Form 8-K or otherwise. In the event that the Parent believes that a notice contains material, non-public information relating to the Parent or any of its Subsidiaries, the Parent so shall indicate to the Collateral Agent and any applicable Noteholder contemporaneously with delivery of such notice, and in the absence of any such indication, the Collateral Agent and each Noteholder shall be allowed to presume that all matters relating to such notice do not constitute material, non-public information relating to the Parent or its Subsidiaries. Nothing contained in this Section 11 shall limit any obligations of the Parent, or any rights of the Collateral Agent or any Noteholder, under Section 4(i) of the Securities Purchase Agreement.

 

[REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK]

 

  32  

 

 

IN WITNESS WHEREOF, each Grantor has caused this Agreement to be executed and delivered by its officer thereunto duly authorized, as of the date first above written.

 

  GRANTORS :
     
  ICAGEN, INC. ,
  a Delaware corporation
     
  By: /s/ Richard Cunningham
    Name: Richard Cunningham
    Title: President and CEO
     
  ICAGEN CORP (FORMERLY KNOWN AS XRPRO CORP.). , a Nevada corporation
     
  By: /s/ Richard Cunningham
    Name: Richard Cunningham
    Title: President and CEO

 

  CALDERA DISCOVERY, INC , a Delaware corporation
     
  By: /s/ Richard Cunningham
    Name: Richard Cunningham
    Title: President and CEO
     
  XRPRO SCIENCES, INC. , a Delaware corporation
     
  By: /s/ Richard Cunningham
    Name: Richard Cunningham
    Title: President and CEO

 

ACCEPTED BY:  
     
GPB Debt Holdings II, LLC,  
as Collateral Agent  

 

 
By:  /s/ David Gentile  
  Name: David Gentile  
  Title: Manager  

 

  33  

 

 

LIST OF EXHIBITS AND SCHEDULES TO SECURITY AND PLEDGE AGREEMENT

 

A. EXHIBITS

 

Exhibit A – IP Security Agreement

 

B. SCHEDULES

 

Schedule I – Controlled Accounts Etc.

 

Schedule II – Copyrights, Etc.

 

Schedule III – Patents, Etc.

 

Schedule IV – Pledged Entities

 

Schedule V – Trademark Licenses

 

Schedule V(a) – Trademarks, Etc.

 

Schedule VI – Commercial Tort Claims

 

Schedule VII – Legal Names, Organizational Identification Numbers; States or Jurisdiction of Organization

 

Schedule VIII – Locations

 

Schedule IX – Securities Etc. of each Grantor

 

Schedule X – Licenses, Etc.

 

Schedule XI – All Intellectual Property and Licenses of Grantors

 

Schedule XII – Pledged Collateral

 

Schedule XIII – [RESERVED]

 

Schedule XIV – [RESERVED]

 

Schedule XV - Pledged Equity

 

Schedule XVI – Locations of Collateral

 

Schedule XVII – Licenses, Etc.

 

Schedule XVIII – Notices. Etc., Re: Exercise of Rights by certain parties under Licenses

 

Schedule XIX – No Termination Etc. of Licenses

 

 

 

 

EXHIBIT A

 

FORM OF INTELLECTUAL PROPERTY SECURITY AGREEMENT

 

INTELLECTUAL PROPERTY SECURITY AGREEMENT

 

This INTELLECTUAL PROPERTY SECURITY AGREEMENT (as amended, modified, supplemented, renewed, restated or replaced from time to time, this “ IP Security Agreement ”), dated May 15, 2017, is made by the Persons listed on the signature pages hereof (collectively, the “ Grantors ”) in favor of GPB Debt Holdings II, LLC, in its capacity as collateral agent (the “ Collateral Agent ”) for itself as a Noteholder and any other Noteholders. All capitalized terms not otherwise defined herein (or as indicated herein as being defined in another document, agreement and/or instrument) shall have the meanings respectively ascribed thereto in the Security Agreement (as defined below).

 

WHEREAS, Icagen, Inc., a Delaware corporation with offices located at 4222 Emperor Blvd., Suite 350, Research Triangle Park, Durham, NC, 27703 (the “ Parent ”), Icagen-T, Inc., a Delaware corporation and a wholly-owned Subsidiary of the Parent with offices located at 2090 E. Innovation Park Drive, Oro Valley, Arizona 85755 (“ ICA-T ”) and GPB Debt Holdings II, LLC, as investor (the “ Buyer ”) are parties to that certain Securities Purchase Agreement, dated May 15, 2017, pursuant to which ICA-T and the Parent shall be required to sell, and the Buyer shall purchase or have the right to purchase, the ICA-T Note (as defined therein) and the Parent Note and Parent Warrant (both terms as defined therein) from ICA-T and the Parent, respectively;

 

WHEREAS, it is a condition precedent to the purchase of the Notes and the Parent Note and Parent Warrants under the Securities Purchase Agreement that each Grantor has executed and delivered that certain Security and Pledge Agreement, dated May 15, 2017, made by the Grantors to the Collateral Agent (as amended, modified, supplemented, renewed, restated or replaced from time to time, the “ Security Agreement ”); and

 

WHEREAS, under the terms of the Security Agreement, the Grantors have granted to the Collateral Agent, for the benefit of the Noteholders, a security interest in, among other property, certain intellectual property and Licenses of the Grantors, and have agreed as a condition thereof to execute this IP Security Agreement for recording with the U.S. Patent and Trademark Office and the United States Copyright Office; and

 

WHEREAS, the Grantors have determined that the execution, delivery and performance of this IP Security Agreement directly benefits, and is in the best interest of, the Grantors.

 

NOW, THEREFORE, in consideration of the premises and the agreements herein and for such other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, and in order to induce the Buyer to perform under the Securities Purchase Agreement, each Grantor agrees with the Collateral Agent, for the benefit of the Noteholders, as follows

 

SECTION 1. Grant of Security . Each Grantor hereby grants to the Collateral Agent for the benefit of the Collateral Agent as a Noteholder and any other Noteholders a security interest in all of such Grantor’s right, title and interest in and to the following (the “ Collateral ”):

 

(i)       the United States Patents and Patent applications set forth in Schedule A hereto;

 

 

 

 

(ii)       the United States Trademarks and service mark registrations and applications set forth in Schedule B hereto (provided that no security interest shall be granted in United States intent-to-use trademark applications to the extent that, and solely during the period in which, the grant of a security interest therein would impair the validity or enforceability of such intent-to-use trademark applications under applicable federal law), together with the goodwill symbolized thereby;

 

(iii)      all United States Copyrights, whether registered or unregistered, now owned or hereafter acquired by such Grantor, including, without limitation, the copyright registrations and applications and exclusive copyright licenses set forth in Schedule C hereto;

 

(iv)      all reissues, divisions, continuations, continuations-in-part, extensions, renewals and reexaminations of any of the foregoing, all rights in the foregoing provided by international treaties or conventions, all rights corresponding thereto throughout the world and all other rights of any kind whatsoever of such Grantor accruing thereunder or pertaining thereto;

 

(v)       any and all claims for damages and injunctive relief for past, present and future infringement, dilution, misappropriation, violation, misuse or breach with respect to any of the foregoing, with the right, but not the obligation, to sue for and collect, or otherwise recover, such damages; and

 

(vi)       any and all proceeds of, collateral for, income, royalties and other payments now or hereafter due and payable with respect to, and supporting obligations relating to, any and all of the Collateral of or arising from any of the foregoing.

 

SECTION 2. Security for Obligations . The grant of a security interest in, the Collateral under this IP Security Agreement by each Grantor) secures the payment of all Obligations of each Grantor now or hereafter existing under or in respect of the Notes and the other Transaction Documents, whether direct or indirect, absolute or contingent, and whether for principal, reimbursement obligations, interest, redemption payments, premiums, penalties, fees, indemnifications, contract causes of action, costs, expenses or otherwise.

 

SECTION 3. Recordation . Each Grantor authorizes and requests that the Register of Copyrights, the Commissioner for Patents and the Commissioner for Trademarks and any other applicable government officer record this IP Security Agreement.

 

SECTION 4. Execution in Counterparts . This IP Security Agreement may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement.

 

SECTION 5. Grants, Rights and Remedies . This IP Security Agreement has been entered into in conjunction with the provisions of the Security Agreement. Each Grantor does hereby acknowledge and confirm that the grant of the security interest hereunder to, and the rights and remedies of, the Collateral Agent with respect to the Collateral are more fully set forth in the Security Agreement, the terms and provisions of which are incorporated herein by reference as if fully set forth herein.

 

  2  

 

 

SECTION 6. Governing Law; Jurisdiction; Jury Trial .

 

(i)       All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by the internal laws of the State of New York, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of New York or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of New York.

 

(ii)       Each Grantor hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in The City of New York, Borough of Manhattan, for the adjudication of any dispute hereunder or in connection herewith or under any of the other Transaction Documents or with any transaction contemplated hereby or thereby, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim, defense or objection that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof to such party at the address for such notices to it under Section 9(f) of the Securities Purchase Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. Nothing contained herein shall be deemed or operate to preclude the Collateral Agent or the Noteholders from bringing suit or taking other legal action against any Grantor in any other jurisdiction to collect on a Grantor’s obligations or to enforce a judgment or other court ruling in favor of the Collateral Agent or a Noteholder.

 

(iii)       WAIVER OF JURY TRIAL, ETC . EACH GRANTOR IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR UNDER ANY OTHER TRANSACTION DOCUMENT OR IN CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT, ANY OTHER TRANSACTION DOCUMENT OR ANY TRANSACTION CONTEMPLATED HEREBY OR THEREBY.

 

(iv)      Each Grantor irrevocably and unconditionally waives any right it may have to claim or recover in any legal action, suit or proceeding referred to in this Section any special, exemplary, indirect, incidental, punitive or consequential damages.

 

[The remainder of the page is intentionally left blank]

 

  3  

 

 

IN WITNESS WHEREOF, each Grantor has caused this Agreement to be duly executed and delivered by its officer thereunto duly authorized as of the date first above written.

 

  GRANTORS :
     
  ICAGEN, INC. ,
  a Delaware corporation
     
  By:
    Name: Richard Cunningham
    Title: President and CEO
     
  ICAGEN CORP. (FORMERLY KNOWN AS XRPRO CORP., FORMERLY KNOWN AS CALDERA PHARMACEUTICALS , INC.), a Nevada corporation
     
  By:
    Name: Richard Cunningham
    Title: President and CEO

 

  CALDERA DISCOVERY, INC , a Delaware corporation
     
  By:
    Name: Richard Cunningham
    Title: President and CEO
     
  XRPRO SCIENCES, INC. , a Delaware corporation
     
  By:
    Name: Richard Cunningham
    Title: President and CEO

 

  4  

 

 

SCHEDULE I

 

Controlled Accounts Etc.

 

  Icagen Inc.  
     
  ##### #####  
       
  Icagen Corp.  
     
  ##### #####  
       

  

Accounts to be closed within 90 days of conclusion of Agreement:

 

Icagen Inc.

 

  ##### #####  
       
  ##### #####  
       
  ##### #####  
       
  ##### #####  
       
  ##### #####  

 

 

 

 

SCHEDULE II

 

Copyrights, Etc.

 

None

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SCHEDULE III

 

Patents, Etc.

 

Reference   Title   Country   Application No.   Pub. No.   Patent No.   Status
ICA-001   METHOD FOR DETECTING BINDING EVENTS USING MICRO-X-RAY FLUORESCENCE SPECTROMETRY   United States   09/859,701   2003-0027129   7,858,385   Patented
ICA-002EP   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   Europe   3748920   1525458   1525458   Patented
ICA-002BE   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   Belgium   3748920   1525458   1525458   Patented
ICA-002CH   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   Switzerland   3748920   1525458   1525458   Patented
ICA-002DE   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   Germany   3748920   1525458   1525458   Patented
ICA-002DK   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   Denmark   3748920   1525458   1525458   Patented
ICA-002ES   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   Spain   3748920   1525458   1525458   Patented

 

 

 

 

Reference   Title   Country   Application No.   Pub. No.   Patent No.   Status
ICA-002FI   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   Finland   3748920   1525458   1525458   Patented
ICA-002FR   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   France   3748920   1525458   1525458   Patented
ICA-002GB   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   United Kingdom   3748920   1525458   1525458   Patented
ICA-002IT   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   Italy   3748920   1525458   1525458   Patented
ICA-002SE   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   Sweden   3748920   1525458   1525458   Patented
ICA-002NL   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   Netherlands   3748920   1525458   1525458   Patented
ICA-002JP   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   Japan   2004-524531   2006-503268   4560403   Patented
ICA-002SG   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   Singapore   200500360-3   109345   109345   Patented

 

 

 

 

Reference   Title   Country   Application No.   Pub. No.   Patent No.   Status
ICA-002C2   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   United States   11/444,660   2007-0003008   7,519,145   Patented
ICA-002C3   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   United States   12/396,592   2009-0175410   7,929,662   Patented
ICA-003EP   METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING   Europe   4755687.3   1644095   1644095   Patented
ICA-003CH   METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING   Switzerland/
Liechtenstein
  4755687.3   1644095   1644095   Patented
ICA-003DE   METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING   Germany   4755687.3   1644095   1644095   Patented
ICA-003FR   METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING   France   4755687.3   1644095   1644095   Patented
ICA-003GB   METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING   United Kingdom   4755687.3   1644095   1644095   Patented
ICA-003IE   METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING   Ireland   4755687.3   1644095   1644095   Patented
ICA-003NL   METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING   Netherlands   4755687.3   1644095   1644095   Patented
ICA-003JP   METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING   Japan   2006-520181   2007527524   4782676   Patented

 

 

 

 

Reference   Title   Country   Application No.   Pub. No.   Patent No.   Status
ICA-003SG   METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING   Singapore   2005085584       118682   Patented
ICA-003   METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING   United States   10/621,825   2005-0011818   6,858,148   Patented
ICA-003C1   METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING   United States   10/986,519   2005-0095636   7,241,381   Patented
ICA-004   DRUG DEVELOPMENT AND MANUFACTURING   United States   10/880,388   2004-0235059   9,157,875   Patented
ICA-005EP   X-RAY FLUORESCENCE ANALYSIS METHOD   Europe   7874491.9   2084519   2084519   Patented
ICA-005CH   X-RAY FLUORESCENCE ANALYSIS METHOD   Switzerland/
Liechtenstein
  07 874 491.9   2084519   2084519   Patented
ICA-005DE   X-RAY FLUORESCENCE ANALYSIS METHOD   Germany   60 2007 024 468.4   2084519   608007024468.4   Patented
ICA-005DK   X-RAY FLUORESCENCE ANALYSIS METHOD   Denmark   07 874 491.9   2084519   2084519   Patented
ICA-005FR1   X-RAY FLUORESCENCE ANALYSIS METHOD   France   07 874 491.9   2084519   2084519   Patented
ICA-005GB   X-RAY FLUORESCENCE ANALYSIS METHOD   United Kingdom   7874491.9   2084519   2084519   Patented
ICA-005HK   ADVANCED DRUG DEVELOPMENT AND MANUFACTURING   Hong Kong (via EP -005EPDV)   13104259.3   1177280   1177280   Patented
ICA-005IE   X-RAY FLUORESCENCE ANALYSIS METHOD   Ireland   7874491.9   1177280   2084519   Patented

 

 

 

 

Reference   Title   Country   Application No.   Pub. No.   Patent No.   Status
ICA-005IT   X-RAY FLUORESCENCE ANALYSIS METHOD   Italy   7874491.9   1177280   2084519   Patented
ICA-005NL   X-RAY FLUORESCENCE ANALYSIS METHOD   Netherlands   7874491.9   1177280   2084519   Patented
ICA-005SE   X-RAY FLUORESCENCE ANALYSIS METHOD   Sweden   7874491.9   1177280   2084519   Patented
ICA-005EPDV   X-RAY MICROSCOPE   Europe   12164870.3   2511844   2511844   Patented
ICA-005CHDV   X-RAY MICROSCOPE   Switzerland and Lichtenstein   12164870.3   2511844   2511844   Patented
ICA-005DEDV   X-RAY MICROSCOPE   Germany   12164870.3   2511844   602007042616.2   Patented
ICA-005FRDV   X-RAY MICROSCOPE   France   12164870.3   2511844   2511844   Patented
ICA-005GBDV   X-RAY MICROSCOPE   United Kingdom   12164870.3   2511844   2511844   Patented
ICA-005HK   ADVANCED DRUG DEVELOPMENT AND MANUFACTURING   Hong Kong (via EP -005EPDV)   2013104259.3   1177280   1177280   Patented
ICA-005IEDV   X-RAY MICROSCOPE   Ireland   12164870.3   2511844   2511844   Patented
ICA-005JP   ADVANCED DRUG DEVELOPMENT AND MANUFACTURING   Japan   2009-532446   2010509566   5143841   Patented
ICA-005JPDV2   ADVANCED DRUG DEVELOPMENT AND MANUFACTURING   Japan   2014-123249   2014-123249   5913441   Patented
ICA-005C1   ADVANCED DRUG DEVELOPMENT AND MANUFACTURING   United States   14/693,094   2015-0309021   N/A   Pending

 

 

 

 

Reference   Title   Country   Application No.   Pub. No.   Patent No.   Status
ICA-006EP   WELL PLATE   Europe   8798006.6   2183644   2183644   Patented
ICA-006BE   WELL PLATE   Belgium   8798007.6   2183644   2183644   Patented
ICA-006CH   WELL PLATE   Switzerland   8798008.6   2183644   2183644   Patented
ICA-006DE   WELL PLATE   Germany   8798009.6   2183644   602008044640.9   Patented
ICA-006DK   WELL PLATE   Denmark   8798010.6   2183644   2183644   Patented
ICA-006ES   WELL PLATE   Spain   8798011.6   2183644   2183644   Patented
ICA-006FI   WELL PLATE   Finland   8798012.6   2183644   2183644   Patented
ICA-006FR   WELL PLATE   France   8798013.6   2183644   2183644   Patented
ICA-006GB   WELL PLATE   United Kingdom   8798014.6   2183644   2183644   Patented
ICA-006IE   WELL PLATE   Ireland   8798015.6   2183644   2183644   Patented
ICA-006IT   WELL PLATE   Italy   8798016.6   2183644   2183644   Patented
ICA-006 NL   WELL PLATE   Netherlands   8798017.6   2183644   2183644   Patented
ICA-006NO   WELL PLATE   Norway   8798018.6   2183644   2183644   Patented
ICA-006SE   WELL PLATE   Sweden   8798019.6   2183644   2183644   Patented
ICA-006JP   WELL PLATE   Japan   2010-521206   2010537171   5628035   Patented
ICA-006JPDV   WELL PLATE   Japan   2013-117600   2013224946   5755682   Patented
ICA-006JPDV2   WELL PLATE   Japan   2014-202871   2015004692   6076308   Patented
ICA-006   WELL PLATE   United States   12/192,762   2009-0046832   8,238,515   Patented
ICA-006C1   WELL PLATE   United States   13/567,613   2013-0034205   8,873,707   Patented
ICA-006C2   WELL PLATE   United States   14/508,322   2015-0023467   9,476,846   Patented
ICA-006C3   WELL PLATE   United States   15/273,767   2017-0010228   N/A   Pending
ICA-007JP   METHOD AND APPARATUS FOR MEASURING PROTEIN POST-TRANSLATIONAL MODIFICATION   Japan   2010-5272   2010539944   5743135   Patented

 

 

 

 

Reference   Title   Country   Application No.   Pub. No.   Patent No.   Status
ICA-007JPDV1   METHOD AND APPARATUS FOR MEASURING PROTEIN POST-TRANSLATIONAL MODIFICATION   Japan   2014-221166   2015033386   N/A   Pending
ICA-007C1/XR7-US2   METHOD AND APPARATUS FOR MEASURING PROTEIN POST-TRANSLATIONAL MODIFICATION   United States   15/052,914   2016-0201111   N/A   Pending
ICA-008CN   METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS   China   200980125952.3   102083365   ZL 200980125952.3   Patented
ICA-008CNDV   METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS   China   201310298029.8   103411988   2077368   Patented
ICA-008CNDV2   METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS   China   201510083796.6   N/A   N/A   Pending
ICA-008EP   METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS   Europe   09774467.6   2306897   N/A   Allowed
ICA-008HK   METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS   Hong Kong   11112984.0   1158478   1158478   Patented

 

 

 

 

Reference   Title   Country   Application No.   Pub. No.   Patent No.   Status
ICA-008   METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS USING X-RAY FLUORESCENCE   United States   12/496,532   2010-0003697   8,431,357   Patented
ICA-008C1   METHOD FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS USING X-RAY FLUORESCENCE USING X-RAY FLUORESCENCE   United States   13/871,697   2013-0236887   9,063,154   Patented
ICA-008C2   METHOD FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS USING X-RAY FLUORESCENCE   United States   14/669,923   2015-0198615   9,506,931   Patented
ICA-008C3   METHOD FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS USING X-RAY FLUORESCENCE   United States   15/334,854   2017-0045530   N/A   Pending
ICA-009   METHOD FOR ANALYSIS USING X-RAY FLUORESCENCE   United States   13/317,341   2012-0093286   9,063,066   Patented
ICA-009C1   METHOD FOR ANALYSIS USING X-RAY FLUORESCENCE   United States   14/715,206   2015-0276631   9,435,756   Patented
ICA-009C2   METHOD FOR ANALYSIS USING X-RAY FLUORESCENCE   United States   14/715,218   2015-0276632   9,442,085   Patented
ICA-009C3   METHOD FOR ANALYSIS USING X-RAY FLUORESCENCE   United States   14/715,233   2015-0260664   9,335,284   Patented
ICA-009C4   METHOD FOR ANALYSIS USING X-RAY FLUORESCENCE   United States   15/227,292   2016-0341678   N/A   Pending
ICA-010PC   METHODS AND APPARATUS FOR MEASURING METALS AND METALLOIDS   International   PCT/US17/28064   N/A   N/A   Pending

 

 

 

 

SCHEDULE IV

 

Pledged Entities

 

Icagen Corp.

 

XRpro Sciences, Inc.

 

Caldera Discovery, Inc.

 

 

 

 

 

 

 

 

 

 

 

 

 

SCHEDULE V

 

Trademark Licenses

 

None

 

 

 

 

 

 

 

 

 

 

 

 

SCHEDULE V(a)

 

Trademarks, Etc.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SCHEDULE VI

 

Commercial Tort Claims

 

None

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SCHEDULE VII

 

Legal Names, Organizational Identification Numbers; States or Jurisdiction of Organization

 

Grantor’s Name   State of Organization   Federal Employer I.D.   Organizational I.D.
Icagen, Inc. (formerly known as; Caldera Pharmaceuticals, Inc.; and XRpro Sciences, Inc.   Delaware North Carolina   #####   3723366
Icagen Corp. (formerly known as XRpro Corp.)   Nevada North Carolina     #####   NV20101523783
Caldera Discovery, Inc.   Delaware   #####   5717856
XRpro Sciences, Inc.   Delaware   #####   5904530

 

 

 

 

SCHEDULE VIII

 

Locations

 

Icagen Corp.

4222 Emperor Boulevard, Suite 350

Research Triangle Park

Durham, NC, 27703

 

Icagen-T, Inc.

2090 E. Innovation Park Drive

Tucson, AZ 85755

 

 

 

 

 

 

 

 

 

SCHEDULE IX

 

Securities Etc. of each Grantor

 

Securities

 

Grantor   Name of Issuer / Pledged Entity   Number of Shares   Class   Certificate No.(s)
Icagen, Inc.   Icagen Corp.   100,000   Common   C01
Icagen, Inc.   Caldera Discovery, Inc.   100   Common   C-01
Icagen, Inc.   XRpro Sciences, Inc   100   Common   C-01

 

Deposit Accounts, Securities Accounts and Commodities Accounts

 

Grantor   Name and Address of Institution   Purpose of the Account   Account No.
Icagen Inc.    #####    #####    #####
             
Icagen Inc.    #####    #####    #####
             
Icagen Inc.    #####    #####    #####
             
Icagen Corp.    #####    #####    #####

 

Foreign Currency Controlled Accounts

 

None

 

 

 

 

SCHEDULE X

 

Licenses, Etc.

 

Hazardous Materials License

 

 

 

 

 

 

 

 

 

 

 

SCHEDULE XI

 

All Intellectual Property of Grantors

 

See Schedule 5(a) and 10

 

Reference   Title   Country   Application No.   Pub. No.   Patent No.   Status
ICA-001   METHOD FOR DETECTING BINDING EVENTS USING MICRO-X-RAY FLUORESCENCE SPECTROMETRY   United States   09/859,701   2003-0027129   7,858,385   Patented
ICA-002EP   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   Europe   3748920   1525458   1525458   Patented
ICA-002BE   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   Belgium   3748920   1525458   1525458   Patented
ICA-002CH   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   Switzerland   3748920   1525458   1525458   Patented
ICA-002DE   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   Germany   3748920   1525458   1525458   Patented
ICA-002DK   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   Denmark   3748920   1525458   1525458   Patented

 

 

 

 

Reference   Title   Country   Application No.   Pub. No.   Patent No.   Status
ICA-002ES   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   Spain   3748920   1525458   1525458   Patented
ICA-002FI   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   Finland   3748920   1525458   1525458   Patented
ICA-002FR   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   France   3748920   1525458   1525458   Patented
ICA-002GB   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   United Kingdom   3748920   1525458   1525458   Patented
ICA-002IT   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   Italy   3748920   1525458   1525458   Patented
ICA-002SE   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   Sweden   3748920   1525458   1525458   Patented
ICA-002NL   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   Netherlands   3748920   1525458   1525458   Patented

 

 

 

 

Reference   Title   Country   Application No.   Pub. No.   Patent No.   Status
ICA-002JP   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   Japan   2004-524531   2006-503268   4560403   Patented
ICA-002SG   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   Singapore   200500360-3   109345   109345   Patented
ICA-002C2   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   United States   11/444,660   2007-0003008   7,519,145   Patented
ICA-002C3   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   United States   12/396,592   2009-0175410   7,929,662   Patented
ICA-003EP   METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING   Europe   4755687.3   1644095   1644095   Patented
ICA-003CH   METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING   Switzerland/
Liechtenstein
  4755687.3   1644095   1644095   Patented
ICA-003DE   METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING   Germany   4755687.3   1644095   1644095   Patented

 

 

 

 

Reference   Title   Country   Application No.   Pub. No.   Patent No.   Status
ICA-003FR   METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING   France   4755687.3   1644095   1644095   Patented
ICA-003GB   METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING   United Kingdom   4755687.3   1644095   1644095   Patented
ICA-003IE   METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING   Ireland   4755687.3   1644095   1644095   Patented
ICA-003NL   METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING   Netherlands   4755687.3   1644095   1644095   Patented
ICA-003JP   METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING   Japan   2006-520181   2007527524   4782676   Patented
ICA-003SG   METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING   Singapore   2005085584       118682   Patented
ICA-003   METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING   United States   10/621,825   2005-0011818   6,858,148   Patented
ICA-003C1   METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING   United States   10/986,519   2005-0095636   7,241,381   Patented
ICA-004   DRUG DEVELOPMENT AND MANUFACTURING   United States   10/880,388   2004-0235059   9,157,875   Patented
ICA-005EP   X-RAY FLUORESCENCE ANALYSIS METHOD   Europe   7874491.9   2084519   2084519   Patented

 

 

 

 

Reference   Title   Country   Application No.   Pub. No.   Patent No.   Status
ICA-005CH   X-RAY FLUORESCENCE ANALYSIS METHOD   Switzerland/
Liechtenstein
  07 874 491.9   2084519   2084519   Patented
ICA-005DE   X-RAY FLUORESCENCE ANALYSIS METHOD   Germany   60 2007 024 468.4   2084519   608007024468.4   Patented
ICA-005DK   X-RAY FLUORESCENCE ANALYSIS METHOD   Denmark   07 874 491.9   2084519   2084519   Patented
ICA-005FR1   X-RAY FLUORESCENCE ANALYSIS METHOD   France   07 874 491.9   2084519   2084519   Patented
ICA-005GB   X-RAY FLUORESCENCE ANALYSIS METHOD   United Kingdom   7874491.9   2084519   2084519   Patented
ICA-005HK   ADVANCED DRUG DEVELOPMENT AND MANUFACTURING   Hong Kong (via EP -005EPDV)   13104259.3   1177280   1177280   Patented
ICA-005IE   X-RAY FLUORESCENCE ANALYSIS METHOD   Ireland   7874491.9   1177280   2084519   Patented
ICA-005IT   X-RAY FLUORESCENCE ANALYSIS METHOD   Italy   7874491.9   1177280   2084519   Patented
ICA-005NL   X-RAY FLUORESCENCE ANALYSIS METHOD   Netherlands   7874491.9   1177280   2084519   Patented
ICA-005SE   X-RAY FLUORESCENCE ANALYSIS METHOD   Sweden   7874491.9   1177280   2084519   Patented
ICA-005EPDV   X-RAY MICROSCOPE   Europe   12164870.3   2511844   2511844   Patented
ICA-005CHDV   X-RAY MICROSCOPE   Switzerland and Lichtenstein   12164870.3   2511844   2511844   Patented
ICA-005DEDV   X-RAY MICROSCOPE   Germany   12164870.3   2511844   602007042616.2   Patented

 

 

 

 

Reference   Title   Country   Application No.   Pub. No.   Patent No.   Status
ICA-005FRDV   X-RAY MICROSCOPE   France   12164870.3   2511844   2511844   Patented
ICA-005GBDV   X-RAY MICROSCOPE   United Kingdom   12164870.3   2511844   2511844   Patented
ICA-005HK   ADVANCED DRUG DEVELOPMENT AND MANUFACTURING   Hong Kong (via EP -005EPDV)   2013104259.3   1177280   1177280   Patented
ICA-005IEDV   X-RAY MICROSCOPE   Ireland   12164870.3   2511844   2511844   Patented
ICA-005JP   ADVANCED DRUG DEVELOPMENT AND MANUFACTURING   Japan   2009-532446   2010509566   5143841   Patented
ICA-005JPDV2   ADVANCED DRUG DEVELOPMENT AND MANUFACTURING   Japan   2014-123249   2014-123249   5913441   Patented
ICA-005C1   ADVANCED DRUG DEVELOPMENT AND MANUFACTURING   United States   14/693,094   2015-0309021   N/A   Pending
ICA-006EP   WELL PLATE   Europe   8798006.6   2183644   2183644   Patented
ICA-006BE   WELL PLATE   Belgium   8798007.6   2183644   2183644   Patented
ICA-006CH   WELL PLATE   Switzerland   8798008.6   2183644   2183644   Patented
ICA-006DE   WELL PLATE   Germany   8798009.6   2183644   602008044640.9   Patented
ICA-006DK   WELL PLATE   Denmark   8798010.6   2183644   2183644   Patented
ICA-006ES   WELL PLATE   Spain   8798011.6   2183644   2183644   Patented
ICA-006FI   WELL PLATE   Finland   8798012.6   2183644   2183644   Patented
ICA-006FR   WELL PLATE   France   8798013.6   2183644   2183644   Patented
ICA-006GB   WELL PLATE   United Kingdom   8798014.6   2183644   2183644   Patented
ICA-006IE   WELL PLATE   Ireland   8798015.6   2183644   2183644   Patented
ICA-006IT   WELL PLATE   Italy   8798016.6   2183644   2183644   Patented
ICA-006 NL   WELL PLATE   Netherlands   8798017.6   2183644   2183644   Patented

 

 

 

 

Reference   Title   Country   Application No.   Pub. No.   Patent No.   Status
ICA-006NO   WELL PLATE   Norway   8798018.6   2183644   2183644   Patented
ICA-006SE   WELL PLATE   Sweden   8798019.6   2183644   2183644   Patented
ICA-006JP   WELL PLATE   Japan   2010-521206   2010537171   5628035   Patented
ICA-006JPDV   WELL PLATE   Japan   2013-117600   2013224946   5755682   Patented
ICA-006JPDV2   WELL PLATE   Japan   2014-202871   2015004692   6076308   Patented
ICA-006   WELL PLATE   United States   12/192,762   2009-0046832   8,238,515   Patented
ICA-006C1   WELL PLATE   United States   13/567,613   2013-0034205   8,873,707   Patented
ICA-006C2   WELL PLATE   United States   14/508,322   2015-0023467   9,476,846   Patented
ICA-006C3   WELL PLATE   United States   15/273,767   2017-0010228   N/A   Pending
ICA-007JP   METHOD AND APPARATUS FOR MEASURING PROTEIN POST-TRANSLATIONAL MODIFICATION   Japan   2010-5272   2010539944   5743135   Patented
ICA-007JPDV1   METHOD AND APPARATUS FOR MEASURING PROTEIN POST-TRANSLATIONAL MODIFICATION   Japan   2014-221166   2015033386   N/A   Pending
ICA-007C1/XR7-US2   METHOD AND APPARATUS FOR MEASURING PROTEIN POST-TRANSLATIONAL MODIFICATION   United States   15/052,914   2016-0201111   N/A   Pending

 

 

 

 

Reference   Title   Country   Application No.   Pub. No.   Patent No.   Status
ICA-008CN   METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS   China   200980125952.3   102083365   ZL 200980125952.3   Patented
ICA-008CNDV   METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS   China   201310298029.8   103411988   2077368   Patented
ICA-008CNDV2   METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS   China   201510083796.6   N/A   N/A   Pending
ICA-008EP   METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS   Europe   09774467.6   2306897   N/A   Allowed
ICA-008HK   METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS   Hong Kong   11112984.0   1158478   1158478   Patented
ICA-008   METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS USING X-RAY FLUORESCENCE   United States   12/496,532   2010-0003697   8,431,357   Patented
ICA-008C1   METHOD FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS USING X-RAY FLUORESCENCE USING X-RAY FLUORESCENCE   United States   13/871,697   2013-0236887   9,063,154   Patented

 

 

 

 

Reference   Title   Country   Application No.   Pub. No.   Patent No.   Status
ICA-008C2   METHOD FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS USING X-RAY FLUORESCENCE   United States   14/669,923   2015-0198615   9,506,931   Patented
ICA-008C3   METHOD FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS USING X-RAY FLUORESCENCE   United States   15/334,854   2017-0045530   N/A   Pending
ICA-009   METHOD FOR ANALYSIS USING X-RAY FLUORESCENCE   United States   13/317,341   2012-0093286   9,063,066   Patented
ICA-009C1   METHOD FOR ANALYSIS USING X-RAY FLUORESCENCE   United States   14/715,206   2015-0276631   9,435,756   Patented
ICA-009C2   METHOD FOR ANALYSIS USING X-RAY FLUORESCENCE   United States   14/715,218   2015-0276632   9,442,085   Patented
ICA-009C3   METHOD FOR ANALYSIS USING X-RAY FLUORESCENCE   United States   14/715,233   2015-0260664   9,335,284   Patented
ICA-009C4   METHOD FOR ANALYSIS USING X-RAY FLUORESCENCE   United States   15/227,292   2016-0341678   N/A   Pending
ICA-010PC   METHODS AND APPARATUS FOR MEASURING METALS AND METALLOIDS   International   PCT/US17/28064   N/A   N/A   Pending

 

 

 

 

SCHEDULE XII

 

Pledged Collateral

 

Icagen, Inc. Delaware Secretary of State - U.S. Bank Equipment Finance-Equipment

 

 

 

 

SCHEDULE XIII

 

[RESERVED]

 

 

 

 

 

 

 

 

 

 

 

 

SCHEDULE XIV

 

[RESERVED]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SCHEDULE XV

 

Pledged Equity

 

Icagen Inc. Icagen Corp. 100,000 common shares C01
       
  XRpro Sciences, Inc. 1,000 common shares C-01
       
  Caldera Discovery, Inc. 100 common shares C-01

 

 

 

 

 

SCHEDULE XVI

 

Locations of Collateral

 

Icagen Inc.

4222 Emperor Boulevard, Suite 350

Research Triangle Park

Durham, NC, 27703

 

Icagen Corp.

4222 Emperor Boulevard, Suite 350

Research Triangle Park

Durham, NC, 27703

 

 

 

 

 

SCHEDULE XVII

 

Licenses, Etc.

 

Hazardous Materials License

 

 

 

 

Schedule XVIII

 

Notices. Etc. Re: Exercise of Rights by certain parties under Licenses

 

None

 

 

 

 

 

 

SCHEDULE XIX

 

No Termination Etc. of Licenses

 

None

 

 

 

 

Exhibit 10.3

 

Execution Version

 

SECURITY AND PLEDGE AGREEMENT FOR OBLIGATIONS OF ICA-T

 

SECURITY AND PLEDGE AGREEMENT FOR OBLIGATIONS OF ICA-T , dated as of May 15, 2017 (this “ Agreement ”), made by Icagen, Inc., a Delaware corporation with offices located at 4222 Emperor Blvd., Suite 350, Research Triangle Park, Durham, NC, 27703 (the “ Parent ”), Icagen-T, Inc., a Delaware corporation and a wholly-owned Subsidiary of the Parent with offices located at 2090 E. Innovation Park Drive, Oro Valley, Arizona 85755 (“ ICA-T ”) and each of the undersigned direct and indirect Domestic Subsidiaries (as defined below) from time to time (together with ICA-T and the Parent, collectively, the “ Grantors ” and each a “ Grantor ”), in favor of GPB Debt Holdings II, LLC (in its capacity as collateral agent for itself as purchaser of the Notes (as defined below) and each other Person who may become a Noteholder (as defined below), the “ Collateral Agent ;” and in its capacity as the purchaser of the Notes, the “ Buyer ”), pursuant to the Securities Purchase Agreement, dated as of May 15, 2017 (as amended, modified, supplemented, extended, renewed, restated or replaced from time to time, the “ Securities Purchase Agreement ”).

 

W I T N E S S E T H :

 

WHEREAS, the Parent, ICA-T and the Buyer are parties to the Securities Purchase Agreement, pursuant to which, among other items (i) ICA-T issued and sold an $8,000,000 aggregate principal amount senior secured convertible note of ICA-T (as such may be amended, modified, supplemented, extended, renewed, restated or replaced from time to time (the “ ICA-T Note ”), and (ii) the Parent issued and sold, among other securities, a $2,000,000 aggregate principal amount senior secured convertible note of the Parent (as such may be amended, modified, supplemented, extended, renewed, restated or replaced from time to time (the “ Parent Note ” and together with the ICA-T Note, collectively, the “ Notes ), to the Buyer;”

 

WHEREAS, the Parent and certain other Grantors from time to time (other than ICA-T) (each a “ Guarantor ” and collectively, the “ Guarantors ”) may execute and deliver one or more guaranties including, but not limited to, that Guaranty of Obligations of ICA-T (as defined below) in form and substance acceptable to and in favor of the Collateral Agent, for the benefit of itself as a Noteholder and any other Noteholder with respect to all of (i) ICA-T’s obligations under the ICA-T Note, the Securities Purchase Agreement and the other Transaction Documents (as defined in the Securities Purchase Agreement), and (ii) the Parent’s obligations under the ICA-T Note;

 

WHEREAS, it is a condition precedent to the Buyer’s obligation to purchase the ICA-T Note, (and the Parent Note and the Parent Warrant) issued pursuant to the Securities Purchase Agreement, that the Grantors (including ICA-T) shall have executed and delivered to the Collateral Agent this Agreement providing for the grant to the Collateral Agent, for the benefit of itself as a Noteholder and any other Noteholder, of a valid, enforceable, and perfected security interest in all personal property of each Grantor to secure all of (i) ICA-T’s obligations under the Transaction Documents, (ii) the Grantors’ (other than ICA-T) obligations under the Guaranty of Obligations of ICA-T, and (iii) the Parent’s obligations under the ICA-T Note; and

 

WHEREAS, each Grantor has determined that the execution, delivery and performance of this Agreement directly and/or indirectly benefits, and is in the best interest of, such Grantor;

 

 

 

 

NOW, THEREFORE, in consideration of the premises and the agreements herein and such other consideration which the parties hereto recognize and acknowledge the sufficiency of and in order to induce the Buyer to perform its obligations under the Securities Purchase Agreement, each Grantor agrees with the Collateral Agent, for the benefit of the Collateral Agent and the Noteholders, as follows:

 

SECTION 1. Definitions.

 

(a)       Reference is hereby made to the Securities Purchase Agreement and the Notes for a statement of the terms thereof. All terms used in this Agreement and the recitals hereto which are defined in the Securities Purchase Agreement, the Notes or in the Code (as defined below), and which are not otherwise defined herein shall have the same meanings herein as set forth therein; provided that terms used herein which are defined in the Code on the date hereof shall continue to have the same meaning notwithstanding any replacement or amendment of the Code except as the Collateral Agent may otherwise determine.

 

(b)       The following terms shall have the respective meanings provided for in the Code: “Accounts” “Account Debtor”, “Cash Proceeds”, “Certificate of Title”, “Chattel Paper”, “Commercial Tort Claim”, “Commodity Account”, “Commodity Contracts”, “Deposit Account”, “Documents”, “Electronic Chattel Paper”, “Equipment”, “Fixtures”, “General Intangibles”, “Goods”, “Instruments”, “Inventory”, “Investment Property”, “Letter-of-Credit Rights”, “Payment Intangibles”, “Proceeds”, “Promissory Notes”, “Security”, “Record”, “Security Account”, “Software”, and “Supporting Obligations”.

 

(c)       As used in this Agreement, the following terms shall have the respective meanings indicated below, such meanings to be applicable equally to both the singular and plural forms of such terms:

 

Affiliate ” of any Person means any other Person which, directly or indirectly, controls or is controlled by or is under common control with such Person and any officer or director of such Person. A Person shall be deemed to be “controlled by” any other Person if such Person possesses, directly or indirectly, power to vote 10% or more of the securities (on a fully diluted basis) having ordinary voting power for the election of directors or managers or power to direct or cause the direction of the management and policies of such Person, whether by contract or otherwise.

 

Bankruptcy Code ” means Chapter 11 of Title 11 of the United States Code, 11 U.S.C §§ 101 et seq. (or other applicable bankruptcy, insolvency or similar laws).

 

Business Day ” means any day other than Saturday, Sunday or other day on which commercial banks in New York City are authorized or required by law to remain closed.

 

Buyer ” shall have the meaning set forth in the recitals hereto.

 

Capital Stock ” means (i) with respect to any Person that is a corporation, any and all shares, interests, participations or other equivalents (however designated and whether or not voting) of corporate stock (including, without limitation, any warrants, options, rights or other securities exercisable or convertible into equity interests or securities of such Person), and (ii) with respect to any Person that is not a corporation, any and all partnership, membership or other equity interests of such Person.

 

  2  

 

 

Closing Date ” means the date of the sale by (i) ICA-T of the ICA-T Note, and (ii) the Parent of the Parent Note and the Parent Warrant to the Buyer pursuant to the terms of the Securities Purchase Agreement.

 

Code ” means Articles 8 or 9 of the Uniform Commercial Code as in effect from time to time in the State of New York; provided that, if perfection or the effect of perfection or non-perfection or the priority of any security interest in any Collateral is governed by the Uniform Commercial Code as in effect in a jurisdiction other than the State of New York, “Code” means the Uniform Commercial Code as in effect from time to time in such other jurisdiction for purposes of the provisions hereof relating to such perfection, effect of perfection or non-perfection or priority.

 

Collateral ” shall have the meaning set forth in Section 2(a) of this Agreement.

 

Collateral Agent ” shall have the meaning set forth in the preamble hereto.

 

Controlled Account Agreement ” means a deposit account control agreement or securities account control agreement with respect to a Pledged Account, in form and substance satisfactory to the Collateral Agent, as the same may be amended, modified, supplemented, extended, renewed, restated or replaced from time to time.

 

Controlled Accounts” means the Deposit Accounts, Commodity Accounts, Securities Accounts, and/or Foreign Currency Controlled Account of the Grantors listed on Schedule I attached hereto.

 

Copyright Licenses ” means all licenses, contracts or other agreements, whether written or oral, naming any Grantor as licensee or licensor and providing for the grant of any right to use or sell any works covered by any Copyright (including, without limitation, all Copyright Licenses set forth in Schedule II hereto).

 

Copyrights ” means all domestic and foreign copyrights, whether registered or not, including, without limitation, all copyright rights throughout the universe (whether now or hereafter arising) in any and all media (whether now or hereafter developed), in and to all original works of authorship fixed in any tangible medium of expression, acquired or used by any Grantor (including, without limitation, all copyrights described in Schedule II hereto), all applications, registrations and recordings thereof (including, without limitation, applications, registrations and recordings in the United States Copyright Office or in any similar office or agency of the United States or any other country or any political subdivision thereof), and all reissues, divisions, continuations, continuations in part and extensions or renewals thereof.

 

Domestic Subsidiary ” means any Subsidiary other than a Foreign Subsidiary.

 

Event of Default ” shall have the meaning set forth in Section 4(a) of the ICA-T Note.

 

  3  

 

 

Excluded Collateral ” means (A) the voting Capital Stock of any Foreign Subsidiary to the extent that (i) such Capital Stock represents more than 65% of the issued and outstanding voting Capital Stock of such Foreign Subsidiary and (ii) to the extent the pledge thereof is prohibited by the laws of such Foreign Subsidiary’s Organization or pledging more than 65% of the total outstanding voting Capital Stock of such Foreign Subsidiary would result in a material adverse tax consequence to a Grantor, (B) accounts receivable and/or Inventory of each Grantor, but only if and to the extent as of any time of determination any such Grantor’s accounts receivable and/or Inventory is being factored pursuant to an existing accounts receivable and/or Inventory financing arrangement between the provider of such financing and such Grantor, provided at all times commencing on the Closing Date (as defined in the Securities Purchase Agreement) that a Grantor’s accounts receivable and/or Inventory does not constitute Excluded Collateral pursuant to (B) of this definition of Excluded Collateral, such shall constitute Collateral and the Collateral Agent for the benefit of itself as a Noteholder and any other Noteholders shall have a senior secured security interest in and a valid, enforceable perfected senior priority Lien on such Grantor’s accounts receivable and/or Inventory and the Parent and each Grantor shall take at any time and from time to time any and all action necessary and/or as reasonably requested by the Collateral Agent to effectuate the same including, but not limited to, providing an opinion of legal counsel to the Parent relating to the above in form and substance satisfactory to the Collateral Agent, and (C) the Capital Stock of ICA-T; provided, the Capital Stock of ICA-T shall not be considered Excluded Collateral and shall constitute Collateral and “ Pledged Equity ” and ICA-T shall be a Pledged Entity commencing on the first calendar day following the date that the Master Services Agreement dated July 15, 2016 by and between Sanofi US Services, Inc. (“ Sanofi ”) and ICA-T (as amended, restated and/or otherwise modified, the “ MSA ”) shall not prohibit the Capital Stock of ICA-T from being pledged as Collateral (the “ Restriction End Date ”) and in connection therewith, ICA-T and the Parent shall take any and all such actions necessary and/or requested by the Collateral Agent to satisfy the Collateral Agent that such and the following has been effectuated and that the Collateral Agent for the benefit of itself as a Noteholder and any other Noteholders has a senior secured security interest in and a perfected senior priority Lien on the Capital Stock of ICA-T and that the Capital Stock of ICA-T is not directly and/or indirectly subject to any security interest and/or Lien of Sanofi and/or any other Person (except the Collateral Agent for the benefit of itself as a Noteholder and the holder of the Parent Note and any other Noteholder and/or other holder of a Parent Note) including, but not limited to, providing an opinion of legal counsel to the Parent relating to the above in form and substance satisfactory to the Collateral Agent (the “ ICA-T Capital Stock Actions ”).

 

Foreign Currency Controlled Accounts” means any Controlled Account of the Parent or its Subsidiaries holding non-United States dollar deposits.

 

Foreign Subsidiary ” means any Subsidiary of a Grantor organized under the laws of a jurisdiction other than the United States, any of the states thereof, Puerto Rico or the District of Columbia.

 

GAAP ” means U.S. generally accepted accounting principles consistently applied.

 

Governmental Authority ” means any nation or government, any Federal, state, city, town, municipality, county, local, foreign or other political subdivision thereof or thereto and any department, commission, board, bureau, instrumentality, agency or other entity exercising executive, legislative, judicial, taxing, regulatory or administrative powers or functions of or pertaining to government.

 

  4  

 

 

Guaranteed Obligations of ICA-T ” shall have the meaning set forth in Section 2 of the Guaranty of Obligations of ICA-T.

 

Guarantor ” or “ Guarantors ” shall have the meaning set forth in the recitals hereto.

 

Guaranty ” or “ Guaranties ” shall mean any additional guaranties required to be entered into pursuant to the Transaction documents with respect to the ICA-T Note.

 

Guaranty of Obligations of ICA-T ” shall mean that Guaranty of Obligations of ICA-T dated the date hereof made by the Grantors (other than ICA-T) and any future grantors.

 

ICA-T Note ” shall have the meaning set forth in the recitals hereto.

 

Insolvency Proceeding ” means any proceeding commenced by or against any Person under any provision of the Bankruptcy Code or under any other bankruptcy or insolvency law, assignments for the benefit of creditors, formal or informal moratoria, compositions, or extensions generally with creditors, or proceedings seeking reorganization, arrangement, or other similar relief.

 

Intellectual Property ” means, collectively, the Copyrights, Trademarks and Patents.

 

Intellectual Property Security Agreement ” means the Intellectual Property Security Agreement required to be delivered pursuant to Section 5(h)(i) of this Agreement, in the form attached hereto as Exhibit A .

 

Licenses ” means, collectively, the Copyright Licenses, the Trademark Licenses and the Patent Licenses, provided any such License does not contain a provision expressly prohibiting the pledge of such License.

 

Lien ” means any mortgage, lien, pledge, charge, security interest, adverse claim or other encumbrance upon or in any property or assets.

 

“Noteholder” means, at any time, the holders of all or any portion of the ICA-T Note at such time.

 

Obligations ” shall have the meaning set forth in Section 3 of this Agreement.

 

Paid in Full” or “ Payment in Full” means the indefeasible payment in full (including by way of redemption) of all Obligations in cash (and/or through the issuance of shares of Parent Common Stock (as defined in the ICA-T Note), by the ICA-T, Parent or a Subsidiary but only if and to the extent permitted by the ICA-T Note and the other Transaction Documents).

 

Parent ” shall have the meaning set forth in the preamble hereto.

 

  5  

 

 

Patent Licenses ” means all licenses, contracts or other agreements, whether written or oral, naming any Grantor as licensee or licensor and providing for the grant of any right to manufacture, use or sell any invention covered by any Patent (including, without limitation, all Patent Licenses set forth in Schedule III hereto).

 

Patents ” means all domestic and foreign letters patent, design patents, utility patents, industrial designs, inventions, trade secrets, ideas, concepts, methods, techniques, processes, proprietary information, technology, know-how, formulae, rights of publicity and other general intangibles of like nature, now existing or hereafter acquired (including, without limitation, all domestic and foreign letters patent, design patents, utility patents, industrial designs, inventions, trade secrets, ideas, concepts, methods, techniques, processes, proprietary information, technology, know-how and formulae described in Schedule III hereto), all applications, registrations and recordings thereof (including, without limitation, applications, registrations and recordings in the United States Patent and Trademark Office, or in any similar office or agency of the United States or any other country or any political subdivision thereof), and all reissues, reexaminations, divisions, continuations, continuations in part and extensions or renewals thereof.

 

Perfection Requirement” or “Perfection Requirements ” shall have the meaning set forth in Section 4(j) of this Agreement.

 

Person ” means an individual, corporation, limited liability Parent, partnership, association, joint-stock Parent, trust, unincorporated organization, joint venture or other enterprise or entity or Governmental Authority.

 

Pledged Accounts ” means all of each Grantor’s right, title and interest in all of its Deposit Accounts, Commodity Accounts and Securities Accounts (in all cases, including, without limitation, all Controlled Accounts and Foreign Currency Control Accounts).

 

Pledged Entity ” means, each Person listed from time to time on Schedule IV hereto as a “Pledged Entity,” together with each other Person, any right in or interest in or to all or a portion of whose Capital Stock is acquired or otherwise owned by a Grantor after the date hereof.

 

Pledged Equity ” means all of each Grantor’s right, title and interest in and to all of the Securities and Capital Stock now or hereafter owned by such Grantor, regardless of class or designation, including all substitutions therefor and replacements thereof, all proceeds thereof and all rights relating thereto, also including any certificates representing the Securities and/or Capital Stock, the right to receive any certificates representing any of the Securities and/or Capital Stock, all warrants, options, share appreciation rights and other rights, contractual or otherwise, in respect thereof, and the right to receive dividends, distributions of income, profits, surplus, or other compensation by way of income or liquidating distributions, in cash or in kind, and cash, instruments, and other property from time to time received, receivable, or otherwise distributed in respect of or in addition to, in substitution of, on account of, or in exchange for any or all of the foregoing; provided , however , that the term Pledged Equity shall include all ICA-T Capital Stock commencing on the Restriction End Date and the Parent, ICA-T and each other Grantor shall take all ICA-T Capital Stock Actions.

 

  6  

 

 

Pledged Operating Agreements ” means all of each Grantor’s rights, powers and remedies under the limited liability Parent operating agreements of each of the Pledged Entities that are limited liability companies, as may be amended, modified, supplemented, extended, renewed, restated or replaced from time to time.

 

Pledged Partnership Agreements ” means all of each Grantor’s rights, powers, and remedies under the partnership agreements of each of the Pledged Entities that are partnerships, as may be amended, modified, supplemented, extended, renewed, restated or replaced from time to time.

 

Securities Purchase Agreement ” shall have the meaning set forth in the recitals hereto.

 

“Subsidiary” means any Person in which a Grantor directly or indirectly (i) owns a majority of the outstanding Capital Stock, voting stock or holds a majority of any equity or similar interest of such Person or (ii) controls or operates a substantial portion of the business, operations or administration of such Person, and all of the foregoing, collectively, “ Subsidiaries ”.

 

Trademark Licenses ” means all licenses, contracts or other agreements, whether written or oral, naming any Grantor as licensor or licensee and providing for the grant of any right concerning any Trademark, together with any goodwill connected with and symbolized by any such licenses, contracts or agreements and the right to prepare for sale or lease and sell or lease any and all Inventory now or hereafter owned by any Grantor and now or hereafter covered by such licenses, contracts or agreements (including, without limitation, all Trademark Licenses described in Schedule V hereto).

 

Trademarks ” means all domestic and foreign trademarks, service marks, collective marks, certification marks, trade names, business names, d/b/a’s, assumed names, Internet domain names, trade styles, designs, logos and other source or business identifiers and all general intangibles of like nature, now or hereafter owned, adopted, acquired or used by any Grantor (including, without limitation, all domestic and foreign trademarks, service marks, collective marks, certification marks, trade names, business names, d/b/a’s, assumed names, Internet domain names, trade styles, designs, logos and other source or business identifiers described in Schedule V(a) hereto), all applications, registrations and recordings thereof (including, without limitation, applications, registrations and recordings in the United States Patent and Trademark Office or in any similar office or agency of the United States, any state thereof or any other country or any political subdivision thereof), and all reissues, extensions or renewals thereof, together with all goodwill of the business symbolized by such marks and all customer lists, formulae and other Records of any Grantor relating to the distribution of products and services in connection with which any of such marks are used.

 

SECTION 2. Grant of Security Interest.

 

(a)       As collateral security for the due and punctual payment and performance of all of the Obligations, as and when due, each Grantor hereby pledges, assigns and grants to the Collateral Agent, for the benefit of itself as a Noteholder itself and for the benefit of any other Noteholders, a continuing security interest in, all personal property and assets of such Grantor, wherever located and whether now or hereafter existing and whether now owned or hereafter acquired, of every kind, nature and description, whether tangible or intangible (collectively, the “ Collateral ”), including, without limitation, the following:

 

(i)        All Accounts (but with regard to accounts receivable, subject to the provisions of Section (B) of the definition of Excluded Collateral);

 

  7  

 

 

(ii)       all Chattel Paper (whether tangible or Electronic Chattel Paper) having a value in excess of $25,000;

 

(iii)      all Commercial Tort Claims having a value in excess of $25,000, including, without limitation, those specified on Schedule VI hereto;

 

(iv)      all Documents;

 

(v)       all Equipment;

 

(vi)      all Fixtures;

 

(vii)     all General Intangibles (including, without limitation, all Payment Intangibles);

 

(viii)    all Goods;

 

(ix)      all Inventory (subject to the provisions of Section (B) of the definition of Excluded Collateral);

 

(x)       all Instruments (including, without limitation, all Promissory Notes and each certificated Security);

 

(xi)      all Investment Property (and, regardless of whether classified as Investment Property under the Code, all Pledged Equity, Pledged Operating Agreements and Pledged Partnership Agreements);

 

(xii)     all Intellectual Property and Licenses;

 

(xiii)    all Letters of Credit and Letter-of-Credit Rights;

 

(xiv)    all Pledged Accounts, all cash and other property from time to time deposited therein, and all monies and property in the possession or under the control of the Collateral Agent or any Noteholder or any Affiliate, representative, agent or correspondent of the Collateral Agent or any such Noteholder;

 

(xv)     all Supporting Obligations;

 

  8  

 

 

(xvi)     all other tangible and intangible personal property of each Grantor (whether or not subject to the Code), including, without limitation, all those relating to ICA-T’s compound library pursuant to which a security interest can be granted upon, all  cell line and plasmid repositories and related items, all Deposit and other accounts and all cash and all investments therein, all proceeds, products, offspring, accessions, rents, profits, income, benefits, substitutions and replacements of and to any of the property of any Grantor described in the preceding clauses of this Section 2(a) (including, without limitation, any proceeds of insurance thereon and all causes of action, claims and warranties now or hereafter held by each Grantor in respect of any of the items listed above), and all books, correspondence, files and other Records, including, without limitation, all tapes, desks, cards, Software, data and computer programs in the possession or under the control of any Grantor or any other Person from time to time acting for any Grantor, in each case, to the extent of such Grantor’s rights therein, that at any time evidence or contain information relating to any of the property described in the preceding clauses of this Section 2(a) or are otherwise necessary or helpful in the collection or realization thereof; and

 

(xvii)    all Proceeds, including all Cash Proceeds and Noncash Proceeds, and products of any and all of the foregoing Collateral;

 

in each case howsoever any Grantor’s interest therein may arise or appear (whether by ownership, security interest, claim or otherwise).

 

(b)       Notwithstanding anything herein to the contrary, the term “ Collateral ” shall not include any Excluded Collateral.

 

(c)       Except for Permitted Liens, each Grantor agrees not to further encumber, or permit any other Lien to exist that encumbers, any of its Copyrights, Copyright applications, Copyright registrations and like protections in each work of authorship and derivative work, whether published or unpublished, any Licenses other than by the parties to the License, Patents, Patent applications and like protections, including improvements, divisions, continuations, renewals, reissues, extensions, and continuations-in-part of the same, Trademarks, service marks and, to the extent permitted under applicable law, any applications therefor, whether registered or not, and the goodwill of the business of such Grantor connected with and symbolized thereby, know-how, operating manuals, trade secret rights, rights to unpatented inventions, and any claims for damage by way of any past, present, or future infringement of any of the foregoing, in each case without the Collateral Agent’s prior written consent (which consent may be withheld or given in the Collateral Agent’s sole discretion).

 

(d)       The Grantors agree that the pledge of the shares of Capital Stock acquired by a Grantor of any and all Persons now or hereafter existing who is a Foreign Subsidiary may be supplemented by one or more separate pledge agreements, deeds of pledge, share charges or other similar agreements or instruments, executed and delivered by the relevant Grantors in favor of the Collateral Agent, which pledge agreements will provide for the pledge of such shares of Capital Stock in accordance with the laws of the applicable foreign jurisdiction but in no event shall Excluded Collateral be pledged. With respect to such shares of Capital Stock, the Collateral Agent may, at any time and from time to time, in its sole discretion, take such actions in such foreign jurisdictions that will result in the perfection of the Lien created in such shares of Capital Stock.

 

(e)       In addition, to secure the prompt and complete payment, performance and observance of the Obligations and in order to induce the Buyer as aforesaid, each Grantor hereby grants to the Collateral Agent, for itself and for the ratable benefit of the Noteholders, a right of set-off against the property of such Grantor held by the Collateral Agent, for itself and for the ratable benefit of the Noteholders, consisting of property described above in Section 2(a) now or hereafter in the possession or custody of or in transit to the Collateral Agent, for any purpose, including safekeeping, collection or pledge, for the account of such Grantor, or as to which such Grantor may have any right or power; provided that such right shall only to be exercised after an Event of Default has occurred and is continuing.

 

  9  

 

 

SECTION 3. Security for Obligations . The security interest created hereby in the Collateral constitutes continuing collateral security for all of the following obligations, whether direct or indirect, absolute or contingent, and whether now existing or hereafter incurred (collectively, the “ Obligations ”):

 

(a)       (i) all payments by ICA-T as and when due and payable (by scheduled maturity, required prepayment, redemption, acceleration, demand or otherwise), of all amounts from time to time owing by it in respect of the Securities Purchase Agreement, this Agreement, the ICA-T Note and the other Transaction Documents to which ICA-T is a party, (ii) all payments by the Parent as and when due and payable (by scheduled maturity, required prepayment, redemption, acceleration, demand or otherwise), of all amounts from time to time owing by the Parent in respect of the ICA-T Note and/or any other obligations of ICA-T pursuant to any other Transaction Document and (iii) in the case of the Guarantors, the payment by such Guarantors, as and when due and payable of all Guaranteed Obligations of ICA-T under the Guaranty of Obligations of ICA-T, including, without limitation, in all cases set forth in (i) – (iii) above, (A) all principal of, interest, redemption amounts, Late Charges (as defined in the ICA-T Note) and other amounts on the ICA-T Note and the other Transaction Documents to which ICA-T is a party (including, without limitation, all interest, redemption amounts, Late Charges and other amounts that accrue after the commencement of any Insolvency Proceeding of any Grantor, whether or not the payment of such interest is enforceable or is allowable in such Insolvency Proceeding), and (B) all fees, interest, Late Charges, premiums, penalties, contract causes of action, costs, commissions, expense reimbursements, indemnifications and all other amounts due or to become due under this Agreement or any of the Transaction Documents; and

 

(b)       the due performance and observance by each Grantor of all of its other obligations from time to time existing in respect of any of the Transaction Documents, including without limitation, with respect to any conversion or redemption rights of the Noteholders under the ICA-T Note.

 

SECTION 4. Representations and Warranties . Each Grantor represents and warrants as follows:

 

(a)        Schedule VII hereto sets forth (i) the exact legal name of each Grantor, and (ii) the state of incorporation, organization or formation and the organizational identification number of each Grantor in such state. The information set forth in Schedule VII hereto with respect to such Grantor is true and accurate in all respects. Such Grantor has not previously changed its name (or operated under any other name), jurisdiction of organization or organizational identification number from those set forth in Schedule VII hereto except as disclosed in Schedule VII hereto.

 

  10  

 

 

(b)       There is no pending or, to its knowledge, written notice threatening any action, suit, proceeding or claim affecting any Grantor before any Governmental Authority or any arbitrator, or any order, judgment or award issued by any Governmental Authority or arbitrator, in each case, that may adversely affect the grant by any Grantor, or the perfection, of the security interest purported to be created hereby in the Collateral, or the exercise by the Collateral Agent of any of its rights or remedies hereunder.

 

(c)       All Federal, state and local tax returns and other reports required by applicable law to be filed by any Grantor have been filed, or extensions have been obtained, and all taxes, assessments and other governmental charges imposed upon any Grantor or any property of any Grantor (including, without limitation, all federal income and social security taxes on employees’ wages) and which have become due and payable on or prior to the date hereof have been paid, except to the extent contested in good faith by proper proceedings which stay the imposition of any penalty, fine or Lien resulting from the non-payment thereof and with respect to which adequate reserves have been set aside for the payment thereof in accordance with GAAP.

 

(d)       All Equipment, Fixtures, Goods and Inventory of each Grantor now existing are, and all Equipment, Fixtures, Goods and Inventory of each Grantor hereafter existing will be, located and/or based at the addresses specified therefor in Schedule VIII hereto, except that each Grantor will give the Collateral Agent written notice of any change in the location of any such Collateral within 20 days of such change, other than to locations set forth on Schedule VIII hereto (and with respect to which the Collateral Agent has filed financing statements and otherwise fully perfected its Liens thereon). Each Grantor’s principal place of business and chief executive office, the place where each Grantor keeps its Records concerning the Collateral and all located at the addresses specified therefor in Schedule VIII hereto. None of the Accounts is or will be evidenced by Promissory Notes or other Instruments.

 

(e)       Set forth in Schedule IX hereto is a complete and accurate list, as of the date of this Agreement, of (i) each Promissory Note, Security and other Instrument owned by each Grantor, (ii) each Pledged Account of each Grantor, together with the name and address of each institution at which each such Pledged Account is maintained, the account number for each such Pledged Account and a description of the purpose of each such Pledged Account and (iii) the name of each Foreign Currency Controlled Account, together with the name and address of each institution at which each such Foreign Currency Controlled Account is maintained and the amount of cash or cash equivalents held in each such Foreign Currency Controlled Account. Set forth in Schedule IX hereto is a complete and correct list of each trade name used by each Grantor and the name of, and each trade name used by, each Person from which each Grantor has acquired any substantial part of the Collateral.

 

  11  

 

 

(f)       Each Grantor has delivered to the Collateral Agent complete and correct copies of each License described in Schedule X hereto, including all schedules and exhibits thereto, which represent all of the Licenses of the Grantors existing on the date of this Agreement. Each such License sets forth the entire agreement and understanding of the parties thereto relating to the subject matter thereof, and there are no other agreements, arrangements or understandings, written or oral, relating to the matters covered thereby or the rights of such Grantor or any of its Affiliates in respect thereof. Each material License now existing is, and any material License entered into in the future will be, the legal, valid and binding obligation of the parties thereto, enforceable against such parties in accordance with its terms except as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization, and similar laws of general application relating to or affecting the rights and remedies of creditors and by general principles of equity. No default under any material License by any such party has occurred, nor does any defense, offset, deduction or counterclaim exist thereunder in favor of any such party.

 

(g)       Each Grantor owns and controls, or otherwise possesses adequate rights to use, all of its Intellectual Property. Schedule XI hereto sets forth a true and complete list of all Intellectual Property and Licenses owned or used by each Grantor as of the date hereof, and applications for grant or registration of Intellectual Property. To the knowledge of each Grantor, all such Intellectual Property of such Grantor is subsisting and in full force and effect, has not been adjudged invalid or unenforceable, and has not been abandoned in whole or in part. Except as set forth in Schedule XI , no such Intellectual Property is the subject of any licensing or franchising agreement. Except as set forth in Schedule XI , no Grantor has any knowledge of any infringement upon or conflict with the Patent, Trademark, Copyright, trade secret rights of others and, each Grantor is not now knowingly infringing or knowingly in conflict with any Patent, Trademark, Copyright, trade secret or similar rights of others, and to the knowledge of each Grantor, no other Person is now infringing or in conflict in any material respect with any such properties, assets and rights owned or used by each Grantor. No Grantor has received any notice that it is violating or has violated the Trademarks, Patents, Copyrights, inventions, trade secrets, proprietary information and technology, know-how, formulae, rights of publicity or other intellectual property rights of any third party.

 

(h)       Each Grantor is and will be at all times the sole and exclusive owner of the Collateral pledged by such Grantor hereunder free and clear of any Liens, except for Permitted Liens thereon. No effective financing statement or other instrument similar in effect covering all or any part of the Collateral is on file in any recording or filing office except such as (i) may have been filed in favor of the Collateral Agent and/or the Noteholders relating to this Agreement or the other Transaction Documents, and (ii) are securing Permitted Liens as of the date hereof and disclosed on Schedule XII hereto.

 

(i)        The exercise by the Collateral Agent of any of its rights and remedies hereunder will not contravene any law or any contractual restriction binding on or otherwise affecting each Grantor or any of its properties and will not result in or require the creation of any Lien, upon or with respect to any of its properties.

 

  12  

 

 

(j)       No authorization or approval or other action by, and no notice to or filing with, any Governmental Authority, is required for (i) the grant by each Grantor, or the perfection, of the security interest purported to be created hereby in the Collateral, or (ii) the exercise by the Collateral Agent of any of its rights and remedies hereunder, except for (A) the filing under the Code as in effect in the applicable jurisdiction of the financing statements described in Schedule XII hereto, all of which financing statements have been duly filed and are in full force and effect, (B) with respect to all Pledged Accounts, and all cash and other property from time to time deposited therein, the execution of a Controlled Account Agreement with the depository or other institution with which the applicable Pledged Accounts are maintained, as provided in Section 5(h)(i) , (C) with respect to Commodity Contracts, the execution of a control agreement with the commodity intermediary with which such Commodity Contract is carried, as provided in Section 5(h)(i) , (D) with respect to the perfection of the security interest created hereby in the United States Intellectual Property and Licenses, the recording of the appropriate Intellectual Property Security Agreement in the United States Patent and Trademark Office or the United States Copyright Office, as applicable (E) with respect to the perfection of the security interest created hereby in any Letter-of-Credit Rights, the consent of the issuer of the applicable letter of credit to the assignment of proceeds as provided in the Code as in effect in the applicable jurisdiction, (G) with respect to Investment Property constituting uncertificated securities, the applicable Grantor causing the issuer thereof either (i) to register the Collateral Agent as the registered owner of such securities or (ii) to agree in an authenticated record with such Grantor and the Collateral Agent that such issuer will comply with instructions with respect to such securities originated by the Collateral Agent without further consent of such Grantor, such authenticated record to be in form and substance satisfactory to the Collateral Agent, (H) with respect to Investment Property constituting certificated securities or instruments, such items to be delivered to and held by or on behalf of the Collateral Agent pursuant hereto in suitable form for transfer by delivery or accompanied by duly executed instruments of transfer or assignment in blank, all in form and substance satisfactory to the Collateral Agent, (I) with respect to any action that may be necessary to obtain control of Collateral constituting Commodity Contracts, Electronic Chattel Paper or Letter of Credit Rights, the taking of such actions, and (J) the Collateral Agent having possession of all Documents, Chattel Paper, Instruments and cash constituting Collateral (subclauses (A) through (J) each a “ Perfection Requirement ” and collectively, the “ Perfection Requirements ”).

 

(k)       This Agreement creates in favor of the Collateral Agent a legal, valid and enforceable security interest in the Collateral, as security for the Obligations. The performance of the Perfection Requirements results in the perfection of such security interest in the Collateral. Such security interest is (or in the case of Collateral in which each Grantor obtains rights after the date hereof, will be), subject only to Permitted Liens and the Perfection Requirements, a first priority, valid, enforceable and perfected security interests in all personal property of each Grantor (other than Excluded Collateral). Such recordings and filings and all other action necessary to perfect and protect such security interest have been duly taken (and, in the case of Collateral in which any Grantor obtains rights after the date hereof, will be duly taken), except for the Collateral Agent’s having possession of all Documents, Chattel Paper, Instruments and cash constituting Collateral after the date hereof and the other actions, filings and recordations described above, including the Perfection Requirements.

 

(l)        As of the date hereof, no Grantor holds any Commercial Tort Claims or has knowledge of any pending Commercial Tort Claims, except for the Commercial Tort Claims described in Schedule VI .

 

  13  

 

 

(m)      All of the Pledged Equity is presently owned by the applicable Grantor as set forth in Schedule XV , and is presently represented by the certificates listed on Schedule XV hereto (if applicable). As of the date hereof, there are no existing options, warrants, calls or commitments of any character whatsoever relating to the Pledged Equity other than as contemplated and permitted by the Transaction Documents. Each Grantor is the sole holder of record and the sole beneficial owner of the Pledged Equity, as applicable. None of the Pledged Equity has been issued or transferred in violation of the securities registration, securities disclosure or similar laws of any jurisdiction to which such issuance or transfer may be subject. The Pledged Equity constitutes 100% or such other percentage as set forth on Schedule XV of the issued and outstanding shares of Capital Stock of the applicable Pledged Entity.

 

(n)       Such Grantor (i) is a corporation, limited liability company or limited partnership, as applicable, duly organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation, organization or formation, (ii) has all requisite corporate, limited liability company or limited partnership power and authority to conduct its business as now conducted and as presently contemplated and to execute and deliver this Agreement and each other Transaction Document to which such Grantor is a party, and to consummate the transactions contemplated hereby and thereby and (iii) is duly qualified to do business and is in good standing in each jurisdiction in which the character of the properties owned or leased by it or in which the transaction of its business makes such qualification necessary, except where the failure to be so qualified would not result in a Material Adverse Effect.

 

(o)       The execution, delivery and performance by each Grantor of this Agreement and each other Transaction Document to which such Grantor is a party (i) have been duly authorized by all necessary corporate, limited liability company or limited partnership action, (ii) do not and will not contravene its charter or by-laws, limited liability company or operating agreement, certificate of partnership or partnership agreement, as applicable, or any applicable law or any contractual restriction binding on such Grantor or its properties, (iii) do not and will not result in or require the creation of any Lien (other than pursuant to any Transaction Document) upon or with respect to any of its assets or properties, and (iv) do not and will not result in any default, noncompliance, suspension, revocation, impairment, forfeiture or nonrenewal of any material permit, license, authorization or approval applicable to it or its operations or any of its assets or properties.

 

(p)       This Agreement and each of the other Transaction Documents to which any Grantor is or will be a party, when delivered, will be, a legal, valid and binding obligation of such Grantor, enforceable against such Grantor in accordance with its terms, except as may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, suretyship or other similar laws and equitable principles (regardless of whether enforcement is sought in equity or at law).

 

(q)       There are no conditions precedent to the effectiveness of this Agreement that have not been satisfied or waived.

 

  14  

 

 

SECTION 5. Covenants as to the Collateral . So long as any of the Obligations shall remain outstanding, unless the Collateral Agent shall otherwise consent in writing:

 

(a)        Further Assurances . Each Grantor will, at its expense, at any time and from time to time, promptly execute and deliver all further instruments and documents and take all further action that the Collateral Agent may reasonably request in order to: (i) perfect and protect the security interest of the Collateral Agent created hereby; (ii) enable the Collateral Agent to exercise and enforce its rights and remedies hereunder in respect of the Collateral, including, without limitation, the Controlled Accounts; or (iii) otherwise effect the purposes of this Agreement, including, without limitation: (A) marking conspicuously all Chattel Paper and each License and, at the request of the Collateral Agent, each of its Records pertaining to the Collateral with a legend, in form and substance satisfactory to the Collateral Agent, indicating that such Chattel Paper, License or Collateral is subject to the security interest created hereby, (B) delivering and pledging to the Collateral Agent each Promissory Note, Security (subject to the limitations set forth in Section 2 ), Chattel Paper or other Instrument, now or hereafter owned by any Grantor, duly endorsed and accompanied by executed instruments of transfer or assignment, all in form and substance satisfactory to the Collateral Agent, (C) executing and filing (to the extent, if any, that any Grantor’s signature is required thereon) or authenticating the filing of, such financing or continuation statements, or amendments thereto, as may be necessary or that the Collateral Agent may reasonably request in order to perfect and preserve the security interest created hereby, (D) furnishing to the Collateral Agent from time to time statements and schedules further identifying and describing the Collateral and such other reports in connection with the Collateral in each case as the Collateral Agent may reasonably request, all in reasonable detail, (E) if any Collateral shall be in the possession of a third party, notifying such Person of the Collateral Agent’s security interest created hereby and obtaining a written acknowledgment from such Person, in form and substance reasonably satisfactory to the Collateral Agent, that such Person holds possession of the Collateral for the benefit of the Collateral Agent (for the benefit the Noteholders), (F) if at any time after the date hereof, any Grantor acquires or holds any Commercial Tort Claim, promptly notifying the Collateral Agent in a writing signed by such Grantor setting forth a brief description of such Commercial Tort Claim and granting to the Collateral Agent a security interest therein and in the proceeds thereof, which writing shall incorporate the provisions hereof and shall be in form and substance satisfactory to the Collateral Agent, (G) upon the acquisition after the date hereof by any Grantor of any motor vehicle or other Equipment subject to a certificate of title or ownership (other than a motor vehicle or Equipment that is subject to a purchase money security interest), causing the Collateral Agent to be listed as the lienholder on such certificate of title or ownership and delivering evidence of the same to the Collateral Agent in accordance with Section 5(j) hereof; and (H) taking all actions required by the Code or by other law, as applicable, in any relevant Code jurisdiction, or by other law as applicable in any foreign jurisdiction.

 

(b)        Location of Collateral . Each Grantor will keep the Collateral (i) at the locations specified therefor on Schedule XVI hereto, or (ii) at such other locations set forth on Schedule XVI and with respect to which the Collateral Agent has filed financing statements and otherwise fully perfected its Liens thereon, or (iii) at such other locations in the United States , provided that 30 days prior to any change in the location of any Collateral to such other location, or upon the acquisition of any Collateral to be kept at such other locations, the Grantors shall give the Collateral Agent written notice thereof and deliver to the Collateral Agent a new Schedule XVI indicating such new locations and such other written statements and schedules as the Collateral Agent may require.

 

(c)        Condition of Equipment . Each Grantor will maintain or cause to be maintained and preserved in good condition, repair and working order, ordinary wear and tear excepted, the Equipment (necessary or useful to its business) and will forthwith, or in the case of any loss or damage to any Equipment of any Grantor within a commercially reasonable time after the occurrence thereof, make or cause to be made all repairs, replacements and other improvements in connection therewith which are necessary or desirable, consistent with past practice, or which the Collateral Agent may request to such end. Any Grantor will promptly furnish to the Collateral Agent a statement describing in reasonable detail any such loss or damage in excess of $50,000 per occurrence to any Equipment.

 

  15  

 

 

(d)        Taxes, Etc . Each Grantor agrees to pay promptly when due all property and other taxes, assessments and governmental charges or levies imposed upon, and all claims (including claims for labor, materials and supplies) against, the Equipment and Inventory, except to the extent the validity thereof is being contested in good faith by proper proceedings which stay the imposition of any penalty, fine or Lien resulting from the non-payment thereof and with respect to which adequate reserves in accordance with GAAP have been set aside for the payment thereof.

 

(e)        Insurance .

 

(i)       Each Grantor will, at its own expense, maintain insurance (including, without limitation, comprehensive general liability, hazard, rent and business interruption insurance) with respect to its properties (including all real properties leased or owned by it) and business, in such amounts and covering such risks, in such form and with responsible and reputable insurance companies or associations as is required by any Governmental Authority having jurisdiction with respect thereto or as is carried generally in accordance with sound business practice by companies in similar businesses similarly situated and in any event, in amount, adequacy and scope reasonably satisfactory to the Collateral Agent.

 

(ii)      To the extent requested by the Collateral Agent at any time and from time to time, each such policy for liability insurance shall provide for all losses to be paid on behalf of the Collateral Agent and any Grantor as their respective interests may appear, and each policy for property damage insurance shall provide for all losses to be adjusted with, and paid directly to, the Collateral Agent. In addition to and without limiting the foregoing, to the extent requested by the Collateral Agent at any time and from time to time, each such policy shall in addition (A) name the Collateral Agent as an additional insured party and/or loss payee, as applicable, thereunder (without any representation or warranty by or obligation upon the Collateral Agent) as its interests may appear, (B) contain an agreement by the insurer that any loss thereunder shall be payable to the Collateral Agent on its own account notwithstanding any action, inaction or breach of representation or warranty by any Grantor, (C) provide that there shall be no recourse against the Collateral Agent for payment of premiums or other amounts with respect thereto, and (D) provide that at least 30 days’ prior written notice of cancellation, lapse, expiration or other adverse change shall be given to the Collateral Agent by the insurer. Any Grantor will, if so requested by the Collateral Agent, deliver to the Collateral Agent original or duplicate policies of such insurance (including certificates demonstrating compliance with this Section 5(e)) and, as often as the Collateral Agent may reasonably request, a report of a reputable insurance broker with respect to such insurance. Any Grantor will also, at the request of the Collateral Agent, execute and deliver instruments of assignment of such insurance policies and cause the respective insurers to acknowledge notice of such assignment.

 

  16  

 

 

(iii)      Reimbursement under any liability insurance maintained by any Grantor pursuant to this Section 5(e) may be paid directly to the Person who shall have incurred liability covered by such insurance. In the case of any loss involving damage to Equipment or Inventory, to the extent paragraph (iv) of this Section 5(e) is not applicable, any proceeds of insurance involving such damage shall be paid to the Collateral Agent, and any Grantor will make or cause to be made the necessary repairs to or replacements of such Equipment or Inventory, and any proceeds of insurance maintained by any Grantor pursuant to this Section 5(e) (except as otherwise provided in paragraph (iv) in this Section 5(e) ) shall be paid by the Collateral Agent to any Grantor as reimbursement for the reasonable costs of such repairs or replacements.

 

(iv)      Notwithstanding anything to the contrary in subsection 5(e)(iii) above, following and during the continuance of an Event of Default (as defined in the Securities Purchase Agreement and the ICA-T Note), all insurance payments in respect of each Grantor’s properties and business shall be paid to the Collateral Agent and applied as specified in Section 7(b) hereof.

 

(f)        Provisions Concerning the Accounts and the Licenses .

 

(i)        Each Grantor will (A) give the Collateral Agent at least 30 days’ prior written notice of any change in such Grantor’s name, identity or organizational structure, (B) maintain its jurisdiction of incorporation, organization or formation as set forth in Schedule VII hereto, (C) immediately notify the Collateral Agent upon obtaining an organizational identification number, if on the date hereof such Grantor did not have such identification number, and (D) keep adequate records concerning the Collateral and permit representatives of the Collateral Agent during normal business hours on reasonable notice to such Grantor, to inspect and make abstracts from such records.

 

  17  

 

 

(ii)       Each Grantor will (except as otherwise provided in this subsection (f)), continue to collect, at its own expense, all amounts due or to become due under the Accounts. In connection with such collections, any Grantor may (and, at the Collateral Agent’s direction, will) take such action as any Grantor or the Collateral Agent may deem necessary or advisable to enforce collection or performance of the Accounts that are not Excluded Collateral; provided , however , that the Collateral Agent shall have the right at any time following the occurrence and during the continuance of an Event of Default to notify the Account Debtors or obligors under any Accounts that are not Excluded Collateral of the assignment of such Accounts to the Collateral Agent and to direct such Account Debtors or obligors to make payment of all amounts due or to become due to any Grantor thereunder directly to the Collateral Agent or its designated agent and, upon such notification and at the expense of any Grantor and to the extent permitted by applicable law, to enforce collection of any such Accounts and to adjust, settle or compromise the amount or payment thereof, in the same manner and to the same extent as any Grantor might have done. After receipt by any Grantor of a notice from the Collateral Agent that the Collateral Agent has notified, intends to notify, or has enforced or intends to enforce any Grantor’s rights against the Account Debtors or obligors under any Accounts as referred to in the proviso to the immediately preceding sentence, (A) all amounts and proceeds (including Instruments) received by any Grantor in respect of the Accounts shall be received in trust for the benefit of the Collateral Agent hereunder (for the benefit the Noteholders), shall be segregated from other funds of any Grantor and shall be forthwith paid over to the Collateral Agent in the same form as so received (with any necessary endorsement) to be applied as specified in Section 7(b) hereof, and (B) no Grantor will adjust, settle or compromise the amount or payment of any Account or release wholly or partly any Account Debtor or obligor thereof or allow any credit or discount thereon. In addition, upon the occurrence and during the continuance of an Event of Default, the Collateral Agent may (in its sole and absolute discretion) direct any or all of the banks and financial institutions with which any Grantor either maintains a Deposit Account or a lockbox (including, without limitation, any Controlled Account) or deposits the proceeds of any Accounts to send immediately to the Collateral Agent by wire transfer (to such deposit account as the Collateral Agent shall specify, or in such other manner as the Collateral Agent shall direct) all or a portion of such securities, cash, investments and other items held by such institution. Any such securities, cash, investments and other items so received by the Collateral Agent shall be applied as specified in accordance with Section 7(b) hereof.

 

(iii)       Upon the occurrence and during the continuance of any breach or default under any material License referred to in Schedule XVII hereto by any party thereto other than any Grantor, each Grantor party thereto will, promptly after obtaining knowledge thereof, give the Collateral Agent written notice of the nature and duration thereof, specifying what action, if any, it has taken and proposes to take with respect thereto and thereafter will take reasonable steps to protect and preserve its rights and remedies in respect of such breach or default, or will obtain or acquire an appropriate substitute License.

 

(iv)       Each Grantor will, at its expense, promptly deliver to the Collateral Agent a copy of each notice or other communication received by it by which any other party to any material License referred to in Schedule XVIII hereto purports to exercise any of its rights or affect any of its obligations thereunder, together with a copy of any reply by such Grantor thereto.

 

(v)        Each Grantor will exercise promptly and diligently each and every right which it may have under each material License (other than any right of termination) and will duly perform and observe in all respects all of its obligations under each material License and will take all action reasonably necessary to maintain such Licenses in full force and effect. No Grantor will, without the prior written consent of the Collateral Agent, cancel, terminate, amend or otherwise modify in any respect, or waive any provision of, any material License referred to in Schedule XIX hereto.

 

  18  

 

 

(g)        Transfers and Other Liens .

 

(i)       Except as otherwise expressly permitted in the other Transaction Documents, no Grantor shall, directly or indirectly, sell, lease, license, assign, transfer, spin-off, split-off, close, convey or otherwise dispose of any Collateral whether in a single transaction or a series of related transactions, other than (A) sales, leases, licenses, assignments, transfers, conveyances and other dispositions of such assets or rights by such Grantor for value in the ordinary course of business consistent with past practices; and (B) sales of Inventory and product in the ordinary course of business.

 

(ii)      Except if expressly permitted under Section 14(e) of the ICA-T Note, no Grantor shall, directly or indirectly, redeem, repurchase or declare or pay any cash dividend or distribution on any of its Capital Stock.

 

(iii)     No Grantor shall, directly or indirectly, without the prior written consent of the Required Holders issue any securities that would cause a breach or default under the ICA-T Note, the Securities Purchase Agreement and/or any other Transaction Document.

 

(iv)     Except for payments to Taglich Brothers, Inc. or an Affiliate thereof for fundraising services they provide (but no payments shall be made to any such parties related to any financing provided to any Grantor by the Buyer), no Grantor shall enter into, renew, extend or be a party to, any transaction or series of related transactions (including, without limitation, the purchase, sale, lease, transfer or exchange of property or assets of any kind or the rendering of services of any kind) with any Affiliate, except in the ordinary course of business in a manner and to an extent consistent with past practice and necessary or desirable for the prudent operation of its business, for fair consideration and on terms no less favorable to it than would be obtainable in a comparable arm’s length transaction with a Person that is not an Affiliate thereof.

 

(v)       No Grantor will create, suffer to exist or grant any Lien upon or with respect to any Collateral other than a Permitted Lien.

 

  19  

 

 

(h)        Intellectual Property .

 

(i)       If applicable, each Grantor shall duly execute and deliver the applicable Intellectual Property Security Agreement. Each Grantor (either itself or through licensees) will, and will cause each licensee thereof to, take all action reasonably necessary and/or requested by the Collateral Agent to maintain all of the Intellectual Property in full force and effect, including, without limitation, using the proper statutory notices, numbers and markings (relating to patent, trademark and copyright rights) and using the Trademarks on each applicable trademark class of goods in order to so maintain the Trademarks in full force and free from any claim of abandonment for non-use, and each Grantor will not (nor permit any licensee thereof to) do any act or knowingly omit to do any act whereby any Intellectual Property may become abandoned, cancelled or invalidated; provided , however , that so long as no Event of Default has occurred and is continuing, no Grantor shall have an obligation to use or to maintain any Intellectual Property (A) that relates solely to any product or work, that is no longer necessary or material and has been, or is in the process of being, discontinued, abandoned or terminated in the ordinary course of business and consistent with the exercise of reasonable business judgment, (B) that is being replaced with Intellectual Property substantially similar to the Intellectual Property that may be abandoned or otherwise become invalid, so long as the failure to use or maintain such Intellectual Property does not materially adversely affect the validity of such replacement Intellectual Property and so long as such replacement Intellectual Property is subject to the Lien created by this Agreement and does not have a Material Adverse Effect on the business of any Grantor or (C) that is substantially the same as another Intellectual Property that is in full force, so long the failure to use or maintain such Intellectual Property does not materially adversely affect the validity of such replacement Intellectual Property and so long as such other Intellectual Property is subject to the Lien and security interest created by this Agreement and does not have a material adverse effect on the business of any Grantor. Each Grantor will cause to be taken all necessary steps in any proceeding before the United States Patent and Trademark Office and the United States Copyright Office or any similar office or agency in any other country or political subdivision thereof to maintain each registration of the Intellectual Property and application for registration of Intellectual Property (other than the Intellectual Property described in the proviso to the immediately preceding sentence), including, without limitation, filing of renewals, affidavits of use, affidavits of incontestability and opposition, interference and cancellation proceedings and payment of maintenance fees, filing fees, taxes or other governmental fees. If any Intellectual Property (other than Intellectual Property described in the proviso to the second sentence of subsection (i) of this clause (h)) is infringed, misappropriated, diluted or otherwise violated in any material respect by a third party, each Grantor shall (x) upon learning of such infringement, misappropriation, dilution or other violation, promptly (but in no event more than five (5) business days after learning of such) notify the Collateral Agent and (y) if reasonably requested by the Collateral Agent promptly sue for infringement, misappropriation, dilution or other violation, seek injunctive relief where appropriate and recover any and all damages for such infringement, misappropriation, dilution or other violation, or take such other actions as such Grantor shall deem appropriate under the circumstances to protect such Intellectual Property. Each Grantor shall furnish to the Collateral Agent from time to time upon its request statements and schedules further identifying and describing the Intellectual Property and Licenses and such other reports in connection with the Intellectual Property and Licenses as the Collateral Agent may reasonably request, all in reasonable detail and promptly upon request of the Collateral Agent, following receipt by the Collateral Agent of any such statements, schedules or reports, each Grantor shall modify this Agreement by amending Schedules II, III and IV and any other applicable Schedule hereto, as the case may be, to include any Intellectual Property and License, as the case may be, which is or hereafter becomes part of the Collateral under this Agreement and shall execute and authenticate such documents and do such acts as shall be necessary or, in the reasonable judgment of the Collateral Agent, desirable to subject such Intellectual Property and Licenses to the Lien and security interest created by this Agreement. Notwithstanding anything herein to the contrary, upon the occurrence and during the continuance of an Event of Default, no Grantor may abandon, surrender or otherwise permit any Intellectual Property to become abandoned, cancelled or invalid without the prior written consent of the Collateral Agent, and if any Intellectual Property is infringed, misappropriated, diluted or otherwise violated in any material respect by a third party, each Grantor will take such reasonable action as the Collateral Agent shall deem appropriate under the circumstances to protect such Intellectual Property.

 

  20  

 

 

(ii)       In the event that any Grantor, either itself or through any agent, employee, licensee or designee, files an application for the registration of any Patent, Trademark or Copyright or the United States Copyright Office or the United States Patent and Trademark Office, as applicable, or in any similar office or agency of the United States or any country or any political subdivision thereof, it shall give the Collateral Agent prompt written notice thereof (but in no event more than one (1) business day after the initial filing of application). Upon request of the Collateral Agent, any Grantor shall execute, authenticate and deliver any and all assignments, agreements, instruments, documents and papers as the Collateral Agent may reasonably request to evidence the Collateral Agent’s security interest hereunder in such Intellectual Property and the General Intangibles of any Grantor relating thereto or represented thereby, and each Grantor hereby appoints the Collateral Agent its attorney-in-fact to execute and/or authenticate and file all such writings for the foregoing purposes, all acts of such attorney being hereby ratified and confirmed, and such power (being coupled with an interest) shall be irrevocable until all Obligations are Paid in Full.

 

(i)        Pledged Accounts .

 

(A)       Each Grantor shall use its reasonable best efforts to, as soon as practical following the Closing Date, but in no event more than sixty (60) calendar days following the Closing Date (the “ CAB Period ”), cause each bank and other financial institution which maintains a Controlled Account (each a “ Controlled Account Bank ”) to execute and deliver to the Collateral Agent, in form and substance satisfactory to the Collateral Agent, a Controlled Account Agreement with respect to such Controlled Account, duly executed by each Grantor and such Controlled Account Bank, pursuant to which such Controlled Account Bank among other things shall irrevocably agree, with respect to such Controlled Account, that (i) at any time after any Grantor, the Collateral Agent or the Buyer shall have notified such Controlled Account Bank that an Event of Default has occurred or is continuing, such Controlled Account Bank will comply with any and all instructions originated by the Collateral Agent directing the disposition of the funds in such Controlled Account without further consent by such Grantor, (ii) such Controlled Account Bank shall waive, subordinate or agree not to exercise any rights of setoff or recoupment or any other claim against the applicable Controlled Account other than for payment of its service fees and other charges directly related to the administration of such Controlled Account and for returned checks or other items of payment, (iii) at any time after any Grantor, the Collateral Agent or the Buyer shall have notified such Controlled Account Bank that an Event of Default has occurred or is continuing, with respect to each such Controlled Account, such Controlled Account Bank shall not comply with any instructions, directions or orders of any form with respect to such Controlled Accounts other than instructions, directions or orders originated by the Collateral Agent, (iv) all funds deposited by any Grantor with such Controlled Account Bank shall be subject to a perfected, first priority security interest in favor of the Collateral Agent, and (v) upon receipt of written notice from the Collateral Agent during the continuance of an Event of Default, such Controlled Account Bank shall immediately send to the Collateral Agent by wire transfer (to such account as the Collateral Agent shall specify, or in such other manner as the Collateral Agent shall direct) all such funds and other items held by it. No Grantor shall create or maintain any Pledged Account without the prior written consent of the Collateral Agent and complying with the terms of this Agreement.

 

  21  

 

 

(B)       If at any time after the expiration of the CAB Period, the average daily balance of any Account that is not subject to a Controlled Account Agreement exceeds $100,000 during any calendar month (including the calendar month in which the Closing Date occurs), the Parent shall, either (x) within two (2) Business Days following such date, transfer to a Controlled Account an amount sufficient to reduce the total aggregate amount of the cash in such Account to an amount not in excess of $100,000 or (y) within twenty-one (21) calendar days following the last day of such calendar month, deliver to the Collateral Agent a Controlled Account Agreement with respect to such Account, duly executed by such Grantor and the depositary bank in which such Account is maintained.

 

(C)       Notwithstanding anything to the contrary contained in Section 5(i)(B) above, and without limiting any of the foregoing, if at any time after the expiration of the CAB Period, the total aggregate amount of the cash of the Parent and any of its Subsidiaries, in the aggregate, that is not held in a Controlled Account exceeds $150,000 (the “ Maximum Free Cash Amount ”), the Parent shall within twenty one (21) Business Days following such date, either (x) transfer to a Controlled Account an amount sufficient to reduce the total aggregate amount of the cash that is not held in a Controlled Account to an amount not in excess of the Maximum Free Cash Amount or (y) deliver to the Collateral Agent a Controlled Account Agreement with respect to such Account (or Accounts), duly executed by such Grantor and the depositary bank in which such Account (or Accounts) is maintained, as necessary to reduce the total aggregate amount of the cash that is not held in a Controlled Account to an amount not in excess of the Maximum Free Cash Amount.

 

(j)        Control . Each Grantor hereby agrees to take any or all action that may be necessary or that the Collateral Agent may reasonably request in order for the Collateral Agent to obtain “control” in accordance with Sections 9-105 through 9-107 of the Code with respect to the following Collateral: (i) Electronic Chattel Paper, (ii) Investment Property, and (iii) Letter-of-Credit Rights.

 

  22  

 

 

(k)        Inspection and Reporting . Each Grantor shall permit the Collateral Agent, or any agent or representatives thereof or such professionals or other Persons as the Collateral Agent may designate at Grantors’ sole cost and expense no more than once per quarter (the “ Quarterly Limitations ”), unless an Event of Default exists and/or with the passage of time, the occurrence of an event or the giving of notice an Event of Default would exist, in which event there shall be no limitations including, but not limited to, the Quarterly Limitations (i) to examine and make copies of and abstracts from any Grantor’s records and books of account, (ii) to visit and inspect its properties, (iii) to verify materials, leases, Instruments, Accounts, Inventory and other assets of any Grantor from time to time, and (iv) to conduct audits, physical counts, appraisals and/or valuations, examinations at the locations of any Grantor. Each Grantor shall also permit the Collateral Agent, or any agent or representatives thereof or such attorneys, accountants or other professionals or other Persons as the Collateral Agent may designate to discuss such Grantor’s affairs, finances and accounts with any of its directors, officers, members, managers managerial employees, independent accountants or any of its other representatives. Without limiting the foregoing, the Collateral Agent may, at any time, in the Collateral Agent’s own name, in the name of a nominee of the Collateral Agent, or in the name of any Grantor communicate (by mail, telephone, facsimile or otherwise) with the Account Debtors of such Grantor, parties to contracts with such Grantor and/or obligors in respect of Instruments of such Grantor to verify with such Persons, to the Collateral Agent’s satisfaction, the existence, amount, terms of, and any other matter relating to, Accounts, Instruments, Chattel Paper, payment intangibles and/or other receivables.

 

(l)        Future Subsidiaries . If any Grantor hereafter creates or acquires any Subsidiary, simultaneously with the creation or acquisition of such Subsidiary, such Grantor shall (i) if such Subsidiary is a Domestic Subsidiary, cause such Subsidiary to become a party to this Agreement as an additional “Grantor” hereunder, (ii) deliver to the Collateral Agent updated Schedules to this Agreement, as appropriate (including, without limitation, an updated Schedule IV to reflect the grant by such Grantor of a Lien on all Pledged Equity now or hereafter owned by such Grantor), (iii) if such Subsidiary is a Domestic Subsidiary, cause such Subsidiary to duly execute and deliver a guaranty of the Obligations in favor of the Collateral Agent in form and substance acceptable to the Collateral Agent, (iv) if such Subsidiary is a (a) Domestic Subsidiary, deliver to the Collateral Agent the stock certificates representing all, and (b) so long as permitted by applicable law, Foreign Subsidiary, deliver to the Collateral Agent the stock certificates representing 65%, of the Capital Stock of such Subsidiary, along with undated stock powers for each such certificates, executed in blank (or, if any such shares of Capital Stock are uncertificated, confirmation and evidence reasonably satisfactory to the Collateral Agent that the security interest in such uncertificated securities has been transferred to and perfected by the Collateral Agent, in accordance with Sections 8-313, 8-321 and 9-115 of the Code or any other similar or local or foreign law that may be applicable), and (v) duly execute and/or cause to be delivered to the Collateral Agent, in form and substance acceptable to the Collateral Agent, such opinions of counsel and other documents as the Collateral Agent shall request with respect thereto; provided , however , that no Grantor shall be required to pledge any Excluded Collateral. Each Grantor hereby authorizes the Collateral Agent to attach such updated Schedules to this Agreement and agrees that all Pledged Equity listed on any updated Schedule delivered to the Collateral Agent shall for all purposes hereunder be considered Collateral. The Grantors agree that the pledge of the shares of Capital Stock acquired by a Grantor of Foreign Subsidiary may be supplemented by one or more separate pledge agreements, deeds of pledge, share charges, or other similar agreements or instruments, executed and delivered by the relevant Grantor in favor of the Collateral Agent, which pledge agreements will provide for the pledge of such shares of Capital Stock in accordance with the laws of the applicable foreign jurisdiction. With respect to such shares of Capital Stock, the Collateral Agent may, at any time and from time to time, in its sole discretion, take actions in such foreign jurisdictions that will result in the perfection of the Lien created in such shares of Capital Stock other than Excluded Collateral.

 

  23  

 

 

SECTION 6. Additional Provisions Concerning the Collateral.

 

(a)       To the maximum extent permitted by applicable law, and for the purpose of taking any action that the Collateral Agent may deem necessary or advisable to accomplish the purposes of this Agreement, each Grantor hereby (i) authorizes the Collateral Agent to execute any such agreements, instruments or other documents in such Grantor’s name and to file such agreements, instruments or other documents in such Grantor’s name and in any appropriate filing office, (ii) authorizes the Collateral Agent at any time and from time to time to file, one or more financing or continuation statements, and amendments thereto, relating to the Collateral (including, without limitation, any such financing statements that (A) describe the Collateral as “all assets” or “all personal property” (or words of similar effect) other than Excluded Collateral or that describe or identify the Collateral by type or in any other manner as the Collateral Agent may determine regardless of whether any particular asset of such Grantor falls within the scope of Article 9 of the Code or whether any particular asset of such Grantor constitutes part of the Collateral, and (B) contain any other information required by Part 5 of Article 9 of the Code for the sufficiency or filing office acceptance of any financing statement, continuation statement or amendment, including, without limitation, whether such Grantor is an organization, the type of organization and any organizational identification number issued to such Grantor) and (iii) ratifies such authorization to the extent that the Collateral Agent has filed any such financing or continuation statements, or amendments thereto, prior to the date hereof. A photocopy or other reproduction of this Agreement or any financing statement covering the Collateral or any part thereof shall be sufficient as a financing statement where permitted by law.

 

(b)       Each Grantor hereby irrevocably appoints (but Collateral Agent shall not use such power until an Event of Default occurs) the Collateral Agent as its attorney-in-fact and proxy, with full authority in the place and stead of such Grantor and in the name of such Grantor or otherwise, from time to time in the Collateral Agent’s discretion to take any action and to execute any instrument which the Collateral Agent may deem necessary or advisable to accomplish the purposes of this Agreement, including, without limitation, (i) to obtain and adjust insurance required to be paid to the Collateral Agent pursuant to Section 5(e) hereof, (ii) to ask, demand, collect, sue for, recover, compound, receive and give acquittance and receipts for moneys due and to become due under or in respect of any Collateral, (iii) to receive, endorse, and collect any drafts or other instruments, documents and chattel paper in connection with clause (i) or (ii) above, (iv) to file any claims or take any action or institute any proceedings which the Collateral Agent may deem necessary or desirable for the collection of any Collateral or otherwise to enforce the rights of the Collateral Agent and the Noteholders with respect to any Collateral, (v) to execute assignments, licenses and other documents to enforce the rights of the Collateral Agent and the Noteholders with respect to any Collateral, and (vi) to verify any and all information with respect to any and all Accounts. This power is coupled with an interest and is irrevocable until all of the Obligations are Paid in Full.

 

  24  

 

 

(c)       For the purpose of enabling the Collateral Agent to exercise rights and remedies hereunder, at such time as the Collateral Agent shall be lawfully entitled to exercise such rights and remedies, and for no other purpose, each Grantor hereby grants to the Collateral Agent, to the extent assignable, an irrevocable, non-exclusive license (exercisable without payment of royalty or other compensation to any Grantor) to use, assign, license or sublicense any Intellectual Property now owned or hereafter acquired by such Grantor, wherever the same may be located, including in such license reasonable access to all media in which any of the licensed items may be recorded or stored and to all computer programs used for the compilation or printout thereof. Notwithstanding anything contained herein to the contrary, but subject to the provisions of the Securities Purchase Agreement that limit the right of any Grantor to dispose of its property, and Section 5(g) and Section 5(h) hereof, so long as no Event of Default shall have occurred and be continuing, any Grantor may exploit, use, enjoy, protect, license, sublicense, assign, sell, dispose of or take other actions with respect to the Intellectual Property in the ordinary course of its business and as otherwise expressly permitted by any of the other Transaction Documents. In furtherance of the foregoing, unless an Event of Default shall have occurred and be continuing, the Collateral Agent shall from time to time, upon the request of any Grantor, execute and deliver any instruments, certificates or other documents, in the form so requested, which such Grantor shall have certified are appropriate (in such Grantor’s judgment) to allow it to take any action permitted above (including relinquishment of the license provided pursuant to this clause (c) as to any Intellectual Property). Further, upon the Payment in Full of all of the Obligations, the Collateral Agent (subject to Section 10(e) hereof) shall release and reassign to any Grantor all of the Collateral Agent’s right, title and interest in and to the Collateral, including the Intellectual Property, and the Licenses, all without recourse, representation or warranty whatsoever. The exercise of rights and remedies hereunder by the Collateral Agent shall not terminate the rights of the holders of any licenses or sublicenses theretofore granted by each Grantor in accordance with the second sentence of this clause (c). Each Grantor hereby releases the Collateral Agent from any claims, causes of action and demands at any time arising out of or with respect to any actions taken or omitted to be taken by the Collateral Agent under the powers of attorney granted herein other than actions taken or omitted to be taken through the Collateral Agent’s gross negligence or willful misconduct, as determined by a final determination of a court of competent jurisdiction.

 

(d)       If any Grantor fails to perform any agreement or obligation contained herein, upon an Event of Default, the Collateral Agent may itself perform, or cause performance of, such agreement or obligation, in the name of such Grantor or the Collateral Agent, and the expenses of the Collateral Agent incurred in connection therewith shall be payable by such Grantor pursuant to Section 8 hereof and shall be secured by the Collateral.

 

  25  

 

 

(e)       The powers conferred on the Collateral Agent hereunder are solely to protect its interest in the Collateral and shall not impose any duty upon it to exercise any such powers. Except for the safe custody of any Collateral in its possession and the accounting for moneys actually received by it hereunder, the Collateral Agent shall have no duty as to any Collateral or as to the taking of any necessary steps to preserve rights against prior parties or any other rights pertaining to any Collateral.

 

(f)       Anything herein to the contrary notwithstanding (i) each Grantor shall remain liable under the Licenses and otherwise with respect to any of the Collateral to the extent set forth therein to perform all of its obligations thereunder to the same extent as if this Agreement had not been executed, (ii) the exercise by the Collateral Agent of any of its rights hereunder shall not release any Grantor from any of its obligations under the Licenses or otherwise in respect of the Collateral, and (iii) the Collateral Agent shall not have any obligation or liability by reason of this Agreement under the Licenses or with respect to any of the other Collateral, nor shall the Collateral Agent be obligated to perform any of the obligations or duties of any Grantor thereunder or to take any action to collect or enforce any claim for payment assigned hereunder.

 

(g)       As long as no Event of Default (as defined under the Notes) shall have occurred and be continuing and until written notice shall be given to the applicable Grantor:

 

(i)       Each Grantor shall have the right, from time to time, to vote and give consents with respect to the Pledged Equity, or any part thereof for all purposes not inconsistent with the provisions of this Agreement, the Securities Purchase Agreement or any other Transaction Document; provided , however , that no vote shall be cast, and no consent shall be given or action taken, which would have the effect of impairing the position or interest of the Collateral Agent in respect of the Pledged Equity or which would authorize, effect or consent to (unless and to the extent expressly permitted by the Securities Purchase Agreement):

 

(A)       the dissolution or liquidation, in whole or in part, of a Pledged Entity;

 

(B)       the consolidation or merger of a Pledged Entity with any other Person;

 

(C)       the sale, disposition or encumbrance of all or substantially all of the assets of a Pledged Entity, except for Liens in favor of the Collateral Agent;

 

(D)       any change in the authorized number of shares, the stated capital or the authorized share capital of a Pledged Entity or the issuance of any additional shares of its Capital Stock; or

 

(E)       the alteration of the voting rights with respect to the Capital Stock of a Pledged Entity.

 

  26  

 

 

(ii)       Each Grantor shall be entitled, from time to time, to collect and receive for its own use all cash dividends and interest paid in respect of the Pledged Equity to the extent not in violation of the Securities Purchase Agreement other than any and all: (A) dividends and interest paid or payable other than in cash in respect of any Pledged Equity, and instruments and other property received, receivable or otherwise distributed in respect of, or in exchange for, any Pledged Equity; (B) dividends and other distributions paid or payable in cash in respect of any Pledged Equity in connection with a partial or total liquidation or dissolution or in connection with a reduction of capital, capital surplus or paid-in capital of a Pledged Entity; and (C) cash paid, payable or otherwise distributed, in respect of principal of, or in redemption of, or in exchange for, any Pledged Equity; provided , however , that until actually paid all rights to such distributions shall remain subject to the Lien created by this Agreement; and

 

(iii)       all dividends and interest (other than such cash dividends and interest as are permitted to be paid to any Grantor in accordance with clause (i) above) and all other distributions in respect of any of the Pledged Equity, whenever paid or made, shall be delivered to the Collateral Agent to hold as Pledged Equity and shall, if received by any Grantor, be received in trust for the benefit of the Collateral Agent (for the benefit of the Noteholders), be segregated from the other property or funds of such Grantor, and be forthwith delivered to the Collateral Agent as Pledged Equity in the same form as so received (with any necessary endorsement).

 

SECTION 7. Remedies Upon Event of Default; Application of Proceeds . If any Event of Default shall have occurred and be continuing:

 

(a)       The Collateral Agent may exercise in respect of the Collateral, in addition to any other rights and remedies provided for herein, in any other Transaction Document or otherwise available to it, all of the rights and remedies of a secured party upon default under the Code (whether or not the Code applies to the affected Collateral), and also may (i) take absolute control of the Collateral, including, without limitation, transfer into the Collateral Agent’s name or into the name of its nominee or nominees (to the extent the Collateral Agent has not theretofore done so) and thereafter receive, for the benefit of the Noteholders, all payments made thereon, give all consents, waivers and ratifications in respect thereof and otherwise act with respect thereto as though it were the outright owner thereof, (ii) require each Grantor to, and each Grantor hereby agrees that it will at its expense and upon request of the Collateral Agent forthwith, assemble all or part of its respective Collateral as directed by the Collateral Agent and make it available to the Collateral Agent at a place or places to be designated by the Collateral Agent that is reasonably convenient to both parties, and the Collateral Agent may enter into and occupy any premises owned or leased by any Grantor where the Collateral or any part thereof is located or assembled for a reasonable period in order to effectuate the Collateral Agent’s rights and remedies hereunder or under law, without obligation to any Grantor in respect of such occupation, and (iii) without notice except as specified below and without any obligation to prepare or process the Collateral for sale, (A) sell the Collateral or any part thereof in one or more parcels at public or private sale (including, without limitation, by credit bid), at any of the Collateral Agent’s offices or elsewhere, for cash, on credit or for future delivery, and at such price or prices and upon such other terms as the Collateral Agent may deem commercially reasonable and/or (B) lease, license or dispose of the Collateral or any part thereof upon such terms as the Collateral Agent may deem commercially reasonable. Each Grantor agrees that, to the extent notice of sale or any other disposition of its respective Collateral shall be required by law, at least ten (10) days’ notice to any Grantor of the time and place of any public sale or the time after which any private sale or other disposition of its respective Collateral is to be made shall constitute reasonable notification. The Collateral Agent shall not be obligated to make any sale or other disposition of any Collateral regardless of notice of sale having been given. The Collateral Agent may adjourn any public or private sale from time to time by announcement at the time and place fixed therefor, and such sale may, without further notice, be made at the time and place to which it was so adjourned. Each Grantor hereby waives any claims against the Collateral Agent and the Noteholders arising by reason of the fact that the price at which its respective Collateral may have been sold at a private sale was less than the price which might have been obtained at a public sale or was less than the aggregate amount of the Obligations, even if the Collateral Agent accepts the first offer received and does not offer such Collateral to more than one offeree, and waives all rights that any Grantor may have to require that all or any part of such Collateral be marshaled upon any sale (public or private) thereof. Each Grantor hereby acknowledges that (i) any such sale of its respective Collateral by the Collateral Agent shall be made without warranty, (ii) the Collateral Agent may specifically disclaim any warranties of title, possession, quiet enjoyment or the like, and (iii) such actions set forth in clauses (i) and (ii) above shall not adversely affect the commercial reasonableness of any such sale of Collateral. In addition to the foregoing, (1) upon written notice to any Grantor from the Collateral Agent after and during the continuance of an Event of Default, such Grantor shall cease any use of the Intellectual Property or any trademark, patent or copyright similar thereto for any purpose described in such notice; (2) the Collateral Agent may, at any time and from time to time after and during the continuance of an Event of Default, upon 5 days’ prior notice to such Grantor, license, whether general, special or otherwise, and whether on an exclusive or non-exclusive basis, any of the Intellectual Property, throughout the universe for such term or terms, on such conditions, and in such manner, as the Collateral Agent shall in its sole discretion determine; and (3) the Collateral Agent may, at any time, pursuant to the authority granted in Section 6 hereof or otherwise (such authority being effective upon the occurrence and during the continuance of an Event of Default), execute and deliver on behalf of such Grantor, one or more instruments of assignment of the Intellectual Property (or any application or registration thereof), in form suitable for filing, recording or registration in any country.

 

  27  

 

 

(b)       Any cash held by the Collateral Agent as Collateral and all Cash Proceeds received by the Collateral Agent in respect of any sale or disposition of or collection from, or other realization upon, all or any part of the Collateral shall be applied as follows (subject to the provisions of the Securities Purchase Agreement): first , to pay any fees, indemnities or expense reimbursements then due to the Collateral Agent (including those described in Section 8 hereof); second , to pay any fees, indemnities or expense reimbursements then due to the Noteholders, on a pro rata basis; third to pay interest due under the ICA-T Note owing to the Noteholders, on a pro rata basis; fourth , to pay or prepay principal in respect of the ICA-T Note, whether or not then due, owing to the Noteholders, on a pro rata basis; fifth , to pay or prepay any other Obligations, whether or not then due, in such order and manner as the Collateral Agent shall elect, consistent with the provisions of the Securities Purchase Agreement and any other Transaction Document. Any surplus of such cash or Cash Proceeds held by the Collateral Agent and remaining after the Payment in Full of all of the Obligations shall be paid over to whomsoever shall be lawfully entitled to receive the same or as a court of competent jurisdiction shall direct.

 

(c)       In the event that the proceeds of any such sale, disposition, collection or realization are insufficient to pay all amounts to which the Collateral Agent and the Noteholders are legally entitled, each Grantor shall be, jointly and severally, liable for the deficiency, together with interest thereon at the highest rate specified in the ICA-T Note for interest on overdue principal thereof or such other rate as shall be fixed by applicable law, together with the costs of collection and the fees, costs, expenses and other charges of any attorneys employed by the Collateral Agent to collect such deficiency.

 

(d)       To the extent that applicable law imposes duties on the Collateral Agent to exercise remedies in a commercially reasonable manner, each Grantor acknowledges and agrees that it is commercially reasonable for the Collateral Agent (i) to fail to incur expenses deemed significant by the Collateral Agent to prepare Collateral for disposition or otherwise to transform raw material or work in process into finished goods or other finished products for disposition, (ii) to fail to obtain third party consents for access to Collateral to be disposed of, or to obtain or, if not required by other law, to fail to obtain governmental or third party consents for the collection or disposition of Collateral to be collected or disposed of, (iii) to fail to exercise collection remedies against Account Debtors or other Persons obligated on Collateral or to remove Liens on or any adverse claims against Collateral, (iv) to exercise collection remedies against Account Debtors and other Persons obligated on Collateral directly or through the use of collection agencies and other collection specialists, (v) to advertise dispositions of Collateral through publications or media of general circulation, whether or not the Collateral is of a specialized nature, (vi) to contact other Persons, whether or not in the same business as any Grantor, for expressions of interest in acquiring all or any portion of such Collateral, (vii) to hire one or more professional auctioneers to assist in the disposition of Collateral, whether or not the Collateral is of a specialized nature, (viii) to dispose of Collateral by utilizing internet sites that provide for the auction of assets of the types included in the Collateral or that have the reasonable capacity of doing so, or that match buyers and sellers of assets, (ix) to dispose of assets in wholesale rather than retail markets, (x) to disclaim disposition warranties, such as title, possession or quiet enjoyment, (xi) to purchase insurance or credit enhancements to insure the Collateral Agent against risks of loss, collection or disposition of Collateral or to provide to the Collateral Agent a guaranteed return from the collection or disposition of Collateral, or (xii) to the extent deemed appropriate by the Collateral Agent, to obtain the services of brokers, investment bankers, consultants, attorneys and other professionals to assist the Collateral Agent in the collection or disposition of any of the Collateral. Each Grantor acknowledges that the purpose of this section is to provide non-exhaustive indications of what actions or omissions by the Collateral Agent would be commercially reasonable in the Collateral Agent’s exercise of remedies against the Collateral and that other actions or omissions by the Collateral Agent shall not be deemed commercially unreasonable solely on account of not being indicated in this section. Without limitation upon the foregoing, nothing contained in this section shall be construed to grant any rights to any Grantor or to impose any duties on the Collateral Agent that would not have been granted or imposed by this Agreement or by applicable law in the absence of this section.

 

  28  

 

 

(e)       The Collateral Agent shall not be required to marshal any present or future collateral security (including, but not limited to, this Agreement and the Collateral) for, or other assurances of payment of, the Obligations or any of them or to resort to such collateral security or other assurances of payment in any particular order, and all of the Collateral Agent’s rights hereunder and in respect of such collateral security and other assurances of payment shall be cumulative and in addition to all other rights, however existing or arising. To the extent that any Grantor lawfully may, each Grantor hereby agrees that it will not invoke any law relating to the marshaling of collateral which might cause delay in or impede the enforcement of the Collateral Agent’s rights under this Agreement or under any other instrument creating or evidencing any of the Obligations or under which any of the Obligations is outstanding or by which any of the Obligations is secured or payment thereof is otherwise assured, and, to the extent that it lawfully may, each Grantor hereby irrevocably waives the benefits of all such laws.

 

SECTION 8. Indemnity and Expenses.

 

(a)       Each Grantor agrees, jointly and severally, to defend, protect, indemnify and hold the Collateral Agent and each of the Noteholders harmless from and against any and all claims, damages, losses, liabilities, obligations, penalties, fees, costs and expenses (including, without limitation, legal fees, costs, expenses, and disbursements of such Person’s counsel) to the extent that they arise out of or otherwise result from this Agreement (including, without limitation, enforcement of this Agreement), except to the extent resulting from such Person’s gross negligence or willful misconduct, as determined by a final judgment of a court of competent jurisdiction no longer subject to appeal.

 

(b)       Each Grantor agrees, jointly and severally, to pay to the Collateral Agent upon demand the amount of any and all costs and expenses, including the reasonable fees, costs, expenses and disbursements of counsel for the Collateral Agent and of any experts and agents (including, without limitation, any collateral trustee which may act as agent of the Collateral Agent), which the Collateral Agent may incur in connection with (i) the preparation, negotiation, execution, delivery, recordation, administration, amendment, waiver or other modification or termination of this Agreement, (ii) the custody, preservation, use or operation of, or the sale of, collection from, or other realization upon, any Collateral, (iii) the exercise or enforcement of any of the rights of the Collateral Agent hereunder, or (iv) the failure by any Grantor to perform or observe any of the provisions hereof.

 

SECTION 9. Notices, Etc . All notices and other communications provided for hereunder shall be in writing and shall be mailed (by certified mail, first-class postage prepaid and return receipt requested), telecopied, e-mailed or delivered, if to any Grantor (other than ICA-T), to the Parent’s address, if to ICA-T, to ICA-T’s address or if to the Collateral Agent or any Noteholder, to it at its respective address, each as set forth in Section 9(f) of the Securities Purchase Agreement; or as to any such Person, at such other address as shall be designated by such Person in a written notice to all other parties hereto complying as to delivery with the terms of this Section 9 . All such notices and other communications shall be effective (a) if sent by certified mail, return receipt requested, when received or three (3) Business Days after deposited in the mails, whichever occurs first, (b) if telecopied or e-mailed, when transmitted (during normal business hours) and confirmation is received, and otherwise, the day after the notice or communication was transmitted and confirmation is received, or (c) if delivered in person, upon delivery. For the avoidance of doubt, all Foreign Subsidiaries, as Grantors, hereby appoint the Parent as its agent for receipt of service of process and all notices and other communications in the United States at the address specified below.

 

  29  

 

 

SECTION 10. Miscellaneous.

 

(a)       No amendment of any provision of this Agreement shall be effective unless it is in writing and signed by each Grantor and the Collateral Agent (and approved by the Required Holders), and no waiver of any provision of this Agreement, and no consent to any departure by each Grantor therefrom, shall be effective unless it is in writing and signed by each Grantor and the Collateral Agent (and approved by the Required Holders), and then such waiver or consent shall be effective only in the specific instance and for the specific purpose for which given.

 

(b)       No failure on the part of the Collateral Agent to exercise, and no delay in exercising, any right reasonably hereunder or under any of the other Transaction Documents shall operate as a waiver thereof; nor shall any single or partial exercise of any such right reasonably preclude any other or further exercise thereof or the exercise of any other right. The rights and remedies of the Collateral Agent or any Noteholder provided herein and in the other Transaction Documents are cumulative and are in addition to, and not exclusive of, any rights or remedies provided by law. The rights of the Collateral Agent or any Noteholder under any of the other Transaction Documents against any party thereto are not conditional or contingent on any attempt by such Person to exercise any of its rights under any of the other Transaction Documents against such party or against any other Person, including but not limited to, any Grantor.

 

(c)       If any provision of this Agreement or any Transaction Document is prohibited by law or otherwise determined to be invalid or unenforceable by a court of competent jurisdiction, the provision that would otherwise be prohibited, invalid or unenforceable shall be deemed amended to apply to the broadest extent that it would be valid and enforceable, and the invalidity or unenforceability of such provision shall not affect the validity of the remaining provisions of this Agreement so long as this Agreement as so modified continues to express, without material change, the original intentions of the parties as to the subject matter hereof and the prohibited nature, invalidity or unenforceability of the provision(s) in question does not substantially impair the respective expectations or reciprocal obligations of the parties or the practical realization of the benefits that would otherwise be conferred upon the parties.  The parties will endeavor in good faith negotiations to replace the prohibited, invalid or unenforceable provision(s) with a valid provision(s), the effect of which comes as close as possible to that of the prohibited, invalid or unenforceable provision(s).

 

(d)       This Agreement shall create a continuing security interest in the Collateral and shall (i) remain in full force and effect until Payment in Full of the Obligations, and (ii) be binding on each Grantor and all other Persons who become bound as debtor to this Agreement in accordance with Section 9-203(d) of the Code and shall inure, together with all rights and remedies of the Collateral Agent and the Noteholders hereunder, to the benefit of the Collateral Agent and the Noteholders and their respective permitted successors, transferees and assigns. Without limiting the generality of clause (ii) of the immediately preceding sentence, without notice to any Grantor, the Collateral Agent and the Noteholders may assign or otherwise transfer their rights and obligations under this Agreement and any of the other Transaction Documents, to any other Person and such other Person shall thereupon become vested with all of the benefits in respect thereof granted to the Collateral Agent and the Noteholders herein or otherwise. Upon any such assignment or transfer, all references in this Agreement to the Collateral Agent or any such Noteholder shall mean the assignee of the Collateral Agent or such Noteholder. None of the rights or obligations of any Grantor hereunder may be assigned or otherwise transferred without the prior written consent of the Collateral Agent, and any such assignment or transfer without such consent of the Collateral Agent shall be null and void.

 

  30  

 

 

(e)       Upon the Payment in Full of the Obligations, (i) this Agreement and the security interests created hereby shall terminate and all rights to the Collateral shall revert to the respective Grantor that granted such security interests hereunder, and (ii) the Collateral Agent will, upon any Grantor’s request and at such Grantor’s expense, (A) return to such Grantor such of the Collateral as shall not have been sold or otherwise disposed of or applied pursuant to the terms hereof and (B) execute and deliver to such Grantor such documents as such Grantor shall reasonably request to evidence such termination, all without any representation, warranty or recourse whatsoever.

 

(f)        Governing Law; Jurisdiction; Jury Trial .

 

(i)       All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed exclusively by the internal laws of the State of New York, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of New York or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of New York.

 

(ii)      Each Grantor hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in The City of New York, Borough of Manhattan, for the adjudication of any dispute hereunder or in connection herewith or under any of the other Transaction Documents or with any transaction contemplated hereby or thereby, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim, defense or objection that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof to such party at the address for such notices to it under Section 9(f) of the Securities Purchase Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. Nothing contained herein shall be deemed or operate to preclude the Collateral Agent or the Noteholders from bringing suit or taking other legal action against any Grantor in any other jurisdiction to collect on a Grantor’s obligations or to enforce a judgment or other court ruling in favor of the Collateral Agent or a Noteholder.

 

  31  

 

 

(iii)        WAIVER OF JURY TRIAL, ETC . EACH GRANTOR IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR UNDER ANY OTHER TRANSACTION DOCUMENT OR IN CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT, ANY OTHER TRANSACTION DOCUMENT OR ANY TRANSACTION CONTEMPLATED HEREBY OR THEREBY.

 

(iv)       Each Grantor irrevocably and unconditionally waives any right it may have to claim or recover in any legal action, suit or proceeding referred to in this Section any special, exemplary, indirect, incidental, punitive or consequential damages.

 

(g)       Section headings herein are included for convenience of reference only and shall not constitute a part of this Agreement for any other purpose.

 

(h)       This Agreement may be executed in any number of counterparts and by different parties hereto in separate counterparts, each of which shall be deemed to be an original, but all of which taken together constitute one and the same Agreement. Delivery of any executed counterpart of a signature page of this Agreement by pdf, facsimile or other electronic transmission shall be effective as delivery of a manually executed counterpart of this Agreement.

 

(i)       This Agreement shall continue to be effective or be reinstated, as the case may be, if at any time any payment of any of the Obligations is rescinded or must otherwise be returned by the Collateral Agent, any Noteholder or any other Person (upon (i) the occurrence of any Insolvency Proceeding of any of the Parent or any Grantor or (ii) otherwise, in all cases as though such payment had not been made).

 

SECTION 11. Material Non-Public Information . Upon receipt or delivery by the Parent of any notice in accordance with the terms of this Agreement, unless the Parent has in good faith determined that the matters relating to such notice do not constitute material, non-public information relating to the Parent or any of its Subsidiaries, the Parent shall within one (1) Business Day after any such receipt or delivery publicly disclose such material, non-public information on a Current Report on Form 8-K or otherwise. In the event that the Parent believes that a notice contains material, non-public information relating to the Parent or any of its Subsidiaries, the Parent so shall indicate to the Collateral Agent and any applicable Noteholder contemporaneously with delivery of such notice, and in the absence of any such indication, the Collateral Agent and each Noteholder shall be allowed to presume that all matters relating to such notice do not constitute material, non-public information relating to the Parent or its Subsidiaries. Nothing contained in this Section 11 shall limit any obligations of the Parent, or any rights of the Collateral Agent or any Noteholder, under Section 4(i) of the Securities Purchase Agreement.

 

[REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK]

 

  32  

 

 

IN WITNESS WHEREOF, each Grantor has caused this Agreement to be executed and delivered by its officer thereunto duly authorized, as of the date first above written.

 

  GRANTORS :
     
  ICAGEN, INC. ,
  a Delaware corporation
     
  By: /s/ Richard Cunningham
    Name: Richard Cunningham
    Title: President and CEO
     
  ICAGEN CORP (FORMERLY KNOWN AS XRPRO CORP.). , a Nevada corporation
     
  By: /s/ Richard Cunningham
    Name: Richard Cunningham
    Title: President and CEO
     
  ICAGEN-T INC. , a Delaware corporation
     
  By: /s/ Richard Cunningham
    Name: Richard Cunningham
    Title: President and CEO
     
  CALDERA DISCOVERY, INC , a Delaware corporation
     
  By: /s/ Richard Cunningham
    Name: Richard Cunningham
    Title: President and CEO
     
  XRPRO SCIENCES, INC. , a Delaware corporation
     
  By: /s/ Richard Cunningham
    Name: Richard Cunningham
    Title: President and CEO

 

ACCEPTED BY:  
     
GPB Debt Holdings II, LLC,  
as Collateral Agent  

 

 
By:  /s/   David Gentile  
  Name: David Gentile  
  Title: Manager  

 

  33  

 

 

LIST OF EXHIBITS AND SCHEDULES TO SECURITY AND PLEDGE AGREEMENT

 

A. EXHIBITS

 

Exhibit A – IP Security Agreement

 

B. SCHEDULES

 

Schedule I – Controlled Accounts Etc.

 

Schedule II – Copyrights, Etc.

 

Schedule III – Patents, Etc.

 

Schedule IV – Pledged Entities

 

Schedule V – Trademark Licenses

 

Schedule V(a) – Trademarks, Etc.

 

Schedule VI – Commercial Tort Claims

 

Schedule VII – Legal Names, Organizational Identification Numbers; States or Jurisdiction of Organization

 

Schedule VIII – Locations

 

Schedule IX – Securities Etc. of each Grantor

 

Schedule X – Licenses, Etc.

 

Schedule XI – All Intellectual Property and Licenses of Grantors

 

Schedule XII – Pledged Collateral

 

Schedule XIII – [RESERVED]

 

Schedule XIV – [RESERVED]

 

Schedule XV - Pledged Equity

 

Schedule XVI – Locations of Collateral

 

Schedule XVII – Licenses, Etc.

 

Schedule XVIII – Notices. Etc., Re: Exercise of Rights by certain parties under Licenses

 

Schedule XIX – No Termination Etc. of Licenses

 

 

 

 

Execution Version

 

EXHIBIT A

 

FORM OF INTELLECTUAL PROPERTY SECURITY AGREEMENT

 

INTELLECTUAL PROPERTY SECURITY AGREEMENT

 

This INTELLECTUAL PROPERTY SECURITY AGREEMENT (as amended, modified, supplemented, renewed, restated or replaced from time to time, this “ IP Security Agreement ”), dated May 15, 2017, is made by the Persons listed on the signature pages hereof (collectively, the “ Grantors ”) in favor of GPB Debt Holdings II, LLC, in its capacity as collateral agent (the “ Collateral Agent ”) for itself as a Noteholder and any other Noteholders. All capitalized terms not otherwise defined herein (or as indicated herein as being defined in another document, agreement and/or instrument) shall have the meanings respectively ascribed thereto in the Security Agreement (as defined below).

 

WHEREAS, Icagen, Inc., a Delaware corporation with offices located at 4222 Emperor Blvd., Suite 350, Research Triangle Park, Durham, NC, 27703 (the “ Parent ”), Icagen-T, Inc., a Delaware corporation and a wholly-owned Subsidiary of the Parent with offices located at 2090 E. Innovation Park Drive, Oro Valley, Arizona 85755 (“ ICA-T ”) and GPB Debt Holdings II, LLC, as investor (the “ Buyer ”) are parties to that certain Securities Purchase Agreement, dated May 15, 2017, pursuant to which ICA-T and the Parent shall be required to sell, and the Buyer shall purchase or have the right to purchase, the ICA-T Note (as defined therein) and the Parent Note and Parent Warrant (both terms as defined therein) from ICA-T and the Parent, respectively;

 

WHEREAS, it is a condition precedent to the purchase of the ICA-T Note and the Parent Note and Parent Warrants under the Securities Purchase Agreement that each Grantor has executed and delivered that certain Security and Pledge Agreement, dated May 15, 2017, made by the Grantors to the Collateral Agent (as amended, modified, supplemented, renewed, restated or replaced from time to time, the “ Security Agreement ”); and

 

WHEREAS, under the terms of the Security Agreement, the Grantors have granted to the Collateral Agent, for the benefit of the Noteholders, a security interest in, among other property, certain intellectual property and Licenses of the Grantors, and have agreed as a condition thereof to execute this IP Security Agreement for recording with the U.S. Patent and Trademark Office and the United States Copyright Office; and

 

WHEREAS, the Grantors have determined that the execution, delivery and performance of this IP Security Agreement directly benefits, and is in the best interest of, the Grantors.

 

NOW, THEREFORE, in consideration of the premises and the agreements herein and for such other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, and in order to induce the Buyer to perform under the Securities Purchase Agreement, each Grantor agrees with the Collateral Agent, for the benefit of the Noteholders, as follows

 

SECTION 1. Grant of Security . Each Grantor hereby grants to the Collateral Agent for the benefit of the Collateral Agent as a Noteholder and any other Noteholders a security interest in all of such Grantor’s right, title and interest in and to the following (the “ Collateral ”):

 

(i)       the United States Patents and Patent applications set forth in Schedule A hereto;

 

 

 

 

(ii)       the United States Trademarks and service mark registrations and applications set forth in Schedule B hereto (provided that no security interest shall be granted in United States intent-to-use trademark applications to the extent that, and solely during the period in which, the grant of a security interest therein would impair the validity or enforceability of such intent-to-use trademark applications under applicable federal law), together with the goodwill symbolized thereby;

 

(iii)      all United States Copyrights, whether registered or unregistered, now owned or hereafter acquired by such Grantor, including, without limitation, the copyright registrations and applications and exclusive copyright licenses set forth in Schedule C hereto;

 

(iv)      all reissues, divisions, continuations, continuations-in-part, extensions, renewals and reexaminations of any of the foregoing, all rights in the foregoing provided by international treaties or conventions, all rights corresponding thereto throughout the world and all other rights of any kind whatsoever of such Grantor accruing thereunder or pertaining thereto;

 

(v)       any and all claims for damages and injunctive relief for past, present and future infringement, dilution, misappropriation, violation, misuse or breach with respect to any of the foregoing, with the right, but not the obligation, to sue for and collect, or otherwise recover, such damages; and

 

(vi)       any and all proceeds of, collateral for, income, royalties and other payments now or hereafter due and payable with respect to, and supporting obligations relating to, any and all of the Collateral of or arising from any of the foregoing.

 

SECTION 2. Security for Obligations . The grant of a security interest in, the Collateral under this IP Security Agreement by each Grantor) secures the payment of all Obligations of each Grantor now or hereafter existing under or in respect of the ICA-T Note and the other Transaction Documents, whether direct or indirect, absolute or contingent, and whether for principal, reimbursement obligations, interest, redemption payments, premiums, penalties, fees, indemnifications, contract causes of action, costs, expenses or otherwise.

 

SECTION 3. Recordation . Each Grantor authorizes and requests that the Register of Copyrights, the Commissioner for Patents and the Commissioner for Trademarks and any other applicable government officer record this IP Security Agreement.

 

SECTION 4. Execution in Counterparts . This IP Security Agreement may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement.

 

SECTION 5. Grants, Rights and Remedies . This IP Security Agreement has been entered into in conjunction with the provisions of the Security Agreement. Each Grantor does hereby acknowledge and confirm that the grant of the security interest hereunder to, and the rights and remedies of, the Collateral Agent with respect to the Collateral are more fully set forth in the Security Agreement, the terms and provisions of which are incorporated herein by reference as if fully set forth herein.

 

  2  

 

 

SECTION 6. Governing Law; Jurisdiction; Jury Trial .

 

(i)       All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by the internal laws of the State of New York, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of New York or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of New York.

 

(ii)       Each Grantor hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in The City of New York, Borough of Manhattan, for the adjudication of any dispute hereunder or in connection herewith or under any of the other Transaction Documents or with any transaction contemplated hereby or thereby, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim, defense or objection that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof to such party at the address for such notices to it under Section 9(f) of the Securities Purchase Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. Nothing contained herein shall be deemed or operate to preclude the Collateral Agent or the Noteholders from bringing suit or taking other legal action against any Grantor in any other jurisdiction to collect on a Grantor’s obligations or to enforce a judgment or other court ruling in favor of the Collateral Agent or a Noteholder.

 

(iii)       WAIVER OF JURY TRIAL, ETC . EACH GRANTOR IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR UNDER ANY OTHER TRANSACTION DOCUMENT OR IN CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT, ANY OTHER TRANSACTION DOCUMENT OR ANY TRANSACTION CONTEMPLATED HEREBY OR THEREBY.

 

(iv)      Each Grantor irrevocably and unconditionally waives any right it may have to claim or recover in any legal action, suit or proceeding referred to in this Section any special, exemplary, indirect, incidental, punitive or consequential damages.

 

[The remainder of the page is intentionally left blank]

 

  3  

 

 

IN WITNESS WHEREOF, each Grantor has caused this Agreement to be duly executed and delivered by its officer thereunto duly authorized as of the date first above written.

 

  GRANTORS :
     
  ICAGEN, INC. ,
  a Delaware corporation
     
  By:
    Name: Richard Cunningham
    Title: President and CEO
     
  ICAGEN CORP. (FORMERLY KNOWN AS XRPRO CORP., FORMERLY KNOWN AS CALDERA PHARMACEUTICALS , INC.), a Nevada corporation
     
  By:
    Name: Richard Cunningham
    Title: President and CEO
     
  ICAGEN-T INC. , a Delaware corporation
     
  By:
    Name: Richard Cunningham
    Title: President and CEO
     
  CALDERA DISCOVERY, INC , a Delaware corporation
     
  By:
    Name: Richard Cunningham
    Title: President and CEO
     
  XRPRO SCIENCES, INC. , a Delaware corporation
     
  By:
    Name: Richard Cunningham
    Title: President and CEO

 

  4  

 

 

SCHEDULE I

 

Controlled Accounts Etc.

 

  Icagen Inc.  
     
   #####  #####  
       
  Icagen Corp.  
     
  #####  #####   
       
  Icagen-T, Inc.  
     
  #####  #####   

 

Accounts to be closed within 90 days of conclusion of Agreement:

 

Icagen Inc.

 

   #####  #####  
       
   #####  #####  
       
   #####  #####  
       
   ##### #####   
       
   #####  #####  

 

 

 

 

SCHEDULE II

 

Copyrights, Etc.

 

None

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SCHEDULE III

 

Patents, Etc.

 

Reference   Title   Country   Application No.   Pub. No.   Patent No.   Status
ICA-001   METHOD FOR DETECTING BINDING EVENTS USING MICRO-X-RAY FLUORESCENCE SPECTROMETRY   United States   09/859,701   2003-0027129   7,858,385   Patented
ICA-002EP   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   Europe   3748920   1525458   1525458   Patented
ICA-002BE   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   Belgium   3748920   1525458   1525458   Patented
ICA-002CH   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   Switzerland   3748920   1525458   1525458   Patented
ICA-002DE   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   Germany   3748920   1525458   1525458   Patented
ICA-002DK   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   Denmark   3748920   1525458   1525458   Patented
ICA-002ES   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   Spain   3748920   1525458   1525458   Patented

 

 

 

 

Reference   Title   Country   Application No.   Pub. No.   Patent No.   Status
ICA-002FI   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   Finland   3748920   1525458   1525458   Patented
ICA-002FR   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   France   3748920   1525458   1525458   Patented
ICA-002GB   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   United Kingdom   3748920   1525458   1525458   Patented
ICA-002IT   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   Italy   3748920   1525458   1525458   Patented
ICA-002SE   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   Sweden   3748920   1525458   1525458   Patented
ICA-002NL   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   Netherlands   3748920   1525458   1525458   Patented
ICA-002JP   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   Japan   2004-524531   2006-503268   4560403   Patented
ICA-002SG   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   Singapore   200500360-3   109345   109345   Patented

 

 

 

 

Reference   Title   Country   Application No.   Pub. No.   Patent No.   Status
ICA-002C2   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   United States   11/444,660   2007-0003008   7,519,145   Patented
ICA-002C3   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   United States   12/396,592   2009-0175410   7,929,662   Patented
ICA-003EP   METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING   Europe   4755687.3   1644095   1644095   Patented
ICA-003CH   METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING   Switzerland/
Liechtenstein
  4755687.3   1644095   1644095   Patented
ICA-003DE   METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING   Germany   4755687.3   1644095   1644095   Patented
ICA-003FR   METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING   France   4755687.3   1644095   1644095   Patented
ICA-003GB   METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING   United Kingdom   4755687.3   1644095   1644095   Patented
ICA-003IE   METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING   Ireland   4755687.3   1644095   1644095   Patented
ICA-003NL   METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING   Netherlands   4755687.3   1644095   1644095   Patented
ICA-003JP   METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING   Japan   2006-520181   2007527524   4782676   Patented

 

 

 

 

Reference   Title   Country   Application No.   Pub. No.   Patent No.   Status
ICA-003SG   METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING   Singapore   2005085584       118682   Patented
ICA-003   METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING   United States   10/621,825   2005-0011818   6,858,148   Patented
ICA-003C1   METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING   United States   10/986,519   2005-0095636   7,241,381   Patented
ICA-004   DRUG DEVELOPMENT AND MANUFACTURING   United States   10/880,388   2004-0235059   9,157,875   Patented
ICA-005EP   X-RAY FLUORESCENCE ANALYSIS METHOD   Europe   7874491.9   2084519   2084519   Patented
ICA-005CH   X-RAY FLUORESCENCE ANALYSIS METHOD   Switzerland/
Liechtenstein
  07 874 491.9   2084519   2084519   Patented
ICA-005DE   X-RAY FLUORESCENCE ANALYSIS METHOD   Germany   60 2007 024 468.4   2084519   608007024468.4   Patented
ICA-005DK   X-RAY FLUORESCENCE ANALYSIS METHOD   Denmark   07 874 491.9   2084519   2084519   Patented
ICA-005FR1   X-RAY FLUORESCENCE ANALYSIS METHOD   France   07 874 491.9   2084519   2084519   Patented
ICA-005GB   X-RAY FLUORESCENCE ANALYSIS METHOD   United Kingdom   7874491.9   2084519   2084519   Patented
ICA-005HK   ADVANCED DRUG DEVELOPMENT AND MANUFACTURING   Hong Kong (via EP -005EPDV)   13104259.3   1177280   1177280   Patented
ICA-005IE   X-RAY FLUORESCENCE ANALYSIS METHOD   Ireland   7874491.9   1177280   2084519   Patented

 

 

 

 

Reference   Title   Country   Application No.   Pub. No.   Patent No.   Status
ICA-005IT   X-RAY FLUORESCENCE ANALYSIS METHOD   Italy   7874491.9   1177280   2084519   Patented
ICA-005NL   X-RAY FLUORESCENCE ANALYSIS METHOD   Netherlands   7874491.9   1177280   2084519   Patented
ICA-005SE   X-RAY FLUORESCENCE ANALYSIS METHOD   Sweden   7874491.9   1177280   2084519   Patented
ICA-005EPDV   X-RAY MICROSCOPE   Europe   12164870.3   2511844   2511844   Patented
ICA-005CHDV   X-RAY MICROSCOPE   Switzerland and Lichtenstein   12164870.3   2511844   2511844   Patented
ICA-005DEDV   X-RAY MICROSCOPE   Germany   12164870.3   2511844   602007042616.2   Patented
ICA-005FRDV   X-RAY MICROSCOPE   France   12164870.3   2511844   2511844   Patented
ICA-005GBDV   X-RAY MICROSCOPE   United Kingdom   12164870.3   2511844   2511844   Patented
ICA-005HK   ADVANCED DRUG DEVELOPMENT AND MANUFACTURING   Hong Kong (via EP -005EPDV)   2013104259.3   1177280   1177280   Patented
ICA-005IEDV   X-RAY MICROSCOPE   Ireland   12164870.3   2511844   2511844   Patented
ICA-005JP   ADVANCED DRUG DEVELOPMENT AND MANUFACTURING   Japan   2009-532446   2010509566   5143841   Patented
ICA-005JPDV2   ADVANCED DRUG DEVELOPMENT AND MANUFACTURING   Japan   2014-123249   2014-123249   5913441   Patented
ICA-005C1   ADVANCED DRUG DEVELOPMENT AND MANUFACTURING   United States   14/693,094   2015-0309021   N/A   Pending

 

 

 

 

Reference   Title   Country   Application No.   Pub. No.   Patent No.   Status
ICA-006EP   WELL PLATE   Europe   8798006.6   2183644   2183644   Patented
ICA-006BE   WELL PLATE   Belgium   8798007.6   2183644   2183644   Patented
ICA-006CH   WELL PLATE   Switzerland   8798008.6   2183644   2183644   Patented
ICA-006DE   WELL PLATE   Germany   8798009.6   2183644   602008044640.9   Patented
ICA-006DK   WELL PLATE   Denmark   8798010.6   2183644   2183644   Patented
ICA-006ES   WELL PLATE   Spain   8798011.6   2183644   2183644   Patented
ICA-006FI   WELL PLATE   Finland   8798012.6   2183644   2183644   Patented
ICA-006FR   WELL PLATE   France   8798013.6   2183644   2183644   Patented
ICA-006GB   WELL PLATE   United Kingdom   8798014.6   2183644   2183644   Patented
ICA-006IE   WELL PLATE   Ireland   8798015.6   2183644   2183644   Patented
ICA-006IT   WELL PLATE   Italy   8798016.6   2183644   2183644   Patented
ICA-006 NL   WELL PLATE   Netherlands   8798017.6   2183644   2183644   Patented
ICA-006NO   WELL PLATE   Norway   8798018.6   2183644   2183644   Patented
ICA-006SE   WELL PLATE   Sweden   8798019.6   2183644   2183644   Patented
ICA-006JP   WELL PLATE   Japan   2010-521206   2010537171   5628035   Patented
ICA-006JPDV   WELL PLATE   Japan   2013-117600   2013224946   5755682   Patented
ICA-006JPDV2   WELL PLATE   Japan   2014-202871   2015004692   6076308   Patented
ICA-006   WELL PLATE   United States   12/192,762   2009-0046832   8,238,515   Patented
ICA-006C1   WELL PLATE   United States   13/567,613   2013-0034205   8,873,707   Patented
ICA-006C2   WELL PLATE   United States   14/508,322   2015-0023467   9,476,846   Patented
ICA-006C3   WELL PLATE   United States   15/273,767   2017-0010228   N/A   Pending
ICA-007JP   METHOD AND APPARATUS FOR MEASURING PROTEIN POST-TRANSLATIONAL MODIFICATION   Japan   2010-5272   2010539944   5743135   Patented

 

 

 

 

Reference   Title   Country   Application No.   Pub. No.   Patent No.   Status
ICA-007JPDV1   METHOD AND APPARATUS FOR MEASURING PROTEIN POST-TRANSLATIONAL MODIFICATION   Japan   2014-221166   2015033386   N/A   Pending
ICA-007C1/XR7-US2   METHOD AND APPARATUS FOR MEASURING PROTEIN POST-TRANSLATIONAL MODIFICATION   United States   15/052,914   2016-0201111   N/A   Pending
ICA-008CN   METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS   China   200980125952.3   102083365   ZL 200980125952.3   Patented
ICA-008CNDV   METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS   China   201310298029.8   103411988   2077368   Patented
ICA-008CNDV2   METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS   China   201510083796.6   N/A   N/A   Pending
ICA-008EP   METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS   Europe   09774467.6   2306897   N/A   Allowed
ICA-008HK   METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS   Hong Kong   11112984.0   1158478   1158478   Patented

 

 

 

 

Reference   Title   Country   Application No.   Pub. No.   Patent No.   Status
ICA-008   METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS USING X-RAY FLUORESCENCE   United States   12/496,532   2010-0003697   8,431,357   Patented
ICA-008C1   METHOD FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS USING X-RAY FLUORESCENCE USING X-RAY FLUORESCENCE   United States   13/871,697   2013-0236887   9,063,154   Patented
ICA-008C2   METHOD FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS USING X-RAY FLUORESCENCE   United States   14/669,923   2015-0198615   9,506,931   Patented
ICA-008C3   METHOD FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS USING X-RAY FLUORESCENCE   United States   15/334,854   2017-0045530   N/A   Pending
ICA-009   METHOD FOR ANALYSIS USING X-RAY FLUORESCENCE   United States   13/317,341   2012-0093286   9,063,066   Patented
ICA-009C1   METHOD FOR ANALYSIS USING X-RAY FLUORESCENCE   United States   14/715,206   2015-0276631   9,435,756   Patented
ICA-009C2   METHOD FOR ANALYSIS USING X-RAY FLUORESCENCE   United States   14/715,218   2015-0276632   9,442,085   Patented
ICA-009C3   METHOD FOR ANALYSIS USING X-RAY FLUORESCENCE   United States   14/715,233   2015-0260664   9,335,284   Patented
ICA-009C4   METHOD FOR ANALYSIS USING X-RAY FLUORESCENCE   United States   15/227,292   2016-0341678   N/A   Pending
ICA-010PC   METHODS AND APPARATUS FOR MEASURING METALS AND METALLOIDS   International   PCT/US17/28064   N/A   N/A   Pending

 

 

 

 

SCHEDULE IV

 

Pledged Entities

 

Icagen Corp.

 

XRpro Sciences, Inc.

 

Caldera Discovery, Inc.

 

 

 

 

 

 

 

 

 

 

 

 

 

SCHEDULE V

 

Trademark Licenses

 

None

 

 

 

 

 

 

 

 

 

 

 

 

SCHEDULE V(a)

 

Trademarks, Etc.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SCHEDULE VI

 

Commercial Tort Claims

 

None

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SCHEDULE VII

 

Legal Names, Organizational Identification Numbers; States or Jurisdiction of Organization

 

Grantor’s Name   State of Organization   Federal Employer I.D.   Organizational I.D.
Icagen, Inc. (formerly known as; Caldera Pharmaceuticals, Inc.; and XRpro Sciences, Inc.   Delaware North Carolina   #####   3723366
Icagen Corp. (formerly known as XRpro Corp.)   Nevada North Carolina     #####   NV20101523783
Caldera Discovery, Inc.   Delaware   #####   5717856
XRpro Sciences, Inc.    Delaware   #####   5904530
Icagen-T, Inc.   Delaware Arizona   #####   6070175

 

 

 

 

SCHEDULE VIII

 

Locations

 

Icagen Corp.

4222 Emperor Boulevard, Suite 350

Research Triangle Park

Durham, NC, 27703

 

Icagen-T, Inc.

2090 E. Innovation Park Drive

Tucson, AZ 85755

 

 

 

 

 

 

 

 

 

SCHEDULE IX

 

Securities Etc. of each Grantor

 

Securities

 

Grantor   Name of Issuer / Pledged Entity   Number of Shares   Class   Certificate No.(s)
Icagen, Inc.   Icagen Corp.   100,000   Common   C01
Icagen, Inc.   Caldera Discovery, Inc.   100   Common   C-01
Icagen, Inc.   XRpro Sciences, Inc   100   Common   C-01

 

Deposit Accounts, Securities Accounts and Commodities Accounts

 

Grantor   Name and Address of Institution   Purpose of the Account   Account No.
Icagen Inc.    #####    #####    #####
             
Icagen Inc.    #####    #####    #####
             
Icagen Inc.    #####    #####    #####
             
Icagen Corp.    #####    #####    #####
             
Icagen-T, Inc.    #####    #####    #####

 

Foreign Currency Controlled Accounts

 

None

 

 

 

 

SCHEDULE X

 

Licenses, Etc.

 

Radioactive Materials License

 

 

 

 

 

 

 

 

 

 

 

SCHEDULE XI

 

All Intellectual Property of Grantors

 

See Schedule 5(a) and 10

 

Reference   Title   Country   Application No.   Pub. No.   Patent No.   Status
ICA-001   METHOD FOR DETECTING BINDING EVENTS USING MICRO-X-RAY FLUORESCENCE SPECTROMETRY   United States   09/859,701   2003-0027129   7,858,385   Patented
ICA-002EP   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   Europe   3748920   1525458   1525458   Patented
ICA-002BE   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   Belgium   3748920   1525458   1525458   Patented
ICA-002CH   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   Switzerland   3748920   1525458   1525458   Patented
ICA-002DE   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   Germany   3748920   1525458   1525458   Patented
ICA-002DK   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   Denmark   3748920   1525458   1525458   Patented

 

 

 

 

Reference   Title   Country   Application No.   Pub. No.   Patent No.   Status
ICA-002ES   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   Spain   3748920   1525458   1525458   Patented
ICA-002FI   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   Finland   3748920   1525458   1525458   Patented
ICA-002FR   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   France   3748920   1525458   1525458   Patented
ICA-002GB   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   United Kingdom   3748920   1525458   1525458   Patented
ICA-002IT   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   Italy   3748920   1525458   1525458   Patented
ICA-002SE   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   Sweden   3748920   1525458   1525458   Patented
ICA-002NL   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   Netherlands   3748920   1525458   1525458   Patented

 

 

 

 

Reference   Title   Country   Application No.   Pub. No.   Patent No.   Status
ICA-002JP   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   Japan   2004-524531   2006-503268   4560403   Patented
ICA-002SG   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   Singapore   200500360-3   109345   109345   Patented
ICA-002C2   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   United States   11/444,660   2007-0003008   7,519,145   Patented
ICA-002C3   FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE   United States   12/396,592   2009-0175410   7,929,662   Patented
ICA-003EP   METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING   Europe   4755687.3   1644095   1644095   Patented
ICA-003CH   METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING   Switzerland/
Liechtenstein
  4755687.3   1644095   1644095   Patented
ICA-003DE   METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING   Germany   4755687.3   1644095   1644095   Patented

 

 

 

 

Reference   Title   Country   Application No.   Pub. No.   Patent No.   Status
ICA-003FR   METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING   France   4755687.3   1644095   1644095   Patented
ICA-003GB   METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING   United Kingdom   4755687.3   1644095   1644095   Patented
ICA-003IE   METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING   Ireland   4755687.3   1644095   1644095   Patented
ICA-003NL   METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING   Netherlands   4755687.3   1644095   1644095   Patented
ICA-003JP   METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING   Japan   2006-520181   2007527524   4782676   Patented
ICA-003SG   METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING   Singapore   2005085584       118682   Patented
ICA-003   METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING   United States   10/621,825   2005-0011818   6,858,148   Patented
ICA-003C1   METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING   United States   10/986,519   2005-0095636   7,241,381   Patented
ICA-004   DRUG DEVELOPMENT AND MANUFACTURING   United States   10/880,388   2004-0235059   9,157,875   Patented
ICA-005EP   X-RAY FLUORESCENCE ANALYSIS METHOD   Europe   7874491.9   2084519   2084519   Patented

 

 

 

 

Reference   Title   Country   Application No.   Pub. No.   Patent No.   Status
ICA-005CH   X-RAY FLUORESCENCE ANALYSIS METHOD   Switzerland/
Liechtenstein
  07 874 491.9   2084519   2084519   Patented
ICA-005DE   X-RAY FLUORESCENCE ANALYSIS METHOD   Germany   60 2007 024 468.4   2084519   608007024468.4   Patented
ICA-005DK   X-RAY FLUORESCENCE ANALYSIS METHOD   Denmark   07 874 491.9   2084519   2084519   Patented
ICA-005FR1   X-RAY FLUORESCENCE ANALYSIS METHOD   France   07 874 491.9   2084519   2084519   Patented
ICA-005GB   X-RAY FLUORESCENCE ANALYSIS METHOD   United Kingdom   7874491.9   2084519   2084519   Patented
ICA-005HK   ADVANCED DRUG DEVELOPMENT AND MANUFACTURING   Hong Kong (via EP -005EPDV)   13104259.3   1177280   1177280   Patented
ICA-005IE   X-RAY FLUORESCENCE ANALYSIS METHOD   Ireland   7874491.9   1177280   2084519   Patented
ICA-005IT   X-RAY FLUORESCENCE ANALYSIS METHOD   Italy   7874491.9   1177280   2084519   Patented
ICA-005NL   X-RAY FLUORESCENCE ANALYSIS METHOD   Netherlands   7874491.9   1177280   2084519   Patented
ICA-005SE   X-RAY FLUORESCENCE ANALYSIS METHOD   Sweden   7874491.9   1177280   2084519   Patented
ICA-005EPDV   X-RAY MICROSCOPE   Europe   12164870.3   2511844   2511844   Patented
ICA-005CHDV   X-RAY MICROSCOPE   Switzerland and Lichtenstein   12164870.3   2511844   2511844   Patented
ICA-005DEDV   X-RAY MICROSCOPE   Germany   12164870.3   2511844   602007042616.2   Patented

 

 

 

 

Reference   Title   Country   Application No.   Pub. No.   Patent No.   Status
ICA-005FRDV   X-RAY MICROSCOPE   France   12164870.3   2511844   2511844   Patented
ICA-005GBDV   X-RAY MICROSCOPE   United Kingdom   12164870.3   2511844   2511844   Patented
ICA-005HK   ADVANCED DRUG DEVELOPMENT AND MANUFACTURING   Hong Kong (via EP -005EPDV)   2013104259.3   1177280   1177280   Patented
ICA-005IEDV   X-RAY MICROSCOPE   Ireland   12164870.3   2511844   2511844   Patented
ICA-005JP   ADVANCED DRUG DEVELOPMENT AND MANUFACTURING   Japan   2009-532446   2010509566   5143841   Patented
ICA-005JPDV2   ADVANCED DRUG DEVELOPMENT AND MANUFACTURING   Japan   2014-123249   2014-123249   5913441   Patented
ICA-005C1   ADVANCED DRUG DEVELOPMENT AND MANUFACTURING   United States   14/693,094   2015-0309021   N/A   Pending
ICA-006EP   WELL PLATE   Europe   8798006.6   2183644   2183644   Patented
ICA-006BE   WELL PLATE   Belgium   8798007.6   2183644   2183644   Patented
ICA-006CH   WELL PLATE   Switzerland   8798008.6   2183644   2183644   Patented
ICA-006DE   WELL PLATE   Germany   8798009.6   2183644   602008044640.9   Patented
ICA-006DK   WELL PLATE   Denmark   8798010.6   2183644   2183644   Patented
ICA-006ES   WELL PLATE   Spain   8798011.6   2183644   2183644   Patented
ICA-006FI   WELL PLATE   Finland   8798012.6   2183644   2183644   Patented
ICA-006FR   WELL PLATE   France   8798013.6   2183644   2183644   Patented
ICA-006GB   WELL PLATE   United Kingdom   8798014.6   2183644   2183644   Patented
ICA-006IE   WELL PLATE   Ireland   8798015.6   2183644   2183644   Patented
ICA-006IT   WELL PLATE   Italy   8798016.6   2183644   2183644   Patented
ICA-006 NL   WELL PLATE   Netherlands   8798017.6   2183644   2183644   Patented

 

 

 

 

Reference   Title   Country   Application No.   Pub. No.   Patent No.   Status
ICA-006NO   WELL PLATE   Norway   8798018.6   2183644   2183644   Patented
ICA-006SE   WELL PLATE   Sweden   8798019.6   2183644   2183644   Patented
ICA-006JP   WELL PLATE   Japan   2010-521206   2010537171   5628035   Patented
ICA-006JPDV   WELL PLATE   Japan   2013-117600   2013224946   5755682   Patented
ICA-006JPDV2   WELL PLATE   Japan   2014-202871   2015004692   6076308   Patented
ICA-006   WELL PLATE   United States   12/192,762   2009-0046832   8,238,515   Patented
ICA-006C1   WELL PLATE   United States   13/567,613   2013-0034205   8,873,707   Patented
ICA-006C2   WELL PLATE   United States   14/508,322   2015-0023467   9,476,846   Patented
ICA-006C3   WELL PLATE   United States   15/273,767   2017-0010228   N/A   Pending
ICA-007JP   METHOD AND APPARATUS FOR MEASURING PROTEIN POST-TRANSLATIONAL MODIFICATION   Japan   2010-5272   2010539944   5743135   Patented
ICA-007JPDV1   METHOD AND APPARATUS FOR MEASURING PROTEIN POST-TRANSLATIONAL MODIFICATION   Japan   2014-221166   2015033386   N/A   Pending
ICA-007C1/XR7-US2   METHOD AND APPARATUS FOR MEASURING PROTEIN POST-TRANSLATIONAL MODIFICATION   United States   15/052,914   2016-0201111   N/A   Pending

 

 

 

 

Reference   Title   Country   Application No.   Pub. No.   Patent No.   Status
ICA-008CN   METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS   China   200980125952.3   102083365   ZL 200980125952.3   Patented
ICA-008CNDV   METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS   China   201310298029.8   103411988   2077368   Patented
ICA-008CNDV2   METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS   China   201510083796.6   N/A   N/A   Pending
ICA-008EP   METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS   Europe   09774467.6   2306897   N/A   Allowed
ICA-008HK   METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS   Hong Kong   11112984.0   1158478   1158478   Patented
ICA-008   METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS USING X-RAY FLUORESCENCE   United States   12/496,532   2010-0003697   8,431,357   Patented
ICA-008C1   METHOD FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS USING X-RAY FLUORESCENCE USING X-RAY FLUORESCENCE   United States   13/871,697   2013-0236887   9,063,154   Patented

 

 

 

 

Reference   Title   Country   Application No.   Pub. No.   Patent No.   Status
ICA-008C2   METHOD FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS USING X-RAY FLUORESCENCE   United States   14/669,923   2015-0198615   9,506,931   Patented
ICA-008C3   METHOD FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS USING X-RAY FLUORESCENCE   United States   15/334,854   2017-0045530   N/A   Pending
ICA-009   METHOD FOR ANALYSIS USING X-RAY FLUORESCENCE   United States   13/317,341   2012-0093286   9,063,066   Patented
ICA-009C1   METHOD FOR ANALYSIS USING X-RAY FLUORESCENCE   United States   14/715,206   2015-0276631   9,435,756   Patented
ICA-009C2   METHOD FOR ANALYSIS USING X-RAY FLUORESCENCE   United States   14/715,218   2015-0276632   9,442,085   Patented
ICA-009C3   METHOD FOR ANALYSIS USING X-RAY FLUORESCENCE   United States   14/715,233   2015-0260664   9,335,284   Patented
ICA-009C4   METHOD FOR ANALYSIS USING X-RAY FLUORESCENCE   United States   15/227,292   2016-0341678   N/A   Pending
ICA-010PC   METHODS AND APPARATUS FOR MEASURING METALS AND METALLOIDS   International   PCT/US17/28064   N/A   N/A   Pending

 

 

 

 

SCHEDULE XII

 

Pledged Collateral

 

Icagen, Inc. Delaware Secretary of State - U.S. Bank Equipment Finance-Equipment
   

Icagen-T, Inc.

Arizona, Pima County-Sanofi U.S. Services Inc-buildings, improvements and fixtures, rents, leases, issues, profits or income on property located in Pima County.
   

Icagen-T, Inc.

Arizona Secretary of State-Sanofi U.S. Services Inc.-chemical libraries and equipment and movable assets owned by Sanofi U.S. Services Inc.
   

Icagen-T, Inc.

Delaware Secretary of State - Sanofi U.S. Services Inc.-chemical libraries and equipment and movable assets owned by Sanofi U.S. Services Inc.
   

Icagen-T, Inc.

Deed of Trust and Assignment of Rents
   

Icagen-T, Inc.

Deed of Sale

 

 

 

 

SCHEDULE XIII

 

[RESERVED]

 

 

 

 

 

 

 

 

 

 

 

 

SCHEDULE XIV

 

[RESERVED]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SCHEDULE XV

 

Pledged Equity

 

Icagen Inc. Icagen Corp. 100,000 common shares C01
       
  XRpro Sciences, Inc. 1,000 common shares C-01
       
  Caldera Discovery, Inc. 100 common shares C-01

 

 

 

 

 

SCHEDULE XVI

 

Locations of Collateral

 

Icagen Inc.

4222 Emperor Boulevard, Suite 350

Research Triangle Park

Durham, NC, 27703

 

Icagen Corp.

4222 Emperor Boulevard, Suite 350

Research Triangle Park

Durham, NC, 27703

 

Icagen-T, Inc.

2090 E Innovation Park Drive

Tucson, AZ 85755

 

 

 

 

 

SCHEDULE XVII

 

Licenses, Etc.

 

None

 

 

 

 

Schedule XVIII

 

Notices. Etc. Re: Exercise of Rights by certain parties under Licenses

 

None

 

 

 

 

 

 

SCHEDULE XIX

 

No Termination Etc. of Licenses

 

None

 

 

 

 

Exhibit 10.4

 

Execution Version

 

GUARANTY OF OBLIGATIONS OF PARENT

 

This GUARANTY, dated as of May 15, 2017 (this “ Guaranty ”), is made by each of the undersigned (each a “ Guarantor ”, and collectively, the “ Guarantors ”), in favor of GPB Debt Holdings II, LLC, a Delaware limited liability company, in its capacity as collateral agent (in such capacity, the “ Collateral Agent ” as hereinafter further defined) for the “Buyer” party to the Securities Purchase Agreement (each as defined below).

 

W I T N E S S E T H :

 

WHEREAS, Icagen, Inc., a Delaware corporation with its executive offices located at 4222 Emperor Blvd., Suite 350, Research Triangle Park, Durham, NC, 27703 (the “ Parent ”), Icagen-T, Inc., a Delaware corporation and a wholly-owned Subsidiary of the Parent with its executive offices located at 2090 E. Innovation Park Drive, Oro Valley, Arizona 85755 (“ ICA-T ”) and GPB Debt Holdings II, LLC, in its capacity as an investor (the “ Buyer ”) are parties to the Securities Purchase Agreement, dated as of May 15, 2017 (as amended, restated, extended, replaced or otherwise modified from time to time and together with all amendments, supplements and exhibits thereto, collectively, the “ Securities Purchase Agreement ”), pursuant to which, among other actions set forth therein, (i) ICA-T shall be required to sell an $8,000,000 aggregate principal amount senior secured note of ICA-T (as such may be amended, restated, extended, replaced or otherwise modified from time to time in accordance with the terms thereof, the “ ICA-T Note ”) and (ii) the Parent shall be required to sell a $2,000,000 aggregate principal amount aggregate principal amount senior secured note of the Parent (as such may be amended, restated, extended, replaced or otherwise modified from time to time in accordance with the terms thereof, the “ Parent Note ” and together with the ICA-T Note, collectively, the “ Notes ”) to the Buyer and the Buyer shall have the right to purchase the Notes;

 

WHEREAS, the Securities Purchase Agreement requires that the Guarantors execute and deliver to the Collateral Agent simultaneously with the execution of the Securities Purchase Agreement (i) a guaranty guaranteeing all of the obligations of the Parent, ICA-T and the Subsidiaries under the Securities Purchase Agreement, the Parent Note, the ICA-T Note and the other Transaction Documents (as defined below); and (ii) a Security and Pledge Agreement, dated as of the date hereof, granting the Collateral Agent for the benefit of the Noteholders a lien on and security interest in all of their assets and properties (the “ Security Agreement ”); and

 

WHEREAS, each Guarantor has determined that the execution, delivery and performance of this Guaranty directly benefits, and is in the best interest of, such Guarantor and that the Buyer would not have entered into the Securities Purchase Agreement and the other Transaction Documents and/or taken the actions required of it under such documents including purchasing the Notes if the Guarantor had executed and delivered this Guaranty.

 

   

 

 

NOW, THEREFORE, in consideration of the premises and the agreements herein and in order to induce the Buyer to perform under the Securities Purchase Agreement, each Guarantor hereby agrees with the Buyer as follows:

 

SECTION 1. Definitions . Reference is hereby made to the Securities Purchase Agreement and the Notes for a statement of the terms thereof. All terms used in this Guaranty and the recitals hereto which are defined in the Securities Purchase Agreement or the Notes, and which are not otherwise defined herein shall have the same meanings herein as set forth therein. In addition, the following terms when used in the Guaranty shall have the meanings set forth below:

 

Bankruptcy Code ” means Chapter 11 of Title 11 of the United States Code, 11 U.S.C §§ 101 et seq. (or other applicable bankruptcy, insolvency or similar laws).

 

Business Day ” means any day other than Saturday, Sunday or other day on which commercial banks in New York City are authorized or required by law to remain closed.

 

Buyer ” shall have the meaning set forth in the recitals hereto.

 

Capital Stock ” means (i) with respect to any Person that is a corporation, any and all shares, interests, participations or other equivalents (however designated and whether or not voting) of corporate stock (including, without limitation, any warrants, options, rights or other securities exercisable or convertible into equity interests or securities of such Person), and (ii) with respect to any Person that is not a corporation, any and all partnership, membership or other equity interests of such Person.

 

“Collateral” means all assets and properties of the Parent and each other Guarantor, wherever located and whether now or hereafter existing and whether now owned or hereafter acquired, of every kind and description, tangible or intangible, including, without limitation, the collateral described in Section 2 of the Security Agreement.

 

Collateral Agent ” shall have the meaning set forth in the recitals hereto.

 

Governmental Authority ” means any nation or government, any Federal, state, city, town, municipality, county, local, foreign or other political subdivision thereof or thereto and any department, commission, board, bureau, instrumentality, agency or other entity exercising executive, legislative, judicial, taxing, regulatory or administrative powers or functions of or pertaining to government.

 

Guaranteed Obligations ” shall have the meaning set forth in Section 2 of this Guaranty.

 

Guarantor ” or “ Guarantors ” shall have the meaning set forth in the first paragraph of this Guaranty.

 

ICA-T Note ” shall have the meaning set forth in the recitals hereto.

 

Indemnified Party ” shall have the meaning set forth in Section 13(a) of this Guaranty

 

Insolvency Proceeding ” means any proceeding commenced by or against any Person under any provision of the Bankruptcy Code or under any other bankruptcy or insolvency law, assignments for the benefit of creditors, formal or informal moratoria, compositions, or extensions generally with creditors, or proceedings seeking reorganization, arrangement, or other similar relief.

 

  2  

 

 

Noteholders ” means the Buyer and any other holder of all or any portion of the ICA-T Note.

 

Obligations ” shall have the meaning set forth in Section 3 of the Security Agreement.

 

Other Taxes ” shall have the meaning set forth in Section 12(a)(iv) of this Guaranty.

 

Paid in Full” or “Payment in Full ” means the indefeasible payment in full in cash (and/or through the issuance of Parent Common Stock (as defined in the Notes) but solely to the extent, in accordance with and pursuant to the terms of the Notes) of all of the Guaranteed Obligations.

 

Parent ” shall have the meaning set forth in the recitals hereto.

 

Person ” means an individual, corporation, limited liability company, partnership, association, joint-stock company, trust, unincorporated organization, joint venture or other enterprise or entity or Governmental Authority.

 

Securities Purchase Agreement ” shall have the meaning set forth in the recitals hereto.

 

Security Agreement ” shall have the meaning set forth in the recitals hereto.

 

Subsidiary” means any Person in which a Guarantor directly or indirectly (i) owns a majority of the outstanding Capital Stock, voting stock or holds any equity or similar interest of such Person including, but not limited to, any Subsidiary of ICA-T or (ii) controls or operates a substantial portion of the business, operations or administration of such Person including, but not limited to, any Subsidiary of ICA-T, and all of the foregoing, collectively, “ Subsidiaries ”.

 

Taxes ” shall have the meaning set forth in Section 12(a) of this Guaranty.

 

Transaction Party ” means the Parent, ICA-T and each other Guarantor, collectively, “ Transaction Parties ”.

 

SECTION 2. Guaranty .

 

(a)       The Guarantors, jointly and severally, hereby unconditionally and irrevocably, guaranty to the Collateral Agent, for the benefit of the Collateral Agent, the Buyer and any other Noteholder the punctual payment, as and when due and payable, by stated maturity, acceleration or otherwise, of all Obligations of including, without limitation, all interest, make-whole, redemption and other amounts that accrue after the commencement of any Insolvency Proceeding of the Parent, ICA-T or any Guarantor, whether or not the payment of such principal, interest, make-whole, redemption and/or other amounts are enforceable or are allowable in such Insolvency Proceeding, and all fees, Late Charges (as defined in the Notes), interest, premiums, penalties, causes of actions, costs, commissions, expense reimbursements, indemnifications and all other amounts due or to become due under the Notes and the other Transaction Documents and (all of the foregoing collectively being the “ Guaranteed Obligations ”), and agree to pay any and all costs and expenses (including reasonable and documented counsel fees and expenses) incurred by the Collateral Agent in enforcing any rights under this Guaranty or any other Transaction Document. Without limiting the generality of the foregoing, each Guarantor’s liability hereunder shall extend to all amounts that constitute part of the Guaranteed Obligations and would be owed by the Parent, ICA-T or any Guarantor to the Collateral Agent or the Buyer under the Securities Purchase Agreement, the Notes and any other Transaction Document but for the fact that they are unenforceable or not allowable due to the existence of an Insolvency Proceeding involving any Transaction Party.

 

  3  

 

 

(b)       Each Guarantor, and by its acceptance of this Guaranty, the Collateral Agent and the Buyer, hereby confirms that it is the intention of all such Persons that this Guaranty and the Guaranteed Obligations of each Guarantor hereunder not constitute a fraudulent transfer or conveyance for purposes of the Bankruptcy Code, the Uniform Fraudulent Conveyance Act, the Uniform Fraudulent Transfer Act or any similar foreign, federal, provincial, state, or other applicable law to the extent applicable to this Guaranty and the Guaranteed Obligations of each Guarantor hereunder. To effectuate the foregoing intention, the Collateral Agent, the Buyer and the Guarantors hereby irrevocably agree that the Guaranteed Obligations of each Guarantor under this Guaranty at any time shall be limited to the maximum amount as will result in the Guaranteed Obligations of such Guarantor under this Guaranty not constituting a fraudulent transfer or conveyance.

 

SECTION 3. Guaranty Absolute; Continuing Guaranty; Assignments .

 

(a)       The Guarantors, jointly and severally, guaranty that the Guaranteed Obligations will be paid strictly in accordance with the terms of the Notes and the other Transaction Documents, regardless of any law, regulation or order now or hereafter in effect in any jurisdiction affecting any of such terms or the rights of the Collateral Agent, the Buyer and/or any other Noteholder with respect thereto. The obligations of each Guarantor under this Guaranty are independent of the Guaranteed Obligations, and a separate action or actions may be brought and prosecuted against any Guarantor to enforce such obligations, irrespective of whether any action is brought against any Transaction Party or whether any Transaction Party is joined in any such action or actions. The liability of any Guarantor under this Guaranty shall be as a primary obligor (and not merely as a surety) and shall be irrevocable, absolute and unconditional irrespective of, and each Guarantor hereby irrevocably waives, to the maximum extent permitted by law, any defenses it may now or hereafter have in any way relating to, any or all of the following:

 

(i)         any lack of validity or enforceability of the Notes and/or any other Transaction Document;

 

(ii)        any change in the time, manner or place of payment of, or in any other term of, all or any of the Guaranteed Obligations, or any other amendment or waiver of or any consent to departure from any Transaction Document, including, without limitation, any increase in the Guaranteed Obligations resulting from the extension of additional credit to any Transaction Party or extension of the maturity of any Guaranteed Obligations or otherwise;

 

(iii)       any taking, exchange, release or non-perfection of any Collateral;

 

  4  

 

 

(iv)       any taking, release or amendment or waiver of or consent to departure from any other guaranty, for all or any of the Guaranteed Obligations;

 

(v)        any change, restructuring or termination of the corporate, limited liability company or partnership structure or existence of any Transaction Party;

 

(vi)       any manner of application of Collateral or any other collateral, or proceeds thereof, to all or any of the Guaranteed Obligations, or any manner of sale or other disposition of any Collateral or any other collateral for all or any of the Guaranteed Obligations or any other Obligations of any Transaction Party under the Transaction Documents or any other assets of any Transaction Party or any of its Subsidiaries;

 

(vii)      any failure of the Collateral Agent, the Buyer and/or any other Noteholder to disclose to any Transaction Party any information relating to the business, condition (financial or otherwise), operations, performance, properties or prospects of any other Transaction Party now or hereafter known to the Collateral Agent, the Buyer and/or any other Noteholder (each Guarantor waiving any duty on the part of the Collateral Agent, the Buyer and/or any other Noteholder to disclose such information);

 

(viii)     taking any action in furtherance of the release of any Guarantor or any other Person that is liable for the Obligations from all or any part of any liability arising under or in connection with any Transaction Document without the prior written consent of the Collateral Agent; or

 

(ix)        any other circumstance (including, without limitation, any statute of limitations) or any existence of or reliance on any representation by the Collateral Agent, the Buyer and/or any other Noteholder that might otherwise constitute a defense available to, or a discharge of, any Transaction Party or any other guarantor or surety.

 

(b)       This Guaranty shall continue to be effective or be reinstated, as the case may be, if at any time any payment of any of the Guaranteed Obligations is rescinded or must otherwise be returned by the Collateral Agent, the Buyer, any other Noteholder and/or any other Person upon the insolvency, bankruptcy or reorganization of any Transaction Party or otherwise, all as though such payment had not been made.

 

(c)       This Guaranty is a continuing guaranty and shall (i) remain in full force and effect until Payment in Full of the Guaranteed Obligations (other than inchoate indemnity obligations) and shall not terminate for any reason prior to the Maturity Date of the Notes (other than Payment in Full of the Guaranteed Obligations), and (ii) be binding upon each Guarantor and its respective successors and assigns. This Guaranty shall inure to the benefit of and be enforceable by the Collateral Agent, the Buyer and/or any other Noteholder and their respective successors, and permitted pledgees, transferees and assigns. Without limiting the generality of the foregoing sentence, the Collateral Agent, the Buyer and/or any other Noteholder may pledge, assign or otherwise transfer all or any portion of its rights, remedies and obligations under and subject to the terms of any Transaction Document to any other Person [other than to the Buyer Affiliate] [(as defined in the Securities Purchase Agreement)] and such other Person shall thereupon become vested with all the benefits in respect thereof granted to the Collateral Agent, the Buyer and/or any other Noteholder (as applicable) herein or otherwise, in each case as provided in the Securities Purchase Agreement or such other Transaction Document.

 

  5  

 

 

SECTION 4. Waivers . To the extent permitted by applicable law, each Guarantor hereby waives promptness, diligence, protest, notice of acceptance and any other notice or formality of any kind with respect to any of the Guaranteed Obligations and this Guaranty and any requirement that the Collateral Agent exhaust any right or take any action against any Transaction Party or any other Person or any Collateral. Each Guarantor acknowledges that it will receive direct and indirect benefits from the financing arrangements contemplated herein and that the waiver set forth in this Section 4 is knowingly made in contemplation of such benefits. The Guarantors hereby waive any right to revoke this Guaranty, and acknowledge that this Guaranty is continuing in nature and applies to all Guaranteed Obligations, whether existing now or in the future. Without limiting the foregoing, to the extent permitted by applicable law, each Guarantor hereby unconditionally and irrevocably waives (a) any defense arising by reason of any claim or defense based upon an election of remedies by the Collateral Agent or the Buyer that in any manner impairs, reduces, releases or otherwise adversely affects the subrogation, reimbursement, exoneration, contribution or indemnification rights of such Guarantor or other rights of such Guarantor to proceed against any of the other Transaction Parties, any other guarantor or any other Person or any Collateral, and (b) any defense based on any right of set-off or counterclaim against or in respect of the Guaranteed Obligations of such Guarantor hereunder. Each Guarantor hereby unconditionally and irrevocably waives any duty on the part of the Collateral Agent, the Buyer and/or any other Noteholder to disclose to such Guarantor any matter, fact or thing relating to the business, condition (financial or otherwise), operations, performance, properties or prospects of any other Transaction Party or any of its Subsidiaries now or hereafter known by the Collateral Agent, the Buyer and/or any other Noteholder.

 

SECTION 5. Subrogation . No Guarantor may exercise any rights that it may now or hereafter acquire against any Transaction Party or any other Guarantor and/or guarantor that arise from the existence, payment, performance or enforcement of any Guarantor’s obligations under this Guaranty, including, without limitation, any right of subrogation, reimbursement, exoneration, contribution or indemnification and any right to participate in any claim or remedy of the Collateral Agent, the Buyer and/or any other Noteholder against any Transaction Party or any other guarantor or any Collateral, whether or not such claim, remedy or right arises in equity or under contract, statute or common law, including, without limitation, the right to take or receive from any Transaction Party or any other guarantor, directly or indirectly, in cash or other property or by set-off or in any other manner, payment or security solely on account of such claim, remedy or right, unless and until there has been Payment in Full of the Guaranteed Obligations. If any amount shall be paid to a Guarantor in violation of the immediately preceding sentence at any time prior to Payment in Full of the Guaranteed Obligations and all other amounts payable under this Guaranty, such amount shall be held in trust for the benefit of the Collateral Agent and shall forthwith be paid to the Collateral Agent to be credited and applied to the Guaranteed Obligations and all other amounts payable under this Guaranty, whether matured or un-matured, in accordance with the terms of the Transaction Document, or to be held as Collateral for any Guaranteed Obligations or other amounts payable under this Guaranty thereafter arising. If (a) any Guarantor shall make payment to the Collateral Agent of all or any part of the Guaranteed Obligations, and (b) there has been Payment in Full of the Guaranteed Obligations, the Collateral Agent will, at such Guarantor’s request and expense, execute and deliver to such Guarantor appropriate documents to evidence payment in Full of the Guaranteed Obligations without recourse and without representation or warranty, necessary to evidence the transfer by subrogation to such Guarantor of an interest in the Guaranteed Obligations resulting from such payment by such Guarantor.

 

  6  

 

 

SECTION 6. Representations, Warranties and Covenants .

 

(a)       Each Guarantor hereby represents and warrants as of the date first written above as follows:

 

(i)         such Guarantor (A) is a corporation, limited liability company or limited partnership duly organized, validly existing and in good standing under the laws of the jurisdiction of its organization as set forth on the signature pages hereto, (B) has all requisite corporate, limited liability company or limited partnership power and authority to conduct its business as now conducted and as presently contemplated and to execute, deliver and perform its obligations under this Guaranty and each other Transaction Document to which such Guarantor is a party, and to consummate the transactions contemplated hereby and thereby and (C) is duly qualified to do business and is in good standing in each jurisdiction in which the character of the properties owned or leased by it or in which the transaction of its business makes such qualification necessary except where the failure to be so qualified (individually or in the aggregate) would not result in a Material Adverse Effect.

 

(ii)        The execution, delivery and performance by such Guarantor of this Guaranty and each other Transaction Document to which such Guarantor is a party (A) have been duly authorized by all necessary corporate, limited liability company or limited partnership action, (B) do not and will not contravene its charter, articles, certificate of formation or by-laws, its limited liability company or operating agreement or its certificate of partnership or partnership agreement, as applicable, or any applicable law or any contractual restriction binding on such Guarantor or its properties do not and will not result in or require the creation of any lien, security interest or encumbrance (other than pursuant to any Transaction Document) upon or with respect to any of its properties, and (C) do not and will not result in any default, noncompliance, suspension, revocation, impairment, forfeiture or nonrenewal of any material permit, license, authorization or approval applicable to it or its operations or any of its properties.

 

(iii)       No authorization or approval or other action by, and no notice to or filing with, any Governmental Authority or other Person is required in connection with the due execution, delivery and performance by such Guarantor of this Guaranty or any of the other Transaction Documents to which such Guarantor is a party (other than expressly provided for in any of the Transaction Documents).

 

  7  

 

 

(iv)       This Guaranty has been duly executed and delivered by each Guarantor and is, and each of the other Transaction Documents to which such Guarantor is or will be a party, when executed and delivered, will be, a legal, valid and binding obligation of such Guarantor, enforceable against such Guarantor in accordance with its terms, except as may be limited by the Bankruptcy Code or other applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, suretyship or similar laws and equitable principles (regardless of whether enforcement is sought in equity or at law).

 

(v)       There is no pending or, to the knowledge of such Guarantor, threatened action, suit or proceeding against such Guarantor or to which any of the properties of such Guarantor is subject, before any court or other Governmental Authority or any arbitrator that (A) if adversely determined, could reasonably be expected to have a Material Adverse Effect or (B) relates to this Guaranty or any of the other Transaction Documents to which such Guarantor is a party or any transaction contemplated hereby or thereby.

 

(vi)       Such Guarantor (A) has read and understands the terms and conditions of the Securities Purchase Agreement and the other Transaction Documents, and (B) now has and will continue to have independent means of obtaining information concerning the affairs, financial condition and business of the Parent and the other Transaction Parties, and has no need of, or right to obtain from the Collateral Agent or the Buyer, any credit or other information concerning the affairs, financial condition or business of the Parent or the other Transaction Parties.

 

(vii)      There are no conditions precedent to the effectiveness of this Guaranty that have not been satisfied or waived.

 

(b)       Each Guarantor covenants and agrees that until Payment in Full of the Guaranteed Obligations, it will comply with each of the covenants which are set forth in Section 4 of the Securities Purchase Agreement as if such Guarantor were a party thereto.

 

SECTION 7. Right of Set-off . Upon the occurrence and during the continuance of any Event of Default, the Collateral Agent, the Buyer and/or any other Noteholder may, and is hereby authorized to, at any time and from time to time, without notice to the Guarantors (any such notice being expressly waived by each Guarantor) and to the fullest extent permitted by law, set-off and apply any and all deposits (general or special, time or demand, provisional or final) at any time held and other indebtedness at any time owing by the Collateral Agent, the Buyer and/or any other Noteholder to or for the credit or the account of any Guarantor against any and all obligations of the Guarantors now or hereafter existing under this Guaranty or any other Transaction Document, irrespective of whether or not the Collateral Agent, the Buyer and/or any other Noteholder shall have made any demand under this Guaranty or any other Transaction Document and although such obligations may be contingent or unmatured. The Collateral Agent, the Buyer and/or any other Noteholder agrees to notify the relevant Guarantor promptly after any such set-off and application made by the Collateral Agent or the Buyer, provided that the failure to give such notice shall not affect the validity of such set-off and application. The rights of the Collateral Agent, the Buyer and/or any other Noteholder under this Section 7 are in addition to other rights and remedies (including, without limitation, other rights of set-off) which the Collateral Agent, the Buyer and/or any other Noteholder may have under this Guaranty or any other Transaction Document in law or otherwise.

 

  8  

 

 

SECTION 8. Limitation on Guaranteed Obligations.

 

(a)       Notwithstanding any provision herein contained to the contrary, each Guarantor’s liability hereunder shall be limited to an amount not to exceed as of any date of determination the greater of:

 

(i)         the amount of all Guaranteed Obligations, plus interest thereon at the applicable Interest Rate as specified in the Notes; and

 

(ii)        the amount which could be claimed by the Collateral Agent from any Guarantor under this Guaranty without rendering such claim voidable or avoidable under the Bankruptcy Code or under any applicable state Uniform Fraudulent Transfer Act, Uniform Fraudulent Conveyance Act or similar statute or common law after taking into account, among other things, Guarantor’s right of contribution and indemnification.

 

(b)       Each Guarantor agrees that the Guaranteed Obligations may at any time and from time to time exceed the amount of the liability of such Guarantor hereunder without impairing the guaranty hereunder or affecting the rights and remedies of the Collateral Agent, the Buyer and/or any other Noteholder hereunder or under applicable law.

 

(c)       No payment made by ICA-T, any Guarantor, any other guarantor or any other Person or received or collected by the Collateral Agent, the Buyer and/or any other Noteholder from ICA-T, any of the Guarantors, any other guarantor or any other Person by virtue of any action or proceeding or any set-off or appropriation or application at any time or from time to time in reduction of or in payment of the Guaranteed Obligations shall be deemed to modify, reduce, release or otherwise affect the liability of any Guarantor hereunder which shall, notwithstanding any such payment (other than any payment made by such Guarantor in respect of the Guaranteed Obligations or any payment received or collected from such Guarantor in respect of the Guaranteed Obligations), remain liable for the Guaranteed Obligations up to the maximum liability of such Guarantor hereunder until after all of the Guaranteed Obligations and all other amounts payable under this Guaranty shall have been Paid in Full.

 

SECTION 9. Notices, Etc . Any notices, consents, waivers or other communications required or permitted to be given under the terms of this Guaranty must be in writing and will be deemed to have been delivered: (i) upon receipt, when delivered personally; (ii) upon receipt, when sent by facsimile or email (provided confirmation of transmission is mechanically or electronically generated or, in the case of email with a read receipt generated and kept on file by the sending party); or (iii) one (1) Business Day after deposit with a nationally recognized overnight courier service with next day delivery specified, in each case, properly addressed to the party to receive the same. All notices and other communications provided for hereunder shall be sent, if to any Guarantor, to the Parent’s address and/or facsimile number, or if to the Collateral Agent, the Buyer and/or any other Noteholder, to it at its respective address and/or facsimile number, each as set forth in Section 9(f) of the Securities Purchase Agreement.

 

  9  

 

 

SECTION 10. Governing Law; Jurisdiction . All questions concerning the construction, validity, enforcement and interpretation of this Guaranty shall be governed by the internal laws of the State of New York, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of New York or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of New York. Each Guarantor hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in The City of New York, Borough of Manhattan, for the adjudication of any dispute hereunder or in connection herewith or under any of the other Transaction Documents or with any transaction contemplated hereby or thereby, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim, obligation or defense that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof to such party at the address for such notices to it under Section 9(f) of the Securities Purchase Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. Nothing contained herein shall be deemed or operate to preclude the Collateral Agent or the Buyer from bringing suit or taking other legal action against any Guarantor in any other jurisdiction to collect on a Guarantor’s obligations or to enforce a judgment or other court ruling in favor of the Collateral Agent or the Buyer. 

 

SECTION 11. WAIVER OF JURY TRIAL, ETC . EACH GUARANTOR HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR UNDER ANY OTHER TRANSACTION DOCUMENT OR IN CONNECTION WITH OR ARISING OUT OF THIS GUARANTY, ANY OTHER TRANSACTION DOCUMENT OR ANY TRANSACTION CONTEMPLATED HEREBY OR THEREBY.

 

SECTION 12. Taxes .

 

(a)       All payments made by any Guarantor hereunder or under any other Transaction Document shall be made in accordance with the terms of the respective Transaction Document and shall be made without set-off, counterclaim, withholding, deduction or other defense. Without limiting the foregoing, all such payments shall be made free and clear of and without deduction or withholding for any present or future taxes, levies, imposts, deductions, charges or withholdings, and all liabilities with respect thereto, excluding taxes imposed on the net income of the Collateral Agent, the Buyer and/or any other Noteholder by the jurisdiction in which the Collateral Agent, the Buyer and/or any other Noteholder is organized or where it has its principal lending office (all such non-excluded taxes, levies, imposts, deductions, charges, withholdings and liabilities, collectively or individually, “ Taxes ”). If any Guarantor shall be required to deduct or to withhold any Taxes from or in respect of any amount payable hereunder or under any other Transaction Document:

 

(i)         the amount so payable shall be increased to the extent necessary so that after making all required deductions and withholdings (including Taxes on amounts payable to the Collateral Agent or the Buyer pursuant to this sentence) the Collateral Agent or the Buyer receives an amount equal to the sum it would have received had no such deduction or withholding been made,

 

  10  

 

 

(ii)        such Guarantor shall make such deduction or withholding,

 

(iii)       such Guarantor shall pay the full amount deducted or withheld to the relevant Governmental Authority in accordance with applicable law, and

 

(iv)       as promptly as possible thereafter, such Guarantor shall send the Collateral Agent or the Buyer an official receipt (or, if an official receipt is not available, such other documentation as shall be satisfactory to the Collateral Agent, as the case may be) showing payment. In addition, each Guarantor agrees to pay any present or future stamp or documentary taxes or any other excise or property taxes, charges or similar levies that arise from any payment made hereunder or from the execution, delivery, registration or enforcement of, or otherwise with respect to, this Guaranty or any other Transaction Document (collectively, “ Other Taxes ”).

 

(b)       Each Guarantor hereby indemnifies and agrees to hold each Indemnified Party harmless from and against Taxes or Other Taxes (including, without limitation, any Taxes or Other Taxes imposed by any jurisdiction on amounts payable under this Section 12 ) paid by any Indemnified Party as a result of any payment made hereunder or from the execution, delivery, registration or enforcement of, or otherwise with respect to, this Guaranty or any other Transaction Document, and any liability (including penalties, interest and expenses for nonpayment, late payment or otherwise) arising therefrom or with respect thereto, whether or not such Taxes or Other Taxes were correctly or legally asserted so long as each Guarantor was provided with the right set forth above. This indemnification shall be paid within thirty (30) days from the date on which the Collateral Agent or the Buyer makes written demand therefor, which demand shall identify the nature and amount of such Taxes or Other Taxes.

 

(c)       If any Guarantor fails to perform any of its obligations under this Section 12 , such Guarantor shall indemnify the Collateral Agent and the Buyer for any taxes, interest or penalties that may become payable as a result of any such failure. The obligations of the Guarantors under this Section 12 shall survive the termination of this Guaranty and the payment of the Obligations and all other amounts payable hereunder.

 

SECTION 13. Indemnification .

 

(a)       Without limitation of any other obligations of any Guarantor or remedies of the Collateral Agent or the Buyer under this Guaranty or applicable law, except to the extent resulting from such Indemnified Party’s gross negligence or willful misconduct, as determined by a final judgment of a court of competent jurisdiction no longer subject to appeal, each Guarantor shall, to the fullest extent permitted by law, indemnify, defend and save and hold harmless the Collateral Agent and the Buyer and each of their affiliates and their respective officers, directors, members, managers, employees, agents and advisors (each, an “ Indemnified Party ”) from and against, and shall pay on demand, any and all claims, damages, losses, liabilities and expenses (including, without limitation, reasonable fees and expenses of counsel) that may be incurred by or asserted or awarded against any Indemnified Party in connection with or as a result of any failure of any Guaranteed Obligations to be the legal, valid and binding obligations of any Transaction Party enforceable against such Transaction Party in accordance with their terms.

 

  11  

 

 

(b)       Each Guarantor hereby also agrees that none of the Indemnified Parties shall have any liability (whether direct or indirect, in contract, tort or otherwise) or any fiduciary duty or obligation to any of the Guarantors or any of their respective affiliates or any of their respective officers, directors, employees, agents and advisors, and each Guarantor hereby agrees not to assert any claim against any Indemnified Party on any theory of liability, for special, indirect, consequential, incidental or punitive damages arising out of or otherwise relating to the facilities, the actual or proposed use of the proceeds of the advances, the Transaction Documents or any of the transactions contemplated by the Transaction Documents.

 

SECTION 14. Miscellaneous .

 

(a)       Each Guarantor will make each payment hereunder in lawful money of the United States of America and in immediately available funds to the Collateral Agent or the Buyer, at such address specified by the Collateral Agent or the Buyer from time to time by notice to the Guarantors.

 

(b)       No amendment or waiver of any provision of this Guaranty and no consent to any departure by any Guarantor therefrom shall in any event be effective unless the same shall be in writing and signed by each Guarantor, the Collateral Agent and the Buyer, and then such waiver or consent shall be effective only in the specific instance and for the specific purpose for which given.

 

(c)       No failure on the part of the Collateral Agent or the Buyer to exercise, and no delay in exercising, any right or remedy hereunder or under any other Transaction Document shall operate as a waiver thereof, nor shall any single or partial exercise of any right hereunder or under any Transaction Document preclude any other or further exercise thereof or the exercise of any other right or remedy. The rights and remedies of the Collateral Agent and the Buyer provided herein and in the other Transaction Documents are cumulative and are in addition to, and not exclusive of, any rights or remedies provided by law. The rights and remedies of the Collateral Agent and the Buyer under any Transaction Document against any party thereto are not conditional or contingent on any attempt by the Collateral Agent or the Buyer to exercise any of their respective rights or remedies under any other Transaction Document against such party or against any other Person.

 

(d)       If any provision of this Guaranty or any Transaction Document is prohibited by law or otherwise determined to be invalid or unenforceable by a court of competent jurisdiction, the provision that would otherwise be prohibited, invalid or unenforceable shall be deemed amended to apply to the broadest extent that it would be valid and enforceable, and the invalidity or unenforceability of such provision shall not affect the validity of the remaining provisions of this Guaranty so long as this Guaranty as so modified continues to express, without material change, the original intentions of the parties as to the subject matter hereof and the prohibited nature, invalidity or unenforceability of the provision(s) in question does not substantially impair the respective expectations or reciprocal obligations of the parties or the practical realization of the benefits that would otherwise be conferred upon the parties.  The parties will endeavor in good faith negotiations to replace the prohibited, invalid or unenforceable provision(s) with a valid provision(s), the effect of which comes as close as possible to that of the prohibited, invalid or unenforceable provision(s).

 

  12  

 

 

(e)       This Guaranty is a continuing guaranty and shall (i) remain in full force and effect until Payment in Full of the Guaranteed Obligations (other than inchoate indemnity obligations) and shall not terminate for any reason prior to the respective Maturity Date of the Notes (other than Payment in Full of the Guaranteed Obligations) and (ii) be binding upon each Guarantor and its respective successors and assigns. This Guaranty shall inure, together with all rights and remedies of the Collateral Agent hereunder, to the benefit of and be enforceable by the Collateral Agent, the Buyer, and their respective successors, and permitted pledgees, transferees and assigns. Without limiting the generality of the foregoing sentence, the Collateral Agent or the Buyer may pledge, assign or otherwise transfer all or any portion of its rights and obligations under and subject to the terms of the Securities Purchase Agreement or any other Transaction Document to any other Person in accordance with the terms thereof, and such other Person shall thereupon become vested with all the benefits in respect thereof granted to the Collateral Agent or the Buyer (as applicable) herein or otherwise, in each case as provided in the Securities Purchase Agreement or such Transaction Document. None of the rights or obligations of any Guarantor hereunder may be assigned or otherwise transferred without the prior written consent of the Buyer.

 

(f)       This Guaranty and the other Transaction Documents reflect the entire understanding of the transaction contemplated hereby and shall not be contradicted or qualified by any other agreement, oral or written, entered into before the date hereof.

 

(g)       The headings of this Guaranty are for convenience of reference and shall not form part of, or affect the interpretation of, this Guaranty.  Unless the context clearly indicates otherwise, each pronoun herein shall be deemed to include the masculine, feminine, neuter, singular and plural forms thereof.  The terms “including,” “includes,” “include” and words of like import shall be construed broadly as if followed by the words “without limitation.”  The terms “herein,” “hereunder,” “hereof” and words of like import refer to this entire Agreement instead of just the provision in which they are found.

 

SECTION 15. Currency Indemnity .

 

If, for the purpose of obtaining or enforcing judgment against Guarantor in any court in any jurisdiction, it becomes necessary to convert into any other currency (such other currency being hereinafter in this Section 15 referred to as the “ Judgment Currency ”) an amount due under this Guaranty in any currency (the “ Obligation Currency ”) other than the Judgment Currency, the conversion shall be made at the rate of exchange prevailing on the Business Day immediately preceding (a) the date of actual payment of the amount due, in the case of any proceeding in the courts of courts of the jurisdiction that will give effect to such conversion being made on such date, or (b) the date on which the judgment is given, in the case of any proceeding in the courts of any other jurisdiction (the applicable date as of which such conversion is made pursuant to this Section 15 being hereinafter in this Section 15 referred to as the “ Judgment Conversion Date ”).

 

If, in the case of any proceeding in the court of any jurisdiction referred to in the preceding paragraph, there is a change in the rate of exchange prevailing between the Judgment Conversion Date and the date of actual receipt of the amount due in immediately available funds, the Guarantors shall pay such additional amount (if any, but in any event not a lesser amount) as may be necessary to ensure that the amount actually received in the Judgment Currency, when converted at the rate of exchange prevailing on the date of payment, will produce the amount of the Obligation Currency which could have been purchased with the amount of’ the Judgment Currency stipulated in the judgment or judicial order at the rate of exchange prevailing on the Judgment Conversion Date. Any amount due from the Guarantors under this Section 15 shall be due as a separate debt and shall not be affected by judgment being obtained for any other amounts due under or in respect of this Guaranty.

 

[REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK]

 

  13  

 

 

IN WITNESS WHEREOF, each Guarantor has caused this Guaranty to be executed by its respective duly authorized officer, as of the date first above written.

     
  GUARANTORS :
     
  ICAGEN, INC. ,
  a Delaware corporation
     
  By: /s/ Richard Cunningham
    Name: Richard Cunningham
    Title: Chief Executive Officer
     
  ICAGEN CORP (FORMERLY KNOWN AS XRPRO CORP.). , a Nevada corporation
     
  By: /s/ Richard Cunningham
    Name: Richard Cunningham
    Title: Chief Executive Officer
     
  CALDERA DISCOVERY, INC. ,
  a Delaware corporation
     
  By: /s/ Richard Cunningham
    Name: Richard Cunningham
    Title: Chief Executive Officer
     
  XRPRO SCIENCES, INC. ,
  a Delaware corporation
     
  By: /s/ Richard Cunningham
    Name: Richard Cunningham
    Title: Chief Executive Officer

     
ACCEPTED BY:  
     
GPB DEBT HOLDINGS II, LLC,  
as Collateral Agent  
     
By: /s/ David Gentile  
  Name: David Gentile  
  Title: Manager  

 

 

14

 

Exhibit 10.5

 

Execution Version

 

GUARANTY OF OBLIGATIONS OF ICA-T

 

This GUARANTY, dated as of May 15, 2017 (this “ Guaranty ”), is made by each of the undersigned (each a “ Guarantor ”, and collectively, the “ Guarantors ”), in favor of GPB Debt Holdings II, LLC, a Delaware limited liability company, in its capacity as collateral agent (in such capacity, the “ Collateral Agent ” as hereinafter further defined) for the “Buyer” party to the Securities Purchase Agreement (each as defined below).

 

W I T N E S S E T H :

 

WHEREAS, Icagen, Inc., a Delaware corporation with its executive offices located at 4222 Emperor Blvd., Suite 350, Research Triangle Park, Durham, NC, 27703 (the “ Parent ”), Icagen-T, Inc., a Delaware corporation and a wholly-owned Subsidiary of the Parent with its executive offices located at 2090 E. Innovation Park Drive, Oro Valley, Arizona 85755 (“ ICA-T ”) and GPB Debt Holdings II, LLC, in its capacity as an investor (the “ Buyer ”) are parties to the Securities Purchase Agreement, dated as of May 15, 2017 (as amended, restated, extended, replaced or otherwise modified from time to time and together with all amendments, supplements and exhibits thereto, collectively, the “ Securities Purchase Agreement ”), pursuant to which, among other actions set forth therein, (i) ICA-T shall be required to sell an $8,000,000 aggregate principal amount senior secured note of ICA-T (as such may be amended, restated, extended, replaced or otherwise modified from time to time in accordance with the terms thereof, the “ ICA-T Note ”) and (ii) the Parent shall be required to sell a $2,000,000 aggregate principal amount aggregate principal amount senior secured note of the Parent (as such may be amended, restated, extended, replaced or otherwise modified from time to time in accordance with the terms thereof, the “ Parent Note ” and together with the ICA-T Note, collectively, the “ Notes ”) to the Buyer and the Buyer shall have the right to purchase the Notes;

 

WHEREAS, the Securities Purchase Agreement requires that the Guarantors execute and deliver to the Collateral Agent simultaneously with the execution of the Securities Purchase Agreement (i) a guaranty guaranteeing all of the obligations of (A) ICA-T under the Securities Purchase Agreement, the ICA-T Note and the other Transaction Documents (as defined below) and (B) the Parent under the ICA-T Note; and (ii) a Security and Pledge Agreement, dated as of the date hereof, granting the Collateral Agent for the benefit of the Noteholders a lien on and security interest in all of their assets and properties (the “ Security Agreement ”); and

 

WHEREAS, each Guarantor has determined that the execution, delivery and performance of this Guaranty directly benefits, and is in the best interest of, such Guarantor and that the Buyer would not have entered into the Securities Purchase Agreement and the other Transaction Documents and/or taken the actions required of it under such documents including purchasing the ICA-T Note if the Guarantor had executed and delivered this Guaranty.

 

NOW, THEREFORE, in consideration of the premises and the agreements herein and in order to induce the Buyer to perform under the Securities Purchase Agreement, each Guarantor hereby agrees with the Buyer as follows:

 

   

 

 

NOW, THEREFORE, in consideration of the premises and the agreements herein and in order to induce the Buyer to perform under the Securities Purchase Agreement, each Guarantor hereby agrees with the Buyer as follows:

 

SECTION 1. Definitions . Reference is hereby made to the Securities Purchase Agreement and the ICA-T Note for a statement of the terms thereof. All terms used in this Guaranty and the recitals hereto which are defined in the Securities Purchase Agreement or the ICA-T Note, and which are not otherwise defined herein shall have the same meanings herein as set forth therein. In addition, the following terms when used in the Guaranty shall have the meanings set forth below:

 

Bankruptcy Code ” means Chapter 11 of Title 11 of the United States Code, 11 U.S.C §§ 101 et seq. (or other applicable bankruptcy, insolvency or similar laws).

 

Business Day ” means any day other than Saturday, Sunday or other day on which commercial banks in New York City are authorized or required by law to remain closed.

 

Buyer ” shall have the meaning set forth in the recitals hereto.

 

Capital Stock ” means (i) with respect to any Person that is a corporation, any and all shares, interests, participations or other equivalents (however designated and whether or not voting) of corporate stock (including, without limitation, any warrants, options, rights or other securities exercisable or convertible into equity interests or securities of such Person), and (ii) with respect to any Person that is not a corporation, any and all partnership, membership or other equity interests of such Person.

 

“Collateral” means all assets and properties of the Parent and each other Guarantor, wherever located and whether now or hereafter existing and whether now owned or hereafter acquired, of every kind and description, tangible or intangible, including, without limitation, the collateral described in Section 2 of the Security Agreement.

 

Collateral Agent ” shall have the meaning set forth in the recitals hereto.

 

Governmental Authority ” means any nation or government, any Federal, state, city, town, municipality, county, local, foreign or other political subdivision thereof or thereto and any department, commission, board, bureau, instrumentality, agency or other entity exercising executive, legislative, judicial, taxing, regulatory or administrative powers or functions of or pertaining to government.

 

Guaranteed Obligations ” shall have the meaning set forth in Section 2 of this Guaranty.

 

Guarantor ” or “ Guarantors ” shall have the meaning set forth in the first paragraph of this Guaranty.

 

ICA-T Note ” shall have the meaning set forth in the recitals hereto.

 

Indemnified Party ” shall have the meaning set forth in Section 13(a) of this Guaranty

 

Insolvency Proceeding ” means any proceeding commenced by or against any Person under any provision of the Bankruptcy Code or under any other bankruptcy or insolvency law, assignments for the benefit of creditors, formal or informal moratoria, compositions, or extensions generally with creditors, or proceedings seeking reorganization, arrangement, or other similar relief.

 

  2  

 

 

Noteholders ” means the Buyer and any other holder of all or any portion of the ICA-T Note.

 

Obligations ” shall have the meaning set forth in Section 3 of the Security Agreement.

 

Other Taxes ” shall have the meaning set forth in Section 12(a)(iv) of this Guaranty.

 

Paid in Full” or “Payment in Full ” means the indefeasible payment in full in cash (and/or through the issuance of Parent Common Stock (as defined in the ICA-T Note) but solely to the extent, in accordance with and pursuant to the terms of the ICA-T Note) of all of the Guaranteed Obligations.

 

Parent ” shall have the meaning set forth in the recitals hereto.

 

Person ” means an individual, corporation, limited liability company, partnership, association, joint-stock company, trust, unincorporated organization, joint venture or other enterprise or entity or Governmental Authority.

 

Securities Purchase Agreement ” shall have the meaning set forth in the recitals hereto.

 

Security Agreement ” shall have the meaning set forth in the recitals hereto.

 

Subsidiary” means any Person in which a Guarantor directly or indirectly (i) owns a majority of the outstanding Capital Stock, voting stock or holds any equity or similar interest of such Person including, but not limited to, any Subsidiary of ICA-T or (ii) controls or operates a substantial portion of the business, operations or administration of such Person including, but not limited to, any Subsidiary of ICA-T, and all of the foregoing, collectively, “ Subsidiaries ”.

 

Taxes ” shall have the meaning set forth in Section 12(a) of this Guaranty.

 

Transaction Party ” means the Parent, ICA-T and each other Guarantor, collectively, “ Transaction Parties ”.

 

SECTION 2. Guaranty .

 

(a)       The Guarantors, jointly and severally, hereby unconditionally and irrevocably, guaranty to the Collateral Agent, for the benefit of the Collateral Agent, the Buyer and any other Noteholder the punctual payment, as and when due and payable, by stated maturity, acceleration or otherwise, of all Obligations of including, without limitation, all interest, make-whole, redemption and other amounts that accrue after the commencement of any Insolvency Proceeding of ICA-T or any Guarantor, whether or not the payment of such principal, interest, make-whole, redemption and/or other amounts are enforceable or are allowable in such Insolvency Proceeding, and all fees, Late Charges (as defined in the ICA-T Note), interest, premiums, penalties, causes of actions, costs, commissions, expense reimbursements, indemnifications and all other amounts due or to become due under the ICA-T Note and the other Transaction Documents and (all of the foregoing collectively being the “ Guaranteed Obligations ”), and agree to pay any and all costs and expenses (including reasonable and documented counsel fees and expenses) incurred by the Collateral Agent in enforcing any rights under this Guaranty or any other Transaction Document. Without limiting the generality of the foregoing, each Guarantor’s liability hereunder shall extend to all amounts that constitute part of the Guaranteed Obligations and would be owed by ICA-T to the Collateral Agent or the Buyer under the Securities Purchase Agreement, the ICA-T Note and any other Transaction Document but for the fact that they are unenforceable or not allowable due to the existence of an Insolvency Proceeding involving any Transaction Party.

 

  3  

 

 

(b)       Each Guarantor, and by its acceptance of this Guaranty, the Collateral Agent and the Buyer, hereby confirms that it is the intention of all such Persons that this Guaranty and the Guaranteed Obligations of each Guarantor hereunder not constitute a fraudulent transfer or conveyance for purposes of the Bankruptcy Code, the Uniform Fraudulent Conveyance Act, the Uniform Fraudulent Transfer Act or any similar foreign, federal, provincial, state, or other applicable law to the extent applicable to this Guaranty and the Guaranteed Obligations of each Guarantor hereunder. To effectuate the foregoing intention, the Collateral Agent, the Buyer and the Guarantors hereby irrevocably agree that the Guaranteed Obligations of each Guarantor under this Guaranty at any time shall be limited to the maximum amount as will result in the Guaranteed Obligations of such Guarantor under this Guaranty not constituting a fraudulent transfer or conveyance.

 

SECTION 3. Guaranty Absolute; Continuing Guaranty; Assignments .

 

(a)       The Guarantors, jointly and severally, guaranty that the Guaranteed Obligations will be paid strictly in accordance with the terms of the ICA-T Note and the other Transaction Documents, regardless of any law, regulation or order now or hereafter in effect in any jurisdiction affecting any of such terms or the rights of the Collateral Agent, the Buyer and/or any other Noteholder with respect thereto. The obligations of each Guarantor under this Guaranty are independent of the Guaranteed Obligations, and a separate action or actions may be brought and prosecuted against any Guarantor to enforce such obligations, irrespective of whether any action is brought against any Transaction Party or whether any Transaction Party is joined in any such action or actions. The liability of any Guarantor under this Guaranty shall be as a primary obligor (and not merely as a surety) and shall be irrevocable, absolute and unconditional irrespective of, and each Guarantor hereby irrevocably waives, to the maximum extent permitted by law, any defenses it may now or hereafter have in any way relating to, any or all of the following:

 

(i)         any lack of validity or enforceability of the ICA-T Note and/or any other Transaction Document;

 

(ii)        any change in the time, manner or place of payment of, or in any other term of, all or any of the Guaranteed Obligations, or any other amendment or waiver of or any consent to departure from any Transaction Document, including, without limitation, any increase in the Guaranteed Obligations resulting from the extension of additional credit to any Transaction Party or extension of the maturity of any Guaranteed Obligations or otherwise;

 

(iii)       any taking, exchange, release or non-perfection of any Collateral;

 

  4  

 

 

(iv)       any taking, release or amendment or waiver of or consent to departure from any other guaranty, for all or any of the Guaranteed Obligations;

 

(v)        any change, restructuring or termination of the corporate, limited liability company or partnership structure or existence of any Transaction Party;

 

(vi)       any manner of application of Collateral or any other collateral, or proceeds thereof, to all or any of the Guaranteed Obligations, or any manner of sale or other disposition of any Collateral or any other collateral for all or any of the Guaranteed Obligations or any other Obligations of any Transaction Party under the Transaction Documents or any other assets of any Transaction Party or any of its Subsidiaries;

 

(vii)      any failure of the Collateral Agent, the Buyer and/or any other Noteholder to disclose to any Transaction Party any information relating to the business, condition (financial or otherwise), operations, performance, properties or prospects of any other Transaction Party now or hereafter known to the Collateral Agent, the Buyer and/or any other Noteholder (each Guarantor waiving any duty on the part of the Collateral Agent, the Buyer and/or any other Noteholder to disclose such information);

 

(viii)     taking any action in furtherance of the release of any Guarantor or any other Person that is liable for the Obligations from all or any part of any liability arising under or in connection with any Transaction Document without the prior written consent of the Collateral Agent; or

 

(ix)       any other circumstance (including, without limitation, any statute of limitations) or any existence of or reliance on any representation by the Collateral Agent, the Buyer and/or any other Noteholder that might otherwise constitute a defense available to, or a discharge of, any Transaction Party or any other guarantor or surety.

 

(b)       This Guaranty shall continue to be effective or be reinstated, as the case may be, if at any time any payment of any of the Guaranteed Obligations is rescinded or must otherwise be returned by the Collateral Agent, the Buyer, any other Noteholder and/or any other Person upon the insolvency, bankruptcy or reorganization of any Transaction Party or otherwise, all as though such payment had not been made.

 

(c)       This Guaranty is a continuing guaranty and shall (i) remain in full force and effect until Payment in Full of the Guaranteed Obligations (other than inchoate indemnity obligations) and shall not terminate for any reason prior to the Maturity Date of the ICA-T Note (other than Payment in Full of the Guaranteed Obligations), and (ii) be binding upon each Guarantor and its respective successors and assigns. This Guaranty shall inure to the benefit of and be enforceable by the Collateral Agent, the Buyer and/or any other Noteholder and their respective successors, and permitted pledgees, transferees and assigns. Without limiting the generality of the foregoing sentence, the Collateral Agent, the Buyer and/or any other Noteholder may pledge, assign or otherwise transfer all or any portion of its rights, remedies and obligations under and subject to the terms of any Transaction Document to any other Person [other than to the Buyer Affiliate] [(as defined in the Securities Purchase Agreement)] and such other Person shall thereupon become vested with all the benefits in respect thereof granted to the Collateral Agent, the Buyer and/or any other Noteholder (as applicable) herein or otherwise, in each case as provided in the Securities Purchase Agreement or such other Transaction Document.

 

  5  

 

 

SECTION 4. Waivers . To the extent permitted by applicable law, each Guarantor hereby waives promptness, diligence, protest, notice of acceptance and any other notice or formality of any kind with respect to any of the Guaranteed Obligations and this Guaranty and any requirement that the Collateral Agent exhaust any right or take any action against any Transaction Party or any other Person or any Collateral. Each Guarantor acknowledges that it will receive direct and indirect benefits from the financing arrangements contemplated herein and that the waiver set forth in this Section 4 is knowingly made in contemplation of such benefits. The Guarantors hereby waive any right to revoke this Guaranty, and acknowledge that this Guaranty is continuing in nature and applies to all Guaranteed Obligations, whether existing now or in the future. Without limiting the foregoing, to the extent permitted by applicable law, each Guarantor hereby unconditionally and irrevocably waives (a) any defense arising by reason of any claim or defense based upon an election of remedies by the Collateral Agent or the Buyer that in any manner impairs, reduces, releases or otherwise adversely affects the subrogation, reimbursement, exoneration, contribution or indemnification rights of such Guarantor or other rights of such Guarantor to proceed against any of the other Transaction Parties, any other guarantor or any other Person or any Collateral, and (b) any defense based on any right of set-off or counterclaim against or in respect of the Guaranteed Obligations of such Guarantor hereunder. Each Guarantor hereby unconditionally and irrevocably waives any duty on the part of the Collateral Agent, the Buyer and/or any other Noteholder to disclose to such Guarantor any matter, fact or thing relating to the business, condition (financial or otherwise), operations, performance, properties or prospects of any other Transaction Party or [any of its Subsidiaries] now or hereafter known by the Collateral Agent, the Buyer and/or any other Noteholder.

 

SECTION 5. Subrogation . No Guarantor may exercise any rights that it may now or hereafter acquire against any Transaction Party or any other Guarantor and/or guarantor that arise from the existence, payment, performance or enforcement of any Guarantor’s obligations under this Guaranty, including, without limitation, any right of subrogation, reimbursement, exoneration, contribution or indemnification and any right to participate in any claim or remedy of the Collateral Agent, the Buyer and/or any other Noteholder against any Transaction Party or any other guarantor or any Collateral, whether or not such claim, remedy or right arises in equity or under contract, statute or common law, including, without limitation, the right to take or receive from any Transaction Party or any other guarantor, directly or indirectly, in cash or other property or by set-off or in any other manner, payment or security solely on account of such claim, remedy or right, unless and until there has been Payment in Full of the Guaranteed Obligations. If any amount shall be paid to a Guarantor in violation of the immediately preceding sentence at any time prior to Payment in Full of the Guaranteed Obligations and all other amounts payable under this Guaranty, such amount shall be held in trust for the benefit of the Collateral Agent and shall forthwith be paid to the Collateral Agent to be credited and applied to the Guaranteed Obligations and all other amounts payable under this Guaranty, whether matured or un-matured, in accordance with the terms of the Transaction Document, or to be held as Collateral for any Guaranteed Obligations or other amounts payable under this Guaranty thereafter arising. If (a) any Guarantor shall make payment to the Collateral Agent of all or any part of the Guaranteed Obligations, and (b) there has been Payment in Full of the Guaranteed Obligations, the Collateral Agent will, at such Guarantor’s request and expense, execute and deliver to such Guarantor appropriate documents to evidence payment in Full of the Guaranteed Obligations without recourse and without representation or warranty, necessary to evidence the transfer by subrogation to such Guarantor of an interest in the Guaranteed Obligations resulting from such payment by such Guarantor.

 

  6  

 

 

SECTION 6. Representations, Warranties and Covenants .

 

(a)       Each Guarantor hereby represents and warrants as of the date first written above as follows:

 

(i)         such Guarantor (A) is a corporation, limited liability company or limited partnership duly organized, validly existing and in good standing under the laws of the jurisdiction of its organization as set forth on the signature pages hereto, (B) has all requisite corporate, limited liability company or limited partnership power and authority to conduct its business as now conducted and as presently contemplated and to execute, deliver and perform its obligations under this Guaranty and each other Transaction Document to which such Guarantor is a party, and to consummate the transactions contemplated hereby and thereby and (C) is duly qualified to do business and is in good standing in each jurisdiction in which the character of the properties owned or leased by it or in which the transaction of its business makes such qualification necessary except where the failure to be so qualified (individually or in the aggregate) would not result in a Material Adverse Effect.

 

(ii)        The execution, delivery and performance by such Guarantor of this Guaranty and each other Transaction Document to which such Guarantor is a party (A) have been duly authorized by all necessary corporate, limited liability company or limited partnership action, (B) do not and will not contravene its charter, articles, certificate of formation or by-laws, its limited liability company or operating agreement or its certificate of partnership or partnership agreement, as applicable, or any applicable law or any contractual restriction binding on such Guarantor or its properties do not and will not result in or require the creation of any lien, security interest or encumbrance (other than pursuant to any Transaction Document) upon or with respect to any of its properties, and (C) do not and will not result in any default, noncompliance, suspension, revocation, impairment, forfeiture or nonrenewal of any material permit, license, authorization or approval applicable to it or its operations or any of its properties.

 

(iii)       No authorization or approval or other action by, and no notice to or filing with, any Governmental Authority or other Person is required in connection with the due execution, delivery and performance by such Guarantor of this Guaranty or any of the other Transaction Documents to which such Guarantor is a party (other than expressly provided for in any of the Transaction Documents).

 

  7  

 

 

(iv)       This Guaranty has been duly executed and delivered by each Guarantor and is, and each of the other Transaction Documents to which such Guarantor is or will be a party, when executed and delivered, will be, a legal, valid and binding obligation of such Guarantor, enforceable against such Guarantor in accordance with its terms, except as may be limited by the Bankruptcy Code or other applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, suretyship or similar laws and equitable principles (regardless of whether enforcement is sought in equity or at law).

 

(v)       There is no pending or, to the knowledge of such Guarantor, threatened action, suit or proceeding against such Guarantor or to which any of the properties of such Guarantor is subject, before any court or other Governmental Authority or any arbitrator that (A) if adversely determined, could reasonably be expected to have a Material Adverse Effect or (B) relates to this Guaranty or any of the other Transaction Documents to which such Guarantor is a party or any transaction contemplated hereby or thereby.

 

(vi)       Such Guarantor (A) has read and understands the terms and conditions of the Securities Purchase Agreement and the other Transaction Documents, and (B) now has and will continue to have independent means of obtaining information concerning the affairs, financial condition and business of the Parent and the other Transaction Parties, and has no need of, or right to obtain from the Collateral Agent or the Buyer, any credit or other information concerning the affairs, financial condition or business of the Parent or the other Transaction Parties.

 

(vii)      There are no conditions precedent to the effectiveness of this Guaranty that have not been satisfied or waived.

 

(b)       Each Guarantor covenants and agrees that until Payment in Full of the Guaranteed Obligations, it will comply with each of the covenants which are set forth in Section 4 of the Securities Purchase Agreement as if such Guarantor were a party thereto.

 

SECTION 7. Right of Set-off . Upon the occurrence and during the continuance of any Event of Default, the Collateral Agent, the Buyer and/or any other Noteholder may, and is hereby authorized to, at any time and from time to time, without notice to the Guarantors (any such notice being expressly waived by each Guarantor) and to the fullest extent permitted by law, set-off and apply any and all deposits (general or special, time or demand, provisional or final) at any time held and other indebtedness at any time owing by the Collateral Agent, the Buyer and/or any other Noteholder to or for the credit or the account of any Guarantor against any and all obligations of the Guarantors now or hereafter existing under this Guaranty or any other Transaction Document, irrespective of whether or not the Collateral Agent, the Buyer and/or any other Noteholder shall have made any demand under this Guaranty or any other Transaction Document and although such obligations may be contingent or unmatured. The Collateral Agent, the Buyer and/or any other Noteholder agrees to notify the relevant Guarantor promptly after any such set-off and application made by the Collateral Agent or the Buyer, provided that the failure to give such notice shall not affect the validity of such set-off and application. The rights of the Collateral Agent, the Buyer and/or any other Noteholder under this Section 7 are in addition to other rights and remedies (including, without limitation, other rights of set-off) which the Collateral Agent, the Buyer and/or any other Noteholder may have under this Guaranty or any other Transaction Document in law or otherwise.

 

  8  

 

 

SECTION 8. Limitation on Guaranteed Obligations.

 

(a)       Notwithstanding any provision herein contained to the contrary, each Guarantor’s liability hereunder shall be limited to an amount not to exceed as of any date of determination the greater of:

 

(i)         the amount of all Guaranteed Obligations, plus interest thereon at the applicable Interest Rate as specified in the ICA-T Note; and

 

(ii)        the amount which could be claimed by the Collateral Agent from any Guarantor under this Guaranty without rendering such claim voidable or avoidable under the Bankruptcy Code or under any applicable state Uniform Fraudulent Transfer Act, Uniform Fraudulent Conveyance Act or similar statute or common law after taking into account, among other things, Guarantor’s right of contribution and indemnification.

 

(b)       Each Guarantor agrees that the Guaranteed Obligations may at any time and from time to time exceed the amount of the liability of such Guarantor hereunder without impairing the guaranty hereunder or affecting the rights and remedies of the Collateral Agent, the Buyer and/or any other Noteholder hereunder or under applicable law.

 

(c)       No payment made by ICA-T, any Guarantor, any other guarantor or any other Person or received or collected by the Collateral Agent, the Buyer and/or any other Noteholder from ICA-T, any of the Guarantors, any other guarantor or any other Person by virtue of any action or proceeding or any set-off or appropriation or application at any time or from time to time in reduction of or in payment of the Guaranteed Obligations shall be deemed to modify, reduce, release or otherwise affect the liability of any Guarantor hereunder which shall, notwithstanding any such payment (other than any payment made by such Guarantor in respect of the Guaranteed Obligations or any payment received or collected from such Guarantor in respect of the Guaranteed Obligations), remain liable for the Guaranteed Obligations up to the maximum liability of such Guarantor hereunder until after all of the Guaranteed Obligations and all other amounts payable under this Guaranty shall have been Paid in Full.

 

SECTION 9. Notices, Etc . Any notices, consents, waivers or other communications required or permitted to be given under the terms of this Guaranty must be in writing and will be deemed to have been delivered: (i) upon receipt, when delivered personally; (ii) upon receipt, when sent by facsimile or email (provided confirmation of transmission is mechanically or electronically generated or, in the case of email with a read receipt generated and kept on file by the sending party); or (iii) one (1) Business Day after deposit with a nationally recognized overnight courier service with next day delivery specified, in each case, properly addressed to the party to receive the same. All notices and other communications provided for hereunder shall be sent, if to any Guarantor, to the Parent’s address and/or facsimile number, or if to the Collateral Agent, the Buyer and/or any other Noteholder, to it at its respective address and/or facsimile number, each as set forth in Section 9(f) of the Securities Purchase Agreement.

 

  9  

 

 

SECTION 10. Governing Law; Jurisdiction . All questions concerning the construction, validity, enforcement and interpretation of this Guaranty shall be governed by the internal laws of the State of New York, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of New York or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of New York. Each Guarantor hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in The City of New York, Borough of Manhattan, for the adjudication of any dispute hereunder or in connection herewith or under any of the other Transaction Documents or with any transaction contemplated hereby or thereby, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim, obligation or defense that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof to such party at the address for such notices to it under Section 9(f) of the Securities Purchase Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. Nothing contained herein shall be deemed or operate to preclude the Collateral Agent or the Buyer from bringing suit or taking other legal action against any Guarantor in any other jurisdiction to collect on a Guarantor’s obligations or to enforce a judgment or other court ruling in favor of the Collateral Agent or the Buyer. 

 

SECTION 11. WAIVER OF JURY TRIAL, ETC . EACH GUARANTOR HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR UNDER ANY OTHER TRANSACTION DOCUMENT OR IN CONNECTION WITH OR ARISING OUT OF THIS GUARANTY, ANY OTHER TRANSACTION DOCUMENT OR ANY TRANSACTION CONTEMPLATED HEREBY OR THEREBY.

 

SECTION 12. Taxes .

 

(a)       All payments made by any Guarantor hereunder or under any other Transaction Document shall be made in accordance with the terms of the respective Transaction Document and shall be made without set-off, counterclaim, withholding, deduction or other defense. Without limiting the foregoing, all such payments shall be made free and clear of and without deduction or withholding for any present or future taxes, levies, imposts, deductions, charges or withholdings, and all liabilities with respect thereto, excluding taxes imposed on the net income of the Collateral Agent, the Buyer and/or any other Noteholder by the jurisdiction in which the Collateral Agent, the Buyer and/or any other Noteholder is organized or where it has its principal lending office (all such non-excluded taxes, levies, imposts, deductions, charges, withholdings and liabilities, collectively or individually, “ Taxes ”). If any Guarantor shall be required to deduct or to withhold any Taxes from or in respect of any amount payable hereunder or under any other Transaction Document:

 

(i)         the amount so payable shall be increased to the extent necessary so that after making all required deductions and withholdings (including Taxes on amounts payable to the Collateral Agent or the Buyer pursuant to this sentence) the Collateral Agent or the Buyer receives an amount equal to the sum it would have received had no such deduction or withholding been made,

 

  10  

 

 

(ii)        such Guarantor shall make such deduction or withholding,

 

(iii)       such Guarantor shall pay the full amount deducted or withheld to the relevant Governmental Authority in accordance with applicable law, and

 

(iv)       as promptly as possible thereafter, such Guarantor shall send the Collateral Agent or the Buyer an official receipt (or, if an official receipt is not available, such other documentation as shall be satisfactory to the Collateral Agent, as the case may be) showing payment. In addition, each Guarantor agrees to pay any present or future stamp or documentary taxes or any other excise or property taxes, charges or similar levies that arise from any payment made hereunder or from the execution, delivery, registration or enforcement of, or otherwise with respect to, this Guaranty or any other Transaction Document (collectively, “ Other Taxes ”).

 

(b)       Each Guarantor hereby indemnifies and agrees to hold each Indemnified Party harmless from and against Taxes or Other Taxes (including, without limitation, any Taxes or Other Taxes imposed by any jurisdiction on amounts payable under this Section 12 ) paid by any Indemnified Party as a result of any payment made hereunder or from the execution, delivery, registration or enforcement of, or otherwise with respect to, this Guaranty or any other Transaction Document, and any liability (including penalties, interest and expenses for nonpayment, late payment or otherwise) arising therefrom or with respect thereto, whether or not such Taxes or Other Taxes were correctly or legally asserted so long as each Guarantor was provided with the right set forth above. This indemnification shall be paid within thirty (30) days from the date on which the Collateral Agent or the Buyer makes written demand therefor, which demand shall identify the nature and amount of such Taxes or Other Taxes.

 

(c)       If any Guarantor fails to perform any of its obligations under this Section 12 , such Guarantor shall indemnify the Collateral Agent and the Buyer for any taxes, interest or penalties that may become payable as a result of any such failure. The obligations of the Guarantors under this Section 12 shall survive the termination of this Guaranty and the payment of the Obligations and all other amounts payable hereunder.

 

SECTION 13. Indemnification .

 

(a)       Without limitation of any other obligations of any Guarantor or remedies of the Collateral Agent or the Buyer under this Guaranty or applicable law, except to the extent resulting from such Indemnified Party’s gross negligence or willful misconduct, as determined by a final judgment of a court of competent jurisdiction no longer subject to appeal, each Guarantor shall, to the fullest extent permitted by law, indemnify, defend and save and hold harmless the Collateral Agent and the Buyer and each of their affiliates and their respective officers, directors, members, managers, employees, agents and advisors (each, an “ Indemnified Party ”) from and against, and shall pay on demand, any and all claims, damages, losses, liabilities and expenses (including, without limitation, reasonable fees and expenses of counsel) that may be incurred by or asserted or awarded against any Indemnified Party in connection with or as a result of any failure of any Guaranteed Obligations to be the legal, valid and binding obligations of any Transaction Party enforceable against such Transaction Party in accordance with their terms.

 

  11  

 

 

(b)       Each Guarantor hereby also agrees that none of the Indemnified Parties shall have any liability (whether direct or indirect, in contract, tort or otherwise) or any fiduciary duty or obligation to any of the Guarantors or any of their respective affiliates or any of their respective officers, directors, employees, agents and advisors, and each Guarantor hereby agrees not to assert any claim against any Indemnified Party on any theory of liability, for special, indirect, consequential, incidental or punitive damages arising out of or otherwise relating to the facilities, the actual or proposed use of the proceeds of the advances, the Transaction Documents or any of the transactions contemplated by the Transaction Documents.

 

SECTION 14. Miscellaneous .

 

(a)       Each Guarantor will make each payment hereunder in lawful money of the United States of America and in immediately available funds to the Collateral Agent or the Buyer, at such address specified by the Collateral Agent or the Buyer from time to time by notice to the Guarantors.

 

(b)       No amendment or waiver of any provision of this Guaranty and no consent to any departure by any Guarantor therefrom shall in any event be effective unless the same shall be in writing and signed by each Guarantor, the Collateral Agent and the Buyer, and then such waiver or consent shall be effective only in the specific instance and for the specific purpose for which given.

 

(c)       No failure on the part of the Collateral Agent or the Buyer to exercise, and no delay in exercising, any right or remedy hereunder or under any other Transaction Document shall operate as a waiver thereof, nor shall any single or partial exercise of any right hereunder or under any Transaction Document preclude any other or further exercise thereof or the exercise of any other right or remedy. The rights and remedies of the Collateral Agent and the Buyer provided herein and in the other Transaction Documents are cumulative and are in addition to, and not exclusive of, any rights or remedies provided by law. The rights and remedies of the Collateral Agent and the Buyer under any Transaction Document against any party thereto are not conditional or contingent on any attempt by the Collateral Agent or the Buyer to exercise any of their respective rights or remedies under any other Transaction Document against such party or against any other Person.

 

(d)       If any provision of this Guaranty or any Transaction Document is prohibited by law or otherwise determined to be invalid or unenforceable by a court of competent jurisdiction, the provision that would otherwise be prohibited, invalid or unenforceable shall be deemed amended to apply to the broadest extent that it would be valid and enforceable, and the invalidity or unenforceability of such provision shall not affect the validity of the remaining provisions of this Guaranty so long as this Guaranty as so modified continues to express, without material change, the original intentions of the parties as to the subject matter hereof and the prohibited nature, invalidity or unenforceability of the provision(s) in question does not substantially impair the respective expectations or reciprocal obligations of the parties or the practical realization of the benefits that would otherwise be conferred upon the parties.  The parties will endeavor in good faith negotiations to replace the prohibited, invalid or unenforceable provision(s) with a valid provision(s), the effect of which comes as close as possible to that of the prohibited, invalid or unenforceable provision(s).

 

  12  

 

 

(e)       This Guaranty is a continuing guaranty and shall (i) remain in full force and effect until Payment in Full of the Guaranteed Obligations (other than inchoate indemnity obligations) and shall not terminate for any reason prior to the respective Maturity Date of the ICA-T Note (other than Payment in Full of the Guaranteed Obligations) and (ii) be binding upon each Guarantor and its respective successors and assigns. This Guaranty shall inure, together with all rights and remedies of the Collateral Agent hereunder, to the benefit of and be enforceable by the Collateral Agent, the Buyer, and their respective successors, and permitted pledgees, transferees and assigns. Without limiting the generality of the foregoing sentence, the Collateral Agent or the Buyer may pledge, assign or otherwise transfer all or any portion of its rights and obligations under and subject to the terms of the Securities Purchase Agreement or any other Transaction Document to any other Person in accordance with the terms thereof, and such other Person shall thereupon become vested with all the benefits in respect thereof granted to the Collateral Agent or the Buyer (as applicable) herein or otherwise, in each case as provided in the Securities Purchase Agreement or such Transaction Document. None of the rights or obligations of any Guarantor hereunder may be assigned or otherwise transferred without the prior written consent of the Buyer.

 

(f)       This Guaranty and the other Transaction Documents reflect the entire understanding of the transaction contemplated hereby and shall not be contradicted or qualified by any other agreement, oral or written, entered into before the date hereof.

 

(g)       The headings of this Guaranty are for convenience of reference and shall not form part of, or affect the interpretation of, this Guaranty.  Unless the context clearly indicates otherwise, each pronoun herein shall be deemed to include the masculine, feminine, neuter, singular and plural forms thereof.  The terms “including,” “includes,” “include” and words of like import shall be construed broadly as if followed by the words “without limitation.”  The terms “herein,” “hereunder,” “hereof” and words of like import refer to this entire Agreement instead of just the provision in which they are found.

 

SECTION 15. Currency Indemnity .

 

If, for the purpose of obtaining or enforcing judgment against Guarantor in any court in any jurisdiction, it becomes necessary to convert into any other currency (such other currency being hereinafter in this Section 15 referred to as the “ Judgment Currency ”) an amount due under this Guaranty in any currency (the “ Obligation Currency ”) other than the Judgment Currency, the conversion shall be made at the rate of exchange prevailing on the Business Day immediately preceding (a) the date of actual payment of the amount due, in the case of any proceeding in the courts of courts of the jurisdiction that will give effect to such conversion being made on such date, or (b) the date on which the judgment is given, in the case of any proceeding in the courts of any other jurisdiction (the applicable date as of which such conversion is made pursuant to this Section 15 being hereinafter in this Section 15 referred to as the “ Judgment Conversion Date ”).

 

If, in the case of any proceeding in the court of any jurisdiction referred to in the preceding paragraph, there is a change in the rate of exchange prevailing between the Judgment Conversion Date and the date of actual receipt of the amount due in immediately available funds, the Guarantors shall pay such additional amount (if any, but in any event not a lesser amount) as may be necessary to ensure that the amount actually received in the Judgment Currency, when converted at the rate of exchange prevailing on the date of payment, will produce the amount of the Obligation Currency which could have been purchased with the amount of’ the Judgment Currency stipulated in the judgment or judicial order at the rate of exchange prevailing on the Judgment Conversion Date. Any amount due from the Guarantors under this Section 15 shall be due as a separate debt and shall not be affected by judgment being obtained for any other amounts due under or in respect of this Guaranty.

 

[REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK]

 

  13  

 

 

IN WITNESS WHEREOF, each Guarantor has caused this Guaranty to be executed by its respective duly authorized officer, as of the date first above written.

     
  GUARANTORS :
     
  ICAGEN, INC. ,
  a Delaware corporation
     
  By: /s/ Richard Cunningham
    Name: Richard Cunningham
    Title: Chief Executive Officer
     
  ICAGEN CORP (FORMERLY KNOWN AS XRPRO CORP.). , a Nevada corporation
     
  By: /s/ Richard Cunningham
    Name: Richard Cunningham
    Title: Chief Executive Officer
     
  CALDERA DISCOVERY, INC. ,
  a Delaware corporation
     
  By: /s/ Richard Cunningham
    Name: Richard Cunningham
    Title: Chief Executive Officer
     
  XRPRO SCIENCES, INC. ,
  a Delaware corporation
     
  By: /s/ Richard Cunningham
    Name: Richard Cunningham
    Title: Chief Executive Officer

     
ACCEPTED BY:  
     
GPB DEBT HOLDINGS II, LLC,  
as Collateral Agent  
     
By: /s/ David Gentile  
  Name: David Gentile  
  Title: Manager  

 

 

14

 

Exhibit 10.6

 

  Execution Version

 

NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED EXCEPT PURSUANT TO (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT OF 1933, AS AMENDED, AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE HOLDER OR THE COMPANY TO SUCH EFFECT, , THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES. ANY TRANSFEREE OF THESE SECURITIES SHOULD CAREFULLY REVIEW THE TERMS HEREIN. THE NUMBER OF SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT MAY BE LESS THAN THE AMOUNTS SET FORTH ON THE FACE HEREOF PURSUANT TO SECTION 1(a) OF THIS WARRANT.

 

ICAGEN, INC.         

 

Warrant To Purchase Common Stock

 

Warrant No.: ICGI-GPB-1

 

Issuance Date: May 15, 2017 (“ Issuance Date ”)

 

Icagen, Inc., a Delaware corporation (the “ Company ”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, GPB Debt Holdings II, LLC, the registered holder hereof or its permitted assigns (the “ Holder ”), is entitled, subject to the terms set forth below, to purchase from the Company, at the Exercise Price (as defined below) then in effect, upon exercise of this Warrant to Purchase Common Stock (including any Warrants to Purchase Common Stock issued in exchange, transfer or replacement hereof, the “ Warrant ”), at any time or times on or after the Issuance Date, but not after 11:59 p.m., New York time, on the Expiration Date (as defined below), 857,143 (subject to adjustment as provided herein) fully paid and non-assessable shares of Common Stock (as defined below) (the “ Warrant Shares ”, and such number of Warrant Shares, the “ Warrant Number ”). Except as otherwise defined herein, capitalized terms in this Warrant shall have the meanings set forth in Section 17 . This Warrant was issued pursuant to Section 1 of that certain Securities Purchase Agreement, dated as of May 15, 2017 (the “ Subscription Date ”), by and among the Company, Icagen-T, Inc., a Delaware corporation, and the Holder, as amended from time to time (the “ Securities Purchase Agreement ”).

 

 

 

 

1.    EXERCISE OF WARRANT .

 

(a)           Mechanics of Exercise . Subject to the terms and conditions hereof (including, without limitation, the limitations set forth in Section 1(f) ), this Warrant may be exercised by the Holder on any day on or after the Issuance Date (an “ Exercise Date ”), in whole or in part, by delivery (whether via facsimile or otherwise) of a written notice, in the form attached hereto as Exhibit A (the “ Exercise Notice ”), of the Holder’s election to exercise this Warrant. Within one (1) Trading Day following an exercise of this Warrant as aforesaid, the Holder shall deliver payment to the Company of an amount equal to the Exercise Price in effect on the date of such exercise multiplied by the number of Warrant Shares as to which this Warrant was so exercised (the “ Aggregate Exercise Price ”) in cash, check or via wire transfer of immediately available funds if the Holder did not notify the Company in such Exercise Notice that such exercise was made pursuant to a Cashless Exercise (as defined in Section 1(d) ). The Holder shall not be required to deliver the original of this Warrant in order to effect an exercise hereunder. Execution and delivery of an Exercise Notice with respect to less than all of the Warrant Shares shall have the same effect as cancellation of the original of this Warrant and issuance of a new Warrant evidencing the right to purchase the remaining number of Warrant Shares. Execution and delivery of an Exercise Notice for all of the then-remaining Warrant Shares shall have the same effect as cancellation of the original of this Warrant after delivery of the Warrant Shares in accordance with the terms hereof. On or before the first (1st) Trading Day following the date on which the Company has received an Exercise Notice, the Company shall transmit by facsimile or electronic mail an acknowledgment of confirmation of receipt of such Exercise Notice, in the form attached hereto as Exhibit B , to the Holder and the Company’s transfer agent (the “ Transfer Agent ”), which confirmation shall constitute an instruction to the Transfer Agent to process such Exercise Notice in accordance with the terms herein. On or before the third (3 rd ) Trading Day following the date on which the Company has received such Exercise Notice (or such earlier date as required pursuant to the 1934 Act or other applicable law, rule or regulation for the settlement of a trade of such Warrant Shares initiated on the applicable Exercise Date), (the “ Share Delivery Date ”), the Company shall; provided that the Aggregate Exercise Price has been delivered in the time period set forth above, unless the Aggregate Exercise Price is paid through a cashless exercise (X) provided that the Transfer Agent is participating in The Depository Trust Company (“ DTC ”) Fast Automated Securities Transfer Program, credit such aggregate number of shares of Common Stock to which the Holder’s or its designee’s balance account with DTC through its Deposit/Withdrawal at Custodian system, or (Y) if the Transfer Agent is not participating in the DTC Fast Automated Securities Transfer Program, upon the request of the Holder, issue and deliver (via reputable overnight courier) to the address as specified in the Exercise Notice, a certificate, registered in the name of the Holder or its designee, for the number of shares of Common Stock to which the Holder shall be entitled pursuant to such exercise. Upon delivery of an Exercise Notice, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date such Warrant Shares are credited to the Holder’s DTC account or the date of delivery of the certificates evidencing such Warrant Shares (as the case may be). If this Warrant is submitted in connection with any exercise pursuant to this Section 1(a) and the number of Warrant Shares represented by this Warrant submitted for exercise is greater than the number of Warrant Shares being acquired upon an exercise and upon surrender of this Warrant to the Company by the Holder, then, at the request of the Holder, the Company shall as soon as practicable and in no event later than three (3) Business Days after any exercise and at its own expense, issue and deliver to the Holder (or its designee) a new Warrant (in accordance with Section 7(d) ) representing the right to purchase the number of Warrant Shares purchasable immediately prior to such exercise under this Warrant, less the number of Warrant Shares with respect to which this Warrant is exercised. No fractional shares of Common Stock are to be issued upon the exercise of this Warrant, but rather the number of shares of Common Stock to be issued shall be rounded up to the nearest whole number. The Company shall pay any and all transfer, stamp, issuance and similar taxes, costs and expenses (including, without limitation, fees and expenses of the Transfer Agent) that may be payable with respect to the issuance and delivery of Warrant Shares upon exercise of this Warrant.

 

  2  

 

 

(b)           Exercise Price . For purposes of this Warrant, “ Exercise Price ” means $3.50, subject to adjustment as provided herein.

 

(c)           Company’s Failure to Timely Deliver Securities . If the Company fails on or prior to the Share Delivery Deadline to issue and deliver to the Holder (or its designee) a certificate and register such shares of Common Stock on the Company’s share register or, credit the balance account of the Holder or the Holder’s designee with DTC for the number of shares of Common Stock to which the Holder is entitled upon the Holder’s exercise hereunder (as the case may be pursuant to this Section 1(c) and/or pursuant to the Company’s obligation pursuant to clause (ii) below) and if on or after such Share Delivery Deadline the Holder purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by the Holder of all or any portion of the number of shares of Common Stock issuable upon such exercise that the Holder anticipated receiving from the Company (a “ Buy-In ”), then, in addition to all other remedies available to the Holder, the Company shall, within three (3) Business Days after the Holder’s request and in the Holder’s discretion, either (i) pay cash to the Holder in an amount equal to the Holder’s total purchase price (including brokerage commissions and other out-of-pocket expenses, if any) for the shares of Common Stock so purchased (including, without limitation, by any other Person in respect, or on behalf, of the Holder) (the “ Buy-In Price ”), at which point the Company’s obligation to so issue and deliver such certificate (and to issue such shares of Common Stock) or credit the balance account of such Holder or such Holder’s designee, as applicable, with DTC for the number of Warrant Shares to which the Holder is entitled upon the Holder’s exercise hereunder (as the case may be) (and to issue such Warrant Shares) shall terminate, or (ii) promptly honor its obligation to so issue and deliver to the Holder a certificate or certificates representing such Warrant Shares or credit the balance account of such Holder or such Holder’s designee, as applicable, with DTC for the number of Warrant Shares to which the Holder is entitled upon the Holder’s exercise hereunder (as the case may be) and pay cash to the Holder in an amount equal to the excess (if any) of the Buy-In Price over the product of (A) such number of Warrant Shares multiplied by (B) the lowest Closing Sale Price or Closing Bid Price (as the case may be) of the Common Stock on any Trading Day during the period commencing on the date of the applicable Exercise Notice and ending on the date of such issuance and payment under this clause (ii) (the “ Buy-In Payment Amount ”). Nothing shall limit the Holder’s right to pursue any other remedies available to it hereunder, at law or in equity, including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver certificates representing shares of Common Stock (or to electronically deliver such shares of Common Stock) upon the exercise of this Warrant as required pursuant to the terms hereof.

 

  3  

 

 

(d)           Cashless Exercise . If the Company is a Trading Issuer and at the applicable time an effective registration statement is not available for the issuance of Warrant Shares and notwithstanding anything contained herein to the contrary (other than Section 1(f) below), the Holder may, in its sole discretion, exercise this Warrant in whole or in part and, in lieu of making the cash payment otherwise contemplated to be made to the Company upon such exercise in payment of the Aggregate Exercise Price, elect instead to receive upon such exercise the “ Net Number ” of Warrant Shares determined according to the following formula (a “ Cashless Exercise ”):

 

Net Number = (A x B) - (A x C)

D

For purposes of the foregoing formula:

 

A= the total number of shares with respect to which this Warrant is then being exercised.

 

B = the lowest Closing Bid Price or Closing Sale Price (as the case may be) during the ten (10) consecutive Trading Days ending at the close of business on the Principal Market immediately prior to the time of exercise as set forth in the applicable Exercise Notice.

 

C = the Exercise Price then in effect for the applicable Warrant Shares at the time of such exercise.

 

D = as applicable: the Closing Sale Price or Closing Bid Price (as the case may be) of the Common Stock on the Trading Day immediately preceding the date of the applicable Exercise Notice.

 

For purposes of Rule 144(d) promulgated under the 1933 Act, as in effect on the Subscription Date, it is intended that the Warrant Shares issued in a Cashless Exercise shall be deemed to have been acquired by the Holder, and the holding period for the Warrant Shares shall be deemed to have commenced, on the date this Warrant was originally issued pursuant to the Securities Purchase Agreement.

 

(e)           Disputes . In the case of a dispute as to the determination of the Exercise Price or the arithmetic calculation of the number of Warrant Shares to be issued pursuant to the terms hereof, the Company shall promptly issue to the Holder the number of Warrant Shares that are not disputed and resolve such dispute in accordance with Section 13 .

 

  4  

 

 

(f)           Limitations on Exercises . The Company shall not effect the exercise of any portion of this Warrant, and the Holder shall not have the right to exercise any portion of this Warrant, pursuant to the terms and conditions of this Warrant and any such exercise shall be null and void and treated as if never made, to the extent that after giving effect to such exercise, the Holder together with the other Attribution Parties collectively would beneficially own in excess of 9.99% (the “ Maximum Percentage ”) of the shares of Common Stock outstanding immediately after giving effect to such exercise, such determination by the Company to be based solely upon the Reported Outstanding Share Number (as defined below) and the number of shares disclosed to the Company by Holder as being beneficially owned by the Holder and the other Attribution Parties. For purposes of the foregoing sentence, the aggregate number of shares of Common Stock beneficially owned by the Holder and the other Attribution Parties shall include the number of shares of Common Stock held by the Holder and all other Attribution Parties plus the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which the determination of such sentence is being made, but shall exclude shares of Common Stock which would be issuable upon (A) exercise of the remaining, unexercised portion of this Warrant beneficially owned by the Holder or any of the other Attribution Parties and (B) exercise or conversion of the unexercised or unconverted portion of any other securities of the Company (including, without limitation, any convertible notes or convertible preferred stock or warrants, including, without limitation, the Warrant) beneficially owned by the Holder or any other Attribution Party subject to a limitation on conversion or exercise analogous to the limitation contained in this Section 1(f)(i) . For purposes of this Section 1(f)(i) , beneficial ownership shall be calculated in accordance with Section 13(d) of the 1934 Act. For purposes of determining the number of outstanding shares of Common Stock the Holder may acquire upon the exercise of this Warrant without exceeding the Maximum Percentage, the Holder may rely on the number of outstanding shares of Common Stock as reflected in (x) the Company’s most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q, Current Report on Form 8-K or other public filing with the SEC, as the case may be, (y) a more recent public announcement by the Company or (z) any other written notice by the Company or the Transfer Agent, if any, setting forth the number of shares of Common Stock outstanding (the “ Reported Outstanding Share Number ”). If the Company receives an Exercise Notice from the Holder at a time when the actual number of outstanding shares of Common Stock is less than the Reported Outstanding Share Number, the Company shall (i) notify the Holder in writing of the number of shares of Common Stock then outstanding and, to the extent that such Exercise Notice would otherwise cause the Holder’s beneficial ownership, as determined pursuant to this Section 1(f)(i) , to exceed the Maximum Percentage, the Holder must notify the Company of a reduced number of Warrant Shares to be acquired pursuant to such Exercise Notice (the number of shares by which such purchase is reduced, the “ Reduction Shares ”) and (ii) as soon as reasonably practicable, the Company shall return to the Holder any exercise price paid by the Holder for the Reduction Shares. For any reason at any time, upon the written or oral request of the Holder, the Company shall within one (1) Business Day confirm orally and in writing or by electronic mail to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder and any other Attribution Party since the date as of which the Reported Outstanding Share Number was reported. In the event that the issuance of shares of Common Stock to the Holder upon exercise of this Warrant results in the Holder and the other Attribution Parties being deemed to beneficially own, in the aggregate, more than the Maximum Percentage of the number of outstanding shares of Common Stock (as determined under Section 13(d) of the 1934 Act), the number of shares so issued by which the Holder’s and the other Attribution Parties’ aggregate beneficial ownership exceeds the Maximum Percentage (the “ Excess Shares ”) shall be deemed null and void and shall be cancelled ab initio , and the Holder shall not have the power to vote or to transfer the Excess Shares. As soon as reasonably practicable after the issuance of the Excess Shares has been deemed null and void, the Company shall return to the Holder the exercise price paid by the Holder for the Excess Shares. Upon delivery of a written notice to the Company, the Holder may from time to time increase (with such increase not effective until the sixty-first (61st) day after delivery of such notice) or decrease the Maximum Percentage to any other percentage not in excess of 9.99% as specified in such notice; provided that any such increase in the Maximum Percentage will not be effective until the sixty-first (61st) day after such notice is delivered to the Company. For purposes of clarity, the shares of Common Stock issuable pursuant to the terms of this Warrant in excess of the Maximum Percentage shall not be deemed to be beneficially owned by the Holder for any purpose including for purposes of Section 13(d) or Rule 16a-1(a)(1) of the 1934 Act. No prior inability to exercise this Warrant pursuant to this paragraph shall have any effect on the applicability of the provisions of this paragraph with respect to any subsequent determination of exercisability. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 1(f)(i) to the extent necessary to correct this paragraph or any portion of this paragraph which may be defective or inconsistent with the intended beneficial ownership limitation contained in this Section 1(f)(i) or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitation contained in this paragraph may not be waived and shall apply to a successor holder of this Warrant.

 

  5  

 

 

 

(g)           Reservation of Shares .

 

(i)           Required Reserve Amount . Commencing on the Closing Date and continuing as long as this Warrant remains outstanding (the “ Share Reserve Period ”), the Company shall at all times keep reserved for issuance under this Warrant at least 200% of the maximum number of shares of Common Stock as shall from time to time be necessary to satisfy the Company’s obligation to issue shares of Common Stock under this Warrant (without regard to any limitations on exercise and assuming for purposes of this Section 1(g) that the Holder does not exercise any portion of this Warrant on a Cashless Basis and in any event does not exercise this Warrant until the last calendar date prior to the Expiration Date)  (the “ Required Reserve Amount ”); provided that at no time shall the number of shares of Common Stock reserved pursuant to this Section 1(g)(i) be reduced.

 

(ii)          Insufficient Authorized Shares . If, notwithstanding Section 1(g)(i) above, and not in limitation thereof, at any time while this Warrants remains outstanding, the Company does not have a sufficient number of authorized and unreserved shares of Common Stock to satisfy its obligation to reserve the Required Reserve Amount (an “ Authorized Share Failure ”), then the Company shall immediately take all action necessary to increase the Company’s authorized shares of Common Stock to an amount sufficient to allow the Company to reserve the Required Reserve Amount for this Warrant. Without limiting the generality of the foregoing sentence, as soon as practicable after the date of the occurrence of an Authorized Share Failure, but in no event later than ninety (90) days after the occurrence of such Authorized Share Failure, the Company shall either (i) hold a meeting of its stockholders for the approval of an increase in the number of authorized shares of Common Stock, or (ii) have cured the Authorized Share Failure by, among other required items, obtaining a written consent of the required percentage of holders of shares Common Stock for the required increase in authorized shares and had taken any and all other such action necessary to rectify the Authorized Share Failure including, but not limited to, providing the non-consenting stockholders with an information statement and a Form 14(C) and filed with the SEC such Form 14(C). In connection with such meeting as set forth in (i) above, the Company shall provide each stockholder with a proxy statement and shall use its best efforts to solicit its stockholders’ approval of such increase in authorized shares of Common Stock and to cause its board of directors to recommend to the stockholders that they approve such proposal. In the event that the Company is prohibited from issuing shares of Common Stock upon an exercise of this Warrant due to the failure by the Company to have sufficient shares of Common Stock available out of the authorized but unissued shares of Common Stock (such unavailable number of shares of Common Stock, the “ Authorization Failure Shares ”), in lieu of delivering such Authorization Failure Shares to the Holder, the Company shall pay cash in exchange for the cancellation of such portion of this Warrant exercisable into such Authorized Failure Shares at a price equal to the sum of (i) the product of (x) such number of Authorization Failure Shares and (y) the greatest Closing Sale Price or Closing Bid Price (as the case may be) of the Common Stock on any Trading Day during the period commencing on the date the Holder delivers the applicable Exercise Notice with respect to such Authorization Failure Shares to the Company and ending on the date of such issuance and payment under this Section 1(g) (or the Exercise Price if the Company is not then a Trading Issuer); and (ii) to the extent the Holder purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by the Holder of Authorization Failure Shares, any Buy-In Payment Amount, brokerage commissions and other out-of-pocket expenses, if any, of the Holder incurred in connection therewith. Nothing contained in this Section 1(g) shall limit any obligations of the Company under any provision of the Securities Purchase Agreement. 

 

  6  

 

 

2.     ADJUSTMENT OF EXERCISE PRICE AND NUMBER OF WARRANT SHARES; RESET OF EXERCISE PRICE . The Exercise Price and number of Warrant Shares issuable upon exercise of this Warrant are subject to adjustment from time to time as set forth in this Section 2.

 

(a)           Stock Dividends and Splits . Without limiting any provision of Section 2(b) or Section 4 , if the Company, at any time on or after the Subscription Date, (i) pays a stock dividend on one or more classes of its then outstanding shares of Common Stock or otherwise makes a distribution on any class of capital stock that is payable in shares of Common Stock, (ii) subdivides (by any stock split, stock dividend, recapitalization or otherwise) one or more classes of its then outstanding shares of Common Stock into a larger number of shares or (iii) combines (by combination, reverse stock split or otherwise) one or more classes of its then outstanding shares of Common Stock into a smaller number of shares, then in each such case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event. Any adjustment made pursuant to clause (i) of this paragraph shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution, and any adjustment pursuant to clause (ii) or (iii) of this paragraph shall become effective immediately after the effective date of such subdivision or combination. If any event requiring an adjustment under this paragraph occurs during the period that an Exercise Price is calculated hereunder, then the calculation of such Exercise Price shall be adjusted appropriately to reflect such event.

 

  7  

 

 

(b)           Adjustment Upon Issuance of Shares of Common Stock Prior to the Closing Date of a Qualifying PO . In addition to and not in limitation of any other rights of the Holder under this Warrant including, but not limited to, Section 2 hereof and/or any other Transaction Document, if, at any time while this Note is outstanding and whenever on or after the Subscription Date but prior to the closing date of a Qualifying PO (as defined below), the Company, the Parent and/or any Subsidiary (as defined in the Securities Purchase Agreement), in any manner sells or grants any option to purchase, issues or sells or grants any right to reprice, and/or otherwise sells, disposes of and/or issues any shares of Common Stock or Common Stock Equivalents (as defined below) (including upon conversion, exercise or otherwise) entitling any Person to acquire shares of Common Stock at a price per share of Common Stock that is lower than the then Exercise Price (such lower price, the “ New Issuance Price ” and each such issuance, a “ Dilutive Issuance ” and collectively, “ Dilutive Issuances ”), (if the holder of shares of Common Stock or Common Stock Equivalents so issued and/or any holder of Common Stock and/or Common Stock Equivalents as of the Subscription Date or issued subsequent thereto, shall at any time, whether by amendment, supplement, operation of purchase price adjustments, reset provisions, floating conversion, exercise or exchange prices or otherwise be entitled under the terms of any such instruments to receive shares of Common Stock at a price per share that is lower than the Exercise Price, such issuance shall be deemed to have occurred for less than the Exercise Price on such date of the Dilutive Issuance), then the then Exercise Price shall be reduced to equal the New Issuance Price.  For purposes of clarification, if the Company, the Parent and/or any Subsidiary issues, sells and/or otherwise disposes of any shares of Common Stock at a price less than the then Exercise Price, the then Exercise Price shall immediately be reduced to the New Issuance Price on the date of such Dilutive Issuance. All adjustments provided for in this Section 2(b) shall be made whenever any such Common Stock or Common Stock Equivalents are issued. Notwithstanding anything to the contrary in the foregoing, if a Dilutive Issuance consists of the issuance and/or sale of both Common Stock and Common Stock Equivalents or two or more Common Stock Equivalents as units (each, a “ Share and/or a CSE Issuance ”), in determining the value of the component parts of the unit issued and/or sold in a Share and/or a CSE Issuance no value will be attributed to Common Stock Equivalents and the New Issuance Price as a result thereof will be the lowest of (i) the lowest purchase price per unit, (ii) the lowest conversion, exercise and/or exchange price to acquire one (1) share of Common Stock of any Common Stock Equivalent included in a unit if a unit also includes shares of Common Stock, and (iii) if no shares of Common Stock are included in a unit, the lowest exercise, conversion and/or exchange price to acquire one (1) share of Common Stock of the Common Stock Equivalents comprising a unit, such lowest price of (i)-(iii) shall be the “ Lowest Price ;” provided , however, a Dilutive Issuance and a resulting New Issuance Price relating to a Share and/or a CSE Issuance shall only occur if the Lowest Price relating to a Share and/or a CSE Issuance is lower than the then Exercise Price. Notwithstanding the foregoing, no adjustment will be made under this Section 2(b) in respect of an Exempt Issuance.   The Company shall notify the Holder in writing, no later than the first Trading Day following the issuance of any Common Stock or Common Stock Equivalents subject to this Section 2(b) , indicating therein the applicable Lowest Price, issuance price, reset price, exchange price, conversion price and Exercise Price and other pricing terms (such notice, the “ Dilutive Issuance Notice ”). For purposes of clarification, whether or not the Parent provides a Dilutive Issuance Notice upon the occurrence of any Dilutive Issuance, the Holder is entitled to receive a number of shares of Common Stock based upon the New Issuance Price on or after the date of such Dilutive Issuance, regardless of whether the Holder accurately refers to the New Issuance Price in any Exercise Notice. For purposes hereof, the term “ Common Stock Equivalents ” means any securities (as defined under the 1933 Act) including, but not limited to, any Options and/or Convertible Securities of the Company, the Parent and/or any Subsidiaries which would entitle the Holder thereof to acquire at any time shares of Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the Holder thereof to receive, shares of Parent Common Stock. If the Parent, the Company and/or any Subsidiary enters into a Variable Rate Transaction (as defined in the Securities Purchase Agreement) despite the prohibition set forth in the Securities Purchase Agreement, the Parent shall be deemed to have issued shares of Common Stock or Common Stock Equivalents at the lowest possible price at which such securities may be converted, exchanged and/or exercised under the terms of such Variable Rate Transaction.

 

  8  

 

 

(c)           Calculations . All calculations under this Section 2 shall be made by rounding to the nearest cent or the nearest 1/100th of a share, as applicable. The number of shares of Common Stock outstanding at any given time shall not include shares owned or held by or for the account of the Company, and the disposition of any such shares shall be considered an issuance or sale of Common Stock.

 

(d)           Voluntary Adjustment By Company . The Company may at any time during the term of this Warrant, with the prior written consent of the Holders, reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by the board of directors of the Company.

 

(e)           Certain Reset Right Upon a Qualifying PO . If on or after the Subscription Date, the Company consummates a Qualifying PO, and on the closing date of such Qualifying PO, the then Exercise Price in effect on such date is greater than the Qualifying PO Per Share Sale Price (as defined below), then the Exercise Price shall automatically and without any action by the Company or otherwise, be reset to the Qualifying PO Per Share Sale Price.  A “ Qualifying PO Per Share Sale Price ” shall be as applicable (i) the gross purchase price a share of Common Stock is sold to the public in the Qualifying PO if only shares of Common Stock are sold to the public in such Qualifying PO, (ii) the gross purchase price a unit consisting of shares of Common Stock and Common Stock Equivalents is sold to the public in the Qualifying PO, or (iii) the sum equal to the gross purchase price of (a) one (1) share of Common Stock, and (b) a Common Stock Equivalent if such are sold to each purchaser in a Qualifying PO but not in a unit.

 

3.     RIGHTS UPON DISTRIBUTION OF ASSETS . In addition to any adjustments provided for elsewhere in this Warrant including, but not limited to, pursuant to Section 2 above, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property, options, evidence of indebtedness or any other assets by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a “ Distribution ”), at any time after the issuance of this Warrant, then, in each such case, the Holder shall to be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations or restrictions on exercise of this Warrant, including without limitation, the Maximum Percentage) immediately before the date on which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (provided, however, that to the extent that the Holder’s right to participate in any such Distribution would result in the Holder and the other Attribution Parties exceeding the Maximum Percentage, then the Holder shall not be entitled to participate in such Distribution to such extent (and shall not be entitled to beneficial ownership of such shares of Common Stock as a result of such Distribution (and beneficial ownership) to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time or times, if ever, as its right thereto would not result in the Holder and the other Attribution Parties exceeding the Maximum Percentage, at which time or times the Holder shall be granted such Distribution (and any Distributions declared or made on such initial Distribution or on any subsequent Distribution held similarly in abeyance) to the same extent as if there had been no such limitation).

 

  9  

 

 

4.           PURCHASE RIGHTS; FUNDAMENTAL TRANSACTIONS .

 

(a)           Purchase Rights . In addition to any adjustments provided for elsewhere in this Warrant including, but not limited to, pursuant to Section 2 above, if at any time the Company grants, issues or sells any Options, Convertible Securities or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of Common Stock (the “ Purchase Rights ”),  then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights , the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations or restrictions on exercise of this Warrant, including without limitation, the Maximum Percentage) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issuance or sale of such Purchase Rights (provided, however, that to the extent that the Holder’s right to participate in any such Purchase Right would result in the Holder and the other Attribution Parties exceeding the Maximum Percentage, then the Holder shall not be entitled to participate in such Purchase Right to such extent (and shall not be entitled to beneficial ownership of such shares of Common Stock as a result of such Purchase Right (and beneficial ownership) to such extent) and such Purchase Right to such extent shall be held in abeyance for the benefit of the Holder until such time or times, if ever, as its right thereto would not result in the Holder and the other Attribution Parties exceeding the Maximum Percentage, at which time or times the Holder shall be granted such right (and any Purchase Right granted, issued or sold on such initial Purchase Right or on any subsequent Purchase Right held similarly in abeyance) to the same extent as if there had been no such limitation).

 

  10  

 

 

(b)           Fundamental Transactions . Subject to the rights of (i) the Company or a Successor Entity (as the case may be) to redeem this Warrant pursuant to Section 4(c)(i) , and (ii) the Holder to require the redemption of this Warrant by the Company or the Successor Entity (as the case may be) pursuant to Section 4(c)(ii) , the Company shall not enter into or be party to a Fundamental Transaction unless (i) the Successor Entity assumes in writing all of the obligations of the Company under this Warrant and the other Transaction Documents (as defined in the Securities Purchase Agreement) in accordance with the provisions of this Section 4(b) pursuant to written agreements in form and substance satisfactory to the Holder and approved by the Holder prior to such Fundamental Transaction, including agreements to deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant, including, without limitation, which is exercisable for a corresponding number of shares of capital stock equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such adjustments to the number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction); and (ii) the Successor Entity (including the Parent Entity) is a publicly traded corporation whose shares of common stock are quoted or listed on an Eligible Market. Upon the closing on the closing date of a Fundamental Transaction (an “ FT Closing Date ”), and subject to the rights of (A) the Company or a Successor Entity (as the case may be) to redeem this Warrant pursuant to Section 4(c)(i) , and (B) the Company or the Successor Entity including the Parent Entity (as the case may be) to redeem this Warrant pursuant to a demand of the Holder pursuant to Section 4(c)(ii), the Successor Entity shall succeed to, and be substituted for (so that from and after the date of the applicable Fundamental Transaction, the provisions of this Warrant and the other Transaction Documents referring to the “Company” shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant and the other Transaction Documents with the same effect as if such Successor Entity had been named as the Company herein. Upon consummation of each Fundamental Transaction, unless there is a redemption under 4(c)(i) or 4(c)(ii), the Successor Entity shall deliver to the Holder confirmation that there shall be issued upon exercise of this Warrant at any time after the consummation of the applicable Fundamental Transaction, in lieu of the shares of Common Stock (or other securities, cash, assets or other property (except such items still issuable under Sections 3 and 4(a) above, which shall continue to be receivable thereafter)) issuable upon the exercise of this Warrant prior to the applicable Fundamental Transaction, such shares of publicly traded common stock (or its equivalent) of the Successor Entity (including its Parent Entity) which the Holder would have been entitled to receive upon the happening of the applicable Fundamental Transaction had this Warrant been exercised immediately prior to the applicable Fundamental Transaction (without regard to any limitations on the exercise of this Warrant), as adjusted in accordance with the provisions of this Warrant. In addition to and not in substitution for any other rights hereunder, prior to the consummation of each Fundamental Transaction pursuant to which holders of shares of Common Stock are entitled to receive securities or other assets with respect to or in exchange for shares of Common Stock (a “ Corporate Event ”), the Company shall make appropriate provision to insure that the Holder will thereafter have the right to receive upon any full or partial (as proportionately determined) exercise of this Warrant at any time (i) prior to the FT Closing Date, and/or (ii) at any time following a FT Closing Date if no redemption occurred on the FT Closing Date unless there is a redemption under Section 4(c)(i) or Section 4(c)(ii) but prior to the Expiration Date, in lieu of the shares of the Common Stock (or other securities, cash, assets or other property (except such items still issuable under Sections 3 and 4(a) above, which shall continue to be receivable thereafter) issuable upon the exercise of the Warrant prior to such Fundamental Transaction, such shares of stock, securities, cash, assets or any other property whatsoever (including warrants or other purchase or subscription rights) which the Holder would have been entitled to receive upon the happening of the applicable Fundamental Transaction had this Warrant been exercised immediately prior to the applicable Fundamental Transaction (without regard to any limitations on the exercise of this Warrant). Provision made pursuant to the preceding sentence shall be in a form and substance reasonably satisfactory to the Holder; provided , however , notwithstanding anything to the contrary or elsewhere, if the Company or the Successor Entity, including the Parent Entity, elects to redeem this Warrant pursuant to Section 4(c)(i) and complies with such related provisions and if on the FT Closing Date this Warrant or any portion of this Warrant is outstanding, the Company shall have the right to redeem this Warrant as provided in Section 4(c)(i) below.

 

  11  

 

 

(c)           Redemption of Warrant in Certain Events.

 

(i)           Company/Successor Entity Fundamental Redemption Right . Subject to the rights of the Holder pursuant to Section 4(c)(ii) and notwithstanding anything to the contrary provided in Section 4(b) above, the Company or any Successor Entity (as the case may be) shall have the right on a FT Closing Date to redeem this Warrant provided the Company or the Successor Entity including a Parent Entity (as the case may be) provides to the Holder written notice of such election pursuant to Section 8 hereof, and paying to the Holder in full, in cash on the FT Closing Date the Black Scholes Value or the Event of Default Black Scholes Value (if on the FT Closing Date an Event of Default (as defined in the Notes) has occurred and is continuing), the “ Warrant Redemption Price ”, in accordance with and pursuant to this Section 4(c)(i) , and on such FT Closing Date the Company or the Successor Entity including a Parent Entity (as the case may be) shall also provide written notice to the Holder of the payment of the Warrant Redemption Price, the amount thereof and the calculations as to how such Warrant Redemption Price was determined (including whether such was the Black Scholes Value or the Event of Default Black Scholes Value). Notwithstanding that the Company or the Successor Entity (as the case may be) has delivered notice of election to redeem this Warrant pursuant to this Section 4(c)(i) the Holder may nevertheless exercise this Warrant in whole or in part at any time and from time to time through and including the last Trading Day prior to the FT Closing Date. If the Warrant Redemption Price is not received by the Holder in full, in cash (by wire transfer or bank check) by 11:59 p.m. (New York City time) by the first (1 st ) Trading Day following the FT Closing Date, the right of the Company or the Successor Entity (as the case may be) shall terminate with respect to that Fundamental Change as shall all future redemption rights of the Company (including to have a Successor Entity do the same) to elect to redeem this Warrant pursuant to Section 4(c)(i) or otherwise and the Holder shall have the same rights set forth in Section 4(b) it would have had but for the election of the Company pursuant to this Section 4(c)(i) . The agreement governing the Fundamental Transaction shall make provision for redemption of the Warrant by the Company or the Successor Entity and also for if the Company or the Successor Entity (as the case may be) elects to redeem this Warrant pursuant to Section 4(c)(i) but fails to timely honor all of their respective obligations pursuant to Section 4(c)(i) .

 

  12  

 

 

(ii)          Mandatory Fundamental Transaction Redemption at the Request of the Holder . Notwithstanding the provisions of Sections 4(b) and/or 4(c)(i) , at the request of the Holder delivered at any time commencing on the earliest to occur of (x) the public disclosure of any Fundamental Transaction, (y) the consummation of any Fundamental Transaction and (z) the Holder first becoming aware of any Fundamental Transaction through the date that is thirty (30) days after the public disclosure of the consummation of such Fundamental Transaction by the Company pursuant to a Current Report on Form 8-K filed with the SEC, the Company or the Successor Entity including the Parent Entity (as the case may be) shall purchase this Warrant from the Holder on the date of such request by paying to the Holder cash an amount equal to the Black Scholes Value (or the Event of Default Black Scholes Value if on the date of the required redemption payment to the Holder, an Event of Default exists). Notwithstanding anything to the contrary contained herein, if the FT Closing Date occurs prior to the foregoing thirty (30) day time period, the Company or Successor Entity (as the case may be) may pay the Warrant Redemption Price on the FT Closing Date and thereafter, if all the redemption procedures required herein including Section 8 are followed and the Warrant is redeemed in full, this Warrant shall terminate.

 

(iii)         Event of Default Redemption . Notwithstanding Section 4(c)(i) and (ii) and Section 4(b) above, at the request of the Holder delivered at any time after the occurrence of an Event of Default (as defined in the Notes and regardless of if the Notes are no longer outstanding), the Company or the Successor Entity (as the case may be) shall purchase this Warrant from the Holder on the date of such request by paying to the Holder cash in an amount equal to the Event of Default Black Scholes Value.

 

(d)           Application . The provisions of this Section 4 shall apply similarly and equally to successive Fundamental Transactions and Corporate Events and shall be applied as if this Warrant (and any such subsequent warrants) were fully exercisable and without regard to any limitations on the exercise of this Warrant (provided that the Holder shall continue to be entitled to the benefit of the Maximum Percentage, applied however with respect to shares of capital stock registered under the 1934 Act and thereafter receivable upon exercise of this Warrant (or any other warrant)).

 

5.     NONCIRCUMVENTION . The Company hereby covenants and agrees that the Company will not, by amendment of its Certificate of Incorporation (as defined in the Securities Purchase Agreement), Bylaws (as defined in the Securities Purchase Agreement) or through any reorganization, transfer of assets, consolidation, merger, scheme of arrangement, dissolution, issuance or sale of securities, or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, and will at all times in good faith carry out all the provisions of this Warrant and take all action as may be required to protect the rights of the Holder. Without limiting the generality of the foregoing, the Company (a) shall not increase the par value of any shares of Common Stock receivable upon the exercise of this Warrant above the Exercise Price then in effect, and (b) shall take all such actions as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and non-assessable shares of Common Stock upon the exercise of this Warrant. Notwithstanding anything herein to the contrary, if after the sixty (60) calendar day anniversary of the Issuance Date, the Holder is not permitted to exercise this Warrant in full for any reason (other than pursuant to restrictions set forth in Section 1(f) hereof), the Company shall use its best efforts to promptly remedy such failure, including, without limitation, obtaining such consents or approvals as necessary to permit such exercise into shares of Common Stock.

 

  13  

 

 

6.     WARRANT HOLDER NOT DEEMED A STOCKHOLDER . Except as otherwise specifically provided herein, the Holder, solely in its capacity as a holder of this Warrant, shall not be entitled to vote or receive dividends or be deemed the holder of share capital of the Company for any purpose, nor shall anything contained in this Warrant be construed to confer upon the Holder, solely in its capacity as the Holder of this Warrant, any of the rights of a stockholder of the Company or any right to vote, give or withhold consent to any corporate action (whether any reorganization, issue of stock, reclassification of stock, consolidation, merger, conveyance or otherwise), receive notice of meetings, receive dividends or subscription rights, or otherwise, prior to the issuance to the Holder of the Warrant Shares which it is then entitled to receive upon the due exercise of this Warrant. In addition, nothing contained in this Warrant shall be construed as imposing any liabilities on the Holder to purchase any securities (upon exercise of this Warrant or otherwise) or as a stockholder of the Company, whether such liabilities are asserted by the Company or by creditors of the Company. Notwithstanding this Section 6, the Company shall provide the Holder with copies of the same notices and other information given to the stockholders of the Company generally, contemporaneously with the giving thereof to the stockholders.

 

7.     REISSUANCE OF WARRANTS.

 

(a)           Transfer of Warrant . If this Warrant is to be transferred, the Holder shall surrender this Warrant to the Company, whereupon the Company will forthwith issue and deliver upon the order of the Holder a new Warrant (in accordance with Section 7(d) ), registered as the Holder may request, representing the right to purchase the number of Warrant Shares being transferred by the Holder and, if less than the total number of Warrant Shares then underlying this Warrant is being transferred, a new Warrant (in accordance with Section 7(d) ) to the Holder representing the right to purchase the number of Warrant Shares not being transferred.

 

(b)           Lost, Stolen or Mutilated Warrant . Upon receipt by the Company of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant (as to which a written certification and the indemnification contemplated below shall suffice as such evidence), and, in the case of loss, theft or destruction, of any indemnification undertaking by the Holder to the Company in customary and reasonable form and, in the case of mutilation, upon surrender and cancellation of this Warrant, the Company shall execute and deliver to the Holder a new Warrant (in accordance with Section 7(d) ) representing the right to purchase the Warrant Shares then underlying this Warrant.

 

(c)           Exchangeable for Multiple Warrants . This Warrant is exchangeable, upon the surrender hereof by the Holder at the principal office of the Company, for a new Warrant or Warrants (in accordance with Section 7(d) ) representing in the aggregate the right to purchase the number of Warrant Shares then underlying this Warrant, and each such new Warrant will represent the right to purchase such portion of such Warrant Shares as is designated by the Holder at the time of such surrender; provided, however, no warrants for fractional shares of Common Stock shall be given.

 

  14  

 

 

(d)           Issuance of New Warrants . Whenever the Company is required to issue a new Warrant pursuant to the terms of this Warrant, such new Warrant (i) shall be of like tenor with this Warrant, (ii) shall represent, as indicated on the face of such new Warrant, the right to purchase the Warrant Shares then underlying this Warrant (or in the case of a new Warrant being issued pursuant to Section 7(a) or Section 7(c) , the Warrant Shares designated by the Holder which, when added to the number of shares of Common Stock underlying the other new Warrants issued in connection with such issuance, does not exceed the number of Warrant Shares then underlying this Warrant), (iii) shall have an issuance date, as indicated on the face of such new Warrant which is the same as the Issuance Date, and (iv) shall have the same rights and conditions as this Warrant.

 

8.     NOTICES . Whenever notice is required to be given under this Warrant, unless otherwise provided herein, such notice shall be given in accordance with Section 9(f) of the Securities Purchase Agreement. The Company shall provide the Holder with prompt written notice of all actions taken pursuant to this Warrant (other than the issuance of shares of Common Stock upon exercise in accordance with the terms hereof), including in reasonable detail a description of such action and the reason therefor. Without limiting the generality of the foregoing, the Company will give written notice to the Holder (i) immediately upon each adjustment of the Exercise Price and the number of Warrant Shares, setting forth in reasonable detail, and certifying, the calculation of such adjustment(s), (ii) at least ten (10) days prior to the date on which the Company closes its books or takes a record (A) with respect to any dividend or distribution upon the shares of Common Stock or (B) for determining rights to vote with respect to any Fundamental Transaction, dissolution or liquidation, provided in each case that such information shall be made known to the public prior to or in conjunction with such notice being provided to the Holder, (iii) at least ten (10) Trading Days prior to an FT Closing Date, and (iv) within one (1) Business Day of the occurrence of an Event of Default (as defined in the Notes), setting forth in reasonable detail any material events with respect to such Event of Default and any efforts by the Company to cure such Event of Default. To the extent that any notice provided hereunder constitutes, or contains, material, non-public information regarding the Company or any of its Subsidiaries, the Company shall simultaneously file such notice with the SEC (as defined in the Securities Purchase Agreement) pursuant to a Current Report on Form 8-K. It is expressly understood and agreed that the time of execution specified by the Holder in each Exercise Notice shall be definitive and may not be disputed or challenged by the Company.

 

9.     AMENDMENT AND WAIVER . Except as otherwise provided herein, the provisions of this Warrant (other than Section 1(f)) may be amended and the Company may take any action herein prohibited, or omit to perform any act herein required to be performed by it, only if the Company has obtained the written consent of the Holder. No waiver shall be effective unless it is in writing and signed by an authorized representative of the waiving party.

 

10.   SEVERABILITY . If any provision of this Warrant is prohibited by law or otherwise determined to be invalid or unenforceable by a court of competent jurisdiction, the provision that would otherwise be prohibited, invalid or unenforceable shall be deemed amended to apply to the broadest extent that it would be valid and enforceable, and the invalidity or unenforceability of such provision shall not affect the validity of the remaining provisions of this Warrant so long as this Warrant as so modified continues to express, without material change, the original intentions of the parties as to the subject matter hereof and the prohibited nature, invalidity or unenforceability of the provision(s) in question does not substantially impair the respective expectations or reciprocal obligations of the parties or the practical realization of the benefits that would otherwise be conferred upon the parties. The parties will endeavor in good faith negotiations to replace the prohibited, invalid or unenforceable provision(s) with a valid provision(s), the effect of which comes as close as possible to that of the prohibited, invalid or unenforceable provision(s).

 

  15  

 

 

11.   GOVERNING LAW . This Warrant shall be governed by and construed and enforced in accordance with, and all questions concerning the construction, validity, interpretation and performance of this Warrant shall be governed by, the internal laws of the State of New York, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of New York or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of New York. The Company hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof to the Company at the address set forth in Section 9(f) of the Securities Purchase Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. The Company hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in The City of New York, Borough of Manhattan, for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. Nothing contained herein shall be deemed or operate to preclude the Holder from bringing suit or taking other legal action against the Company in any other jurisdiction to collect on the Company’s obligations to the Holder, to realize on any collateral or any other security for such obligations, or to enforce a judgment or other court ruling in favor of the Holder. THE COMPANY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING OUT OF THIS WARRANT OR ANY TRANSACTION CONTEMPLATED HEREBY.

 

12.   CONSTRUCTION; HEADINGS . This Warrant shall be deemed to be jointly drafted by the Company and the Holder and shall not be construed against any Person as the drafter hereof. The headings of this Warrant are for convenience of reference and shall not form part of, or affect the interpretation of, this Warrant. Terms used in this Warrant but defined in the other Transaction Documents shall have the meanings ascribed to such terms on the Closing Date (as defined in the Securities Purchase Agreement) in such other Transaction Documents unless otherwise consented to in writing by the Holder.

 

13.   DISPUTE RESOLUTION .

 

(a)           Submission to Dispute Resolution .

  

(i)        In the case of a dispute relating to the Exercise Price, the Closing Sale Price, the Closing Bid Price, the Lowest Price, the Black Scholes Value, the Event of Default Black Scholes Value or fair market value or the arithmetic calculation of the number of Warrant Shares (as the case may be) (including, without limitation, a dispute relating to the determination of any of the foregoing), the Company or the Holder (as the case may be) shall submit the dispute to the other party via facsimile (A) if by the Company, within two (2) Business Days after the occurrence of the circumstances giving rise to such dispute or (B) if by the Holder, at any time after the Holder learned of the circumstances giving rise to such dispute. If the Holder and the Company are unable to promptly resolve such dispute relating to such Exercise Price, such Closing Sale Price, such Closing Bid Price, such Lowest Price, such Black Scholes Value, such Event of Default Black Scholes Value or such fair market value or such arithmetic calculation of the number of Warrant Shares (as the case may be), at any time after the second (2nd) Business Day following such initial notice by the Company or the Holder (as the case may be) of such dispute to the Company or the Holder (as the case may be), then the Holder may, at its sole option, select an independent, reputable investment bank to resolve such dispute.

 

  16  

 

 

 

(ii)       The Holder and the Company shall each deliver to such investment bank (A) a copy of the initial dispute submission so delivered in accordance with the first sentence of this Section 13 and (B) written documentation supporting its position with respect to such dispute, in each case, no later than 5:00 p.m. (New York time) by the fifth (5th) Business Day immediately following the date on which the Holder selected such investment bank (the “ Dispute Submission Deadline ”) (the documents referred to in the immediately preceding clauses (A) and (B) are collectively referred to herein as the “ Required Dispute Documentation ”) (it being understood and agreed that if either the Holder or the Company fails to so deliver all of the Required Dispute Documentation by the Dispute Submission Deadline, then the party who fails to so submit all of the Required Dispute Documentation shall no longer be entitled to (and hereby waives its right to) deliver or submit any written documentation or other support to such investment bank with respect to such dispute and such investment bank shall resolve such dispute based solely on the Required Dispute Documentation that was delivered to such investment bank prior to the Dispute Submission Deadline). Unless otherwise agreed to in writing by both the Company and the Holder or otherwise requested by such investment bank, neither the Company nor the Holder shall be entitled to deliver or submit any written documentation or other support to such investment bank in connection with such dispute (other than the Required Dispute Documentation).

 

(iii)      The Company and the Holder shall cause such investment bank to determine the resolution of such dispute and notify the Company and the Holder of such resolution no later than ten (10) Business Days immediately following the Dispute Submission Deadline. The fees and expenses of such investment bank shall be borne solely by the Company, and such investment bank’s resolution of such dispute shall be final and binding upon all parties absent manifest error.

 

  17  

 

 

(b)           Miscellaneous . The Company expressly acknowledges and agrees that (i) this Section 13 constitutes an agreement to arbitrate between the Company and the Holder (and constitutes an arbitration agreement) under the rules then in effect under § 7501, et seq. of the New York Civil Practice Law and Rules (“ CPLR ”) and that the Holder is authorized to apply for an order to compel arbitration pursuant to CPLR § 7503(a) in order to compel compliance with this Section 13, (ii) a dispute relating to the Exercise Price includes, without limitation, disputes as to (A) whether an issuance or sale or deemed issuance or sale of Common Stock occurred under Section 2(b), (B) the consideration per share at which an issuance or deemed issuance of Common Stock occurred, (C) whether any issuance or sale or deemed issuance or sale of Common Stock was an issuance or sale or deemed issuance or sale of Excluded Securities, (D) whether an agreement, instrument, security or the like constitutes and Option or Convertible Security and (E) whether a Dilutive Issuance occurred, (iii) the terms of this Warrant and each other applicable Transaction Document shall serve as the basis for the selected investment bank’s resolution of the applicable dispute, such investment bank shall be entitled (and is hereby expressly authorized) to make all findings, determinations and the like that such investment bank determines are required to be made by such investment bank in connection with its resolution of such dispute (including, without limitation, determining (A) whether an issuance or sale or deemed issuance or sale of Common Stock occurred under Section 2(b), (B) the consideration per share at which an issuance or deemed issuance of Common Stock occurred, (C) whether any issuance or sale or deemed issuance or sale of Common Stock was an issuance or sale or deemed issuance or sale of Excluded Securities, (D) whether an agreement, instrument, security or the like constitutes and Option or Convertible Security and (E) whether a Dilutive Issuance occurred) and in resolving such dispute such investment bank shall apply such findings, determinations and the like to the terms of this Warrant and any other applicable Transaction Documents, (iv) the Holder (and only the Holder), in its sole discretion, shall have the right to submit any dispute described in this Section 13 to any state or federal court sitting in The City of New York, Borough of Manhattan in lieu of utilizing the procedures set forth in this Section 13 and (v) nothing in this Section 13 shall limit the Holder from obtaining any injunctive relief or other equitable remedies (including, without limitation, with respect to any matters described in this Section 13).

 

14.   REMEDIES, CHARACTERIZATION, OTHER OBLIGATIONS, BREACHES AND INJUNCTIVE RELIEF . The remedies provided in this Warrant shall be cumulative and in addition to all other remedies available under this Warrant and the other Transaction Documents, at law or in equity (including a decree of specific performance and/or other injunctive relief), and nothing herein shall limit the right of the Holder to pursue actual and consequential damages for any failure by the Company to comply with the terms of this Warrant. The Company covenants to the Holder that there shall be no characterization concerning this instrument other than as expressly provided herein. Amounts set forth or provided for herein with respect to payments, exercises and the like (and the computation thereof) shall be the amounts to be received by the Holder and shall not, except as expressly provided herein, be subject to any other obligation of the Company (or the performance thereof). The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Holder and that the remedy at law for any such breach may be inadequate. The Company therefore agrees that, in the event of any such breach or threatened breach, the holder of this Warrant shall be entitled, in addition to all other available remedies, to an injunction restraining any breach, without the necessity of showing economic loss and without any bond or other security being required. The Company shall provide all information and documentation to the Holder that is requested by the Holder to enable the Holder to confirm the Company’s compliance with the terms and conditions of this Warrant (including, without limitation, compliance with Section 2 hereof). The issuance of shares and certificates for shares as contemplated hereby upon the exercise of this Warrant shall be made without charge to the Holder or such shares for any issuance tax or other costs in respect thereof, provided that the Company shall not be required to pay any tax which may be payable in respect of any transfer involved in the issuance and delivery of any certificate in a name other than the Holder or its agent on its behalf.

 

  18  

 

 

15.   PAYMENT OF COLLECTION, ENFORCEMENT AND OTHER COSTS . If (a) this Warrant is placed in the hands of an attorney for collection or enforcement or is collected or enforced through any legal proceeding or the holder otherwise takes action to collect amounts due under this Warrant or to enforce the provisions of this Warrant or (b) there occurs any bankruptcy, reorganization, receivership of the company or other proceedings affecting company creditors’ rights and involving a claim under this Warrant, then the Company shall pay the costs incurred by the Holder for such collection, enforcement or action or in connection with such bankruptcy, reorganization, receivership or other proceeding, including, without limitation, attorneys’ fees and disbursements.

 

16.   TRANSFER . This Warrant may be offered for sale, sold, transferred or assigned without the consent of the Company, except as may otherwise be required by Section 2(f) of the Securities Purchase Agreement.

 

17.   CERTAIN DEFINITIONS . For purposes of this Warrant, the following terms shall have the following meanings:

 

(a)          “ 1933 Act ” means the Securities Act of 1933, as amended, and the rules and regulations thereunder.

 

(b)          “ 1934 Act ” means the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder.

 

(c)          “ Affiliate ” or “ affiliate ” means, with respect to any Person, any other Person that directly or indirectly controls, is controlled by, or is under common control with, such Person, it being understood for purposes of this definition that “control” of a Person means the power directly or indirectly either to vote 10% or more of the stock having ordinary voting power for the election of directors of such Person or direct or cause the direction of the management and policies of such Person whether by contract or otherwise.

 

(d)          “ Attribution Parties ” means, collectively, the following Persons and entities: (i) any investment vehicle, including, any funds, feeder funds or managed accounts, currently, or from time to time after the Issuance Date, directly or indirectly managed or advised by the Holder’s investment manager or any of its Affiliates or principals, (ii) any direct or indirect Affiliates of the Holder or any of the foregoing, (iii) any Person acting or who could be deemed to be acting as a Group together with the Holder or any of the foregoing and (iv) any other Persons whose beneficial ownership of the Company’s Common Stock would or could be aggregated with the Holder’s and the other Attribution Parties for purposes of Section 13(d) of the 1934 Act. For clarity, the purpose of the foregoing is to subject collectively the Holder and all other Attribution Parties to the Maximum Percentage.

 

  19  

 

 

(e)          “ Black Scholes Value ” means the value of the unexercised portion of this Warrant remaining on the date of the Holder’s applicable request pursuant to Section 4(c)(ii) or the Company’s or the Successor Entity’s election (as the case may be) pursuant to Section 4(c)(i) , as a result of a Fundamental Transaction, which value is calculated using the Black Scholes Option Pricing Model obtained from the “OV” function on Bloomberg utilizing (i) an underlying price per share equal to the greater of (1) the highest Closing Sale Price or Closing Bid Price (as the case may be) of the Common Stock during the period beginning on the Trading Day immediately preceding the announcement of the applicable Fundamental Transaction (or the consummation of the applicable Fundamental Transaction, if earlier) and ending on the Trading Day of the Holder’s request pursuant to Section 4(c)(ii) or the Company’s or the Successor Entity’s election (as the case may be) pursuant to Section 4(c)(i) , and (2) as a result of a Fundamental Transaction, the sum of the price per share being offered in cash in the applicable Fundamental Transaction (if any) plus the value of the non-cash consideration being offered in the applicable Fundamental Transaction (if any), (ii) a strike price equal to the Exercise Price in effect on the date of the Holder’s request pursuant to Section 4(c)(ii) or the Company’s or the Successor Entity’s election (as the case may be) pursuant to Section 4(c)(i) as a result of a Fundamental Transaction, (iii) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the greater of (1) the remaining term of this Warrant as of the date of the aforementioned request pursuant to either Section 4(c)(i) or Section 4(c)(ii) as a result of a Fundamental Transaction and (2) the remaining term of this Warrant as of the date of consummation of the applicable Fundamental Transaction or as of the date of the aforementioned request pursuant to either Section 4(c)(i) or Section 4(c)(ii) as a result of a Fundamental Transaction if such request is prior to the date of the consummation of the applicable Fundamental Transaction, (iv) a zero cost of borrow and (v) an expected volatility equal to the greater of 100% and the 30 day volatility obtained from the “HVT” function on Bloomberg (determined utilizing a 365 day annualization factor) as of the Trading Day immediately following the earliest to occur of (A) the public disclosure of the applicable Fundamental Transaction, (B) the consummation of the applicable Fundamental Transaction and (C) the date on which the Holder first became aware of the applicable Fundamental Transaction.

 

(f)          “ Bloomberg ” means Bloomberg, L.P.

 

(g)          “ Business Day ” means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized or required by law to remain closed.

 

(h)          “ Closing Sale Price ” or “ Closing Bid Price ” means, for any security as of any date, the last closing bid price and last closing trade price, respectively, for such security on the Principal Market, as reported by Bloomberg, or, if the Principal Market begins to operate on an extended hours basis and does not designate the closing bid price or the closing trade price (as the case may be) then the last bid price or last trade price, respectively, of such security prior to 4:00:00 p.m., New York time, as reported by Bloomberg, or, if the Principal Market is not the principal securities exchange or trading market for such security, the last closing bid price or last trade price, respectively, of such security on the principal securities exchange or trading market where such security is listed or traded as reported by Bloomberg, or if the foregoing do not apply, the last closing bid price or last trade price, respectively, of such security in the over-the-counter market on the electronic bulletin board for such security as reported by Bloomberg, or, if no closing bid price or last trade price, respectively, is reported for such security by Bloomberg, the average of the bid prices, or the ask prices, respectively, of any market makers for such security as reported in the “pink sheets” by OTC Markets Group Inc. (formerly Pink Sheets LLC). If the Closing Bid Price or the Closing Sale Price cannot be calculated for a security on a particular date on any of the foregoing bases, the Closing Bid Price or the Closing Sale Price (as the case may be) of such security on such date shall be the fair market value as mutually determined by the Company and the Holder. If the Company and the Holder are unable to agree upon the fair market value of such security, then such dispute shall be resolved in accordance with the procedures in Section 24 . All such determinations shall be appropriately adjusted for any stock splits, stock dividends, stock combinations, recapitalizations or other similar transactions during such period.

 

  20  

 

 

(i)          “ Common Stock ” means (i) the Company’s shares of common stock, $0.001 par value per share, and (ii) any capital stock into which such common stock shall have been changed or any share capital resulting from a reclassification of such common stock.

 

(j)           “ Convertible Securities ” means any stock or other security (other than Options) that is at any time and under any circumstances, directly or indirectly, convertible into, exercisable or exchangeable for, or which otherwise entitles the holder thereof to acquire, any shares of Common Stock.

 

(k)          “ Eligible Market ” means The New York Stock Exchange, the NYSE MKT, the Nasdaq Capital Market, the Nasdaq Global Select Market, the Nasdaq Global Market or the Principal Market.

 

(l)          “ Event of Default Black Scholes Value ” means the value of the unexercised portion of this Warrant remaining on the date of the Holder’s request pursuant to Section 4(c)(ii) as a result of an Event of Default, which value is calculated using the Black Scholes Option Pricing Model obtained from the “OV” function on Bloomberg utilizing (i) an underlying price per share equal to the highest Closing Sale Price or Closing Bid Price (as the case may be) of the Common Stock during the period beginning on the date of the occurrence of the Event of Default through the date all Events of Default have been cured or, if earlier, the Trading Day of the Holder’s request pursuant to Section 4(c)(ii) as a result of an Event of Default, (ii) a strike price equal to the Exercise Price in effect on the date of the Holder’s request pursuant to Section 4(c)(ii) as a result of an Event of Default, (iii) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the greater of (1) the remaining term of this Warrant as of the date of the Holder’s request pursuant to Section 4(c)(ii) as a result of an Event of Default and (2) the remaining term of this Warrant as of the date of the occurrence of such Event of Default, (iv) a zero cost of borrow and (v) an expected volatility equal to the greater of 100% and the 30 day volatility obtained from the “HVT” function on Bloomberg (determined utilizing a 365 day annualization factor) as of the Trading Day immediately following later of (x) the date of the occurrence of such Event of Default and (y) the date of the public announcement of such Event of Default.

 

(m)          “ Expiration Date ” means the date that is the fifth (5th) anniversary of the Issuance Date or, if such date falls on a day other than a Business Day or on which trading does not take place on the Principal Market (a “ Holiday ”), the next date that is not a Holiday.

 

  21  

 

 

(n)          “ Fundamental Transaction ” means that (i) the Company or any of its Subsidiaries shall, directly or indirectly, in one or more related transactions (1) consolidate or merge with or into (whether or not the Company or any of its Subsidiaries is the surviving corporation) any other Person, or (2) sell, lease, license, assign, transfer, convey or otherwise dispose of all or substantially all of its respective properties or assets to any other Person, or (3) allow any other Person to make a purchase, tender or exchange offer that is accepted by the holders of more than 50% of the outstanding shares of Voting Stock of the Company (not including any shares of Voting Stock of the Company held by the Person or Persons making or party to, or associated or affiliated with the Persons making or party to, such purchase, tender or exchange offer), or (4) consummate a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with any other Person whereby such other Person acquires more than 50% of the outstanding shares of Voting Stock of the Company (not including any shares of Voting Stock of the Company held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business combination), or (ii) any “person” or “group” (as these terms are used for purposes of Sections 13(d) and 14(d) of the 1934 Act and the rules and regulations promulgated thereunder) is or shall become the “beneficial owner” (as defined in Rule 13d-3 under the 1934 Act), directly or indirectly, of 50% of the aggregate ordinary voting power represented by issued and outstanding Voting Stock of the Company. Notwithstanding the above, a Fundamental Transaction shall not be deemed to occur as a result of a reincorporation merger of the Company provided other than the place of incorporation of the Company no other material changes occur to the Company, as a result of such reincorporation merger.

 

(o)          “ Note ” has the meaning ascribed to such term in the Securities Purchase Agreement, and shall include all notes issued in exchange therefor or replacement thereof.

 

(p)           “ Options ” means any rights, warrants or options to subscribe for or purchase shares of Common Stock or Convertible Securities.

 

(q)          “ Option Value ” means (I) if the Company is a Trading Issuer, the value of the applicable Option or Convertible Security (as the case may be) using the Black Scholes Option Pricing model obtained from the “OV” function on Bloomberg determined as of the date of issuance of the Option or Convertible Security (as the case may be) utilizing (i) an underlying price per share equal to the Closing Bid Price or Closing Sale Price (as the case may be) of the Common Stock on the Trading Day immediately preceding the public announcement of the execution of definitive documents with respect to the issuance of such Option or Convertible Security (as the case may be), (ii) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the remaining term of such Option or Convertible Security (as the case may be) as of the date of issuance of such Option or Convertible Security (as the case may be), (iii) a zero cost of borrow and (iv) an expected volatility equal to the greater of 100% and the 100 day volatility obtained from the “HVT” function on Bloomberg (determined utilizing a 365 day annualization factor) as of the Trading Day immediately following the date of issuance of such Option or Convertible Security (as the case may be)., or (II) if the Company is not a Trading Issuer (or the value of an Option cannot be determined pursuant to (I)), of this definition of “Option Value,” the value of an Option or Convertible Security (as the case may be) shall be determined pursuant to Section 24 .

 

(r)          “ Parent Entity ” of a Person means an entity that, directly or indirectly, controls the applicable Person and whose common stock or equivalent equity security is quoted or listed on an Eligible Market, or, if there is more than one such Person or Parent Entity, the Person or Parent Entity with the largest public market capitalization as of the date of consummation of the Fundamental Transaction.

 

  22  

 

 

(s)          “ Person ” means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization, any other entity or a government or any department or agency thereof.

 

(t)          “ Principal Market ” means as of a particular date, the Eligible Market on such date that the Common Stock is principally traded or quoted on.

 

(u)          “ Resale Eligibility Date ” means the earlier to occur of (i) the date the SEC declares effective a registration statement registering the resale of shares of Common Stock issuable upon exercise of this Warrant, and (ii) the initial date any of the shares of Common Stock issuable upon exercise of this Warrant are eligible to be resold pursuant to Rule 144 (as defined in the Securities Purchase Agreement).

 

(v)         “ SEC ” means the United States Securities and Exchange Commission or the successor thereto.

 

(w)          “ Successor Entity ” means the Person (or, if so elected by the Holder, the Parent Entity) formed by, resulting from or surviving any Fundamental Transaction or the Person (or, if so elected by the Holder, the Parent Entity) with which such Fundamental Transaction shall have been entered into.

 

(x)          “ Trading Day ” means, as applicable, (x) with respect to all price or trading volume determinations relating to the Common Stock, any day on which the Common Stock is traded on the Principal Market, or, if the Principal Market is not the principal trading market for the Common Stock, then on the principal securities exchange or securities market on which the Common Stock is then traded, provided that “Trading Day” shall not include any day on which the Common Stock is scheduled to trade on such exchange or market for less than 4.5 hours or any day that the Common Stock is suspended from trading during the final hour of trading on such exchange or market (or if such exchange or market does not designate in advance the closing time of trading on such exchange or market, then during the hour ending at 4:00:00 p.m., New York time) unless such day is otherwise designated as a Trading Day in writing by the Holder or (y) with respect to all determinations other than price determinations relating to the Common Stock, any day on which The New York Stock Exchange (or any successor thereto) is open for trading of securities.

 

(y)          “ Voting Stock ” of a Person means capital stock of such Person of the class or classes pursuant to which the holders thereof have the general voting power to elect, or the general power to appoint, at least a majority of the board of directors, managers, trustees or other similar governing body of such Person (irrespective of whether or not at the time capital stock of any other class or classes shall have or might have voting power by reason of the happening of any contingency).

 

 

[ signature page follows ]

 

  23  

 

 

IN WITNESS WHEREOF, the Company has caused this Warrant to Purchase Common Stock to be duly executed as of the Issuance Date set out above.

 

  ICAGEN, INC.
     
  By: /s/ Richard Cunningham
  Name: Richard Cunningham
  Title: Chief Executive Officer

 

  24  

 

 

EXHIBIT A

 

EXERCISE NOTICE

 

TO BE EXECUTED BY THE REGISTERED HOLDER TO EXERCISE THIS

WARRANT TO PURCHASE COMMON STOCK

 

ICAGEN, INC.

 

The undersigned holder hereby exercises the right to purchase _________________ of the shares of Common Stock (“ Warrant Shares ”) of Icagen, Inc., a Delaware corporation (the “ Company ”), evidenced by Warrant to Purchase Common Stock No. _______ (the “ Warrant ”). Capitalized terms used herein and not otherwise defined shall have the respective meanings set forth in the Warrant.

 

1. Form of Exercise Price . The Holder intends that payment of the Aggregate Exercise Price shall be made as:

 

  ____________  

a “ Cash Exercise ” with respect to _________________ Warrant Shares; and/or

 

       
       
 

____________

 

  a “ Cashless Exercise ” with respect to _______________ Warrant Shares.

 

 In the event that the Holder has elected a Cashless Exercise with respect to some or all of the Warrant Shares to be issued pursuant hereto, the Holder hereby represents and warrants that (i) this Exercise Notice was executed by the Holder at __________ [a.m.][p.m.] on the date set forth below and (ii) if applicable, the Closing Sale Price or Closing Bid Price as of such time of execution of this Exercise Notice was $________.

 

☐  If this Exercise Notice is being delivered after the Alternate Exercise Eligibility Date, check here if Holder is electing to use the following Alternate Exercise Price in this exercise:____________.

 

2. Payment of Exercise Price . In the event that the Holder has elected a Cash Exercise with respect to some or all of the Warrant Shares to be issued pursuant hereto, the Holder shall pay the Aggregate Exercise Price in the sum of $___________________ to the Company in accordance with the terms of the Warrant.

 

  25  

 

 

3. Delivery of Warrant Shares . The Company shall deliver to Holder, or its designee or agent as specified below, __________ Warrant Shares in accordance with the terms of the Warrant. Delivery shall be made to Holder, or for its benefit, as follows:

 

☐  Check here if requesting delivery as a certificate to the following name and to the following address:

 

  Issue to:  
     
     
     
     

 

☐  Check here if requesting delivery by Deposit/Withdrawal at Custodian as follows:

 

  DTC Participant:  
     
  DTC Number:  
     
  Account Number:  

 

Date:    
     
     
Name of Registered Holder  

 

By:    
Name:    
Title:    
     
Tax ID:    
     
Facsimile:    
     
E-mail Address:  

 

  27  

 

 

EXHIBIT B

 

ACKNOWLEDGMENT

 

The Company hereby acknowledges this Exercise Notice and hereby directs ______________ to issue the above indicated number of shares of Common Stock in accordance with the Transfer Agent Instructions dated May 15, 2017, from Icagen, Inc. and acknowledged and agreed to by _______________.

 

 

  ICAGEN, INC.
     
  By:  
    Name:
    Title:

 

 

28

 

 

Exhibit 10.7

 

WHEN RECORDED, RETURN to:

Gusrae Kaplan Nusbaum PLLC

120 Wall Street, 25th Floor

New York, NY 10005

Attention: Lawrence G. Nusbaum, Esq.

 

DEED OF TRUST, ASSIGNMENT OF RENTS, FIXTURE FILING AND

SECURITY AGREEMENT

 

TRUSTOR: Icagen-T, Inc.
   
TRUSTOR’S MAILING 2090 E. Innovation Park Drive
ADDRESS: Oro Valley, Arizona 85755
   
BENEFICIARY: GPB Debt Holdings II, LLC
   
BENEFICIARY’S MAILING 535 West 24th Street, 4th Floor
ADDRESS: New York, New York 10011
   
TRUSTEE: First American Title Insurance Company
   
TRUSTEE MAILING 2425 E. Camelback Rd. Suite 300
ADDRESS: Phoenix, Arizona 85016

 

REAL PROPERTY in Pima County, State of Arizona, described as:

 

See attached Exhibit A

 

THIS DEED OF TRUST, ASSIGNMENT OF RENTS, FIXTURE FILING AND SECURITY AGREEMENT (this “ Deed of Trust ”) is made between the Trustor, Trustee and Beneficiary named above. Trustor irrevocably grants and conveys to Trustee in trust for the sole benefit of the Beneficiary, with power of sale, the above-described Real Property (the “ Real Property ”), together with and all buildings, improvements and fixtures located thereon or hereinafter erected thereon (collectively, the “ Fixtures ”), together with the leases, rents, issues, profits, or income thereof (collectively, the “ Property Income ” and together with the Real Property and the Fixtures, collectively, the “ Property ”); subject, however, to the right, power and authority hereinafter given to and conferred upon Beneficiary to collect and apply such Property Income; and subject to all covenants, conditions, restrictions, rights-of-way and easements of record.

 

 

 

 

THIS DEED OF TRUST IS MADE FOR THE PURPOSE OF SECURING: (a) performance of each agreement and obligation of Trustor contained in this Deed of Trust (as such might be properly amended and/or modified after the date thereof and hereof); (b) performance of each agreement and obligation of Trustor (including, but not limited to, all payment obligations including of principal, interest, penalties, liquidated damages, Late Charges (as defined in the $8,000,000 senior secured convertible note of the Trustor in favor of the Beneficiary as set forth below), redemption amounts and/or otherwise) under that certain secured convertible note of ICA-T, in the aggregate original principal amount of $8,000,000, executed by Trustor in favor of Beneficiary (as such might be properly amended or modified after the date thereof); (c) performance of each agreement and obligation of Trustor under that certain Securities Purchase Agreement, dated as of May 15, 2017, by and among, Icagen, Inc., a Delaware corporation (“ Icagen ”), Trustor and Beneficiary (the “ Purchase Agreement ”) (as such might be properly amended or modified after the date thereof); (d) performance of each obligation and agreement of Trustor under that certain ICA-T Security and Pledge Agreement for Obligations of ICA-T, dated as of May 15, 2017, executed by Trustor and other parties thereto, in favor of Beneficiary (as such might be properly amended or modified after the date thereof); and (e) the performance of each agreement and obligation of the Trustor under the other Transaction Documents (as defined in the Purchase Agreement) (as any such Transaction Documents might be properly amended or modified after the date thereof) (collectively, the “ GPB Senior Note Documents ”).

 

This Deed of Trust is also a security agreement under the Arizona Uniform Commercial Code for all Property which, under applicable law, may be subject to a security interest under the Arizona Uniform Commercial Code, whether acquired now or in the future, and all products and cash and non-cash proceeds thereof (collectively, “ UCC Collateral ”), and Trustor hereby grants to Trustee for the benefit of the Beneficiary a security interest in the UCC Collateral. Trustor shall execute and deliver to Trustee, upon Trustee’s or Beneficiary’s request, any and all financing statements, continuation statements and amendments and/or similar and/or related items, in such form as Trustee or Beneficiary may require to perfect, protect, maintain and/or continue to perfect the perfection of this security interest. Without the express prior written consent of the Beneficiary, Trustor shall not directly and/or indirectly create or, permit and/or continue to permit to exist, any lien or security interest in any of the UCC Collateral, other than as created hereby and/or to the extent expressly created by the Sanofi Deed of Trust. Upon default by Trustor in the performance of any agreement and/or obligations secured hereby, Beneficiary shall have all rights and remedies of a secured party under the Uniform Commercial Code, in addition to all rights and remedies provided by this Deed of Trust, the GPB Senior Note Documents and/or existing under applicable law or otherwise. In exercising any of its rights and remedies, Beneficiary may exercise its rights and remedies against the UCC Collateral separately or together, and in any order, without in any way affecting the availability of Beneficiary’s other rights and remedies. This Deed of Trust constitutes a financing statement with respect to any part of the Property which is or may at any time and from time to time become a fixture under applicable law.

 

This Deed of Trust is to be effective, on the date of its recording, as a financing statement filed as a fixture filing. This Deed of Trust covers goods which are or at any time and from time to time to become fixtures and such collateral is related to the real property described in Exhibit A attached hereto. The Trustor is the debtor. A mailing address for the debtor is set forth on the cover page of this Deed of Trust. The Trustor (debtor) is a Delaware corporation. The secured party is the Beneficiary. The mailing address for the secured party is set forth on the cover page of this Deed of Trust.

 

  2  

 

 

TO PROTECT THE SECURITY OF THIS DEED OF TRUST, TRUSTOR AGREES:

 

1.       To keep the Property in good condition and repair; not to remove or demolish any building thereon; to complete or restore promptly and in good and workmanlike manner any building which may be constructed, damaged or destroyed thereon and to pay when due all claims for labor performed and materials furnished therefor; to comply with all laws affecting the Property or requiring any alterations or improvements to be made thereon; not to commit or permit waste thereof; not to commit, suffer or permit any act upon the Property in violation of law; and do all other acts which from the character or use of the Property may be reasonably necessary

 

2.       To provide, maintain and deliver to Beneficiary fire, casualty and other insurance policies satisfactory to and with loss payable to Beneficiary. The amount collected under any fire or other casualty insurance policy may be applied by Beneficiary toward payment of the obligations and agreements secured hereby, subject only to the obligations of the Grantor to Sanofi as and to the extent expressly set forth in the Sanofi Deed of Trust (defined below); provided , however , that all such insurance proceeds shall not be applied toward such obligations but instead will be made available to Trustor for the repair and restoration of the Property if all of the following conditions are met:

 

(i)       Trustor shall have delivered written notice to Beneficiary of Trustor’s intention to commence repairs and restoration within fifteen (15) days following the adjustment or settlement of any claim or claims under any insurance policies;

 

(ii)      No default by Trustor hereunder, or under any of the other GPB Senior Note Documents, shall have occurred and be continuing;

 

(iii)     All insurance proceeds shall have been deposited with a third party escrow agent (“ Escrow Agent ”) that is acceptable to Trustor and Beneficiary, in their reasonable discretion, and Escrow Agent will be instructed to disburse such insurance proceeds in accordance with the provisions of this Section 2 ;

 

(iv)     Within fifteen (15) days after the deposit of such insurance proceeds with Escrow Agent, Trustor shall have remitted to Escrow Agent an amount necessary (as reasonably determined by a third party architect or general contractor engaged by Trustor), if any, to pay the difference between (A) the estimated cost of restoration and repair of the damaged improvements, and (B) the amount of insurance proceeds deposited with Escrow Agent in respect of such damage and destruction;

 

(v)       Trustor shall have delivered to Beneficiary (A) a budget of all costs of repair and restoration of the damaged improvements, and (B) a construction contract for such repair and restoration work in form and content and with a third party contractor reasonably acceptable to Beneficiary; and

 

(vi)      All applicable governmental authorities shall have approved the final plans and specifications for repair and restoration of the damaged improvements.

 

In the event all of the foregoing conditions have been fulfilled, all proceeds so applied to the reconstruction of the damaged improvements shall be disbursed only as repairs or replacements are effected and as continuing expenses become due and payable. After completion of the repair and restoration of the damaged improvements to a condition substantially equivalent to that in effect immediately prior to the casualty event and payment in full of all of the costs of repair and restoration as evidenced by a certificate to such effect signed by Trustor and verified by Trustor’s architect or general contractor, as applicable, any remaining proceeds shall be paid over by Escrow Agent to Trustor. Not in limitation of the foregoing, the lien of this Deed of Trust shall continue to encumber the repaired or replaced improvements in all respects without any new or additional title exceptions or change in lien priority.

 

  3  

 

 

3.       To appear in and defend any action or proceeding purporting to affect the security hereof or the rights or powers of Beneficiary or Trustee and to pay all costs and expenses of Beneficiary and Trustee, including cost of evidence of title and attorneys’ fees in a reasonable sum, in any such action or proceeding in which Beneficiary or Trustee may appear or be named and in any suit brought by Beneficiary to foreclose this Deed of Trust.

 

4.       To pay, before delinquent, all taxes and assessments affecting the Property, and to pay, when due, all encumbrances, charges and liens, with interest, on said Property or any part thereof which appear to be prior or superior hereto; all costs, fees and expenses of this Deed of Trust including, without limiting the generality of the foregoing, the fees of Trustee for issuance of any Deed of Partial Release and Partial Reconveyance or Deed of Release and Full Reconveyance and all lawful charges, costs and expenses in the event of reinstatement of, following default in, this Deed of Trust or the obligations secured hereby.

 

If Trustor defaults under this Deed of Trust, the Sanofi Documents (as defined in the Purchase Agreement) and/or any of the other GPB Senior Note Documents and such default remains uncured beyond any express applicable notice and/or expressly stated cure period, then Beneficiary or Trustee, without obligation to do so and without notice to or demand upon Trustor (all of which Trustor hereby expressly waives to the maximum amount permitted by applicable law) and without releasing Trustor from any obligation hereof, may make or do the same in such manner and to such extent as either may deem necessary to protect the security hereof, Beneficiary or Trustee being authorized to enter upon the Property for such purposes: appear in and defend any action or proceeding purporting to affect the security hereof or the rights or powers of Beneficiary or Trustee; pay, purchase, contest or compromise any encumbrance, charge or lien which in the judgment of either appears to be prior or superior hereto; and, in exercising any such powers, pay necessary expenses, employ counsel, and pay counsel’s reasonable fees and costs.

 

5.       To pay promptly upon written demand from Beneficiary or Trustee all sums expended by Beneficiary or Trustee pursuant to the provisions hereof, together with interest from the date of expenditure at the highest rate as allowed under applicable Arizona law. Any amounts so paid by Beneficiary or Trustee shall become part of the obligations secured by this Deed of Trust and a lien on the Property or shall become immediately due and payable at option of Beneficiary or Trustee. In either event, such amounts shall be in addition to the $8,000,000 aggregate of obligations, accrued interest, Late Charges, liquidated damages, penalties, redemption amounts and other charges due Beneficiary as secured hereby.

 

6.       To maintain, during the term of this Deed of Trust, in full force, at its own expense, a policy or policies of comprehensive liability insurance, including property damage, written by one or more insurance companies licensed to do business in Arizona, which shall insure both Trustor and Beneficiary against liability for injury to persons or property and for the death of any person occurring in or about the Property.

 

  4  

 

 

7.       To not grant any mining rights with regard to any portion of the Property, to not establish any wells on the Property, and to not construct any improvements on the Property (except as expressly permitted or required in this Deed of Trust) without, in each such instance, the prior written consent of Beneficiary, which consent shall not be unreasonably withheld, conditioned or delayed.

 

IT IS MUTUALLY AGREED:

 

8.       That any award of damages in connection with any condemnation, or any such taking, or for injury to the Property by reason of public use or for damages for private trespass or injury thereto shall be deposited with Escrow Agent and released to Trustor to repair or restore any damage caused to the Property by such condemnation or taking, subject to the same terms and conditions applicable to casualty insurance proceeds in Section 2 , above. After completion of restoration of any such damage to the Property and payment in full of all of the costs of restoration, as evidenced by a certificate to such effect signed by Trustor and verified by Trustor’s architect or general contractor, as applicable, any remaining condemnation award shall be paid over by Escrow Agent to Trustor.

 

9.       That time is of the essence of this Deed of Trust and that, by accepting payment of any sum secured hereby after its due date, Beneficiary does not waive its right either to require prompt payment when due of all other sums so secured or to declare default for failure so to pay.

 

10.       That, at any time or from time to time, and without notice, upon written request of Beneficiary, without liability therefor, without affecting the personal liability of any person for performance of the obligations secured hereby, without affecting the security hereof for the full amount secured hereby on all property remaining subject hereto and without the necessity that any sum representing the value or any portion thereof of the property affected by Trustee’s action be credited on the indebtedness, Trustee may: (a) release and reconvey all or any part of the Property; (b) consent to the making and recording, or either, of any map or plat of the Property or any part thereof; (c) join in granting any easement thereon; and (d) join in or consent to any extension agreement or any agreement subordinating the lien, encumbrance or charge hereof.

 

11.       If all agreements and obligations secured by this Deed of Trust have been satisfied and performed as so acknowledged in writing by the Beneficiary, then and only in that event, all rights under this Deed of Trust shall terminate and the Property shall become wholly clear of the liens, security interests, conveyances and assignments evidenced hereby, which shall be promptly reconveyed of record by Beneficiary in due form at Trustor’s cost. The Property and all right, title and interest conveyed to Trustee hereunder shall be released and conveyed, without covenant or warranty, express or implied. The recitals in such reconveyance of any matters or facts shall be conclusive proof of the truthfulness thereof. The grantee in such reconveyance may be described as “the person or persons legally entitled thereto”.

 

  5  

 

 

12.       That, as additional security, Trustor hereby gives to and confers upon Beneficiary the right, power and authority, commencing on the date of recording hereof and during the continuance of this Deed of Trust, to collect the Property Income, subject to the Sanofi Deed of Trust, reserving to Trustor the right, so long as no default by Trustor in the performance of any obligations secured hereby and/ or under any of the other GPB Senior Note Documents has occurred and is continuing, to collect and retain such Property Income as it becomes due and payable. Upon and during the continuance of any such default, Beneficiary, Trustee and/or any of their respective agents, representatives and/or employees may at any time, without notice, either in person, by agent or by a receiver to be appointed by a court, and without regard to the adequacy of any security for the indebtedness hereby secured, enter upon and take possession of the Property or any part thereof, sue for or otherwise collect the Property Income in its own name, including that past due and unpaid, and apply the same, less costs and expenses of operation and collection, including reasonable attorneys’ fees, upon any indebtedness, agreement and/or other obligation secured hereby and in any such order and in any such amounts as from time to time Beneficiary may so determine. The entering upon and taking possession of the Property, the collection of the Property Income and the application thereof as aforesaid, shall not cure or waive any default or notice of Trustee’s sale hereunder or invalidate any act done pursuant to such notice.

 

13.       That, upon default by Trustor in the performance of any of its agreements and/or obligations secured hereby, or under any of the GPB Senior Note Documents, Beneficiary shall deposit with Trustee this Deed of Trust and all documents evidencing expenditures and other amounts owed and secured hereby, as may be required by statute to commence foreclosure.

 

Trustee shall record and give notice of Trustee’s sale and shall sell the Property at public auction, all in the manner required by applicable law. Any persons, including Trustee or Beneficiary, may purchase at such sale. Trustee shall deliver to such purchaser its deed conveying the Property so sold, but without any covenant or warranty, express or implied. Trustor requests that a copy of any notice of Trustee’s sale hereunder be mailed to Trustor at its address set forth above.

 

After deducting all costs, fees and expenses of Trustee of exercising the power of sale conferred hereby, including, but not limited to, cost of evidence of title in connection with the Trustee’s sale and reasonable attorneys’ fees (it being agreed that all such amounts shall be in addition to the $8,000,000, plus all accrued interest, Late Charges, liquidated damages, penalties, redemption amounts and other charges due Beneficiary as secured hereby), Trustee shall apply the proceeds of the Trustee’s sale in the manner provided by applicable law. To the extent permitted by applicable law, an action may be maintained by Beneficiary to recover a deficiency judgment for any balance due hereunder.

 

In lieu of sale, pursuant to the power of sale conferred hereby, this Deed of Trust may be foreclosed in the same manner provided by law for the foreclosure of mortgages on real property. Beneficiary shall also have all other rights and remedies available to it hereunder and at law or in equity. All rights and remedies shall be cumulative.

 

14.       That Trustee may resign by mailing or delivering notice thereof to Beneficiary and Trustor. Beneficiary may appoint a successor Trustee in the manner prescribed by applicable law. A successor Trustee herein shall, without conveyance from the predecessor Trustee, succeed to all the predecessor’s title, estate, rights, powers and duties.

 

  6  

 

 

15.       The term Beneficiary shall mean the owner and holder of all of the obligations and agreements secured by this Deed of Trust, whether or not named as “Beneficiary” herein. In this Deed of Trust, whenever the context so requires, the masculine gender includes the feminine and neuter, and the singular number includes the plural.

 

16.       That Trustee accepts this trust when this Deed of Trust, duly executed and acknowledged, is made a public record as provided by law. Except as required by applicable law, Trustee is not obligated to notify any party hereto of a pending sale under any other deed of trust or of any action or proceeding in which Trustor, Beneficiary or Trustee shall be a party unless brought by Trustee.

 

17.       That the trust relationship created by this Deed of Trust is limited solely to the creation and enforcement of a security interest in real property. All of Trustee’s duties, whether fiduciary or otherwise, are strictly limited to those duties imposed by this instrument and A.R.S.§ 33-801 et seq . and no additional duties, burdens or responsibilities are or shall be placed on Trustee.

 

18.       This Deed of Trust and the other GPB Senior Note Documents are and shall be subject and subordinate in all respects to the liens, terms, covenants and conditions of but only to the extent and in the amount expressly provided in the Deed of Trust and Assignment of Rents, dated as of July 13, 2016 (the “ Sanofi Deed of Trust ”), between Trustor, Sanofi US Services, Inc., as beneficiary thereunder (“ Sanofi ”), and the trustee named therein

 

18.       That this Deed of Trust applies to, inures to the benefit of and binds all parties hereto, their heirs, legatees, devisees, administrators, executors, successors and assigns.

 

  7  

 

 

  TRUSTOR:
   
  Icagen-T, Inc.,
  a Delaware corporation
     
DATED:  May 15, 2017 By: /s/ Richard Cunningham
  Name:  Richard Cunningham
  Its: Chief Executive Officer

 

STATE OF ___________)  
  ) ss.  
COUNTY OF  _________)  

 

The foregoing instrument was acknowledged before me, the undersigned Notary Public, this ____ day of May, 2017 by ______________________, the _____________ of Icagen-T, Inc., a Delaware corporation, being authorized to do so.

 

   
  Notary Public

 

  8  

 

 

EXHIBIT A

 

LEGAL DESCRIPTION

 

LOTS 9 AND 10 OF RANCHO VISTOSO NEIGHBORHOOD 3, ACCORDING TO THE PLAT OF RECORD IN THE OFFICE OF THE COUNTY RECORDER OF PIMA COUNTY, ARIZONA, RECORDED IN BOOK 56 OF MAPS, PAGE 65 AND MINOR PLAT CHANGE RECORDED AS DOCKET 13222, PAGE 196.

 

 

 

9

 

Exhibit 10.8

 

SUPREME COURT OF THE STATE OF NEW YORK

 

COUNTY OF NEW YORK

 

GPB Debt Holdings II, LLC

 

Plaintiff,

 

v.

 

Icagen, Inc.

 

Defendant.

 

Index No.:

 

AFFIDAVIT OF CONFESSION OF JUDGMENT

 

 

 

 

State of New York )
  ) ss:
County of NEW YORK )

 

Richard Cunningham, being duly sworn, deposes and says:

 

1.       I am the Chief Executive Officer of Icagen, Inc., a Delaware corporation with its principal place of business located at 4222 Emperor Blvd., Suite 350, Research Triangle Park, Durham North Carolina 27703, the above captioned Defendant (the “Defendant”).

 

2.       I am duly authorized to make this affidavit for and on behalf of the Defendant.

 

3.       For purposes of this Confession of Judgment, Defendant irrevocably submits to the jurisdiction and venue of any state or federal court of competent jurisdiction located in any county of New York and authorize entry of the judgment herein in such court.

 

4.       Defendant hereby confesses judgment, pursuant to CPLR § 3218, in favor of GPB Debt Holdings II, LLC (the “Plaintiff”) and authorizes entry of such judgment by the Plaintiff against the Defendant (“Judgment”) in an amount equal to the sum of (i) Two Million Dollars ($2,000,000) (the “Principal Amount”), (ii) interest at the rate of thirteen (13%) percent per annum on such $2,000,000 Principal Amount, and (iii) all other amounts owed to Plaintiff pursuant to the Note (as defined below), less any subsequent payments or reductions received by the Plaintiff (the “Confessed Amount”).

 

1

 

 

5.       This affidavit is for a debt justly due to the Plaintiff from the Defendant arising from the following facts:

 

a.       Defendant makes this affidavit pursuant to that Securities Purchase Agreement dated as of May 15, 2017, by and among the Defendant, Icagen-T, Inc., a Delaware company and wholly owned subsidiary of Defendant, and the Plaintiff (the “SPA”). A copy of the SPA is attached hereto as Exhibit A .

 

b.       Pursuant to the SPA, the Defendant sold to Plaintiff, and Plaintiff purchased from the Defendant, a senior secured convertible note of the Company dated May 15, 2017 in the original aggregate principal amount of $2,000,000 due May 15, 2020 a copy of which is attached hereto as Exhibit B (the “Note”).

 

c.       The SPA further provides that in the event of any event of default under the Note, Defendant consents to the filing and enforcement by Plaintiff of this Affidavit of Confession of Judgment for the Confessed Amount, plus costs, disbursements and reasonable attorneys’ fees in enforcing and collecting against Defendant on said Judgment.

 

6.       Defendant authorizes Plaintiff or its assignee to enter Judgment upon presenting this affidavit to the Court, along with an affidavit of Plaintiff or its assignee’s counsel attesting that a default under the Note has occurred, that notice of default was provided to Defendant and Defendant has not cured said default in the manner permitted in the Note.

 

7.       I understand and agree that this affidavit authorizes entry of judgment in this Court under the terms hereof, without further proceedings, notices and/or other action and also authorizes execution against the Defendant pursuant to such judgment, and that such judgment will be entitled to receive full faith and credit under the Constitution of the United States.

 

8.       This affidavit is not for the purpose of securing Plaintiff against a contingent liability.

 

9.       This affidavit is not connected with a purchase of commodities and is not prohibited by § 3201 of the New York Civil Practice Law and Rules.

 

2

 

 

I declare under penalty of perjury that the foregoing is true and correct.

 

  ICAGEN, INC.
     
  By: /s/ Richard Cunningham
  Name:  Richard Cunningham
  Title: Chief Executive Officer

 

STATE OF )
     ss.:
COUNTY OF )

 

On the       day of May in the year 2017 before me, the undersigned personally appeared _____________, personally known to me or proved to me on the basis of satisfactory evidence to be the individual whose name is subscribed to the within the instrument and acknowledged to me that he executed the same in his capacity, that by his signature on the instrument, the individual, or the person upon behalf of which the individual acted, executed the instrument, and that such individual made such appearance before the undersigned in the City of Ridgefield, State of Connecticut.

 

     
  Notary Public  
     
[Seal]    
     

 

  3  

 

 

SUPREME COURT OF THE STATE OF NEW YORK

 

COUNTY OF NEW YORK

 

GPB Debt Holdings II, LLC

 

Plaintiff,

 

v.

 

Icagen-T, Inc.

 

Defendant.

 

Index No.:

 

AFFIDAVIT OF CONFESSION OF JUDGMENT

 

 

 

 

State of New York )
  ) ss:
County of NEW YORK )

 

Richard Cunningham, being duly sworn, deposes and says:

 

1.       am the Chief Executive Officer of Icagen-T, Inc., a Delaware corporation with its principal place of business located at 2090 E. Innovation Park Drive, Oro Valley, Arizona 85755, the above captioned Defendant (the “Defendant”).

 

2.       I am duly authorized to make this affidavit for and on behalf of the Defendant.

 

3.       For purposes of this Confession of Judgment, Defendant irrevocably submits to the jurisdiction and venue of any state or federal court of competent jurisdiction located in any county of New York and authorize entry of the judgment herein in such court.

 

4.       Defendant hereby confesses judgment, pursuant to CPLR § 3218, in favor of GPB Debt Holdings II, LLC (the “Plaintiff”) and authorizes entry of such judgment by the Plaintiff against the Defendant (“Judgment”) in an amount equal to the sum of (i) Eight Million Dollars ($8,000,000) (the “Principal Amount”), (ii) interest at the rate of thirteen (13%) percent per annum on such $8,000,000 Principal Amount, and (iii) all other amounts owed to Plaintiff pursuant to the Note (as defined below), less any subsequent payments or reductions received by the Plaintiff (the “Confessed Amount”).

 

1

 

 

5.       This affidavit is for a debt justly due to the Plaintiff from the Defendant arising from the following facts:

 

a.       Defendant makes this affidavit pursuant to that Securities Purchase Agreement dated as of May 15, 2017, by and among the Defendant, Icagen, Inc., a Delaware company and the parent entity of the Defendant, the Defendant, and the Plaintiff (the “SPA”). A copy of the SPA is attached hereto as Exhibit A .

 

b.       Pursuant to the SPA, the Defendant sold to Plaintiff, and Plaintiff purchased from the Defendant, a senior secured convertible note of the Company dated May 15, 2017 in the original aggregate principal amount of $8,000,000 due May 15, 2020 a copy of which is attached hereto as Exhibit B (the “Note”).

 

c.       The SPA further provides that in the event of any event of default under the Note, Defendant consents to the filing and enforcement by Plaintiff of this Affidavit of Confession of Judgment for the Confessed Amount, plus costs, disbursements and reasonable attorneys’ fees in enforcing and collecting against Defendant on said Judgment.

 

6.       Defendant authorizes Plaintiff or its assignee to enter Judgment upon presenting this affidavit to the Court, along with an affidavit of Plaintiff or its assignee’s counsel attesting that a default under the Note has occurred, that notice of default was provided to Defendant and Defendant has not cured said default in the manner permitted in the Note.

 

7.       I understand and agree that this affidavit authorizes entry of judgment in this Court under the terms hereof, without further proceedings, notices and/or other action and also authorizes execution against the Defendant pursuant to such judgment, and that such judgment will be entitled to receive full faith and credit under the Constitution of the United States.

 

8.       This affidavit is not for the purpose of securing Plaintiff against a contingent liability.

 

9.       This affidavit is not connected with a purchase of commodities and is not prohibited by § 3201 of the New York Civil Practice Law and Rules.

 

2

 

 

I declare under penalty of perjury that the foregoing is true and correct.

 

  ICAGEN-T, INC.
     
  By: /s/ Richard Cunningham
  Name:  Richard Cunningham
  Title: Chief Executive Officer

 

STATE OF )
     ss.:
COUNTY OF )

 

On the       day of May in the year 2017 before me, the undersigned personally appeared _____________, personally known to me or proved to me on the basis of satisfactory evidence to be the individual whose name is subscribed to the within the instrument and acknowledged to me that he executed the same in his capacity, that by his signature on the instrument, the individual, or the person upon behalf of which the individual acted, executed the instrument, and that such individual made such appearance before the undersigned in the City of Ridgefield, State of Connecticut.

 

     
  Notary Public  
     
[Seal]    
     

 

 

3

 

 

Exhibit 10.9

 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

SETTLEMENT AND RELEASE AGREEMENT

 

This Settlement and Release Agreement (“Agreement”) is made and entered into this 11th day of May, 2017, between Icagen, Inc. f/k/a Caldera Pharmaceuticals, Inc. (“Icagen”) and Dentons US LLP (“Dentons”). Icagen and Dentons may be referred to herein individually as a “Party” or collectively as the “Parties.”

 

WHEREAS, Dentons previously provided legal services to Icagen ( the “Representation”), including in connection with litigation commenced by Icagen against the Regents of the University of California and/or related parties;

 

WHEREAS, following disputes between them, Dentons and Icagen entered into a Settlement and Release Agreement (the "2013 Settlement Agreement"), a copy of which is attached as Exhibit A, fully and finally resolving any and all claims and potential claims arising out of, based upon, or relating to the Representation;

 

WHEREAS, Icagen did not make any payment to Dentons under the 2013 Settlement Agreement;

 

WHEREAS on April 22, 2014, Dentons filed a complaint in the Circuit Court of Cook County, Illinois, captioned Dentons vs. Caldera Pharmaceuticals, Inc. bearing docket number 14 L 50351, seeking entry of a judgment by confession against Icagen (the “Illinois Lawsuit”) based upon the 2013 Settlement Agreement.

 

WHEREAS, on May 7, 2014, a judgment was entered in the Illinois Lawsuit in favor of Dentons and against Icagen, in the amount of three million and fifty thousand dollars ($3,050,000.00) plus costs of suit (the “Judgment”), a copy of which is attached as Exhibit B, which Judgment remains outstanding;

 

WHEREAS, Icagen filed the following lawsuits against Dentons in San Francisco Superior Court (collectively, the "California Lawsuits"): (1) an action styled Richard Roe, et al. v. White Corporation, et al. , bearing docket no. 14 CGC 538762, which action was dismissed without prejudice; (2) an action styled Richard Roe, et al. v. White Corporation, et al. , bearing docket no. 15 CGC 544238, which action was dismissed without prejudice; and (3) an action styled Richard Roe, et al. v. White Corporation, et al. , bearing docket no. 17 CGC 558125, which remains pending;

 

WHEREAS, the Parties now desire to fully and finally settle any and all claims and potential claims arising out of, based upon, or relating to the 2013 Settlement Agreement, the Illinois Lawsuit, the Judgment, and the California Lawsuits;

 

NOW, THEREFORE, in consideration of the mutual covenants, conditions and promises contained herein, and other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Parties agree as follows:

 

1.             Payment . Icagen shall pay Dentons the sum of One Million Four Hundred Thousand Dollars ($1,400,000.00) as follows:

 

(a)        $250,000 to be received by Dentons no later than May 15, 2017;

 

 

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

(b)        $250,000 to be received by Dentons no later than June 1, 2017 or the date of the closing of Icagen's pending debt financing, whichever is sooner;

 

[*****]

 

All sums paid herein shall paid by wire transfer directed to:

 

[*****]

 

2.            Security . Simultaneous with the execution of this Agreement, Icagen shall execute and deliver to Dentons an ink original Affidavit in Support of Confession of Judgment in the amount of $3,891,549.32 (i.e., the amount of the Judgment plus costs of suit plus accrued interest through May 15, 2017) and in the form annexed hereto as Exhibit C (the “Confession of Judgment”). Upon collection of full payment in accordance with Paragraph 1 of this Agreement, Dentons shall return the ink original Confession of Judgment to Icagen. If Dentons fails to timely receive, when due, any of the payments in accordance with Paragraph 1, then Icagen shall be in default of the Agreement (“Default”) and shall have five (5) business days from the delivery of the notice to cure the Default. Notice shall be delivered by (i) a nationally recognized next day courier service, or (ii) first class registered or certified mail, postage prepaid. Notices hereunder shall be delivered to:

 

Mr. Richard Cunningham
Icagen, Inc.
4222 Emperor Blvd, Suite 350
Durham, NC 27703

 

With a copy to:

 

Leslie Marlow
Gracin & Marlow LLP
405 Lexington Avenue, 26th Floor
New York, New York 10174

 

Failure by Icagen to cure the Default within five (5) business days from delivery of notice of the Default shall result in the immediate right of Dentons to file the Confession of Judgment upon an affidavit or affirmation of noncompliance in a court of competent jurisdiction, in the amount of $3,891,549.32 plus accrued statutory interest subsequent to May 15, 2017, less any payments made subsequent to the execution of this Agreement and through the date of Default, plus interest.

 

3.              Existing Pleadings/Judgment .

 

(a)       Within five (5) business days following execution of this Agreement, Icagen will discontinue or dismiss the California Lawsuits with prejudice and will provide Dentons with Filed-stamped copies demonstrating such dismissal or discontinuance with prejudice. Icagen represents that it has not filed any other claims or proceedings against Dentons.

 

  2  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

(b)       Within five (5) business days following receipt of the payments in accordance with Paragraphs 1(a) and (b) herein (i.e., following timely receipt by Dentons from Icagen of payments of no less than $500,000), either Party shall file an agreed motion in the Circuit Court of Cook County, Illinois in the Illinois Lawsuit seeking (i) to vacate the Judgment of May 7, 2014; (ii) to dismiss the Illinois Lawsuit with prejudice; (iii) the entry of an agreed order in the form attached hereto as Exhibit D (“Agreed Order”) and (iv) the Court’s approval of a Release of Judgment in the form attached hereto as Exhibit E (“Release of Judgment. Dentons agrees to furnish Icagen with a signed Agreed Order and two signed ink originals of the Release of Judgment within five (5) business days following receipt of the payments from Icagen under paragraphs 1(a) and 1(b) of this Agreement.

 

(c)       Dentons represents that it has not filed any claims, proceedings or judgments against Icagen other than the Illinois Litigation.

 

(d)       Nothing herein shall prejudice Dentons’ right, in the event of Icagen's breach of this Agreement, to file the Confession of Judgment as set forth in paragraph 2, above.

 

4.            Full and Complete Settlement . The Parties agree that this Agreement and the terms set forth herein, shall and hereby do effectuate a full and complete settlement of all claims and potential claims arising out of, based upon, or relating to the 2013 Settlement Agreement, the Illinois Lawsuit, the Judgment and the California Lawsuits (collectively, the “Released Claims”). For avoidance of doubt, the 2013 Settlement Agreement shall remain in full force and effect, except that the Parties shall have no further rights or obligations under paragraphs 1 through 4 thereof, which are superceded by the provisions of this Agreement.

 

5.             Mutual Releases .

 

(a)       [*****]

 

6.             Unknown Claims . The Parties acknowledge and understand that there is a risk that, subsequent to the execution of this Agreement, they may discover, incur or suffer Released Claims which were unknown or unanticipated at the time of the execution of this Agreement, and which if known on the date of the execution of this Agreement might have materially affected their decision to enter into and execute this Agreement. The Parties further agree that, by reason of the release contained herein, they are assuming the risk of such unknown Released Claims and agree that this Agreement applies thereto.

 

7.             Forbearance From Suit .

 

(a)       Icagen, and all persons acting by, through, under or in concert with it, hereby promise, covenant and agree not to initiate, file or otherwise commence, assert, bring, join, participate in, or otherwise maintain against the Dentons Released Parties, in any court, agency, or other tribunal in any jurisdiction, either directly or indirectly, any claim which they now have, own or hold or claim to have, own or hold, or at any time heretofore had, owned or held, or claimed to have had, owned or held, or may hereinafter have, own or hold, or claim to have, own or hold against the Dentons Released Parties, arising out of, based upon, or relating to the Released Claims.

 

  3  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

(b)       Dentons, and all persons acting by, through, under or in concert with it, hereby promise, covenant and agree not to initiate, file or otherwise commence, assert, bring, join, participate in, or otherwise maintain against the Icagen Released Parties, in any court, agency, or other tribunal in any jurisdiction, either directly or indirectly, any claim which they now have, own or hold or claim to have, own or hold, or at any time heretofore had, owned or held, or claimed to have had, owned or held, or may hereinafter have, own or hold, or claim to have, own or hold against the Icagen Released Parties, arising out of, based upon, or relating to the Released Claims.

 

8.            Cal. Civ. Code Section 1542 . The parties specifically acknowledges that they are aware of and familiar with the provisions of California Civil Code Section 1542, which provides as follows:

 

“A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM OR HER MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR.”

 

Being aware of this section, the Parties hereby expressly waive and relinquish all rights and benefits they may have pursuant to said Code Section as well as any other statutes or common law principles of similar effect.

 

9.           Compromise . The Parties agree that this Agreement is in compromise and settlement of a dispute between them, and it shall not be considered as an admission of the truth or correctness of any claim allegation against them, or of fault or liability by them, each Party denying any fault or liability, except that Icagen acknowledges that it has not disputed, and will not dispute, that Dentons properly obtained the Judgment against it.

 

10.        Full and Independent Knowledge . Each of the Parties represents that it has been represented by separate counsel of its choice in connection with the preparation and review of this Agreement, its representative has specifically discussed, or had the opportunity to specifically discuss, with such attorney the meaning and effect of this Agreement, and that its representative has carefully read and understands the scope and effect of each provision contained herein. Dentons has not represented, advised, or served as Icagen's counsel in connection with this Agreement.

 

11.        Warranties . Each of the Parties represents and warrants that it has full power and authority to enter into and perform this Agreement. Each of the Parties further represents and warrants that it has not heretofore assigned, transferred, encumbered or otherwise conveyed, or purported to assign, transfer, encumber or otherwise convey, in whole or in part, to any person or entity, any Released Claims released hereunder.

 

12.        Confidentiality . Except to the extent necessary to enforce or carry out this Agreement or as otherwise required by law, the Parties shall maintain the terms and existence of this Agreement strictly confidential. Prior to responding to any request, subpoena, or order by any court or governmental agency for disclosure of this Agreement and/or the compromise and settlement effected thereby, the Party to which the request, subpoena, or order has been directed shall notify all other Parties, in writing, within seven (7) days of such request, subpoena, or order and to afford those Parties the opportunity to object to the request, subpoena, or order before responding thereto. Notwithstanding the foregoing: [*****]; (b) the Parties shall have the right to disclose the terms of this Agreement to the extent necessary to comply with their financial, legal, reporting, regulatory and securities obligations, including, to the extent that Icagen concludes that such filing is required, the filing of this Agreement as an exhibit to Icagen’s periodic filings with the Securities and Exchange Commission, provided, however, that Icagen will request confidential treatment of certain non-financial terms of the Agreement based on input from Dentons; (c) the Parties may disclose this Agreement to their attorneys, accountants, financial advisors, bankers, financiers, and potential and actual investors, provided such individuals are made aware of this Confidentiality provision and agree to be bound thereby.

 

  4  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

13.            Successors . This Agreement shall be binding upon and inure to the benefit of the successors, heirs and assigns of each of the Parties hereto.

 

14. Miscellaneous .

 

(a)       This Agreement shall be construed in accordance with and governed by the laws of the State of Illinois, United States of America, without regard to conflict of laws provisions. The Parties agree that the sole venue for disputes arising out of, related to and/or connected with this Agreement shall be the state courts situated in Cook County, Illinois.

 

(b)       The Parties agree that this Agreement may be executed in counterparts and that a copy signed by a Party will be fully enforceable against such Party. Unless an ink original is required herein (e.g. the Release of Judgment and the Confession of Judgment), this Agreement, and documents relating to this Agreement, may be executed and transmitted by facsimile, email or any other electronic means.

 

(c)       This document contains the entire agreement between the Parties hereto with respect to the subject matter hereof, and supersedes and cancels all previous agreements, contracts, covenants, commitments, obligations, and writings between the parties pertaining to the subject matter hereof. Each of the Parties further represents that no other understandings, statements, promises, or inducements contrary to the terms of this Agreement, whether oral or written, exist, and that he/it does not rely and has not relied upon any representation or statement made by another Party or any of their representatives with regard to the subject matter of this Agreement (other than those representations and statements made in this Agreement).

 

(d)       This Agreement shall be construed as a whole, according to its fair meaning, and shall not be construed strictly for or against any of the Parties hereto.

 

(e)       This Agreement may not be amended, altered, modified or waived, in whole or in part, except in a writing executed by the Parties to this Agreement.

 

(f)       If any provision of this Agreement is held invalid or otherwise unenforceable, the enforceability of the remaining provisions shall not be impaired thereby.

 

(g)       The failure of any Party to insist upon strict adherence to any term of this Agreement on any occasion shall not be considered a waiver thereof or deprive that Party of the right thereafter to insist upon strict adherence to that term or any other term of this Agreement.

 

  5  

Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

IN WITNESS WHEREOF, the Parties have each executed this Agreement as of the date first set forth above.

 

ICAGEN, INC. f/k/a   DENTONS US LLP
CALDERA PHARMACEUTICALS, INC.      
         
By: /s/ Richard Cunningham   By: /s/ Edward J. Reich
Title: Chief Executive Officer   Title: U.S. General Counsel and Partner
         
Agreed as to form:      
       
BLUMENTHAL LAW GROUP P.C.      
         
By: Grant Blumenthal      
Title: Counsel for Icagen, Inc. f/k/a      
  Caldera Pharmaceuticals, Inc.      

 

  6  
 

 

EXHIBIT A

 

[*****]

 

 

 

 

 

 

 

 

 

 

 

 

 

  A- 1  
 

 

EXHIBIT B

 

IN THE CIRCUIT COURT OF COOK COUNTY, ILLINOIS

 

DENTONS US LLP,

 

Plaintiff,

 

vs.

 

CALDERA PHARMACEUTICALS, INC.,

 

Defendant.

)

)

) Case No. 14L50351

)

)

)

)

)

)

)

 

JUDGMENT ORDER

 

It is ordered that plaintiff Dentons US LLP recover from defendant Caldera Pharmaceuticals, Inc.   $3,050,000 and costs of suit. Execution may issue.

 

Plaintiff may withdraw the original documents upon filing certified copies with the clerk.

 

  _________________________, ________________
   
  ENTER:
   
  /s/ Doruthy Brown
  Judge                                                        Judge’s No.

 

 

 

Atty. No.: 6205749

Name: Andrew R. McGaan

Atty. for: Dentons US LLP

Address: 300 N. LaSalle St.

City/State/Zip: Chicago, IL 60654

Telephone: 312-862-2000

 

 

  B- 1  
 

 

EXHIBIT C

 

DENTONS US LLP,

 

Plaintiff,

 

vs.

 

ICAGEN, INC. f/k/a CALDERA

PHARMACEUTICALS, INC.,

 

Defendant.

)

)

) Case No. _______

)

)

) AFFIDAVIT OF RICHARD CUNNINGHAM

)

)

)

)

 

RICHARD CUNNINGHAM, under penalty of perjury, hereby swears that the following information is true and correct to the best of my knowledge and information:

 

1.       I am the CEO and President of defendant Icagen, Inc. f/k/a Caldera Pharmaceuticals, Inc. (“Icagen”). Icagen is a Delaware corporation having its principal place of business at 4222 Emperor Blvd., Suite 350, Research Triangle Park, Durham, North Carolina 27703.

 

2.       I make this Affidavit in connection with a certain agreement dated May __, 2017 (“the Agreement”) between Icagen and plaintiff Dentons US LLP (“Dentons”) to confess judgment on behalf of Icagen in this Court in favor of plaintiff for the sum of three million eight hundred and ninety-one thousand five hundred and forty nine dollars and thirty two cents ($3,891,549.32), less any amounts paid pursuant to the Agreement, and to authorize Dentons to enter judgment for that sum against Icagen in this Court.

 

  C- 1  
 

 

3.       This Confession of Judgment is for a debt justly due to Dentons pursuant to a 2013 Settlement Agreement between Dentons and Icagen, and a Judgment entered pursuant thereto in the amount of three million and fifty thousand dollars ($3,050,000), plus costs of suit and interest, which resolved Dentons’ claim for fees and disbursements owed for professional services rendered to Icagen from 2011 through July 5, 2013. Pursuant to the Agreement, Dentons has agreed to compromise the amounts due and accept, inter alia, payment in the amount of one million four hundred thousand dollars ($1,400,000.00), to be paid pursuant to a schedule set forth therein.

 

4.       In the event Icagen defaults in making any payment set forth in the Agreement on a timely basis, Dentons is required to give Icagen written notice of such default.

 

5.       If Icagen fails to cure said default within five (5) business days after notice is delivered as required by the Agreement, Icagen shall immediately become obligated to Dentons for the full three million eight hundred and ninety one thousand five hundred and forty nine dollars and thirty cents ($3,891,549.32), less any amounts paid pursuant to the Agreement.

 

6.       If Icagen fails to cure the default within five (5) business days after notice is delivered in accordance with the Agreement, Icagen hereby irrevocably confesses judgment in favor of Dentons for the full three million eight hundred and ninety-one thousand five hundred and forty-nine dollars and thirty cents ($3,891,549.32), less any amounts paid pursuant to the Agreement.

 

  C- 2  
 

 

7.       Accordingly, if Icagen fails to cure the default within five (5) business days after notice is delivered in accordance with the Agreement, judgment may be entered hereunder against Icagen, Inc. f/k/a Caldera Pharmaceuticals, Inc. and in favor of Dentons US LLP in the amount of three million eight hundred and ninety-one thousand five hundred and forty-nine dollars and thirty cents ($3,891,549.32), less any amounts paid pursuant to the Agreement, plus court filing fees, upon the filing of this Affidavit together with an Affidavit from a representative of Dentons stating that payment required by the Agreement was not timely made and setting forth the full amount then due, including the basis for calculation, plus court filing fees.

 

FURTHER, AFFIANT SAYETH NOT.

 

  /s/ Richard Cunningham 
  Richard Cunningham

 

SUBSCRIBE and SWORN to before

me this 11 th May, 2017

 
 

/s/ James O. Whitmore
Notary Public

 

  C- 3  
 

 

EXHIBIT D

 

IN THE CIRCUIT COURT OF COOK COUNTY, ILLINOIS

 

DENTONS LLP

 

vs

 

CALDERA PHARMACEUTICALS, INC
n/k/a ICAGEN, INC

)

)

) No. 14 L 50351

)

)

)

 

AGREED ORDER TO VACATE JUDGMENT
AND DISMISS WITH PREJUDICE

 

This matter before the Court on the Agreed Motion of Dentons LLP and Caldera Pharmaceuticals, Inc n/k/a Icagen, Inc, due notice given and the Court and parties being fully advised in the premises, it is hereby ordered that:

 

1. The Judgment of May 7, 2014, in the amount of $3,050,00.00 plus costs of suit is hereby
vacated.
     
2. This matter is dismissed with prejudice with each side to bear their own attorneys’ fees and costs.

 

AGREED:
Dentons LLP,   Caldera Pharmaceuticals, Inc
  By its counsel of record   n/k/a Icagen, Inc, by its counsel of record

 

Date:  
       
      ENTER:
         
         
        Judge Judge’s No.

 

__________________(No.______________)

Dentons LLP

300 N. LaSalle Street

Chicago, Illinois 60654

Tel: (312) 862-2000

 

  D- 1  
 

 

EXHIBIT E

 

IN THE CIRCUIT COURT OF
COOK COUNTY, ILLINOIS

 

Dentons, LLP

 

v.

 

Caldera Pharmaceuticals, Inc.

k/n/a Icagen, Inc.

     
    Recorder’s Stamp
     
                           No. 14 L 50351

 

RELEASE OF JUDGMENT

 

Dentons, LLP, the Judgment Creditor, having received full consideration for this release, releases the judgment entered on May 7, 2014, against Defendant, Caldera Pharmaceuticals Inc., k/n/a Icagen, Inc. for $3,050,000.00.

 

 
Attorney of Record for Dentons, LLP

 

APPROVED:
    Judge                   Judge’s No.

 

__________________ (No.__________________)

Dentons LLP

300 N. LaSalle Street

Chicago, Illinois 60654

Tel: (312) 862-2000

 

 

 

E-1